{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Wall of Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import getpass\n",
    "import requests\n",
    "import json\n",
    "from langchain_community.document_loaders import JSONLoader\n",
    "import pprint\n",
    "from langchain_text_splitters import RecursiveJsonSplitter\n",
    "from langchain_qdrant import QdrantVectorStore\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from qdrant_client import QdrantClient\n",
    "from bs4 import BeautifulSoup\n",
    "import xml.etree.ElementTree as ET\n",
    "import shutil\n",
    "from ftplib import FTP\n",
    "import tarfile\n",
    "from langchain.prompts import ChatPromptTemplate\n",
    "from operator import itemgetter\n",
    "from langchain.schema.output_parser import StrOutputParser\n",
    "from langchain.schema.runnable import RunnablePassthrough\n",
    "import subprocess\n",
    "import pandas\n",
    "from bs4 import BeautifulSoup\n",
    "import fnmatch"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Enter OpenAI API Key"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ[\"OPENAI_API_KEY\"] = getpass.getpass(\"OpenAI API Key:\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Enter RAGAS API Key"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ[\"RAGAS_APP_TOKEN\"] = getpass.getpass(\"Please enter your Ragas API key!\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Enter Qdrant API Key"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ[\"QDRANT_API_KEY\"] = getpass.getpass(\"Please enter your Qdrant API key!\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieve Projects (University of Utah Pediatrics projects only for the time being)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define the directory and file path\n",
    "directory = 'data'\n",
    "file_path = os.path.join(directory, 'projects_data.json')\n",
    "\n",
    "# Create the directory if it doesn't exist\n",
    "if not os.path.exists(directory):\n",
    "    os.makedirs(directory)\n",
    "\n",
    "# Define the endpoint URL\n",
    "url = \"https://api.reporter.nih.gov/v2/projects/search\"\n",
    "\n",
    "# Define the JSON body for the request\n",
    "json_body = {\n",
    "        \"criteria\":\n",
    "        {\n",
    "            \"org_names\": [\"UNIVERSITY OF UTAH\"],\n",
    "            \"dept_types\": [\"PEDIATRICS\"]\n",
    "        },\n",
    "        \"include_fields\": [\n",
    "             \"ApplId\",\"SubprojectId\",\"FiscalYear\",\"Organization\", \"ProjectNum\",\n",
    "             \"ProjectNumSplit\",\"ContactPiName\",\"AllText\",\"FullStudySection\",\n",
    "             \"ProjectStartDate\",\"ProjectEndDate\", \"AwardAmount\", \"ActivityCode\", \n",
    "             \"AgencyIcAdmin\", \"AwardType\", \"AwardNoticeDate\", \"BudgetStart\", \n",
    "             \"BudgetEnd\", \"CoreProjectNum\", \"OrganizationType\", \"OpportunityNumber\",\n",
    "             \"AgencyIcFundings\", \"FundingMechanism\", \"SpendingCategoriesDesc\", \"PhrText\",\n",
    "             \"PrincipalInvestigators\", \"PrefTerms\", \"ProjectTitle\", \"DirectCostAmt\",\n",
    "             \"IndirectCostAmt\", \"IsActive\", \"Terms\", \"AbstractText\", \"AgencyCode\",\n",
    "             \"ProjectDetailUrl\"\n",
    "         ],\n",
    "         \"offset\":0,\n",
    "         \"limit\":100,\n",
    "         \"sort_field\":\"project_start_date\",\n",
    "          \"sort_order\":\"desc\"\n",
    "   }\n",
    "\n",
    "# Make the POST request with JSON body\n",
    "response = requests.post(url, json=json_body)\n",
    "\n",
    "# Check if the request was successful\n",
    "if response.status_code == 200:\n",
    "    # Parse the JSON response\n",
    "    data = response.json()\n",
    "    \n",
    "    # Save the JSON data to a file\n",
    "    \n",
    "    with open(file_path, 'w') as file:\n",
    "        json.dump(data, file, indent=4)  # indent=4 for pretty printing\n",
    "    # Do something with the data\n",
    "    #pprint.pprint(data)\n",
    "else:\n",
    "    print(f\"Request failed with status code {response.status_code}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieve Publications (Limited to Projects Retrieved Above)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "file_path = os.path.join(directory, 'publications_data.json')\n",
    "core_proj_nums = \"\"\n",
    "\n",
    "for i in range(0, len(data['results'])):\n",
    "    core_proj_num = data['results'][i]['core_project_num']\n",
    "    if i == 0:\n",
    "        core_proj_nums += \"\\\"\" + core_proj_num + \"\\\"\"\n",
    "    else:\n",
    "        core_proj_nums += \", \\\"\" + core_proj_num + \"\\\"\"\n",
    "    \n",
    "publications_endpoint = \"https://api.reporter.nih.gov/v2/publications/search\"\n",
    "\n",
    "# Define the JSON body for the request\n",
    "json_body = {\n",
    "    \"criteria\": {\n",
    "        \"coreProjectNums\": [\n",
    "        core_proj_nums\n",
    "        ]\n",
    "    },\n",
    "    \"offset\": 0,\n",
    "    \"limit\": 100,\n",
    "    \"sortField\": \"string\",\n",
    "    \"sortOrder\": \"string\"\n",
    "}\n",
    "\n",
    "# Make the POST request with JSON body\n",
    "response = requests.post(publications_endpoint, json=json_body)\n",
    "\n",
    "# Check if the request was successful\n",
    "if response.status_code == 200:\n",
    "    # Parse the JSON response\n",
    "    publications_data = response.json()\n",
    "    #pprint.pprint(publications_data)\n",
    "    \n",
    "    # Save the JSON data to a file\n",
    "    \n",
    "    with open(file_path, 'w') as file:\n",
    "        json.dump(publications_data, file, indent=4)  # indent=4 for pretty printing\n",
    "    # Do something with the data\n",
    "    #pprint.pprint(data)\n",
    "else:\n",
    "    print(f\"Request failed with status code {response.status_code}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieve PMCID (for retrieving FHS download link)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_pmcid(pmid):\n",
    "    base_url = \"https://pubmed.ncbi.nlm.nih.gov/\"\n",
    "    url = base_url + str(pmid)\n",
    "    response = requests.get(url)\n",
    "    \n",
    "    # Check if the request was successful\n",
    "    if response.status_code == 200:\n",
    "        # Parse the HTML content using BeautifulSoup\n",
    "        soup = BeautifulSoup(response.content, 'html.parser')\n",
    "        \n",
    "        # Extract publication from the webpage\n",
    "        pmcid = soup.find('a', attrs={'class': 'id-link', 'data-ga-action': 'PMCID'}).get_text(strip=\"true\")\n",
    "        \n",
    "        # Print the extracted text\n",
    "        return pmcid\n",
    "    else:\n",
    "        print(f\"Failed to retrieve webpage. Status code: {response.status_code}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PMC7081964\n"
     ]
    }
   ],
   "source": [
    "pmcid = retrieve_pmcid(32191811)\n",
    "print(pmcid)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieve FHS Link (for downloading publication)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_ftp_link(pmcid):\n",
    "    url = \"https://www.ncbi.nlm.nih.gov/pmc/utils/oa/oa.fcgi?id=\" + pmcid\n",
    "    response = requests.get(url)\n",
    "    \n",
    "    # Check if the request was successful\n",
    "    if response.status_code == 200:\n",
    "        # Parse the XML content\n",
    "        root = ET.fromstring(response.content)\n",
    "\n",
    "        # Find the link\n",
    "        ftp_link = None\n",
    "        for link in root.findall(\".//link\"):\n",
    "            if link.get('format') == 'tgz':\n",
    "                ftp_link = link.get('href')\n",
    "                break\n",
    "\n",
    "        return ftp_link"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_package/c4/64/PMC7081964.tar.gz\n"
     ]
    }
   ],
   "source": [
    "ftp_link = retrieve_ftp_link(pmcid)\n",
    "print(ftp_link)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieve Publication"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_publication(ftp_link):\n",
    "    modified_ftp_link = ftp_link.replace(\"ftp://\", \"\")\n",
    "    \n",
    "    # FTP server details\n",
    "    ftp_server = modified_ftp_link[0:modified_ftp_link.find(\"/\")]\n",
    "    reversed_ftp_link = modified_ftp_link[::-1]\n",
    "    file_to_download = reversed_ftp_link[0:reversed_ftp_link.find(\"/\")][::-1]\n",
    "    ftp_directory = (modified_ftp_link.replace(ftp_server, \"\")).replace(f\"/{file_to_download}\", \"\")\n",
    "    local_directory = \"data\"\n",
    "    local_file_path = os.path.join(local_directory, file_to_download)\n",
    "\n",
    "    ftp = FTP(ftp_server)\n",
    "    ftp.login()\n",
    "    ftp.cwd(ftp_directory)\n",
    "    with open(local_file_path, 'wb') as local_file:\n",
    "        ftp.retrbinary(f\"RETR {file_to_download}\", local_file.write)\n",
    "    ftp.close()\n",
    "\n",
    "    # Open the tar.gz file\n",
    "    with tarfile.open(local_file_path, 'r:gz') as tar_ref:\n",
    "        # Extract all contents to the specified directory\n",
    "        tar_ref.extractall(\"data\")\n",
    "        \n",
    "    # Check if the file exists\n",
    "    if os.path.exists(local_file_path):\n",
    "        # Delete the file\n",
    "        os.remove(local_file_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 353,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/53/qt49q2y578gf4p14hcjbpshc0000gn/T/ipykernel_9255/2942949143.py:22: DeprecationWarning: Python 3.14 will, by default, filter extracted tar archives and reject files or modify their metadata. Use the filter argument to control this behavior.\n",
      "  tar_ref.extractall(\"data\")\n"
     ]
    }
   ],
   "source": [
    "retrieve_publication(ftp_link)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Clean Up Publications"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_up_publications(directory_path):\n",
    "    # Check if the parent directory exists\n",
    "    if os.path.exists(directory_path):\n",
    "        # Iterate over all entries in the parent directory\n",
    "        for entry in os.listdir(directory_path):\n",
    "            entry_path = os.path.join(directory_path, entry)\n",
    "            \n",
    "            # Check if the entry is a directory\n",
    "            if os.path.isdir(entry_path) and entry != 'Opportunities':\n",
    "                # Remove the subdirectory and all its contents\n",
    "                shutil.rmtree(entry_path)\n",
    "                print(f\"Subdirectory '{entry_path}' has been deleted.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Subdirectory 'data/PMC7081964' has been deleted.\n"
     ]
    }
   ],
   "source": [
    "directory_path = \"data\"\n",
    "\n",
    "clean_up_publications(directory_path)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Funding Opportunities (no API access sadly)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 0}, page_content='Title: Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)\\nRelease_Date: 1/22/2025\\nExpired_Date: 1/8/2027\\nActivity_Code: R34\\nParent_Organization: NIH\\nOrganization: NIDA\\nParticipating_Orgs: NCCIH, NIA, NIAAA, NICHD, NIDCR, NIEHS, NIMH, NINR, OBSSR, ODP, ORWH, THRO\\nDocument_Number: PAR-25-378\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-378.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 1}, page_content='Title: New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)\\nRelease_Date: 1/22/2025\\nExpired_Date: 3/7/2026\\nActivity_Code: R03\\nParent_Organization: NIH\\nOrganization: NIDDK\\nParticipating_Orgs: OD\\nDocument_Number: RFA-DK-26-009\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-009.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 2}, page_content='Title: Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)\\nRelease_Date: 1/21/2025\\nExpired_Date: 1/8/2027\\nActivity_Code: R01\\nParent_Organization: NIH\\nOrganization: NIDA\\nParticipating_Orgs: NCI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, NINR, NLM, OBSSR, ODP, ORWH, THRO\\nDocument_Number: PAR-25-379\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-379.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 3}, page_content='Title: Laboratory Flexible Funding Model (LFFM)\\nRelease_Date: 1/17/2025\\nExpired_Date: 1/11/2028\\nActivity_Code: U19\\nParent_Organization: FDA\\nOrganization: FDA\\nParticipating_Orgs: None\\nDocument_Number: RFA-FD-25-007\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-007.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 4}, page_content='Title: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-011\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-011.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 5}, page_content='Title: Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-010\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-010.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 6}, page_content='Title: Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trial Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-009\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-009.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 7}, page_content='Title: Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)\\nRelease_Date: 1/16/2025\\nExpired_Date: 6/14/2025\\nActivity_Code: U19\\nParent_Organization: NIH\\nOrganization: NIAID\\nParticipating_Orgs: None\\nDocument_Number: RFA-AI-24-079\\nDocument_Type: RFA\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-079.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 8}, page_content='Title: Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)\\nRelease_Date: 1/15/2025\\nExpired_Date: 3/9/2026\\nActivity_Code: R01\\nParent_Organization: NIH\\nOrganization: NIDDK\\nParticipating_Orgs: OD\\nDocument_Number: RFA-DK-26-007\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-007.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 9}, page_content='Title: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)\\nRelease_Date: 1/15/2025\\nExpired_Date: 10/26/2027\\nActivity_Code: U19\\nParent_Organization: NIH\\nOrganization: NIMH\\nParticipating_Orgs: None\\nDocument_Number: PAR-25-353\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html')]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "528"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain.document_loaders import CSVLoader\n",
    "\n",
    "# Path to your CSV file\n",
    "csv_file_path = \"data/Opportunities/NIH_Funding_Opportunities_20250221.csv\"\n",
    "\n",
    "# Load CSV file as LangChain documents\n",
    "loader = CSVLoader(file_path=csv_file_path)\n",
    "opportunities_summary = loader.load()\n",
    "\n",
    "print(opportunities_summary[0:10])\n",
    "len(opportunities_summary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = OpenAIEmbeddings(model=\"text-embedding-3-small\")\n",
    "\n",
    "url = \"https://e788c0ea-f5df-4d96-85ac-350da677aadf.us-west-2-0.aws.cloud.qdrant.io\"\n",
    "\n",
    "opportunities_summary_qdrant = QdrantVectorStore.from_documents(\n",
    "    opportunities_summary,\n",
    "    embeddings,\n",
    "    url=url,\n",
    "    prefer_grpc=False,\n",
    "    api_key=os.environ[\"QDRANT_API_KEY\"],\n",
    "    collection_name=\"opportunities_summary\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'input_documents': [Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 0}, page_content='Title: Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)\\nRelease_Date: 1/22/2025\\nExpired_Date: 1/8/2027\\nActivity_Code: R34\\nParent_Organization: NIH\\nOrganization: NIDA\\nParticipating_Orgs: NCCIH, NIA, NIAAA, NICHD, NIDCR, NIEHS, NIMH, NINR, OBSSR, ODP, ORWH, THRO\\nDocument_Number: PAR-25-378\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-378.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 1}, page_content='Title: New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)\\nRelease_Date: 1/22/2025\\nExpired_Date: 3/7/2026\\nActivity_Code: R03\\nParent_Organization: NIH\\nOrganization: NIDDK\\nParticipating_Orgs: OD\\nDocument_Number: RFA-DK-26-009\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-009.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 2}, page_content='Title: Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)\\nRelease_Date: 1/21/2025\\nExpired_Date: 1/8/2027\\nActivity_Code: R01\\nParent_Organization: NIH\\nOrganization: NIDA\\nParticipating_Orgs: NCI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, NINR, NLM, OBSSR, ODP, ORWH, THRO\\nDocument_Number: PAR-25-379\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-379.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 3}, page_content='Title: Laboratory Flexible Funding Model (LFFM)\\nRelease_Date: 1/17/2025\\nExpired_Date: 1/11/2028\\nActivity_Code: U19\\nParent_Organization: FDA\\nOrganization: FDA\\nParticipating_Orgs: None\\nDocument_Number: RFA-FD-25-007\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-007.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 4}, page_content='Title: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-011\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-011.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 5}, page_content='Title: Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-010\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-010.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 6}, page_content='Title: Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trial Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-009\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-009.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 7}, page_content='Title: Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)\\nRelease_Date: 1/16/2025\\nExpired_Date: 6/14/2025\\nActivity_Code: U19\\nParent_Organization: NIH\\nOrganization: NIAID\\nParticipating_Orgs: None\\nDocument_Number: RFA-AI-24-079\\nDocument_Type: RFA\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-079.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 8}, page_content='Title: Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)\\nRelease_Date: 1/15/2025\\nExpired_Date: 3/9/2026\\nActivity_Code: R01\\nParent_Organization: NIH\\nOrganization: NIDDK\\nParticipating_Orgs: OD\\nDocument_Number: RFA-DK-26-007\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-007.html'), Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 9}, page_content='Title: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)\\nRelease_Date: 1/15/2025\\nExpired_Date: 10/26/2027\\nActivity_Code: U19\\nParent_Organization: NIH\\nOrganization: NIMH\\nParticipating_Orgs: None\\nDocument_Number: PAR-25-353\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html')], 'output_text': 'The National Institutes of Health (NIH) is launching several funding opportunities between January 15, 2025, and January 2027. Key initiatives include the \"Intervention Research to Improve Native American Health\" program (R34, clinical trial optional), managed by the National Institute on Drug Abuse (NIDA), aimed at enhancing health outcomes for Native American populations (document PAR-25-378). The NIDDK is also offering New Investigator Gateway Awards for Collaborative T1D Research (R03) from January 22, 2025, to March 7, 2026, which do not allow clinical trials (RFA-DK-26-009).\\n\\nAdditional funding opportunities include the Laboratory Flexible Funding Model (RFA-FD-25-007) and various projects under the MACS/WIHS Combined Cohort Study (RFA-HL-26-011, RFA-HL-26-010, RFA-HL-26-009), all of which prohibit clinical trials and involve multiple NIH organizations. The NIAID has announced funding for Asthma and Allergic Diseases Cooperative Research Centers (RFA-AI-24-079, clinical trial optional) from January 16, 2025, to June 14, 2025. Lastly, the NIDDK\\'s collaborative research opportunity utilizing Type 1 Diabetes biosamples and data (RFA-DK-26-007) will be available until March 9, 2026, and the NIMH\\'s National Cooperative Drug/Device Discovery/Development Groups (U19, clinical trial optional) will be open until October 26, 2027. More details for each program can be found at the provided NIH grants URLs.'}\n"
     ]
    }
   ],
   "source": [
    "from langchain.chains.summarize import load_summarize_chain\n",
    "from langchain.chat_models import ChatOpenAI\n",
    "\n",
    "llm = ChatOpenAI(model_name=\"gpt-4o-mini\")  # Use GPT-4 or any other model\n",
    "summarizer = load_summarize_chain(llm, chain_type=\"map_reduce\")\n",
    "\n",
    "summary = summarizer.invoke(opportunities_summary[0:10])\n",
    "\n",
    "# Print summary\n",
    "print(summary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'input_documents': [Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 0}, page_content='Title: Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)\\nRelease_Date: 1/22/2025\\nExpired_Date: 1/8/2027\\nActivity_Code: R34\\nParent_Organization: NIH\\nOrganization: NIDA\\nParticipating_Orgs: NCCIH, NIA, NIAAA, NICHD, NIDCR, NIEHS, NIMH, NINR, OBSSR, ODP, ORWH, THRO\\nDocument_Number: PAR-25-378\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-378.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 1}, page_content='Title: New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)\\nRelease_Date: 1/22/2025\\nExpired_Date: 3/7/2026\\nActivity_Code: R03\\nParent_Organization: NIH\\nOrganization: NIDDK\\nParticipating_Orgs: OD\\nDocument_Number: RFA-DK-26-009\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-009.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 2}, page_content='Title: Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)\\nRelease_Date: 1/21/2025\\nExpired_Date: 1/8/2027\\nActivity_Code: R01\\nParent_Organization: NIH\\nOrganization: NIDA\\nParticipating_Orgs: NCI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, NINR, NLM, OBSSR, ODP, ORWH, THRO\\nDocument_Number: PAR-25-379\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-379.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 3}, page_content='Title: Laboratory Flexible Funding Model (LFFM)\\nRelease_Date: 1/17/2025\\nExpired_Date: 1/11/2028\\nActivity_Code: U19\\nParent_Organization: FDA\\nOrganization: FDA\\nParticipating_Orgs: None\\nDocument_Number: RFA-FD-25-007\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-007.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 4}, page_content='Title: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-011\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-011.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 5}, page_content='Title: Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-010\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-010.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 6}, page_content='Title: Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trial Not Allowed)\\nRelease_Date: 1/16/2025\\nExpired_Date: 5/3/2025\\nActivity_Code: U01\\nParent_Organization: NIH\\nOrganization: NHLBI\\nParticipating_Orgs: NCI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIMH, NIMHD, NINR, ORWH\\nDocument_Number: RFA-HL-26-009\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-009.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 7}, page_content='Title: Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)\\nRelease_Date: 1/16/2025\\nExpired_Date: 6/14/2025\\nActivity_Code: U19\\nParent_Organization: NIH\\nOrganization: NIAID\\nParticipating_Orgs: None\\nDocument_Number: RFA-AI-24-079\\nDocument_Type: RFA\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-079.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 8}, page_content='Title: Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)\\nRelease_Date: 1/15/2025\\nExpired_Date: 3/9/2026\\nActivity_Code: R01\\nParent_Organization: NIH\\nOrganization: NIDDK\\nParticipating_Orgs: OD\\nDocument_Number: RFA-DK-26-007\\nDocument_Type: RFA\\nClinical_Trials: Not_Allowed\\nURL: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-007.html'),\n",
      "                     Document(metadata={'source': 'data/Opportunities/NIH_Funding_Opportunities_20250221.csv', 'row': 9}, page_content='Title: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)\\nRelease_Date: 1/15/2025\\nExpired_Date: 10/26/2027\\nActivity_Code: U19\\nParent_Organization: NIH\\nOrganization: NIMH\\nParticipating_Orgs: None\\nDocument_Number: PAR-25-353\\nDocument_Type: PAR\\nClinical_Trials: Optional\\nURL: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html')],\n",
      " 'output_text': 'The National Institutes of Health (NIH) is launching several '\n",
      "                'funding opportunities between January 15, 2025, and January '\n",
      "                '2027. Key initiatives include the \"Intervention Research to '\n",
      "                'Improve Native American Health\" program (R34, clinical trial '\n",
      "                'optional), managed by the National Institute on Drug Abuse '\n",
      "                '(NIDA), aimed at enhancing health outcomes for Native '\n",
      "                'American populations (document PAR-25-378). The NIDDK is also '\n",
      "                'offering New Investigator Gateway Awards for Collaborative '\n",
      "                'T1D Research (R03) from January 22, 2025, to March 7, 2026, '\n",
      "                'which do not allow clinical trials (RFA-DK-26-009).\\n'\n",
      "                '\\n'\n",
      "                'Additional funding opportunities include the Laboratory '\n",
      "                'Flexible Funding Model (RFA-FD-25-007) and various projects '\n",
      "                'under the MACS/WIHS Combined Cohort Study (RFA-HL-26-011, '\n",
      "                'RFA-HL-26-010, RFA-HL-26-009), all of which prohibit clinical '\n",
      "                'trials and involve multiple NIH organizations. The NIAID has '\n",
      "                'announced funding for Asthma and Allergic Diseases '\n",
      "                'Cooperative Research Centers (RFA-AI-24-079, clinical trial '\n",
      "                'optional) from January 16, 2025, to June 14, 2025. Lastly, '\n",
      "                \"the NIDDK's collaborative research opportunity utilizing Type \"\n",
      "                '1 Diabetes biosamples and data (RFA-DK-26-007) will be '\n",
      "                \"available until March 9, 2026, and the NIMH's National \"\n",
      "                'Cooperative Drug/Device Discovery/Development Groups (U19, '\n",
      "                'clinical trial optional) will be open until October 26, 2027. '\n",
      "                'More details for each program can be found at the provided '\n",
      "                'NIH grants URLs.'}\n"
     ]
    }
   ],
   "source": [
    "pprint.pprint(summary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Limit opportunity count\n",
    "opportunity_count = 10\n",
    "\n",
    "# Path to the CSV file\n",
    "csv_file_path = \"data/Opportunities/NIH_Funding_Opportunities_20250221.csv\"\n",
    "\n",
    "# Load the CSV data into a DataFrame\n",
    "df = pandas.read_csv(csv_file_path)\n",
    "\n",
    "# Extract the html files \n",
    "counter = 0\n",
    "\n",
    "for index, row in df.iterrows():\n",
    "    output_file = \"data/Opportunities/\" + row['Document_Number'] + \".html\"\n",
    "    # Construct the curl command\n",
    "    curl_command = [\n",
    "        \"curl\",\n",
    "        \"-X\", \"GET\",  # or \"POST\", \"PUT\", etc.\n",
    "        row['URL'],\n",
    "        \"-o\", output_file\n",
    "    ]\n",
    "    \n",
    "    # Execute the curl command\n",
    "    try:\n",
    "        result = subprocess.run(curl_command, check=True, text=True, capture_output=True)\n",
    "    except subprocess.CalledProcessError as e:\n",
    "        print(\"An error occurred:\", e)\n",
    "        \n",
    "    counter += 1\n",
    "    \n",
    "    # Limit to opportunity count\n",
    "    if counter > opportunity_count:\n",
    "        break"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create HTML splitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_text_splitters import HTMLSectionSplitter\n",
    "\n",
    "headers_to_split_on = [(\"h1\", \"Header 1\"), (\"h2\", \"Header 2\"), (\"h3\", \"Header 3\")]\n",
    "\n",
    "html_splitter = HTMLSectionSplitter(\n",
    "    headers_to_split_on=headers_to_split_on\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Clean up HTML files and split (for the golden chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Path to the directory containing HTML files\n",
    "directory_path = \"data/Opportunities\"\n",
    "\n",
    "def clean_html(html_raw):\n",
    "    soup = BeautifulSoup(html_raw.replace(\"\\n\", \"\").replace(\"\\t\", \"\"), 'html.parser')\n",
    "    # Remove div tags (could use some more work)\n",
    "    for div_tag in soup.find_all('div'):\n",
    "        div_tag.replaceWithChildren()\n",
    "    # Remove script tags \n",
    "    for script in soup.find_all('script'):\n",
    "        script.decompose()\n",
    "    # Remove title tags\n",
    "    for title in soup.find_all('title'):\n",
    "        opportunity_title = title.string\n",
    "        title.decompose()\n",
    "    # Remove meta tags \n",
    "    for meta in soup.find_all('meta'):\n",
    "        meta.decompose()\n",
    "    # Add metadata to header tags \n",
    "    for header in soup.find_all(['h1', 'h2', 'h3']):\n",
    "        if header.string is not None:\n",
    "            header.string.replace_with(f\"{opportunity_title} {header.string}\")\n",
    "    # Return clean file\n",
    "    return soup.prettify() \n",
    "\n",
    "# Initialize opportunities document list\n",
    "opportunities = []\n",
    "\n",
    "# Iterate over each file in the directory\n",
    "for filename in os.listdir(directory_path):\n",
    "    # Check if the file is an HTML file\n",
    "    if fnmatch.fnmatch(filename, '*.html'):\n",
    "        file_path = os.path.join(directory_path, filename)\n",
    "        #Read html file\n",
    "        with open(file_path, 'r') as f:\n",
    "            html_raw = f.read()\n",
    "        #Add cleaned and chunked html file to opportunities list\n",
    "        opportunities.extend(html_splitter.split_text(clean_html(html_raw)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2446"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(opportunities)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "for row in opportunities:\n",
    "    if 'Header 1' in row.metadata:\n",
    "        row.page_content = row.metadata['Header 1'] + ' ' + row.page_content\n",
    "    elif 'Header 2' in row.metadata:\n",
    "        row.page_content = row.metadata['Header 2'] + ' ' + row.page_content\n",
    "    elif 'Header 3' in row.metadata:\n",
    "        row.page_content = row.metadata['Header 3'] + ' ' + row.page_content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "opportunities = [doc for doc in opportunities if doc.metadata.get('Header 1') != '#TITLE#']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'Header 1': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 1. Overview Information'}, page_content=\"PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 1. Overview Information PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 1. Overview Information\\n    \\n \\n \\n   Participating Organization(s)\\n    \\n    National Institutes of Health (\\n     \\n     NIH\\n     \\n    )\\n    \\n \\n \\n   Components of Participating Organizations\\n    \\n    National Institute on Minority Health and Health Disparities (\\n     \\n     NIMHD\\n     \\n    )\\n     \\n \\n     National Institute on Aging (\\n      \\n      NIA\\n      \\n     )\\n     \\n \\n     National Institute of Dental and Craniofacial Research (\\n      \\n      NIDCR\\n      \\n     )\\n     \\n \\n     National Institute of Nursing Research (\\n      \\n      NINR\\n      \\n     )\\n     \\n \\n     National Cancer Institute (\\n      \\n      NCI\\n      \\n     )\\n     \\n \\n     All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.\\n     \\n \\n     Office of Research on Women's Health (\\n      \\n      ORWH\\n      \\n     )\\n     \\n \\n \\n   Funding Opportunity Title\\n    \\n    Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed)\\n    \\n \\n \\n   Activity Code\\n    \\n \\n     R01\\n     \\n    Research Project Grant\\n    \\n \\n \\n   Announcement Type\\n   Reissue of\\n    \\n    PAR-23-303\\n    \\n \\n \\n \\n   Related Notices\\n    \\n \\n \\n      April 4, 2024\\n      \\n     - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice\\n      \\n      NOT-OD-24-084\\n      \\n     .\\n     \\n \\n \\n      August 31, 2022\\n      \\n     - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice\\n      \\n      NOT-OD-22-198\\n      \\n     .\\n     \\n \\n \\n      August 5, 2022\\n      \\n     - Implementation Details for the NIH Data Management and Sharing Policy. See Notice\\n      \\n      NOT-OD-22-189\\n      \\n     .\\n     \\n \\n \\n \\n   Funding Opportunity Number (FON)\\n    \\n    PAR-25-377\\n    \\n \\n \\n   Companion Funding Opportunity\\n   None\\n    \\n \\n   Number of Applications\\n    \\n    See Section III. 3. Additional Information on Eligibility.\\n    \\n \\n \\n   Assistance Listing Number(s)\\n   93.307, 93.866, 93.361, 93.313, 93.121, 93.393\\n    \\n \\n   Funding Opportunity Purpose\\n    \\n    This Notice of Funding Opportunity (NOFO) is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025.\\n    \\n \\n    This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address\\xa0health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.\\n    \\n \\n \\n   Funding Opportunity Goal(s)\\n    \\n    Objectives: \\xa0Through R01-funded projects, this funding announcement aims at supporting \\xa0innovative projects to enhance our understanding of social, behavioral, clinical and health services factors that can directly and demonstrably contribute to the improvement in minority health and the elimination of health disparities.\\n    \\n This variable defines that we need to start a new row.\"),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Key Dates'}, page_content='PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Key Dates PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Key Dates\\n    \\n \\n \\n   Posted Date\\n   January 08, 2025\\n    \\n \\n   Open Date (Earliest Submission Date)\\n   January 05, 2024\\n    \\n \\n   Letter of Intent Due Date(s)\\n    \\n    Thirty (30) days before the application submission deadline.\\n    \\n This variable defines that we need to start a new row.  \\n \\n \\n   The following table includes NIH\\n    \\n    standard due dates\\n    \\n   marked with an asterisk.\\n    \\n \\n \\n \\n       Application Due Dates\\n       \\n \\n       Review and Award Cycles\\n       \\n \\n \\n \\n       New\\n       \\n \\n       Renewal / Resubmission / Revision (as allowed)\\n       \\n \\n       AIDS - New/Renewal/Resubmission/Revision, as allowed\\n       \\n \\n       Scientific Merit Review\\n       \\n \\n       Advisory Council Review\\n       \\n \\n       Earliest Start Date\\n       \\n \\n \\n \\n \\n \\n       February 05, 2025  *\\n       \\n \\n       March 05, 2025 *\\n       \\n \\n       May 07, 2025 *\\n       \\n \\n       July 2025\\n       \\n \\n       October 2025\\n       \\n \\n       December 2025\\n       \\n \\n \\n \\n       June 05, 2025  *\\n       \\n \\n       July 05, 2025 *\\n       \\n \\n       September 07, 2025 *\\n       \\n \\n       November 2025\\n       \\n \\n       January 2026\\n       \\n \\n       April 2026\\n       \\n \\n \\n \\n       October 05, 2025  *\\n       \\n \\n       November 05, 2025 *\\n       \\n \\n       January 07, 2026 *\\n       \\n \\n       March 2026\\n       \\n \\n       May 2026\\n       \\n \\n       July 2026\\n       \\n \\n \\n \\n       February 05, 2026  *\\n       \\n \\n       March 05, 2026 *\\n       \\n \\n       May 07, 2026 *\\n       \\n \\n       July 2026\\n       \\n \\n       October 2026\\n       \\n \\n       December 2026\\n       \\n \\n \\n \\n       June 05, 2026  *\\n       \\n \\n       July 05, 2026 *\\n       \\n \\n       September 07, 2026 *\\n       \\n \\n       November 2026\\n       \\n \\n       January 2027\\n       \\n \\n       April 2027\\n       \\n \\n \\n \\n       October 05, 2026  *\\n       \\n \\n       November 05, 2026 *\\n       \\n \\n       January 07, 2027 *\\n       \\n \\n       March 2027\\n       \\n \\n       May 2027\\n       \\n \\n       July 2027\\n       \\n \\n \\n \\n \\n \\n \\n    All applications are due by 5:00 PM local time of applicant organization.\\n    \\n \\n    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.\\n    \\n \\n \\n \\n    No late applications will be accepted for this Notice of Funding Opportunity (NOFO).\\n    \\n \\n \\n   Expiration Date\\n   January 08, 2027\\n    \\n \\n   Due Dates for E.O. 12372\\n    \\n    Not Applicable\\n    \\n This variable defines that we need to start a new row.  \\n \\n \\n   Required Application Instructions\\n    \\n    It is critical that applicants follow the instructions in the Research (R) Instructions in the\\n     \\n     How to Apply - Application Guide\\n     \\n    , except where instructed to do otherwise (in this NOFO or in a Notice from\\n     \\n     NIH Guide for Grants and Contracts\\n     \\n    ).\\n    \\n \\n    Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.\\n    \\n \\n \\n     Applications that do not comply with these instructions may be delayed or not accepted for review.\\n     \\n \\n \\n    .assist_button {    background-color: #4CAF50; /* Green */    border: none;    color: white;    padding: 8px 16px;    text-align: center;    text-decoration: none;    display: inline-block;    font-size: 14px;}.important {color: #F00;font-weight: bold;font-size 14px;}\\n    \\n \\n    There are several options available to submit your application through Grants.gov to NIH and             Department of Health and Human Services partners. You\\n     \\n     must\\n     \\n    use one of these submission             options to access the application forms for this opportunity.\\n    \\n \\n \\n     Use the NIH ASSIST system to prepare, submit and track your application online.\\n      \\n \\n \\n \\n \\n     Use an institutional system-to-system (S2S) solution to prepare and submit your application             to Grants.gov and\\n      \\n      eRA Commons\\n      \\n     to track your             application. Check with your institutional officials regarding availability.\\n      \\n \\n \\n \\n     Use\\n      \\n      Grants.gov\\n      \\n     Workspace to prepare and submit your application and\\n      \\n      eRA Commons\\n      \\n     to track your application.\\n     \\n \\n \\n    Table of Contents\\n     \\n     Part 1. Overview Information\\n     \\n \\n     Key Dates\\n     \\n \\n     Part 2. Full Text of Announcement\\n     \\n \\n     Section I. Notice of Funding Opportunity Description\\n     \\n \\n     Section II. Award Information\\n     \\n \\n     Section III. Eligibility Information\\n     \\n \\n     Section IV. Application and Submission Information\\n     \\n \\n     Section V. Application Review Information\\n     \\n \\n     Section VI. Award Administration Information\\n     \\n \\n     Section VII. Agency Contacts\\n     \\n \\n     Section VIII. Other Information'),\n",
      " Document(metadata={'Header 1': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 2. Full Text of Announcement'}, page_content='PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 2. Full Text of Announcement PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 2. Full Text of Announcement'),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section I. Notice of Funding Opportunity Description'}, page_content=\"PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section I. Notice of Funding Opportunity Description PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section I. Notice of Funding Opportunity Description\\n    \\n \\n \\n \\n \\n     Key Definitions\\n     \\n \\n \\n \\n     Healthcare models\\n     \\n    refer to existing or newly proposed models of patient-centered care. Examples of existing healthcare models include the Chronic Care Model, the eHealth Enhanced Chronic Care Model, the Community-Based Transition Model, the Nurse Management Model, the Home-Based Model, the Integrated Delivery Systems Model, the Patient-Centered Model, and the Value-Based Care Models, among others.\\n    \\n \\n \\n     Multicomponent\\n     \\n    refers to frameworks with more than one component of a healthcare (e.g., healthcare system or organization, clinician decision support, clinical information system, patient self-management support, delivery system design).\\n    \\n \\n \\n     Multilevel\\n     \\n    refers to the multidimensional framework of determinants relevant to understanding minority health and addressing health disparities. This concept is further described under the NIMHD Research Framework (\\n     \\n     https://www.nimhd.nih.gov/about/overview/research-framework/\\n     \\n    ).\\n    \\n \\n \\n \\n      Background\\n      \\n \\n \\n \\n    Non-communicable and chronic diseases (NCDs) have been progressively recognized and studied in Latin America. There is notable variability in both NCDs prevalence and mortality across countries. For instance, in 2019, 81% of all-cause fatalities throughout Latin America were associated with NCDs. For example, the prevalence of diabetes is increasing throughout the region, yet has been consistently higher in Mexico and Puerto Rico, where it is also one of the five leading causes of death. Suicide and homicide are associated with a significant proportion of deaths throughout Latin America, while the burden of non-fatal interpersonal violence is also significant. COVID-19 broadly impacted Latin America, leaving behind strained healthcare systems and long-term consequences that are yet to be understood.\\n    \\n \\n    At the same time, multiple innovations have been emerging throughout Latin America that could impact the health of all Hispanic/Latino persons across the hemisphere and transcend to other populations. For example, significant breakthroughs in understanding mechanisms of premature onset Alzheimers disease (AD), clinical manifestations preceding AD and clinical phenotypes of AD in different Latin American countries have been emerging. Insights on genetic ancestry, social determinants of health and risk for Type 2 diabetes, and pharmacogenomics and dosing of anticoagulation therapy have also been described. Furthermore, the integration of various digital technologies into health care including cancer care, multidisciplinary diabetic foot care, management of diabetic retinopathy referral, and rapid assessment of retinopathy/blindness, innovative comprehensive diabetes care models (including enhanced diabetes self-management), and team-based primary care models have been successful in different settings.\\n    \\n \\n    As of 2020, 62.1 million (18.9%) persons living in the U.S. 50 States self-identified as Hispanic/Latino. Despite the cumulative evidence supporting guidelines for prevention, diagnosis, and care for many non-communicable and chronic diseases (NCDs), the prevalence, and awareness, treatment, and control goals for these conditions among U.S. Hispanics/Latinos continues being unacceptably high and needs attention. These facts also highlight the significant need for additional research on Hispanic/Latino health with a focus on effective prevention and models of healthcare.\\xa0In addition to NCDs, interpersonal violence and suicide are among the top three leading causes of death among U.S. Hispanic/Latino persons aged 15-34 years. In 2020, the previously documented longer life expectancy among the U.S. Hispanic/Latino population compared to White and Black or African American persons significantly narrowed because of the high mortality associated with COVID-19.\\n    \\n \\n    The landmark Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was initiated in 2006 and has documented differences in the prevalence of health risk factors and NCDs among U.S. Hispanic/Latino persons from different heritage groups. For example, a significantly higher prevalence of five cardiovascular risk factors and self-reported cardiovascular disease (CVD) among participants of Puerto Rican descent, and a greater prevalence of hypertension among Hispanic/Latino persons of Caribbean descent were reported compared to other Hispanic/Latino heritage populations in HCHS/SOL. People of Puerto Rican descent had a greater risk of developing chronic kidney disease (CKD), and those of Mexican, Puerto Rican and Dominican descent had a higher prevalence of diabetes compared to other Hispanic/Latino heritage populations in HCHS/SOL. In contrast, analyses at the population level have found that U.S. Hispanics/Latinos (as a group) have consistently lower all-cause, cardiovascular and cancer mortality compared to White and Black or African American persons. However, various studies have documented higher all-cause, cardiovascular and cancer mortality rates among U.S. Hispanic/Latino persons of Puerto Rican descent compared to those of Mexican or Cuban descent.\\n    \\n \\n    The U.S. Hispanic/Latino population is constituted by communities that have lived in the mainland long before it became the U.S., have immigrated to the U.S., or live in U.S. territories. Many U.S. Hispanics/Latinos maintain contact with their or their ancestors country of origin. Considering the parallel similarities and differences between U.S. Hispanic/Latino groups and among Latin American countries, bold and strategic U.S. and Latin America collaborations have strong potential to improve health outcomes and the reduction \\xa0of health disparities among these populations. Therefore, the overarching goal of this NOFO is to support innovative and collaborative research on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address\\xa0these pressing issues. Such collaborations could uncover mechanisms or mediators of previously described differences among Latin American and U.S. Hispanic/Latino populations, and further the understanding of the sociocultural, environmental, clinical care/research and healthcare contexts that cannot be understood or identified through research conducted solely in the U.S. Furthermore, such research could eventually inform future interventions to promote timely prevention, diagnosis and care for persons with NCDs more effectively across the hemisphere.\\n    \\n \\n \\n \\n      Research Objectives\\n      \\n \\n \\n \\n    This NOFO will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address\\xa0health and health care disparities related to NCDs with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos. Those NCDs include obesity, diabetes and related complications, cardiovascular and cerebrovascular diseases, hypertension, hypercholesterolemia/dyslipidemia, cancer, chronic lung disease (including asthma), chronic kidney disease, osteoarthritis, as well as chronic liver disease and cirrhosis. In addition, sleep disordered breathing, cognitive impairment and dementia, geriatric conditions and longevity, and mental and behavioral health conditions have been increasingly studied in Hispanic/Latino persons in the U.S. and throughout Latin America, yet their diagnosis is often delayed. Considering the significant incidence of both fatal and non-fatal interpersonal violence across Latin America and U.S. Hispanic/Latino communities, research in this topic is also of interest.\\xa0Although most studies on NCDs have focused on adults, some studies have highlighted the increasing prevalence of children with chronic diseases and their unique needs. Therefore, children will be included in this initiative.\\n    \\n \\n    The initiative will support the analysis of existing health care datasets and health care systems to explore health disparities within the context of clinical/health services and/or health care systems. The evaluation of existing interventions integrated into health care and/or community settings and how health equity is attained is of primary interest. The evaluation and validation of clinical/health services epidemiology metrics and measurements, especially focused on quality of clinical data from underrepresented groups, including Indigenous and Afro-Latino populations, and those living with low income and low resources are a priority. The evaluation of the impact of health care and/or public policies (e.g., policies addressing specific health risk factors outside the health care context, or sociopolitical policies that could impact funding and access to health care services) on community and/or patient health outcomes and health/health care disparities is\\xa0 also a priority. Such evaluation would inform research findings, and not advocate for specific policies. Studies that incorporate comparative analyses involving more than one Latin American country and/or of available data from U.S. Hispanic/Latino populations are also of interest.\\xa0Study methods could include retrospective and/or prospective data analyses (multi-component or multi-level), natural experiments, and mixed-methods studies, and other methods appropriate for the evaluation of clinical/health outcomes, interventions, health care systems, or policies.\\n    \\n \\n    Projects will include studies conducted in Latin American countries where Spanish is the main language. Studies performed in countries (including Puerto Rico) more highly represented in the U.S. Hispanic/Latino population will be prioritized. Puerto Rico would be considered both a U.S. territory and part of Latin America. Research teams are expected to include both U.S.-based and Latin America-based investigators; Puerto Rico-based teams are not required to include investigators from other U.S.-based institutions. U.S.-based institutions -including Puerto Rico-will be the award recipients, but the proportion of the budget and research activities would be significantly larger for Latin America-based institutions (in the range of 30% to U.S.-based institutions and 70% to Latin America-based institutions), \\xa0where the majority of the research is expected to be conducted. Research teams are also expected to include at least one PI or MPI from institutions in Latin America. The expectations regarding the research teams' composition are based on the ability and experience of local investigators to facilitate studies involving populations with whom they are acquainted in the geographic areas of interest, and who would have a better understanding of the health conditions, public health and healthcare needs, healthcare systems, or social determinants of health -including culture and language-in the locations where the studies will take place. Collaborations (e.g., consultative, or subject-matter expert role) with investigators or research teams from Latin American countries with low representation in the U.S. Hispanic/Latino population are welcome.\\n    \\n \\n \\n \\n      Specific Areas of Interest\\n      \\n \\n    include but are not limited to studies that:\\n    \\n \\n \\n     Explore and describe access to and utilization of health services, quality of care and associated clinical and health outcomes related to NCDs, especially among underserved populations including Indigenous, Afro-Latino, and rural and suburban communities. Special focus on factors that mediate or facilitate clinical decision-making, factors that mediate, facilitate, or disrupt the patient-clinician communication/relationship, and the role and effectiveness of different health care system/model components on quality of care are of interest.\\n     \\n \\n     Explore and describe\\n      \\n      clinical disease phenotypes\\n      \\n     (for example, unusual or newly recognized clinical manifestations) of NCDs (e.g., diabetes, hypertension, cancer, heart failure, long COVID-19, asthma, chronic obstructive pulmonary disease, chronic kidney disease, liver disease, dementia, and other neurodegenerative disorders, and other chronic diseases), leading to more accurate and timely diagnoses, tailored and effective prevention and care and/or reducing health/health care disparities.\\n     \\n \\n     Explore the risk profile and burden of\\n      \\n      interpersonal violence\\n      \\n     on health, that could lead to potential\\n      \\n      interventions.\\n      \\n \\n \\n     Evaluate\\n      \\n      emerging lessons and best practices\\n      \\n     from existing primary care models and health care settings interventions on the optimal integration of guidelines of diagnosis and care for NCDs in primary care setting. Lessons and best practices based on location (e.g., urban, rural) and resources are of interest.\\n     \\n \\n     Evaluate\\n      \\n      interventions\\n      \\n     at the clinical (including clinical trials and patient-level interventions embedded within health care settings), health care system (healthcare models, policy change, interventions in health care system's components), or community level on the optimization of health outcomes (e.g., attaining recommended goals) and the reduction of health or health care disparities.\\n     \\n \\n     Evaluate the\\n      \\n      impact of health, healthcare and/or public policies\\n      \\n     (including policies in U.S. territories) on patient-level clinical outcomes (including risk factors), healthcare systems (including models of healthcare delivery), or population-level health outcomes. The validation and/or evaluation of metrics to assess impact are encouraged. Comparisons across countries, and/or between different geographic locations (e.g., urban, suburban, rural) are also of interest.\\n     \\n \\n     Assess the\\n      \\n      conceptualization of community and the contextualization of social determinants of health (SDoH)\\n      \\n     , and how these can be optimally integrated into community-engaged research and the assessment of health/health care disparities across the region.\\n     \\n \\n     Evaluate the\\n      \\n      effective integration of social services\\n      \\n     (e.g., food security, housing, education) with\\n      \\n      healthcare\\n      \\n     and its impact on health disparities and health outcomes.\\n     \\n \\n     Assess the impact of\\n      \\n      interpersonal violence\\n      \\n     on\\n      \\n      collective mental health\\n      \\n     , and potential community-level interventions to reduce its impact on equitable health care access and optimal health care quality.\\n     \\n \\n     Explore the\\n      \\n      conceptualization of race, ethnicity,\\n      \\n     and\\n      \\n      colorism\\n      \\n     throughout Latin America and among U.S. Hispanics/Latinos, and how it relates to racism and discrimination, SDoH, health care and health outcomes to inform how to intervene to improve health outcomes.\\n     \\n \\n     Evaluate\\n      \\n      interventions or policies\\n      \\n     that address\\n      \\n      discrimination, racism, oppression, and mistreatment\\n      \\n     experienced by Indigenous, Afro-Latino, and other marginalized and underserved populations across the region and how they relate to health disparities and health outcomes.\\n     \\n \\n     Explore mechanisms\\n      \\n      underlying aging and age-related changes, resilience and protective health factors\\n      \\n     , and specifically related to\\n      \\n      mortality or longevity.\\n      \\n \\n \\n     Validate and/or evaluate metrics to better capture\\n      \\n      clinical/phenotypic data representative of diverse populations\\n      \\n     , including Indigenous and Afro-Latino populations, to improve knowledge of health disparities and to inform policy interventions.\\n     \\n \\n     Explore strategies that strengthen\\n      \\n      relationships between evidence producers and decision makers\\n      \\n     , and the resulting impact of research findings on health equity.\\n     \\n \\n     Assess\\n      \\n      health care systems\\n      \\n     effective management of\\n      \\n      public health emergencies, disasters, and other humanitarian crises\\n      \\n     . Studies that assess\\n      \\n      community vulnerability and resilience\\n      \\n     to these events are also of interest.\\n     \\n \\n     Evaluate policies that integrate a holistic health approach that recognizes the interconnection between people and the planet, including Indigenous knowledge systems.\\n     \\n \\n     Include\\n      \\n      comparative studies\\n      \\n     between communities in Latin America and U.S. Hispanics/Latinos on any of the research areas of interest described above.\\n     \\n \\n \\n \\n     Applications with the following attributes will be deemed non-responsive to this NOFO:\\n     \\n \\n \\n \\n     Research that is exclusively qualitative.\\n     \\n \\n     Studies focused on improvement on health outcomes without aiming at reaching health equity.\\n     \\n \\n     Epidemiological studies that are exclusively population-based.\\n     \\n \\n     Studies not focused on NCDs.\\n     \\n \\n     Studies in countries with low representation in the U.S. Hispanic/Latino population.\\n     \\n \\n     Applications lacking key personnel from Latin America with substantial and equitable involvement and leadership in the research activities. (Note: Applications must include at least one PI or MPI from a Latin America-based institution.)\\n     \\n \\n     Studies in Latin American countries where Spanish is not the main language.\\n     \\n \\n     Applications in which most of the work is performed by U.S.-based investigators.\\n     \\n \\n     Applications in which the proposed research team does not demonstrate strong partnerships (e.g., strong relationships with Latin American collaborators \\xa0 including policymakers, community workers and experts in implementation and others, as required in the proposed research strategy)\\n     \\n \\n     Proposals focused on training/education/career development.\\n     \\n \\n \\n \\n     Annual Grantee Meetings\\n     \\n    : Awardees will be expected to participate in an annual investigators' meeting. These meetings will provide opportunities for sharing scientific findings from the funded projects and facilitate interactions between research teams and NIH program staff members with scientific and regional expertise. Applicants should budget for the Principal Investigator(s) and at least one Latin America project member to attend the planned annual grantee meeting in person. Investigators teams (Latin American and U.S. collaborators) and NIH staff will be expected to participate in monthly teleconference calls or at other appropriate intervals. They may also be expected to participate in collaborative working groups that meet periodically by teleconference call.\\n    \\n \\n \\n     Standardization and Coordination:\\n     \\n    Funded investigators will be expected to collaborate on and report key common variables in a standardized manner. Investigators may also be asked to collaborate in the development of formative tools, approaches to dissemination, and other areas of shared investigator interest.\\n    \\n \\n    Additionally, NIMHD will hold a pre-application informational webinar for this NOFO. Date, time, and other details will be posted at:\\n     \\n     https://www.nimhd.nih.gov/news-events/conferences-events/\\n     \\n \\n \\n \\n     Information relevant to other specific Institutes/Centers/Offices:\\n     \\n \\n \\n \\n     National Cancer Institute (NCI)\\n     \\n \\n \\n \\n     NCI\\n     \\n    is committed to promoting equity in cancer prevention, diagnosis, treatment, and survivorship for all populations. Cancer health inequities are in large part attributable to social determinants of health (SDOH). However, the definitive knowledge of specific mechanisms through which SDOH shape cancer health inequities is limited, and effective strategies to mitigate harmful SDOH remain scarce.\\xa0 For this NOFO, NCI is interested in proposals that apply innovative community-engaged research approaches to surface, synthesize and integrate lived experience to inform contextual understanding of key mechanisms of SDOH influence and to identify high leverage intervention opportunities to maximize potential impact for mitigating a given cancer health inequity in Latin America.\\xa0In the context of this NOFO, lived experience refers to the engagement of individuals who have a personal understanding of the sociocultural, socioeconomic, and political contexts through direct life experience and how this context may drive cancer health disparities. Lived experience provides unique insight into patterns, common behaviors, challenges, and barriers among individuals who share similar experiences providing a deeper understanding of contextual social issues. The NCI areas of interest include, but are not limited to:\\n    \\n \\n \\n     Integration of lived experience in new frameworks to conceptualize and surface key mechanisms of SDOH influence that represent intervention opportunities.\\n     \\n \\n     Integration of lived experience to test assumptions embedded in extant frameworks for conceptualizing and targeting the key mechanisms of SDOH influence.\\n     \\n \\n     Novel methods and emerging strategies to measure and quantify lived experience across multiple contexts/sectors including changes over time.\\n     \\n \\n     Innovative approaches to model complex, dynamic changes in lived experiences and their impact on SDOH causal web.\\n     \\n \\n     Develop and validate locally appropriate language to measure and define anthropological context (e.g., individualism vs. collectivism, gender egalitarianism, power distance) to enhance the understanding of context on SDOH causal webs.\\n     \\n \\n     Proposals should meaningfully engage communities experiencing health inequities in Latin America throughout the entire research process, including at the conceptualization, implementation, and evaluation stages. In addition, proposals should\\xa0explicitly address the complex relationships between multiple SDOH drivers.\\n     \\n \\n \\n \\n     National Aging Institute (NIA)\\n     \\n \\n \\n \\n     NIA\\n     \\n    promotes genetic, biological, clinical, behavioral, social, and economic research related to aging and life course health, including research on Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD). A strategic priority of NIA is the understanding of health differences and development of strategies to improve the health status and well-being of older adult Hispanic populations in the United States and Latin America. NIA encourages comparisons between and within different countries in general aging and AD/ADRD outcomes.\\xa0NIA supports applications on the above-mentioned areas that are relevant to understanding processes of aging as they unfold over the life course or relevant to age-related diseases and health-related challenges experienced by midlife or older adults. NIA has made substantial investments to encourage cross-national research to examine how different policy, institutional, environmental, economic, and social contexts lead to different later life outcomes, including those related to AD/ADRD. NIA interests in this area include, but are not limited to, the following:\\n    \\n \\n \\n     Explore and describe access to and utilization of health services, quality of care and associated general aging and AD/ADRD outcomes, especially among underserved populations including Indigenous, Afro-Latino, and rural and suburban communities.\\n     \\n \\n     Compare and describe access to and utilization of health services, quality of care and associated general aging and AD/ADRD outcomes among Hispanic/Latino persons living in\\xa0 the United States, and countries in Latin America.\\n     \\n \\n     Identify genetic risk and protective factors for AD/ADRD that impact disease trajectory.\\n     \\n \\n     Fully reveal the genetic architecture of AD/ADRD in multiple race and ethnicity categories.\\n     \\n \\n     Determine whether cognitive/neuropsychiatric sequelae of SARS-CoV-2 infection place individuals at an increased risk of Alzheimer's disease or related dementias (ADRD).\\n     \\n \\n     In addition to considering other theories, models and/or frameworks, resea\\n      \\n      r\\n      \\n     ch is encouraged to consider\\n      \\n      NIAs Health Disparities Framework\\n      \\n \\n      (\\n      \\n \\n      https://www.nia.nih.gov/research/osp/framework\\n      \\n     ).\\n     \\n \\n \\n    In addition, the\\n     \\n     Health and Retirement Study (HRS) International Family of Studies\\n     \\n    provides nationally representative, longitudinal data for older people with multidisciplinary content for individual countries. These studies are modeled after the HRS in the U.S. Several studies have been conducted in Latin America including Mexico (\\n     \\n     Mexican Health and Aging Study\\n     \\n \\n     (MHAS)\\n     \\n    , Puerto Rico and the Dominican Republic (\\n     \\n     The Caribbean-American Dementia and Aging Study\\n     \\n    (CADAS), Brazil\\n     \\n     Brazilian Longitudinal Study\\n     \\n    (ELSI-Brazil), Costa Rica\\n     \\n     Costa Rican Longevity and Healthy Aging Study\\n     \\n    (CRELES).\\xa0 The\\n     \\n     Harmonized Cognitive Assessment Protocol\\n     \\n \\n     (HCAP)\\n     \\n    is a sub-study within the Health and Retirement Study (HRS) in the US and within some of the studies in the HRS International Family of Studies.\\xa0 The HCAP seeks to measure and understand dementia risk by collecting a carefully selected set of established cognitive and neuropsychological assessments and informant reports to better characterize cognitive function among older people. HCAP data has been collected in two Latin American countries: Mexico (\\n     \\n     Mexican Health and Aging Study: Cognitive Aging Ancillary Study\\n     \\n    (Mex-Cog)) and Chile (\\n     \\n     Chile-Cog\\n     \\n \\n     )\\n     \\n    . The\\n     \\n     Gateway to Global Aging\\n     \\n    is a free public resource that facilitates cross-national analyses using this data.\\n    \\n \\n    NIA welcomes applications that propose cross-national analyses of HRS and/or HCAP data from the US and/or countries in Latin America or analysis of data from an individual Latin American country.\\n    \\n \\n    Topics of interest include, but are not limited to:\\n    \\n \\n \\n     How do different health policy contexts influence later life health outcomes including those related to AD/ADRD among Hispanics/Latinos in the U.S. and Latin Americans?\\n     \\n \\n     How do different social contexts, including issues related to structural racism, lead to different later life health outcomes among Hispanics/Latinos in the U.S. compared to their counterparts in Latin America?\\n     \\n \\n     Are there protective factors that appear to improve later life outcomes for Hispanics/Latinos in the U.S. and/or their counterparts in Latin America?\\n     \\n \\n     What are the factors that affect the rate of aging across the lifespan, including those contributing to healthy or accelerated aging and/or prevention or slowing of common adverse age-related changes?\\n     \\n \\n \\n \\n     National Institute of Nursing Research (NINR)\\n     \\n \\n \\n    NINR supports research to solve pressing health challenges and inform practice and policy - optimizing health and advancing health equity into the future. NINR discovers solutions to health challenges through the lenses of health equity, social determinants of health, population and community health, prevention and health promotion, and systems and models of care. Drawing on the strengths of nursings holistic, contextualized perspective, core values, and broad reach, NINR funds multilevel and cross-sectoral research that examines the factors that impact health across the many settings in which nurses practice, including homes, schools, workplaces, clinics, justice settings, and the community. Observational, intervention, and implementation research are of interest.\\n    \\n \\n \\n     Office of Research in Women's Health (ORWH)\\n     \\n \\n \\n \\n     ORWH\\n     \\n    is part of the Office of the Director of NIH and works in partnership with the 27 NIH Institutes and Centers to ensure that women's health research is part of the scientific framework at the NIH and is supported in the larger scientific community. To optimally improve population health, research, clinical interventions, and outreach communications must consider sex, gender, income, race and ethnicity, and geography and seek to ensure that high quality health tools, resources, therapies, etc. are acceptable and accessible to all. ORWH is interested in providing support for interdisciplinary, behavioral, clinical, and/or translational studies incorporating intersectional analyses, including women who are understudied, underrepresented, and underreported in research. Proposals seeking to understand where inequities exist and their impact on populations of women experiencing high rates of non-communicable chronic disease are of particular interest. Projects must align with at least one of the strategic goals and objectives outlined in the 2019-2023 Trans-NIH Strategic Plan for Womens Health Research.\\n    \\n \\n \\n \\n    See\\n     \\n     Section VIII. Other Information\\n     \\n    for award authorities and regulations.\"),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section II. Award Information'}, page_content='PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section II. Award Information PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section II. Award Information\\n    \\n \\n \\n   Funding Instrument\\n    \\n    Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.\\n    \\n \\n \\n   Application Types Allowed\\n   New\\n    \\n   Resubmission\\n    \\n   Revision\\n    \\n \\n \\n \\n    The\\n     \\n     OER Glossary\\n     \\n    and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.\\n    \\n \\n \\n   Clinical Trial?\\n    \\n    Not Allowed: Only accepting applications that do not propose clinical trials.\\n    \\n \\n \\n \\n \\n     Need help determining whether you are doing a clinical trial?\\n     \\n \\n \\n \\n   Funds Available and Anticipated Number of Awards\\n    \\n    The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.\\n    \\n \\n \\n   Award Budget\\n   Application budgets are not limited but need to reflect the actual needs of the proposed project.\\n    \\n \\n   Award Project Period\\n    \\n    The scope of the proposed project should determine the project period. The maximum project period is 5 years.\\n    \\n This variable defines that we need to start a new row.  \\n \\n \\n \\n    NIH grants policies as described in the\\n     \\n     NIH Grants Policy Statement\\n     \\n    will apply to the applications submitted and awards made from this NOFO.'),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section III. Eligibility Information'}, page_content='PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section III. Eligibility Information PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section III. Eligibility Information\\n    \\n \\n \\n \\n    1. Eligible Applicants\\n    \\n \\n \\n   Eligible Organizations\\n    \\n    Higher Education Institutions\\n    \\n \\n \\n     Public/State Controlled Institutions of Higher Education\\n     \\n \\n     Private Institutions of Higher Education\\n     \\n \\n \\n    The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:\\n    \\n \\n \\n     Hispanic-serving Institutions\\n     \\n \\n     Historically Black Colleges and Universities (HBCUs)\\n     \\n \\n     Tribally Controlled Colleges and Universities (TCCUs)\\n     \\n \\n     Alaska Native and Native Hawaiian Serving Institutions\\n     \\n \\n     Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)\\n     \\n \\n \\n    Nonprofits Other Than Institutions of Higher Education\\n    \\n \\n \\n     Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)\\n     \\n \\n     Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)\\n     \\n \\n \\n    For-Profit Organizations\\n    \\n \\n \\n     Small Businesses\\n     \\n \\n     For-Profit Organizations (Other than Small Businesses)\\n     \\n \\n \\n    Local Governments\\n    \\n \\n \\n     State Governments\\n     \\n \\n     County Governments\\n     \\n \\n     City or Township Governments\\n     \\n \\n     Special District Governments\\n     \\n \\n     Indian/Native American Tribal Governments (Federally Recognized)\\n     \\n \\n     Indian/Native American Tribal Governments (Other than Federally Recognized).\\n     \\n \\n \\n \\n \\n    Federal Governments\\n    \\n \\n \\n     Eligible Agencies of the Federal Government\\n     \\n \\n     U.S. Territory or Possession\\n     \\n \\n \\n \\n \\n    Other\\n    \\n \\n \\n     Independent School Districts\\n     \\n \\n     Public Housing Authorities/Indian Housing Authorities\\n     \\n \\n     Native American Tribal Organizations (other than Federally recognized tribal governments)\\n     \\n \\n     Faith-based or Community-based Organizations\\n     \\n \\n     Regional Organizations\\n     \\n \\n \\n \\n   Foreign Organizations\\n    \\n \\n \\n    Non-domestic (non-U.S.) Entities (Foreign Organizations)\\n     \\n     are not\\n     \\n    eligible to apply.\\n    \\n \\n \\n \\n    Non-domestic (non-U.S.) components of U.S. Organizations\\n     \\n     are not\\n     \\n    eligible to apply.\\n    \\n \\n \\n \\n    Foreign components, as\\n     \\n     defined in the NIH Grants Policy Statement\\n     \\n    ,\\n     \\n     are\\n     \\n    allowed.\\n    \\n \\n \\n   Required Registrations\\n    \\n \\n     Applicant Organizations\\n     \\n \\n \\n    Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference the\\n     \\n     NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\\n     \\n    for additional information.\\n    \\n \\n \\n \\n      System for Award Management (SAM) \\n      \\n     Applicants must complete and maintain an active registration,\\n      \\n      which requires renewal at least annually\\n      \\n     . The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.\\n      \\n \\n \\n        NATO Commercial and Government Entity (NCAGE) Code\\n        \\n        Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.\\n       \\n \\n       Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.\\n       \\n \\n \\n \\n \\n      eRA Commons\\n      \\n     - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their\\xa0Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.\\n     \\n \\n \\n      Grants.gov\\n      \\n      Applicants must have an active SAM registration in order to complete the Grants.gov registration.\\n     \\n \\n \\n \\n     Program Directors/Principal Investigators (PD(s)/PI(s))\\n     \\n \\n \\n    All PD(s)/PI(s) must have an eRA Commons account. \\xa0PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.\\n    \\n \\n \\n   Eligible Individuals (Program Director/Principal Investigator)\\n    \\n    Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.\\n    \\n \\n    For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply-Application Guide.\\n    \\n \\n \\n \\n    2. Cost Sharing\\n    \\n \\n    This NOFO does not require cost sharing as defined in the\\n     \\n     NIH Grants Policy Statement Section 1.2 Definition of Terms\\n     \\n    .\\n    \\n \\n \\n \\n    3. Additional Information on Eligibility\\n    \\n \\n    Number of Applications\\n    \\n \\n \\n \\n    Applicant organizations may submit more than one application, provided that each application is scientifically distinct.\\n    \\n \\n    The NIH will not accept duplicate or highly overlapping applications under review at the same time, per\\n     \\n     NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application\\n     \\n    . This means that the NIH will not accept:\\n    \\n \\n \\n     A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.\\n     \\n \\n     A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.\\n     \\n \\n     An application that has substantial overlap with another application pending appeal of initial peer review (see\\n      \\n      NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications\\n      \\n     ).'),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section IV. Application and Submission Information'}, page_content='PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section IV. Application and Submission Information PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section IV. Application and Submission Information\\n    \\n \\n \\n \\n    1. Requesting an Application Package\\n    \\n \\n    The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.\\n    \\n \\n \\n \\n    2. Content and Form of Application Submission\\n    \\n \\n    It is critical that applicants follow the instructions in the Research (R) Instructions in the\\n     \\n     How to Apply - Application Guide\\n     \\n    except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.\\n    \\n \\n \\n \\n    Letter of Intent\\n    \\n \\n    Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.\\n    \\n \\n    By the date listed in\\n     \\n     Part 1. Overview Information\\n     \\n    , prospective applicants are asked to submit a letter of intent that includes the following information:\\n    \\n \\n \\n     Descriptive title of proposed activity\\n     \\n \\n     Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)\\n     \\n \\n     Names of other key personnel\\n     \\n \\n     Participating institution(s)\\n     \\n \\n     Number and title of this funding opportunity\\n     \\n \\n \\n    The letter of intent should be sent to:\\n    \\n \\n    Larissa Avils-Santa, MD, MPH\\n     \\n    Director, Division of Clinical and Health Services Research\\n     \\n    National Institute on Minority Health and Health Disparities (NIMHD)\\n     \\n    Telephone: 301-827-6924\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n \\n \\n    Page Limitations\\n    \\n \\n    All page limitations described in the\\n     \\n     How to Apply- Application Guide\\n     \\n    and the\\n     \\n     Table of Page Limits\\n     \\n    must be followed.\\n    \\n \\n \\n   Instructions for Application Submission\\n    \\n    The following section supplements the instructions found in the\\n     \\n     How to Apply- Application Guide\\n     \\n    and should be used for preparing an application to this NOFO.\\n    \\n \\n \\n \\n    SF424(R&R) Cover\\n    \\n \\n    All instructions in the\\n     \\n \\n      How to Apply - Application Guide\\n      \\n \\n    must be followed.\\n    \\n \\n \\n \\n    SF424(R&R) Project/Performance Site Locations\\n    \\n \\n    All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n    SF424(R&R) Other Project Information\\n    \\n \\n    All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n    SF424(R&R) Senior/Key Person Profile\\n    \\n \\n    All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n    R&R or Modular Budget\\n    \\n \\n    All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n    R&R Subaward Budget\\n    \\n \\n    All instructions in the How to Apply-Application Guide must be followed.\\n    \\n \\n \\n \\n    PHS 398 Cover Page Supplement\\n    \\n \\n    All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n    PHS 398 Research Plan\\n    \\n \\n    All instructions in the How to Apply- Application Guide must be followed, with the following additional instructions:\\n    \\n \\n \\n \\n \\n     Resource Sharing Plan\\n     \\n    :\\xa0Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply- Application Guide.\\n    \\n \\n \\n \\n \\n     Research Strategy\\n     \\n    : Describe how the proposed activities at foreign sites will contribute to the knowledge that will improve minority health and/or help to reduce or eliminate health disparities in the United States.\\n    \\n \\n \\n \\n \\n     Other Plan(s):\\n     \\n \\n \\n    All instructions in the How to Apply-Application Guide must be followed, with the following additional instructions:\\n    \\n \\n \\n \\n \\n     All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.\\n     \\n \\n \\n \\n \\n \\n     Appendix:\\n     \\n    Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply- Application Guide.\\n    \\n \\n \\n     No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.\\n     \\n \\n \\n \\n \\n    PHS Human Subjects and Clinical Trials Information\\n    \\n \\n    When involving human subjects research, clinical research, and/or NIH-defined\\xa0clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply- Application Guide, with the following additional instructions:\\n    \\n \\n    If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the\\n     \\n     Study Record: PHS Human Subjects and Clinical Trials Information\\n     \\n    form or\\n     \\n     Delayed Onset Study\\n     \\n    record.\\n    \\n \\n \\n     Study Record: PHS Human Subjects and Clinical Trials Information\\n     \\n \\n \\n    All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n \\n     Delayed Onset Study\\n     \\n \\n \\n    Note:\\n     \\n     Delayed onset\\n     \\n    does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n    PHS Assignment Request Form\\n    \\n \\n    All instructions in the How to Apply- Application Guide must be followed.\\n    \\n \\n \\n \\n    3. Unique Entity Identifier and System for Award Management (SAM)\\n    \\n \\n    See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov\\n    \\n \\n \\n \\n    4. Submission Dates and Times\\n    \\n \\n    Part I.\\xa0contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or\\n     \\n     Federal holiday\\n     \\n    , the application deadline is automatically extended to the next business day.\\n    \\n \\n    Organizations must submit applications to\\n     \\n     Grants.gov\\n     \\n    (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the\\n     \\n     eRA Commons\\n     \\n    , NIHs electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. \\xa0If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the\\n     \\n     NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\\n     \\n    .\\n    \\n \\n \\n     Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.\\n     \\n \\n \\n    Information on the submission process and a definition of on-time submission are provided in the How to Apply-Application Guide.\\n    \\n \\n \\n \\n    5. Intergovernmental Review (E.O. 12372)\\n    \\n \\n    This initiative is not subject to\\n     \\n     intergovernmental review.\\n     \\n \\n \\n \\n \\n    6. Funding Restrictions\\n    \\n \\n    All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the\\n     \\n     NIH Grants Policy Statement\\n     \\n    .\\n    \\n \\n    Pre-award costs are allowable only as described in the\\n     \\n     NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.\\n     \\n \\n \\n \\n   7. Other Submission Requirements and Information\\n    \\n    Applications must be submitted electronically following the instructions described in the How to Apply Application Guide. Paper applications will not be accepted.\\n    \\n \\n    Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.\\n    \\n \\n    For assistance with your electronic application or for more information on the electronic submission process, visit\\n     \\n     How to Apply  Application Guide\\n     \\n    . If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the\\n     \\n     Dealing with System Issues\\n     \\n    guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.\\n    \\n \\n \\n     Important reminders:\\n     \\n \\n \\n    All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form\\n     \\n     .\\n     \\n    Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.\\n    \\n \\n    The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organizations profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply Application Guide.\\n    \\n \\n    See\\n     \\n     more tips\\n     \\n    for avoiding common errors.\\n    \\n \\n \\n \\n    Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.\\n    \\n \\n \\n \\n    In order to expedite review, applicants are requested to notify the NIMHD Referral Office by email at\\n     \\n     [email\\xa0protected]\\n     \\n    when the application has been submitted. Please include the NOFO number and title, PD/PI name, and title of the application.\\n    \\n \\n \\n \\n    Requests of $500,000 or more for direct costs in any year\\n    \\n \\n    Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.\\n    \\n \\n \\n   Mandatory Disclosure\\n    \\n    Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures,\\n     \\n     2 CFR 200.113\\n     \\n    and\\n     \\n     NIH Grants Policy Statement Section 4.1.35\\n     \\n    .\\n    \\n \\n    Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the\\n     \\n     HHS Office of Inspector Grant Self Disclosure Program\\n     \\n    at\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n    .\\n    \\n \\n \\n \\n    Post Submission Materials\\n    \\n \\n    Applicants are required to follow the instructions for post-submission materials, as described in\\n     \\n     the policy'),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section V. Application Review Information'}, page_content='PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section V. Application Review Information PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section V. Application Review Information\\n    \\n \\n \\n \\n    1. Criteria\\n    \\n \\n    Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the\\n     \\n     NIH mission\\n     \\n    are evaluated for scientific and technical merit through the NIH peer review system.\\n    \\n \\n \\n   Overall Impact\\n    \\n    Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following scored review criteria and additional review criteria (as applicable for the project proposed). An application does not need to be strong in all categories to be judged likely to have a major scientific impact.\\n    \\n \\n \\n   Scored Review Criteria\\n    \\n    Reviewers will consider Factors 1, 2 and 3 in the determination of scientific merit, and in providing an overall impact score. In addition, Factors 1 and 2 will each receive a separate factor score.\\n    \\n \\n \\n \\n    Factor 1. Importance of the Research (Significance and Innovation)\\n    \\n \\n \\n \\n \\n \\n        Significance\\n        \\n \\n \\n \\n \\n       Evaluate the importance of the proposed research in the context of current scientific challenges and opportunities, either for advancing knowledge within the field, or more broadly. Assess whether the application addresses an important gap in knowledge in the field, would solve a critical problem, or create a valuable conceptual or technical advance.\\n       \\n \\n       Evaluate the rationale for undertaking the study, the rigor of the scientific background for the work (e.g., prior literature and/or preliminary data) and whether the scientific background justifies the proposed study.\\n       \\n \\n \\n \\n \\n        Innovation\\n        \\n \\n \\n \\n \\n       Evaluate the extent to which innovation influences the importance of undertaking the proposed research. Note that while technical or conceptual innovation can influence the importance of the proposed research, a project that is not applying novel concepts or approaches may be of critical importance for the field.\\n       \\n \\n       Evaluate whether the proposed work applies novel concepts, methods or technologies\\xa0or uses existing concepts, methods, technologies\\xa0in novel ways, to enhance\\xa0the overall impact of the project.\\n       \\n \\n \\n \\n \\n \\n    Factor 2. Rigor and Feasibility (Approach)\\n    \\n \\n \\n \\n \\n \\n        Approach\\n        \\n \\n \\n \\n \\n       Evaluate the scientific quality of the proposed work. Evaluate the likelihood that compelling, reproducible findings will result (rigor) and assess whether the proposed studies can be done well and within the timeframes proposed (feasibility).\\n       \\n \\n \\n \\n \\n        Rigor:\\n        \\n \\n \\n \\n \\n       Evaluate the potential to produce unbiased, reproducible, robust data.\\n       \\n \\n       Evaluate the rigor of experimental design and whether appropriate controls are in place.\\n       \\n \\n       Evaluate whether the sample size is sufficient and well-justified.\\n       \\n \\n       Assess the quality of the plans for analysis, interpretation, and reporting of results.\\n       \\n \\n       Evaluate whether the investigators presented adequate plans to address relevant biological variables, such as sex or age, in the design, analysis, and reporting.\\n       \\n \\n       For applications involving human subjects or vertebrate animals, also evaluate:\\n        \\n \\n         the rigor of the intervention or study manipulation (if applicable to the study design).\\n         \\n \\n         whether outcome variables are justified.\\n         \\n \\n         whether the results will be generalizable or, in the case of a rare disease/special group, relevant to the particular subgroup.\\n         \\n \\n         whether the sample is appropriate and sufficiently diverse to address the proposed question(s).\\n         \\n \\n \\n \\n       For applications involving human subjects, including clinical trials, assess the adequacy of inclusion plans as appropriate for the scientific goals of the research. Considerations of appropriateness may include disease/condition/behavior incidence, prevalence, or population burden, population representation, and/or current state of the science.\\n       \\n \\n \\n \\n \\n        Feasibility:\\n        \\n \\n \\n \\n \\n       Evaluate whether the proposed approach is sound and achievable, including plans to address problems or new challenges that emerge in the work. For proposed studies in which feasibility may be less certain, evaluate whether the uncertainty is balanced by the potential for major advances.\\n       \\n \\n       For applications involving human subjects, including clinical trials, evaluate the adequacy and feasibility of the plan to recruit and retain an appropriately diverse population of participants. Additionally, evaluate the likelihood of successfully achieving the proposed enrollment based on age, racial, ethnic, and sex or gender categories.\\n       \\n \\n       For clinical trial applications, evaluate whether the study timeline and milestones are feasible.\\n       \\n \\n \\n \\n \\n \\n \\n        Specific to this NOFO:\\n        \\n       Evaluate whether the applicant has described how the proposed activities at foreign sites will contribute to the knowledge that will improve minority health (and especially, Hispanic/Latino health) and/or help to reduce or eliminate health disparities in the United States.\\n       \\n \\n \\n \\n    Factor 3. Expertise and Resources (Investigator(s) and Environment)\\n    \\n \\n \\n \\n \\n \\n        Investigator(s)\\n        \\n \\n \\n \\n      Evaluate whether the investigator(s) have demonstrated background, training, and expertise, as appropriate for their career stage, to conduct the proposed work. For Multiple Principal Investigator (MPI) applications, assess the quality of the leadership plan to facilitate coordination and collaboration.\\n      \\n \\n \\n \\n        Environment\\n        \\n \\n \\n \\n      Evaluate whether the institutional resources are appropriate to ensure the successful execution of the proposed work.\\n      \\n \\n \\n \\n \\n \\n   Additional Review Criteria\\n    \\n    As applicable for the project proposed, reviewers will consider the following additional items while determining scientific and technical merit, but will not give criterion scores for these items, and should consider them in providing an overall impact score.\\n    \\n \\n \\n \\n    Protections for Human Subjects\\n    \\n \\n \\n \\n      For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects; 2) adequacy of protection against risks; 3) potential benefits to the subjects and others; 4) importance of the knowledge to be gained; and 5) data and safety monitoring for clinical trials.\\n      \\n \\n      For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, evaluate: 1) the justification for the exemption; 2) human subjects involvement and characteristics; and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the\\n       \\n       Guidelines for the Review of Human Subjects\\n       \\n      .\\n      \\n \\n \\n \\n \\n    Vertebrate Animals\\n    \\n \\n \\n \\n      When the proposed research includes Vertebrate Animals, evaluate the involvement of live vertebrate animals according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. For additional information on review of the Vertebrate Animals section, please refer to the\\n       \\n       Worksheet for Review of the Vertebrate Animals Section\\n       \\n      .\\n      \\n \\n \\n \\n \\n    Biohazards\\n    \\n \\n \\n \\n      When the proposed research includes Biohazards, evaluate whether specific materials or procedures that will be used are significantly hazardous to research personnel and/or the environment, and whether adequate protection is proposed.\\n      \\n \\n \\n \\n \\n    Resubmissions\\n    \\n \\n \\n \\n      As applicable, evaluate the full application as now presented.\\n      \\n \\n \\n \\n \\n    Renewals\\n    \\n \\n \\n \\n     As applicable, evaluate the progress made in the last funding period.\\n     \\n \\n \\n \\n     Not applicable. Renewals are not included in this funding announcement.\\n     \\n \\n \\n    Revisions\\n    \\n \\n \\n \\n \\n \\n     As applicable, evaluate the appropriateness of the proposed expansion of the scope of the project.\\n     \\n \\n \\n \\n   Additional Review Considerations\\n    \\n    As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.\\n    \\n \\n \\n \\n    Authentication of Key Biological and/or Chemical Resources\\n    \\n \\n \\n \\n     For projects involving key biological and/or chemical resources, evaluate the brief plans proposed for identifying and ensuring the validity of those resources.\\n     \\n \\n \\n \\n \\n \\n     Not Applicable\\n     \\n \\n \\n    Budget and Period of Support\\n    \\n \\n \\n \\n     Evaluate whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.\\n     \\n \\n \\n \\n \\n \\n \\n    2. Review and Selection Process\\n    \\n \\n \\n \\n    Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by Center for Scientific Review, in accordance with\\n     \\n     NIH peer review policies and practices\\n     \\n    , using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.\\n    \\n \\n \\n \\n    As part of the scientific peer review, all applications will receive a written critique.\\n    \\n \\n \\n \\n    Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.\\n    \\n \\n \\n \\n    Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:\\n    \\n \\n \\n     Scientific and technical merit of the proposed project as determined by scientific peer review.\\n     \\n \\n     Availability of funds.\\n     \\n \\n     Relevance of the proposed project to program priorities.\\n     \\n \\n \\n \\n \\n    If the application is under consideration for funding, NIH will request \"just-in-time\" information from the applicant as described in the\\n     \\n     NIH Grants Policy Statement Section 2.5.1. Just-in-Time Procedures\\n     \\n    . This request is not a Notice of Award nor should it be construed to be an indicator of possible funding.\\n    \\n \\n    Prior to making an award, NIH reviews an applicants federal award history in SAM.gov to ensure sound business practices.\\xa0An applicant can review and comment on any information in the Responsibility/Qualification records available in SAM.gov. NIH will consider any comments by the applicant in the Responsibility/Qualification records in SAM.gov to ascertain the applicants integrity, business ethics, and performance record of managing Federal awards per 2 CFR Part 200.206 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.\\n    \\n \\n \\n \\n    3. Anticipated Announcement and Award Dates\\n    \\n \\n    After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the\\n     \\n     eRA Commons\\n     \\n    .\\xa0Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.\\n    \\n \\n    Information regarding the disposition of applications is available in the\\n     \\n     NIH Grants Policy Statement Section 2.4.4 Disposition of Applications\\n     \\n    .'),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section VI. Award Administration Information'}, page_content=\"PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section VI. Award Administration Information PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section VI. Award Administration Information\\n    \\n \\n \\n \\n    1. Award Notices\\n    \\n \\n    A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipients business official.\\n    \\n \\n    In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.\\n    \\n \\n    Recipients must comply with any funding restrictions described in\\n     \\n     Section IV.6. Funding Restrictions\\n     \\n    . Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk. \\xa0For more information on the Notice of Award, please refer to the\\n     \\n     NIH Grants Policy Statement Section 5. The Notice of Award\\n     \\n    and NIH Grants & Funding website, see\\n     \\n     Award Process.\\n     \\n \\n \\n \\n \\n    Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.\\n    \\n \\n \\n \\n    2. Administrative and National Policy Requirements\\n    \\n \\n    The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:\\n    \\n \\n \\n     The rules listed at\\n      \\n      2 CFR Part 200\\n      \\n     , Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.\\n     \\n \\n     All NIH grant and cooperative agreement awards include the\\n      \\n      NIH Grants Policy Statement\\n      \\n     as part of the terms and conditions in the Notice of Award (NoA). The NoA includes the requirements of this NOFO. For these terms of award, see the\\n      \\n      NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General\\n      \\n     and\\n      \\n      Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities\\n      \\n     .\\n     \\n \\n     If a recipient receives an award, the recipient must follow all applicable nondiscrimination laws. The recipient agrees to this when registering in SAM.gov. The recipient must also submit an Assurance of Compliance (\\n      \\n      HHS-690\\n      \\n     ). To learn more, see the\\n      \\n      Laws and Regulations Enforced by the\\xa0HHS Office for Civil Rights website\\n      \\n     .\\n      \\n \\n       HHS recognizes that NIH research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigators scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.\\n       \\n \\n \\n \\n \\n    All federal statutes and regulations relevant to federal financial assistance, including those highlighted in\\n     \\n     NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.\\n     \\n \\n \\n    Recipients are responsible for ensuring that their activities comply with all applicable federal regulations.\\xa0 NIH may terminate awards under certain circumstances.\\xa0 See\\n     \\n     2 CFR Part 200.340 Termination\\n     \\n    and\\n     \\n     NIH Grants Policy Statement Section 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support\\n     \\n    .\\n    \\n \\n    Successful recipients under this NOFO agree that:\\n    \\n \\n    Where the award funding involves implementing, acquiring, or upgrading health IT for activities by any funded entity, recipients and subrecipient(s) are required to: Use health IT that meets standards and implementation specifications adopted in 45 CFR part 170, Subpart B, if such standards and implementation specifications can support the activity.\\xa0 Visit\\n     \\n     https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B\\n     \\n    to learn more.\\n    \\n \\n    Where the award funding involves implementing, acquiring, or upgrading health IT for activities by eligible clinicians in ambulatory settings, or hospitals, eligible under Sections 4101, 4102, and 4201 of the HITECH Act, use health IT certified under the ONC Health IT Certification Program if certified technology can support the activity. Visit\\n     \\n     https://www.healthit.gov/topic/certification-ehrs/certification-health-it\\n     \\n    to learn more.\\n    \\n \\n    Pursuant to the Cybersecurity Act of 2015, Div. N,  405, Pub. Law 114-113, 6 USC  1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.\\n    \\n \\n    Successful recipients under this NOFO agree that:\\n    \\n \\n    When recipients, subrecipients, or third-party entities have:\\n    \\n \\n \\n     ongoing and consistent access to HHS owned or operated information or operational technology systems; and\\n     \\n \\n     receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.\\n     \\n \\n \\n    Recipients shall develop plans and procedures, modeled after the\\n     \\n     NIST Cybersecurity framework\\n     \\n    , to protect HHS systems and data. Please refer to\\n     \\n     NIH Post-Award Monitoring and Reporting\\n     \\n    for additional information.\\n    \\n \\n \\n   Cooperative Agreement Terms and Conditions of Award\\n    \\n    Not Applicable\\n    \\n \\n \\n   3. Data Management and Sharing\\n    \\n    Consistent with the 2023 NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the\\n     \\n     NIH Grants Policy Statement\\n     \\n    . Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.\\n    \\n \\n \\n \\n    4. Reporting\\n    \\n \\n    When multiple years are involved, recipients will be required to submit the\\n     \\n     Research Performance Progress Report (RPPR)\\n     \\n    annually and financial statements as required in the\\n     \\n     NIH Grants Policy Statement Section 8.4.1 Reporting.\\n     \\n    To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see\\n     \\n     Post-Award Monitoring and Reporting\\n     \\n    .\\n    \\n \\n \\n \\n    A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the\\n     \\n     NIH Grants Policy Statement Section 8.6 Closeout\\n     \\n    . NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.\"),\n",
      " Document(metadata={'Header 2': 'PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section VII. Agency Contacts'}, page_content=\"PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section VII. Agency Contacts PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Section VII. Agency Contacts\\n    \\n \\n \\n \\n    We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.\\n    \\n \\n \\n   Application Submission Contacts\\n    \\n    eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten\\xa0submission by the due date, and post-submission issues)\\n    \\n \\n    Finding Help Online:\\n     \\n     https://www.era.nih.gov/need-help\\n     \\n    (preferred method of contact)\\n     \\n    Telephone: 301-402-7469 or 866-504-9552 (Toll Free)\\n    \\n \\n    General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n    (preferred method of contact)\\n     \\n    Telephone: 301-480-7075\\n    \\n \\n    Grants.gov Customer Support\\xa0(Questions regarding Grants.gov registration and Workspace)\\n     \\n    Contact Center Telephone: 800-518-4726\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n \\n   Scientific/Research Contact(s)\\n    \\n    Larissa Avils-Santa, MD, MPH\\n     \\n    Director, Division of Clinical and Health Services Research\\n     \\n    National Institute on Minority Health and Health Disparities (NIMHD)\\n     \\n    Telephone: 301-827-6924\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n \\n \\n    Frank Bandiera, Ph.D.\\n     \\n    NATIONAL INSTITUTE ON AGING (NIA)\\n     \\n    Phone: 301-496-3131\\n     \\n    E-mail:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n    Hiroko Iida, DDS, MPH\\n     \\n    NIDCR - NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH\\n     \\n    Phone: 301-594-7404\\n     \\n    E-mail:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n    Randiak Alaro\\n     \\n    National Cancer Institute (NCI)\\n     \\n    Telephone: 240-660-1036\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n    Annina Catherine Burns, PhD, RD\\n     \\n    ORWH - Office of Research on Women's Health\\n     \\n    Phone: none\\n     \\n    E-mail:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n    Leigh A. Willis, PhD, MPH\\n     \\n    National Institute of Nursing Research (NINR)\\n     \\n    Telephone: 240-687-1634\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n \\n \\n   Peer Review Contact(s)\\n    \\n    Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).\\n    \\n \\n \\n   Financial/Grants Management Contact(s)\\n    \\n    Priscilla Grant, JD\\n     \\n    Chief Grants Management Officer\\n     \\n    National Institute on Minority Health and Health Disparities (NIMHD)\\n     \\n    Telephone: 301-594-8412\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n \\n \\n    Ryan Blakeney\\n     \\n    NATIONAL INSTITUTE ON AGING (NIA)\\n     \\n    Phone: 301-451-9802\\n     \\n    E-mail:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n    Gabriel Hidalgo, MBA\\n     \\n    NIDCR - NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH\\n     \\n    Phone: 301-827-4630\\n     \\n    E-mail:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n    Crystal Wolfrey\\n     \\n    National Cancer Institute (NCI)\\n     \\n    Telephone: 240-276-6277\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\\n      \\n \\n \\n \\n    Jenna Briggs\\n     \\n    National Institute of Nursing Research (NINR)\\n     \\n    Telephone: 301-480-0639\\n     \\n    Email:\\n     \\n \\n      [email\\xa0protected]\")]\n"
     ]
    }
   ],
   "source": [
    "pprint.pprint(opportunities[0:10])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 1. Overview Information PAR-25-377: Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Part 1. Overview Information\\n    \\n \\n \\n   Participating Organization(s)\\n    \\n    National Institutes of Health (\\n     \\n     NIH\\n     \\n    )\\n    \\n \\n \\n   Components of Participating Organizations\\n    \\n    National Institute on Minority Health and Health Disparities (\\n     \\n     NIMHD\\n     \\n    )\\n     \\n \\n     National Institute on Aging (\\n      \\n      NIA\\n      \\n     )\\n     \\n \\n     National Institute of Dental and Craniofacial Research (\\n      \\n      NIDCR\\n      \\n     )\\n     \\n \\n     National Institute of Nursing Research (\\n      \\n      NINR\\n      \\n     )\\n     \\n \\n     National Cancer Institute (\\n      \\n      NCI\\n      \\n     )\\n     \\n \\n     All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.\\n     \\n \\n     Office of Research on Women's Health (\\n      \\n      ORWH\\n      \\n     )\\n     \\n \\n \\n   Funding Opportunity Title\\n    \\n    Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed)\\n    \\n \\n \\n   Activity Code\\n    \\n \\n     R01\\n     \\n    Research Project Grant\\n    \\n \\n \\n   Announcement Type\\n   Reissue of\\n    \\n    PAR-23-303\\n    \\n \\n \\n \\n   Related Notices\\n    \\n \\n \\n      April 4, 2024\\n      \\n     - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice\\n      \\n      NOT-OD-24-084\\n      \\n     .\\n     \\n \\n \\n      August 31, 2022\\n      \\n     - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice\\n      \\n      NOT-OD-22-198\\n      \\n     .\\n     \\n \\n \\n      August 5, 2022\\n      \\n     - Implementation Details for the NIH Data Management and Sharing Policy. See Notice\\n      \\n      NOT-OD-22-189\\n      \\n     .\\n     \\n \\n \\n \\n   Funding Opportunity Number (FON)\\n    \\n    PAR-25-377\\n    \\n \\n \\n   Companion Funding Opportunity\\n   None\\n    \\n \\n   Number of Applications\\n    \\n    See Section III. 3. Additional Information on Eligibility.\\n    \\n \\n \\n   Assistance Listing Number(s)\\n   93.307, 93.866, 93.361, 93.313, 93.121, 93.393\\n    \\n \\n   Funding Opportunity Purpose\\n    \\n    This Notice of Funding Opportunity (NOFO) is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025.\\n    \\n \\n    This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address\\xa0health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.\\n    \\n \\n \\n   Funding Opportunity Goal(s)\\n    \\n    Objectives: \\xa0Through R01-funded projects, this funding announcement aims at supporting \\xa0innovative projects to enhance our understanding of social, behavioral, clinical and health services factors that can directly and demonstrably contribute to the improvement in minority health and the elimination of health disparities.\\n    \\n This variable defines that we need to start a new row.\""
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "opportunities[0].page_content"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Clean Up HTML Files"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_up_html_files(directory_path):\n",
    "    # Iterate over each file in the directory\n",
    "    for filename in os.listdir(directory_path):\n",
    "        # Check if the file is an HTML file\n",
    "        if fnmatch.fnmatch(filename, '*.html'):\n",
    "            file_path = os.path.join(directory_path, filename)\n",
    "            # Delete the HTML file\n",
    "            os.remove(file_path)\n",
    "            print(f\"Deleted file: {file_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Deleted file: data/Opportunities/RFA-AI-24-079.html\n",
      "Deleted file: data/Opportunities/RFA-DK-26-007.html\n",
      "Deleted file: data/Opportunities/RFA-FD-25-007.html\n",
      "Deleted file: data/Opportunities/RFA-HL-26-009.html\n",
      "Deleted file: data/Opportunities/PAR-25-353.html\n",
      "Deleted file: data/Opportunities/RFA-HL-26-011.html\n",
      "Deleted file: data/Opportunities/RFA-HL-26-010.html\n",
      "Deleted file: data/Opportunities/PAR-25-352.html\n",
      "Deleted file: data/Opportunities/PAR-25-379.html\n",
      "Deleted file: data/Opportunities/PAR-25-378.html\n",
      "Deleted file: data/Opportunities/RFA-DK-26-009.html\n"
     ]
    }
   ],
   "source": [
    "# Path to the directory containing HTML files\n",
    "directory_path = \"data/Opportunities\"\n",
    "\n",
    "clean_up_html_files(directory_path)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Projects\n",
    "Reference: https://python.langchain.com/v0.2/docs/how_to/document_loader_json/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 1}, page_content='{\"appl_id\": 10985653, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1K23HD113825-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K23\", \"award_amount\": 167455, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K23\", \"ic_code\": \"HD\", \"serial_num\": \"113825\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 12163589, \"first_name\": \"Kristina\", \"middle_name\": \"Irene\", \"last_name\": \"Suorsa-Johnson\", \"is_contact_pi\": true, \"full_name\": \"Kristina Irene Suorsa-Johnson\", \"title\": \"\"}], \"contact_pi_name\": \"SUORSA-JOHNSON, KRISTINA IRENE\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 167455, \"direct_cost_ic\": 155051, \"indirect_cost_ic\": 12404}], \"project_start_date\": \"2024-09-18T12:09:00Z\", \"project_end_date\": \"2029-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-206\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": \"M\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Health, Behavior, and Context Study Section[CHHD-M]\"}, \"award_notice_date\": \"2024-09-18T12:09:00Z\", \"core_project_num\": \"K23HD113825\", \"terms\": \"<0-11 years old><Address><Adolescent and Young Adult><Anatomic Sites><Anatomic structures><Anatomy><Award><Care Givers><Caregivers><Caring><Child><Child Youth><Childhood><Children (0-21)><Clinic><Clinic Visits><Clinical><Clinical Management><Clinical Trials><Code><Coding System><Collaborations><Conflict><Conflict (Psychology)><Data><Decision Aid><Decision Making><Dedications><Development><Differences of sex development><Doctor of Philosophy><Education><Education and Training><Educational Materials><Educational aspects><Elements><Ensure><Exercise><Feedback><Funding><Future><Gender and Sexual Minorities><Genital Organs><Genitalia><Genitourinary><Genitourinary Surgery><Genitourinary system><Goals><Health><Health Care Providers><Health Instruction><Health Personnel><Health Tutoring><Health education><Healthcare Providers><Healthcare worker><Infant><International><Intervention><Intervention Strategies><Interview><Investigators><Jordan><K23 Award><K23 Mechanism><K23 Program><Knowledge><Leadership><Licensing><Life><Lived experience><Lived experiences><Medical><Mentored Patient-Oriented Research Career Development Award><Mentored Patient-Oriented Research Career Development Award (K23)><Mentors><Methods><Modeling><NICHD><NIH><National Institute of Child Health and Human Development><National Institute of Children\\'s Health and Human Development><National Institutes of Health><Nature><Operative Procedures><Operative Surgical Procedures><Outcome><Outcome Measure><Participant><Patients><Perception><Persons><Ph.D.><PhD><Population><Process><Provider><Psychologist><Randomized><Randomized, Controlled Trials><Recommendation><Registries><Research><Research Personnel><Research Resources><Research Training><Researchers><Resources><Risk><Sexual Development><Sexual Health><Sexual and Gender Minorities><Site><Standardization><Surgical><Surgical Interventions><Surgical Procedure><Survey Instrument><Surveys><Techniques><Testing><Training Programs><Training and Education><Translational Research><Translational Science><United States National Institutes of Health><Urogenital><Urogenital Surgery><Urogenital Surgical Procedures><Urogenital System><Work><acceptability and feasibility><care as usual><career><career development><child patients><community advisory board><community advisory committee><community advisory panel><design><designing><developmental><disorder of sexual development><dissemination science><evidence base><health care personnel><health care worker><health provider><health workforce><healthcare personnel><implementation science><improved><innovate><innovation><innovative><interventional strategy><kids><measurable outcome><medical personnel><multi-site trial><multisite trial><outcome measurement><participant engagement><patient engagement><pediatric><pediatric health outcomes><pediatric patients><physical conditioning><physical health><pilot test><pilot trial><preference><psychosocial><psychosocial outcome><psychosocial sequelae><randomisation><randomization><randomized control trial><randomly assigned><recruit><reproductive><sex development><sex development disorder><shared decision making><skills><standardized care><success><support tools><surgery><tool><translation research><translational investigation><treatment as usual><treatment provider><trial design><user centered design><usual care><youngster>\", \"pref_terms\": \"Address;Adolescent and Young Adult;Anatomy;Award;Caregivers;Caring;Child;Childhood;Clinic;Clinic Visits;Clinical;Clinical Management;Clinical Trials;Code;Collaborations;Conflict (Psychology);Data;Decision Aid;Decision Making;Dedications;Development;Doctor of Philosophy;Education;Educational Materials;Elements;Ensure;Exercise;Feedback;Funding;Future;Genitalia;Genitourinary system;Goals;Health;Health Personnel;Health education;Infant;International;Intervention;Interview;Jordan;Knowledge;Leadership;Licensing;Life;Lived experience;Medical;Mentored Patient-Oriented Research Career Development Award;Mentors;Methods;Modeling;National Institute of Child Health and Human Development;Nature;Operative Surgical Procedures;Outcome;Outcome Measure;Participant;Patients;Perception;Persons;Population;Process;Provider;Psychologist;Randomized;Randomized, Controlled Trials;Recommendation;Registries;Research;Research Personnel;Research Training;Resources;Risk;Sexual Development;Sexual Health;Sexual and Gender Minorities;Site;Standardization;Surveys;Techniques;Testing;Training Programs;Training and Education;Translational Research;United States National Institutes of Health;Urogenital Surgical Procedures;Work;acceptability and feasibility;career;career development;community advisory board;design;dissemination science;evidence base;implementation science;improved;innovation;multi-site trial;patient engagement;pediatric health outcomes;pediatric patients;physical conditioning;pilot test;pilot trial;preference;psychosocial;psychosocial outcome;recruit;reproductive;sex development disorder;shared decision making;skills;standardized care;success;support tools;tool;treatment as usual;trial design;user centered design\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThe proposed 5-year K23 award describes a research training program for Kristina Suorsa-Johnson, PhD, a\\\\nlicensed pediatric psychologist who specializes in differences of sex development (DSD). Her overarching\\\\ncareer goal is to become an independently funded investigator focused on improving the psychosocial and\\\\nhealth outcomes of pediatric patients with DSD by creating tools to facilitate patient engagement in medical\\\\ndecision making through shared decision making (SDM). This award provides support for Dr. Suorsa-Johnson\\\\nto achieve the following Career Development Aims: Aim 1: Obtain expertise in SDM, including the\\\\ndevelopment of decision aids (DAs) for adolescents and young adults (AYAs); Aim 2: Gain sexual health\\\\neducation training, particularly as it relates to the creation of educational materials to enhance surgical SDM;\\\\nAim 3: Develop expertise in evaluating and implementing DAs; and Aim 4: Expand and strengthen research\\\\nleadership and management skills. To achieve these goals, Dr. Suorsa-Johnson has assembled a dedicated\\\\nteam of mentors and advisors with expertise in SDM (Angela Fagerlin, PhD), SDM in AYAs (Ellen Lipstein,\\\\nMD), sexual health education (Jordan Rullo, PhD), dissemination and implementation science (Jennie Hill,\\\\nPhD), qualitative design and clinical trials (Melissa Watt, PhD and Angela Fagerlin, PhD), multi-site trial design\\\\n(Gregory Stoddard, MBA, MPH), urogenital/gonadal surgeries in AYAs (Kathleen van Leeuwen, PhD), and\\\\nDSD education (David Sandberg, PhD and Erica Weidler, MEd, MS). A person with lived experience, Noi\\\\nLiang, MBA, MCPA, is consulting to ensure all aspects of the project align with the needs of those with DSD.\\\\nDSD are congenital conditions where chromosomal, gonadal, or anatomical sex development is atypical. AYAs\\\\nwith DSD make critical and potentially irreversible, life-altering urogenital/gonadal surgical decisions. However,\\\\nwe know little about how AYAs approach surgical decision making and no standardized SDM resources exist.\\\\nAs such, Dr. Suorsa-Johnson proposes to create and pilot a set of surgical DAs for AYAs with DSD. This will\\\\nbe achieved through three Specific Aims: Aim 1: Identify informational needs and values influencing surgical\\\\ndecision making for AYAs with DSD; Aim 2: Develop a set of evidence-based DAs for surgical decisions to\\\\nfacilitate SDM for AYAs and their caregivers; and Aim 3: Pilot test and refine DA content, delivery, and\\\\nfeasibility. This project will result in a set of surgical decision aids ready to be tested in a multi-site trial.\\\\nThis project is significant because it will change how we provide care and improve engagement in surgical\\\\ndecision making for this underserved, NIH-designated sexual and gender minority subpopulation. This\\\\ninnovative project is the first to explore the needs of AYAs with DSD making surgical decisions from a SDM\\\\nframework and create associated decision support tools.\", \"project_title\": \"Adolescents and Young Adults: Dilemmas, Education, and Choices Impacting Decisions (AYAs DECIDe) Study\", \"phr_text\": \"PROJECT NARRATIVE\\\\nAdolescents and young adults with differences of sex development make critical and potentially irreversible,\\\\nlife-altering surgical decisions about their bodies without standardized resources to support their engagement\\\\nin shared decision making. To fill this gap, the proposed research will examine the decisional needs of\\\\nadolescents and young adults with differences of sex development, as well as develop and pilot a set of\\\\nsurgical decision aids addressing identified needs. Standardized decision aid use will promote adolescent and\\\\nyoung adult engagement in shared decision making, leading to improved care, patient health, and\\\\npsychosocial outcomes.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-18T12:09:00Z\", \"budget_end\": \"2025-06-30T12:06:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 155051, \"indirect_cost_amt\": 12404, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10985653\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 2}, page_content='{\"appl_id\": 11088654, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"3U24TR004315-03S1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"3\", \"activity_code\": \"U24\", \"award_amount\": 797002, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"3\", \"activity_code\": \"U24\", \"ic_code\": \"TR\", \"serial_num\": \"004315\", \"support_year\": \"03\", \"full_support_year\": \"03S1\", \"suffix_code\": \"S1\"}, \"principal_investigators\": [{\"profile_id\": 10458455, \"first_name\": \"Jamie\", \"middle_name\": \"P.\", \"last_name\": \"Dwyer\", \"is_contact_pi\": false, \"full_name\": \"Jamie P. Dwyer\", \"title\": \"PROFESSOR OF MEDICINE\"}, {\"profile_id\": 9256467, \"first_name\": \"KATHERINE\", \"middle_name\": \"ANN\", \"last_name\": \"SWARD\", \"is_contact_pi\": false, \"full_name\": \"KATHERINE ANN SWARD\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 797002, \"direct_cost_ic\": 517534, \"indirect_cost_ic\": 279468}], \"project_start_date\": \"2024-09-01T12:09:00Z\", \"project_end_date\": \"2027-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-272\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"01\", \"name\": \"ZTR1(01)\"}, \"award_notice_date\": \"2024-09-04T12:09:00Z\", \"core_project_num\": \"U24TR004315\", \"terms\": \"<Acute pain management><Administrative Supplement><Clinical Trials><Clinical Trials Data Monitoring Committees><Clinical Trials Network><Collaborations><Collection><Common Data Element><Data><Data Analyses><Data Analysis><Data Bases><Data Collection><Data Monitoring Committees><Data Set><Data and Safety Monitoring Boards><Databases><Deposit><Deposition><Development><Dose><HEAL Initiative><Helping End Addiction Long-term><Helping End Addiction Longterm><Helping to End Addiction Long-term><Helping to End Addiction Longterm><IRB><IRBs><Institutional Review Boards><Investigators><Leadership><Monitor><NIH><National Institutes of Health><Opiate Addiction><Opiate Dependence><Opiates><Opioid><Pain><Pain Control><Pain Therapy><Pain management><Painful><Preparation><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Randomized><Regimen><Reporting><Research Personnel><Research Resources><Researchers><Resources><Risk Assessment><Risk Reduction><Safety Monitoring Boards><Scientific Publication><Speed><System><Training><Translational Research><Translational Science><United States National Institutes of Health><Universities><Utah><Work><Writing><addiction><addictive disorder><chronic pain><comparative effectiveness trial><cost><data base><data ecosystem><data interpretation><data management><data sharing><data sharing ecosystem><depository><design><designing><developmental><effectiveness research><opioid addiction><opioid dependence><opioid dependent><pain treatment><preparations><prevention effectiveness trial><programs><randomisation><randomization><randomly assigned><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><repository><risk-reducing><success><translation research><translational investigation>\", \"pref_terms\": \"Acute pain management;Administrative Supplement;Clinical Trials;Clinical Trials Data Monitoring Committees;Clinical Trials Network;Collaborations;Collection;Common Data Element;Data;Data Analyses;Data Collection;Data Set;Databases;Deposition;Development;Dose;Helping to End Addiction Long-term;Institutional Review Boards;Leadership;Monitor;Opiate Addiction;Opioid;Pain;Pain management;Preparation;Protocols documentation;Public Health;Publications;Quality Control;Randomized;Regimen;Reporting;Research Personnel;Resources;Risk Assessment;Risk Reduction;Speed;System;Training;Translational Research;United States National Institutes of Health;Universities;Utah;Work;Writing;addiction;chronic pain;comparative effectiveness trial;cost;data ecosystem;data management;data sharing;design;effectiveness research;prevention effectiveness trial;programs;repository;success\", \"abstract_text\": \"Abstract\\\\nThe NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scientic solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. Five ERN trials have been implemented with data coordination support from the\\\\nUniversity of Utah Data Coordinating Resource Center. This proposal is written to provide continued support for\\\\nthree of these trials that are expected to require no-cost extensions. As the Data Coordination Resource Center,\\\\nwe will continue to work collaboratively with each ERN study team and the other HEAL ERN Resource Centers\\\\nto 1) develop, implement and monitor the ERN trials; 2) help respond to issues/protocol changes that emerge\\\\nduring trial implementation and initiate timely necessary changes to assure trial success; 3) provide collection\\\\nand analysis of data; and 4) assist with timely publication of study results. Our supplement application has two\\\\nSpecic Aims: Specifc Aim 1: Work with ERN investigators and other HEAL ERN Resource Centers to provide\\\\ncollaborative clinical trial expertise and assistance in study and protocol design, single IRB, study implementation\\\\nand management, accrual of subjects, interim study reporting, nal study analyses, and assistance with timely\\\\npublication and dissemination of study results. Specific Aim 2: Provide comprehensive data management for\\\\ncurrent and new ERN trials, including database and data collection systems, data management plans, data\\\\nrisk assessment and quality control, implementation of randomization, assistance with Data Safety Monitoring\\\\nBoard (DSMB) reports, and training for using the data collection systems. Additionally, we will facilitate sharing\\\\nof data from HEAL/ERN trials by incorporating HEAL Common Data Elements(CDEs) into protocols, continuing\\\\nto support NIH program staff in development of HEAL CDEs, continued participation in the HEAL Collective\\\\nBoard, and preparation of nal data sets suitable for deposit in NIH-designated repositories for incorporation into\\\\nthe HEAL Data Ecosystem. Our continued collaboration with ERN investigators and integration with the other\\\\nResource Centers will maximize the likelihood of successful and timely completion of the HEAL ERN clinical\\\\ntrials, leading to translation of research ndings to the effective management of acute and chronic pain, while\\\\nminimizing addictive opioid dosing regimens.\", \"project_title\": \"HEAL ERN: Data Coordinating Resource Center\", \"phr_text\": \"Narrative\\\\nThe NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scientic solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. The University of Utah will provide data coordination support for these trials, leading to\\\\nmore effective management of acute and chronic pain while reducing the risk of opioid addiction.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 517534, \"indirect_cost_amt\": 279468, \"project_detail_url\": \"https://reporter.nih.gov/project-details/11088654\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 3}, page_content='{\"appl_id\": 10787066, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1R21HD113931-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R21\", \"award_amount\": 253167, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R21\", \"ic_code\": \"HD\", \"serial_num\": \"113931\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 6593835, \"first_name\": \"Gerard\", \"middle_name\": \"Thomas\", \"last_name\": \"Berry\", \"is_contact_pi\": false, \"full_name\": \"Gerard Thomas Berry\", \"title\": \"\"}, {\"profile_id\": 7717532, \"first_name\": \"Kent\", \"middle_name\": \"\", \"last_name\": \"Lai\", \"is_contact_pi\": true, \"full_name\": \"Kent  Lai\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 78415525, \"first_name\": \"Estela\", \"middle_name\": \"\", \"last_name\": \"Rubio-Gozalbo\", \"is_contact_pi\": false, \"full_name\": \"Estela  Rubio-Gozalbo\", \"title\": \"\"}], \"contact_pi_name\": \"LAI, KENT \", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 253167, \"direct_cost_ic\": 198635, \"indirect_cost_ic\": 54532}], \"project_start_date\": \"2024-08-23T12:08:00Z\", \"project_end_date\": \"2026-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-195\", \"full_study_section\": {\"srg_code\": \"ICER\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Integrative and Clinical Endocrinology and Reproduction Study Section[ICER]\"}, \"award_notice_date\": \"2024-08-23T12:08:00Z\", \"core_project_num\": \"R21HD113931\", \"terms\": \"<12-20 years old><AAV vector><AAV-based vector><Adolescence><Adolescent><Adolescent Youth><Adolescent and Young Adult><Affect><Alleles><Allelomorphs><Antibodies><Appearance><Applications Grants><Assay><Baby Formula><Benign><Bioassay><Biological Assay><Biopolymers><Brachydanio rerio><Brain><Brain Nervous System><Cannot achieve a pregnancy><Cell Body><Cell Function><Cell Line><Cell Physiology><Cell Process><CellLine><Cells><Cellular Function><Cellular Physiology><Cellular Process><Classic Galactosemia><Classical galactosemia><Clinical><Complementary DNA><Complex><Complication><D-Galactose><DNA Therapy><DNA delivery><Danio rerio><Data><Development><Diagnosis><Diagnostic Findings><Diet><Difficulty conceiving><Disease><Disorder><Dysfunction><Early Diagnosis><Ectopic Expression><Embryo><Embryonic><Encapsulated><Encephalon><Event><Evolution><FSH Receptors><Failure><Fecundability><Fecundity><Fertility><Fishes><Follicle Stimulating Hormone><Follicle Stimulating Hormone Receptor><Follicular Fluid><Follitropin><Functional disorder><Galactopyranose><Galactopyranoside><Galactose><Galactose Metabolism><Galactose Metabolism Pathway><Galactose-1-Phosphate Uridyl-Transferase Deficiency Disease><Galactosemias><Gametes><Gene Delivery><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Transfer Clinical><General Population><General Public><Genes><Genetic><Genetic Diseases><Genetic Intervention><Germ Cells><Germ-Line Cells><Gonadal Steroid Hormones><Grant Proposals><Hereditary><Hereditary Disease><Hereditary Metabolic Disorder><Histologic><Histologically><Histology><Hormone Receptor><Human><Human Cell Line><Image><Immunoblotting><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Impairment><Inborn Errors of Metabolism><Inborn Genetic Diseases><Infant><Infant formula><Infertility><Inherited><Inherited disorder><Life><Ligands><Liquor Folliculi><Liver><Modality><Modeling><Modern Man><Molecular><Muellerian inhibiting hormone><Mullerian-inhibiting factor><Neonatal><Neonatal Screening><Newborn Infant Screening><OMIM><Online Mendelian Inheritance In Man><Oocytes><Ovarian><Ovarian Follicle Antral Fluid><Ovary><Ovocytes><Pathogenesis><Pathogenicity><Patients><Pattern><Peptide Fragments><Physiopathology><Play><Polymers><Premature Menopause><Puberty><RNA Seq><RNA sequencing><RNAseq><RT-PCR><RTPCR><Recombinants><Reproduction><Reproductive Cells><Reverse Transcriptase Polymerase Chain Reaction><Role><Severities><Sex Cell><Sex Hormones><Sex Steroid Hormones><Signal Pathway><Signs and Symptoms><Somatic Cell><Specificity><Strains Cell Lines><Subcellular Process><System><Technology><Testing><Time><Transcript Expression Analyses><Transcript Expression Analysis><Transcription Regulation><Transcriptional Control><Transcriptional Regulation><Transfection><Tropism><UDPglucose Hexose-1-Phosphate Uridylyltransferase Deficiency><UTP Hexose-1-Phosphate Uridylyltransferase Deficiency><Variant><Variation><Western Blotting><Western Immunoblotting><Woman><Zebra Danio><Zebra Fish><Zebrafish><adeno-associated viral vector><adeno-associated virus vector><adolescence (12-20)><adult youth><analyze gene expression><anti-mullerian factor><anti-mullerian hormone><cDNA><cell type><cultured cell line><curative intervention><curative therapeutic><curative therapy><curative treatments><deliver DNA><design><designing><developmental><diet restriction><dietary><dietary restriction><diets><disease diagnosis><early detection><early menopause><experiment><experimental research><experimental study><experiments><expression vector><feasibility testing><fertility cessation><fertility loss><folliculogenesis><galactose 1 phosphate uridylyl transferase deficiency><galactose-1-phosphate><gene expression analysis><gene expression assay><gene repair therapy><gene replacement therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic condition><genetic disorder><genetic therapy><genomic therapy><gonadal steroids><granulosa cell><hepatic body system><hepatic organ system><hereditary disorder><heritable disorder><iPS><iPSC><iPSCs><imaging><in vitro testing><inborn error><inborn metabolism disorder><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent stem cell><infancy><infantile><infertile><inherited diseases><inherited genetic disease><inherited genetic disorder><initial cell><innovative technologies><insight><juvenile><juvenile human><milk formula><mullerian inhibiting substance><mullerian regression factor><mullerian-inhibiting hormone><mullerian-inhibitory substance><nano particle><nano particle delivery><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><neonatal period><neonate><newborn screening><nucleic acid therapy><nucleic acid-based therapeutics><ovarian damage><pathophysiology><pituitary gonadal axis><plasmid DNA><polymer><polymeric><postnatal><premature age of menopause><prenatal><prevent><preventing><protein blotting><restoration><restricted diet><reverse transcriptase PCR><scRNA-seq><screening program><sex steroid><sexual cell><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic nucleic acids><transcriptional profiling><transcriptome sequencing><transcriptomic sequencing><unborn><uptake><young adult><young adulthood>\", \"pref_terms\": \"Adolescence;Adolescent;Adolescent and Young Adult;Affect;Alleles;Antibodies;Appearance;Applications Grants;Benign;Biological Assay;Biopolymers;Brain;Cell Line;Cell Physiology;Cells;Classical galactosemia;Clinical;Complementary DNA;Complex;Complication;DNA delivery;Data;Development;Diagnosis;Diet;Disease;Early Diagnosis;Ectopic Expression;Embryo;Encapsulated;Event;Evolution;Failure;Fertility;Fishes;Follicle Stimulating Hormone;Follicle Stimulating Hormone Receptor;Follicular Fluid;Functional disorder;Galactose;Galactose Metabolism Pathway;Galactosemias;Gene Delivery;Gene Expression Profiling;General Population;Genes;Genetic;Genetic Diseases;Germ Cells;Gonadal Steroid Hormones;Hereditary Disease;Histologic;Histology;Hormone Receptor;Human;Human Cell Line;Image;Immunohistochemistry;Impairment;Inborn Errors of Metabolism;Infant;Infant formula;Infertility;Inherited;Life;Ligands;Liver;Modality;Modeling;Molecular;Neonatal;Neonatal Screening;Online Mendelian Inheritance In Man;Oocytes;Ovarian;Ovary;Pathogenesis;Pathogenicity;Patients;Pattern;Peptide Fragments;Play;Polymers;Premature Menopause;Puberty;Recombinants;Reproduction;Reverse Transcriptase Polymerase Chain Reaction;Role;Severities;Signal Pathway;Signs and Symptoms;Somatic Cell;Specificity;System;Technology;Testing;Time;Transcriptional Regulation;Transfection;Tropism;Variant;Western Blotting;Woman;Zebrafish;adeno-associated viral vector;cell type;curative treatments;design;dietary;dietary restriction;disease diagnosis;experimental study;expression vector;feasibility testing;folliculogenesis;galactose-1-phosphate;gene replacement therapy;gene therapy;gene-targeted therapy;granulosa cell;in vitro testing;induced pluripotent stem cell;infancy;innovative technologies;insight;mullerian-inhibiting hormone;nanoparticle;nanoparticle delivery;neonatal period;neonate;nucleic acid-based therapeutics;ovarian damage;pituitary gonadal axis;plasmid DNA;postnatal;prenatal;prevent;restoration;screening program;single-cell RNA sequencing;targeted treatment;transcriptome sequencing;uptake;young adult\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\nHereditary deficiency of galactose-1-phosphate uridylyltransferase (GALT, E.C. 2.7.7.12) activity in humans\\\\ncan lead to a potentially lethal disease called Classic Galactosemia (OMIM 230400). Despite the life-saving\\\\nconsequences of newborn screening, early diagnosis, and a galactose-restricted diet, affected women\\\\ninvariably show ovarian damage and fertility impairment representing the greatest burden of their disease.\\\\nThere are currently no satisfactory treatments available to prevent this complication. Recently, insights into\\\\nthe underlying pathophysiology and innovative technological advancements have become available, and\\\\noptions for curative treatment have emerged. Using this momentum, we aim to develop a treatment to\\\\nprevent fertility impairments. We aim to 1) develop a non-viral nucleic acid therapy approach that targets the\\\\novary and 2) determine the optimal timing to rescue the ovarian function. Folliculogenesis is driven by the\\\\ncross-talk between oocytes and granulosa cells. Restoration of GALT activity in these cells could possibly\\\\nrescue the ovarian damage.\\\\nIn this pilot grant application, we will explore a new modality of gene therapy using nanoparticles\\\\nencapsulating episomal GALT cDNA within a non-viral expression vector. This will include determination of\\\\nthe optimal cationic polymer layer for delivery of episomal DNA plasmids expressing GFP or GALT to\\\\ngranulosa cell lines and the addition of ligands to encourage uptake and promote specificity.\\\\nIn addition, we will determine the optimal window of opportunity for this treatment. A prenatal origin has been\\\\nconsidered for decades whereas the data currently available, albeit scarce, favor a postnatal origin. There is\\\\nundoubtedly early damage, but whether treatments aimed to prevent ovarian damage needs to be started in\\\\nthe neonatal period, or treating in infancy or adolescence would suffice, is not clear. This will be studied using\\\\nthe zebrafish model for classic galactosemia that mimics the fertility impairments and is suitable for studies\\\\nthrough development. Zebrafish reproduction is regulated by the brain-pituitary-gonadal axis, comparable\\\\nto the human situation. For this purpose, RNA-seq, histology/immunohistochemistry of follicole\\\\ndevelopment and single cell RNA-seq of oocytes and granulosa cells at 4 developmental stages will\\\\nbe studied. These studies will uncover developmental stage and cell-specific alterations in the affected\\\\novaries. Distinctive patterns at the different stages are expected to reveal at which stage(s) damage\\\\ncan be prevented/halted using ovary targeted gene therapy.\", \"project_title\": \"Optimal Window of Opportunity for Granulosa Cell Gene Therapy in Galactosemia\", \"phr_text\": \"PROJECT NARRATIVE\\\\n Hypergonadotropic hypoestrogenic infertility due to ovarian damage is the greatest burden for women\\\\nsuffering from hereditary Classic Galactosemia, an inborn error of metabolism included in the newborn\\\\nscreening programs. Timely diagnosis and introduction of diet have shown to be beneficial, but diet does not\\\\nprevent ovarian damage, which invariably affects women with this disease. This project aims to develop gene-\\\\nbased therapy targeted to the ovary to prevent or halt the damage cascade and determine the optimal window\\\\nof opportunity for this treatment.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-08-23T12:08:00Z\", \"budget_end\": \"2025-07-31T12:07:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 198635, \"indirect_cost_amt\": 54532, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10787066\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 4}, page_content='{\"appl_id\": 10985761, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1K23HD112591-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K23\", \"award_amount\": 167001, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K23\", \"ic_code\": \"HD\", \"serial_num\": \"112591\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 16247237, \"first_name\": \"Kathleen\", \"middle_name\": \"Marie\", \"last_name\": \"Job\", \"is_contact_pi\": true, \"full_name\": \"Kathleen Marie Job\", \"title\": \"RESEARCH ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"JOB, KATHLEEN MARIE\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 167001, \"direct_cost_ic\": 154828, \"indirect_cost_ic\": 12173}], \"project_start_date\": \"2024-07-16T12:07:00Z\", \"project_end_date\": \"2029-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-205\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": \"B\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Obstetrics and Maternal-Fetal Biology Study Section[CHHD-B]\"}, \"award_notice_date\": \"2024-07-16T12:07:00Z\", \"core_project_num\": \"K23HD112591\", \"terms\": \"<21+ years old><Address><Adrenal Cortex Hormones><Adult><Adult Human><Affect><Anatomic Sites><Anatomic structures><Anatomy><Area><Asthma><Binding Proteins><Biological><Blood flow><Bronchial Asthma><Cessation of life><Chronic><Chronic Disease><Chronic Illness><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Design><Collection><Corticoids><Corticosteroids><Creatinine Clearance><Creatinine clearance measurement><Data><Death><Development><Development and Research><Dose><Drug Exposure><Drug Kinetics><Drug Modelings><Drug Prescribing><Drug Prescriptions><Drugs><Equilibrium><Ethics><Event><Exposure to><FDA approved><Failure><Fetus><Future><Gestation><Goals><Health><Human><Incidence><Individual><Infant><Inhalation><Inhaling><Injury><Interdisciplinary Research><Interdisciplinary Study><Intermediary Metabolism><Investigators><Jobs><K23 Award><K23 Mechanism><K23 Program><Leadership><Leukotriene Antagonists><Leukotriene Receptor Antagonists><Ligand Binding Protein><Ligand Binding Protein Gene><Link><Literature><Maternal-fetal medicine><Medication><Mentored Patient-Oriented Research Career Development Award><Mentored Patient-Oriented Research Career Development Award (K23)><Mentors><Mentorship><Metabolic Processes><Metabolism><Methodology><Methods><Mission><Modeling><Modern Man><Mothers><Multidisciplinary Collaboration><Multidisciplinary Research><NIH><National Institutes of Health><Occupations><Organ Size><Outcome><PBPK><Pharmaceutical Epidemiology><Pharmaceutical Preparations><Pharmacoepidemiology><Pharmacokinetics><Pharmacology><Phase><Phlebotomy><Physiologic><Physiological><Physiology><Population><Pregnancy><Professional Positions><Prospective Studies><Protein Binding><Public Health><R & D><R&D><Regimen><Research><Research Design><Research Personnel><Researchers><Safety><Sampling><Science><Special Population><Specialist><Study Type><Survey Instrument><Surveys><Symptoms><Techniques><Therapeutic><Time><Toxic effect><Toxicities><Training><Treatment Failure><United States><United States National Institutes of Health><Venous blood sampling><adulthood><appropriate dose><asthma model><balance><balance function><biologic><bound protein><career><career development><chronic disorder><clinical care><computer based prediction><design><designing><developmental><disability><dose information><drug action><drug disposition><drug epidemiology><drug/agent><efficacy trial><ethical><fetal><fluticasone><improved outcome><inflammation marker><inflammatory marker><injuries><innovate><innovation><innovative><interest><maternal morbidity><medication prescription><montelukast><optimal drug dosage><optimal drug dose><participant enrollment><patient centered><patient enrollment><patient oriented><pharmacodynamic model><pharmacoepidemiologic><pharmacoepidemiological><pharmacokinetic model><pharmacometrics><physiologically based pharmacokinetics><predictive modeling><pregnant><prescribed medication><programs><prospective><research and development><skill acquisition><skill development><skills><standard of care><study design><therapy failure>\", \"pref_terms\": \"Address;Adrenal Cortex Hormones;Adult;Affect;Anatomy;Area;Asthma;Binding Proteins;Biological;Blood flow;Cessation of life;Chronic;Chronic Disease;Clinical;Clinical Research;Clinical Trials;Clinical Trials Design;Collection;Creatinine clearance measurement;Data;Development;Dose;Drug Exposure;Drug Kinetics;Drug Modelings;Drug Prescriptions;Equilibrium;Ethics;Event;Exposure to;FDA approved;Failure;Fetus;Future;Goals;Health;Human;Incidence;Individual;Infant;Inhalation;Injury;Interdisciplinary Study;Leadership;Leukotriene Antagonists;Link;Literature;Maternal-fetal medicine;Mentored Patient-Oriented Research Career Development Award;Mentors;Mentorship;Metabolism;Methodology;Methods;Mission;Modeling;Mothers;Occupations;Organ Size;Outcome;Pharmaceutical Preparations;Pharmacoepidemiology;Pharmacology;Phase;Physiological;Physiology;Population;Pregnancy;Prospective Studies;Public Health;Regimen;Research;Research Design;Research Personnel;Safety;Sampling;Science;Special Population;Specialist;Surveys;Symptoms;Techniques;Therapeutic;Time;Toxic effect;Training;Treatment Failure;United States;United States National Institutes of Health;Venous blood sampling;appropriate dose;asthma model;career;career development;clinical care;design;disability;dose information;drug action;drug disposition;efficacy trial;fetal;fluticasone;improved outcome;inflammatory marker;innovation;interest;maternal morbidity;montelukast;participant enrollment;patient oriented;pharmacodynamic model;pharmacokinetic model;pharmacometrics;physiologically based pharmacokinetics;predictive modeling;pregnant;programs;prospective;research and development;skill acquisition;skills;standard of care\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThis is an application for a K23 award for Dr. Kathleen M. Job, a clinical pharmacologist and young\\\\ninvestigator pursuing patient-oriented clinical research into how pregnancy and chronic disease\\\\ninfluences drug disposition and action. This K23 award will provide Dr. Job with support necessary for\\\\ncareer development in the following areas: (1) advanced pharmacometric techniques; (2) pregnancy\\\\nand maternal-fetal science; (3) clinical trial design and management in pregnant populations; and (4)\\\\nleading an interdisciplinary research program. By acquiring these skills, Dr. Job will fulfill her career\\\\ngoal of becoming an independent investigator who advances clinical care by integrating physiology\\\\nand pharmacology into approaches for designing, conducting, and interpreting clinical trials in\\\\npregnant individuals. To achieve these goals, Dr. Job has assembled a mentoring team comprising a\\\\nprimary mentor, Dr. Kevin Watt, an expert in PBPK modeling in special populations, and co-mentors,\\\\nDr. Torri Metz, a specialist in maternal-fetal medicine and clinical research, Dr. Christina Chambers,\\\\nan expert in epidemiology of drugs during pregnancy and health outcomes, and Dr. Andr\\\\u00e9 Dallmann,\\\\na leader in physiologically-based pharmacokinetic (PBPK) modeling in pregnant populations.\\\\nAsthma is the most common chronic condition associated with pregnancy and affects up to 300,000\\\\npregnancies every year in the United States. Asthma drugs are critical for achieving and maintaining\\\\nproper control of asthma symptoms. The pharmacokinetics of these drugs can be affected by the\\\\naltered physiology and lead to unacceptable drug-related toxicity or treatment failure. Progressive\\\\nchanges to physiology occur throughout pregnancy. In the current proposal, Dr. Kathleen Job will\\\\ndetermine optimal dosing of two common asthma medications in pregnant individuals. In Aim 1, she\\\\nwill develop maternal-fetal PBPK models for these asthma medications. In Aim 2, she will evaluate\\\\nmodel predictions with data from prospective clinical pharmacokinetic studies in pregnant individuals\\\\nwith asthma. In Aim 3, she will develop pharmacodynamic models for the drugs of interest in pregnant\\\\nindividuals with asthma with data collected as part of the prospective clinical pharmacokinetic studies\\\\nin pregnant individuals. Findings will inform a Phase II/III Phase II/III safety and efficacy trial in\\\\npregnant individuals with asthma and build a platform that can be applied to dosing of any drug at any\\\\nstage of pregnancy. This research will prepare Dr. Job to design and implement scientifically rigorous\\\\nand ethical drug trials in pregnant populations.\", \"project_title\": \"Physiologically-Based Pharmacokinetic (PBPK) Modeling of Asthma Drugs during Pregnancy\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe lack of appropriate dosing information in pregnant individuals with uncontrolled asthma is an\\\\nunmet public health need that can result in therapeutic failure and death. This proposal will build a\\\\nframework for the use of physiologically based pharmacokinetic (PBPK) modeling for pregnant\\\\nindividuals with asthma. These developed PBPK models can be broadly applied to inform dosing of\\\\nother drugs, improve outcomes in pregnant individuals, and further the NIH\\\\u2019s mission to reduce illness\\\\nand disability.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-07-16T12:07:00Z\", \"budget_end\": \"2025-06-30T12:06:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 154828, \"indirect_cost_amt\": 12173, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10985761\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 5}, page_content='{\"appl_id\": 10785881, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1R01NR020784-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R01\", \"award_amount\": 631544, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R01\", \"ic_code\": \"NR\", \"serial_num\": \"020784\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 9481582, \"first_name\": \"Flory\", \"middle_name\": \"L\", \"last_name\": \"Nkoy\", \"is_contact_pi\": true, \"full_name\": \"Flory L Nkoy\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"NKOY, FLORY L\", \"agency_ic_admin\": {\"code\": \"NR\", \"abbreviation\": \"NINR\", \"name\": \"National Institute of Nursing Research\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"NR\", \"name\": \"National Institute of Nursing Research\", \"abbreviation\": \"NINR\", \"total_cost\": 631544, \"direct_cost_ic\": 446078, \"indirect_cost_ic\": 185466}], \"project_start_date\": \"2024-06-12T12:06:00Z\", \"project_end_date\": \"2029-03-31T12:03:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-20-180\", \"full_study_section\": {\"srg_code\": \"ZRG1\", \"srg_flex\": null, \"sra_designator_code\": \"HSS\", \"sra_flex_code\": \"B\", \"group_code\": \"90\", \"name\": \"Special Emphasis Panel[ZRG1 HSS-B (90)]\"}, \"award_notice_date\": \"2024-06-12T12:06:00Z\", \"core_project_num\": \"R01NR020784\", \"terms\": \"<0-11 years old><Accident and Emergency department><Active Follow-up><Acute><Adherence><Admission><Admission activity><Affect><Age><Asthma><Attention><Body System><Bronchial Asthma><Caring><Child><Child Support><Child Youth><Child health care><Childhood><Children (0-21)><Children with Disabilities><Children\\'s Hospital><Chronic><Chronic Disease><Chronic Illness><Clinic><Complex><Data><Dependence><Deterioration><Diabetes Mellitus><Disabled Children><Disparity population><Domiciliary Care><ED visit><ER visit><Early Diagnosis><Early Intervention><Early identification><Emergency Department><Emergency care visit><Emergency department visit><Emergency hospital visit><Emergency room><Emergency room visit><Ethnic Origin><Ethnicity><Family><Feedback><Fever><Focus Groups><Graph><Handicapped Children><Health><Health Care Costs><Health Care Providers><Health Costs><Health Inequity><Health Personnel><Health Status><Healthcare><Healthcare Costs><Healthcare Providers><Healthcare worker><Home><Home Care Services><Hospital Admission><Hospitalization><Hospitalized Child><Hospitals><Impairment><Impoverished><Incentives><Inequalities in Health><Inequities in Health><Inequity><Length of Stay><Level of Health><Liquid substance><Medical><Methods><Minority><Mobile Health App><Mobile Health Application><Modeling><Monitor><Multi-center studies><Multicenter Studies><Neurologic><Neurological><Number of Days in Hospital><Observation research><Observation study><Observational Study><Observational research><Organ System><Outcome><Pain><Painful><Parents><Pediatric Hospitals><Personal Satisfaction><Poverty><Pyrexia><QOL><Quality of life><Race><Races><Randomized><Recurrence><Recurrent><Reporting><Respiratory distress><Risk><Seizures><Self Efficacy><Severities><Stress><Subgroup><Symptoms><System><Technology><Testing><Visit><Work><active followup><acute symptom><ages><arm><care as usual><care coordination><care giving><care services><care systems><caregiving><child healthcare><chronic disorder><coordinating care><cost><demographics><design><designing><determine efficacy><diabetes><disadvantaged group><disadvantaged individual><disadvantaged people><disadvantaged population><disadvantaged subgroup><disparities across groups><disparity across subgroups><disparity among groups><disparity among subgroups><disparity between groups><disparity between subgroups><disparity in care><disparity in healthcare><early detection><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><ethnic minority><evaluate efficacy><examine efficacy><experience><febrile><febris><feeding><financial incentive><financial reward><fluid><follow up><follow-up><followed up><followup><group disparity><group inequality><group inequity><health care><health care disparity><health care inequality><health care inequity><health care personnel><health care worker><health inequalities><health level><health literacy><health provider><health workforce><healthcare disparity><healthcare inequality><healthcare inequity><healthcare personnel><high risk><home health care><home healthcare><homes><hospital days><hospital length of stay><hospital stay><improved><improved outcome><inequalities among populations><inequalities between populations><inequalities in populations><inequality across populations><inequality among groups><inequality between groups><inequality in groups><inequities among populations><inequities between populations><inequities in populations><inequity across groups><inequity across populations><inequity between groups><inequity in groups><kids><liquid><m-Health app><m-Health application><mHealth app><mHealth application><mHealth therapeutic><mHealth therapy><mHealth treatment><medical personnel><mental state><mental status><mhealth interventions><mobile health intervention><mobile health therapeutic><mobile health therapy><mobile health treatment><monetary incentive><multimorbidity><multiple chronic conditions><novel><parent><pediatric><pediatric care><pediatric health care><pediatric healthcare><physical disability><physically disabled><physically handicapped><pilot trial><population inequality><population inequity><preference><prevent><preventing><programs><racial><racial background><racial minority><racial origin><randomisation><randomization><randomly assigned><remote monitoring><satisfaction><social><social health determinants><subgroup disparity><treatment as usual><treatment provider><unequal group><unequal population><usual care><well-being><wellbeing><youngster>\", \"pref_terms\": \"Accident and Emergency department;Acute;Adherence;Admission activity;Affect;Age;Asthma;Attention;Body System;Caring;Child;Child Support;Child health care;Childhood;Chronic;Chronic Disease;Clinic;Complex;Data;Dependence;Deterioration;Diabetes Mellitus;Disabled Children;Disparity population;Early Diagnosis;Early Intervention;Early identification;Emergency department visit;Ethnic Origin;Family;Feedback;Fever;Focus Groups;Graph;Health;Health Care Costs;Health Personnel;Health Status;Healthcare;Home;Home Care Services;Hospitalization;Hospitalized Child;Hospitals;Impairment;Incentives;Inequity;Length of Stay;Liquid substance;Medical;Methods;Minority;Mobile Health Application;Modeling;Monitor;Multicenter Studies;Neurologic;Observational Study;Outcome;Pain;Parents;Pediatric Hospitals;Personal Satisfaction;Poverty;Quality of life;Race;Randomized;Recurrence;Reporting;Respiratory distress;Risk;Seizures;Self Efficacy;Severities;Stress;Subgroup;Symptoms;System;Technology;Testing;Visit;Work;acute symptom;arm;care coordination;care systems;caregiving;cost;demographics;design;efficacy evaluation;ethnic minority;experience;feeding;financial incentive;follow-up;health care disparity;health inequalities;health literacy;high risk;improved;improved outcome;mental state;mhealth interventions;multiple chronic conditions;novel;physically handicapped;pilot trial;preference;prevent;programs;racial minority;remote monitoring;satisfaction;social;social health determinants;treatment as usual\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nChildren with medical complexity (CMC) are the most vulnerable of children with chronic diseases, who have\\\\ncomplex, multisystem chronic diseases affecting \\\\u22653 organ systems, severe functional limitations and technology\\\\ndependencies. CMC have high health care needs, and account for 40% of hospitalized children and 35% of all\\\\npediatric health care costs. Due to high medical fragility, CMC have frequent acute deteriorations superimposed\\\\non their chronic conditions, leading to recurrent emergency department (ED)/hospital admissions and affecting\\\\nquality of life (QOL). To reduce ED/hospital admissions for CMC, remote monitoring is suggested, with use of\\\\nmHealth apps to regularly assess their health status remotely and identify early signs of acute deterioration,\\\\nallowing for early interventions to prevent ED/hospital admissions. Yet no app to support remote monitoring of\\\\nCMC exists. Variable, multisystem conditions among CMC make it difficult to develop an app. Also, many CMC\\\\nare at high-risk for health care inequities, with minorities having higher unmet needs, but the impacts of health\\\\ncare inequities and social determinants of health (SDOH) on ED/hospital admissions in CMC are rarely studied.\\\\nFortunately, ED/hospital admissions for CMC are often preceded by a limited set of shared (crosscutting) acute\\\\nsymptoms. These crosscutting symptoms rarely occur suddenly. Studies suggest that they usually start as subtle\\\\nsigns, often unnoticed by parents until they escalate to prompt an ED/hospital visit. Thus, crosscutting symptoms\\\\noffer an opportunity for a novel and practical approach for developing a remote monitoring app for CMC,\\\\ndespite their multiple, variable underlying conditions. In a focus group, parents identified the crosscutting\\\\nsymptoms that most often preceded their children\\\\u2019s hospital admissions, and conveyed their needs, preferences\\\\nand key functionalities that led to MyChildCMC, the first app designed to monitor and identify early signs of\\\\ncrosscutting symptoms in CMC. In a pilot trial of 50 subjects, we confirmed feasibility of MyChildCMC use by\\\\nparents, ability to detect early signs 2-14 days prior to ED/hospital admissions, and use leading significantly to\\\\nfewer hospital days than controls. The current study will assess the efficacy and sustainability of MyChildCMC\\\\nin a fully-powered 6-month, 2-arm (MyChildCMC vs usual care) trial of CMC (age 1-18 years) and their parents.\\\\nParents assigned to MyChildCMC will use the app daily for 6 months, both arms will receive financial incentive\\\\nfor participation, then we will stop the incentive and follow subjects for 6 more months to assess sustainability at\\\\n12 months. We will also assess if MyChildCMC use will help reduce or eliminate inequities in ED/hospital\\\\nadmissions. Specific Aims are: 1) Determine MyChildCMC\\\\u2019s efficacy on 1.a. Child (ED/hospital use, hospital\\\\ndays and QOL) and 1.b. Parent (satisfaction, self-efficacy and stress) outcomes; 2) Compare ED/hospital use\\\\namong racial/ethnic and SDOH subgroups to assess potential effect of MyChildCMC on inequities; 3) Use mixed\\\\nmethods to identify child and parent factors associated with MyChildCMC\\\\u2019s use adherence and sustainability.\", \"project_title\": \"A Novel mHealth Intervention to Improve Outcomes of Children with Medical Complexity\", \"phr_text\": \"PROJECT NARRATIVE\\\\nFindings from this project will provide an effective, practical, and generalizable approach to supporting home\\\\nmonitoring of children with medical complexity (CMC). This will also serve as a model for reducing recurring\\\\nemergency department (ED) visits and hospital admissions associated with CMC, generalizable to all children\\\\nwith other multiple chronic conditions.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-06-12T12:06:00Z\", \"budget_end\": \"2025-03-31T12:03:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 446078, \"indirect_cost_amt\": 185466, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10785881\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 6}, page_content='{\"appl_id\": 10866279, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1K99HD114846-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K99\", \"award_amount\": 121770, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K99\", \"ic_code\": \"HD\", \"serial_num\": \"114846\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 78924158, \"first_name\": \"J\", \"middle_name\": \"Porter\", \"last_name\": \"Hunt\", \"is_contact_pi\": true, \"full_name\": \"J Porter Hunt\", \"title\": \"POSTDOCTORAL FELLOW\"}], \"contact_pi_name\": \"HUNT, J PORTER\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 121770, \"direct_cost_ic\": 112750, \"indirect_cost_ic\": 9020}], \"project_start_date\": \"2024-05-10T12:05:00Z\", \"project_end_date\": \"2026-04-30T12:04:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-187\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": \"A\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Pediatrics Study Section[CHHD-A]\"}, \"award_notice_date\": \"2024-05-10T12:05:00Z\", \"core_project_num\": \"K99HD114846\", \"terms\": \"<Affect><ages><Age><inhibitor><Award><Blood-Brain Barrier><Hemato-Encephalic Barrier><bloodbrain barrier><Blood - brain barrier anatomy><Brain Nervous System><Encephalon><Brain><Cefatriaxone><Ceftriaxone><CNS agent><Central Nervous System Drugs><centrally acting drug><Central Nervous System Agents><CNS Diseases><CNS disorder><Central Nervous System Disorders><Central Nervous System Diseases><CNS infection><Central Nervous System Infectious Disease><Central Nervous System Infectious Disorder><Central Nervous System Infections><cerebral spinal fluid><spinal fluid><Cerebrospinal Fluid><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Child><Clinical Study><Clinical Research><Clinical Trials><depression><Mental Depression><Disorder><Disease><Drug Modelings><Drug Therapy><drug treatment><Pharmacotherapy><Drugs><Medication><drug/agent><Pharmaceutical Preparations><Engineering><Epileptic Seizures><Epileptics><Seizure Disorder><epilepsia><epileptogenic><Epilepsy><Faculty><Future><History><histories><Recording of previous events><Children\\'s Hospital><Pediatric Hospitals><Modern Man><Human><In Vitro><Infection><Literature><Meningitis><Mentors><Mentorship><Methods><Molecular Structure><Macromolecular Structure><Nervous System Disorder><Nervous System Diseases><Neurologic Disorders><Neurological Disorders><neurological disease><Patients><Permeability><Drug Kinetics><Pharmacokinetics><Physiology><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Public Health><Research><Research Design><Study Type><study design><Research Personnel><Investigators><Researchers><Resources><Research Resources><Risk><Safety><Spinal Puncture><Lumbar Puncture><Time><Tissues><Body Tissues><Universities><Utah><Vancomycin><Work><Cefepime><cefepim><cytokine><Measures><Dexmedetomidine><therapy failure><Treatment Failure><career><improved><Clinical><Phase><Physiologic><Physiological><Chemicals><Training><pediatric><Childhood><insight><Ligand Binding Protein><Ligand Binding Protein Gene><Protein Binding><bound protein><Binding Proteins><Measurement><Cell Components><Cell Structure><Cellular Structures><Funding><Therapeutic><Inflammatory><tool><Knowledge><Disorder Management><Disease Management><Levetiracetam><System><experience><Membrane Transport Proteins><Membrane Transporters><drug efficacy><lipophilicity><Toxic effect><Toxicities><skills><simulation><models and simulation><model-based simulation><Drug Exposure><Modeling><Sampling><Property><mathematical model><Math Models><mathematic model><mathematical modeling><Central Nervous System><CNS Nervous System><Neuraxis><Address><Dose><Concentration measurement><Data><Minimal Risk Study><Qualifying><in vitro Model><Principal Investigator><Process><Ventricular><Pathway interactions><pathway><virtual><pharmacokinetic model><predictive modeling><computer based prediction><design><designing><Outcome><prospective><Biological Markers><bio-markers><biologic marker><biomarker><Regimen><Drug Targeting><specific biomarkers><Infrastructure><pharmacometrics><blood-brain barrier permeabilization><BBB permeabilization><BBB permeable><blood-brain barrier permeable><bloodbrain barrier permeabilization><bloodbrain barrier permeable>\", \"pref_terms\": \"Address;Affect;Age;Award;Binding Proteins;Biological Markers;Blood - brain barrier anatomy;Brain;Cefepime;Ceftriaxone;Cellular Structures;Central Nervous System;Central Nervous System Agents;Central Nervous System Diseases;Central Nervous System Infections;Cerebrospinal Fluid;Chemicals;Child;Childhood;Clinical;Clinical Research;Clinical Trials;Concentration measurement;Data;Dexmedetomidine;Disease;Disease Management;Dose;Drug Exposure;Drug Kinetics;Drug Modelings;Drug Targeting;Engineering;Epilepsy;Faculty;Funding;Future;Human;In Vitro;Infection;Inflammatory;Infrastructure;Knowledge;Levetiracetam;Literature;Measurement;Measures;Membrane Transport Proteins;Meningitis;Mental Depression;Mentors;Mentorship;Methods;Minimal Risk Study;Modeling;Molecular Structure;Nervous System Disorder;Outcome;Pathway interactions;Patients;Pediatric Hospitals;Permeability;Pharmaceutical Preparations;Pharmacotherapy;Phase;Physiological;Physiology;Plasma;Principal Investigator;Process;Property;Public Health;Qualifying;Recording of previous events;Regimen;Research;Research Design;Research Personnel;Resources;Risk;Safety;Sampling;Spinal Puncture;System;Therapeutic;Time;Tissues;Toxic effect;Training;Treatment Failure;Universities;Utah;Vancomycin;Ventricular;Work;blood-brain barrier permeabilization;career;cytokine;design;drug efficacy;experience;improved;in vitro Model;inhibitor;insight;lipophilicity;mathematical model;models and simulation;pharmacokinetic model;pharmacometrics;predictive modeling;prospective;simulation;skills;specific biomarkers;tool;virtual\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nMillions of children throughout the world suffer from neurological diseases, including epilepsy, depression, and\\\\ninfections. Pharmacotherapy is a mainstay of treatment efforts, but optimal dosing is virtually unknown\\\\nbecause of the difficulty in measuring drug concentrations in the brain. The extent of brain exposure depends\\\\non drug properties and the permeability of the blood brain barrier (BBB). BBB permeability is affected by age\\\\nand disease and may change over time. In order to adequately characterize exposure, multiple concentration\\\\nmeasurements are needed over time. However, serial lumbar punctures in children are rarely advised or\\\\nindicated. Consequently, the exposure in the brain of most drugs to treat neurological diseases in children is\\\\nunknown. This lack of data to guide therapy risks toxicity and treatment failure in children. We have developed\\\\nan approach that combines sophisticated pharmacokinetic modeling with opportunistic, non-invasive, serial\\\\ndrug concentration measurements in the cerebrospinal fluid (CSF) to determine optimal dosing. The work of\\\\nthis proposal will provide a platform to optimize dosing of drugs that treat neurological diseases across the\\\\npediatric age spectrum. This platform combines: 1) In vitro models of the BBB; 2) Opportunistic plasma and\\\\nCSF pharmacokinetic (PK) studies in children with external ventricular drains (EVDs). EVDs therapeutically\\\\nremove CSF from the patient and permit non-invasive, serial CSF sampling to measure drug concentrations; 3)\\\\nPhysiologically-based pharmacokinetic modeling (PBPK) to predict plasma and CSF drug exposure in children.\\\\nPBPK models can be modified to reflect differences in age and disease state. The principal investigator (PI)\\\\nhas a background in chemical and biomolecular engineering, in vitro systems, and modeling and simulation,\\\\nand is conducting an ongoing plasma and CSF PK study in children with EVDs. To elucidate mechanisms of\\\\ndrug passage into the CSF and to optimize CNS drug dosing in children, the PI will pursue training through the\\\\nK99/R00 Pathway to Independence Award mechanism at the University of Utah. To guide this training, an\\\\nexperienced mentorship team will provide expertise in clinical trials, in vitro models, membrane transporters,\\\\nand sophisticated pharmacometric methods. In the mentored phase, in vitro BBB models will measure BBB\\\\npermeability of five drugs commonly used in children in the context of age and disease. These measurements\\\\nand information from the literature will inform pediatric CNS-PBPK models of these drugs in children. Then,\\\\nCNS-PBPK models will be optimized using serial plasma and CSF PK measurements from children with EVDs\\\\nacross disease states and the pediatric age spectrum, and optimal dosing regimens will be determined. In the\\\\nindependent phase, the PI will conduct a prospective PK and safety trial to validate optimal, patient-specific\\\\ndosing regimens for two drugs targeting the CNS in children. This work will create a platform to define and\\\\ndesign optimal CNS pharmacotherapy for children.\", \"project_title\": \"Optimal Dosing of CNS Drugs for Children\", \"phr_text\": \"NARRATIVE\\\\nThis research will enhance public health by improving the safety and efficacy of drugs that treat diseases of the\\\\ncentral nervous system (CNS) in children. Specifically, this research will provide significant new insight\\\\nregarding the mechanisms of drug passage into the CNS of children and enable optimal, patient-specific\\\\npharmacotherapy to treat CNS diseases in children.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-05-10T12:05:00Z\", \"budget_end\": \"2025-04-30T12:04:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 112750, \"indirect_cost_amt\": 9020, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10866279\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 7}, page_content='{\"appl_id\": 10889661, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1R01CA282698-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R01\", \"award_amount\": 608023, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R01\", \"ic_code\": \"CA\", \"serial_num\": \"282698\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 11233567, \"first_name\": \"Anne\", \"middle_name\": \"C\", \"last_name\": \"Kirchhoff\", \"is_contact_pi\": true, \"full_name\": \"Anne C Kirchhoff\", \"title\": \"ASSISTANT PROFESSOR\"}, {\"profile_id\": 10724158, \"first_name\": \"Jim\", \"middle_name\": \"Albert\", \"last_name\": \"Vanderslice\", \"is_contact_pi\": false, \"full_name\": \"Jim Albert Vanderslice\", \"title\": \"\"}], \"contact_pi_name\": \"KIRCHHOFF, ANNE C\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 608023, \"direct_cost_ic\": 414915, \"indirect_cost_ic\": 193108}], \"project_start_date\": \"2024-05-10T12:05:00Z\", \"project_end_date\": \"2028-04-30T12:04:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-23-153\", \"full_study_section\": {\"srg_code\": \"SEDH\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Social and Environmental Determinants of Health Study Section[SEDH]\"}, \"award_notice_date\": \"2024-05-20T12:05:00Z\", \"core_project_num\": \"R01CA282698\", \"terms\": \"<ages><Age><Air><Air Pollution><Behavior Conditioning Therapy><Behavior Modification><Behavior Treatment><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Conditioning Therapy><behavior intervention><behavioral intervention><Behavior Therapy><Breast Cancer><malignant breast tumor><Malignant Breast Neoplasm><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Malignant Neoplasms><Female Breast Cancer><Mammary Carcinoma of the Female Breast><Female Breast Carcinoma><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Cardiovascular system><Data Sources><Death><Cessation of life><Diagnosis><faces><facial><Face><Female><Grant><Health><Heart><History><histories><Recording of previous events><Hospital Admission><Hospitalization><indexing><Lung Respiratory System><pulmonary><Lung><Pulmonary Diseases><Pulmonary Disorder><disease of the lung><disorder of the lung><lung disorder><Lung Diseases><Morbidity - disease rate><Morbidity><mortality><Resources><Research Resources><Risk><Smoke><Temperature><Tissues><Body Tissues><United States><Utah><Woman><Work><Measures><Hispanic><density><improved><Acute><Physiologic><Physiological><Medical><Survivors><Evaluation><Susceptibility><Predisposition><Individual><Oncologist><Lung damage><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><lung injury><Exposure to><Supportive Therapy><Supportive care><Event><Pattern><respiratory><interest><experience><success><cohort><Toxic effect><Toxicities><novel><cardiovascular risk factor><cardiovascular risk><Sampling><response><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><cancer-directed therapy><model design><extreme temperature><low socioeconomic status><low SES><low socio-economic position><low socio-economic status><low socioeconomic position><Late Effects><Adverse Late Effects><Data><Population Database><Subgroup><Cancer Control><Cancer Control Science><Cancer Survivor><Cancer Survivorship><Development><developmental><climate change><climatic changes><global climate change><childhood cancer survivor><pediatric cancer survivor><Outcome><Population><innovation><innovate><innovative><Impairment><Wildfire><wild fire><wildland fire><chemotherapy><high risk><risk mitigation><public health emergency><epidemiologic data><Epidemiological data><Epidemiology data><Emergency department visit><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><personalized medicine><personalization of treatment><personalized therapy><personalized treatment><climate impact><Breast Cancer survivor><Breast Cancer survivorship><Breast Cancer therapy><Treatment-related toxicity><therapeutic toxicity><therapy associated toxicity><therapy related toxicity><therapy toxicity><treatment toxicity><treatment-associated toxicity><Cardiac health><Heart health><data resource><health management><health care management><healthcare management><extreme weather><lung health><pulmonary health><climate-related exposures><climate exposure>\", \"pref_terms\": \"Acute;Age;Air;Air Pollution;Behavior Therapy;Breast Cancer survivor;Breast Cancer survivorship;Breast Cancer therapy;Cancer Control;Cancer Survivor;Cancer Survivorship;Cardiac health;Cardiovascular system;Cessation of life;Data;Data Sources;Development;Diagnosis;Emergency department visit;Evaluation;Event;Exposure to;Face;Female;Female Breast Carcinoma;Grant;Health;Heart;Hispanic;Hospitalization;Impairment;Individual;Late Effects;Lung;Lung Diseases;Malignant Breast Neoplasm;Malignant Neoplasms;Measures;Medical;Morbidity - disease rate;Oncologist;Outcome;Pattern;Physiological;Population;Population Database;Predisposition;Recording of previous events;Resources;Risk;Sampling;Smoke;Subgroup;Supportive care;Survivors;Temperature;Tissues;Toxic effect;Treatment-related toxicity;United States;Utah;Wildfire;Woman;Work;cancer therapy;cardiovascular risk factor;chemotherapy;childhood cancer survivor;climate change;climate impact;climate-related exposures;cohort;data resource;density;epidemiologic data;experience;extreme temperature;extreme weather;health management;high risk;improved;indexing;innovation;interest;low socioeconomic status;lung health;lung injury;model design;mortality;novel;personalized medicine;public health emergency;respiratory;response;risk mitigation;success\", \"abstract_text\": \"ABSTRACT\\\\nClimate change is a global public health emergency that will increase cardiovascular (CV) and\\\\nrespiratory/pulmonary (R/P) morbidity and mortality as the population is exposed to more frequent extreme\\\\ntemperature events and high levels of air pollution from wildfires. The synergistic effects of heat in the\\\\npresence of elevated air pollution increases mortality. CV and R/P morbidity and mortality are also health\\\\nconsequences of certain breast cancer therapies that cause the heart and lungs to function at lower than\\\\noptimal levels. This therapy-related tissue damage may increase survivors\\' susceptibility to CV and R/P\\\\ndisease from extreme temperature and air pollution. In this grant, we will identify breast cancer survivors\\'\\\\nunique health risks from climate change, by elucidating: \\\\u00b7 Exposure mechanisms/timeframes of interest,\\\\nincluding whether pre-diagnosis exposure climate-related conditions (temperature, wildfire smoke, air pollution)\\\\nduring cancer therapy and post-diagnosis acute exposure to these conditions predispose breast cancer\\\\nsurvivors to greater CV and R/P toxicity; \\\\u00b7 How survivors\\' risks compare to individuals without cancer; and \\\\u00b7\\\\nWhich breast cancer survivors face the greatest health risks from climate change, such as Hispanic women or\\\\nthose with low socioeconomic status. To answer these questions, we will utilize a statewide Utah cohort of\\\\n21,835 female breast cancer survivors developed using the Utah Population Database, an epidemiologic data\\\\nresource that contains lifetime medical data and longitudinal residential histories. This resource enables us to\\\\nmeasure exposure to temperature and air pollution both prior to diagnosis and in the years following. We will\\\\nalso utilize a cancer-free, age-matched female population sample (N=65,503). We aim to: 1) Determine if pre-\\\\ndiagnosis, long-term exposure to extreme temperature and air pollution are associated with CV and R/P health\\\\noutcomes occurring while BC survivors are on therapy, limited to <5 years from diagnosis. 2) Estimate the\\\\nassociation of CV and R/P health outcomes and post-diagnosis, short-term exposure to extreme temperature\\\\nand air pollution from diagnosis onwards. 3) Identify differences in the effect of pre-diagnosis, long-term\\\\nexposure to extreme temperature and air pollution on the CV and R/P health outcomes between breast cancer\\\\nsurvivors and a cancer-free cohort. By identifying extreme temperature conditions and air pollution levels that\\\\nare specifically harmful to breast cancer survivors and whether high-risk survivor subgroups face greater risk,\\\\nthis will allow the development of supportive care efforts to manage cancer-related health effects that are\\\\nexacerbated due to climate change.\", \"project_title\": \"Breast cancer survivorship in the era of climate change: Impact of extreme weather, air pollution, and cancer therapy on heart and lung health\", \"phr_text\": \"NARRATIVE\\\\nClimate change will exacerbate cardiovascular (CV) and respiratory/pulmonary (R/P) morbidity through\\\\nincreasing extreme temperatures and periods of high levels of air pollution from wildfires. Certain cancer\\\\ntherapies can increase breast cancer survivors\\' propensity for CV and R/P disease, and may increase\\\\nsurvivors\\' susceptibility to health problems from climate change. We will determine whether: 1) survivors\\\\nexposed to extreme temperature and air pollution prior to diagnosis have a higher risk for therapy-related CV\\\\nand R/P problems, and 2) if post-diagnosis short term exposure to extreme temperature and air pollution\\\\nduring treatment increases survivors\\' risk for CV and R/P problems related to climate change.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-05-10T12:05:00Z\", \"budget_end\": \"2025-04-30T12:04:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 414915, \"indirect_cost_amt\": 193108, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10889661\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 8}, page_content='{\"appl_id\": 10840620, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1UM1HL172706-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"UM1\", \"award_amount\": 433117, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"UM1\", \"ic_code\": \"HL\", \"serial_num\": \"172706\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 79107406, \"first_name\": \"Antonio\", \"middle_name\": \"\", \"last_name\": \"Cabrera\", \"is_contact_pi\": false, \"full_name\": \"Antonio  Cabrera\", \"title\": \"\"}, {\"profile_id\": 16438020, \"first_name\": \"DONGNGAN\", \"middle_name\": \"\", \"last_name\": \"TRUONG\", \"is_contact_pi\": false, \"full_name\": \"DONGNGAN  TRUONG\", \"title\": \"PEDIATRIC CARDIOLOGIST\"}, {\"profile_id\": 9837284, \"first_name\": \"Richard\", \"middle_name\": \"Vincent\", \"last_name\": \"Williams\", \"is_contact_pi\": true, \"full_name\": \"Richard Vincent Williams\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"WILLIAMS, RICHARD VINCENT\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 433117, \"direct_cost_ic\": 281245, \"indirect_cost_ic\": 151872}], \"project_start_date\": \"2024-01-08T12:01:00Z\", \"project_end_date\": \"2030-12-31T12:12:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HL-24-001\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"Q\", \"group_code\": \"O2\", \"name\": \"Special Emphasis Panel[ZHL1 CSR-Q (O2)]\"}, \"award_notice_date\": \"2024-01-05T12:01:00Z\", \"core_project_num\": \"UM1HL172706\", \"terms\": \"<Affect><AI system><Computer Reasoning><Machine Intelligence><Artificial Intelligence><Award><Clinical Study><Clinical Research><Communities><Eligibility><Protocol Screening><Eligibility Determination><Environment><ethical><Ethics><Family><Foundations><Genotype><Goals><Grant><Generalized Growth><Tissue Growth><ontogeny><Growth><Health><Heart><Cardiac Diseases><Cardiac Disorders><heart disorder><Heart Diseases><Heterogeneity><History><histories><Recording of previous events><Children\\'s Hospital><Pediatric Hospitals><intern><Internships><Investments><Leadership><Learning><Mentors><Mentorship><Mission><Music><Oxandrolone><Oxandrin><Patients><Perception><Phenotype><Physicians><Productivity><Publications><Scientific Publication><Quality of life><QOL><Race><Races><racial><racial background><racial origin><Research><Research Design><Study Type><study design><Research Personnel><Investigators><Researchers><Resources><Research Resources><Role><social role><Rural Population><Rural group><Rural people><rural individual><Scholarship><Science><Testing><Universities><Utah><Vision><Sight><visual function><Work><Writing><Outcomes Research><Advocacy><Caring><Cardiac Malformation><Heart Malformation><abnormal heart development><congenital cardiac abnormality><congenital cardiac anomalies><congenital cardiac disease><congenital cardiac disorder><congenital cardiac malformation><congenital heart anomaly><congenital heart disease><congenital heart disorder><congenital heart malformation><congenital heart abnormality><improved><Site><Clinical><Training><Lesion><pediatric><Childhood><insight><Individual><Rural><Fostering><Interdisciplinary Research><Multidisciplinary Collaboration><Multidisciplinary Research><Interdisciplinary Study><Funding><Ethnicity><Ethnic Origin><Collaborations><Native Americans><Multi-center studies><Multicenter Studies><Exposure to><tool><Knowledge><programs><Scientist><Hour><Complex><experience><Performance><success><care delivery><skills><Disease Outcome><Participant><empowerment><member><Alaska Native><Alaska Indian><Alaskan American><Alaskan Indian><Alaskan Native><Alaskan Native American><Positioning Attribute><Position><Readability><Genomics><Bioinformatics><Bio-Informatics><Institution><Address><Data><International><Native Hawaiian or Other Pacific Islander><Native Hawaiian and Other Pacific Islander><Native Hawaiian and Pacific Islander><Native Hawaiian or Pacific Islander><Research Infrastructure><Ancillary Study><Clinical Data><Electronic Health Record><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><National Heart, Lung, and Blood Institute><NHLBI><design><designing><next generation><Outcome><Population><frontier><innovation><innovate><innovative><atrioventricular septal defect><AVSD><atrioventricular canal defect><clinical care><social health determinants><Big Data><BigData><precision medicine><precision-based medicine><personalized medicine><personalization of treatment><personalized therapy><personalized treatment><health data><Data Science><Pediatric cardiology><outcome prediction><improved outcome><Pediatric Cardiac Genomics Consortium><Underrepresented Populations><Underrepresented Groups><under representation of groups><under represented groups><under represented people><under represented populations><underrepresentation of groups><underrepresented people><racial minority><health care disparity><disparity in care><disparity in healthcare><health care inequality><health care inequity><healthcare disparity><healthcare inequality><healthcare inequity><health care availability><access to health care><access to healthcare><accessibility of health care><accessibility to health care><accessibility to healthcare><health care access><health care service access><health care service availability><healthcare access><healthcare accessibility><healthcare availability><healthcare service access><healthcare service availability><genomic data><genomic data-set><genomic dataset><data resource><rural underserved><rural under served><recruit><participant retention><Infrastructure><web platform><internet based platform><internet platform><web based platform><web based system><web enabled platform><equity, diversity, and inclusion><diversity, equity, and inclusiveness><diversity and equity><Artificial Intelligence platform><AI based platform><AI platform><ethnic minority><Inequity><Equity>\", \"pref_terms\": \"Address;Advocacy;Affect;Alaska Native;Ancillary Study;Artificial Intelligence;Artificial Intelligence platform;Award;Big Data;Bioinformatics;Caring;Childhood;Clinical;Clinical Data;Clinical Research;Collaborations;Communities;Complex;Data;Data Science;Disease Outcome;Electronic Health Record;Eligibility Determination;Environment;Equity;Ethics;Ethnic Origin;Exposure to;Family;Fostering;Foundations;Funding;Genomics;Genotype;Goals;Grant;Growth;Health;Heart;Heart Diseases;Heterogeneity;Hour;Individual;Inequity;Infrastructure;Institution;Interdisciplinary Study;International;Internships;Investments;Knowledge;Leadership;Learning;Lesion;Mentors;Mentorship;Mission;Multicenter Studies;Music;National Heart, Lung, and Blood Institute;Native Americans;Native Hawaiian or Other Pacific Islander;Outcome;Outcomes Research;Oxandrolone;Participant;Patients;Pediatric Cardiac Genomics Consortium;Pediatric Hospitals;Pediatric cardiology;Perception;Performance;Phenotype;Physicians;Population;Positioning Attribute;Productivity;Publications;Quality of life;Race;Readability;Recording of previous events;Research;Research Design;Research Infrastructure;Research Personnel;Resources;Role;Rural;Rural Population;Scholarship;Science;Scientist;Site;Testing;Training;Underrepresented Populations;Universities;Utah;Vision;Work;Writing;atrioventricular septal defect;care delivery;clinical care;congenital heart abnormality;data resource;design;diversity and equity;empowerment;equity, diversity, and inclusion;ethnic minority;experience;frontier;genomic data;health care availability;health care disparity;health data;improved;improved outcome;innovation;insight;member;next generation;outcome prediction;participant retention;personalized medicine;precision medicine;programs;racial minority;recruit;rural underserved;skills;social health determinants;success;tool;web platform\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nUtah has been one of the most productive Core Clinical Research Centers in the Pediatric Heart Network\\\\n(PHN) since its inception in 2001 and has supported the mission to improve health outcomes for individuals\\\\nwith congenital (CHD) and pediatric acquired heart disease, disseminate collaborative findings, train and\\\\neducate new investigators, and provide support and advocacy for families during the conduct of excellent,\\\\nethical clinical research. During the current funding cycle, PHN Utah implemented a leadership transition plan\\\\nwith the next generation of locally and PHN trained researchers joining senior investigators with >20 years of\\\\nPHN experience. They led 6 studies and made substantial contributions to PHN scientific discoveries and\\\\nadministrative activities. Recruitment and retention of participants was among the highest of all centers due to\\\\nthe committed, diverse PHN Utah team with 24-hour coverage to approach every eligible patient. The long-\\\\nstanding collaborations among Utah investigators, planned leadership transition, and continued strong\\\\ninstitutional support will allow a seamless transition into the next cycle. Going forward, the increasing diversity\\\\nof the Intermountain West will provide unique access to participants unrepresented in research: rural and\\\\nfrontier populations, Native American/Alaska Native, and Native Hawaiian/Pacific Islander communities. PHN\\\\nUtah is ideally positioned to contribute to a more equitable, diverse, and inclusive PHN focused on addressing\\\\nhealth care inequities and the 2 specific pillars to support transformational impact: 1) addressing existing\\\\ninequity in clinical outcomes and 2) big data/data science using existing infrastructure. PHN Utah will expand\\\\ntheir successful collaboration with Utah\\\\u2019s Pediatric Cardiac Genomics Consortium to develop a robust\\\\nmechanism for extracting and sharing pertinent, machine-readable clinical data from Electronic Health Records\\\\nacross all PHN sites and use a robust Artificial Intelligence platform to explore the complex interplay between\\\\nphenotype; genotype; maternal, clinical, social determinants of health (SDOH), and racial/ethnic factors; and\\\\nclinical outcomes. Our aims are to 1) enhance PHN Utah\\\\u2019s exemplary performance and leadership by building\\\\non prior experience with a new vision and additional expertise and infrastructure informed by lessons learned\\\\nfrom PHN leadership roles, collaborations, and studies, 2) address EDI issues in all aspects of research and\\\\ntraining to amplify successes in mentoring the next generation of researchers in an increasingly diverse and\\\\ninclusive research environment, and 3) create the PHN Data Resource consisting of clinical, genomic, and\\\\nSDOH data to empower equitable, personalized outcomes prediction. PHN Utah is committed to the overall\\\\nmission of the PHN, has a proven track record of contributions to the success of the PHN, effective leadership\\\\nlocally and within the PHN, strong institutional support, proven mentorship of the next generation of physician\\\\nscientists, and will add significant resources to address equity and diversity, and provide existing infrastructure\\\\nto support a big data approach to personalized medicine.\", \"project_title\": \"Pediatric Heart Network (PHN) - Utah Center\", \"phr_text\": \"PROJECT NARRATIVE\\\\nAs a Core Clinical Research Center for >20 years, Pediatric Heart Network (PHN) Utah has supported the\\\\nmission to improve outcomes for individuals with congenital heart disease and pediatric acquired heart\\\\ndisease, and made particularly exceptional contributions to scientific discoveries, administrative activities, and\\\\ntraining the next generation of researchers. Going forward, PHN Utah will bring participants from unique\\\\nunderrepresented groups as well as additional resources and expertise to address inequities in all aspects of\\\\nresearch with the infrastructure and experience to lead a big data approach to collecting clinical, genomic, and\\\\nsocial determinants of health data to empower equitable personalized outcome prediction. Based on its history\\\\nof excellence, well defined leadership transition plan, and unique research infrastructure, PHN Utah is ideally\\\\npoised to seamlessly move into the next cycle and increase their considerable contributions as a Clinical\\\\nResearch Center.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-01-08T12:01:00Z\", \"budget_end\": \"2024-12-31T12:12:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 281245, \"indirect_cost_amt\": 151872, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10840620\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 9}, page_content='{\"appl_id\": 10991821, \"subproject_id\": null, \"fiscal_year\": 2025, \"project_num\": \"5R01HL167866-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 586682, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HL\", \"serial_num\": \"167866\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 9221216, \"first_name\": \"Sihem\", \"middle_name\": \"\", \"last_name\": \"Boudina\", \"is_contact_pi\": false, \"full_name\": \"Sihem  Boudina\", \"title\": \"ASSISTANT PROFESSOR\"}, {\"profile_id\": 7717532, \"first_name\": \"Kent\", \"middle_name\": \"\", \"last_name\": \"Lai\", \"is_contact_pi\": true, \"full_name\": \"Kent  Lai\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 12270331, \"first_name\": \"Eva\", \"middle_name\": \"\", \"last_name\": \"Morava-Kozicz\", \"is_contact_pi\": false, \"full_name\": \"Eva  Morava-Kozicz\", \"title\": \"\"}], \"contact_pi_name\": \"LAI, KENT \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2025, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 586682, \"direct_cost_ic\": 451535, \"indirect_cost_ic\": 135147}], \"project_start_date\": \"2023-12-01T12:12:00Z\", \"project_end_date\": \"2027-11-30T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-185\", \"full_study_section\": {\"srg_code\": \"MPPB\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Integrative Myocardial Physiology/Pathophysiology B Study Section[MPPB]\"}, \"award_notice_date\": \"2024-11-14T12:11:00Z\", \"core_project_num\": \"R01HL167866\", \"terms\": \"<Address><Affect><Age><ages><Aspartate><Asystole><Bgn protein><biglycan><Biochemical><biological signal transduction><Blood Serum><Body Tissues><bone proteoglycan I><Cardiac><Cardiac Arrest><Cardiac Diseases><Cardiac Disorders><cardiac function><cardiac metabolism><Cardiac Muscle Cells><Cardiac Myocytes><Cardiocyte><cardiomyocyte><Cardiomyopathies><Cell Communication and Signaling><Cell Signaling><Citric Acid Cycle><Classification><Clinical><Clotting><Co-Immunoprecipitations><Coagulation><Coagulation Process><Complex><Complication><Congenital disorders of glycosylation><Congestive Cardiomyopathy><Cranin><D-Galactose><D-Glucose><Defect><Development><developmental><Dextrose><Dilated Cardiomyopathy><Disease><disease phenotype><Disorder><Dysfunction><Dystroglycan><early onset><Echocardiogram><Echocardiography><effective therapy><effective treatment><Endocrine><Energy Expenditure><Energy Metabolism><Ensure><evidence base><Failure><Fiber><Fibroblasts><Frequencies><function of the heart><Functional disorder><Future><Galactopyranose><Galactopyranoside><Galactose><Gene Delivery><gene replacement><gene signatures><Generations><Genes><Genetic Alteration><Genetic Change><Genetic defect><genetic signature><genome mutation><Glucose><glucose 1 phosphate><Glucose-6-Phosphate><Glycogen><Glycogen Storage Disease><glycogenesis><glycogenolysis><Glycogenosis><Glycolysis><Glycoprotein GP-2><glycoproteomics><glycosylation><Goals><Heart><Heart Arrest><Heart Diseases><heart disorder><heart function><heart metabolism><Heart Muscle Cells><Heart myocyte><heart sonography><Hemostatic Agents><Hemostatics><hepatic body system><hepatic disease><Hepatic Disorder><hepatic organ system><hepatopathy><Hereditary><Hereditary Metabolic Disorder><Hexadecanoates><Hormonal><Human><Hypoglycemia><hypoglycemic><hypoglycemic episodes><Impairment><improved><in vivo><Inborn Errors of Metabolism><inborn metabolism disorder><Individual><Inherited><insight><Integrins><Integrins Extracellular Matrix><Intermediate Filaments><Intervention><Intervention Strategies><interventional strategy><Intracellular Communication and Signaling><Knock-out Mice><Knockout Mice><KO mice><Krebs Cycle><L-Aspartate><Laminin><Left><Left Ventricles><Left Ventricular Ejection Fraction><Left ventricular structure><Life><Liver><Liver diseases><liver disorder><liver function><LVEF><Measures><Medical><Merosin><Metabolic><Metabolic Glycosylation><metabolic profile><metabolism measurement><metabolomics><metabonomics><Mice><Mice Mammals><Mitochondria><mitochondrial><mitochondrial dysfunction><Modern Man><mouse model><Murine><murine model><Mus><Muscle><Muscle Cells><Muscle Tissue><muscular><Mutation><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><myocardium disease><myocardium disorder><Myocytes><Myofibrils><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><Null Mouse><OMIM><Online Mendelian Inheritance In Man><Oral><Ortholog><Orthologous Gene><oxidation><Palmitates><Pathogenicity><Pathology><pathophysiology><Patients><PG-S1><Phenotype><Physiopathology><Play><Preparation><preparations><Production><Protein Glycosylation><Proteins><proteoglycan I><proteoglycan S1><Research><resistance to therapy><resistant to therapy><Role><Sarcoglycans><Serum><Severities><Siderophilin><Signal Transduction><Signal Transduction Systems><Signaling><Skin><social role><Supplementation><Swelling><Symptoms><System><Systematics><TCA cycle><Testing><therapeutic evaluation><therapeutic resistance><therapeutic testing><therapy resistant><Time><Tissues><Tracer><transcriptomics><Transferrin><Transthoracic Echocardiography><treatment resistance><Tricarboxylic Acid Cycle><Ventricular><\\\\u03b1-DG><\\\\u03b1-Dystroglycan><\\\\u03b1DG>\", \"pref_terms\": \"Address;Affect;Age;Aspartate;Biochemical;Cardiac;Cardiac Myocytes;Cardiomyopathies;Citric Acid Cycle;Classification;Clinical;Co-Immunoprecipitations;Coagulation Process;Complex;Complication;Congenital disorders of glycosylation;Defect;Development;Dilated Cardiomyopathy;Disease;Dystroglycan;Echocardiography;Endocrine;Energy Metabolism;Ensure;Failure;Fiber;Fibroblasts;Frequencies;Functional disorder;Future;Galactose;Gene Delivery;Generations;Genes;Glucose;Glucose-6-Phosphate;Glycogen;Glycogen Storage Disease;Glycolysis;Goals;Heart;Heart Arrest;Heart Diseases;Hemostatic Agents;Hormonal;Human;Hypoglycemia;Impairment;Inborn Errors of Metabolism;Individual;Inherited;Integrins;Intermediate Filaments;Intervention;Knockout Mice;Laminin;Left;Left Ventricular Ejection Fraction;Left ventricular structure;Life;Liver;Liver diseases;Measures;Medical;Merosin;Metabolic;Mitochondria;Mus;Muscle;Muscle Cells;Mutation;Myofibrils;Online Mendelian Inheritance In Man;Oral;Orthologous Gene;Palmitates;Pathogenicity;Pathology;Patients;Phenotype;Play;Preparation;Production;Protein Glycosylation;Proteins;Research;Role;Sarcoglycans;Serum;Severities;Signal Transduction;Skin;Supplementation;Swelling;Symptoms;System;Testing;Time;Tissues;Tracer;Transferrin;Ventricular;biglycan;disease phenotype;early onset;effective therapy;evidence base;gene replacement;genetic signature;glucose 1 phosphate;glycogenesis;glycogenolysis;glycoproteomics;glycosylation;heart function;heart metabolism;improved;in vivo;insight;liver function;metabolic profile;metabolomics;mitochondrial dysfunction;mouse model;novel;novel therapeutics;oxidation;therapeutic evaluation;therapy resistant;transcriptomics;\\\\u03b1-Dystroglycan\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\n Phosphoglucomutase 1 (PGM1) catalyzes the interconversion of glucose-1 phosphate (Glc-1P) and glucose-6\\\\nphosphate (Glc-6P) and therefore, it plays a fundamental role in glycolysis, glycogenesis, and glycogenolysis.\\\\nConsequently, inherited deficiency of PGM1 in humans has previously been identified as Glycogen Storage Disorder\\\\n(GSD) Type 14, but has lately been revealed as a Congenital Disorders of Glycosylation (CDG) with mixed type I and\\\\ntype II glycosylation defects. The liver, the skeletomuscular, endocrine and coagulation systems all get involved over\\\\ntime, but the most life-threatening complication is the early onset of dilated cardiomyopathy (DCM). Recently, we\\\\ndiscovered that oral D-galactose supplementation improved serum transferrin hypoglycosylation, liver function, endocrine\\\\nabnormalities, and reduces frequency of hypoglycemic episodes, but does not alleviate the fatal cardiomyopathy and most\\\\nmuscle symptoms. To study the pathobiology of cardiac disease in PGM1-CDG patients, we constructed cardiomyocyte-\\\\nspecific conditional Pgm2 (mouse ortholog of human PGM1) knockout mice (Pgm2 cKO) mice. Using\\\\nechocardiography, we corroborated a DCM phenotype with significantly reduced ejection fraction and left ventricular\\\\ndilation similar to those seen in PGM1-CDG patients. Ultrastructural analysis revealed Z-disk disarray,\\\\nswollen/fragmented mitochondria and macroscopic thickening in the heart of a PGM1-CDG patient. Preliminary\\\\ntranscriptomic analysis of hearts from Pgm2 cKO mice demonstrates a gene signature of DCM. Assessing the\\\\nglycoproteomic profile of left ventricular tissue of Pgm2 cKO mice, our group showed significant glycosylation defects in\\\\nsarcolemmal proteins including Laminin-211 (Merosin), sarcoglycans and biglycan. Collectively, not only does our\\\\nmouse model recapitulate the cardiac phenotypes of PGM1-CDG patients, but our characterization to-date also supports\\\\nthe overarching hypothesis that altered glycosylation alone cannot fully explain the pathobiology of cardiac symptoms in\\\\nPGM1-CDG patients as other biochemical and metabolic disturbances may also contribute. To test this hypothesis, we\\\\nwill (1) examine for altered energy metabolism, and (2) clarify the role played by aberrant glycosylation of sarcolemmal\\\\nproteins in the DCM development in the Pgm2 cKO mice. Lastly, we will test the therapeutic potential of PGM1 gene\\\\nreplacement in the Pgm2 cKO mice by assessing whether PGM1 augmentation will restore the energetic deficit and\\\\nreverse Lamnin-211 glycosylation abnormalities resulting in improved cardiac function and survival in Pgm2\\\\ncKO mice.\", \"project_title\": \"Pathobiological mechanisms of cardiac disease in PGM1-CDG\", \"phr_text\": \"PROJECT NARRATIVE\\\\nPhosphoglucomutase I Deficiency, an inborn error of metabolism, was formerly classified as Glycogen Storage Disorder\\\\nType 14, although recent research demonstrated that it is also a Congenital Disorder of Glycosylation (CDG) with mixed\\\\nglycosylation defects. Many aspects of the pathophysiology of the complex disease phenotypes, which include the\\\\ntherapy-resistant lethal dilated cardiomyopathy (DCM) remains unclear, despite oral galactose supplementation improves\\\\nsome other clinical symptoms. The long-term goals of this project are to employ cardiac-specific conditional Pgm2-\\\\nknockout mouse model to (a) define the pathogenic mechanisms of the cardiac phenotypes; and (b) develop effective, safe\\\\nand evidence-based therapies to address the unmet medical needs of the patients.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-12-01T12:12:00Z\", \"budget_end\": \"2025-11-30T12:11:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 451535, \"indirect_cost_amt\": 135147, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10991821\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 10}, page_content='{\"appl_id\": 10824796, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1R01HL167866-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R01\", \"award_amount\": 659131, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R01\", \"ic_code\": \"HL\", \"serial_num\": \"167866\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 9221216, \"first_name\": \"Sihem\", \"middle_name\": \"\", \"last_name\": \"Boudina\", \"is_contact_pi\": false, \"full_name\": \"Sihem  Boudina\", \"title\": \"ASSISTANT PROFESSOR\"}, {\"profile_id\": 7717532, \"first_name\": \"Kent\", \"middle_name\": \"\", \"last_name\": \"Lai\", \"is_contact_pi\": true, \"full_name\": \"Kent  Lai\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 12270331, \"first_name\": \"Eva\", \"middle_name\": \"\", \"last_name\": \"Morava-Kozicz\", \"is_contact_pi\": false, \"full_name\": \"Eva  Morava-Kozicz\", \"title\": \"\"}], \"contact_pi_name\": \"LAI, KENT \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 659131, \"direct_cost_ic\": 497655, \"indirect_cost_ic\": 161476}], \"project_start_date\": \"2023-12-01T12:12:00Z\", \"project_end_date\": \"2027-11-30T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-185\", \"full_study_section\": {\"srg_code\": \"MPPB\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Integrative Myocardial Physiology/Pathophysiology B Study Section[MPPB]\"}, \"award_notice_date\": \"2023-11-27T12:11:00Z\", \"core_project_num\": \"R01HL167866\", \"terms\": \"<Affect><ages><Age><Congestive Cardiomyopathy><Dilated Cardiomyopathy><Krebs Cycle><TCA cycle><Tricarboxylic Acid Cycle><Citric Acid Cycle><Systematics><Classification><Complication><Disorder><Disease><Echocardiogram><Transthoracic Echocardiography><heart sonography><Echocardiography><Energy Expenditure><Energy Metabolism><Fibroblasts><Future><D-Galactose><Galactopyranose><Galactopyranoside><Galactose><Genes><D-Glucose><Dextrose><Glucose><Glycogen><Glycogenosis><Glycogen Storage Disease><Glycolysis><Metabolic Glycosylation><glycosylation><Goals><Heart><Asystole><Cardiac Arrest><Heart Arrest><Cardiac Diseases><Cardiac Disorders><heart disorder><Heart Diseases><Hemostatics><Hemostatic Agents><Modern Man><Human><hypoglycemic><hypoglycemic episodes><Hypoglycemia><Integrins Extracellular Matrix><Integrins><Intermediate Filaments><Glycoprotein GP-2><Laminin><hepatic body system><hepatic organ system><Liver><Hepatic Disorder><hepatic disease><hepatopathy><liver disorder><Liver diseases><Inborn Errors of Metabolism><Hereditary Metabolic Disorder><inborn metabolism disorder><Mitochondria><mitochondrial><Mus><Mice><Mice Mammals><Murine><Muscle><Muscle Tissue><muscular><Mutation><Genetic Alteration><Genetic Change><Genetic defect><genome mutation><Myofibrils><oxidation><Palmitates><Hexadecanoates><Pathology><Patients><Phenotype><Play><Production><Proteins><Research><Role><social role><Signal Transduction><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Swelling><Testing><Time><Tissues><Body Tissues><Transferrin><Siderophilin><biglycan><Bgn protein><PG-S1><bone proteoglycan I><proteoglycan I><proteoglycan S1><glucose 1 phosphate><Glucose-6-Phosphate><Generations><Measures><L-Aspartate><Aspartate><Cranin><Dystroglycan><improved><Left><Clinical><Biochemical><Medical><KO mice><Knock-out Mice><Null Mouse><Knockout Mice><Ensure><Fiber><Cardiac Muscle Cells><Cardiocyte><Heart Muscle Cells><Heart myocyte><cardiomyocyte><Cardiac Myocytes><Left Ventricles><Left ventricular structure><Blood Serum><Serum><Failure><cardiac function><function of the heart><heart function><liver function><insight><Individual><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Metabolic><Protein Glycosylation><Merosin><Life><LVEF><Left Ventricular Ejection Fraction><Frequencies><Hereditary><Inherited><Severities><Complex><Oral><System><Hormonal><Endocrine><glycogenesis><glycogenolysis><heart metabolism><cardiac metabolism><Muscle Cells><Myocytes><novel><gene replacement><Cardiomyopathies><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><myocardium disease><myocardium disorder><Intervention><Intervention Strategies><interventional strategy><Online Mendelian Inheritance In Man><OMIM><Skin><Pathogenicity><therapeutic evaluation><therapeutic testing><\\\\u03b1-Dystroglycan><\\\\u03b1-DG><\\\\u03b1DG><Coagulation Process><Clotting><Coagulation><metabolomics><metabolism measurement><metabonomics><Orthologous Gene><Ortholog><Address><Co-Immunoprecipitations><Sarcoglycans><Defect><Symptoms><Supplementation><in vivo><Preparation><preparations><Tracer><Ventricular><Cardiac><Gene Delivery><Development><developmental><early onset><therapy resistant><resistance to therapy><resistant to therapy><therapeutic resistance><treatment resistance><disease phenotype><Impairment><transcriptomics><novel therapeutics><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapy><mitochondrial dysfunction><mouse model><murine model><evidence base><effective therapy><effective treatment><genetic signature><gene signatures><metabolic profile><glycoproteomics><Congenital disorders of glycosylation>\", \"pref_terms\": \"Address;Affect;Age;Aspartate;Biochemical;Cardiac;Cardiac Myocytes;Cardiomyopathies;Citric Acid Cycle;Classification;Clinical;Co-Immunoprecipitations;Coagulation Process;Complex;Complication;Congenital disorders of glycosylation;Defect;Development;Dilated Cardiomyopathy;Disease;Dystroglycan;Echocardiography;Endocrine;Energy Metabolism;Ensure;Failure;Fiber;Fibroblasts;Frequencies;Functional disorder;Future;Galactose;Gene Delivery;Generations;Genes;Glucose;Glucose-6-Phosphate;Glycogen;Glycogen Storage Disease;Glycolysis;Goals;Heart;Heart Arrest;Heart Diseases;Hemostatic Agents;Hormonal;Human;Hypoglycemia;Impairment;Inborn Errors of Metabolism;Individual;Inherited;Integrins;Intermediate Filaments;Intervention;Knockout Mice;Laminin;Left;Left Ventricular Ejection Fraction;Left ventricular structure;Life;Liver;Liver diseases;Measures;Medical;Merosin;Metabolic;Mitochondria;Mus;Muscle;Muscle Cells;Mutation;Myofibrils;Online Mendelian Inheritance In Man;Oral;Orthologous Gene;Palmitates;Pathogenicity;Pathology;Patients;Phenotype;Play;Preparation;Production;Protein Glycosylation;Proteins;Research;Role;Sarcoglycans;Serum;Severities;Signal Transduction;Skin;Supplementation;Swelling;Symptoms;System;Testing;Time;Tissues;Tracer;Transferrin;Ventricular;biglycan;disease phenotype;early onset;effective therapy;evidence base;gene replacement;genetic signature;glucose 1 phosphate;glycogenesis;glycogenolysis;glycoproteomics;glycosylation;heart function;heart metabolism;improved;in vivo;insight;liver function;metabolic profile;metabolomics;mitochondrial dysfunction;mouse model;novel;novel therapeutics;oxidation;therapeutic evaluation;therapy resistant;transcriptomics;\\\\u03b1-Dystroglycan\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\n Phosphoglucomutase 1 (PGM1) catalyzes the interconversion of glucose-1 phosphate (Glc-1P) and glucose-6\\\\nphosphate (Glc-6P) and therefore, it plays a fundamental role in glycolysis, glycogenesis, and glycogenolysis.\\\\nConsequently, inherited deficiency of PGM1 in humans has previously been identified as Glycogen Storage Disorder\\\\n(GSD) Type 14, but has lately been revealed as a Congenital Disorders of Glycosylation (CDG) with mixed type I and\\\\ntype II glycosylation defects. The liver, the skeletomuscular, endocrine and coagulation systems all get involved over\\\\ntime, but the most life-threatening complication is the early onset of dilated cardiomyopathy (DCM). Recently, we\\\\ndiscovered that oral D-galactose supplementation improved serum transferrin hypoglycosylation, liver function, endocrine\\\\nabnormalities, and reduces frequency of hypoglycemic episodes, but does not alleviate the fatal cardiomyopathy and most\\\\nmuscle symptoms. To study the pathobiology of cardiac disease in PGM1-CDG patients, we constructed cardiomyocyte-\\\\nspecific conditional Pgm2 (mouse ortholog of human PGM1) knockout mice (Pgm2 cKO) mice. Using\\\\nechocardiography, we corroborated a DCM phenotype with significantly reduced ejection fraction and left ventricular\\\\ndilation similar to those seen in PGM1-CDG patients. Ultrastructural analysis revealed Z-disk disarray,\\\\nswollen/fragmented mitochondria and macroscopic thickening in the heart of a PGM1-CDG patient. Preliminary\\\\ntranscriptomic analysis of hearts from Pgm2 cKO mice demonstrates a gene signature of DCM. Assessing the\\\\nglycoproteomic profile of left ventricular tissue of Pgm2 cKO mice, our group showed significant glycosylation defects in\\\\nsarcolemmal proteins including Laminin-211 (Merosin), sarcoglycans and biglycan. Collectively, not only does our\\\\nmouse model recapitulate the cardiac phenotypes of PGM1-CDG patients, but our characterization to-date also supports\\\\nthe overarching hypothesis that altered glycosylation alone cannot fully explain the pathobiology of cardiac symptoms in\\\\nPGM1-CDG patients as other biochemical and metabolic disturbances may also contribute. To test this hypothesis, we\\\\nwill (1) examine for altered energy metabolism, and (2) clarify the role played by aberrant glycosylation of sarcolemmal\\\\nproteins in the DCM development in the Pgm2 cKO mice. Lastly, we will test the therapeutic potential of PGM1 gene\\\\nreplacement in the Pgm2 cKO mice by assessing whether PGM1 augmentation will restore the energetic deficit and\\\\nreverse Lamnin-211 glycosylation abnormalities resulting in improved cardiac function and survival in Pgm2\\\\ncKO mice.\", \"project_title\": \"Pathobiological mechanisms of cardiac disease in PGM1-CDG\", \"phr_text\": \"PROJECT NARRATIVE\\\\nPhosphoglucomutase I Deficiency, an inborn error of metabolism, was formerly classified as Glycogen Storage Disorder\\\\nType 14, although recent research demonstrated that it is also a Congenital Disorder of Glycosylation (CDG) with mixed\\\\nglycosylation defects. Many aspects of the pathophysiology of the complex disease phenotypes, which include the\\\\ntherapy-resistant lethal dilated cardiomyopathy (DCM) remains unclear, despite oral galactose supplementation improves\\\\nsome other clinical symptoms. The long-term goals of this project are to employ cardiac-specific conditional Pgm2-\\\\nknockout mouse model to (a) define the pathogenic mechanisms of the cardiac phenotypes; and (b) develop effective, safe\\\\nand evidence-based therapies to address the unmet medical needs of the patients.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2023-12-01T12:12:00Z\", \"budget_end\": \"2024-11-30T12:11:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 497655, \"indirect_cost_amt\": 161476, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10824796\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 11}, page_content='{\"appl_id\": 10575222, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"1R21HD110817-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R21\", \"award_amount\": 227760, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R21\", \"ic_code\": \"HD\", \"serial_num\": \"110817\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 77919370, \"first_name\": \"Allison\", \"middle_name\": \"\", \"last_name\": \"Judkins\", \"is_contact_pi\": true, \"full_name\": \"Allison  Judkins\", \"title\": \"ASSOCIATE PROFESSOR OF PEDIATRICS\"}], \"contact_pi_name\": \"JUDKINS, ALLISON \", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 227760, \"direct_cost_ic\": 150000, \"indirect_cost_ic\": 77760}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2025-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-195\", \"full_study_section\": {\"srg_code\": \"CIDH\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Clinical Informatics and Digital Health Study Section[CIDH]\"}, \"award_notice_date\": \"2023-08-23T12:08:00Z\", \"core_project_num\": \"R21HD110817\", \"terms\": \"<adolescent girl><Female Adolescents><21+ years old><Adult Human><adulthood><Adult><Affect><Africa><ages><Age><Anemia><Hemolytic Anemia><Asia><Attention><Blood><Blood Reticuloendothelial System><Carbon Monoxide><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Classification><Systematics><Color><Community Health Aides><community health worker><Decision Making><Diagnosis><Disease><Disorder><Feasibility Studies><Fetus><Government><Health><Health care facility><Health Facilities><Healthcare Facility><care facilities><Blood Tests><Hematologic Tests><Hematological Tests><Hematology Testing><Hemoglobin concentration result><hemoglobin level><Hemoglobin><Incidence><India><Infant><Low Birth Weight Infant><low birth weight><low birthweight><Small for Gestational Age Infant><small for gestational age><Maternal Mortality><maternal death><Methods><Morbidity - disease rate><Morbidity><mortality><Mothers><Patients><Perception><Physical Examination><Medical Inspection><physical examinations><Pregnancy><Gestation><Pregnant Women><expectant mother><expecting mother><pregnant mothers><Public Health><Reference Standards><Resources><Research Resources><Running><Skin Pigmentation><Specificity><Surveys><Survey Instrument><Testing><Measures><Prematurely delivering><Preterm Birth><premature childbirth><premature delivery><preterm delivery><Premature Birth><improved><Chronic><Clinical><Variation><Variant><Adolescent Youth><juvenile><juvenile human><Adolescent><Evaluation><Training><Visual><Rural><Measurement><participant recruitment><Patient Recruitments><Fe element><Iron><tool><instrument><Diagnostic><Exhalation><Exhaling><Respiratory Expiration><System><Country><brain metabolism><novel><pregnant teen><pregnant adolescent><teens who are pregnant><Devices><portability><Vulnerable Populations><vulnerable group><vulnerable individual><vulnerable people><Skin><Provider><Data><Predictive Value><in vivo><Validation><validations><Nutritional><nutritious><Process><Community Health><community-based health><Development><developmental><point of care><productivity loss><cost><burden of disease><disease burden><years of life lost to disability><years of life lost to disease><burden of illness><health economics><Outcome><Population><Prevalence><12 years of age><age 12 years><twelve year old><twelve years of age><12 year old><tertiary care><clinical relevance><clinically relevant><high risk><combat><minimally invasive><patient population><standard of care><effective treatment><effective therapy><clinical decision-making><screenings><screening><LMIC><low and middle-income countries><screening program><maternal risk><antenatal care><acceptability and feasibility><feasibility testing><Resource-limited setting><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><diagnostic tool><Non-Invasive Detection><Noninvasive Detection>\", \"pref_terms\": \"12 year old;Adolescent;Adult;Affect;Africa;Age;Anemia;Asia;Attention;Blood;Blood Tests;Carbon Monoxide;Child;Chronic;Classification;Clinical;Color;Community Health;Community Health Aides;Country;Data;Decision Making;Development;Devices;Diagnosis;Diagnostic;Disease;Evaluation;Exhalation;Feasibility Studies;Female Adolescents;Fetus;Government;Health;Health care facility;Hemoglobin;Hemoglobin concentration result;Hemolytic Anemia;Incidence;India;Infant;Iron;Low Birth Weight Infant;Maternal Mortality;Measurement;Measures;Methods;Morbidity - disease rate;Mothers;Non-Invasive Detection;Nutritional;Outcome;Patient Recruitments;Patients;Perception;Physical Examination;Population;Predictive Value;Pregnancy;Pregnant Women;Premature Birth;Prevalence;Process;Provider;Public Health;Reference Standards;Resource-limited setting;Resources;Running;Rural;Skin;Skin Pigmentation;Small for Gestational Age Infant;Specificity;Surveys;System;Testing;Training;Validation;Variant;Visual;Vulnerable Populations;acceptability and feasibility;antenatal care;brain metabolism;burden of illness;clinical decision-making;clinically relevant;combat;cost;diagnostic tool;effective therapy;feasibility testing;health economics;high risk;improved;in vivo;instrument;low and middle-income countries;maternal risk;minimally invasive;mortality;novel;patient population;point of care;portability;pregnant teen;productivity loss;screening;screening program;standard of care;tertiary care;tool\", \"abstract_text\": \"Project Summary\\\\nValidation and Feasibility Non-Invasive Anemia Diagnostic Tool (ASIST Device)\\\\nThis project will establish the accuracy and feasibility of our novel non-invasive, portable, low-\\\\ncost device to diagnose chronic nutritional and hemolytic anemia in resource poor areas. This\\\\ndevice has the potential to mitigate the prevalence of anemia in LMICs, improving health\\\\noutcomes, especially in pregnant women and adolescent girls.\\\\nDespite increased attention from the WHO, anemia continues to be a formidable public health\\\\nissue affecting a third of the world\\'s population, with much of the disease burden in low- and\\\\nmiddle- income countries (LMICs). Pregnant women and young children are the most vulnerable\\\\nof these populations. Severe anemia in pregnancy contributes significantly to preventable\\\\nmorbidity and mortality both during pregnancy and in the delivery process. For the fetus of an\\\\nanemic mother, there are long-term neurodevelopmental consequences.\\\\nIn resource-rich countries, anemia can be diagnosed using minimally invasive point of care\\\\ndevices and nutritional and hemolytic causes can be differentiated without invasive testing using\\\\nexhaled Carbon Monoxide, a breakdown product of hemoglobin. In low- and middle-income\\\\ncountries (LMICs), where this type of testing is not readily available, the diagnosis of anemia is\\\\noften inaccurate or missed all together. Based on the global burden of anemia, especially in\\\\nLMICs, there is a need for a low-cost device that can non-invasively detect anemia and help to\\\\ndistinguish between nutritional and hemolytic causes to inform clinical decision making.\", \"project_title\": \"Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings\", \"phr_text\": \"Project Narrative\\\\nThis project will result in the pilot validity and feasibility testing of a novel, non-invasive device\\\\nfor screening high-risk patient populations for anemia, and assist in differentiating between\\\\nhemolytic and non-hemolytic causes. Anemia remains pervasive public health issue, which\\\\naffects one third of the world\\\\u2019s population, particularly in pregnant women and adolescent\\\\ngirls. There is an urgent need for an effective, non-invasive tool to combat this issue.\", \"spending_categories_desc\": \"Bioengineering; Clinical Research; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Health Services; Hematology; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Pregnancy; Preterm, Low Birth Weight and Health of the Newborn; Social Determinants of Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-01T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 150000, \"indirect_cost_amt\": 77760, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10575222\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 12}, page_content='{\"appl_id\": 10912427, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5R21HD110817-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R21\", \"award_amount\": 192500, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R21\", \"ic_code\": \"HD\", \"serial_num\": \"110817\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 77919370, \"first_name\": \"Allison\", \"middle_name\": \"\", \"last_name\": \"Judkins\", \"is_contact_pi\": true, \"full_name\": \"Allison  Judkins\", \"title\": \"ASSOCIATE PROFESSOR OF PEDIATRICS\"}], \"contact_pi_name\": \"JUDKINS, ALLISON \", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 192500, \"direct_cost_ic\": 125000, \"indirect_cost_ic\": 67500}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2025-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-195\", \"full_study_section\": {\"srg_code\": \"CIDH\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Clinical Informatics and Digital Health Study Section[CIDH]\"}, \"award_notice_date\": \"2024-08-05T12:08:00Z\", \"core_project_num\": \"R21HD110817\", \"terms\": \"<0-11 years old><12 year old><12 years of age><21+ years old><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Africa><Age><Anemia><Asia><Attention><Blood><Blood Reticuloendothelial System><Blood Tests><Carbon Monoxide><Child><Child Youth><Children (0-21)><Chronic><Classification><Clinical><Color><Community Health><Community Health Aides><Country><Data><Decision Making><Development><Devices><Diagnosis><Diagnostic><Disease><Disorder><Evaluation><Exhalation><Exhaling><Fe element><Feasibility Studies><Female Adolescents><Fetus><Gestation><Government><Health><Health Facilities><Health care facility><Healthcare Facility><Hematologic Tests><Hematological Tests><Hematology Testing><Hemoglobin><Hemoglobin concentration result><Hemolytic Anemia><Incidence><India><Infant><Iron><LMIC><Low Birth Weight Infant><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Maternal Mortality><Measurement><Measures><Medical Inspection><Methods><Morbidity><Morbidity - disease rate><Mothers><Non-Invasive Detection><Noninvasive Detection><Nutritional><Outcome><Patient Recruitments><Patients><Perception><Physical Examination><Population><Predictive Value><Pregnancy><Pregnant Women><Premature Birth><Prematurely delivering><Preterm Birth><Prevalence><Process><Provider><Public Health><Reference Standards><Research Resources><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Resources><Respiratory Expiration><Running><Rural><Skin><Skin Pigmentation><Small for Gestational Age Infant><Specificity><Survey Instrument><Surveys><System><Systematics><Testing><Training><Validation><Variant><Variation><Visual><Vulnerable Populations><acceptability and feasibility><adolescent girl><adolescents who are pregnant><adulthood><age 12 years><ages><antenatal care><brain metabolism><burden of disease><burden of illness><care facilities><clinical decision-making><clinical relevance><clinically relevant><combat><community health worker><community-based health><cost><developmental><diagnostic tool><disease burden><effective therapy><effective treatment><expectant mother><expecting mother><feasibility testing><health economics><hemoglobin level><high risk><improved><in vivo><instrument><juvenile><juvenile human><kids><low and middle-income countries><low birth weight><low birthweight><maternal death><maternal risk><minimally invasive><mortality><novel><nutritious><participant recruitment><patient population><physical examinations><point of care><portability><pregnant adolescent><pregnant mothers><pregnant teen><premature childbirth><premature delivery><preterm delivery><productivity loss><screening><screening program><screenings><small for gestational age><standard of care><teens who are pregnant><tertiary care><tool><twelve year old><twelve years of age><validations><vulnerable group><vulnerable individual><vulnerable people><youngster>\", \"pref_terms\": \"12 year old;Adolescent;Adult;Affect;Africa;Age;Anemia;Asia;Attention;Blood;Blood Tests;Carbon Monoxide;Child;Chronic;Classification;Clinical;Color;Community Health;Community Health Aides;Country;Data;Decision Making;Development;Devices;Diagnosis;Diagnostic;Disease;Evaluation;Exhalation;Feasibility Studies;Female Adolescents;Fetus;Government;Health;Health care facility;Hemoglobin;Hemoglobin concentration result;Hemolytic Anemia;Incidence;India;Infant;Iron;Low Birth Weight Infant;Maternal Mortality;Measurement;Measures;Methods;Morbidity - disease rate;Mothers;Non-Invasive Detection;Nutritional;Outcome;Patient Recruitments;Patients;Perception;Physical Examination;Population;Predictive Value;Pregnancy;Pregnant Women;Premature Birth;Prevalence;Process;Provider;Public Health;Reference Standards;Resource-limited setting;Resources;Running;Rural;Skin;Skin Pigmentation;Small for Gestational Age Infant;Specificity;Surveys;System;Testing;Training;Validation;Variant;Visual;Vulnerable Populations;acceptability and feasibility;antenatal care;brain metabolism;burden of illness;clinical decision-making;clinically relevant;combat;cost;diagnostic tool;effective therapy;feasibility testing;health economics;high risk;improved;in vivo;instrument;low and middle-income countries;maternal risk;minimally invasive;mortality;novel;patient population;point of care;portability;pregnant teen;productivity loss;screening;screening program;standard of care;tertiary care;tool\", \"abstract_text\": \"Project Summary\\\\nValidation and Feasibility Non-Invasive Anemia Diagnostic Tool (ASIST Device)\\\\nThis project will establish the accuracy and feasibility of our novel non-invasive, portable, low-\\\\ncost device to diagnose chronic nutritional and hemolytic anemia in resource poor areas. This\\\\ndevice has the potential to mitigate the prevalence of anemia in LMICs, improving health\\\\noutcomes, especially in pregnant women and adolescent girls.\\\\nDespite increased attention from the WHO, anemia continues to be a formidable public health\\\\nissue affecting a third of the world\\'s population, with much of the disease burden in low- and\\\\nmiddle- income countries (LMICs). Pregnant women and young children are the most vulnerable\\\\nof these populations. Severe anemia in pregnancy contributes significantly to preventable\\\\nmorbidity and mortality both during pregnancy and in the delivery process. For the fetus of an\\\\nanemic mother, there are long-term neurodevelopmental consequences.\\\\nIn resource-rich countries, anemia can be diagnosed using minimally invasive point of care\\\\ndevices and nutritional and hemolytic causes can be differentiated without invasive testing using\\\\nexhaled Carbon Monoxide, a breakdown product of hemoglobin. In low- and middle-income\\\\ncountries (LMICs), where this type of testing is not readily available, the diagnosis of anemia is\\\\noften inaccurate or missed all together. Based on the global burden of anemia, especially in\\\\nLMICs, there is a need for a low-cost device that can non-invasively detect anemia and help to\\\\ndistinguish between nutritional and hemolytic causes to inform clinical decision making.\", \"project_title\": \"Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings\", \"phr_text\": \"Project Narrative\\\\nThis project will result in the pilot validity and feasibility testing of a novel, non-invasive device\\\\nfor screening high-risk patient populations for anemia, and assist in differentiating between\\\\nhemolytic and non-hemolytic causes. Anemia remains pervasive public health issue, which\\\\naffects one third of the world\\\\u2019s population, particularly in pregnant women and adolescent\\\\ngirls. There is an urgent need for an effective, non-invasive tool to combat this issue.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 125000, \"indirect_cost_amt\": 67500, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10912427\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 13}, page_content='{\"appl_id\": 10918215, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5K08HG013111-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"K08\", \"award_amount\": 269246, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"K08\", \"ic_code\": \"HG\", \"serial_num\": \"013111\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 14797210, \"first_name\": \"Sabrina\", \"middle_name\": \"\", \"last_name\": \"Malone Jenkins\", \"is_contact_pi\": true, \"full_name\": \"Sabrina  Malone Jenkins\", \"title\": \"NEONATOLOGIST\"}], \"contact_pi_name\": \"MALONE JENKINS, SABRINA \", \"agency_ic_admin\": {\"code\": \"HG\", \"abbreviation\": \"NHGRI\", \"name\": \"National Human Genome Research Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HG\", \"name\": \"National Human Genome Research Institute\", \"abbreviation\": \"NHGRI\", \"total_cost\": 269246, \"direct_cost_ic\": 249302, \"indirect_cost_ic\": 19944}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2028-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-203\", \"full_study_section\": {\"srg_code\": \"GNOM\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Genome Research Study Section[GNOM-G]\"}, \"award_notice_date\": \"2024-08-28T12:08:00Z\", \"core_project_num\": \"K08HG013111\", \"terms\": \"<Acceleration><Address><Adoption><Application Context><Career Development Awards><Career Development Awards and Programs><Career Development Programs K-Series><Characteristics><Clinical><Consensus><Critical Care><Data><Development Plans><Diagnosis><Dissemination and Implementation><Education and Training><Ensure><Evidence based intervention><Family><Fostering><Funding><Future><Genomic medicine><Genomics><Goals><Guidelines><Health><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Human><Infrastructure><Institution><Intervention><Intervention Strategies><Investigators><K-Awards><K-Series Research Career Programs><Knowledge><Life><Logic><Maintenance><Mentors><Methodology><Modeling><Modern Man><Neonatal><Neonatal Intensive Care Units><Newborn Intensive Care Units><Outcome><PRISM framework><PRISM model><Patients><Perception><Physicians><Pilot Projects><Practical Robust Implementation and Sustainability Model><Pragmatic, Robust Implementation and Sustainability Model><Provider><RE-AIM><Reach, Effectiveness, Adoption, Implementation, and Maintenance><Recommendation><Research><Research Career Program><Research Personnel><Research Resources><Researchers><Resources><Role><Rural><Scientist><Specific qualifier value><Specified><Speed><Survey Instrument><Surveys><Techniques><Technology><Testing><Time><Training><Training and Education><Translational Research><Translational Science><barriers to implementation><career><career development><clinical applicability><clinical application><clinical care><clinical implementation><clinical trial implementation><cognitive task><contextual factors><critically ill newborn><design><designing><disparity in care><disparity in healthcare><dissemination science><education resources><educational resources><effectiveness/implementation hybrid><empowerment><entire genome><evidence base><experience><full genome><genome sequencing><health care disparity><health care inequality><health care inequity><health care personnel><health care settings><health care worker><health provider><health workforce><healthcare disparity><healthcare inequality><healthcare inequity><healthcare personnel><healthcare settings><implementation barriers><implementation challenges><implementation of clinical trials><implementation research><implementation science><implementation strategy><improved><innovate><innovation><innovative><interventional strategy><medical personnel><member><metropolitan><multidisciplinary><neonatal ICU><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pilot study><precision medicine><precision-based medicine><programs><reach, efficacy, adoption, implementation, and maintenance><skills><social role><standard of care><strategies for implementation><success><task analysis><tool><translation research><translational investigation><treatment provider><under served area><under served geographic area><under served location><under served region><underserved area><underserved geographic area><underserved location><underserved region><uptake><usability><whole genome>\", \"pref_terms\": \"Acceleration;Address;Adoption;Characteristics;Clinical;Consensus;Critical Care;Data;Development Plans;Diagnosis;Dissemination and Implementation;Ensure;Evidence based intervention;Family;Fostering;Funding;Future;Genomic medicine;Genomics;Goals;Guidelines;Health;Health Personnel;Human;Infrastructure;Institution;Intervention;K-Series Research Career Programs;Knowledge;Life;Logic;Maintenance;Mentors;Methodology;Modeling;Neonatal;Neonatal Intensive Care Units;Outcome;Patients;Perception;Physicians;Pilot Projects;Practical Robust Implementation and Sustainability Model;Provider;Reach, Effectiveness, Adoption, Implementation, and Maintenance;Recommendation;Research;Research Personnel;Resources;Role;Rural;Scientist;Specific qualifier value;Speed;Surveys;Techniques;Technology;Testing;Time;Training;Training and Education;Translational Research;career;career development;clinical application;clinical care;clinical implementation;clinical trial implementation;cognitive task;contextual factors;critically ill newborn;design;dissemination science;education resources;effectiveness/implementation hybrid;empowerment;evidence base;experience;genome sequencing;health care disparity;health care settings;implementation barriers;implementation research;implementation science;implementation strategy;improved;innovation;member;metropolitan;multidisciplinary;personalized medicine;precision medicine;programs;skills;standard of care;success;task analysis;tool;underserved area;uptake;usability;whole genome\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nCurrent recommendations indicate that rapid whole genome sequencing should be the standard of care for\\\\ncritically ill newborns. The disconnect between these guidelines and the adoption of whole genome sequencing\\\\nin the neonatal intensive care unit delays diagnoses and life-saving therapies. The effects are greater in rural\\\\nLevel 3 settings where healthcare inequities exist. Translational science strategies to implement genomic\\\\nmedicine into clinical care are sorely needed, but currently lacking. This proposal is a dissemination and\\\\nimplementation science project addressing the lack of use of rapid whole genome sequencing in Level 4\\\\n(tertiary, metropolitan, higher resourced) and Level 3 (non-tertiary, rural, lower resourced) neonatal intensive\\\\ncare units by developing Level-specific logic models outlining specific barriers and facilitators, developing and\\\\nleveraging strategies that address these barriers, and test these strategies in a small-scale demonstration\\\\nproject.\\\\nThe overall goal of the integrated career development plan is to prepare the candidate to become an expert in\\\\ndissemination and implementation science and improve the clinical application of personalized medicine in\\\\nneonatal critical care settings. The training and research will be conducted at an institution with a strong record\\\\nof providing excellent support and robust training and educational resources. The candidate\\\\u2019s department is\\\\ncommitted to the success of this early career physician-scientist, providing protected research time, resources,\\\\nand support needed to complete the proposed research and training aims. The career development aims focus\\\\non needed skills in dissemination and implementation science providing the candidate with the necessary tools\\\\nas an independent investigator to integrate technology into the neonatal intensive care unit that will aid in\\\\nbetter diagnosis and improve human health. These aims will be overseen by an experienced multidisciplinary\\\\nmentoring team who ensure the candidate\\\\u2019s success.\", \"project_title\": \"Addressing the research-practice gap in the implementation of rapid whole genome sequencing in the NICU\", \"phr_text\": \"PROJECT NARRATIVE\\\\nWhile studies confirm that rapid whole genome sequencing accelerates diagnoses and life-saving therapies in\\\\ncritically ill newborns, its adoption in clinical setting is lagging. We propose a dissemination and implementation\\\\nscience project to decrease healthcare inequities and improve adoption of genome sequencing in Level 4\\\\n(tertiary, metropolitan, higher resourced) and Level 3 (non-tertiary, rural, lower resourced) neonatal intensive\\\\ncare units.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 249302, \"indirect_cost_amt\": 19944, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10918215\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 14}, page_content='{\"appl_id\": 10738147, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"1U24HL165014-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"U24\", \"award_amount\": 561767, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"165014\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 14088426, \"first_name\": \"John\", \"middle_name\": \"\", \"last_name\": \"VanBuren\", \"is_contact_pi\": true, \"full_name\": \"John  VanBuren\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"VANBUREN, JOHN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 561767, \"direct_cost_ic\": 364784, \"indirect_cost_ic\": 196983}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2029-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-22-193\", \"full_study_section\": {\"srg_code\": \"CLTR\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"MA\", \"name\": \"Clinical Trials Review Study Section[CLTR (MA)]\"}, \"award_notice_date\": \"2023-08-22T12:08:00Z\", \"core_project_num\": \"U24HL165014\", \"terms\": \"<Adoption><21+ years old><Adult Human><adulthood><Adult><ages><Age><Biometry><Biometrics><Biostatistics><Brain><Brain Nervous System><Encephalon><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Child Care><Puericulture><Clinical Trials><Communication><Complement><Complement Proteins><Critical Illness><Critically Ill><Data Collection><Gel><Goals><Heart><Heart Arrest><Asystole><Cardiac Arrest><Hospitals><Hyperventilation><Intratracheal Intubation><Endotracheal Intubation><tracheal intubation><Larynx><Laryngeal><Larynx Head and Neck><voice box><Leadership><Lung><Lung Respiratory System><pulmonary><Maintenance><Manuals><Masks><Methods><Oxygen><O element><O2 element><Paramedical Personnel><Paramedic><Patients><Production><Public Health><Recommendation><Research><Research Personnel><Investigators><Researchers><Resuscitation><Survival Rate><Testing><Universities><Utah><Generations><Technical Expertise><technical skills><United States Agency for Healthcare Research and Quality><AHCPR><AHRQ><Agency for Health Care Policy and Research><Agency for Healthcare Research and Quality><United States Agency for Health Care Policy and Research><Data Set><Caring><Laryngeal Mask Airway><Laryngeal Masks><Guidelines><Tube><critically ill child><Critically ill children><improved><Solid><Clinical><Training><pediatric><Childhood><Hypoxic><Oxygen Deficiency><Hypoxia><Life><Bradycardia><Protocols documentation><Protocol><Techniques><data management><experience><skills><novel><Categories><Devices><Human Resources><Manpower><personnel><Reporting><Chest><Thorace><Thoracic><Thorax><disorder subtype><disease subgroups><disease subtype><Airway failure><Respiratory Failure><preventing><prevent><Data><Interruption><Qualifying><Enrollment><enroll><Monitor><Preparation><preparations><Data Coordination Center><data management and coordinating center><data management center><Data Coordinating Center><designing><design><injured child><injured children><injury in children><pediatric injury><Childhood Injury><Trauma><innovate><innovative><innovation><multidisciplinary><evidence base><patient population><pragmatic effectiveness trial><pragmatic trial><operations><operation><Pre-hospital care><Prehospital care><Prehospitalization care><Pre-hospitalization care><trial design><improved outcome><Traumatic injury><study population><relative effectiveness><emergency settings><pediatric emergency><feasibility trial><out-of-hospital cardiac arrest><critical injury><devastating injury><severe injury><ventilation><clinical trial analysis>\", \"pref_terms\": \"Adoption;Adult;Age;Biometry;Bradycardia;Brain;Caring;Categories;Chest;Child;Child Care;Childhood;Childhood Injury;Clinical;Clinical Trials;Communication;Complement;Critical Illness;Critically ill children;Data;Data Collection;Data Coordinating Center;Data Set;Devices;Enrollment;Gel;Generations;Goals;Guidelines;Heart;Heart Arrest;Hospitals;Human Resources;Hyperventilation;Hypoxia;Interruption;Intratracheal Intubation;Laryngeal Masks;Larynx;Leadership;Life;Lung;Maintenance;Manuals;Masks;Methods;Monitor;Oxygen;Paramedical Personnel;Patients;Pre-hospitalization care;Preparation;Production;Protocols documentation;Public Health;Qualifying;Recommendation;Reporting;Research;Research Personnel;Respiratory Failure;Resuscitation;Solid;Survival Rate;Technical Expertise;Techniques;Testing;Training;Trauma;Traumatic injury;Tube;United States Agency for Healthcare Research and Quality;Universities;Utah;clinical trial analysis;data management;design;disorder subtype;emergency settings;evidence base;experience;feasibility trial;improved;improved outcome;innovation;multidisciplinary;novel;operation;out-of-hospital cardiac arrest;patient population;pediatric emergency;pragmatic trial;prevent;relative effectiveness;severe injury;skills;study population;trial design;ventilation\", \"abstract_text\": \"Project Summary\\\\nWe propose the novel Pediatric Prehospital Airway Resuscitation Trial (Pedi-PART) to determine the best paramedic\\\\nstrategies for managing the airway in critically ill or injured children. Requirements of a clinical trial include the\\\\nfollowing: a) study of common paramedic airway techniques, b) integration of the range of critical conditions\\\\nrequiring airway management, c) an enrolled study population large enough to yield meaningful results, and d)\\\\ninnovative approaches to enhance the feasibility and applicability of the trial. A key innovation will be the novel\\\\nBayesian Adaptive Sequential Platform Trial (BASiC-PT) framework used to determine the relative effectiveness\\\\nof three airway techniques (BVM, ETI, SGA) across three disease subgroups (cardiac arrest, trauma, respiratory\\\\nfailure) for all pediatric age categories, maximizing available information while minimizing the number of patients.\\\\nThe novel design of Pedi-PART overcomes analytic, logistical, and financial barriers that make a traditional trial\\\\ndesign infeasible. Our aims are:\\\\nSpecific Aim 1. To provide biostatistical leadership and expertise, assistance in protocol design, study imple-\\\\n mentation and management, data collection and management, study reporting and metrics, assistance in\\\\n interim and final study analyses, and production of public use research datasets in the establishment and\\\\n execution of the Pedi-PART study.\\\\nSpecific Aim 2. To provide logistical support and technical expertise for Pedi-PART investigators and coordina-\\\\n tors, through effective study training, efficient quality monitoring, communication and engagement of study\\\\n personnel, maintenance of study regulatory documents, and preparation of useful study materials (e.g.,\\\\n manual of operations) to enhance the implementation of the trial.\\\\n Pedi-PART is a pragmatic trial designed to provide a solid evidence base for best practice in paramedic\\\\npediatric airway management. These results will identify the ideal airway techniques to be used, enabling the\\\\ngeneration of guidelines for the highest level of prehospital care for children here and across the globe.\", \"project_title\": \"2/2: Pediatric Prehospital Airway Resuscitation Trial (Pedi-PART)\", \"phr_text\": \"Project Narrative\\\\nResuscitation from critical illness requires skillful delivery of oxygen. This project will compare three paramedic\\\\nstrategies for delivering life-saving oxygen to critically-ill children. The findings will improve public health by\\\\ndefining approaches to improve survival and reduce years of life loss among critically-ill children.\", \"spending_categories_desc\": \"Cardiovascular; Childhood Injury; Clinical Research; Clinical Trials and Supportive Activities; Comparative Effectiveness Research; Emergency Care; Heart Disease; Lung; Pediatric; Physical Injury - Accidents and Adverse Effects\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-01T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 364784, \"indirect_cost_amt\": 196983, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10738147\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 15}, page_content='{\"appl_id\": 10721786, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"1K08HG013111-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K08\", \"award_amount\": 269246, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K08\", \"ic_code\": \"HG\", \"serial_num\": \"013111\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 14797210, \"first_name\": \"Sabrina\", \"middle_name\": \"\", \"last_name\": \"Malone Jenkins\", \"is_contact_pi\": true, \"full_name\": \"Sabrina  Malone Jenkins\", \"title\": \"NEONATOLOGIST\"}], \"contact_pi_name\": \"MALONE JENKINS, SABRINA \", \"agency_ic_admin\": {\"code\": \"HG\", \"abbreviation\": \"NHGRI\", \"name\": \"National Human Genome Research Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HG\", \"name\": \"National Human Genome Research Institute\", \"abbreviation\": \"NHGRI\", \"total_cost\": 269246, \"direct_cost_ic\": 249302, \"indirect_cost_ic\": 19944}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2028-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-203\", \"full_study_section\": {\"srg_code\": \"GNOM\", \"srg_flex\": \"G\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Genome Research Study Section[GNOM-G]\"}, \"award_notice_date\": \"2023-09-01T12:09:00Z\", \"core_project_num\": \"K08HG013111\", \"terms\": \"<healthcare personnel><medical personnel><treatment provider><Human><Modern Man><Neonatal Intensive Care Units><Newborn Intensive Care Units><neonatal ICU><Logic><Maintenance><Mentors><Methodology><Patients><Perception><Physicians><Pilot Projects><pilot study><Recommendation><Research><Research Personnel><Investigators><Researchers><Resources><Research Resources><Role><social role><Surveys><Survey Instrument><Technology><Testing><Time><Guidelines><career><improved><Clinical><Specified><Specific qualifier value><Ensure><Training><Rural><Fostering><Development Plans><Funding><uptake><tool><Consensus><Knowledge><Life><programs><Scientist><Techniques><contextual factors><Application Context><Training and Education><Education and Training><experience><success><metropolitan><Speed><skills><empowerment><member><Modeling><career development><Intervention><Intervention Strategies><interventional strategy><Genomics><Provider><Institution><genome sequencing><Address><Data><K-Series Research Career Programs><Career Development Awards><Career Development Awards and Programs><Career Development Programs K-Series><K-Awards><Research Career Program><Translational Research><Translational Science><translation research><translational investigation><Characteristics><implementation research><designing><design><Outcome><Neonatal><innovate><innovative><innovation><Evidence based intervention><multidisciplinary><clinical applicability><clinical application><task analysis><usability><implementation science><clinical care><evidence base><standard of care><critically ill newborn><precision-based medicine><precision medicine><personalization of treatment><personalized therapy><personalized treatment><personalized medicine><cognitive task><Genomic medicine><entire genome><full genome><whole genome><disparity in care><disparity in healthcare><health care inequality><health care inequity><healthcare disparity><healthcare inequality><healthcare inequity><health care disparity><healthcare settings><health care settings><clinical implementation><strategies for implementation><implementation strategy><Infrastructure><educational resources><education resources><Dissemination and Implementation><RE-AIM><reach, efficacy, adoption, implementation, and maintenance><Reach, Effectiveness, Adoption, Implementation, and Maintenance><PRISM framework><PRISM model><Pragmatic, Robust Implementation and Sustainability Model><Practical Robust Implementation and Sustainability Model><under served area><under served geographic area><under served location><under served region><underserved geographic area><underserved location><underserved region><underserved area><barriers to implementation><implementation challenges><implementation barriers><implementation of clinical trials><clinical trial implementation><dissemination science><effectiveness/implementation hybrid><Acceleration><Adoption><Critical Care><Diagnosis><Family><Future><Goals><Health><Health Personnel><Health Care Providers><Healthcare Providers><Healthcare worker><health care personnel><health care worker><health provider><health workforce>\", \"pref_terms\": \"Acceleration;Address;Adoption;Characteristics;Clinical;Consensus;Critical Care;Data;Development Plans;Diagnosis;Dissemination and Implementation;Ensure;Evidence based intervention;Family;Fostering;Funding;Future;Genomic medicine;Genomics;Goals;Guidelines;Health;Health Personnel;Human;Infrastructure;Institution;Intervention;K-Series Research Career Programs;Knowledge;Life;Logic;Maintenance;Mentors;Methodology;Modeling;Neonatal;Neonatal Intensive Care Units;Outcome;Patients;Perception;Physicians;Pilot Projects;Practical Robust Implementation and Sustainability Model;Provider;Reach, Effectiveness, Adoption, Implementation, and Maintenance;Recommendation;Research;Research Personnel;Resources;Role;Rural;Scientist;Specific qualifier value;Speed;Surveys;Techniques;Technology;Testing;Time;Training;Training and Education;Translational Research;career;career development;clinical application;clinical care;clinical implementation;clinical trial implementation;cognitive task;contextual factors;critically ill newborn;design;dissemination science;education resources;effectiveness/implementation hybrid;empowerment;evidence base;experience;genome sequencing;health care disparity;health care settings;implementation barriers;implementation research;implementation science;implementation strategy;improved;innovation;member;metropolitan;multidisciplinary;personalized medicine;precision medicine;programs;skills;standard of care;success;task analysis;tool;underserved area;uptake;usability;whole genome\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nCurrent recommendations indicate that rapid whole genome sequencing should be the standard of care for\\\\ncritically ill newborns. The disconnect between these guidelines and the adoption of whole genome sequencing\\\\nin the neonatal intensive care unit delays diagnoses and life-saving therapies. The effects are greater in rural\\\\nLevel 3 settings where healthcare inequities exist. Translational science strategies to implement genomic\\\\nmedicine into clinical care are sorely needed, but currently lacking. This proposal is a dissemination and\\\\nimplementation science project addressing the lack of use of rapid whole genome sequencing in Level 4\\\\n(tertiary, metropolitan, higher resourced) and Level 3 (non-tertiary, rural, lower resourced) neonatal intensive\\\\ncare units by developing Level-specific logic models outlining specific barriers and facilitators, developing and\\\\nleveraging strategies that address these barriers, and test these strategies in a small-scale demonstration\\\\nproject.\\\\nThe overall goal of the integrated career development plan is to prepare the candidate to become an expert in\\\\ndissemination and implementation science and improve the clinical application of personalized medicine in\\\\nneonatal critical care settings. The training and research will be conducted at an institution with a strong record\\\\nof providing excellent support and robust training and educational resources. The candidate\\\\u2019s department is\\\\ncommitted to the success of this early career physician-scientist, providing protected research time, resources,\\\\nand support needed to complete the proposed research and training aims. The career development aims focus\\\\non needed skills in dissemination and implementation science providing the candidate with the necessary tools\\\\nas an independent investigator to integrate technology into the neonatal intensive care unit that will aid in\\\\nbetter diagnosis and improve human health. These aims will be overseen by an experienced multidisciplinary\\\\nmentoring team who ensure the candidate\\\\u2019s success.\", \"project_title\": \"Addressing the research-practice gap in the implementation of rapid whole genome sequencing in the NICU\", \"phr_text\": \"PROJECT NARRATIVE\\\\nWhile studies confirm that rapid whole genome sequencing accelerates diagnoses and life-saving therapies in\\\\ncritically ill newborns, its adoption in clinical setting is lagging. We propose a dissemination and implementation\\\\nscience project to decrease healthcare inequities and improve adoption of genome sequencing in Level 4\\\\n(tertiary, metropolitan, higher resourced) and Level 3 (non-tertiary, rural, lower resourced) neonatal intensive\\\\ncare units.\", \"spending_categories_desc\": \"Biotechnology; Clinical Research; Dissemination and Implementation Research; Genetics; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Human Genome; Infant Mortality; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Precision Medicine; Preterm, Low Birth Weight and Health of the Newborn; Rural Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-01T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 249302, \"indirect_cost_amt\": 19944, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10721786\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 16}, page_content='{\"appl_id\": 10913615, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5K23HD112548-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"K23\", \"award_amount\": 173420, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"K23\", \"ic_code\": \"HD\", \"serial_num\": \"112548\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10987811, \"first_name\": \"Elizabeth\", \"middle_name\": \"Marie\", \"last_name\": \"Keating\", \"is_contact_pi\": true, \"full_name\": \"Elizabeth Marie Keating\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"KEATING, ELIZABETH MARIE\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 173420, \"direct_cost_ic\": 162000, \"indirect_cost_ic\": 11420}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2028-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-206\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Pediatrics Study Section[CHHD-A]\"}, \"award_notice_date\": \"2024-08-07T12:08:00Z\", \"core_project_num\": \"K23HD112548\", \"terms\": \"<0-11 years old><Access to Care><Address><Affect><Africa South of the Sahara><Assess implementation><Assessment instrument><Assessment tool><Award><Career Development Awards><Career Development Awards and Programs><Career Development Programs K-Series><Caring><Cessation of life><Child><Child Youth><Childhood><Childhood Injury><Children (0-21)><Clinical Investigator><Clinical Trials><Clinical Trials Design><Communities><Complex><Consolidated Framework for Implementation Research><Consolidated Framework for Implementation Science><Consolidated Framework for Implementing Change><Data><Death><Dedications><District Hospitals><Educational workshop><Effectiveness><Emergencies><Emergency Medicine><Emergency Situation><Ensure><Evaluation><Evaluation Research><Feedback><Fellowship><Focus Groups><Foundations><Future><Goals><Health><Health Care Providers><Health Facilities><Health Personnel><Health Services Accessibility><Health care facility><Health system><Healthcare Facility><Healthcare Providers><Healthcare worker><Hospital Referrals><Hour><Implementation assessment><Infrastructure><Injury><Interdisciplinary Research><Interdisciplinary Study><International><Intervention><Intervention Strategies><Interview><Investigators><K-Awards><K-Series Research Career Programs><Knowledge><LMIC><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Medical><Medical center><Mentors><Mentorship><Methods><Morbidity><Morbidity - disease rate><Multidisciplinary Collaboration><Multidisciplinary Research><NICHD><NIH><National Institute of Child Health and Human Development><National Institute of Children\\'s Health and Human Development><National Institutes of Health><Outcome><Patients><Physicians><Position><Positioning Attribute><Prevention><Process><Public Health><QOC><Qualitative Methods><Quality of Care><Registries><Research><Research Career Program><Research Personnel><Researchers><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Risk Assessment><Scientist><Site><Strategic Planning><Sub-Saharan Africa><Subsaharan Africa><System><Tanzania><Techniques><Time><Training><Trauma><Trauma Research><Traumatic injury><Triage><United States National Institutes of Health><Work><Workshop><acceptability and feasibility><access to health services><access to services><access to treatment><accessibility to health services><adolescent trauma><availability of services><care access><care facilities><career><career development><child patients><childhood trauma><context for implementation><develop therapy><disability><evaluate implementation><evaluation of implementation><evidence base><experience><formative assessment><formative evaluation><global health><health care personnel><health care worker><health provider><health service access><health services availability><health workforce><healthcare personnel><implementation context><implementation evaluation><implementation framework><implementation intervention><implementation outcomes><implementation research framework><implementation science><implementation science framework><improved><improved outcome><injured><injured child><injured children><injuries><injury in children><innovate><innovation><innovative><intervention development><intervention refinement><interventional strategy><kids><low and middle-income countries><medical personnel><mortality><multi-component intervention><multi-faceted intervention><multi-modal intervention><multicomponent intervention><multidisciplinary><multifaceted intervention><multimodal intervention><novel><pediatric><pediatric emergency><pediatric injury><pediatric patients><pediatric trauma><pilot test><qualitative reasoning><responsible research conduct><service availability><skills><success><therapy development><tool><trauma in children><treatment access><treatment development><treatment provider><youngster>\", \"pref_terms\": \"Address;Affect;Africa South of the Sahara;Assessment tool;Award;Caring;Cessation of life;Child;Childhood;Childhood Injury;Clinical Investigator;Clinical Trials;Clinical Trials Design;Communities;Complex;Consolidated Framework for Implementation Research;Data;Dedications;District Hospitals;Educational workshop;Effectiveness;Emergency Medicine;Emergency Situation;Ensure;Evaluation;Evaluation Research;Feedback;Fellowship;Focus Groups;Foundations;Future;Goals;Health;Health Personnel;Health Services Accessibility;Health care facility;Health system;Hospital Referrals;Hour;Infrastructure;Injury;Interdisciplinary Study;International;Intervention;Interview;K-Series Research Career Programs;Knowledge;Medical;Medical center;Mentors;Mentorship;Methods;Morbidity - disease rate;National Institute of Child Health and Human Development;Outcome;Patients;Physicians;Positioning Attribute;Prevention;Process;Public Health;Qualitative Methods;Quality of Care;Registries;Research;Research Personnel;Resource-limited setting;Risk Assessment;Scientist;Site;Strategic Planning;System;Tanzania;Techniques;Time;Training;Trauma;Trauma Research;Traumatic injury;Triage;United States National Institutes of Health;Work;acceptability and feasibility;career;career development;disability;evidence base;experience;formative assessment;global health;implementation context;implementation evaluation;implementation framework;implementation intervention;implementation outcomes;implementation science;improved;improved outcome;injured;innovation;intervention refinement;low and middle-income countries;mortality;multi-component intervention;multidisciplinary;novel;pediatric emergency;pediatric patients;pediatric trauma;pilot test;responsible research conduct;skills;success;therapy development;tool\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nEvery day, 1900 children die from an injury. More than 95% of these pediatric injury deaths occur in low- and\\\\nmiddle-income countries (LMICs), with children in sub-Saharan Africa disproportionately affected. In sub-\\\\nSaharan Africa, pediatric morbidity and mortality could be minimized if children with serious injuries received\\\\ntimely quality care. The objective of the proposed research is to develop and pilot a locally-relevant,\\\\nmulticomponent intervention to streamline the triage process (e.g. patient assessment, stabilization, and\\\\ndisposition) for pediatric injury patients in Tanzania. This health systems intervention will work at the first level\\\\nof medical contact (e.g., health center and district hospital), in order to facilitate timely disposition and referrals,\\\\nand subsequently decrease time to definitive care. The proposed study has three aims: 1) With a mixed\\\\nmethods approach, describe the barriers to pediatric injury care at the first medical contact; 2) Iteratively\\\\ndevelop the P-KIDs CARE intervention using a nominal group technique and conduct a pre-implementation\\\\nassessment and refinement; 3) Pilot the P-KIDs CARE intervention and perform an implementation-focused\\\\nformative evaluation. This career development award is being proposed by Dr. Elizabeth Keating, a Pediatric\\\\nEmergency Medicine physician-scientist focused on resource-limited settings like Tanzania. During the award\\\\nperiod, the candidate will gain the training and mentorship to become an independent clinical investigator\\\\nfocused on developing novel, scalable health systems interventions in resource-limited settings. Along with\\\\ndeveloping this innovative intervention, the candidate will gain skills in implementation science, health systems\\\\nintervention development, global clinical trial design, and the responsible conduct of research. The candidate\\\\u2019s\\\\ncareer development will be guided by an impressive multi-disciplinary and international team of experienced\\\\nmentors with extensive expertise in health systems intervention development, global clinical trials, and trauma\\\\nmanagement. This proposal speaks to NIH\\\\u2019s strategic goals by building capacity for systems-level trauma\\\\nresearch in LMICs. By the end of this project, Dr. Keating will have a unique combination of research expertise\\\\nand will be prepared to submit an R01 proposal that has the potential to improve outcomes for injured children\\\\nin sub-Saharan Africa.\", \"project_title\": \"P-KIDs CARE: An Intervention to Address Health Systems Delays to Care for Injured Children in Tanzania\", \"phr_text\": \"PROJECT NARRATIVE\\\\nPediatric injuries are a leading cause of morbidity and mortality in children worldwide. This K23 Career\\\\nDevelopment Award will develop and pilot test a health systems intervention to streamline the triage process\\\\n(e.g. patient assessment, stabilization, and disposition), and improve time to definitive care and outcomes of\\\\npediatric injury patients. By completing the proposed research and training plans with the support of her multi-\\\\ndisciplinary mentorship team, Dr. Keating seeks to create a scalable intervention to address a critical public\\\\nhealth challenge while launching an independent career as a Pediatric Emergency Medicine physician-\\\\nscientist.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 162000, \"indirect_cost_amt\": 11420, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10913615\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 17}, page_content='{\"appl_id\": 10722628, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"1K23HD112548-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K23\", \"award_amount\": 174960, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K23\", \"ic_code\": \"HD\", \"serial_num\": \"112548\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10987811, \"first_name\": \"Elizabeth\", \"middle_name\": \"Marie\", \"last_name\": \"Keating\", \"is_contact_pi\": true, \"full_name\": \"Elizabeth Marie Keating\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"KEATING, ELIZABETH MARIE\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 174960, \"direct_cost_ic\": 162000, \"indirect_cost_ic\": 12960}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2028-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-206\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": \"A\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Pediatrics Study Section[CHHD-A]\"}, \"award_notice_date\": \"2023-08-24T12:08:00Z\", \"core_project_num\": \"K23HD112548\", \"terms\": \"<Affect><Sub-Saharan Africa><Subsaharan Africa><Africa South of the Sahara><Award><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Clinical Investigator><Clinical Trials><Communities><Cessation of life><Death><Dedications><Emergency Situation><Emergencies><Emergency Medicine><Evaluation Research><Feedback><Fellowship><Focus Groups><Foundations><Future><Goals><Health><Health care facility><Health Facilities><Healthcare Facility><care facilities><Health Personnel><Health Care Providers><Healthcare Providers><Healthcare worker><health care personnel><health care worker><health provider><health workforce><healthcare personnel><medical personnel><treatment provider><Health Services Accessibility><Access to Care><access to health services><access to services><access to treatment><accessibility to health services><availability of services><care access><health service access><health services availability><service availability><treatment access><Hospital Referrals><District Hospitals><Interview><Mentors><Mentorship><Methods><Morbidity - disease rate><Morbidity><mortality><United States National Institutes of Health><NIH><National Institutes of Health><Patients><Physicians><Public Health><Registries><Research><Research Personnel><Investigators><Researchers><Tanzania><Time><Triage><Work><Risk Assessment><Caring><injuries><Injury><career><improved><Site><Medical><Ensure><Evaluation><Training><disability><pediatric><Childhood><Workshop><Educational workshop><Interdisciplinary Research><Multidisciplinary Collaboration><Multidisciplinary Research><Interdisciplinary Study><tool><Knowledge><Scientist><Hour><Complex><Techniques><System><Medical center><experience><success><skills><novel><Prevention><Positioning Attribute><Position><career development><Quality of Care><QOC><Intervention><Intervention Strategies><interventional strategy><Effectiveness><Address><global health><Health system><Qualitative Methods><qualitative reasoning><Data><International><National Institute of Child Health and Human Development><NICHD><National Institute of Children\\'s Health and Human Development><K-Series Research Career Programs><Career Development Awards><Career Development Awards and Programs><Career Development Programs K-Series><K-Awards><Research Career Program><Strategic Planning><Clinical Trials Design><Process><adolescent trauma><childhood trauma><trauma in children><pediatric trauma><injured><injured child><injured children><injury in children><pediatric injury><Childhood Injury><Outcome><Trauma><innovate><innovative><innovation><Trauma Research><multidisciplinary><implementation science><develop therapy><intervention development><treatment development><therapy development><evidence base><responsible research conduct><multi-faceted intervention><multi-modal intervention><multicomponent intervention><multifaceted intervention><multimodal intervention><multi-component intervention><child patients><pediatric patients><Assessment instrument><Assessment tool><formative evaluation><formative assessment><LMIC><low and middle-income countries><improved outcome><Traumatic injury><pediatric emergency><Infrastructure><implementation research framework><implementation science framework><implementation framework><Consolidated Framework for Implementation Science><Consolidated Framework for Implementing Change><Consolidated Framework for Implementation Research><implementation intervention><acceptability and feasibility><implementation outcomes><intervention refinement><Assess implementation><Implementation assessment><evaluate implementation><evaluation of implementation><implementation evaluation><Resource-limited setting><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><implementation context><context for implementation><pilot test>\", \"pref_terms\": \"Address;Affect;Africa South of the Sahara;Assessment tool;Award;Caring;Cessation of life;Child;Childhood;Childhood Injury;Clinical Investigator;Clinical Trials;Clinical Trials Design;Communities;Complex;Consolidated Framework for Implementation Research;Data;Dedications;District Hospitals;Educational workshop;Effectiveness;Emergency Medicine;Emergency Situation;Ensure;Evaluation;Evaluation Research;Feedback;Fellowship;Focus Groups;Foundations;Future;Goals;Health;Health Personnel;Health Services Accessibility;Health care facility;Health system;Hospital Referrals;Hour;Infrastructure;Injury;Interdisciplinary Study;International;Intervention;Interview;K-Series Research Career Programs;Knowledge;Medical;Medical center;Mentors;Mentorship;Methods;Morbidity - disease rate;National Institute of Child Health and Human Development;Outcome;Patients;Physicians;Positioning Attribute;Prevention;Process;Public Health;Qualitative Methods;Quality of Care;Registries;Research;Research Personnel;Resource-limited setting;Risk Assessment;Scientist;Site;Strategic Planning;System;Tanzania;Techniques;Time;Training;Trauma;Trauma Research;Traumatic injury;Triage;United States National Institutes of Health;Work;acceptability and feasibility;career;career development;disability;evidence base;experience;formative assessment;global health;implementation context;implementation evaluation;implementation framework;implementation intervention;implementation outcomes;implementation science;improved;improved outcome;injured;innovation;intervention refinement;low and middle-income countries;mortality;multi-component intervention;multidisciplinary;novel;pediatric emergency;pediatric patients;pediatric trauma;pilot test;responsible research conduct;skills;success;therapy development;tool\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nEvery day, 1900 children die from an injury. More than 95% of these pediatric injury deaths occur in low- and\\\\nmiddle-income countries (LMICs), with children in sub-Saharan Africa disproportionately affected. In sub-\\\\nSaharan Africa, pediatric morbidity and mortality could be minimized if children with serious injuries received\\\\ntimely quality care. The objective of the proposed research is to develop and pilot a locally-relevant,\\\\nmulticomponent intervention to streamline the triage process (e.g. patient assessment, stabilization, and\\\\ndisposition) for pediatric injury patients in Tanzania. This health systems intervention will work at the first level\\\\nof medical contact (e.g., health center and district hospital), in order to facilitate timely disposition and referrals,\\\\nand subsequently decrease time to definitive care. The proposed study has three aims: 1) With a mixed\\\\nmethods approach, describe the barriers to pediatric injury care at the first medical contact; 2) Iteratively\\\\ndevelop the P-KIDs CARE intervention using a nominal group technique and conduct a pre-implementation\\\\nassessment and refinement; 3) Pilot the P-KIDs CARE intervention and perform an implementation-focused\\\\nformative evaluation. This career development award is being proposed by Dr. Elizabeth Keating, a Pediatric\\\\nEmergency Medicine physician-scientist focused on resource-limited settings like Tanzania. During the award\\\\nperiod, the candidate will gain the training and mentorship to become an independent clinical investigator\\\\nfocused on developing novel, scalable health systems interventions in resource-limited settings. Along with\\\\ndeveloping this innovative intervention, the candidate will gain skills in implementation science, health systems\\\\nintervention development, global clinical trial design, and the responsible conduct of research. The candidate\\\\u2019s\\\\ncareer development will be guided by an impressive multi-disciplinary and international team of experienced\\\\nmentors with extensive expertise in health systems intervention development, global clinical trials, and trauma\\\\nmanagement. This proposal speaks to NIH\\\\u2019s strategic goals by building capacity for systems-level trauma\\\\nresearch in LMICs. By the end of this project, Dr. Keating will have a unique combination of research expertise\\\\nand will be prepared to submit an R01 proposal that has the potential to improve outcomes for injured children\\\\nin sub-Saharan Africa.\", \"project_title\": \"P-KIDs CARE: An Intervention to Address Health Systems Delays to Care for Injured Children in Tanzania\", \"phr_text\": \"PROJECT NARRATIVE\\\\nPediatric injuries are a leading cause of morbidity and mortality in children worldwide. This K23 Career\\\\nDevelopment Award will develop and pilot test a health systems intervention to streamline the triage process\\\\n(e.g. patient assessment, stabilization, and disposition), and improve time to definitive care and outcomes of\\\\npediatric injury patients. By completing the proposed research and training plans with the support of her multi-\\\\ndisciplinary mentorship team, Dr. Keating seeks to create a scalable intervention to address a critical public\\\\nhealth challenge while launching an independent career as a Pediatric Emergency Medicine physician-\\\\nscientist.\", \"spending_categories_desc\": \"Childhood Injury; Clinical Research; Clinical Trials and Supportive Activities; Dissemination and Implementation Research; Emergency Care; Health Services; Pediatric; Physical Injury - Accidents and Adverse Effects; Prevention; Unintentional Childhood Injury\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-01T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 162000, \"indirect_cost_amt\": 12960, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10722628\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 18}, page_content='{\"appl_id\": 10724935, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"1K01HL169489-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K01\", \"award_amount\": 133966, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K01\", \"ic_code\": \"HL\", \"serial_num\": \"169489\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12484456, \"first_name\": \"Natalia\", \"middle_name\": \"\", \"last_name\": \"Torres\", \"is_contact_pi\": true, \"full_name\": \"Natalia  Torres\", \"title\": \"ASSOCIATE INSTRUCTOR\"}], \"contact_pi_name\": \"TORRES, NATALIA \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 133966, \"direct_cost_ic\": 124043, \"indirect_cost_ic\": 9923}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2028-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HL-22-011\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"A\", \"group_code\": \"M1\", \"name\": \"Special Emphasis Panel[ZHL1 CSR-A (M1)]\"}, \"award_notice_date\": \"2023-08-21T12:08:00Z\", \"core_project_num\": \"K01HL169489\", \"terms\": \"<Action Potentials><Adrenergic Drugs><Adrenergics><Adrenergic Agents><21+ years old><Adult Human><adulthood><Adult><Arrhythmia><Cardiac Arrhythmia><Heart Arrhythmias><Atrial Fibrillation><Auricular Fibrillation><Automobile Driving><driving><Award><Western Blotting><Immunoblotting><Western Immunoblotting><protein blotting><Calcium><Cardiovascular system><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Cell Nucleus><Nucleus><Cells><Cell Body><Chromatin><Sudden Death><Down-Regulation><Electrophysiology (science)><Electrophysiology><Neurophysiology / Electrophysiology><electrophysiological><Family><Fishes><Foundations><Future><Gene Deletion><gene deletion mutation><Genes><Regulator Genes><Transcriptional Regulatory Elements><regulatory gene><trans acting element><Goals><Healthcare Systems><Health Care Systems><Heart><Heart Atrium><Atrial><Cardiac Atrium><atrium><Heart Diseases><Cardiac Diseases><Cardiac Disorders><heart disorder><Heart failure><cardiac failure><Homeostasis><Autoregulation><Physiological Homeostasis><Human><Modern Man><Ion Channel><Ionic Channels><Membrane Channels><Leadership><Maintenance><Maps><Mentors><Mission><Morbidity - disease rate><Morbidity><mortality><United States National Institutes of Health><NIH><National Institutes of Health><Optics><optical><Patients><Research><Risk><Role><social role><Sarcoplasmic Reticulum><Signal Transduction><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Stress><Stroke><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><stroked><strokes><Testing><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><Genetic Transcription><Gene Transcription><RNA Expression><Transcription><Tretinoin><ATRA><Retinoic Acid><Trans Vitamin A Acid><Tretinoinum><Vitamin A Acid><all-trans-Retinoic Acid><all-trans-Vitamin A acid><trans-Retinoic Acid><Zebrafish><Brachydanio rerio><Danio rerio><Zebra Danio><Zebra Fish><transcription factor USF><Upstream Stimulatory Factor><Upstream Transcription Factor><helix-loop-helix activator USF><transcription factor MLTF><Measures><Tachyarrhythmias><tachyrhythmia><Mediating><career><Acute><Chronic><Clinical><Adolescent Youth><juvenile><juvenile human><Adolescent><Hospitalization cost><Hospital Costs><Link><Susceptibility><Predisposition><Cardiac Muscle Cells><Cardiocyte><Heart Muscle Cells><Heart myocyte><cardiomyocyte><Cardiac Myocytes><insight><Individual><Research Activity><Cooperative Learning><Experiential Learning><Active Learning><Funding><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Genetic Predisposition to Disease><Genetic Predisposition><Genetic Susceptibility><Genetic propensity><Inherited Predisposition><Inherited Susceptibility><genetic etiology><genetic mechanism of disease><genetic vulnerability><genetically predisposed><Knowledge><Event><autosome><stressor><Gene Silencing><Gene Inactivation><transcriptional silencing><Animal Model><Animal Models and Related Studies><model of animal><Transgenic Organisms><transgenic><skills><novel><Pathogenesis><Regulation><Modeling><career development><Property><response><Genomics><Short interfering RNA><siRNA><Small Interfering RNA><Data><Economic Burden><Regulatory Pathway><Transcript><Principal Investigator><Molecular><Cardiac><Development><developmental><Pathway interactions><pathway><Output><Gene variant><allele variant><allelic variant><genomic variant><genetic variant><Prevalence><Heritability><Predisposition gene><predisposing gene><susceptibility allele><susceptibility locus><susceptibility variant><Susceptibility Gene><multidisciplinary><therapeutic target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic strategies><novel therapy approach><novel therapeutic intervention><clinical practice><Secure><RNA Seq><RNA sequencing><RNAseq><transcriptomic sequencing><transcriptome sequencing><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><ATAC sequencing><ATACseq><ATAC-seq><multiomics><multiple omics><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><CRISPR/Cas technology><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><transcriptional reprogramming><therapeutically effective><induced pluripotent stem cell derived cardiomyocytes><iPS cell derived cardiomyocytes><iPSC derived cardiomyocytes><pharmacologic>\", \"pref_terms\": \"ATAC-seq;Action Potentials;Active Learning;Acute;Adolescent;Adrenergic Agents;Adult;Animal Model;Arrhythmia;Atrial Fibrillation;Automobile Driving;Award;CRISPR/Cas technology;Calcium;Cardiac;Cardiac Myocytes;Cardiovascular system;Cell Nucleus;Cells;Chromatin;Chronic;Clinical;Data;Development;Down-Regulation;Economic Burden;Electrophysiology (science);Event;Family;Fishes;Foundations;Functional disorder;Funding;Future;Gene Deletion;Gene Silencing;Genes;Genetic Predisposition to Disease;Genetic Transcription;Genomics;Goals;Healthcare Systems;Heart;Heart Atrium;Heart Diseases;Heart failure;Heritability;Homeostasis;Hospital Costs;Human;Individual;Ion Channel;Knowledge;Leadership;Link;Maintenance;Maps;Measures;Mediating;Mentors;Mission;Modeling;Molecular;Morbidity - disease rate;Optics;Output;Pathogenesis;Pathway interactions;Patients;Predisposition;Prevalence;Principal Investigator;Property;Regulation;Regulator Genes;Regulatory Pathway;Research;Research Activity;Risk;Role;Sarcoplasmic Reticulum;Secure;Signal Transduction;Small Interfering RNA;Stress;Stroke;Sudden Death;Susceptibility Gene;Tachyarrhythmias;Testing;Transcript;Transgenic Organisms;Tretinoin;United States National Institutes of Health;Western Blotting;Zebrafish;autosome;career;career development;clinical practice;genetic variant;induced pluripotent stem cell derived cardiomyocytes;insight;mortality;multidisciplinary;multiple omics;novel;novel therapeutic intervention;pharmacologic;response;single-cell RNA sequencing;skills;stressor;targeted treatment;therapeutic target;therapeutically effective;transcription factor;transcription factor USF;transcriptional reprogramming;transcriptome sequencing\", \"abstract_text\": \"PROJECT ABSTRACT\\\\nAtrial fibrillation (AF) is the most common clinical cardiac arrhythmia, with a strong component of heritability.\\\\nPatients with AF are at significant risk for debilitating complications, such as stroke, heart failure and sudden\\\\ndeath. Emerging evidence suggests that both common and rare genetic variants in cardiac transcription factors\\\\ncontribute to AF susceptibility. This link between transcription factors and AF offers exciting opportunities to\\\\ninvestigate previously unrecognized pathways to identify novel \\\\u201cupstream\\\\u201d therapeutic targets. We recently\\\\nidentified the cardiac transcription factor NFATC1 as a novel AF susceptibility gene in a family with autosomal\\\\ndominant young-onset AF. The overall goal of this proposal is to explore the molecular and electrophysiological\\\\nrole of NFATC1 in cardiac excitability. Our central hypothesis is that NFATC1 directly regulates genes involved\\\\nin maintaining calcium homeostasis in the atrium. We proposed three specific aims to test this hypothesis: (1)\\\\nidentify NFATC1 transcriptional effectors linked to calcium homeostasis in atria; (2) establish the\\\\nelectrophysiological consequences of NFATC1 disruption in atrial cells; and (3) define NFATC1 modulation of\\\\nadrenergic signaling in the heart. The output of this project will be a comprehensive understanding of the\\\\ntranscriptional networks mediated by NFATC1 that impact calcium homeostasis and promote arrhythmogenesis,\\\\nlaying the foundation for potential future therapies.\\\\nThe research activities proposed in this career mentored award will provide experiential learning in support of\\\\nmy career development objectives. These include (1) expanding my skills into genomics research, optical\\\\nmapping and new animal models that are more suitable for the study of arrhythmias, (2) strengthen my research\\\\nleadership and management skills, and (3) enhance my grantsmanship to secure independent funding.\\\\nAchieving these goals will allow me to develop a research career as an independent principal investigator of a\\\\nmultidisciplinary cardiovascular research lab that makes substantial contributions to understanding the\\\\ndevelopment of heart disease.\", \"project_title\": \"A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility\", \"phr_text\": \"PROJECT NARATIVE\\\\nAtrial Fibrillation is the most common type of cardiac arrhythmia in clinical practice, with a projected rise in\\\\nprevalence and increased economic burden due to its complications. Our proposed studies will help determine\\\\nhow transcription factors regulate cardiac excitability, advancing our mechanistic understanding of the genetic\\\\nsusceptibility to cardiac arrhythmias. This project is relevant to the NIH mission because it will lay the foundation\\\\nfor future development of new therapeutic approaches to atrial fibrillation\", \"spending_categories_desc\": \"Biotechnology; Cardiovascular; Genetics; Heart Disease; Human Genome\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-01T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 124043, \"indirect_cost_amt\": 9923, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10724935\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 19}, page_content='{\"appl_id\": 10911333, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5K01HL169489-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"K01\", \"award_amount\": 133966, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"K01\", \"ic_code\": \"HL\", \"serial_num\": \"169489\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12484456, \"first_name\": \"Natalia\", \"middle_name\": \"\", \"last_name\": \"Torres\", \"is_contact_pi\": true, \"full_name\": \"Natalia  Torres\", \"title\": \"ASSOCIATE INSTRUCTOR\"}], \"contact_pi_name\": \"TORRES, NATALIA \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 133966, \"direct_cost_ic\": 124043, \"indirect_cost_ic\": 9923}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2028-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HL-22-011\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"A\", \"group_code\": \"M1\", \"name\": \"ZHL1-CSR-A(M1)\"}, \"award_notice_date\": \"2024-08-21T12:08:00Z\", \"core_project_num\": \"K01HL169489\", \"terms\": \"<21+ years old><ATAC sequencing><ATAC-seq><ATACseq><ATRA><Action Potentials><Active Learning><Acute><Adolescent><Adolescent Youth><Adrenergic Agents><Adrenergic Drugs><Adrenergics><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Apoplexy><Arrhythmia><Assay for Transposase-Accessible Chromatin using sequencing><Atrial><Atrial Fibrillation><Auricular Fibrillation><Automobile Driving><Autoregulation><Award><Basal Transcription Factor><Basal transcription factor genes><Brachydanio rerio><Brain Vascular Accident><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Calcium><Cardiac><Cardiac Arrhythmia><Cardiac Atrium><Cardiac Diseases><Cardiac Disorders><Cardiac Muscle Cells><Cardiac Myocytes><Cardiocyte><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Cas nuclease technology><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cells><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><Chromatin><Chronic><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Cooperative Learning><Danio rerio><Data><Development><Down-Regulation><Dysfunction><Economic Burden><Electrophysiology><Electrophysiology (science)><Event><Experiential Learning><Family><Fishes><Foundations><Functional disorder><Funding><Future><Gene Deletion><Gene Inactivation><Gene Silencing><Gene Transcription><Gene variant><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic Transcription><Genetic propensity><Genomics><Goals><Health Care Systems><Healthcare Systems><Heart><Heart Arrhythmias><Heart Atrium><Heart Diseases><Heart Muscle Cells><Heart Vascular><Heart failure><Heart myocyte><Heritability><Homeostasis><Hospital Costs><Hospitalization cost><Human><Immunoblotting><Individual><Inherited Predisposition><Inherited Susceptibility><Intracellular Communication and Signaling><Ion Channel><Ionic Channels><Knowledge><Leadership><Link><Maintenance><Maps><Measures><Mediating><Membrane Channels><Mentors><Mission><Modeling><Modern Man><Molecular><Morbidity><Morbidity - disease rate><NIH><National Institutes of Health><Neurophysiology / Electrophysiology><Nucleus><Optics><Output><Pathogenesis><Pathway interactions><Patients><Physiological Homeostasis><Physiopathology><Predisposition><Predisposition gene><Prevalence><Principal Investigator><Property><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Regulation><Regulatory Pathway><Research><Research Activity><Retinoic Acid><Risk><Role><Sarcoplasmic Reticulum><Secure><Short interfering RNA><Signal Transduction><Signal Transduction Systems><Signaling><Small Interfering RNA><Stress><Stroke><Sudden Death><Susceptibility><Susceptibility Gene><Tachyarrhythmias><Testing><Trans Vitamin A Acid><Transcript><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transgenic Organisms><Tretinoin><Tretinoinum><United States National Institutes of Health><Upstream Stimulatory Factor><Upstream Transcription Factor><Vitamin A Acid><Western Blotting><Western Immunoblotting><Zebra Danio><Zebra Fish><Zebrafish><adulthood><all-trans-Retinoic Acid><all-trans-Vitamin A acid><allele variant><allelic variant><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><atrium><autosome><biological signal transduction><brain attack><cardiac failure><cardiomyocyte><career><career development><cerebral vascular accident><cerebrovascular accident><circulatory system><clinical practice><developmental><driving><electrophysiological><gene deletion mutation><genetic etiology><genetic mechanism of disease><genetic variant><genetic vulnerability><genetically predisposed><genomic variant><heart disorder><helix-loop-helix activator USF><hiPSC><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible stem cells><iPS cell derived cardiomyocytes><iPSC derived cardiomyocytes><induced human pluripotent stem cells><induced pluripotent stem cell derived cardiomyocytes><insight><juvenile><juvenile human><model of animal><mortality><multidisciplinary><multiomics><multiple omics><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><optical><panomics><pathophysiology><pathway><pharmacologic><predisposing gene><protein blotting><response><scRNA-seq><siRNA><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><skills><social role><stressor><stroked><strokes><susceptibility allele><susceptibility locus><susceptibility variant><tachyrhythmia><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><therapeutically effective><trans-Retinoic Acid><transcription factor><transcription factor MLTF><transcription factor USF><transcriptional reprogramming><transcriptional silencing><transcriptome sequencing><transcriptomic sequencing><transgenic>\", \"pref_terms\": \"ATAC-seq;Action Potentials;Active Learning;Acute;Adolescent;Adrenergic Agents;Adult;Animal Model;Arrhythmia;Atrial Fibrillation;Automobile Driving;Award;CRISPR/Cas technology;Calcium;Cardiac;Cardiac Myocytes;Cardiovascular system;Cell Nucleus;Cells;Chromatin;Chronic;Clinical;Data;Development;Down-Regulation;Economic Burden;Electrophysiology (science);Event;Family;Fishes;Foundations;Functional disorder;Funding;Future;Gene Deletion;Gene Silencing;Genes;Genetic Predisposition to Disease;Genetic Transcription;Genomics;Goals;Healthcare Systems;Heart;Heart Atrium;Heart Diseases;Heart failure;Heritability;Homeostasis;Hospital Costs;Human;Individual;Ion Channel;Knowledge;Leadership;Link;Maintenance;Maps;Measures;Mediating;Mentors;Mission;Modeling;Molecular;Morbidity - disease rate;Optics;Output;Pathogenesis;Pathway interactions;Patients;Predisposition;Prevalence;Principal Investigator;Property;Regulation;Regulatory Pathway;Research;Research Activity;Risk;Role;Sarcoplasmic Reticulum;Secure;Signal Transduction;Small Interfering RNA;Stress;Stroke;Sudden Death;Susceptibility Gene;Tachyarrhythmias;Testing;Transcript;Transgenic Organisms;Tretinoin;United States National Institutes of Health;Western Blotting;Zebrafish;autosome;career;career development;clinical practice;genetic variant;human induced pluripotent stem cells;induced pluripotent stem cell derived cardiomyocytes;insight;mortality;multidisciplinary;multiple omics;novel;novel therapeutic intervention;pharmacologic;response;single-cell RNA sequencing;skills;stressor;targeted treatment;therapeutic target;therapeutically effective;transcription factor;transcription factor USF;transcriptional reprogramming;transcriptome sequencing\", \"abstract_text\": \"PROJECT ABSTRACT\\\\nAtrial fibrillation (AF) is the most common clinical cardiac arrhythmia, with a strong component of heritability.\\\\nPatients with AF are at significant risk for debilitating complications, such as stroke, heart failure and sudden\\\\ndeath. Emerging evidence suggests that both common and rare genetic variants in cardiac transcription factors\\\\ncontribute to AF susceptibility. This link between transcription factors and AF offers exciting opportunities to\\\\ninvestigate previously unrecognized pathways to identify novel \\\\u201cupstream\\\\u201d therapeutic targets. We recently\\\\nidentified the cardiac transcription factor NFATC1 as a novel AF susceptibility gene in a family with autosomal\\\\ndominant young-onset AF. The overall goal of this proposal is to explore the molecular and electrophysiological\\\\nrole of NFATC1 in cardiac excitability. Our central hypothesis is that NFATC1 directly regulates genes involved\\\\nin maintaining calcium homeostasis in the atrium. We proposed three specific aims to test this hypothesis: (1)\\\\nidentify NFATC1 transcriptional effectors linked to calcium homeostasis in atria; (2) establish the\\\\nelectrophysiological consequences of NFATC1 disruption in atrial cells; and (3) define NFATC1 modulation of\\\\nadrenergic signaling in the heart. The output of this project will be a comprehensive understanding of the\\\\ntranscriptional networks mediated by NFATC1 that impact calcium homeostasis and promote arrhythmogenesis,\\\\nlaying the foundation for potential future therapies.\\\\nThe research activities proposed in this career mentored award will provide experiential learning in support of\\\\nmy career development objectives. These include (1) expanding my skills into genomics research, optical\\\\nmapping and new animal models that are more suitable for the study of arrhythmias, (2) strengthen my research\\\\nleadership and management skills, and (3) enhance my grantsmanship to secure independent funding.\\\\nAchieving these goals will allow me to develop a research career as an independent principal investigator of a\\\\nmultidisciplinary cardiovascular research lab that makes substantial contributions to understanding the\\\\ndevelopment of heart disease.\", \"project_title\": \"A novel regulator of Ca2+ homeostasis and arrhythmia susceptibility\", \"phr_text\": \"PROJECT NARATIVE\\\\nAtrial Fibrillation is the most common type of cardiac arrhythmia in clinical practice, with a projected rise in\\\\nprevalence and increased economic burden due to its complications. Our proposed studies will help determine\\\\nhow transcription factors regulate cardiac excitability, advancing our mechanistic understanding of the genetic\\\\nsusceptibility to cardiac arrhythmias. This project is relevant to the NIH mission because it will lay the foundation\\\\nfor future development of new therapeutic approaches to atrial fibrillation\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 124043, \"indirect_cost_amt\": 9923, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10911333\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 20}, page_content='{\"appl_id\": 10912061, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5U24HL165014-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 606888, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"165014\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 14088426, \"first_name\": \"John\", \"middle_name\": \"\", \"last_name\": \"VanBuren\", \"is_contact_pi\": true, \"full_name\": \"John  VanBuren\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"VANBUREN, JOHN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 606888, \"direct_cost_ic\": 394083, \"indirect_cost_ic\": 212805}], \"project_start_date\": \"2023-09-01T12:09:00Z\", \"project_end_date\": \"2029-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-22-193\", \"full_study_section\": {\"srg_code\": \"CLTR\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"MA\", \"name\": \"Clinical Trials Review Study Section[CLTR(MA)]\"}, \"award_notice_date\": \"2024-08-21T12:08:00Z\", \"core_project_num\": \"U24HL165014\", \"terms\": \"<0-11 years old><21+ years old><AHCPR><AHRQ><Adoption><Adult><Adult Human><Age><Agency for Health Care Policy and Research><Agency for Healthcare Research and Quality><Airway failure><Asystole><Biometrics><Biometry><Biostatistics><Bradycardia><Brain><Brain Nervous System><Cardiac Arrest><Caring><Categories><Chest><Child><Child Care><Child Youth><Childhood><Childhood Injury><Children (0-21)><Clinical><Clinical Trials><Communication><Complement><Complement Proteins><Critical Illness><Critically Ill><Critically ill children><Data><Data Collection><Data Coordinating Center><Data Coordination Center><Data Set><Devices><Encephalon><Endotracheal Intubation><Enrollment><Gel><Generations><Goals><Guidelines><Heart><Heart Arrest><Hospitals><Human Resources><Hyperventilation><Hypoxia><Hypoxic><Interruption><Intratracheal Intubation><Investigators><Laryngeal><Laryngeal Mask Airway><Laryngeal Masks><Larynx><Larynx Head and Neck><Leadership><Life><Lung><Lung Respiratory System><Maintenance><Manpower><Manuals><Masks><Methods><Monitor><O element><O2 element><Oxygen><Oxygen Deficiency><Paramedic><Paramedical Personnel><Patients><Pre-hospital care><Pre-hospitalization care><Prehospital care><Prehospitalization care><Preparation><Production><Protocol><Protocols documentation><Public Health><Puericulture><Qualifying><Recommendation><Reporting><Research><Research Personnel><Researchers><Respiratory Failure><Resuscitation><Solid><Survival Rate><Technical Expertise><Techniques><Testing><Thorace><Thoracic><Thorax><Training><Trauma><Traumatic injury><Tube><United States Agency for Health Care Policy and Research><United States Agency for Healthcare Research and Quality><Universities><Utah><adulthood><ages><clinical trial analysis><complementation><critical injury><critically ill child><data management><data management and coordinating center><data management center><design><designing><devastating injury><disease subgroups><disease subtype><disorder subtype><emergency settings><enroll><evidence base><experience><feasibility trial><improved><improved outcome><injured child><injured children><injury in children><innovate><innovation><innovative><kids><life year loss><multidisciplinary><novel><operation><operations><out-of-hospital cardiac arrest><out-of-hospital sudden cardiac arrest><patient population><pediatric><pediatric emergency><pediatric injury><personnel><pragmatic effectiveness trial><pragmatic trial><preparations><prevent><preventing><pulmonary><relative effectiveness><severe injury><skills><study population><technical skills><tracheal intubation><trial design><ventilation><voice box><years of life lost><youngster>\", \"pref_terms\": \"Adoption;Adult;Age;Biometry;Bradycardia;Brain;Caring;Categories;Chest;Child;Child Care;Childhood;Childhood Injury;Clinical;Clinical Trials;Communication;Complement;Critical Illness;Critically ill children;Data;Data Collection;Data Coordinating Center;Data Set;Devices;Enrollment;Gel;Generations;Goals;Guidelines;Heart;Heart Arrest;Hospitals;Human Resources;Hyperventilation;Hypoxia;Interruption;Intratracheal Intubation;Laryngeal Masks;Larynx;Leadership;Life;Lung;Maintenance;Manuals;Masks;Methods;Monitor;Oxygen;Paramedical Personnel;Patients;Pre-hospitalization care;Preparation;Production;Protocols documentation;Public Health;Qualifying;Recommendation;Reporting;Research;Research Personnel;Respiratory Failure;Resuscitation;Solid;Survival Rate;Technical Expertise;Techniques;Testing;Training;Trauma;Traumatic injury;Tube;United States Agency for Healthcare Research and Quality;Universities;Utah;clinical trial analysis;data management;design;disorder subtype;emergency settings;evidence base;experience;feasibility trial;improved;improved outcome;innovation;multidisciplinary;novel;operation;out-of-hospital cardiac arrest;patient population;pediatric emergency;pragmatic trial;prevent;relative effectiveness;severe injury;skills;study population;trial design;ventilation;years of life lost\", \"abstract_text\": \"Project Summary\\\\nWe propose the novel Pediatric Prehospital Airway Resuscitation Trial (Pedi-PART) to determine the best paramedic\\\\nstrategies for managing the airway in critically ill or injured children. Requirements of a clinical trial include the\\\\nfollowing: a) study of common paramedic airway techniques, b) integration of the range of critical conditions\\\\nrequiring airway management, c) an enrolled study population large enough to yield meaningful results, and d)\\\\ninnovative approaches to enhance the feasibility and applicability of the trial. A key innovation will be the novel\\\\nBayesian Adaptive Sequential Platform Trial (BASiC-PT) framework used to determine the relative effectiveness\\\\nof three airway techniques (BVM, ETI, SGA) across three disease subgroups (cardiac arrest, trauma, respiratory\\\\nfailure) for all pediatric age categories, maximizing available information while minimizing the number of patients.\\\\nThe novel design of Pedi-PART overcomes analytic, logistical, and financial barriers that make a traditional trial\\\\ndesign infeasible. Our aims are:\\\\nSpecific Aim 1. To provide biostatistical leadership and expertise, assistance in protocol design, study imple-\\\\n mentation and management, data collection and management, study reporting and metrics, assistance in\\\\n interim and final study analyses, and production of public use research datasets in the establishment and\\\\n execution of the Pedi-PART study.\\\\nSpecific Aim 2. To provide logistical support and technical expertise for Pedi-PART investigators and coordina-\\\\n tors, through effective study training, efficient quality monitoring, communication and engagement of study\\\\n personnel, maintenance of study regulatory documents, and preparation of useful study materials (e.g.,\\\\n manual of operations) to enhance the implementation of the trial.\\\\n Pedi-PART is a pragmatic trial designed to provide a solid evidence base for best practice in paramedic\\\\npediatric airway management. These results will identify the ideal airway techniques to be used, enabling the\\\\ngeneration of guidelines for the highest level of prehospital care for children here and across the globe.\", \"project_title\": \"2/2: Pediatric Prehospital Airway Resuscitation Trial (Pedi-PART)\", \"phr_text\": \"Project Narrative\\\\nResuscitation from critical illness requires skillful delivery of oxygen. This project will compare three paramedic\\\\nstrategies for delivering life-saving oxygen to critically-ill children. The findings will improve public health by\\\\ndefining approaches to improve survival and reduce years of life loss among critically-ill children.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 394083, \"indirect_cost_amt\": 212805, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10912061\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 21}, page_content='{\"appl_id\": 10660663, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"1R01CA276825-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R01\", \"award_amount\": 672704, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R01\", \"ic_code\": \"CA\", \"serial_num\": \"276825\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 11233567, \"first_name\": \"Anne\", \"middle_name\": \"C\", \"last_name\": \"Kirchhoff\", \"is_contact_pi\": true, \"full_name\": \"Anne C Kirchhoff\", \"title\": \"ASSISTANT PROFESSOR\"}, {\"profile_id\": 7742978, \"first_name\": \"Elyse\", \"middle_name\": \"R.\", \"last_name\": \"Park\", \"is_contact_pi\": false, \"full_name\": \"Elyse R. Park\", \"title\": \"\"}], \"contact_pi_name\": \"KIRCHHOFF, ANNE C\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 672704, \"direct_cost_ic\": 487414, \"indirect_cost_ic\": 185290}], \"project_start_date\": \"2023-06-14T12:06:00Z\", \"project_end_date\": \"2028-05-31T12:05:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-21-035\", \"full_study_section\": {\"srg_code\": \"ICSC\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Interdisciplinary Clinical Care in Specialty Care Settings Study Section[ICSC]\"}, \"award_notice_date\": \"2023-06-14T12:06:00Z\", \"core_project_num\": \"R01CA276825\", \"terms\": \"<21+ years old><Adult Human><adulthood><Adult><Affect><After Care><After-Treatment><post treatment><Aftercare><ages><Age><Behavioral Sciences><Breast><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><cost effectiveness><Diagnosis><Education><Educational aspects><Future><Goals><Healthcare Systems><Health Care Systems><Health Services Accessibility><Access to Care><access to health services><access to services><access to treatment><accessibility to health services><availability of services><care access><health service access><health services availability><service availability><treatment access><Hospitals><Insurance><Health Insurance><health insurance plan><Interview><literacy><Lymphoma><Germinoblastic Sarcoma><Germinoblastoma><Malignant Lymphoma><Reticulolymphosarcoma><Parents><parent><Recommendation><Recurrence><Recurrent><Resources><Research Resources><Schools><Surveys><Survey Instrument><survivorship><Testing><Time><United States><Universities><Utah><Work><health care><Healthcare><Hispanic><medical costs><Medical Care Costs><Treatment Cost><economic analysis><economic assessment><economic evaluation><Caring><Guidelines><improved><Survivors><Link><adult youth><young adulthood><young adult><Rural><Policies><Ethnicity><Ethnic Origin><randomized control trial><Randomized, Controlled Trials><tool><Knowledge><programs><Location><Operative Surgical Procedures><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Services><Clinics and Hospitals><Clinics or Hospitals><experience><success><Participant><Patient Self-Report><Self-Report><Reporting><Radiation><Sampling><Intervention><Intervention Strategies><interventional strategy><cancer recurrence><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer-directed therapy><cancer care><Malignant Soft Tissue Neoplasm><malignant soft tissue tumor><sarcoma><Address><Recurrent Malignant Neoplasm><Recurrent Cancer><Recurrent Malignant Tumor><Cost Effectiveness Analysis><cost efficient analysis><cost-effective analysis><Data><National Cancer Institute><NCI Organization><National Comprehensive Cancer Network><NCCN><Randomized><randomisation><randomization><randomly assigned><Subgroup><Cancer Survivor><Enrollment><enroll><Patient-Focused Outcomes><Patient outcome><Patient-Centered Outcomes><patient oriented outcomes><follow-up><Active Follow-up><active followup><follow up><followed up><followup><Colorectal Cancer><Colo-rectal Cancer><Electronic Health Record><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><Pathway interactions><pathway><pilot trial><cost><Behavioral Model><data integration><designing><design><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy examination><evaluate efficacy><examine efficacy><efficacy evaluation><pediatric cancer survivor><childhood cancer survivor><Outcome><Population><health application><chemotherapy><evidence base><primary outcome><secondary outcome><care as usual><usual care><treatment as usual><oncology service><intervention effect><efficacy testing><Randomization trial><randomized trial><arm><improved outcome><health service utilization><health service use><rurality><recruit><barrier to health care><barrier to healthcare><barrier to treatment><obstacle to care><obstacle to healthcare><barrier to care><intervention arm><treatment arm><financial toxicity><financial burden><financial distress><financial strain><financial stress><Financial Hardship><data infrastructure><budget impact><virtual patient><Latine><Latinx><pilot test><virtual health><patient navigation><comparison control><compare to control>\", \"pref_terms\": \"Address;Adult;Affect;Aftercare;Age;Behavioral Model;Behavioral Sciences;Breast;Cancer Survivor;Caring;Clinics and Hospitals;Colorectal Cancer;Cost Effectiveness Analysis;Data;Diagnosis;Education;Electronic Health Record;Enrollment;Ethnic Origin;Financial Hardship;Future;Goals;Guidelines;Health Insurance;Health Services Accessibility;Healthcare;Healthcare Systems;Hispanic;Hospitals;Insurance;Intervention;Interview;Knowledge;Latinx;Link;Location;Lymphoma;Malignant Neoplasms;Medical Care Costs;National Cancer Institute;National Comprehensive Cancer Network;Operative Surgical Procedures;Outcome;Parents;Participant;Pathway interactions;Patient Self-Report;Patient-Focused Outcomes;Policies;Population;Radiation;Randomized;Randomized, Controlled Trials;Recommendation;Recurrence;Recurrent Malignant Neoplasm;Reporting;Resources;Rural;Sampling;Schools;Services;Subgroup;Surveys;Survivors;Testing;Time;Treatment Cost;United States;Universities;Utah;Work;arm;barrier to care;budget impact;cancer care;cancer recurrence;cancer therapy;chemotherapy;childhood cancer survivor;comparison control;cost;cost effectiveness;data infrastructure;data integration;design;economic evaluation;efficacy evaluation;efficacy testing;evidence base;experience;financial toxicity;follow-up;health application;health service use;improved;improved outcome;intervention effect;literacy;oncology service;patient navigation;pilot test;pilot trial;primary outcome;programs;randomized trial;recruit;rurality;sarcoma;secondary outcome;success;survivorship;tool;treatment arm;treatment as usual;virtual health;virtual patient;young adult\", \"abstract_text\": \"ABSTRACT\\\\nThe first year after cancer treatment ends is a critical time to establish survivorship care for young adult (YA)\\\\ncancer survivors ages 26 to 39. Receipt of evidence-based survivorship care, including surveillance for cancer\\\\nrecurrence based on national guidelines, remain low among YA survivors. At the same time, YAs ages 26 to\\\\n39 have the highest rate of both uninsurance and underinsurance among US adults. Our team\\\\u2019s prior work\\\\ndemonstrated that YA cancer survivors report low understanding of their health insurance and the services it\\\\ncovers, which affects their ability to navigate care. Together, these issues can lead to significant access to care\\\\nbarriers and severe medical cost consequences for this population. This proposal addresses the urgent need\\\\nto improve YA cancer survivors\\\\u2019 health insurance literacy and decrease financial toxicity, thus improving their\\\\nability to receive recommended survivorship care. Guided by Andersen and Aday\\\\u2019s Behavioral Model of Health\\\\nServices Use, we developed and pilot-tested a 4-session virtual patient navigation intervention for YA cancer\\\\nsurvivors that was adapted from a pilot program for childhood cancer survivors. Initial results support feasibility,\\\\nacceptability, and preliminary efficacy of both of these pilot trials with YA survivors ages 26 to 39. We now\\\\npropose a randomized controlled trial to test the efficacy of this program (\\\\u201cCHAT-S\\\\u201d) to improve health\\\\ninsurance literacy, financial toxicity due to medical costs, and post-treatment surveillance for recurrence among\\\\nYA cancer survivors ages 26 to 39. We plan to randomize N=300 (N=200 intervention; N=100 usual care) YAs\\\\nwith breast, testicular, lymphoma, sarcoma, and colorectal cancer who have completed initial treatment within\\\\nthe past year from 14 locations in the University of Utah Healthcare (UUHC) and Intermountain Healthcare (IH)\\\\nsystems. UUHC and IH have many rural (20%) and Hispanic/Latinx (18%) YA cancer survivors; we will\\\\noversample these important subgroups. We will determine whether CHAT-S improves health insurance literacy\\\\nand financial toxicity at 6-month follow-up (primary outcomes). Further, UUHC and IH have an integrated data\\\\ninfrastructure which allows us to capture electronic health records and claims data to investigate whether\\\\nCHAT-S improves surveillance care for recurrence at 18-month follow-up (secondary outcome). We will\\\\nexplore moderators (e.g., rurality, ethnicity) of the intervention effects. Finally, to inform future dissemination,\\\\nwe will conduct a budget impact analysis and a short-term and long-term time horizon cost-effectiveness\\\\nanalysis of CHAT-S. This proposal addresses the National Cancer Institute\\\\u2019s goal of improving the care of\\\\ncancer survivors and mitigating financial toxicity. We will demonstrate that a virtual health insurance literacy\\\\nintervention can improve insurance literacy, financial toxicity, and surveillance care among YA cancer\\\\nsurvivors, and provide guidance to improving survivorship care across the United States.\", \"project_title\": \"A Randomized Controlled Trial to Improve Health Insurance Literacy and Surveillance among Young Adult Cancer Survivors\", \"phr_text\": \"NARRATIVE\\\\nWe propose a randomized controlled trial to test a 4-session virtual health insurance navigation intervention\\\\nthat will increase knowledge about health insurance, reduce financial burden, and improve surveillance for\\\\nrecurrence among 300 young adult cancer survivors ages 26 to 39. We will combine self-reported survey data\\\\nwith electronic health records and claims data to examine the trial outcomes and efficacy. We will also conduct\\\\nan economic evaluation using cost-effectiveness and budget impact analyses, to establish the sustainability of\\\\nthe intervention at improving outcomes of young adult survivors through increasing their health insurance\\\\nknowledge and decreasing their financial burden.\", \"spending_categories_desc\": \"Cancer; Clinical Research; Clinical Trials and Supportive Activities; Comparative Effectiveness Research; Cost Effectiveness Research; Health Disparities Research; Health Disparities and Racial or Ethnic Minority Health Research; Health Services; Pediatric; Prevention; Rural Health; Social Determinants of Health; Women\\'s Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-06-14T12:06:00Z\", \"budget_end\": \"2024-05-31T12:05:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 487414, \"indirect_cost_amt\": 185290, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10660663\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 22}, page_content='{\"appl_id\": 10867316, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5R01CA276825-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 613806, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"CA\", \"serial_num\": \"276825\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 11233567, \"first_name\": \"Anne\", \"middle_name\": \"C\", \"last_name\": \"Kirchhoff\", \"is_contact_pi\": true, \"full_name\": \"Anne C Kirchhoff\", \"title\": \"ASSISTANT PROFESSOR\"}, {\"profile_id\": 7742978, \"first_name\": \"Elyse\", \"middle_name\": \"R.\", \"last_name\": \"Park\", \"is_contact_pi\": false, \"full_name\": \"Elyse R. Park\", \"title\": \"\"}], \"contact_pi_name\": \"KIRCHHOFF, ANNE C\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 613806, \"direct_cost_ic\": 461588, \"indirect_cost_ic\": 152218}], \"project_start_date\": \"2023-06-14T12:06:00Z\", \"project_end_date\": \"2028-05-31T12:05:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-21-035\", \"full_study_section\": {\"srg_code\": \"ICSC\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Interdisciplinary Clinical Care in Specialty Care Settings Study Section[ICSC]\"}, \"award_notice_date\": \"2024-05-16T12:05:00Z\", \"core_project_num\": \"R01CA276825\", \"terms\": \"<21+ years old><Adult Human><adulthood><Adult><Affect><After Care><After-Treatment><post treatment><Aftercare><ages><Age><Behavioral Sciences><Breast><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Malignant Neoplasms><cost effectiveness><Diagnosis><Future><Goals><Health Care Systems><Healthcare Systems><Access to Care><access to health services><access to services><access to treatment><accessibility to health services><availability of services><care access><health service access><health services availability><service availability><treatment access><Health Services Accessibility><Hospitals><Insurance><health insurance plan><Health Insurance><Interview><literacy><Germinoblastic Sarcoma><Germinoblastoma><Malignant Lymphoma><Reticulolymphosarcoma><Lymphoma><Parents><parent><Recommendation><Recurrence><Recurrent><Resources><Research Resources><Schools><Surveys><Survey Instrument><survivorship><Testing><Time><United States><Universities><Utah><Work><health care><Healthcare><Hispanic><medical costs><medical expenses><Medical Care Costs><Treatment Cost><economic analysis><economic assessment><economic evaluation><Caring><Guidelines><improved><Survivors><Link><adult youth><young adulthood><young adult><Rural><Policies><Ethnicity><Ethnic Origin><randomized control trial><Randomized, Controlled Trials><tool><Knowledge><programs><Location><Operative Surgical Procedures><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Services><Clinics and Hospitals><Clinics or Hospitals><experience><success><Participant><Patient Self-Report><Self-Report><Reporting><Radiation><Sampling><Intervention><Intervention Strategies><interventional strategy><cancer recurrence><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><cancer-directed therapy><cancer care><Sarcoma><Malignant Soft Tissue Neoplasm><malignant soft tissue tumor><Address><Cost Effectiveness Analysis><cost efficient analysis><cost-effective analysis><Data><National Cancer Institute><NCI Organization><National Comprehensive Cancer Network><NCCN><Randomized><randomisation><randomization><randomly assigned><Subgroup><Cancer Survivor><Enrollment><enroll><Patient-Focused Outcomes><Patient outcome><Patient-Centered Outcomes><patient oriented outcomes><follow-up><Active Follow-up><active followup><follow up><followed up><followup><Colorectal Cancer><Electronic Health Record><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><Pathway interactions><pathway><pilot trial><cost><Behavioral Model><data integration><design><designing><efficacy evaluation><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy examination><evaluate efficacy><examine efficacy><childhood cancer survivor><pediatric cancer survivor><Outcome><Population><health application><chemotherapy><evidence base><primary outcome><secondary outcome><treatment as usual><care as usual><usual care><oncology service><intervention effect><efficacy testing><randomized trial><Randomization trial><arm><improved outcome><health service use><health service utilization><rurality><recruit><barrier to care><barrier to health care><barrier to healthcare><barrier to treatment><obstacle to care><obstacle to healthcare><treatment arm><intervention arm><financial toxicity><Financial Hardship><financial adversity><financial burden><financial distress><financial insecurity><financial strain><financial stress><data infrastructure><budget impact><virtual patient><Latinx><Latine><pilot test><virtual health><patient navigation><comparison control><compare to control><cancer survivorship care><cancer survivor care>\", \"pref_terms\": \"Address;Adult;Affect;Aftercare;Age;Behavioral Model;Behavioral Sciences;Breast;Cancer Survivor;Caring;Clinics and Hospitals;Colorectal Cancer;Cost Effectiveness Analysis;Data;Diagnosis;Electronic Health Record;Enrollment;Ethnic Origin;Financial Hardship;Future;Goals;Guidelines;Health Insurance;Health Services Accessibility;Healthcare;Healthcare Systems;Hispanic;Hospitals;Insurance;Intervention;Interview;Knowledge;Latinx;Link;Location;Lymphoma;Malignant Neoplasms;Medical Care Costs;National Cancer Institute;National Comprehensive Cancer Network;Operative Surgical Procedures;Outcome;Parents;Participant;Pathway interactions;Patient Self-Report;Patient-Focused Outcomes;Policies;Population;Radiation;Randomized;Randomized, Controlled Trials;Recommendation;Recurrence;Reporting;Resources;Rural;Sampling;Sarcoma;Schools;Services;Subgroup;Surveys;Survivors;Testing;Time;Treatment Cost;United States;Universities;Utah;Work;arm;barrier to care;budget impact;cancer care;cancer recurrence;cancer survivorship care;cancer therapy;chemotherapy;childhood cancer survivor;comparison control;cost;cost effectiveness;data infrastructure;data integration;design;economic evaluation;efficacy evaluation;efficacy testing;evidence base;experience;financial toxicity;follow-up;health application;health service use;improved;improved outcome;intervention effect;literacy;oncology service;patient navigation;pilot test;pilot trial;primary outcome;programs;randomized trial;recruit;rurality;secondary outcome;success;survivorship;tool;treatment arm;treatment as usual;virtual health;virtual patient;young adult\", \"abstract_text\": \"ABSTRACT\\\\nThe first year after cancer treatment ends is a critical time to establish survivorship care for young adult (YA)\\\\ncancer survivors ages 26 to 39. Receipt of evidence-based survivorship care, including surveillance for cancer\\\\nrecurrence based on national guidelines, remain low among YA survivors. At the same time, YAs ages 26 to\\\\n39 have the highest rate of both uninsurance and underinsurance among US adults. Our team\\\\u2019s prior work\\\\ndemonstrated that YA cancer survivors report low understanding of their health insurance and the services it\\\\ncovers, which affects their ability to navigate care. Together, these issues can lead to significant access to care\\\\nbarriers and severe medical cost consequences for this population. This proposal addresses the urgent need\\\\nto improve YA cancer survivors\\\\u2019 health insurance literacy and decrease financial toxicity, thus improving their\\\\nability to receive recommended survivorship care. Guided by Andersen and Aday\\\\u2019s Behavioral Model of Health\\\\nServices Use, we developed and pilot-tested a 4-session virtual patient navigation intervention for YA cancer\\\\nsurvivors that was adapted from a pilot program for childhood cancer survivors. Initial results support feasibility,\\\\nacceptability, and preliminary efficacy of both of these pilot trials with YA survivors ages 26 to 39. We now\\\\npropose a randomized controlled trial to test the efficacy of this program (\\\\u201cCHAT-S\\\\u201d) to improve health\\\\ninsurance literacy, financial toxicity due to medical costs, and post-treatment surveillance for recurrence among\\\\nYA cancer survivors ages 26 to 39. We plan to randomize N=300 (N=200 intervention; N=100 usual care) YAs\\\\nwith breast, testicular, lymphoma, sarcoma, and colorectal cancer who have completed initial treatment within\\\\nthe past year from 14 locations in the University of Utah Healthcare (UUHC) and Intermountain Healthcare (IH)\\\\nsystems. UUHC and IH have many rural (20%) and Hispanic/Latinx (18%) YA cancer survivors; we will\\\\noversample these important subgroups. We will determine whether CHAT-S improves health insurance literacy\\\\nand financial toxicity at 6-month follow-up (primary outcomes). Further, UUHC and IH have an integrated data\\\\ninfrastructure which allows us to capture electronic health records and claims data to investigate whether\\\\nCHAT-S improves surveillance care for recurrence at 18-month follow-up (secondary outcome). We will\\\\nexplore moderators (e.g., rurality, ethnicity) of the intervention effects. Finally, to inform future dissemination,\\\\nwe will conduct a budget impact analysis and a short-term and long-term time horizon cost-effectiveness\\\\nanalysis of CHAT-S. This proposal addresses the National Cancer Institute\\\\u2019s goal of improving the care of\\\\ncancer survivors and mitigating financial toxicity. We will demonstrate that a virtual health insurance literacy\\\\nintervention can improve insurance literacy, financial toxicity, and surveillance care among YA cancer\\\\nsurvivors, and provide guidance to improving survivorship care across the United States.\", \"project_title\": \"A Randomized Controlled Trial to Improve Health Insurance Literacy and Surveillance among Young Adult Cancer Survivors\", \"phr_text\": \"NARRATIVE\\\\nWe propose a randomized controlled trial to test a 4-session virtual health insurance navigation intervention\\\\nthat will increase knowledge about health insurance, reduce financial burden, and improve surveillance for\\\\nrecurrence among 300 young adult cancer survivors ages 26 to 39. We will combine self-reported survey data\\\\nwith electronic health records and claims data to examine the trial outcomes and efficacy. We will also conduct\\\\nan economic evaluation using cost-effectiveness and budget impact analyses, to establish the sustainability of\\\\nthe intervention at improving outcomes of young adult survivors through increasing their health insurance\\\\nknowledge and decreasing their financial burden.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-06-01T12:06:00Z\", \"budget_end\": \"2025-05-31T12:05:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 461588, \"indirect_cost_amt\": 152218, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10867316\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 23}, page_content='{\"appl_id\": 10622189, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"1RC2TR004391-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"RC2\", \"award_amount\": 769741, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"RC2\", \"ic_code\": \"TR\", \"serial_num\": \"004391\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 6413677, \"first_name\": \"PAUL\", \"middle_name\": \"\", \"last_name\": \"ESTABROOKS\", \"is_contact_pi\": false, \"full_name\": \"PAUL  ESTABROOKS\", \"title\": \"PROFESSOR AND ASSOCIATE DEAN\"}, {\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": true, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"TRISTANI-FIROUZI, MARTIN \", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"TR\", \"name\": \"National Center for Advancing Translational Sciences\", \"abbreviation\": \"NCATS\", \"total_cost\": 769741, \"direct_cost_ic\": 499967, \"indirect_cost_ic\": 269774}], \"project_start_date\": \"2023-06-05T12:06:00Z\", \"project_end_date\": \"2028-05-31T12:05:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-21-340\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": \"CI\", \"sra_flex_code\": \"6\", \"group_code\": \"01\", \"name\": \"Special Emphasis Panel[ZTR1 CI-6 (01)]\"}, \"award_notice_date\": \"2023-06-05T12:06:00Z\", \"core_project_num\": \"RC2TR004391\", \"terms\": \"<Acceleration><Adoption><Diagnosis><Explosion><Faculty><Foundations><Patient Care><Patient Care Delivery><Genome><Goals><Recording of previous events><History><histories><Industry><Intensive Care Units><Neonatal Intensive Care Units><Newborn Intensive Care Units><neonatal ICU><Investments><Laboratories><Methods><United States National Institutes of Health><NIH><National Institutes of Health><Patients><Research><Science><Computer software><Software><Technology><Universities><Utah><Genetic Variation><Genetic Diversity><Guidelines><improved><Area><Clinical><Variation><Variant><intuitive><Intuition><Fostering><Genetic><tool><Diagnostic><Life><programs><Complex><success><diagnostic accuracy><Accuracy of Diagnosis><novel><empowerment><portability><Genomics><genome sequencing><Data><Clinical Sciences><Emerging Technologies><Emergent Technologies><Translational Research><Translational Science><translation research><translational investigation><Process><point of care><Electronic Health Record><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><clinical phenotype><designing><design><innovate><innovative><innovation><interoperability><open source><implementation science><clinical care><precision-based medicine><precision medicine><Precision care><individualized care><individualized patient care><personalized patient care><personalized care><genomic variation><Genomic medicine><entire genome><full genome><whole genome><genomic data-set><genomic dataset><genomic data><translational genomics><clinical implementation><genomic science><genome sciences><Infrastructure><bio-informatics tool><bioinformatics tool><Visualization><Dissemination and Implementation><diagnostic system><diagnostic platform><National Center for Advancing Translational Sciences><NCATS><dissemination science><diagnostic tool><rare mendelian disorder><rare mendelian condition><rare mendelian disease><electronic health information><electronic health record system><EHR system>\", \"pref_terms\": \"Acceleration;Adoption;Area;Clinical;Clinical Sciences;Complex;Computer software;Data;Diagnosis;Diagnostic;Dissemination and Implementation;Electronic Health Record;Emerging Technologies;Explosion;Faculty;Fostering;Foundations;Genetic;Genetic Variation;Genome;Genomic medicine;Genomics;Goals;Guidelines;Industry;Infrastructure;Intensive Care Units;Intuition;Investments;Laboratories;Life;Methods;National Center for Advancing Translational Sciences;Neonatal Intensive Care Units;Patient Care;Patients;Process;Recording of previous events;Research;Science;Technology;Translational Research;United States National Institutes of Health;Universities;Utah;Variant;Visualization;bioinformatics tool;clinical care;clinical implementation;clinical phenotype;design;diagnostic accuracy;diagnostic platform;diagnostic tool;dissemination science;electronic health information;electronic health record system;empowerment;genome sciences;genome sequencing;genomic data;genomic variation;implementation science;improved;innovation;interoperability;novel;open source;personalized care;point of care;portability;precision medicine;programs;rare mendelian disorder;success;tool;translational genomics;whole genome\", \"abstract_text\": \"SUMMARY\\\\nWhile the past decade has seen an explosion in basic genomic research, the clinical implementation of\\\\ngenomic medicine remains elusive. This Specialized Innovation Program (SIP) will identify and overcome\\\\nbarriers that impede the translational science of rapid genomic medicine discoveries at the point of care by\\\\nassembling the infrastructure, technology, and strategies to design and develop a rapid genomic diagnostic\\\\nplatform, using the newborn intensive care unit (NICU) as a laboratory. Emerging clinical guidelines support\\\\nthe value and utility of rapid whole-genome sequencing in the NICU, yet multiple barriers impede the\\\\nwidespread use of this technology at the point of care. Specifically, (1) less than half of rare Mendelian\\\\ndiseases are solvable using current sequencing and analytical technologies; (2) industry electronic health\\\\nrecord (EHR)-based genomic medicine applications are essentially nonexistent, with a lack of EHR-interfaced\\\\nplatforms that allow for visualization and team-based interpretation of genomic sequencing; (3) translational\\\\nscience strategies to implement genomic medicine into clinical care are currently lacking. To overcome these\\\\nbarriers, the SIP will design and develop an innovative, collaborative, patient-focused, and EHR-interfaced\\\\ntranslational platform that efficiently integrates rapid genomic medicine at the point of care, using the NICU as\\\\na laboratory. Aim 1 will design novel tools that will improve the discovery of all forms of genetic variation,\\\\nincluding difficult-to-detect complex structural variants. These novel tools will be shared as open-source\\\\nsoftware, with accompanying tools for dissemination and implementation, to empower translational genomic\\\\nscience across the CTSA network. Aim 2 will deploy a portable EHR-interfaced platform for rapid genomic\\\\ndiagnostics that is appropriate, acceptable, and feasible across EHR systems and will catalyze clinical and\\\\ntranslational science locally, regionally, and nationally. Aim 3 will use a participatory planning strategy and\\\\nstate of the science dissemination and implementation science methods to develop, tailor, and operationalize\\\\nstrategies to support NICU adoption, implementation, and sustainability of a translational platform for rapid\\\\ngenomic diagnostics. These strategies will be compiled into a generalizable blueprint to foster genomic\\\\ninnovations across the CTSA network and empower broader adoption and sustained implementation of\\\\ngenomic medicine.\", \"project_title\": \"CTSA RC2 Program at University of Utah: A Translational Platform for Rapid Genomic Medicine\", \"phr_text\": \"NARRATIVE\\\\nThe goal of this Specialized Innovation Program is to identify and overcome barriers that impede the\\\\ntranslational science of rapid genomic medicine discoveries at the point of care by assembling the\\\\ninfrastructure, technology, and strategies to design and develop a rapid genomic diagnostic platform, using the\\\\nnewborn intensive care unit as our laboratory. We will design and develop an innovative, collaborative, patient-\\\\nfocused, and electronic health record-interfaced translational platform that efficiently integrates rapid genomic\\\\nmedicine at the point of care.\", \"spending_categories_desc\": \"Bioengineering; Biotechnology; Clinical Research; Dissemination and Implementation Research; Genetics; Human Genome; Networking and Information Technology R&D (NITRD); Patient Safety; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Precision Medicine; Preterm, Low Birth Weight and Health of the Newborn\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-06-05T12:06:00Z\", \"budget_end\": \"2024-05-31T12:05:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 499967, \"indirect_cost_amt\": 269774, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10622189\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 24}, page_content='{\"appl_id\": 10857258, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5RC2TR004391-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"RC2\", \"award_amount\": 769918, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"RC2\", \"ic_code\": \"TR\", \"serial_num\": \"004391\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 6413677, \"first_name\": \"PAUL\", \"middle_name\": \"\", \"last_name\": \"ESTABROOKS\", \"is_contact_pi\": false, \"full_name\": \"PAUL  ESTABROOKS\", \"title\": \"PROFESSOR AND ASSOCIATE DEAN\"}, {\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": true, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"TRISTANI-FIROUZI, MARTIN \", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"TR\", \"name\": \"National Center for Advancing Translational Sciences\", \"abbreviation\": \"NCATS\", \"total_cost\": 769918, \"direct_cost_ic\": 499947, \"indirect_cost_ic\": 269971}], \"project_start_date\": \"2023-06-05T12:06:00Z\", \"project_end_date\": \"2028-05-31T12:05:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-21-340\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": \"CI\", \"sra_flex_code\": \"6\", \"group_code\": \"01\", \"name\": \"ZTR1-CI-6(01)\"}, \"award_notice_date\": \"2024-05-17T12:05:00Z\", \"core_project_num\": \"RC2TR004391\", \"terms\": \"<Acceleration><Adoption><Diagnosis><Explosion><Faculty><Foundations><Patient Care Delivery><care for patients><care of patients><caring for patients><Patient Care><Genome><Goals><History><histories><Recording of previous events><Industry><Intensive Care Units><Newborn Intensive Care Units><neonatal ICU><Neonatal Intensive Care Units><Investments><Laboratories><Methods><United States National Institutes of Health><NIH><National Institutes of Health><Patients><Research><Science><Computer software><Software><Technology><Universities><Utah><Genetic Variation><Genetic Diversity><Guidelines><improved><Area><Clinical><Variation><Variant><intuitive><Intuition><Fostering><Genetic><tool><Diagnostic><Life><programs><Complex><success><diagnostic accuracy><Accuracy of Diagnosis><novel><empowerment><portability><Genomics><genome sequencing><Data><Clinical Sciences><Emerging Technologies><Emergent Technologies><Translational Research><Translational Science><translation research><translational investigation><Process><point of care><Electronic Health Record><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><clinical phenotype><design><designing><innovation><innovate><innovative><interoperability><open source><implementation science><clinical care><precision medicine><precision-based medicine><personalized care><Precision care><individualized care><individualized patient care><personalized patient care><genomic variation><Genomic medicine><whole genome><entire genome><full genome><genomic data><genomic data-set><genomic dataset><translational genomics><clinical implementation><genome sciences><genomic science><Infrastructure><bioinformatics tool><bio-informatics tool><Visualization><Dissemination and Implementation><diagnostic platform><diagnostic system><National Center for Advancing Translational Sciences><NCATS><dissemination science><diagnostic tool><rare mendelian disorder><rare mendelian condition><rare mendelian disease><electronic health information><electronic health record system><EHR system>\", \"pref_terms\": \"Acceleration;Adoption;Area;Clinical;Clinical Sciences;Complex;Computer software;Data;Diagnosis;Diagnostic;Dissemination and Implementation;Electronic Health Record;Emerging Technologies;Explosion;Faculty;Fostering;Foundations;Genetic;Genetic Variation;Genome;Genomic medicine;Genomics;Goals;Guidelines;Industry;Infrastructure;Intensive Care Units;Intuition;Investments;Laboratories;Life;Methods;National Center for Advancing Translational Sciences;Neonatal Intensive Care Units;Patient Care;Patients;Process;Recording of previous events;Research;Science;Technology;Translational Research;United States National Institutes of Health;Universities;Utah;Variant;Visualization;bioinformatics tool;clinical care;clinical implementation;clinical phenotype;design;diagnostic accuracy;diagnostic platform;diagnostic tool;dissemination science;electronic health information;electronic health record system;empowerment;genome sciences;genome sequencing;genomic data;genomic variation;implementation science;improved;innovation;interoperability;novel;open source;personalized care;point of care;portability;precision medicine;programs;rare mendelian disorder;success;tool;translational genomics;whole genome\", \"abstract_text\": \"SUMMARY\\\\nWhile the past decade has seen an explosion in basic genomic research, the clinical implementation of\\\\ngenomic medicine remains elusive. This Specialized Innovation Program (SIP) will identify and overcome\\\\nbarriers that impede the translational science of rapid genomic medicine discoveries at the point of care by\\\\nassembling the infrastructure, technology, and strategies to design and develop a rapid genomic diagnostic\\\\nplatform, using the newborn intensive care unit (NICU) as a laboratory. Emerging clinical guidelines support\\\\nthe value and utility of rapid whole-genome sequencing in the NICU, yet multiple barriers impede the\\\\nwidespread use of this technology at the point of care. Specifically, (1) less than half of rare Mendelian\\\\ndiseases are solvable using current sequencing and analytical technologies; (2) industry electronic health\\\\nrecord (EHR)-based genomic medicine applications are essentially nonexistent, with a lack of EHR-interfaced\\\\nplatforms that allow for visualization and team-based interpretation of genomic sequencing; (3) translational\\\\nscience strategies to implement genomic medicine into clinical care are currently lacking. To overcome these\\\\nbarriers, the SIP will design and develop an innovative, collaborative, patient-focused, and EHR-interfaced\\\\ntranslational platform that efficiently integrates rapid genomic medicine at the point of care, using the NICU as\\\\na laboratory. Aim 1 will design novel tools that will improve the discovery of all forms of genetic variation,\\\\nincluding difficult-to-detect complex structural variants. These novel tools will be shared as open-source\\\\nsoftware, with accompanying tools for dissemination and implementation, to empower translational genomic\\\\nscience across the CTSA network. Aim 2 will deploy a portable EHR-interfaced platform for rapid genomic\\\\ndiagnostics that is appropriate, acceptable, and feasible across EHR systems and will catalyze clinical and\\\\ntranslational science locally, regionally, and nationally. Aim 3 will use a participatory planning strategy and\\\\nstate of the science dissemination and implementation science methods to develop, tailor, and operationalize\\\\nstrategies to support NICU adoption, implementation, and sustainability of a translational platform for rapid\\\\ngenomic diagnostics. These strategies will be compiled into a generalizable blueprint to foster genomic\\\\ninnovations across the CTSA network and empower broader adoption and sustained implementation of\\\\ngenomic medicine.\", \"project_title\": \"CTSA RC2 Program at University of Utah: A Translational Platform for Rapid Genomic Medicine\", \"phr_text\": \"NARRATIVE\\\\nThe goal of this Specialized Innovation Program is to identify and overcome barriers that impede the\\\\ntranslational science of rapid genomic medicine discoveries at the point of care by assembling the\\\\ninfrastructure, technology, and strategies to design and develop a rapid genomic diagnostic platform, using the\\\\nnewborn intensive care unit as our laboratory. We will design and develop an innovative, collaborative, patient-\\\\nfocused, and electronic health record-interfaced translational platform that efficiently integrates rapid genomic\\\\nmedicine at the point of care.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-06-01T12:06:00Z\", \"budget_end\": \"2025-05-31T12:05:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 499947, \"indirect_cost_amt\": 269971, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10857258\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 25}, page_content='{\"appl_id\": 10846547, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5U01DP006702-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U01\", \"award_amount\": 950000, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U01\", \"ic_code\": \"DP\", \"serial_num\": \"006702\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10887809, \"first_name\": \"Aimee\", \"middle_name\": \"O\", \"last_name\": \"Hersh\", \"is_contact_pi\": true, \"full_name\": \"Aimee O Hersh\", \"title\": \"ASSOCIATE PROFESSOR\"}, {\"profile_id\": 11260486, \"first_name\": \"Andrea\", \"middle_name\": \"\", \"last_name\": \"Knight\", \"is_contact_pi\": false, \"full_name\": \"Andrea  Knight\", \"title\": \"\"}, {\"profile_id\": 11372225, \"first_name\": \"Mary Beth\", \"middle_name\": \"F.\", \"last_name\": \"Son\", \"is_contact_pi\": false, \"full_name\": \"Mary Beth F. Son\", \"title\": \"\"}], \"contact_pi_name\": \"HERSH, AIMEE O\", \"agency_ic_admin\": {\"code\": \"DP\", \"abbreviation\": \"NCCDPHP\", \"name\": \"National Center for Chronic Disease Prev and Health Promo\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"DP\", \"name\": \"National Center for Chronic Disease Prev and Health Promo\", \"abbreviation\": \"NCCDPHP\", \"total_cost\": 950000, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2022-09-30T12:09:00Z\", \"project_end_date\": \"2027-09-29T12:09:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DP-22-002\", \"full_study_section\": {\"srg_code\": \"ZDP1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"01\", \"name\": \"ZDP1-KVA(01)\"}, \"award_notice_date\": \"2024-07-05T12:07:00Z\", \"core_project_num\": \"U01DP006702\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"PROJECT SUMMARY\\\\nSystemic Lupus Erythematosus is a systemic autoimmune condition which is life long and can be life threatening.\\\\nUp to 15-20% of all SLE patients are diagnosed in childhood (<18 years of age). Although it is estimated that up\\\\nto 10,000 children in the United States have pediatric-onset SLE (pSLE), the natural history, treatment and\\\\noutcomes for this vulnerable population of children have not been well defined.\\\\nWe propose to use the well-established Childhood Arthritis and Rheumatology Research Alliance (CARRA)\\\\npSLE registry, which currently includes 870 patients followed longitudinally for up to ten years (goal of enrolling\\\\n1300-1400 participants), in order to thoroughly assess the biologic/disease related factors, as well as the non-\\\\nbiologic factors, which can impact short and long-term pSLE outcomes. This proposal will address critical gaps\\\\nin pSLE knowledge including description of treatments for lupus nephritis and the prevalence and outcomes of\\\\nneuropsychiatric pSLE, the two primary causes of pSLE short and long-term morbidity. In addition, we will\\\\ndescribe important patient reported outcomes including pain, quality of life and disability, and long-term\\\\noutcomes, including transition to adulthood.\\\\nResearch findings will be disseminated through patient/family partnerships with a goal of developing future\\\\ninterventions to improve the health and well- being of patients with pSLE.\", \"project_title\": \"DP22-002 Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts - 2022\", \"phr_text\": \"PROJECTIVE NARRATIVE\\\\nSystemic Lupus Erythematosus is a life long autoimmune condition which can be life-threatening. Up to 20% of\\\\nall Lupus patients are children diagnosed prior to 18 years of age. This study will utilize a large cohort of pediatric\\\\nLupus patients in a long-term United States registry to understand the disease, best treatments and what factors\\\\ninfluences important outcomes important to both patients and providers.\", \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2024-09-30T12:09:00Z\", \"budget_end\": \"2025-09-29T12:09:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10846547\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 26}, page_content='{\"appl_id\": 10552476, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1U01DP006702-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"U01\", \"award_amount\": 879548, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"U01\", \"ic_code\": \"DP\", \"serial_num\": \"006702\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10887809, \"first_name\": \"Aimee\", \"middle_name\": \"O\", \"last_name\": \"Hersh\", \"is_contact_pi\": true, \"full_name\": \"Aimee O Hersh\", \"title\": \"ASSOCIATE PROFESSOR\"}, {\"profile_id\": 11260486, \"first_name\": \"Andrea\", \"middle_name\": \"\", \"last_name\": \"Knight\", \"is_contact_pi\": false, \"full_name\": \"Andrea  Knight\", \"title\": \"\"}, {\"profile_id\": 11372225, \"first_name\": \"Mary Beth\", \"middle_name\": \"F.\", \"last_name\": \"Son\", \"is_contact_pi\": false, \"full_name\": \"Mary Beth F. Son\", \"title\": \"\"}], \"contact_pi_name\": \"HERSH, AIMEE O\", \"agency_ic_admin\": {\"code\": \"DP\", \"abbreviation\": \"NCCDPHP\", \"name\": \"National Center for Chronic Disease Prev and Health Promo\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"DP\", \"name\": \"National Center for Chronic Disease Prev and Health Promo\", \"abbreviation\": \"NCCDPHP\", \"total_cost\": 879548, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2022-09-30T12:09:00Z\", \"project_end_date\": \"2027-09-29T12:09:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DP-22-002\", \"full_study_section\": {\"srg_code\": \"ZDP1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"01\", \"name\": \"Special Emphasis Panel[ZDP1 KVA (01)]\"}, \"award_notice_date\": \"2022-07-16T12:07:00Z\", \"core_project_num\": \"U01DP006702\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"PROJECT SUMMARY\\\\nSystemic Lupus Erythematosus is a systemic autoimmune condition which is life long and can be life threatening.\\\\nUp to 15-20% of all SLE patients are diagnosed in childhood (<18 years of age). Although it is estimated that up\\\\nto 10,000 children in the United States have pediatric-onset SLE (pSLE), the natural history, treatment and\\\\noutcomes for this vulnerable population of children have not been well defined.\\\\nWe propose to use the well-established Childhood Arthritis and Rheumatology Research Alliance (CARRA)\\\\npSLE registry, which currently includes 870 patients followed longitudinally for up to ten years (goal of enrolling\\\\n1300-1400 participants), in order to thoroughly assess the biologic/disease related factors, as well as the non-\\\\nbiologic factors, which can impact short and long-term pSLE outcomes. This proposal will address critical gaps\\\\nin pSLE knowledge including description of treatments for lupus nephritis and the prevalence and outcomes of\\\\nneuropsychiatric pSLE, the two primary causes of pSLE short and long-term morbidity. In addition, we will\\\\ndescribe important patient reported outcomes including pain, quality of life and disability, and long-term\\\\noutcomes, including transition to adulthood.\\\\nResearch findings will be disseminated through patient/family partnerships with a goal of developing future\\\\ninterventions to improve the health and well- being of patients with pSLE.\", \"project_title\": \"Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts - 2022\", \"phr_text\": \"PROJECTIVE NARRATIVE\\\\nSystemic Lupus Erythematosus is a life long autoimmune condition which can be life-threatening. Up to 20% of\\\\nall Lupus patients are children diagnosed prior to 18 years of age. This study will utilize a large cohort of pediatric\\\\nLupus patients in a long-term United States registry to understand the disease, best treatments and what factors\\\\ninfluences important outcomes important to both patients and providers.\", \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2022-09-30T12:09:00Z\", \"budget_end\": \"2023-09-29T12:09:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10552476\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 27}, page_content='{\"appl_id\": 10670255, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5U01DP006702-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U01\", \"award_amount\": 878144, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U01\", \"ic_code\": \"DP\", \"serial_num\": \"006702\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10887809, \"first_name\": \"Aimee\", \"middle_name\": \"O\", \"last_name\": \"Hersh\", \"is_contact_pi\": true, \"full_name\": \"Aimee O Hersh\", \"title\": \"ASSOCIATE PROFESSOR\"}, {\"profile_id\": 11260486, \"first_name\": \"Andrea\", \"middle_name\": \"\", \"last_name\": \"Knight\", \"is_contact_pi\": false, \"full_name\": \"Andrea  Knight\", \"title\": \"\"}, {\"profile_id\": 11372225, \"first_name\": \"Mary Beth\", \"middle_name\": \"F.\", \"last_name\": \"Son\", \"is_contact_pi\": false, \"full_name\": \"Mary Beth F. Son\", \"title\": \"\"}], \"contact_pi_name\": \"HERSH, AIMEE O\", \"agency_ic_admin\": {\"code\": \"DP\", \"abbreviation\": \"NCCDPHP\", \"name\": \"National Center for Chronic Disease Prev and Health Promo\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"DP\", \"name\": \"National Center for Chronic Disease Prev and Health Promo\", \"abbreviation\": \"NCCDPHP\", \"total_cost\": 878144, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2022-09-30T12:09:00Z\", \"project_end_date\": \"2027-09-29T12:09:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DP-22-002\", \"full_study_section\": {\"srg_code\": \"ZDP1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"01\", \"name\": \"ZDP1-KVA(01)\"}, \"award_notice_date\": \"2023-05-19T12:05:00Z\", \"core_project_num\": \"U01DP006702\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"PROJECT SUMMARY\\\\nSystemic Lupus Erythematosus is a systemic autoimmune condition which is life long and can be life threatening.\\\\nUp to 15-20% of all SLE patients are diagnosed in childhood (<18 years of age). Although it is estimated that up\\\\nto 10,000 children in the United States have pediatric-onset SLE (pSLE), the natural history, treatment and\\\\noutcomes for this vulnerable population of children have not been well defined.\\\\nWe propose to use the well-established Childhood Arthritis and Rheumatology Research Alliance (CARRA)\\\\npSLE registry, which currently includes 870 patients followed longitudinally for up to ten years (goal of enrolling\\\\n1300-1400 participants), in order to thoroughly assess the biologic/disease related factors, as well as the non-\\\\nbiologic factors, which can impact short and long-term pSLE outcomes. This proposal will address critical gaps\\\\nin pSLE knowledge including description of treatments for lupus nephritis and the prevalence and outcomes of\\\\nneuropsychiatric pSLE, the two primary causes of pSLE short and long-term morbidity. In addition, we will\\\\ndescribe important patient reported outcomes including pain, quality of life and disability, and long-term\\\\noutcomes, including transition to adulthood.\\\\nResearch findings will be disseminated through patient/family partnerships with a goal of developing future\\\\ninterventions to improve the health and well- being of patients with pSLE.\", \"project_title\": \"Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts - 2022\", \"phr_text\": \"PROJECTIVE NARRATIVE\\\\nSystemic Lupus Erythematosus is a life long autoimmune condition which can be life-threatening. Up to 20% of\\\\nall Lupus patients are children diagnosed prior to 18 years of age. This study will utilize a large cohort of pediatric\\\\nLupus patients in a long-term United States registry to understand the disease, best treatments and what factors\\\\ninfluences important outcomes important to both patients and providers.\", \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2023-09-30T12:09:00Z\", \"budget_end\": \"2024-09-29T12:09:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10670255\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 28}, page_content='{\"appl_id\": 10909920, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5U24TR004315-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 3350650, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"TR\", \"serial_num\": \"004315\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10458455, \"first_name\": \"Jamie\", \"middle_name\": \"P.\", \"last_name\": \"Dwyer\", \"is_contact_pi\": false, \"full_name\": \"Jamie P. Dwyer\", \"title\": \"PROFESSOR OF MEDICINE\"}, {\"profile_id\": 9256467, \"first_name\": \"KATHERINE\", \"middle_name\": \"ANN\", \"last_name\": \"SWARD\", \"is_contact_pi\": false, \"full_name\": \"KATHERINE ANN SWARD\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 3350650, \"direct_cost_ic\": 2175747, \"indirect_cost_ic\": 1174903}], \"project_start_date\": \"2022-09-23T12:09:00Z\", \"project_end_date\": \"2027-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-TR-22-012\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": \"CI\", \"sra_flex_code\": \"9\", \"group_code\": \"01\", \"name\": \"ZTR1-CI-9(01)\"}, \"award_notice_date\": \"2024-08-17T12:08:00Z\", \"core_project_num\": \"U24TR004315\", \"terms\": \"<Acute pain management><Award><Clinical><Clinical Trials><Clinical Trials Data Monitoring Committees><Clinical Trials Network><Collaborations><Collection><Common Data Element><Cooperative Agreements><Data><Data Analyses><Data Analysis><Data Bases><Data Collection><Data Monitoring Committees><Data Set><Data and Safety Monitoring Boards><Databases><Deposit><Deposition><Development><Dose><Funding><Future><HEAL Initiative><Hb SS disease><HbSS disease><Helping End Addiction Long-term><Helping End Addiction Longterm><Helping to End Addiction Long-term><Helping to End Addiction Longterm><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><IRB><IRBs><Infrastructure><Institution><Institutional Review Boards><Investigators><Meta-Analysis><Monitor><NCATS><NIH><National Center for Advancing Translational Sciences><National Institutes of Health><Nature><Opiate Addiction><Opiate Dependence><Opiates><Opioid><Outcome><Pain Control><Pain Therapy><Pain management><Phase><Preparation><Principal Investigator><Process><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Randomized><Regimen><Reporting><Research><Research Personnel><Research Resources><Researchers><Resources><Risk Assessment><Risk Reduction><Safety><Safety Monitoring Boards><Scientific Publication><Sickle Cell Anemia><Speed><System><Testing><Training><Translational Research><Translational Science><U-Series Cooperative Agreements><United States National Institutes of Health><Universities><Utah><Work><Writing><addiction><addictive disorder><chronic pain><comparative effectiveness trial><data base><data ecosystem><data interpretation><data management><data sharing><data sharing ecosystem><depository><design><designing><developmental><effectiveness research><innovate><innovation><innovative><opioid addiction><opioid dependence><opioid dependent><pain treatment><preparations><prevention effectiveness trial><programs><randomisation><randomization><randomly assigned><recruit><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><repository><response><risk-reducing><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><success><translation research><translational investigation>\", \"pref_terms\": \"Acute pain management;Award;Clinical;Clinical Trials;Clinical Trials Data Monitoring Committees;Clinical Trials Network;Collaborations;Collection;Common Data Element;Data;Data Analyses;Data Collection;Data Set;Databases;Deposition;Development;Dose;Funding;Future;Helping to End Addiction Long-term;Infrastructure;Institution;Institutional Review Boards;Meta-Analysis;Monitor;National Center for Advancing Translational Sciences;Nature;Opiate Addiction;Opioid;Outcome;Pain management;Phase;Preparation;Principal Investigator;Process;Protocols documentation;Public Health;Publications;Quality Control;Randomized;Regimen;Reporting;Research;Research Personnel;Resources;Risk Assessment;Risk Reduction;Safety;Sickle Cell Anemia;Speed;System;Testing;Training;Translational Research;U-Series Cooperative Agreements;United States National Institutes of Health;Universities;Utah;Work;Writing;addiction;chronic pain;comparative effectiveness trial;data ecosystem;data management;data sharing;design;effectiveness research;innovation;prevention effectiveness trial;programs;recruit;repository;response;success\", \"abstract_text\": \"Project Summary\\\\n The NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scienti\\\\ufb01c solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. Five ERN trials have been implemented with data coordination support from the\\\\nUniversity of Utah Trial Innovation Center. This proposal is written in response to RFA-TR-22-012 to provide\\\\ncontinued support for these \\\\ufb01ve trials, as well as two additional trials that may be funded in response to RFA-AT-22-\\\\n005 (\\\\u201cHEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness\\\\nResearch Network Cooperative Agreement\\\\u201d). The University of Utah is responding to be the Data Coordination\\\\nResource Center (DCRC).\\\\n We will continue to work collaboratively with each ERN study team and the other HEAL ERN Resource\\\\nCenters to 1) develop, implementand monitor the ERN trials; 2) help respond to issues/protocol changes that\\\\nemerge during trial implementation and initiate timely necessary changes to assure trial success; 3) provide\\\\ncollection and analysis of data; and 4) assist with timely publication of study results.\\\\n Our application has three Speci\\\\ufb01c Aims: 1. Work with ERN investigators and other HEAL ERN Resource\\\\nCenters to provide collaborative clinical trial expertise and assistance in study and protocol design, single IRB,\\\\nstudy implementation and management, accrual of subjects, interim study reporting, \\\\ufb01nal study analyses, and\\\\nassistance with timely publication and dissemination of study results. 2. Provide comprehensive data manage-\\\\nment for current and new ERN trials, including database and data collection systems, data management plans,\\\\ndata risk assessment and quality control, implementation of randomization, assistance with Data Safety Monitor-\\\\ning Board (DSMB) reports, and training for using the data collection systems. 3. Facilitate sharing of data from\\\\nHEAL/ERN trials by incorporating HEAL Common Data Elements(CDEs) into protocols, continuing to support\\\\nNIH program staff in development of HEAL CDEs, continued participation in the HEAL Collective Board, and\\\\npreparation of \\\\ufb01nal data sets suitable for deposit in NIH-designated repositories for incorporation into the HEAL\\\\nData Ecosystem.\\\\n Our collaboration with ERN investigators and integration with the other Resource Centers will maximize the\\\\nlikelihood of successful and timely completion of the HEAL ERN clinical trials, leading to translation of research\\\\n\\\\ufb01ndings to the effective management of acute and chronic pain, while minimizing addictive opioid dosing regi-\\\\nmens.\", \"project_title\": \"HEAL ERN: Data Coordinating Resource Center\", \"phr_text\": \"Project Narrative\\\\n The NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scienti\\\\ufb01c solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. The University of Utah will provide data coordination support for these trials, leading to\\\\nmore effective management of acute and chronic pain while reducing the risk of opioid addiction.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 2175747, \"indirect_cost_amt\": 1174903, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10909920\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 29}, page_content='{\"appl_id\": 10591779, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1U24TR004315-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"U24\", \"award_amount\": 604783, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"U24\", \"ic_code\": \"TR\", \"serial_num\": \"004315\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": true, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}, {\"profile_id\": 10458455, \"first_name\": \"Jamie\", \"middle_name\": \"P.\", \"last_name\": \"Dwyer\", \"is_contact_pi\": false, \"full_name\": \"Jamie P. Dwyer\", \"title\": \"PROFESSOR OF MEDICINE\"}, {\"profile_id\": 9256467, \"first_name\": \"KATHERINE\", \"middle_name\": \"ANN\", \"last_name\": \"SWARD\", \"is_contact_pi\": false, \"full_name\": \"KATHERINE ANN SWARD\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": false, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"DEAN, JONATHAN MICHAEL\", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 604783, \"direct_cost_ic\": 393782, \"indirect_cost_ic\": 211001}], \"project_start_date\": \"2022-09-23T12:09:00Z\", \"project_end_date\": \"2027-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-TR-22-012\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": \"CI\", \"sra_flex_code\": \"9\", \"group_code\": \"01\", \"name\": \"Special Emphasis Panel[ZTR1 CI-9 (01)]\"}, \"award_notice_date\": \"2022-09-23T12:09:00Z\", \"core_project_num\": \"U24TR004315\", \"terms\": \"<Pain management><Pain Control><Pain Therapy><pain treatment><Sickle Cell Anemia><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><Award><Clinical Trials><Data Analyses><Data Analysis><data interpretation><Data Collection><Future><NIH><National Institutes of Health><United States National Institutes of Health><Public Health><Scientific Publication><Publications><Quality Control><Research><Investigators><Researchers><Research Personnel><Research Resources><Resources><Risk><Safety><Testing><Time><Translations><Universities><Utah><Work><Risk Assessment><chronic pain><Data Set><Dataset><Clinical><Phase><Training><Data Bases><data base><Databases><Opiates><Opioid><Funding><Collaborations><Deposit><Deposition><Nature><programs><Protocol><Protocols documentation><System><Opiate Dependence><opioid addiction><opioid dependence><opioid dependent><Opiate Addiction><data management><success><Speed><Reporting><response><depository><repository><Meta-Analysis><Clinical Trials Data Monitoring Committees><Data Monitoring Committees><Data and Safety Monitoring Boards><Safety Monitoring Boards><Institution><Dose><Cooperative Agreements><U-Series Cooperative Agreements><Data><randomisation><randomization><randomly assigned><Randomized><Collection><Translational Research><Translational Science><translation research><Monitor><Preparation><Principal Investigator><Common Data Element><Process><Development><developmental><prevention effectiveness trial><effectiveness research><Clinical Trials Network><design><designing><Outcome><innovation><innovate><innovative><addiction><addictive disorder><data sharing><Regimen><Institutional Review Boards><IRB><IRBs><recruit><Infrastructure><Acute pain management><data ecosystem><data sharing ecosystem><comparative effectiveness trial><Helping to End Addiction Long-term><HEAL Initiative><Helping End Addiction Long-term><Helping End Addiction Longterm><Helping to End Addiction Longterm><National Center for Advancing Translational Sciences><NCATS>\", \"pref_terms\": \"Acute pain management;Award;Clinical;Clinical Trials;Clinical Trials Data Monitoring Committees;Clinical Trials Network;Collaborations;Collection;Common Data Element;Data;Data Analyses;Data Collection;Data Set;Databases;Deposition;Development;Dose;Funding;Future;Helping to End Addiction Long-term;Infrastructure;Institution;Institutional Review Boards;Meta-Analysis;Monitor;National Center for Advancing Translational Sciences;Nature;Opiate Addiction;Opioid;Outcome;Pain management;Phase;Preparation;Principal Investigator;Process;Protocols documentation;Public Health;Publications;Quality Control;Randomized;Regimen;Reporting;Research;Research Personnel;Resources;Risk;Risk Assessment;Safety;Sickle Cell Anemia;Speed;System;Testing;Time;Training;Translational Research;Translations;U-Series Cooperative Agreements;United States National Institutes of Health;Universities;Utah;Work;addiction;chronic pain;comparative effectiveness trial;data ecosystem;data management;data sharing;design;effectiveness research;innovation;prevention effectiveness trial;programs;recruit;repository;response;success\", \"abstract_text\": \"Project Summary\\\\n The NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scienti\\\\ufb01c solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. Five ERN trials have been implemented with data coordination support from the\\\\nUniversity of Utah Trial Innovation Center. This proposal is written in response to RFA-TR-22-012 to provide\\\\ncontinued support for these \\\\ufb01ve trials, as well as two additional trials that may be funded in response to RFA-AT-22-\\\\n005 (\\\\u201cHEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness\\\\nResearch Network Cooperative Agreement\\\\u201d). The University of Utah is responding to be the Data Coordination\\\\nResource Center (DCRC).\\\\n We will continue to work collaboratively with each ERN study team and the other HEAL ERN Resource\\\\nCenters to 1) develop, implementand monitor the ERN trials; 2) help respond to issues/protocol changes that\\\\nemerge during trial implementation and initiate timely necessary changes to assure trial success; 3) provide\\\\ncollection and analysis of data; and 4) assist with timely publication of study results.\\\\n Our application has three Speci\\\\ufb01c Aims: 1. Work with ERN investigators and other HEAL ERN Resource\\\\nCenters to provide collaborative clinical trial expertise and assistance in study and protocol design, single IRB,\\\\nstudy implementation and management, accrual of subjects, interim study reporting, \\\\ufb01nal study analyses, and\\\\nassistance with timely publication and dissemination of study results. 2. Provide comprehensive data manage-\\\\nment for current and new ERN trials, including database and data collection systems, data management plans,\\\\ndata risk assessment and quality control, implementation of randomization, assistance with Data Safety Monitor-\\\\ning Board (DSMB) reports, and training for using the data collection systems. 3. Facilitate sharing of data from\\\\nHEAL/ERN trials by incorporating HEAL Common Data Elements(CDEs) into protocols, continuing to support\\\\nNIH program staff in development of HEAL CDEs, continued participation in the HEAL Collective Board, and\\\\npreparation of \\\\ufb01nal data sets suitable for deposit in NIH-designated repositories for incorporation into the HEAL\\\\nData Ecosystem.\\\\n Our collaboration with ERN investigators and integration with the other Resource Centers will maximize the\\\\nlikelihood of successful and timely completion of the HEAL ERN clinical trials, leading to translation of research\\\\n\\\\ufb01ndings to the effective management of acute and chronic pain, while minimizing addictive opioid dosing regi-\\\\nmens.\", \"project_title\": \"HEAL ERN: Data Coordinating Resource Center\", \"phr_text\": \"Project Narrative\\\\n The NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scienti\\\\ufb01c solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. The University of Utah will provide data coordination support for these trials, leading to\\\\nmore effective management of acute and chronic pain while reducing the risk of opioid addiction.\", \"spending_categories_desc\": \"Brain Disorders; Chronic Pain; Clinical Research; Clinical Trials and Supportive Activities; Comparative Effectiveness Research; Neurosciences; Opioids; Pain Research; Patient Safety\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-09-23T12:09:00Z\", \"budget_end\": \"2023-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 393782, \"indirect_cost_amt\": 211001, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10591779\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 30}, page_content='{\"appl_id\": 10888874, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"3U24TR004315-02S1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"3\", \"activity_code\": \"U24\", \"award_amount\": 2081355, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"3\", \"activity_code\": \"U24\", \"ic_code\": \"TR\", \"serial_num\": \"004315\", \"support_year\": \"02\", \"full_support_year\": \"02S1\", \"suffix_code\": \"S1\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": true, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}, {\"profile_id\": 10458455, \"first_name\": \"Jamie\", \"middle_name\": \"P.\", \"last_name\": \"Dwyer\", \"is_contact_pi\": false, \"full_name\": \"Jamie P. Dwyer\", \"title\": \"PROFESSOR OF MEDICINE\"}, {\"profile_id\": 9256467, \"first_name\": \"KATHERINE\", \"middle_name\": \"ANN\", \"last_name\": \"SWARD\", \"is_contact_pi\": false, \"full_name\": \"KATHERINE ANN SWARD\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": false, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"DEAN, JONATHAN MICHAEL\", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 2081355, \"direct_cost_ic\": 1351529, \"indirect_cost_ic\": 729826}], \"project_start_date\": \"2022-09-23T12:09:00Z\", \"project_end_date\": \"2027-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-272\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"01\", \"name\": \"ZTR1(01)\"}, \"award_notice_date\": \"2023-09-01T12:09:00Z\", \"core_project_num\": \"U24TR004315\", \"terms\": \"<Pain Control><Pain Therapy><pain treatment><Pain management><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><Sickle Cell Anemia><Award><Biometry><Biometrics><Biostatistics><Clinical Trials><United States National Institutes of Health><NIH><National Institutes of Health><Public Health><Resources><Research Resources><Surveys><Survey Instrument><Universities><Utah><Work><Clinical><sickle RBC><sickle erythrocyte><sickle red blood cell><Sickle Cell><Arm Pain><Opiates><Opioid><programs><Services><Speed><Administrative Supplement><U-Series Cooperative Agreements><Cooperative Agreements><National Institute of Drug Abuse><NIDA><National Institute on Drug Abuse><Preparation><preparations><Common Data Element><National Institute of Neurological Disorders and Stroke><NINDS><National Institute of Neurological Diseases and Stroke><effectiveness research><Data Coordination Center><data management and coordinating center><data management center><Data Coordinating Center><parent grant><arm><operations><operation><IRB><IRBs><Institutional Review Boards><Infrastructure><HEAL Initiative><Helping End Addiction Long-term><Helping End Addiction Longterm><Helping to End Addiction Longterm><Helping to End Addiction Long-term>\", \"pref_terms\": \"Administrative Supplement;Arm Pain;Award;Biometry;Clinical;Clinical Trials;Common Data Element;Data Coordinating Center;Helping to End Addiction Long-term;Infrastructure;Institutional Review Boards;National Institute of Drug Abuse;National Institute of Neurological Disorders and Stroke;Opioid;Pain management;Preparation;Public Health;Resources;Services;Sickle Cell;Sickle Cell Anemia;Speed;Surveys;U-Series Cooperative Agreements;United States National Institutes of Health;Universities;Utah;Work;arm;effectiveness research;operation;parent grant;programs\", \"abstract_text\": \"Abstract\\\\nThe NIH has created the Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to\\\\nthe national opioid public health crisis. As part of the HEAL initiative, RFA-AT-23-002 HEAL Initiative: Sickle Cell\\\\nDisease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative\\\\nAgreement (UG3/UH3, Clinical Trial Required) was posted; and it is anticipated that two awards will be selected\\\\nto conduct trials through the NIH HEAL Pain Management Effectiveness Research Network (ERN). The two trials\\\\nwill be managed by different mechanisms. The first trial (herein referred to as the primary trial) will be managed\\\\nsimilarly to the five ongoing HEAL ERN trials. The three HEAL ERN resource centers will function as an integrated\\\\ninfrastructure to provide clinical coordinating center (CCC) support (Duke/Vanderbilt), data coordinating center\\\\n(DCC) support (Utah), and biostatistics support (Hopkins/Tufts). The second trial (herein referred to as the\\\\nsecondary trial) will be managed by the University of Utah for both CCC and DCC support. For both trials Utah\\\\nwill provide single institutional review board (sIRB) services. In addition to the Sickle Cell trials, this supplement\\\\nalso covers Utah support for the HEAL Common Data Elements (CDE) Program for one year. Efforts to date\\\\non the CDE Program focused on the pain arm of HEAL, led by the National Institute of Neurological Disorders\\\\nand Stroke (NINDS). The National Institute on Drug Abuse (NIDA) leads the Opioid arm, which is beginning CDE\\\\nefforts. This CDE supplement request covers work to be performed by the HEAL CDE team at the University\\\\nof Utah, and supports three main activities: (1) CDE document preparation (NINDS), (2) HEAL CDE program\\\\nadministrative operations (NINDS), and (3) Survey of instruments used by OUD studies (NIDA). The University\\\\nof Utah HEAL ERN Resource Center is requesting an administrative supplement to enable support of the NIH\\\\nHEAL initiative as described above. The supplement will support the following specific aims:\\\\nSpecific Aim 1. Provide data coordinating center support for the primary sickle cell trial, working with the other\\\\n ERN Resource Centers in the same manner as the current five ERN trials, as detailed in the parent grant.\\\\nSpecific Aim 2. Provide comprehensive clinical and coordinating center support for the secondary sickle cell\\\\ntrial.\\\\nSpecific Aim 3. Support the HEAL CDE Project through (1) CDE document preparation, (2) HEAL CDE program\\\\n administrative operations, and (3) survey of instruments used for OUD studies.\", \"project_title\": \"HEAL Sickle Cell and CDE Supplement\", \"phr_text\": \"Narrative\\\\nThe HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness\\\\nResearch Network Cooperative Agreement will support two trials. This supplement will cover University of Utah\\\\nsupport for the these two trials and support for the HEAL common data elements program.\", \"spending_categories_desc\": \"Chronic Pain; Clinical Research; Hematology; Neurosciences; Pain Research; Rare Diseases; Sickle Cell Disease\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-04T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 1351529, \"indirect_cost_amt\": 729826, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10888874\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 31}, page_content='{\"appl_id\": 10709596, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5U24TR004315-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 3121104, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"TR\", \"serial_num\": \"004315\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": false, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}, {\"profile_id\": 10458455, \"first_name\": \"Jamie\", \"middle_name\": \"P.\", \"last_name\": \"Dwyer\", \"is_contact_pi\": false, \"full_name\": \"Jamie P. Dwyer\", \"title\": \"PROFESSOR OF MEDICINE\"}, {\"profile_id\": 9256467, \"first_name\": \"KATHERINE\", \"middle_name\": \"ANN\", \"last_name\": \"SWARD\", \"is_contact_pi\": false, \"full_name\": \"KATHERINE ANN SWARD\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 3121104, \"direct_cost_ic\": 2026691, \"indirect_cost_ic\": 1094413}], \"project_start_date\": \"2022-09-23T12:09:00Z\", \"project_end_date\": \"2027-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-TR-22-012\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": \"CI\", \"sra_flex_code\": \"9\", \"group_code\": \"01\", \"name\": \"ZTR1-CI-9(01)\"}, \"award_notice_date\": \"2023-08-18T12:08:00Z\", \"core_project_num\": \"U24TR004315\", \"terms\": \"<Pain Control><Pain Therapy><pain treatment><Pain management><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><Sickle Cell Anemia><Award><Clinical Trials><Data Analyses><Data Analysis><data interpretation><Data Collection><Future><United States National Institutes of Health><NIH><National Institutes of Health><Public Health><Publications><Scientific Publication><Quality Control><Research><Research Personnel><Investigators><Researchers><Resources><Research Resources><Safety><Testing><Universities><Utah><Work><Writing><Risk Assessment><chronic pain><Data Set><Clinical><Phase><Training><Data Bases><data base><Databases><Opiates><Opioid><Funding><Collaborations><Deposition><Deposit><Nature><programs><Protocols documentation><Protocol><System><Opiate Addiction><Opiate Dependence><opioid addiction><opioid dependence><opioid dependent><data management><success><Speed><Reporting><response><repository><depository><Meta-Analysis><Clinical Trials Data Monitoring Committees><Data Monitoring Committees><Data and Safety Monitoring Boards><Safety Monitoring Boards><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><risk-reducing><Risk Reduction><Institution><Dose><U-Series Cooperative Agreements><Cooperative Agreements><Data><Randomized><randomisation><randomization><randomly assigned><Collection><Translational Research><Translational Science><translation research><translational investigation><Monitor><Preparation><preparations><Principal Investigator><Common Data Element><Process><Development><developmental><prevention effectiveness trial><effectiveness research><Clinical Trials Network><designing><design><Outcome><innovate><innovative><innovation><addictive disorder><addiction><data sharing><Regimen><IRB><IRBs><Institutional Review Boards><recruit><Infrastructure><Acute pain management><data sharing ecosystem><data ecosystem><comparative effectiveness trial><HEAL Initiative><Helping End Addiction Long-term><Helping End Addiction Longterm><Helping to End Addiction Longterm><Helping to End Addiction Long-term><National Center for Advancing Translational Sciences><NCATS>\", \"pref_terms\": \"Acute pain management;Award;Clinical;Clinical Trials;Clinical Trials Data Monitoring Committees;Clinical Trials Network;Collaborations;Collection;Common Data Element;Data;Data Analyses;Data Collection;Data Set;Databases;Deposition;Development;Dose;Funding;Future;Helping to End Addiction Long-term;Infrastructure;Institution;Institutional Review Boards;Meta-Analysis;Monitor;National Center for Advancing Translational Sciences;Nature;Opiate Addiction;Opioid;Outcome;Pain management;Phase;Preparation;Principal Investigator;Process;Protocols documentation;Public Health;Publications;Quality Control;Randomized;Regimen;Reporting;Research;Research Personnel;Resources;Risk Assessment;Risk Reduction;Safety;Sickle Cell Anemia;Speed;System;Testing;Training;Translational Research;U-Series Cooperative Agreements;United States National Institutes of Health;Universities;Utah;Work;Writing;addiction;chronic pain;comparative effectiveness trial;data ecosystem;data management;data sharing;design;effectiveness research;innovation;prevention effectiveness trial;programs;recruit;repository;response;success\", \"abstract_text\": \"Project Summary\\\\n The NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scienti\\\\ufb01c solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. Five ERN trials have been implemented with data coordination support from the\\\\nUniversity of Utah Trial Innovation Center. This proposal is written in response to RFA-TR-22-012 to provide\\\\ncontinued support for these \\\\ufb01ve trials, as well as two additional trials that may be funded in response to RFA-AT-22-\\\\n005 (\\\\u201cHEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness\\\\nResearch Network Cooperative Agreement\\\\u201d). The University of Utah is responding to be the Data Coordination\\\\nResource Center (DCRC).\\\\n We will continue to work collaboratively with each ERN study team and the other HEAL ERN Resource\\\\nCenters to 1) develop, implementand monitor the ERN trials; 2) help respond to issues/protocol changes that\\\\nemerge during trial implementation and initiate timely necessary changes to assure trial success; 3) provide\\\\ncollection and analysis of data; and 4) assist with timely publication of study results.\\\\n Our application has three Speci\\\\ufb01c Aims: 1. Work with ERN investigators and other HEAL ERN Resource\\\\nCenters to provide collaborative clinical trial expertise and assistance in study and protocol design, single IRB,\\\\nstudy implementation and management, accrual of subjects, interim study reporting, \\\\ufb01nal study analyses, and\\\\nassistance with timely publication and dissemination of study results. 2. Provide comprehensive data manage-\\\\nment for current and new ERN trials, including database and data collection systems, data management plans,\\\\ndata risk assessment and quality control, implementation of randomization, assistance with Data Safety Monitor-\\\\ning Board (DSMB) reports, and training for using the data collection systems. 3. Facilitate sharing of data from\\\\nHEAL/ERN trials by incorporating HEAL Common Data Elements(CDEs) into protocols, continuing to support\\\\nNIH program staff in development of HEAL CDEs, continued participation in the HEAL Collective Board, and\\\\npreparation of \\\\ufb01nal data sets suitable for deposit in NIH-designated repositories for incorporation into the HEAL\\\\nData Ecosystem.\\\\n Our collaboration with ERN investigators and integration with the other Resource Centers will maximize the\\\\nlikelihood of successful and timely completion of the HEAL ERN clinical trials, leading to translation of research\\\\n\\\\ufb01ndings to the effective management of acute and chronic pain, while minimizing addictive opioid dosing regi-\\\\nmens.\", \"project_title\": \"HEAL ERN: Data Coordinating Resource Center\", \"phr_text\": \"Project Narrative\\\\n The NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scienti\\\\ufb01c solutions to the\\\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\\\nreducing risk of addiction. The University of Utah will provide data coordination support for these trials, leading to\\\\nmore effective management of acute and chronic pain while reducing the risk of opioid addiction.\", \"spending_categories_desc\": \"Brain Disorders; Chronic Pain; Clinical Research; Clinical Trials and Supportive Activities; Comparative Effectiveness Research; Neurosciences; Opioids; Pain Research; Patient Safety; Prevention\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-01T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 2026691, \"indirect_cost_amt\": 1094413, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10709596\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 32}, page_content='{\"appl_id\": 10697386, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R03EB033576-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R03\", \"award_amount\": 81119, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R03\", \"ic_code\": \"EB\", \"serial_num\": \"033576\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 11817462, \"first_name\": \"Venkata\", \"middle_name\": \"K\", \"last_name\": \"Yellepeddi\", \"is_contact_pi\": true, \"full_name\": \"Venkata K Yellepeddi\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"YELLEPEDDI, VENKATA K\", \"agency_ic_admin\": {\"code\": \"EB\", \"abbreviation\": \"NIBIB\", \"name\": \"National Institute of Biomedical Imaging and Bioengineering\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"EB\", \"name\": \"National Institute of Biomedical Imaging and Bioengineering\", \"abbreviation\": \"NIBIB\", \"total_cost\": 81119, \"direct_cost_ic\": 53193, \"indirect_cost_ic\": 27926}], \"project_start_date\": \"2022-09-06T12:09:00Z\", \"project_end_date\": \"2024-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-200\", \"full_study_section\": {\"srg_code\": \"NANO\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Nanotechnology Study Section[NANO]\"}, \"award_notice_date\": \"2023-06-23T12:06:00Z\", \"core_project_num\": \"R03EB033576\", \"terms\": \"<Animals><Canis familiaris><Canine Species><Dogs><Dogs Mammals><canine><domestic dog><Drug Modelings><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Goals><Recording of previous events><History><histories><Human><Modern Man><Literature><Mathematics><Math><Mus><Mice><Mice Mammals><Murine><Organism><living system><Phagocytes><Phagocytic Cell><amebocyte><Drug Kinetics><Pharmacokinetics><Clinical Pharmacology><Physiology><Publishing><Oryctolagus cuniculus><Domestic Rabbit><Rabbits><Rabbits Mammals><Rattus><Common Rat Strains><Rat><Rats Mammals><Research><Rodent><Rodentia><Rodents Mammals><Silicon Dioxide><Cristobalite><Sand><Silica><Tridymite><Translating><Utah><Porosity><Drug Delivery><Drug Delivery Systems><macromolecule><Organ><Site><Surface><Clinical><Physiologic><Physiological><Medical><uptake><R-Series Research Projects><R01 Mechanism><R01 Program><Research Grants><Research Projects><Research Project Grants><Therapeutic><Shapes><tool><Knowledge><Complex><Techniques><System><biomaterial compatibility><biocompatibility><experience><lymphatic circulation><lymphatic transport><Performance><Animal Model><Animal Models and Related Studies><model of animal><Toxic effect><Toxicities><Laboratory Study><Modeling><Property><Address><Dose><Data><Mononuclear><Pre-Clinical Model><Preclinical Models><in vivo><Clinical Data><Rodent Model><Principal Investigator><Characteristics><Development><developmental><pre-clinical><preclinical><pharmacokinetic model><computer based prediction><prediction model><predictive modeling><nanovessel><nanocarrier><nano particle><nano-sized particle><nanosized particle><nanoparticle><Biodistribution><innovate><innovative><innovation><clinically translatable><clinical translation><first in man><first-in-human><nanoparticle drug><Infrastructure><PBPK><physiologically based pharmacokinetics><Mathematical Models and Simulations><Mathematical Model Simulation><delivery vehicle><delivery vector>\", \"pref_terms\": \"Address;Animal Model;Animals;Biodistribution;Canis familiaris;Characteristics;Clinical;Clinical Data;Clinical Pharmacology;Complex;Data;Development;Dose;Drug Delivery Systems;Drug Kinetics;Drug Modelings;Goals;Human;Infrastructure;Knowledge;Laboratory Study;Literature;Mathematical Model Simulation;Mathematics;Medical;Modeling;Mononuclear;Mus;Organ;Organism;Oryctolagus cuniculus;Performance;Phagocytes;Pharmaceutical Preparations;Physiological;Physiology;Porosity;Pre-Clinical Model;Principal Investigator;Property;Publishing;Rattus;Recording of previous events;Research;Research Project Grants;Rodent;Rodent Model;Shapes;Silicon Dioxide;Site;Surface;System;Techniques;Therapeutic;Toxic effect;Translating;Utah;biomaterial compatibility;clinical translation;delivery vehicle;experience;first-in-human;in vivo;innovation;lymphatic circulation;macromolecule;nanocarrier;nanoparticle;nanoparticle drug;pharmacokinetic model;physiologically based pharmacokinetics;pre-clinical;predictive modeling;tool;uptake\", \"abstract_text\": \"PROJECT SUMMARY\\\\nSilica nanoparticles are multifunctional and biocompatible inorganic nanocarriers with enormous potential for\\\\ndrug delivery. Their unique structural composition and porosity facilitates the loading of large therapeutic\\\\npayloads for site-specific drug delivery. Since past two decades our team characterized silica nanoparticles\\\\nand obtained data on cellular uptake, pharmacokinetics, and toxicity in rodents. However, very little is known\\\\nabout pharmacokinetics and biodistribution of silica nanoparticles in humans. A better understanding of the\\\\npharmacokinetics of silica nanoparticles in humans is essential for their clinical translation. Physiologically\\\\nbased pharmacokinetic (PBPK) modeling is well established strategy to translate mechanistic knowledge from\\\\nanimals to humans. We propose to develop PBPK models of silica nanoparticles in mice and rats and\\\\nextrapolate them to humans to establish a relationship between organ accumulation, and human dose. PBPK\\\\nmodels integrate compound specific data with physiology of the organism to predict the pharmacokinetics of\\\\ndrugs. PBPK models are mechanistic and can account for complex in vivo transport mechanisms of\\\\nnanoparticles such as opsonization, mononuclear phagocyte system uptake, lymphatic transport, and cellular\\\\ninternalization. Once the predictive performance of nanoparticle PBPK models in preclinical models is verified,\\\\nthe mechanisms governing nanoparticle PK can be easily extrapolated to humans by replacing relevant\\\\nphysiological information. The final human nanoparticle PBPK model extrapolated from animals can be used\\\\nfor first-in-human predictions. There are no PBPK models available for silica nanoparticles that can incorporate\\\\nall relevant properties required for extrapolation to humans. Our long-term goal is to successfully translate\\\\nsilica nanoparticles to human clinical use as drug delivery vehicles. The objective of this proposal is to translate\\\\nthe mechanisms of nanoparticle distribution from rodents to humans. The Specific Aims of the proposal are: 1)\\\\nDevelop and validate PBPK models for various silica nanoparticles in mice and rats, 2) Extrapolate the rodent\\\\nPBPK model of silica nanoparticles to humans and verify the predictions using clinical data. The proposed\\\\nresearch addresses a significant unmet need for evaluating the relationship between dose and organ\\\\naccumulation of silica nanoparticles in humans. Our research project is innovative because we use\\\\nmathematical modeling and simulation techniques that use data obtained from our laboratory studies and\\\\npublished literature. The data obtained from this research project will be used for submitting an R01 application\\\\nto develop and validate PBPK models for silica nanoparticles with drugs and macromolecules. The PBPK\\\\nmodels for the R01 proposal will include larger animal species such as dogs and rabbits.\", \"project_title\": \"Physiologically Based Pharmacokinetic Modeling of Silica Nanoparticles\", \"phr_text\": \"PROJECT NARRATIVE\\\\nSilica nanoparticles showed potential as drug delivery systems in preclinical animal models. Despite extensive\\\\nresearch efforts they are not approved for human clinical use as drug delivery systems. This proposal will\\\\ndevelop a mathematical tool to understand the pharmacokinetics of silica nanoparticles, to allow clinical\\\\ntranslation of silica nanoparticles.\", \"spending_categories_desc\": \"Bioengineering; Nanotechnology\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-07-01T12:07:00Z\", \"budget_end\": \"2024-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 53193, \"indirect_cost_amt\": 27926, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10697386\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 33}, page_content='{\"appl_id\": 10508729, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1R03EB033576-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R03\", \"award_amount\": 81119, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R03\", \"ic_code\": \"EB\", \"serial_num\": \"033576\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 11817462, \"first_name\": \"Venkata\", \"middle_name\": \"K\", \"last_name\": \"Yellepeddi\", \"is_contact_pi\": true, \"full_name\": \"Venkata K Yellepeddi\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"YELLEPEDDI, VENKATA K\", \"agency_ic_admin\": {\"code\": \"EB\", \"abbreviation\": \"NIBIB\", \"name\": \"National Institute of Biomedical Imaging and Bioengineering\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"EB\", \"name\": \"National Institute of Biomedical Imaging and Bioengineering\", \"abbreviation\": \"NIBIB\", \"total_cost\": 81119, \"direct_cost_ic\": 53193, \"indirect_cost_ic\": 27926}], \"project_start_date\": \"2022-09-06T12:09:00Z\", \"project_end_date\": \"2024-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-200\", \"full_study_section\": {\"srg_code\": \"NANO\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Nanotechnology Study Section[NANO]\"}, \"award_notice_date\": \"2022-09-05T12:09:00Z\", \"core_project_num\": \"R03EB033576\", \"terms\": \"<Animals><Canis familiaris><Canine Species><Dogs><Dogs Mammals><canine><domestic dog><Drug Modelings><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Goals><Recording of previous events><History><Human><Modern Man><Literature><Mathematics><Math><Mus><Mice><Mice Mammals><Murine><living system><Organism><Phagocytic Cell><amebocyte><Phagocytes><Pharmacokinetics><Drug Kinetics><Clinical Pharmacology><Physiology><Publishing><Domestic Rabbit><Rabbits><Rabbits Mammals><Oryctolagus cuniculus><Common Rat Strains><Rat><Rats Mammals><Rattus><Research><Rodentia><Rodents Mammals><Rodent><Cristobalite><Sand><Silica><Tridymite><Silicon Dioxide><Translating><Utah><Porosity><Drug Delivery Systems><Drug Delivery><macromolecule><Organ><Site><Surface><Clinical><Physiological><Physiologic><Medical><uptake><R-Series Research Projects><R01 Mechanism><R01 Program><Research Grants><Research Projects><Research Project Grants><Therapeutic><Shapes><tool><Knowledge><Complex><Techniques><System><biocompatibility><biomaterial compatibility><experience><lymphatic transport><lymphatic circulation><Performance><Animal Models and Related Studies><model of animal><model organism><Animal Model><Toxicities><Toxic effect><Laboratory Study><Modeling><Property><Address><Dose><Data><Mononuclear><Preclinical Models><Pre-Clinical Model><in vivo><Clinical Data><Rodent Model><Principal Investigator><Characteristics><Development><developmental><pre-clinical><preclinical><pharmacokinetic model><predictive modeling><computer based prediction><prediction model><nanocarrier><nano carrier><nanoparticle><nano particle><nano-sized particle><nanosized particle><Biodistribution><innovation><innovate><innovative><clinical translation><first-in-human><first in man><nanoparticle drug><nano particle drug><Infrastructure><physiologically based pharmacokinetics><PBPK><Mathematical Model Simulation><Mathematical Models and Simulations><delivery vehicle><delivery vector>\", \"pref_terms\": \"Address;Animal Model;Animals;Biodistribution;Canis familiaris;Characteristics;Clinical;Clinical Data;Clinical Pharmacology;Complex;Data;Development;Dose;Drug Delivery Systems;Drug Kinetics;Drug Modelings;Goals;Human;Infrastructure;Knowledge;Laboratory Study;Literature;Mathematical Model Simulation;Mathematics;Medical;Modeling;Mononuclear;Mus;Organ;Organism;Oryctolagus cuniculus;Performance;Phagocytes;Pharmaceutical Preparations;Physiological;Physiology;Porosity;Pre-Clinical Model;Principal Investigator;Property;Publishing;Rattus;Recording of previous events;Research;Research Project Grants;Rodent;Rodent Model;Shapes;Silicon Dioxide;Site;Surface;System;Techniques;Therapeutic;Toxic effect;Translating;Utah;biomaterial compatibility;clinical translation;delivery vehicle;experience;first-in-human;in vivo;innovation;lymphatic circulation;macromolecule;nanocarrier;nanoparticle;nanoparticle drug;pharmacokinetic model;physiologically based pharmacokinetics;pre-clinical;predictive modeling;tool;uptake\", \"abstract_text\": \"PROJECT SUMMARY\\\\nSilica nanoparticles are multifunctional and biocompatible inorganic nanocarriers with enormous potential for\\\\ndrug delivery. Their unique structural composition and porosity facilitates the loading of large therapeutic\\\\npayloads for site-specific drug delivery. Since past two decades our team characterized silica nanoparticles\\\\nand obtained data on cellular uptake, pharmacokinetics, and toxicity in rodents. However, very little is known\\\\nabout pharmacokinetics and biodistribution of silica nanoparticles in humans. A better understanding of the\\\\npharmacokinetics of silica nanoparticles in humans is essential for their clinical translation. Physiologically\\\\nbased pharmacokinetic (PBPK) modeling is well established strategy to translate mechanistic knowledge from\\\\nanimals to humans. We propose to develop PBPK models of silica nanoparticles in mice and rats and\\\\nextrapolate them to humans to establish a relationship between organ accumulation, and human dose. PBPK\\\\nmodels integrate compound specific data with physiology of the organism to predict the pharmacokinetics of\\\\ndrugs. PBPK models are mechanistic and can account for complex in vivo transport mechanisms of\\\\nnanoparticles such as opsonization, mononuclear phagocyte system uptake, lymphatic transport, and cellular\\\\ninternalization. Once the predictive performance of nanoparticle PBPK models in preclinical models is verified,\\\\nthe mechanisms governing nanoparticle PK can be easily extrapolated to humans by replacing relevant\\\\nphysiological information. The final human nanoparticle PBPK model extrapolated from animals can be used\\\\nfor first-in-human predictions. There are no PBPK models available for silica nanoparticles that can incorporate\\\\nall relevant properties required for extrapolation to humans. Our long-term goal is to successfully translate\\\\nsilica nanoparticles to human clinical use as drug delivery vehicles. The objective of this proposal is to translate\\\\nthe mechanisms of nanoparticle distribution from rodents to humans. The Specific Aims of the proposal are: 1)\\\\nDevelop and validate PBPK models for various silica nanoparticles in mice and rats, 2) Extrapolate the rodent\\\\nPBPK model of silica nanoparticles to humans and verify the predictions using clinical data. The proposed\\\\nresearch addresses a significant unmet need for evaluating the relationship between dose and organ\\\\naccumulation of silica nanoparticles in humans. Our research project is innovative because we use\\\\nmathematical modeling and simulation techniques that use data obtained from our laboratory studies and\\\\npublished literature. The data obtained from this research project will be used for submitting an R01 application\\\\nto develop and validate PBPK models for silica nanoparticles with drugs and macromolecules. The PBPK\\\\nmodels for the R01 proposal will include larger animal species such as dogs and rabbits.\", \"project_title\": \"Physiologically Based Pharmacokinetic Modeling of Silica Nanoparticles\", \"phr_text\": \"PROJECT NARRATIVE\\\\nSilica nanoparticles showed potential as drug delivery systems in preclinical animal models. Despite extensive\\\\nresearch efforts they are not approved for human clinical use as drug delivery systems. This proposal will\\\\ndevelop a mathematical tool to understand the pharmacokinetics of silica nanoparticles, to allow clinical\\\\ntranslation of silica nanoparticles.\", \"spending_categories_desc\": \"Bioengineering; Nanotechnology\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-09-06T12:09:00Z\", \"budget_end\": \"2023-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 53193, \"indirect_cost_amt\": 27926, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10508729\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 34}, page_content='{\"appl_id\": 10464159, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1R21AG074498-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R21\", \"award_amount\": 205806, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R21\", \"ic_code\": \"AG\", \"serial_num\": \"074498\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 7891123, \"first_name\": \"Anthony\", \"middle_name\": \"John\", \"last_name\": \"Donato\", \"is_contact_pi\": true, \"full_name\": \"Anthony John Donato\", \"title\": \"\"}, {\"profile_id\": 10749791, \"first_name\": \"Raphael\", \"middle_name\": \"M.\", \"last_name\": \"Franzini\", \"is_contact_pi\": false, \"full_name\": \"Raphael M. Franzini\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"DONATO, ANTHONY JOHN\", \"agency_ic_admin\": {\"code\": \"AG\", \"abbreviation\": \"NIA\", \"name\": \"National Institute on Aging\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"AG\", \"name\": \"National Institute on Aging\", \"abbreviation\": \"NIA\", \"total_cost\": 205806, \"direct_cost_ic\": 137504, \"indirect_cost_ic\": 68302}], \"project_start_date\": \"2022-09-05T12:09:00Z\", \"project_end_date\": \"2024-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-19-305\", \"full_study_section\": {\"srg_code\": \"CMAD\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cellular Mechanisms in Aging and Development Study Section[CMAD]\"}, \"award_notice_date\": \"2022-09-05T12:09:00Z\", \"core_project_num\": \"R21AG074498\", \"terms\": \"<absorption><Age><ages><Elderly><advanced age><elders><geriatric><late life><later life><older adult><older person><senior citizen><Aging><Animals><Antihypertensive Agents><Anti-Hypertensive Agents><Anti-Hypertensive Drugs><Anti-Hypertensives><Antihypertensive Drugs><Antihypertensives><Hypotensive Agent><Hypotensive Drugs><Biological Assay><Assay><Bioassay><Biologic Assays><Cardiovascular Diseases><cardiovascular disorder><Cell Line><CellLine><Strains Cell Lines><cultured cell line><Cells><Cell Body><Chronic Disease><Chronic Illness><chronic disorder><Computing Methodologies><computational methodology><computational methods><computer based method><computer methods><computing method><Diabetes Mellitus><diabetes><Disease><Disorder><DNA><Deoxyribonucleic Acid><DNA Damage><DNA Injury><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Enzymes><Enzyme Gene><Equilibrium><balance><balance function><Glucose><D-Glucose><Dextrose><Goals><Histidine><In Vitro><Inflammation><Lead><Pb element><heavy metal Pb><heavy metal lead><Libraries><Lipids><Metabolic Diseases><Metabolic Disorder><Thesaurismosis><metabolism disorder><Metabolism><Intermediary Metabolism><Metabolic Processes><Methods><middle age><mid life><mid-life><middle aged><midlife><Morbidity - disease rate><Morbidity><mortality><Mus><Mice><Mice Mammals><Murine><Neuron Degeneration><neural degeneration><neurodegeneration><neurodegenerative><neurological degeneration><neuronal degeneration><Nerve Degeneration><3-Pyridinecarboxamide><Nicotinamide><Nicotinamidum><Nicotinic acid amide><Nicotylamide><Pellagra-Preventing Factor><Vitamin B 3><Vitamin B3><Vitamin PP><Niacinamide><Nicotinamide Mononucleotide><Patients><Pharmacokinetics><Drug Kinetics><Protein Phosphorylation><Phosphorylation><Proteins><Scientific Publication><Publications><Pyrophosphates><Diphosphates><Research><Risk Factors><social role><Role><Stress><Tail><Testing><Tissues><Body Tissues><nicotinamide phosphoribosyltransferase><NMN pyrophosphorylase><Measures><ADP Ribose Transferases><ADP-Ribosyltransferase><ADPRTs><ART Transferases><ARTases><Health Benefit><Custom><base><cofactor><improved><Phase><Physiological><Physiologic><Biochemical><Link><Chemicals><excretion><Excretory function><R-Series Research Projects><R01 Mechanism><R01 Program><Research Grants><Research Projects><Research Project Grants><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Therapeutic><Reaction><Route><cell type><chemical library><small molecule libraries><Animal Models and Related Studies><model of animal><model organism><Animal Model><Structure><Property><sarcopenic><sarcopenia><drug discovery><Pathogenicity><Silent Mating Type Information Regulator 2-like Proteins><Sir2-like Proteins><Sirtuins><Pharmaceutical Agent><Pharmaceuticals><Pharmacological Substance><Pharmacologic Substance><preventing><prevent><Causality><causation><disease causation><Etiology><Deacetylase><Address><Dose><ATP Hydrolysis><Preclinical Models><Pre-Clinical Model><in vitro Assay><in vivo><Cellular Assay><cell assay><Translational Research><Translational Science><translation research><Process><Development><developmental><Pathway interactions><pathway><pre-clinical><preclinical><preclinical study><pre-clinical study><age related><age dependent><functional decline><decline in function><decline in functional status><functional status decline><burden of illness><burden of disease><disease burden><years of life lost to disability><years of life lost to disease><design><designing><Outcome><aged><Coupling><innovation><innovate><innovative><Resistance><resistant><mitochondrial dysfunction><mouse model><murine model><drug candidate><screening><nutritional supplementation><Pharmacology Study><Pharmacological Study><healthspan><health-span><lead candidate><appropriate dose><optimal drug dosage><optimal drug dose>\", \"pref_terms\": \"ADP Ribose Transferases;ATP Hydrolysis;Address;Age;Aging;Animal Model;Animals;Antihypertensive Agents;Biochemical;Biological Assay;Cardiovascular Diseases;Cell Line;Cells;Cellular Assay;Chemicals;Chronic Disease;Computing Methodologies;Coupling;Custom;DNA;DNA Damage;Deacetylase;Development;Diabetes Mellitus;Diphosphates;Disease;Dose;Drug Kinetics;Elderly;Enzymes;Equilibrium;Etiology;Excretory function;Functional disorder;Glucose;Goals;Health Benefit;Histidine;In Vitro;Inflammation;Lead;Libraries;Link;Lipids;Measures;Metabolic Diseases;Metabolism;Methods;Morbidity - disease rate;Mus;Nerve Degeneration;Niacinamide;Nicotinamide Mononucleotide;Outcome;Pathogenicity;Pathway interactions;Patients;Pharmaceutical Preparations;Pharmacologic Substance;Pharmacology Study;Phase;Phosphorylation;Physiological;Pre-Clinical Model;Process;Property;Proteins;Publications;Reaction;Research;Research Project Grants;Resistance;Risk Factors;Role;Route;Sirtuins;Stress;Structure;Tail;Testing;Therapeutic;Tissues;Translational Research;absorption;age related;aged;appropriate dose;base;burden of illness;cell type;cofactor;design;drug candidate;drug discovery;functional decline;healthspan;improved;in vitro Assay;in vivo;innovation;lead candidate;middle age;mitochondrial dysfunction;mortality;mouse model;nicotinamide phosphoribosyltransferase;nutritional supplementation;pre-clinical;preclinical study;prevent;sarcopenia;screening;small molecule libraries\", \"abstract_text\": \"Abstract\\\\nAdvancing age is a primary risk factor for numerous chronic diseases including cardiovascular and metabolic\\\\ndiseases, as well as sarcopenia. Increasing evidence suggests that the levels of the cofactor NAD+ and the\\\\nactivity of NAD+-dependent proteins such as sirtuins have close links to the process of aging and development\\\\nof chronic diseases. While many studies exploring the health benefit of nutritional supplementation with sirtuin\\\\nactivators and NAD+-precursors have had encouraging preclinical results, there are currently no drug\\\\ncandidates that directly act on NAD+-metabolism. The objective of the proposed research project is to develop\\\\na potent activator of nicotinamide phosphorybosyltransferase (NAMPT), the enzyme that catalyzes the rate\\\\nlimiting step in NAD+ synthesis, and to evaluate its ability to reverse age-related physiological dysfunction in a\\\\npreclinical mouse model. Although previous studies have established that NAMPT activation can have age-\\\\ndelaying and disease-preventing effects, no currently available therapeutics are directed at modulating NAMPT\\\\nactivity per se. The proposed research addresses the key limitation towards accessing such drug candidates,\\\\nwhich is the lack of a potent, selective, and mechanistically validated lead molecules for NAMPT activation with\\\\na favorable absorption, distribution, metabolism and excretion (ADME) profile. To access such a compound, in\\\\nthe R21 phase of this application, we propose to develop and screen a NAMPT-focused DNA-encoded\\\\nchemical library and to use computational drug discovery methods to advance screening hits into potent lead\\\\ncandidate compounds. The efficacy of NAMPT activators will be tested with in vitro assays and in three\\\\ndifferent cell lines. Once candidate compounds are identified, the R33 phase will consist, first of\\\\ncomprehensive pharmacokinetic studies in lead candidate compounds to determine the appropriate dose and\\\\nroute of administration for in vivo studies. The lead compound will then be utilized to assess the impact of\\\\ntreatment on physiological measures of healthspan in middle-aged and old mice. The project, if successful, will\\\\ndeliver preclinical lead compounds for the development of first-in-class therapeutics that directly target the\\\\naging-related pathways of a wide range of chronic diseases. In the long term, such drugs may help decrease\\\\nthe morbidity and mortality of geriatric patients.\", \"project_title\": \"Improving healthspan through discovery of potent NAMPT activators from a DNA-encoded library\", \"phr_text\": \"Narrative\\\\nThe objective of the proposed research project is to develop a potent activator of nicotinamide\\\\nphosphorybosyltransferase (NAMPT), the enzyme that catalyzes the rate limiting step in NAD+ synthesis, and\\\\nto evaluate its ability to prevent and possibly reverse the progression of aging-related chronic diseases in a\\\\npreclinical model. The R21 phase will develop and screen a NAMPT-focused DNA-encoded chemical library and\\\\nuse computational drug discovery methods to advance screening hits into potent lead candidates, as well as\\\\ndetermine the efficacy of identified NAMPT activators in vitro. The R33 phase will utilize pharmacokinetic studies\\\\nto determine dose and route of administration of lead compounds that will be used in studies assessing the\\\\nimpact of treatment on physiological measures of healthspan in middle-aged and old mice.\", \"spending_categories_desc\": \"Aging; Cardiovascular; Neurodegenerative; Prevention\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-09-05T12:09:00Z\", \"budget_end\": \"2023-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 137504, \"indirect_cost_amt\": 68302, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10464159\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 35}, page_content='{\"appl_id\": 10370913, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1K22CA258671-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K22\", \"award_amount\": 198348, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K22\", \"ic_code\": \"CA\", \"serial_num\": \"258671\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 14228461, \"first_name\": \"JONATHAN\", \"middle_name\": \"ERIC\", \"last_name\": \"CONSTANCE\", \"is_contact_pi\": true, \"full_name\": \"JONATHAN ERIC CONSTANCE\", \"title\": \"ASSISTANT PROFESSOR, PEDIATRICS\"}], \"contact_pi_name\": \"CONSTANCE, JONATHAN ERIC\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 198348, \"direct_cost_ic\": 183656, \"indirect_cost_ic\": 14692}], \"project_start_date\": \"2022-08-01T12:08:00Z\", \"project_end_date\": \"2025-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-467\", \"full_study_section\": {\"srg_code\": \"ZCA1\", \"srg_flex\": null, \"sra_designator_code\": \"RTRB\", \"sra_flex_code\": \"R\", \"group_code\": \"O2\", \"name\": \"Special Emphasis Panel[ZCA1 RTRB-R (O2)]\"}, \"award_notice_date\": \"2022-08-01T12:08:00Z\", \"core_project_num\": \"K22CA258671\", \"terms\": \"<Affect><Opioid Analgesics><opiate analgesia><opiate analgesic><opiate pain medication><opiate pain reliever><opioid analgesia><opioid anesthetic><opioid pain medication><opioid pain reliever><opioid painkiller><malignant breast neoplasm><Breast Cancer><malignant breast tumor><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cell Death><necrocytosis><Cell Line><CellLine><Strains Cell Lines><cultured cell line><Cell Separation><Cell Isolation><Cell Segregation><Cell Separation Technology><cell sorting><Cell Survival><Cell Viability><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Cessation of life><Death><Diagnosis><Disease><Disorder><Drug resistance><drug resistant><resistance to Drug><resistant to Drug><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Fentanyl><Actiq><Duragesic><Fentanest><Fentyl><Phentanyl><Flow Cytometry><Flow Cytofluorometries><Flow Cytofluorometry><Flow Microfluorimetry><Flow Microfluorometry><flow cytophotometry><Genes><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><glioblastoma multiforme><spongioblastoma multiforme><Goals><In Vitro><leukemia><Acute Lymphocytic Leukemia><Acute Lymphoblastic Leukemia><Acute Lymphoid Leukemia><Precursor Cell Lymphoblastic Leukemia><Precursor Lymphoblastic Leukemia><acute lymphatic leukemia><acute lymphogenous leukemia><acute lymphomatic leukemia><Mixed B- and T-Cell Leukemia><Acute B- and T-Cell Leukemia><B- and T-Cell Acute Lymphoblastic Leukemia><B- and T-Cell Acute Lymphocytic Leukemia><Mixed-Cell Acute Lymphocytic Leukemia><Mixed-Cell Leukemia><Literature><malignant stomach neoplasm><Gastric Body Cancer><Gastric Cancer><Gastric Cardia Cancer><Gastric Fundus Cancer><Gastric Pylorus Cancer><Malignant Gastric Neoplasm><Malignant Gastric Tumor><Stomach Cancer><gastric malignancy><malignant stomach tumor><stomach fundus cancer><stomach pylorus cancer><Study models><Morphine><Infumorph><Kadian><MS Contin><MSir><Morphia><Oramorph><Oramorph SR><Roxanol><Statex SR><NIH><National Institutes of Health><United States National Institutes of Health><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Secondary Neoplasm><Secondary Tumor><cancer metastasis><tumor cell metastasis><Neoplasm Metastasis><Dihydrohydroxycodeinone><Oxycodeinon><Oxycodone SR><Oxycontin><Roxicodone><Oxycodone><Patients><Pharmacokinetics><Drug Kinetics><Pharmacology><Ph 1 Chromosome><Ph1 Chromosome><Philadelphia Chromosome><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma><Public Health><Relapse><Research Proposals><Risk><social role><Role><Signal Pathway><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Signal Transduction><Testing><mu opioid receptors><\\\\u03bc opioid receptors><\\\\u03bc-OR><\\\\u03bcOR><Immunophenotyping><Immunologic Subtyping><immunophenotype><Mediating><Treatment Failure><therapy failure><base><Clinical><Physiological><Physiologic><Medical><Link><Ensure><peripheral blood><insight><Malignant Tumor of the Lung><Pulmonary Cancer><Pulmonary malignant Neoplasm><lung cancer><Malignant neoplasm of lung><Opiates><Opioid><Relapsed Disease><Recurrent disease><Metabolic><Malignant Cell><cancer cell><Supportive Therapy><Supportive care><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Absence of pain sensation><Malignant Tumor of the Prostate><Malignant prostatic tumor><Prostate CA><Prostate Cancer><Prostatic Cancer><Malignant neoplasm of prostate><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Malignant Hematopoietic Neoplasm><blood cancer><Hematopoietic Neoplasms><Chemotherapy Protocol><Chemotherapy Regimen><Combination Chemotherapy Regimen><Quimioterapia><cancer chemotherapy><Chemotherapy-Oncologic Procedure><Dimensions><Frequencies><cell type><Esophageal Cancer><Esophagus Cancer><Malignant Esophageal Neoplasm><Malignant Esophageal Tumor><Malignant Tumor of the Esophagus><oesophageal cancer><Malignant neoplasm of esophagus><early experience><experience><genotoxicity><tumor growth><cell killing><Animal Models and Related Studies><model of animal><model organism><Animal Model><Drug Interactions><Sampling><response><High Throughput Assay><high throughput screening><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer-directed therapy><cancer diagnosis><Neuraxis><CNS Nervous System><Central Nervous System><Molecular Interaction><Binding><PTK Inhibitors><Protein Tyrosine Kinase Inhibitors><TK Inhibitors><Tyrosine Kinase Inhibitor><Age-Years><cytotoxic><Data><Molecular Target><Apoptotic><Collection><Enrollment><enroll><K-562><K562><K562 blasts><Leukemic Cell><Newly Diagnosed><Molecular><Knock-out><Knockout><Image><imaging><Pathway interactions><pathway><Outcome><Population><cancer type><prospective><Resistance><resistant><clinically relevant><clinical relevance><chemotherapy><standard of care><biobank><biorepository><prescription opioid><licit opioid><opiate medication><opioid medication><prescribed opiate><prescribed opioid><prescription opiate><Clustered Regularly Interspaced Short Palindromic Repeats><CRISPR><CRISPR/Cas system><precision medicine><precision-based medicine><personalized medicine><personalization of treatment><personalized therapy><personalized treatment><leukemia treatment><genetic approach><genetic strategy><opioid use><opiate consumption><opiate drug use><opiate intake><opiate use><opioid consumption><opioid drug use><opioid intake><interpatient variability><inter-patient variability><opioid exposure><opiate exposed><opiate exposure><opioid exposed><chronic myeloid leukemia cell><chronic myelogenous leukemia cell><treatment risk><Chemoresistance><chemoresistant><chemotherapy resistance><chemotherapy resistant>\", \"pref_terms\": \"Absence of pain sensation;Acute Lymphocytic Leukemia;Affect;Age-Years;Animal Model;Apoptotic;Binding;Cell Death;Cell Line;Cell Separation;Cell Survival;Cessation of life;Chemoresistance;Chemotherapy-Oncologic Procedure;Child;Clinical;Clustered Regularly Interspaced Short Palindromic Repeats;Collection;Data;Diagnosis;Dimensions;Disease;Drug Interactions;Drug Kinetics;Drug resistance;Enrollment;Ensure;Fentanyl;Flow Cytometry;Frequencies;Genes;Glioblastoma;Goals;Hematopoietic Neoplasms;Image;Immunophenotyping;In Vitro;K-562;Knock-out;Leukemic Cell;Link;Literature;Malignant Neoplasms;Malignant neoplasm of esophagus;Malignant neoplasm of lung;Malignant neoplasm of prostate;Mediating;Medical;Metabolic;Mixed B- and T-Cell Leukemia;Molecular;Molecular Target;Morphine;Neoplasm Metastasis;Neuraxis;Newly Diagnosed;Opioid;Opioid Analgesics;Outcome;Oxycodone;Pathway interactions;Patients;Pharmaceutical Preparations;Pharmacology;Philadelphia Chromosome;Physiological;Plasma;Population;Public Health;Recurrent disease;Relapse;Research Proposals;Resistance;Risk;Role;Sampling;Signal Pathway;Signal Transduction;Study models;Supportive care;Testing;Treatment Failure;Tyrosine Kinase Inhibitor;United States National Institutes of Health;base;biobank;cancer cell;cancer diagnosis;cancer therapy;cancer type;cell killing;cell type;chemotherapy;chronic myeloid leukemia cell;clinically relevant;cytotoxic;early experience;experience;genetic approach;genotoxicity;high throughput screening;insight;interpatient variability;leukemia;leukemia treatment;malignant breast neoplasm;malignant stomach neoplasm;mu opioid receptors;opioid exposure;opioid use;peripheral blood;personalized medicine;precision medicine;prescription opioid;prospective;response;standard of care;treatment risk;tumor growth\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nRoutinely prescribed analgesic opioids are potent activators of the mu-opioid receptor (\\\\u00b5OR; OPRM1 gene),\\\\nexpressed in many cancer types, and can impact cancer cell survival and the efficacy of lifesaving\\\\nchemotherapy. For patients with cancer, opioid use often coincides with chemotherapy, making opioid-\\\\nchemotherapy interactions inevitable. For some cancers, including lung, prostate, gastric, breast, and\\\\nesophageal cancers, opioid use and increased \\\\u00b5OR expression are linked to increased tumor growth,\\\\nmetastases, and shorter patient survival. In contrast, in vitro and animal model studies for glioblastoma, certain\\\\nbreast cancers, and T- and B-cell acute leukemias, opioids stimulate cancer cell death and, in some cases,\\\\nenhance cytotoxic chemotherapeutic response. The seemingly paradoxical effects likely have a concentration-\\\\ndependent dimension as physiologic opioid exposures have tended to induce pro-proliferative effects while\\\\nsupraphysiologic opioid exposures are typically associated with cancer cell death. While \\\\u00b5OR activation can\\\\nenhance the killing effect of genotoxic chemotherapy in acute lymphoblastic leukemia, our preliminary data\\\\ndemonstrate opioids antagonize the apoptotic response of Philadelphia chromosome-positive (Ph+) chronic\\\\nmyeloid leukemia cells (K562) to molecularly-targeted tyrosine kinase inhibitor (TKI) chemotherapy. As\\\\nleukemias are treated with both genotoxic and molecularly targeted chemotherapy assessing the potential for\\\\nclinically used opioids to antagonize or synergize in leukemic cell killing is an urgent medical need. We\\\\npropose to test the central hypothesis, that chemotherapeutic response will change in the presence of\\\\nclinically relevant concentrations of opioids, in three Aims. Specific Aim 1: Quantify standard-of-care\\\\nopioid exposures and determinants of exposure in patients with leukemia. Hypothesis 1: Interpatient variability\\\\nin opioid exposure will exceed 50% due to inherent metabolic differences, disease status, and treatment-\\\\nrelated pharmacokinetic alterations. Specific Aim 2: In leukemic cell lines, changes in response to\\\\nchemotherapy based on leukemic subtype and \\\\u00b5OR function will be determined. Hypothesis 2: Clinically-\\\\nexperienced concentrations of opioids will change chemotherapeutic response in different leukemic subtypes\\\\ncorresponding with \\\\u00b5OR function by >25%. Specific Aim 3: In patients with leukemia, the frequency of opioid-\\\\nchemotherapy DDIs based on clinical and molecular factors will be determined. Hypothesis 3: Clinical and\\\\nmolecular features associated with opioid-chemotherapy DDI conferring chemotherapy resistance are present\\\\nin >20% of patients prescribed opioids. Understanding the impact of \\\\u00b5OR activity on chemotherapeutic\\\\nresponse across similar but biologically distinct leukemia cell types will provide new insights into mechanisms\\\\nunderlying drug resistance, relapse, or non-response and drive precision medicine in opioid prescribing. This\\\\nproposal will provide key preliminary data to support an NIH R01 aimed at predicting altered chemotherapeutic\\\\nresponse due to supportive care medication exposure among patients undergoing treatment for leukemia.\", \"project_title\": \"Opioid-induced changes to chemotherapeutic activity in blood cancer\", \"phr_text\": \"PROJECT NARRATIVE\\\\nIt is desirable to avoid detrimental drug interactions to ensure each patient achieves the best possible\\\\nresponse to their chemotherapy. The goal of this research proposal is to determine the impact of opioid-\\\\nchemotherapy interactions on chemotherapeutic efficacy in blood cancer.\", \"spending_categories_desc\": \"Cancer; Clinical Research; Hematology; Opioids; Orphan Drug; Patient Safety; Pediatric; Precision Medicine; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-08-01T12:08:00Z\", \"budget_end\": \"2023-07-31T12:07:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 183656, \"indirect_cost_amt\": 14692, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10370913\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 36}, page_content='{\"appl_id\": 10895587, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5K22CA258671-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"K22\", \"award_amount\": 201134, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"K22\", \"ic_code\": \"CA\", \"serial_num\": \"258671\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 14228461, \"first_name\": \"JONATHAN\", \"middle_name\": \"ERIC\", \"last_name\": \"CONSTANCE\", \"is_contact_pi\": true, \"full_name\": \"JONATHAN ERIC CONSTANCE\", \"title\": \"ASSISTANT PROFESSOR, PEDIATRICS\"}], \"contact_pi_name\": \"CONSTANCE, JONATHAN ERIC\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 201134, \"direct_cost_ic\": 186235, \"indirect_cost_ic\": 14899}], \"project_start_date\": \"2022-08-01T12:08:00Z\", \"project_end_date\": \"2025-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-467\", \"full_study_section\": {\"srg_code\": \"ZCA1\", \"srg_flex\": null, \"sra_designator_code\": \"RTRB\", \"sra_flex_code\": \"R\", \"group_code\": \"O2\", \"name\": \"ZCA1-RTRB-R(O2)\"}, \"award_notice_date\": \"2024-07-08T12:07:00Z\", \"core_project_num\": \"K22CA258671\", \"terms\": \"<0-11 years old><Absence of pain sensation><Absence of sensibility to pain><Actiq><Acute Lymphoblastic Leukemia><Acute Lymphocytic Leukemia><Acute Lymphoid Leukemia><Affect><Age Years><Animal Model><Animal Models and Related Studies><Apoptotic><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Blood Plasma><Breast Cancer><CNS Nervous System><CRISPR><CRISPR/Cas system><Cancer Treatment><Cancers><Cell Communication and Signaling><Cell Death><Cell Isolation><Cell Line><Cell Segregation><Cell Separation><Cell Separation Technology><Cell Signaling><Cell Survival><Cell Viability><CellLine><Central Nervous System><Cessation of life><Chemoresistance><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Child><Child Youth><Children (0-21)><Chronic Myeloid Leukemia t(9;22) (q34;q11), BCR/ABL Positive><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Collection><Combination Chemotherapy Regimen><Data><Death><Diagnosis><Dihydrohydroxycodeinone><Dimensions><Disease><Disorder><Drug Interactions><Drug Kinetics><Drug resistance><Drugs><Duragesic><Enrollment><Ensure><Esophageal Cancer><Esophagus Cancer><Feels no pain><Fentanest><Fentanyl><Fentyl><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Frequencies><Gastric Body Cancer><Gastric Cancer><Gastric Cardia Cancer><Gastric Fundus Cancer><Gastric Pylorus Cancer><Genes><Glioblastoma><Goals><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><High Throughput Assay><Image><Immunologic Subtyping><Immunophenotyping><In Vitro><Infumorph><Intracellular Communication and Signaling><K-562><K562><K562 blasts><Kadian><Knock-out><Knockout><Leukemic Cell><Life><Link><Literature><MS Contin><MSir><Malignant Breast Neoplasm><Malignant Cell><Malignant Esophageal Neoplasm><Malignant Esophageal Tumor><Malignant Gastric Neoplasm><Malignant Gastric Tumor><Malignant Hematopoietic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Esophagus><Malignant Tumor of the Lung><Malignant Tumor of the Prostate><Malignant neoplasm of esophagus><Malignant neoplasm of lung><Malignant neoplasm of prostate><Malignant prostatic tumor><Mediating><Medical><Medication><Metabolic><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Molecular><Molecular Interaction><Molecular Target><Morphia><Morphine><NIH><National Institutes of Health><Neoplasm Metastasis><Neuraxis><Newly Diagnosed><No sensitivity to pain><Opiates><Opioid><Opioid Analgesics><Oramorph><Oramorph SR><Outcome><Oxycodeinon><Oxycodone><Oxycodone SR><Oxycontin><PTK Inhibitors><Pathway interactions><Patients><Ph\\' Chromosome Positive Chronic Myelocytic Leukemia><Ph\\' Chromosome Positive Chronic Myelogenous Leukemia><Ph\\' Chromosome Positive Chronic Myeloid Leukemia><Ph\\' Positive Chronic Granulocytic Leukemia><Ph1 Chromosome Positive Chronic Myelocytic Leukemia><Ph1 Chromosome Positive Chronic Myelogenous Leukemia><Ph1 Chromosome Positive Chronic Myeloid Leukemia><Ph1 Positive Chronic Granulocytic Leukemia><Pharmaceutical Preparations><Pharmacokinetics><Phentanyl><Philadelphia Chromosome Positive CML><Philadelphia Chromosome Positive Chronic Granulocytic Leukemia><Philadelphia Chromosome Positive Chronic Myelocytic Leukemia><Philadelphia Chromosome Positive Chronic Myelogenous Leukemia><Philadelphia Chromosome Positive Chronic Myeloid Leukemia><Physiologic><Physiological><Plasma><Plasma Serum><Population><Precursor Cell Lymphoblastic Leukemia><Precursor Lymphoblastic Leukemia><Proliferating><Prostate CA><Prostate Cancer><Prostate malignancy><Prostatic Cancer><Protein Tyrosine Kinase Inhibitors><Public Health><Pulmonary Cancer><Pulmonary malignant Neoplasm><Quimioterapia><Recurrent disease><Relapse><Relapsed Disease><Research Proposals><Resistance><Reticuloendothelial System, Serum, Plasma><Risk><Role><Roxanol><Roxicodone><Sampling><Secondary Neoplasm><Secondary Tumor><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Statex SR><Stomach Cancer><Strains Cell Lines><Study models><Supportive Therapy><Supportive care><T-Cells><T-Lymphocyte><TK Inhibitors><Testing><Therapeutic><Therapeutic Effect><Treatment Efficacy><Treatment Failure><Tyrosine Kinase Inhibitor><United States National Institutes of Health><acute leukemia cell><acute lymphatic leukemia><acute lymphogenous leukemia><acute lymphomatic leukemia><analgesia><anti-cancer therapy><biobank><biological signal transduction><biorepository><blood cancer><cancer cell><cancer chemotherapy><cancer diagnosis><cancer metastasis><cancer of blood><cancer of the blood><cancer therapy><cancer type><cancer-directed therapy><cell killing><cell sorting><cell type><chemoresistant><chemotherapy><chemotherapy resistance><chemotherapy resistant><chronic myelogenous leukemia cell><chronic myeloid leukemia cell><clinical relevance><clinically relevant><cultured cell line><cytotoxic><drug resistant><drug/agent><early experience><enroll><experience><flow cytophotometry><gastric malignancy><genetic approach><genetic strategy><genotoxicity><glioblastoma multiforme><high throughput screening><imaging><immunophenotype><insight><inter-patient variability><interpatient variability><intervention efficacy><kids><leukemia><leukemia treatment><leukemic therapy><licit opioid><lung cancer><malignancy><malignant breast tumor><malignant stomach neoplasm><malignant stomach tumor><model of animal><mu opioid receptors><necrocytosis><neoplasm/cancer><oesophageal cancer><opiate analgesia><opiate analgesic><opiate consumption><opiate drug use><opiate exposure><opiate intake><opiate medication><opiate pain medication><opiate pain reliever><opiate use><opioid analgesia><opioid anesthetic><opioid consumption><opioid drug use><opioid exposure><opioid intake><opioid medication><opioid pain medication><opioid pain reliever><opioid painkiller><opioid use><pathway><peripheral blood><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacologic><precision medicine><precision-based medicine><prescribed opiate><prescribed opioid><prescription opiate><prescription opioid><prospective><resistance to Drug><resistant><resistant to Drug><response><response to therapy><response to treatment><social role><spongioblastoma multiforme><standard of care><stomach fundus cancer><stomach pylorus cancer><synergism><therapeutic efficacy><therapeutic response><therapy efficacy><therapy failure><therapy response><thymus derived lymphocyte><treatment response><treatment responsiveness><treatment risk><tumor cell metastasis><tumor growth><youngster><\\\\u03bc opioid receptors><\\\\u03bc-OR><\\\\u03bcOR>\", \"pref_terms\": \"Absence of pain sensation;Acute Lymphocytic Leukemia;Affect;Age Years;Animal Model;Apoptotic;B-Lymphocytes;Binding;Cell Death;Cell Line;Cell Separation;Cell Survival;Central Nervous System;Cessation of life;Chemoresistance;Chemotherapy-Oncologic Procedure;Child;Clinical;Clustered Regularly Interspaced Short Palindromic Repeats;Collection;Data;Diagnosis;Dimensions;Disease;Drug Interactions;Drug Kinetics;Drug resistance;Enrollment;Ensure;Fentanyl;Flow Cytometry;Frequencies;Genes;Glioblastoma;Goals;Hematopoietic Neoplasms;Image;Immunophenotyping;In Vitro;K-562;Knock-out;Leukemic Cell;Life;Link;Literature;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of esophagus;Malignant neoplasm of lung;Malignant neoplasm of prostate;Mediating;Medical;Metabolic;Molecular;Molecular Target;Morphine;Neoplasm Metastasis;Newly Diagnosed;Opioid;Opioid Analgesics;Outcome;Oxycodone;Pathway interactions;Patients;Pharmaceutical Preparations;Philadelphia Chromosome Positive Chronic Myelogenous Leukemia;Physiological;Plasma;Population;Proliferating;Public Health;Recurrent disease;Relapse;Research Proposals;Resistance;Risk;Role;Sampling;Signal Pathway;Signal Transduction;Study models;Supportive care;T-Lymphocyte;Testing;Therapeutic;Therapeutic Effect;Treatment Efficacy;Treatment Failure;Tyrosine Kinase Inhibitor;United States National Institutes of Health;acute leukemia cell;biobank;cancer cell;cancer diagnosis;cancer therapy;cancer type;cell killing;cell type;chemotherapy;chronic myeloid leukemia cell;clinically relevant;cytotoxic;early experience;experience;genetic approach;genotoxicity;high throughput screening;insight;interpatient variability;leukemia;leukemia treatment;malignant stomach neoplasm;mu opioid receptors;opioid exposure;opioid use;peripheral blood;personalized medicine;pharmacologic;precision medicine;prescription opioid;prospective;response;standard of care;synergism;treatment response;treatment risk;tumor growth\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nRoutinely prescribed analgesic opioids are potent activators of the mu-opioid receptor (\\\\u00b5OR; OPRM1 gene),\\\\nexpressed in many cancer types, and can impact cancer cell survival and the efficacy of lifesaving\\\\nchemotherapy. For patients with cancer, opioid use often coincides with chemotherapy, making opioid-\\\\nchemotherapy interactions inevitable. For some cancers, including lung, prostate, gastric, breast, and\\\\nesophageal cancers, opioid use and increased \\\\u00b5OR expression are linked to increased tumor growth,\\\\nmetastases, and shorter patient survival. In contrast, in vitro and animal model studies for glioblastoma, certain\\\\nbreast cancers, and T- and B-cell acute leukemias, opioids stimulate cancer cell death and, in some cases,\\\\nenhance cytotoxic chemotherapeutic response. The seemingly paradoxical effects likely have a concentration-\\\\ndependent dimension as physiologic opioid exposures have tended to induce pro-proliferative effects while\\\\nsupraphysiologic opioid exposures are typically associated with cancer cell death. While \\\\u00b5OR activation can\\\\nenhance the killing effect of genotoxic chemotherapy in acute lymphoblastic leukemia, our preliminary data\\\\ndemonstrate opioids antagonize the apoptotic response of Philadelphia chromosome-positive (Ph+) chronic\\\\nmyeloid leukemia cells (K562) to molecularly-targeted tyrosine kinase inhibitor (TKI) chemotherapy. As\\\\nleukemias are treated with both genotoxic and molecularly targeted chemotherapy assessing the potential for\\\\nclinically used opioids to antagonize or synergize in leukemic cell killing is an urgent medical need. We\\\\npropose to test the central hypothesis, that chemotherapeutic response will change in the presence of\\\\nclinically relevant concentrations of opioids, in three Aims. Specific Aim 1: Quantify standard-of-care\\\\nopioid exposures and determinants of exposure in patients with leukemia. Hypothesis 1: Interpatient variability\\\\nin opioid exposure will exceed 50% due to inherent metabolic differences, disease status, and treatment-\\\\nrelated pharmacokinetic alterations. Specific Aim 2: In leukemic cell lines, changes in response to\\\\nchemotherapy based on leukemic subtype and \\\\u00b5OR function will be determined. Hypothesis 2: Clinically-\\\\nexperienced concentrations of opioids will change chemotherapeutic response in different leukemic subtypes\\\\ncorresponding with \\\\u00b5OR function by >25%. Specific Aim 3: In patients with leukemia, the frequency of opioid-\\\\nchemotherapy DDIs based on clinical and molecular factors will be determined. Hypothesis 3: Clinical and\\\\nmolecular features associated with opioid-chemotherapy DDI conferring chemotherapy resistance are present\\\\nin >20% of patients prescribed opioids. Understanding the impact of \\\\u00b5OR activity on chemotherapeutic\\\\nresponse across similar but biologically distinct leukemia cell types will provide new insights into mechanisms\\\\nunderlying drug resistance, relapse, or non-response and drive precision medicine in opioid prescribing. This\\\\nproposal will provide key preliminary data to support an NIH R01 aimed at predicting altered chemotherapeutic\\\\nresponse due to supportive care medication exposure among patients undergoing treatment for leukemia.\", \"project_title\": \"Opioid-induced changes to chemotherapeutic activity in blood cancer\", \"phr_text\": \"PROJECT NARRATIVE\\\\nIt is desirable to avoid detrimental drug interactions to ensure each patient achieves the best possible\\\\nresponse to their chemotherapy. The goal of this research proposal is to determine the impact of opioid-\\\\nchemotherapy interactions on chemotherapeutic efficacy in blood cancer.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-08-01T12:08:00Z\", \"budget_end\": \"2025-07-31T12:07:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 186235, \"indirect_cost_amt\": 14899, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10895587\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 37}, page_content='{\"appl_id\": 10674695, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5K22CA258671-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"K22\", \"award_amount\": 201457, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"K22\", \"ic_code\": \"CA\", \"serial_num\": \"258671\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 14228461, \"first_name\": \"JONATHAN\", \"middle_name\": \"ERIC\", \"last_name\": \"CONSTANCE\", \"is_contact_pi\": true, \"full_name\": \"JONATHAN ERIC CONSTANCE\", \"title\": \"ASSISTANT PROFESSOR, PEDIATRICS\"}], \"contact_pi_name\": \"CONSTANCE, JONATHAN ERIC\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 201457, \"direct_cost_ic\": 186534, \"indirect_cost_ic\": 14923}], \"project_start_date\": \"2022-08-01T12:08:00Z\", \"project_end_date\": \"2025-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-467\", \"full_study_section\": {\"srg_code\": \"ZCA1\", \"srg_flex\": null, \"sra_designator_code\": \"RTRB\", \"sra_flex_code\": \"R\", \"group_code\": \"O2\", \"name\": \"ZCA1-RTRB-R(O2)\"}, \"award_notice_date\": \"2023-07-28T12:07:00Z\", \"core_project_num\": \"K22CA258671\", \"terms\": \"<Affect><opiate analgesia><opiate analgesic><opiate pain medication><opiate pain reliever><opioid analgesia><opioid anesthetic><opioid pain medication><opioid pain reliever><opioid painkiller><Opioid Analgesics><B-Lymphocytes><B blood cells><B cell><B cells><B-Cells><B-cell><malignant breast neoplasm><Breast Cancer><malignant breast tumor><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cell Death><necrocytosis><Cell Line><CellLine><Strains Cell Lines><cultured cell line><Cell Separation><Cell Isolation><Cell Segregation><Cell Separation Technology><cell sorting><Cell Survival><Cell Viability><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Cessation of life><Death><Diagnosis><Disease><Disorder><Drug resistance><drug resistant><resistance to Drug><resistant to Drug><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Fentanyl><Actiq><Duragesic><Fentanest><Fentyl><Phentanyl><Flow Cytometry><Flow Cytofluorometries><Flow Cytofluorometry><Flow Microfluorimetry><Flow Microfluorometry><flow cytophotometry><Genes><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><glioblastoma multiforme><spongioblastoma multiforme><Goals><In Vitro><leukemia><Acute Lymphocytic Leukemia><Acute Lymphoblastic Leukemia><Acute Lymphoid Leukemia><Precursor Cell Lymphoblastic Leukemia><Precursor Lymphoblastic Leukemia><acute lymphatic leukemia><acute lymphogenous leukemia><acute lymphomatic leukemia><Literature><malignant stomach neoplasm><Gastric Body Cancer><Gastric Cancer><Gastric Cardia Cancer><Gastric Fundus Cancer><Gastric Pylorus Cancer><Malignant Gastric Neoplasm><Malignant Gastric Tumor><Stomach Cancer><gastric malignancy><malignant stomach tumor><stomach fundus cancer><stomach pylorus cancer><Study models><Morphine><Infumorph><Kadian><MS Contin><MSir><Morphia><Oramorph><Oramorph SR><Roxanol><Statex SR><United States National Institutes of Health><NIH><National Institutes of Health><Neoplasm Metastasis><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Secondary Neoplasm><Secondary Tumor><cancer metastasis><tumor cell metastasis><Oxycodone><Dihydrohydroxycodeinone><Oxycodeinon><Oxycodone SR><Oxycontin><Roxicodone><Patients><Drug Kinetics><Pharmacokinetics><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Public Health><Relapse><Research Proposals><Risk><Role><social role><Signal Pathway><Signal Transduction><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><T-Lymphocyte><T-Cells><thymus derived lymphocyte><Testing><mu opioid receptors><\\\\u03bc opioid receptors><\\\\u03bc-OR><\\\\u03bcOR><Immunophenotyping><Immunologic Subtyping><immunophenotype><Mediating><therapy failure><Treatment Failure><Clinical><Physiologic><Physiological><Medical><Link><Ensure><peripheral blood><insight><Malignant Tumor of the Lung><Pulmonary Cancer><Pulmonary malignant Neoplasm><lung cancer><Malignant neoplasm of lung><Opiates><Opioid><Relapsed Disease><Recurrent disease><Chronic Myeloid Leukemia t(9;22) (q34;q11), BCR/ABL Positive><Ph\\' Chromosome Positive Chronic Myelocytic Leukemia><Ph\\' Chromosome Positive Chronic Myelogenous Leukemia><Ph\\' Chromosome Positive Chronic Myeloid Leukemia><Ph\\' Positive Chronic Granulocytic Leukemia><Ph1 Chromosome Positive Chronic Myelocytic Leukemia><Ph1 Chromosome Positive Chronic Myelogenous Leukemia><Ph1 Chromosome Positive Chronic Myeloid Leukemia><Ph1 Positive Chronic Granulocytic Leukemia><Philadelphia Chromosome Positive CML><Philadelphia Chromosome Positive Chronic Granulocytic Leukemia><Philadelphia Chromosome Positive Chronic Myelocytic Leukemia><Philadelphia Chromosome Positive Chronic Myeloid Leukemia><Philadelphia Chromosome Positive Chronic Myelogenous Leukemia><Therapeutic><Metabolic><cancer cell><Malignant Cell><Supportive care><Supportive Therapy><Absence of pain sensation><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Malignant neoplasm of prostate><Malignant Tumor of the Prostate><Malignant prostatic tumor><Prostate CA><Prostate Cancer><Prostate malignancy><Prostatic Cancer><Hematopoietic Neoplasms><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Malignant Hematopoietic Neoplasm><blood cancer><cancer of blood><cancer of the blood><Life><Chemotherapy-Oncologic Procedure><Chemotherapy Protocol><Chemotherapy Regimen><Combination Chemotherapy Regimen><Quimioterapia><cancer chemotherapy><Dimensions><Frequencies><cell type><Malignant neoplasm of esophagus><Esophageal Cancer><Esophagus Cancer><Malignant Esophageal Neoplasm><Malignant Esophageal Tumor><Malignant Tumor of the Esophagus><oesophageal cancer><early experience><experience><genotoxicity><tumor growth><cell killing><synergism><Animal Model><Animal Models and Related Studies><model of animal><Drug Interactions><Sampling><response><high throughput screening><High Throughput Assay><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer-directed therapy><cancer diagnosis><Central Nervous System><CNS Nervous System><Neuraxis><Molecular Interaction><Binding><PTK Inhibitors><Protein Tyrosine Kinase Inhibitors><TK Inhibitors><Tyrosine Kinase Inhibitor><Age Years><cytotoxic><Data><Molecular Target><Proliferating><Apoptotic><Collection><Enrollment><enroll><K-562><K562><K562 blasts><Leukemic Cell><Newly Diagnosed><Molecular><Knock-out><Knockout><Therapeutic Effect><Image><imaging><Pathway interactions><pathway><intervention efficacy><therapeutic efficacy><therapy efficacy><Treatment Efficacy><Outcome><Population><cancer type><prospective><resistant><Resistance><clinical relevance><clinically relevant><chemotherapy><standard of care><response to therapy><response to treatment><therapeutic response><therapy response><treatment response><biorepository><biobank><licit opioid><opiate medication><opioid medication><prescribed opiate><prescribed opioid><prescription opiate><prescription opioid><CRISPR><CRISPR/Cas system><Clustered Regularly Interspaced Short Palindromic Repeats><precision-based medicine><precision medicine><personalization of treatment><personalized therapy><personalized treatment><personalized medicine><leukemic therapy><leukemia treatment><genetic strategy><genetic approach><opiate consumption><opiate drug use><opiate intake><opiate use><opioid consumption><opioid drug use><opioid intake><opioid use><inter-patient variability><interpatient variability><opiate exposed><opiate exposure><opioid exposed><opioid exposure><acute leukemia cell><chronic myelogenous leukemia cell><chronic myeloid leukemia cell><treatment risk><chemoresistant><chemotherapy resistance><chemotherapy resistant><Chemoresistance><pharmacologic>\", \"pref_terms\": \"Absence of pain sensation;Acute Lymphocytic Leukemia;Affect;Age Years;Animal Model;Apoptotic;B-Lymphocytes;Binding;Cell Death;Cell Line;Cell Separation;Cell Survival;Central Nervous System;Cessation of life;Chemoresistance;Chemotherapy-Oncologic Procedure;Child;Clinical;Clustered Regularly Interspaced Short Palindromic Repeats;Collection;Data;Diagnosis;Dimensions;Disease;Drug Interactions;Drug Kinetics;Drug resistance;Enrollment;Ensure;Fentanyl;Flow Cytometry;Frequencies;Genes;Glioblastoma;Goals;Hematopoietic Neoplasms;Image;Immunophenotyping;In Vitro;K-562;Knock-out;Leukemic Cell;Life;Link;Literature;Malignant Neoplasms;Malignant neoplasm of esophagus;Malignant neoplasm of lung;Malignant neoplasm of prostate;Mediating;Medical;Metabolic;Molecular;Molecular Target;Morphine;Neoplasm Metastasis;Newly Diagnosed;Opioid;Opioid Analgesics;Outcome;Oxycodone;Pathway interactions;Patients;Pharmaceutical Preparations;Philadelphia Chromosome Positive Chronic Myelogenous Leukemia;Physiological;Plasma;Population;Proliferating;Public Health;Recurrent disease;Relapse;Research Proposals;Resistance;Risk;Role;Sampling;Signal Pathway;Signal Transduction;Study models;Supportive care;T-Lymphocyte;Testing;Therapeutic;Therapeutic Effect;Treatment Efficacy;Treatment Failure;Tyrosine Kinase Inhibitor;United States National Institutes of Health;acute leukemia cell;biobank;cancer cell;cancer diagnosis;cancer therapy;cancer type;cell killing;cell type;chemotherapy;chronic myeloid leukemia cell;clinically relevant;cytotoxic;early experience;experience;genetic approach;genotoxicity;high throughput screening;insight;interpatient variability;leukemia;leukemia treatment;malignant breast neoplasm;malignant stomach neoplasm;mu opioid receptors;opioid exposure;opioid use;peripheral blood;personalized medicine;pharmacologic;precision medicine;prescription opioid;prospective;response;standard of care;synergism;treatment response;treatment risk;tumor growth\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nRoutinely prescribed analgesic opioids are potent activators of the mu-opioid receptor (\\\\u00b5OR; OPRM1 gene),\\\\nexpressed in many cancer types, and can impact cancer cell survival and the efficacy of lifesaving\\\\nchemotherapy. For patients with cancer, opioid use often coincides with chemotherapy, making opioid-\\\\nchemotherapy interactions inevitable. For some cancers, including lung, prostate, gastric, breast, and\\\\nesophageal cancers, opioid use and increased \\\\u00b5OR expression are linked to increased tumor growth,\\\\nmetastases, and shorter patient survival. In contrast, in vitro and animal model studies for glioblastoma, certain\\\\nbreast cancers, and T- and B-cell acute leukemias, opioids stimulate cancer cell death and, in some cases,\\\\nenhance cytotoxic chemotherapeutic response. The seemingly paradoxical effects likely have a concentration-\\\\ndependent dimension as physiologic opioid exposures have tended to induce pro-proliferative effects while\\\\nsupraphysiologic opioid exposures are typically associated with cancer cell death. While \\\\u00b5OR activation can\\\\nenhance the killing effect of genotoxic chemotherapy in acute lymphoblastic leukemia, our preliminary data\\\\ndemonstrate opioids antagonize the apoptotic response of Philadelphia chromosome-positive (Ph+) chronic\\\\nmyeloid leukemia cells (K562) to molecularly-targeted tyrosine kinase inhibitor (TKI) chemotherapy. As\\\\nleukemias are treated with both genotoxic and molecularly targeted chemotherapy assessing the potential for\\\\nclinically used opioids to antagonize or synergize in leukemic cell killing is an urgent medical need. We\\\\npropose to test the central hypothesis, that chemotherapeutic response will change in the presence of\\\\nclinically relevant concentrations of opioids, in three Aims. Specific Aim 1: Quantify standard-of-care\\\\nopioid exposures and determinants of exposure in patients with leukemia. Hypothesis 1: Interpatient variability\\\\nin opioid exposure will exceed 50% due to inherent metabolic differences, disease status, and treatment-\\\\nrelated pharmacokinetic alterations. Specific Aim 2: In leukemic cell lines, changes in response to\\\\nchemotherapy based on leukemic subtype and \\\\u00b5OR function will be determined. Hypothesis 2: Clinically-\\\\nexperienced concentrations of opioids will change chemotherapeutic response in different leukemic subtypes\\\\ncorresponding with \\\\u00b5OR function by >25%. Specific Aim 3: In patients with leukemia, the frequency of opioid-\\\\nchemotherapy DDIs based on clinical and molecular factors will be determined. Hypothesis 3: Clinical and\\\\nmolecular features associated with opioid-chemotherapy DDI conferring chemotherapy resistance are present\\\\nin >20% of patients prescribed opioids. Understanding the impact of \\\\u00b5OR activity on chemotherapeutic\\\\nresponse across similar but biologically distinct leukemia cell types will provide new insights into mechanisms\\\\nunderlying drug resistance, relapse, or non-response and drive precision medicine in opioid prescribing. This\\\\nproposal will provide key preliminary data to support an NIH R01 aimed at predicting altered chemotherapeutic\\\\nresponse due to supportive care medication exposure among patients undergoing treatment for leukemia.\", \"project_title\": \"Opioid-induced changes to chemotherapeutic activity in blood cancer\", \"phr_text\": \"PROJECT NARRATIVE\\\\nIt is desirable to avoid detrimental drug interactions to ensure each patient achieves the best possible\\\\nresponse to their chemotherapy. The goal of this research proposal is to determine the impact of opioid-\\\\nchemotherapy interactions on chemotherapeutic efficacy in blood cancer.\", \"spending_categories_desc\": \"Cancer; Childhood Leukemia; Clinical Research; Hematology; Opioids; Orphan Drug; Patient Safety; Pediatric; Pediatric Cancer; Precision Medicine; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-08-01T12:08:00Z\", \"budget_end\": \"2024-07-31T12:07:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 186534, \"indirect_cost_amt\": 14923, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10674695\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 38}, page_content='{\"appl_id\": 10842351, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5K23AR079778-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"K23\", \"award_amount\": 173092, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"K23\", \"ic_code\": \"AR\", \"serial_num\": \"079778\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 14138687, \"first_name\": \"Jody\", \"middle_name\": \"\", \"last_name\": \"Lin\", \"is_contact_pi\": true, \"full_name\": \"Jody  Lin\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"LIN, JODY \", \"agency_ic_admin\": {\"code\": \"AR\", \"abbreviation\": \"NIAMS\", \"name\": \"National Institute of Arthritis and Musculoskeletal and Skin Diseases\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"AR\", \"name\": \"National Institute of Arthritis and Musculoskeletal and Skin Diseases\", \"abbreviation\": \"NIAMS\", \"total_cost\": 173092, \"direct_cost_ic\": 160500, \"indirect_cost_ic\": 12592}], \"project_start_date\": \"2022-07-15T12:07:00Z\", \"project_end_date\": \"2027-05-31T12:05:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-206\", \"full_study_section\": {\"srg_code\": \"AMS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Arthritis and Musculoskeletal and Skin Diseases Special Grants Study Section[AMS]\"}, \"award_notice_date\": \"2024-05-31T12:05:00Z\", \"core_project_num\": \"K23AR079778\", \"terms\": \"<Adoption><21+ years old><Adult Human><adulthood><Adult><Pain Control><Pain Therapy><pain treatment><Pain management><Award><Biometrics><Biostatistics><Biometry><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Child><life change><Climacteric><Communication><co-morbid><co-morbidity><comorbidity><consultation><Consultations><Decision Making><Dedications><Disorder><Disease><Elements><balance><balance function><Equilibrium><Exercise><faces><facial><Face><Family><Foundations><Future><Goals><Grant><Health><Health Services Evaluation><Medical Care Research><services research><Health Services Research><Heterogeneity><Pb element><heavy metal Pb><heavy metal lead><Lead><Leadership><Mentors><Morbidity - disease rate><Morbidity><mortality><Orthopedics><Orthopedic><Orthopedic Surgical Profession><Pain><Painful><Parents><parent><Pathology><Patients><Physicians><Pilot Projects><pilot study><Psychology><Research><Research Personnel><Investigators><Researchers><Risk><Science><scoliosis><Spinal Fusion><Spondylosyndeses><Testing><Training Activity><training module><Training Programs><Universities><Utah><Work><Wrestling><health care><Healthcare><measurable outcome><outcome measurement><Outcome Measure><doubt><Uncertainty><improved><Clinical><Medical><Neurological><Neurologic><Multi-center trial><Multicenter Trials><Training><pediatric><Childhood><satisfaction><Research Activity><Collaborations><randomized control trial><Randomized, Controlled Trials><Anatomic Abnormality><Anatomical Abnormality><Deformity><tool><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Impaired cognition><Patient Preferences><Knowledge><Life><programs><Scientist><Musculoskeletal><Spinal><Operative Surgical Procedures><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><preference><experience><success><Proxy><Hospitalists><skills><expectation><novel><Agreement><Communication Methods><Benefits and Risks><Modeling><career development><Intervention><Intervention Strategies><interventional strategy><disorder control><disease control><Physical therapy><Physiatric Procedure><Physical Medicine Procedure><Physical Therapeutics><Physiotherapy><Provider><Address><Health system><Adherence><Cost Effectiveness Analysis><cost efficient analysis><cost-effective analysis><health communication><Randomized><randomisation><randomization><randomly assigned><Research Training><Process><Modification><Development><developmental><neuromuscular><design><designing><Outcome><Population><innovation><innovate><innovative><multidisciplinary><implementation science><high risk><clinical practice><shared decision making><respiratory health><Airway health><support tools><Neuromuscular conditions><individual patient><improved outcome><experimental study><experiment><experimental research><experiments><clinical decision support><implementation strategy><strategies for implementation><surgical risk><surgery risk><treatment risk><effectiveness evaluation><assess effectiveness><determine effectiveness><effectiveness assessment><evaluate effectiveness><examine effectiveness><acceptability and feasibility><effectiveness outcome><effectiveness-related outcomes><feasibility testing><implementation facilitators><facilitators to implementation><human centered design><Mobility decline><Decline in mobility><Decrease in mobility><Decreased mobility><Diminished mobility><Mobility impairment><Reduced mobility><Reduction in mobility>\", \"pref_terms\": \"Address;Adherence;Adoption;Adult;Agreement;Award;Benefits and Risks;Biometry;Child;Childhood;Climacteric;Clinical;Collaborations;Communication;Communication Methods;Consultations;Cost Effectiveness Analysis;Decision Making;Dedications;Deformity;Development;Disease;Elements;Equilibrium;Exercise;Face;Family;Foundations;Future;Goals;Grant;Health;Health Services Research;Health system;Healthcare;Heterogeneity;Hospitalists;Impaired cognition;Intervention;Knowledge;Lead;Leadership;Life;Medical;Mentors;Mobility decline;Modeling;Modification;Morbidity - disease rate;Multicenter Trials;Musculoskeletal;Neurologic;Neuromuscular conditions;Operative Surgical Procedures;Orthopedics;Outcome;Outcome Measure;Pain;Pain management;Parents;Pathology;Patient Preferences;Patients;Physical therapy;Physicians;Pilot Projects;Population;Process;Provider;Proxy;Psychology;Randomized;Randomized, Controlled Trials;Research;Research Activity;Research Personnel;Research Training;Risk;Science;Scientist;Spinal;Spinal Fusion;Testing;Training;Training Activity;Training Programs;Uncertainty;Universities;Utah;Work;Wrestling;acceptability and feasibility;career development;clinical decision support;clinical practice;comorbidity;design;disorder control;effectiveness evaluation;effectiveness outcome;expectation;experience;experimental study;feasibility testing;health communication;high risk;human centered design;implementation facilitators;implementation science;implementation strategy;improved;improved outcome;individual patient;innovation;mortality;multidisciplinary;neuromuscular;novel;preference;programs;respiratory health;satisfaction;scoliosis;shared decision making;skills;success;support tools;surgical risk;tool;treatment risk\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThis proposal describes a 5-year research training program for Jody Lin, MD, MS, a pediatric hospitalist at the\\\\nUniversity of Utah. Dr. Lin\\\\u2019s long-term goal is to become an independent physician scientist who develops\\\\nscalable decision support tools to improve outcomes for children with medical complexity through shared\\\\ndecision making (SDM). The award will support Dr. Lin to accomplish the following goals: 1) Gain expertise in\\\\nthe psychology of decision making, 2) Undergo advanced training in risk communication strategies in settings\\\\nof uncertainty, 3) Obtain experience in applying implementation science to the design of decision support tools,\\\\n4) Acquire leadership skills in assembling and managing multidisciplinary scientific teams. Dr. Lin will be\\\\nsupported by an outstanding team of mentors who are dedicated to her success and possess diverse expertise\\\\nin decision science (Dr. Fagerlin), health communication (Dr. Kaphingst), implementation science (Dr. Asch),\\\\nand pediatric orthopaedics (Dr. Narayanan). Dr. Lin also has three advisors with expertise in children with\\\\nmedical complexity, career development, and biostatistics.\\\\nIn spite of broad recognition that SDM is a promising approach to improving outcomes for children with medical\\\\ncomplexity, little is known about how to improve SDM for these children in the clinical setting. This project will\\\\ndevelop and test the feasibility of a novel decision support tool on surgical treatment decision making for\\\\nchildren with neuromuscular scoliosis (NMS). The aims of the project are as follows. In aim 1, Dr. Lin will apply\\\\nnew skills in health communication to identify effective risk communication methods to communicate\\\\nuncertainty in decision making for children with NMS. In aim 2, Dr. Lin will design a decision support tool for\\\\nuse during orthopaedic consultation for children with NMS, including discoveries from aim 1. In aim 3, Dr. Lin\\\\nwill conduct a pilot feasibility and acceptability study of the decision support tool. This study will inform the\\\\ndevelopment of a large, multicenter trial of the decision support tool for children with NMS.\\\\nThrough the training and research activities embedded in this proposal, Dr. Lin will address gaps in our\\\\nunderstanding of how to support treatment decision making for children with NMS. This study will serve as a\\\\ncritical model for developing decision supports for clinical decisions in the growing population of children with\\\\nmedical complexity. Completion of the proposed activities will prepare Dr. Lin to independently lead a larger\\\\nresearch program evaluating and developing decision support to improve outcomes for populations of children\\\\nand adults with multiple comorbid conditions through better SDM.\", \"project_title\": \"Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis\", \"phr_text\": \"PROJECT NARRATIVE\\\\nFor the growing population of children with medical complexity, many medical decisions have no clear best\\\\ntreatment option; such decisions should be guided by individual patient preferences and values and clear\\\\ncommunication of decision-related uncertainty through the use of shared decision making. This proposal\\\\ndevelops a decision support tool for parents and providers of children with neuromuscular scoliosis who are\\\\ndeciding whether to undergo spinal fusion, a potentially life changing surgery but one that has significant\\\\ncomplications. This work will serve as the foundation for using shared decision making to improve outcomes\\\\nfor children with medical complexity by supporting informed health care decisions and by using implementation\\\\nscience to develop scalable decision support tools that improve shared decision making.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-06-01T12:06:00Z\", \"budget_end\": \"2025-05-31T12:05:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 160500, \"indirect_cost_amt\": 12592, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10842351\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 39}, page_content='{\"appl_id\": 10663314, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5K23AR079778-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"K23\", \"award_amount\": 173155, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"K23\", \"ic_code\": \"AR\", \"serial_num\": \"079778\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 14138687, \"first_name\": \"Jody\", \"middle_name\": \"\", \"last_name\": \"Lin\", \"is_contact_pi\": true, \"full_name\": \"Jody  Lin\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"LIN, JODY \", \"agency_ic_admin\": {\"code\": \"AR\", \"abbreviation\": \"NIAMS\", \"name\": \"National Institute of Arthritis and Musculoskeletal and Skin Diseases\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"AR\", \"name\": \"National Institute of Arthritis and Musculoskeletal and Skin Diseases\", \"abbreviation\": \"NIAMS\", \"total_cost\": 173155, \"direct_cost_ic\": 160500, \"indirect_cost_ic\": 12655}], \"project_start_date\": \"2022-07-15T12:07:00Z\", \"project_end_date\": \"2027-05-31T12:05:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-206\", \"full_study_section\": {\"srg_code\": \"AMS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Arthritis and Musculoskeletal and Skin Diseases Special Grants Study Section[AMS]\"}, \"award_notice_date\": \"2023-05-16T12:05:00Z\", \"core_project_num\": \"K23AR079778\", \"terms\": \"<Adoption><21+ years old><Adult Human><adulthood><Adult><Pain Control><Pain Therapy><pain treatment><Pain management><Award><Biometry><Biometrics><Biostatistics><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Climacteric><life change><Communication><comorbidity><co-morbid><co-morbidity><Consultations><consultation><Decision Making><Dedications><Disease><Disorder><Elements><Equilibrium><balance><balance function><Exercise><Face><faces><facial><Family><Foundations><Future><Goals><Grant><Health><Health Services Research><Health Services Evaluation><Medical Care Research><services research><Heterogeneity><Lead><Pb element><heavy metal Pb><heavy metal lead><Leadership><Mentors><Morbidity - disease rate><Morbidity><mortality><Orthopedics><Orthopedic><Orthopedic Surgical Profession><Pain><Painful><Parents><parent><Pathology><Patients><Physicians><Pilot Projects><pilot study><Psychology><Research><Research Personnel><Investigators><Researchers><Risk><Science><scoliosis><Spinal Fusion><Spondylosyndeses><Vertebral column><Spinal Column><Spine><backbone><Testing><Training Activity><training module><Training Programs><Universities><Utah><Work><Wrestling><health care><Healthcare><measurable outcome><outcome measurement><Outcome Measure><doubt><Uncertainty><improved><Clinical><Medical><Neurological><Neurologic><Multi-center trial><Multicenter Trials><Training><pediatric><Childhood><satisfaction><Research Activity><Collaborations><randomized control trial><Randomized, Controlled Trials><Anatomic Abnormality><Anatomical Abnormality><Deformity><tool><Impaired cognition><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Patient Preferences><Knowledge><Life><programs><Scientist><Musculoskeletal><Spinal><Operative Surgical Procedures><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><preference><experience><success><Proxy><Hospitalists><skills><expectation><novel><Agreement><Communication Methods><Benefits and Risks><Modeling><career development><Intervention><Intervention Strategies><interventional strategy><disorder control><disease control><Physical therapy><Physiatric Procedure><Physical Medicine Procedure><Physical Therapeutics><Physiotherapy><Provider><Address><Health system><Adherence><Cost Effectiveness Analysis><cost efficient analysis><cost-effective analysis><health communication><Randomized><randomisation><randomization><randomly assigned><Research Training><Process><Modification><Development><developmental><neuromuscular><designing><design><Outcome><Population><innovate><innovative><innovation><Impairment><multidisciplinary><implementation science><high risk><clinical practice><shared decision making><Airway health><respiratory health><support tools><Neuromuscular conditions><individual patient><improved outcome><experiment><experimental research><experiments><experimental study><clinical decision support><strategies for implementation><implementation strategy><surgery risk><surgical risk><treatment risk><assess effectiveness><determine effectiveness><effectiveness assessment><evaluate effectiveness><examine effectiveness><effectiveness evaluation><acceptability and feasibility><effectiveness-related outcomes><effectiveness outcome><feasibility testing><facilitators to implementation><implementation facilitators><human centered design>\", \"pref_terms\": \"Address;Adherence;Adoption;Adult;Agreement;Award;Benefits and Risks;Biometry;Child;Childhood;Climacteric;Clinical;Collaborations;Communication;Communication Methods;Consultations;Cost Effectiveness Analysis;Decision Making;Dedications;Deformity;Development;Disease;Elements;Equilibrium;Exercise;Face;Family;Foundations;Future;Goals;Grant;Health;Health Services Research;Health system;Healthcare;Heterogeneity;Hospitalists;Impaired cognition;Impairment;Intervention;Knowledge;Lead;Leadership;Life;Medical;Mentors;Modeling;Modification;Morbidity - disease rate;Multicenter Trials;Musculoskeletal;Neurologic;Neuromuscular conditions;Operative Surgical Procedures;Orthopedics;Outcome;Outcome Measure;Pain;Pain management;Parents;Pathology;Patient Preferences;Patients;Physical therapy;Physicians;Pilot Projects;Population;Process;Provider;Proxy;Psychology;Randomized;Randomized, Controlled Trials;Research;Research Activity;Research Personnel;Research Training;Risk;Science;Scientist;Spinal;Spinal Fusion;Testing;Training;Training Activity;Training Programs;Uncertainty;Universities;Utah;Vertebral column;Work;Wrestling;acceptability and feasibility;career development;clinical decision support;clinical practice;comorbidity;design;disorder control;effectiveness evaluation;effectiveness outcome;expectation;experience;experimental study;feasibility testing;health communication;high risk;human centered design;implementation facilitators;implementation science;implementation strategy;improved;improved outcome;individual patient;innovation;mortality;multidisciplinary;neuromuscular;novel;preference;programs;respiratory health;satisfaction;scoliosis;shared decision making;skills;success;support tools;surgical risk;tool;treatment risk\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThis proposal describes a 5-year research training program for Jody Lin, MD, MS, a pediatric hospitalist at the\\\\nUniversity of Utah. Dr. Lin\\\\u2019s long-term goal is to become an independent physician scientist who develops\\\\nscalable decision support tools to improve outcomes for children with medical complexity through shared\\\\ndecision making (SDM). The award will support Dr. Lin to accomplish the following goals: 1) Gain expertise in\\\\nthe psychology of decision making, 2) Undergo advanced training in risk communication strategies in settings\\\\nof uncertainty, 3) Obtain experience in applying implementation science to the design of decision support tools,\\\\n4) Acquire leadership skills in assembling and managing multidisciplinary scientific teams. Dr. Lin will be\\\\nsupported by an outstanding team of mentors who are dedicated to her success and possess diverse expertise\\\\nin decision science (Dr. Fagerlin), health communication (Dr. Kaphingst), implementation science (Dr. Asch),\\\\nand pediatric orthopaedics (Dr. Narayanan). Dr. Lin also has three advisors with expertise in children with\\\\nmedical complexity, career development, and biostatistics.\\\\nIn spite of broad recognition that SDM is a promising approach to improving outcomes for children with medical\\\\ncomplexity, little is known about how to improve SDM for these children in the clinical setting. This project will\\\\ndevelop and test the feasibility of a novel decision support tool on surgical treatment decision making for\\\\nchildren with neuromuscular scoliosis (NMS). The aims of the project are as follows. In aim 1, Dr. Lin will apply\\\\nnew skills in health communication to identify effective risk communication methods to communicate\\\\nuncertainty in decision making for children with NMS. In aim 2, Dr. Lin will design a decision support tool for\\\\nuse during orthopaedic consultation for children with NMS, including discoveries from aim 1. In aim 3, Dr. Lin\\\\nwill conduct a pilot feasibility and acceptability study of the decision support tool. This study will inform the\\\\ndevelopment of a large, multicenter trial of the decision support tool for children with NMS.\\\\nThrough the training and research activities embedded in this proposal, Dr. Lin will address gaps in our\\\\nunderstanding of how to support treatment decision making for children with NMS. This study will serve as a\\\\ncritical model for developing decision supports for clinical decisions in the growing population of children with\\\\nmedical complexity. Completion of the proposed activities will prepare Dr. Lin to independently lead a larger\\\\nresearch program evaluating and developing decision support to improve outcomes for populations of children\\\\nand adults with multiple comorbid conditions through better SDM.\", \"project_title\": \"Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis\", \"phr_text\": \"PROJECT NARRATIVE\\\\nFor the growing population of children with medical complexity, many medical decisions have no clear best\\\\ntreatment option; such decisions should be guided by individual patient preferences and values and clear\\\\ncommunication of decision-related uncertainty through the use of shared decision making. This proposal\\\\ndevelops a decision support tool for parents and providers of children with neuromuscular scoliosis who are\\\\ndeciding whether to undergo spinal fusion, a potentially life changing surgery but one that has significant\\\\ncomplications. This work will serve as the foundation for using shared decision making to improve outcomes\\\\nfor children with medical complexity by supporting informed health care decisions and by using implementation\\\\nscience to develop scalable decision support tools that improve shared decision making.\", \"spending_categories_desc\": \"Clinical Research; Clinical Trials and Supportive Activities; Dissemination and Implementation Research; Neurosciences; Pain Research; Patient Safety; Pediatric; Rehabilitation\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-06-01T12:06:00Z\", \"budget_end\": \"2024-05-31T12:05:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 160500, \"indirect_cost_amt\": 12655, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10663314\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 40}, page_content='{\"appl_id\": 10449660, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1K23AR079778-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K23\", \"award_amount\": 173129, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K23\", \"ic_code\": \"AR\", \"serial_num\": \"079778\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 14138687, \"first_name\": \"Jody\", \"middle_name\": \"\", \"last_name\": \"Lin\", \"is_contact_pi\": true, \"full_name\": \"Jody  Lin\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"LIN, JODY \", \"agency_ic_admin\": {\"code\": \"AR\", \"abbreviation\": \"NIAMS\", \"name\": \"National Institute of Arthritis and Musculoskeletal and Skin Diseases\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"AR\", \"name\": \"National Institute of Arthritis and Musculoskeletal and Skin Diseases\", \"abbreviation\": \"NIAMS\", \"total_cost\": 173129, \"direct_cost_ic\": 160500, \"indirect_cost_ic\": 12629}], \"project_start_date\": \"2022-07-15T12:07:00Z\", \"project_end_date\": \"2027-05-31T12:05:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-206\", \"full_study_section\": {\"srg_code\": \"AMS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Arthritis and Musculoskeletal and Skin Diseases Special Grants Study Section[AMS]\"}, \"award_notice_date\": \"2022-07-11T12:07:00Z\", \"core_project_num\": \"K23AR079778\", \"terms\": \"<Adoption><Adult><21+ years old><Adult Human><adulthood><Pain management><Pain Control><Pain Therapy><pain treatment><Award><Biometry><Biometrics><Biostatistics><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Climacteric><life change><Communication><comorbidity><co-morbid><co-morbidity><Consultations><Decision Making><Disease><Disorder><Elements><Equilibrium><balance><balance function><Exercise><Face><faces><facial><Family><Foundations><Future><Goals><Grant><Health><Health Services Research><Health Services Evaluation><Medical Care Research><services research><Heterogeneity><Lead><Pb element><heavy metal Pb><heavy metal lead><Leadership><Mentors><Morbidity - disease rate><Morbidity><mortality><Orthopedic><Orthopedic Surgical Profession><Orthopedics><Painful><Pain><Parents><Pathology><Patients><Physicians><pilot study><Pilot Projects><Psychology><Research><Investigators><Researchers><Research Personnel><Risk><Science><scoliosis><Spondylosyndeses><Spinal Fusion><Testing><Training Activity><training module><Training Programs><Universities><Utah><Work><Wrestling><Healthcare><health care><Outcome Measure><Uncertainty><doubt><base><improved><Clinical><Medical><Neurologic><Neurological><Multicenter Trials><Multi-center trial><Training><pediatric><Childhood><satisfaction><Research Activity><root><Plant Roots><Collaborations><randomized control trial><Randomized Controlled Trials><Anatomic Abnormality><Anatomical Abnormality><Deformity><tool><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Impaired cognition><Patient Preferences><Knowledge><Life><programs><Scientist><Musculoskeletal><Spinal><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Operative Surgical Procedures><preference><experience><success><Proxy><Hospitalists><skills><expectation><novel><Agreement><Communication Methods><Benefits and Risks><Modeling><career development><Intervention Strategies><interventional strategy><Intervention><disorder control><disease control><Physical therapy><Physiatric Procedure><Physical Medicine Procedure><Physical Therapeutics><Physiotherapy><Provider><Address><Health system><Adherence><cost efficient analysis><cost-effective analysis><Cost Effectiveness Analysis><health communication><randomisation><randomization><randomly assigned><Randomized><Research Training><Process><Modification><Development><developmental><neuromuscular><design><designing><Outcome><Population><innovation><innovate><innovative><Impairment><multidisciplinary><implementation science><high risk><clinical practice><shared decision making><respiratory health><Airway health><support tools><Neuromuscular conditions><individual patient><improved outcome><experimental study><experiment><experimental research><clinical decision support><implementation strategy><strategies for implementation><surgical risk><surgery risk><treatment risk><effectiveness evaluation><assess effectiveness><determine effectiveness><effectiveness assessment><evaluate effectiveness><acceptability and feasibility><effectiveness outcome><effectiveness-related outcomes><feasibility testing><implementation facilitators><facilitators to implementation><human centered design>\", \"pref_terms\": \"Address;Adherence;Adoption;Adult;Agreement;Award;Benefits and Risks;Biometry;Child;Childhood;Climacteric;Clinical;Collaborations;Communication;Communication Methods;Consultations;Cost Effectiveness Analysis;Decision Making;Deformity;Development;Disease;Elements;Equilibrium;Exercise;Face;Family;Foundations;Future;Goals;Grant;Health;Health Services Research;Health system;Healthcare;Heterogeneity;Hospitalists;Impaired cognition;Impairment;Intervention;Knowledge;Lead;Leadership;Life;Medical;Mentors;Modeling;Modification;Morbidity - disease rate;Multicenter Trials;Musculoskeletal;Neurologic;Neuromuscular conditions;Operative Surgical Procedures;Orthopedics;Outcome;Outcome Measure;Pain;Pain management;Parents;Pathology;Patient Preferences;Patients;Physical therapy;Physicians;Pilot Projects;Plant Roots;Population;Process;Provider;Proxy;Psychology;Randomized;Randomized Controlled Trials;Research;Research Activity;Research Personnel;Research Training;Risk;Science;Scientist;Spinal;Spinal Fusion;Testing;Training;Training Activity;Training Programs;Uncertainty;Universities;Utah;Work;Wrestling;acceptability and feasibility;base;career development;clinical decision support;clinical practice;comorbidity;design;disorder control;effectiveness evaluation;effectiveness outcome;expectation;experience;experimental study;feasibility testing;health communication;high risk;human centered design;implementation facilitators;implementation science;implementation strategy;improved;improved outcome;individual patient;innovation;mortality;multidisciplinary;neuromuscular;novel;preference;programs;respiratory health;satisfaction;scoliosis;shared decision making;skills;success;support tools;surgical risk;tool;treatment risk\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThis proposal describes a 5-year research training program for Jody Lin, MD, MS, a pediatric hospitalist at the\\\\nUniversity of Utah. Dr. Lin\\\\u2019s long-term goal is to become an independent physician scientist who develops\\\\nscalable decision support tools to improve outcomes for children with medical complexity through shared\\\\ndecision making (SDM). The award will support Dr. Lin to accomplish the following goals: 1) Gain expertise in\\\\nthe psychology of decision making, 2) Undergo advanced training in risk communication strategies in settings\\\\nof uncertainty, 3) Obtain experience in applying implementation science to the design of decision support tools,\\\\n4) Acquire leadership skills in assembling and managing multidisciplinary scientific teams. Dr. Lin will be\\\\nsupported by an outstanding team of mentors who are dedicated to her success and possess diverse expertise\\\\nin decision science (Dr. Fagerlin), health communication (Dr. Kaphingst), implementation science (Dr. Asch),\\\\nand pediatric orthopaedics (Dr. Narayanan). Dr. Lin also has three advisors with expertise in children with\\\\nmedical complexity, career development, and biostatistics.\\\\nIn spite of broad recognition that SDM is a promising approach to improving outcomes for children with medical\\\\ncomplexity, little is known about how to improve SDM for these children in the clinical setting. This project will\\\\ndevelop and test the feasibility of a novel decision support tool on surgical treatment decision making for\\\\nchildren with neuromuscular scoliosis (NMS). The aims of the project are as follows. In aim 1, Dr. Lin will apply\\\\nnew skills in health communication to identify effective risk communication methods to communicate\\\\nuncertainty in decision making for children with NMS. In aim 2, Dr. Lin will design a decision support tool for\\\\nuse during orthopaedic consultation for children with NMS, including discoveries from aim 1. In aim 3, Dr. Lin\\\\nwill conduct a pilot feasibility and acceptability study of the decision support tool. This study will inform the\\\\ndevelopment of a large, multicenter trial of the decision support tool for children with NMS.\\\\nThrough the training and research activities embedded in this proposal, Dr. Lin will address gaps in our\\\\nunderstanding of how to support treatment decision making for children with NMS. This study will serve as a\\\\ncritical model for developing decision supports for clinical decisions in the growing population of children with\\\\nmedical complexity. Completion of the proposed activities will prepare Dr. Lin to independently lead a larger\\\\nresearch program evaluating and developing decision support to improve outcomes for populations of children\\\\nand adults with multiple comorbid conditions through better SDM.\", \"project_title\": \"Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis\", \"phr_text\": \"PROJECT NARRATIVE\\\\nFor the growing population of children with medical complexity, many medical decisions have no clear best\\\\ntreatment option; such decisions should be guided by individual patient preferences and values and clear\\\\ncommunication of decision-related uncertainty through the use of shared decision making. This proposal\\\\ndevelops a decision support tool for parents and providers of children with neuromuscular scoliosis who are\\\\ndeciding whether to undergo spinal fusion, a potentially life changing surgery but one that has significant\\\\ncomplications. This work will serve as the foundation for using shared decision making to improve outcomes\\\\nfor children with medical complexity by supporting informed health care decisions and by using implementation\\\\nscience to develop scalable decision support tools that improve shared decision making.\", \"spending_categories_desc\": \"Clinical Research; Clinical Trials and Supportive Activities; Dissemination and Implementation Research; Neurosciences; Pain Research; Patient Safety; Pediatric; Rehabilitation\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-07-15T12:07:00Z\", \"budget_end\": \"2023-05-31T12:05:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 160500, \"indirect_cost_amt\": 12629, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10449660\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 41}, page_content='{\"appl_id\": 10515976, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1R21HL159629-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R21\", \"award_amount\": 114375, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R21\", \"ic_code\": \"HL\", \"serial_num\": \"159629\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 6763667, \"first_name\": \"L. LuAnn\", \"middle_name\": \"\", \"last_name\": \"Minich\", \"is_contact_pi\": true, \"full_name\": \"L. LuAnn  Minich\", \"title\": \"PROFESSOR OF PEDIATRICS\"}], \"contact_pi_name\": \"MINICH, L. LUANN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 114375, \"direct_cost_ic\": 75000, \"indirect_cost_ic\": 39375}], \"project_start_date\": \"2022-07-08T12:07:00Z\", \"project_end_date\": \"2024-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-20-078\", \"full_study_section\": {\"srg_code\": \"CHSA\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cancer, Heart, and Sleep Epidemiology A Study Section[CHSA]\"}, \"award_notice_date\": \"2022-07-08T12:07:00Z\", \"core_project_num\": \"R21HL159629\", \"terms\": \"<Adult><21+ years old><Adult Human><adulthood><Age><ages><Autoimmune Diseases><autoimmune condition><autoimmune disorder><Birth><Parturition><Body Size><Body Surface Area><Cardiovascular system><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Disease><Disorder><Echocardiography><Echocardiogram><Transthoracic Echocardiography><heart sonography><Endocrine System Diseases><Endocrine Diseases><Endocrine Diseases and Manifestations><endocrine disorder><Goals><Growth><Generalized Growth><Tissue Growth><ontogeny><Heart><Heart Diseases><Cardiac Diseases><Cardiac Disorders><heart disorder><Heart failure><cardiac failure><Heart Rate><Cardiac Chronotropism><Hematological Disease><Blood Diseases><Hematologic Diseases><Hematological Disorder><blood disorder><indexing><Lead><Pb element><heavy metal Pb><heavy metal lead><Longitudinal Studies><long-term study><longitudinal outcome studies><longterm study><Lung diseases><Pulmonary Diseases><Pulmonary Disorder><disease of the lung><disorder of the lung><lung disorder><Methods><Movement><body movement><North America><Pathology><Racial Group><Racial Stocks><Race><Reference Ranges><Reference Values><Research><Investigators><Researchers><Research Personnel><Risk><Software><Computer software><Standardization><Technology><Weight><Gender><Measures><Left Ventricular Function><Population Heterogeneity><diverse populations><heterogeneous population><population diversity><Data Set><Dataset><base><detector><improved><Left><Area><Clinical><Residual state><Residual><Variant><Variation><Evaluation><pediatric><Childhood><cardiac function><function of the heart><heart function><Data Bases><data base><Databases><Measurement><Left Ventricular Dysfunction><tool><Disorder Management><Disease Management><Dimensions><Frequencies><Dependence><Protocol><Protocols documentation><Ejection Fraction><EFRAC><Height><computer imaging><digital imaging><cohort><Participant><Categories><sleep diseases><sleep dysfunction><sleep illness><sleep problem><Sleep Disorders><Sampling><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer-directed therapy><Thickness><Thick><BMI><BMI percentile><BMI z-score><Quetelet index><Body mass index><SFRAC><Shortening Fraction><Address><Length><Reproducibility><Resolution><Process><sex><Myocardial><Ventricular><Cardiac><Image><imaging><age related><age dependent><age effect><aging effect><Sepsis><blood infection><bloodstream infection><cost effective><Population><prospective><Trauma><18 year old><18 years of age><age 18 years><eighteen year old><eighteen years of age><clinical care><standard of care><clinical practice><flexibility><flexible><Pediatric cardiology><outcome prediction><predictive outcomes><predictors of outcomes><predict clinical outcome><clinical outcome prediction><predictor of clinical outcome><secondary analysis><Prognosis>\", \"pref_terms\": \"18 year old;Address;Adult;Age;Area;Autoimmune Diseases;Birth;Body Size;Body Surface Area;Body mass index;Cardiac;Cardiovascular system;Categories;Child;Childhood;Clinical;Computer software;Data Set;Databases;Dependence;Dimensions;Disease;Disease Management;EFRAC;Echocardiography;Endocrine System Diseases;Evaluation;Frequencies;Gender;Goals;Growth;Heart;Heart Diseases;Heart Rate;Heart failure;Height;Hematological Disease;Image;Lead;Left;Left Ventricular Dysfunction;Left Ventricular Function;Length;Longitudinal Studies;Lung diseases;Measurement;Measures;Methods;Movement;Myocardial;North America;Participant;Pathology;Pediatric cardiology;Population;Population Heterogeneity;Process;Prognosis;Protocols documentation;Race;Reference Values;Reproducibility;Research;Research Personnel;Residual state;Resolution;Risk;Sampling;Sepsis;Shortening Fraction;Sleep Disorders;Standardization;Technology;Thick;Trauma;Variant;Ventricular;Weight;age effect;age related;base;cancer therapy;clinical care;clinical practice;cohort;cost effective;detector;digital imaging;flexibility;heart function;improved;indexing;outcome prediction;predict clinical outcome;prospective;secondary analysis;sex;standard of care;tool\", \"abstract_text\": \"PROJECT SUMMARY\\\\nIn children, calculating ejection (EF) and shortening fraction (SF) using echocardiography (echo) is the\\\\nstandard of care for evaluating left ventricular (LV) function. Despite their ubiquitous use, EF and SF are poorly\\\\nreproducible, calculated from multiple measurements each with their own error that is propagated, and\\\\nmeasure endocardial volume change without directly measuring contractility. Deformation strain is\\\\nfundamentally different from EF and SF. Instead of measuring volumes, echo software technology provides\\\\nspeckle-tracking of myocardial movement to measure regional and global myocardial deformation to obtain LV\\\\nstrain. Since this process is automated, it removes a large degree of observer-dependence. In addition, since\\\\nstrain is a single measurement rather than a derived parameter calculated from multiple measurements, the\\\\nerror for machine-derived strain should be substantially reduced. LV strain has been widely studied in adults\\\\nwhere normal reference ranges are validated and it is used to predict clinical outcomes and refine therapies. In\\\\ncontrast, LV strain reference values based on a large, diverse population of children are not available and\\\\nstrain remains largely a research tool in the pediatric population. To address this, we will establish Z-scores\\\\nusing the PHN Echo Database. This database includes all images needed for LV strain measurements from\\\\n3526 echoes obtained in a well-characterized population of healthy children ranging in age from birth to 18\\\\nyears. Z-scores account for the effects of maturation and growth by considering body size, age, gender, and/or\\\\nrace when evaluating whether measurements are normal or, if abnormal, how many standard deviations they\\\\ndeviate from the mean. Establishing Z-scores is the most powerful and flexible approach to normalizing\\\\ncardiovascular parameters for the effects of age and body size and has become the standard approach in\\\\npediatric cardiology. We will determine if independent parameters such as age, height, weight, body surface\\\\narea, or heart rate can predict changes in LV strain with maturation and/or growth. To guide clinical use, we will\\\\ndetermine the feasibility and reproducibility of LV strain measurements for images collected as part of routine\\\\nclinical care rather than as part of a rigorous research protocol. We will evaluate the effect of sampling\\\\nfrequency on Z-scores for clinically indicated studies by comparing those with \\\\u226530 vs. <30 frames/heartbeat in\\\\neach age category. This project is highly significant and will impact nearly every pediatric subspecialty. LV\\\\nstrain Z-scores will enable longitudinal studies to determine if LV strain is more predictive of outcomes than EF\\\\nor SF in children. If so, strain would move into clinical use and lead to a paradigm shift in the evaluation and\\\\nmanagement of diseases where the child is at risk for LV dysfunction and subsequent heart failure. The PHN\\\\ndatabase of normal echo images obtained as routine clinical care from a large, well-characterized population of\\\\nhealthy children provides a unique, cost-effective opportunity to establish normal LV strain Z-scores and rapidly\\\\ndeploy them for use in the real world setting of a busy pediatric echo lab.\", \"project_title\": \"Analysis of the Pediatric Heart Network Echocardiogram Database to Establish Left Ventricular Strain Z-scores\", \"phr_text\": \"PROJECT NARRATIVE\\\\nBecause normal reference ranges are known, evaluation of cardiac strain has been valuable as an earlier\\\\ndetector of abnormal function and a better predictor of outcomes in adults at risk for heart failure. Obtaining\\\\nnormal reference values for growing children is more complicated and we will use an established database of\\\\nechocardiograms obtained from healthy children across North America spanning all ages (birth to age 18\\\\nyears) to establish ranges that will allow us to distinguish a normal measurement from an abnormal one. This\\\\nproject has the potential to completely change how we evaluate children at risk for heart failure and allow us to\\\\nstart treatment of the underlying disease earlier and adjust therapy more reliably for children with compromised\\\\nheart function\", \"spending_categories_desc\": \"Bioengineering; Biomedical Imaging; Cardiovascular; Heart Disease; Minority Health; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-07-08T12:07:00Z\", \"budget_end\": \"2023-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 75000, \"indirect_cost_amt\": 39375, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10515976\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 42}, page_content='{\"appl_id\": 10662569, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R21HL159629-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R21\", \"award_amount\": 114375, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R21\", \"ic_code\": \"HL\", \"serial_num\": \"159629\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 6763667, \"first_name\": \"L. LuAnn\", \"middle_name\": \"\", \"last_name\": \"Minich\", \"is_contact_pi\": true, \"full_name\": \"L. LuAnn  Minich\", \"title\": \"PROFESSOR OF PEDIATRICS\"}], \"contact_pi_name\": \"MINICH, L. LUANN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 114375, \"direct_cost_ic\": 75000, \"indirect_cost_ic\": 39375}], \"project_start_date\": \"2022-07-08T12:07:00Z\", \"project_end_date\": \"2025-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-20-078\", \"full_study_section\": {\"srg_code\": \"CHSA\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cancer, Heart, and Sleep Epidemiology A Study Section[CHSA]\"}, \"award_notice_date\": \"2023-06-03T12:06:00Z\", \"core_project_num\": \"R21HL159629\", \"terms\": \"<21+ years old><Adult Human><adulthood><Adult><ages><Age><Autoimmune Diseases><autoimmune condition><autoimmune disorder><autoimmunity disease><Birth><Parturition><Body Size><Body Surface Area><Cardiovascular system><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Disease><Disorder><Echocardiography><Echocardiogram><Transthoracic Echocardiography><heart sonography><Endocrine System Diseases><Endocrine Diseases><Endocrine Diseases and Manifestations><endocrine disorder><Goals><Growth><Generalized Growth><Tissue Growth><ontogeny><Heart><Heart Diseases><Cardiac Diseases><Cardiac Disorders><heart disorder><Heart failure><cardiac failure><Heart Rate><Cardiac Chronotropism><Hematological Disease><Blood Diseases><Hematologic Diseases><Hematological Disorder><blood disorder><indexing><Longitudinal Studies><long-term study><longitudinal outcome studies><longterm study><Lung diseases><Pulmonary Diseases><Pulmonary Disorder><disease of the lung><disorder of the lung><lung disorder><Methods><Movement><body movement><North America><Pathology><Race><Races><racial><racial background><racial origin><Reference Values><Reference Ranges><Research><Research Personnel><Investigators><Researchers><Risk><Computer software><Software><Standardization><Technology><Weight><weights><Gender><Measures><Left Ventricular Function><diverse populations><heterogeneous population><population diversity><Population Heterogeneity><Data Set><detector><improved><Left><Area><Clinical><Residual><Residual state><Variation><Variant><Evaluation><pediatric><Childhood><cardiac function><function of the heart><heart function><Data Bases><data base><Databases><Measurement><Left Ventricular Dysfunction><tool><Disease Management><Disorder Management><Dimensions><Frequencies><Dependence><Protocols documentation><Protocol><EFRAC><Ejection Fraction><Height><digital imaging><computer imaging><cohort><Participant><Categories><Sleep Disorders><sleep diseases><sleep dysfunction><sleep illness><sleep problem><Sampling><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer-directed therapy><Thickness><Thick><BMI><BMI percentile><BMI z-score><Quetelet index><Body mass index><Shortening Fraction><SFRAC><Address><Length><Reproducibility><Resolution><resolutions><Process><sex><Myocardial><Ventricular><Cardiac><Image><imaging><age dependent><age related><aging effect><age effect><blood infection><bloodstream infection><Sepsis><cost effective><Population><prospective><Trauma><18 years of age><age 18 years><eighteen year old><eighteen years of age><18 year old><clinical care><standard of care><clinical practice><flexible><flexibility><Pediatric cardiology><predictive outcomes><predictors of outcomes><outcome prediction><clinical outcome prediction><predictor of clinical outcome><predict clinical outcome><secondary analysis><Prognosis>\", \"pref_terms\": \"18 year old;Address;Adult;Age;Area;Autoimmune Diseases;Birth;Body Size;Body Surface Area;Body mass index;Cardiac;Cardiovascular system;Categories;Child;Childhood;Clinical;Computer software;Data Set;Databases;Dependence;Dimensions;Disease;Disease Management;EFRAC;Echocardiography;Endocrine System Diseases;Evaluation;Frequencies;Gender;Goals;Growth;Heart;Heart Diseases;Heart Rate;Heart failure;Height;Hematological Disease;Image;Left;Left Ventricular Dysfunction;Left Ventricular Function;Length;Longitudinal Studies;Lung diseases;Measurement;Measures;Methods;Movement;Myocardial;North America;Participant;Pathology;Pediatric cardiology;Population;Population Heterogeneity;Process;Prognosis;Protocols documentation;Race;Reference Values;Reproducibility;Research;Research Personnel;Residual state;Resolution;Risk;Sampling;Sepsis;Shortening Fraction;Sleep Disorders;Standardization;Technology;Thick;Trauma;Variant;Ventricular;Weight;age effect;age related;cancer therapy;clinical care;clinical practice;cohort;cost effective;detector;digital imaging;flexibility;heart function;improved;indexing;outcome prediction;predict clinical outcome;prospective;secondary analysis;sex;standard of care;tool\", \"abstract_text\": \"PROJECT SUMMARY\\\\nIn children, calculating ejection (EF) and shortening fraction (SF) using echocardiography (echo) is the\\\\nstandard of care for evaluating left ventricular (LV) function. Despite their ubiquitous use, EF and SF are poorly\\\\nreproducible, calculated from multiple measurements each with their own error that is propagated, and\\\\nmeasure endocardial volume change without directly measuring contractility. Deformation strain is\\\\nfundamentally different from EF and SF. Instead of measuring volumes, echo software technology provides\\\\nspeckle-tracking of myocardial movement to measure regional and global myocardial deformation to obtain LV\\\\nstrain. Since this process is automated, it removes a large degree of observer-dependence. In addition, since\\\\nstrain is a single measurement rather than a derived parameter calculated from multiple measurements, the\\\\nerror for machine-derived strain should be substantially reduced. LV strain has been widely studied in adults\\\\nwhere normal reference ranges are validated and it is used to predict clinical outcomes and refine therapies. In\\\\ncontrast, LV strain reference values based on a large, diverse population of children are not available and\\\\nstrain remains largely a research tool in the pediatric population. To address this, we will establish Z-scores\\\\nusing the PHN Echo Database. This database includes all images needed for LV strain measurements from\\\\n3526 echoes obtained in a well-characterized population of healthy children ranging in age from birth to 18\\\\nyears. Z-scores account for the effects of maturation and growth by considering body size, age, gender, and/or\\\\nrace when evaluating whether measurements are normal or, if abnormal, how many standard deviations they\\\\ndeviate from the mean. Establishing Z-scores is the most powerful and flexible approach to normalizing\\\\ncardiovascular parameters for the effects of age and body size and has become the standard approach in\\\\npediatric cardiology. We will determine if independent parameters such as age, height, weight, body surface\\\\narea, or heart rate can predict changes in LV strain with maturation and/or growth. To guide clinical use, we will\\\\ndetermine the feasibility and reproducibility of LV strain measurements for images collected as part of routine\\\\nclinical care rather than as part of a rigorous research protocol. We will evaluate the effect of sampling\\\\nfrequency on Z-scores for clinically indicated studies by comparing those with \\\\u226530 vs. <30 frames/heartbeat in\\\\neach age category. This project is highly significant and will impact nearly every pediatric subspecialty. LV\\\\nstrain Z-scores will enable longitudinal studies to determine if LV strain is more predictive of outcomes than EF\\\\nor SF in children. If so, strain would move into clinical use and lead to a paradigm shift in the evaluation and\\\\nmanagement of diseases where the child is at risk for LV dysfunction and subsequent heart failure. The PHN\\\\ndatabase of normal echo images obtained as routine clinical care from a large, well-characterized population of\\\\nhealthy children provides a unique, cost-effective opportunity to establish normal LV strain Z-scores and rapidly\\\\ndeploy them for use in the real world setting of a busy pediatric echo lab.\", \"project_title\": \"Analysis of the Pediatric Heart Network Echocardiogram Database to Establish Left Ventricular Strain Z-scores\", \"phr_text\": \"PROJECT NARRATIVE\\\\nBecause normal reference ranges are known, evaluation of cardiac strain has been valuable as an earlier\\\\ndetector of abnormal function and a better predictor of outcomes in adults at risk for heart failure. Obtaining\\\\nnormal reference values for growing children is more complicated and we will use an established database of\\\\nechocardiograms obtained from healthy children across North America spanning all ages (birth to age 18\\\\nyears) to establish ranges that will allow us to distinguish a normal measurement from an abnormal one. This\\\\nproject has the potential to completely change how we evaluate children at risk for heart failure and allow us to\\\\nstart treatment of the underlying disease earlier and adjust therapy more reliably for children with compromised\\\\nheart function\", \"spending_categories_desc\": \"Bioengineering; Biomedical Imaging; Cardiovascular; Heart Disease; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-07-01T12:07:00Z\", \"budget_end\": \"2025-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 75000, \"indirect_cost_amt\": 39375, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10662569\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 43}, page_content='{\"appl_id\": 10371619, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1R34HL152047-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R34\", \"award_amount\": 382239, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R34\", \"ic_code\": \"HL\", \"serial_num\": \"152047\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 12036359, \"first_name\": \"Michael\", \"middle_name\": \"David\", \"last_name\": \"Johnson\", \"is_contact_pi\": true, \"full_name\": \"Michael David Johnson\", \"title\": \"ASSISTANT PROFESSOR OF PEDIATRICS\"}, {\"profile_id\": 7371263, \"first_name\": \"JOSEPH\", \"middle_name\": \"J\", \"last_name\": \"ZORC\", \"is_contact_pi\": false, \"full_name\": \"JOSEPH J ZORC\", \"title\": \"\"}], \"contact_pi_name\": \"JOHNSON, MICHAEL DAVID\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 382239, \"direct_cost_ic\": 268190, \"indirect_cost_ic\": 114049}], \"project_start_date\": \"2022-04-01T12:04:00Z\", \"project_end_date\": \"2024-03-31T12:03:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-21-079\", \"full_study_section\": {\"srg_code\": \"SSPT\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"OA\", \"name\": \"NHLBI Single-Site and Pilot Clinical Trials Study Section[SSPT (OA)]\"}, \"award_notice_date\": \"2022-03-31T12:03:00Z\", \"core_project_num\": \"R34HL152047\", \"terms\": \"<Adrenal Cortex Hormones><Corticoids><Corticosteroids><Albuterol><Proventil><Salbutamol><Ventolin><Sickle Cell Anemia><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><Breathing><Respiratory Aspiration><Respiratory Inspiration><inspiration><Asthma><Bronchial Asthma><Blood Pressure><Blood Pressure Monitors><Continuous Sphygmomanometers><Bronchodilator Agents><Bronchial-Dilating Agents><Bronchodilators><lumen dilator><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Chronic Disease><Chronic Illness><chronic disorder><Clinical Trials><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Future><Goals><Hospitalization><Hospital Admission><Hypotension><Low Blood Pressure><Vascular Hypotensive Disorder><Ions><Magnesium><Mg element><Magnesium Sulfate><Magnesium SO4><Medicine><Needles><Patients><Pharmacokinetics><Drug Kinetics><Pharmacology><pilot study><Pilot Projects><Sham Treatment><sham therapy><Placebos><Publishing><Recommendation><Research><Safety><Saline Solution><Saline><Savings><Schools><Serum Magnesium Level><Standardization><Steroid Compound><Steroids><Testing><Time><Translating><Work><Measures><Cost Savings><Health Care Costs><Health Costs><Healthcare Costs><Guidelines><Critically ill children><critically ill child><base><Blood specimen><Blood Sample><improved><Procedures><Site><Acute><Clinical><Multicenter Trials><Multi-center trial><Hospital Costs><Hospitalization cost><Evaluation><Blood Serum><Serum><pediatric><Childhood><Funding><Asthma in Children><Pediatric asthma><Childhood Asthma><randomized control trial><Randomized Controlled Trials><Intravenous><Knowledge><Life><Complex><Protocol><Protocols documentation><Respiratory distress><Emergency Department><Emergency room><Accident and Emergency department><Infusion><Infusion procedures><experience><novel><Applied Science><Applied Research><Study Subject><Devices><Reporting><Position><Positioning Attribute><Pharmacodynamics><Modeling><Adverse Experience><Adverse event><Intervention Strategies><interventional strategy><Intervention><patient safety><preventing><prevent><Address><Length><Dose><Consent><Data><Direct Costs><randomisation><randomization><randomly assigned><Randomized><Enrollment><enroll><Facilities and Administrative Costs><Indirect Costs><Patient-Focused Outcomes><Patient outcome><Patient-Centered Outcomes><Monitor><Intravenous Bolus><IV bolus><Development><developmental><Emergency Care><ED care><ER care><Emergency Department care><Emergency Room care><Emergency healthcare><Emergency medical care><Emergency health care><National Heart, Lung, and Blood Institute><NHLBI><pilot trial><double-blind placebo controlled trial><double-blind placebo control trial><double-masked controlled trial><pharmacokinetic model><pharmacodynamic model><design><designing><prospective><standard care><standard treatment><randomized trial><Randomization trial><arm><Inhalation><Inhaling><pediatric emergency><clinical database><randomized placebo-controlled clinical trial><placebo controlled trial><placebo control trial><Home>\", \"pref_terms\": \"Accident and Emergency department;Acute;Address;Adrenal Cortex Hormones;Adverse event;Albuterol;Applied Research;Asthma;Blood Pressure;Blood Pressure Monitors;Blood specimen;Breathing;Bronchodilator Agents;Child;Childhood;Childhood Asthma;Chronic Disease;Clinical;Clinical Trials;Complex;Consent;Cost Savings;Critically ill children;Data;Development;Devices;Direct Costs;Dose;Drug Kinetics;Emergency Care;Enrollment;Evaluation;Facilities and Administrative Costs;Funding;Future;Goals;Guidelines;Health Care Costs;Home;Hospital Costs;Hospitalization;Hypotension;Infusion procedures;Inhalation;Intervention;Intravenous;Intravenous Bolus;Ions;Knowledge;Length;Life;Magnesium;Magnesium Sulfate;Measures;Medicine;Modeling;Monitor;Multicenter Trials;National Heart, Lung, and Blood Institute;Needles;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Pharmacodynamics;Pharmacology;Pilot Projects;Placebos;Positioning Attribute;Procedures;Protocols documentation;Publishing;Randomized;Randomized Controlled Trials;Recommendation;Reporting;Research;Respiratory distress;Safety;Saline;Savings;Schools;Serum;Serum Magnesium Level;Sickle Cell Anemia;Site;Standardization;Steroids;Study Subject;Testing;Time;Translating;Work;arm;base;clinical database;design;double-blind placebo controlled trial;experience;improved;novel;patient safety;pediatric emergency;pharmacodynamic model;pharmacokinetic model;pilot trial;placebo controlled trial;prevent;prospective;randomized placebo-controlled clinical trial;randomized trial;standard care\", \"abstract_text\": \"PROJECT SUMMARY ABSTRACT\\\\nAsthma is the most common chronic illness of childhood and a leading cause of hospitalization and healthcare\\\\ncosts for children. Most children hospitalized for asthma first receive breathing treatments and steroid\\\\nmedicines in an emergency department (ED) according to national guidelines. An additional medicine,\\\\nintravenous magnesium sulfate (IVMg), may help severely sick children avoid hospitalization. National asthma\\\\nguidelines recommend IVMg for severely sick children, but note a lack of consistent evidence to support this\\\\nrecommendation. Only about one in four children hospitalized for asthma received IVMg in the ED. Estimates\\\\nof the potential effects of broader use of IVMg on hospitalization are limited by the small size of prior trials, but\\\\nincreased use could potentially avoid 18,000 hospitalizations each year, producing direct cost savings of $65\\\\nmillion yearly in addition to saving significant indirect costs of missed school and parental work.\\\\nA few major questions remain about IVMg. First, it has not been tested early in ED treatment, when the impact\\\\non hospitalization would be greatest. Second, the clinical impact of hypotension, a driver of low utilization, is\\\\nnot characterized in prior trials or clinical databases. Third, no trials have compared different IVMg doses or\\\\nmeasured serum magnesium levels to optimize dosing, so the most effective dose is unknown.\\\\nAll prior trials of IVMg in children with asthma have been small. A large randomized, placebo-controlled clinical\\\\ntrial of IVMg that could answer whether IVMg can reduce hospitalization might be challenging for a few\\\\nreasons. First, enrolling patients fast enough to give IVMg early in ED treatment is challenging. Second,\\\\nunderstanding blood pressure changes after IVMg is essential to plan safety monitoring for a larger trial. Third,\\\\nlittle pharmacologic information has been gathered to guide the doses of IVMg to be tested. We must conduct\\\\na small pilot clinical trial to test our procedures and gather necessary information to plan the large trial.\\\\nThe Pediatric Emergency Care Applied Research Network (PECARN) is a network of children\\\\u2019s EDs that has\\\\nconducted similar research involving acutely ill children. Our goals in this project are to:\\\\n1. Demonstrate the feasibility of enrolling children in the ED with severe acute asthma in a\\\\n multicenter, randomized, controlled trial of placebo, low-dose IVMg, or high-dose IVMg.\\\\n2. Demonstrate the feasibility of timely delivery of study medication to enrolled patients and\\\\n assessment of blood pressure and associated adverse events in a standardized protocol.\\\\n3. Externally validate a previously constructed PK model and develop a combined PK/PD model for\\\\n IVMg using magnesium (total and ionized) serum concentrations and their correlation with\\\\n measures of safety and respiratory distress in children with asthma.\\\\nAfter completing this pilot trial in three sites, we will plan a multi-center randomized trial of IVMg in children with\\\\nsevere acute asthma at more sites to enroll enough children to know if IVMg can reduce hospitalization.\", \"project_title\": \"Intravenous Magnesium: Prompt Use for Asthma in Children Treated in the Emergency Department (IMPACT-ED)\", \"phr_text\": \"PROJECT NARRATIVE\\\\nMany children currently being hospitalized with severe asthma could potentially avoid hospitalization and be\\\\nsent home if their treatment in the emergency department was more effective. We will conduct a pilot trial that\\\\nwill lead to a larger study to conclusively answer whether a simple and inexpensive medicine, intravenous\\\\nmagnesium sulfate, can be used in the emergency department to prevent hospitalization for these children.\", \"spending_categories_desc\": \"Asthma; Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Health Services; Lung; Patient Safety; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-04-01T12:04:00Z\", \"budget_end\": \"2023-03-31T12:03:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 268190, \"indirect_cost_amt\": 114049, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10371619\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 44}, page_content='{\"appl_id\": 10599339, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R34HL152047-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R34\", \"award_amount\": 355681, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R34\", \"ic_code\": \"HL\", \"serial_num\": \"152047\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12036359, \"first_name\": \"Michael\", \"middle_name\": \"David\", \"last_name\": \"Johnson\", \"is_contact_pi\": true, \"full_name\": \"Michael David Johnson\", \"title\": \"ASSISTANT PROFESSOR OF PEDIATRICS\"}, {\"profile_id\": 7371263, \"first_name\": \"JOSEPH\", \"middle_name\": \"J\", \"last_name\": \"ZORC\", \"is_contact_pi\": false, \"full_name\": \"JOSEPH J ZORC\", \"title\": \"\"}], \"contact_pi_name\": \"JOHNSON, MICHAEL DAVID\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 355681, \"direct_cost_ic\": 267495, \"indirect_cost_ic\": 88186}], \"project_start_date\": \"2022-04-01T12:04:00Z\", \"project_end_date\": \"2024-09-30T12:09:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-21-079\", \"full_study_section\": {\"srg_code\": \"SSPT\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"OA\", \"name\": \"NHLBI Single-Site and Pilot Clinical Trials Study Section[SSPT(OA)]\"}, \"award_notice_date\": \"2023-06-28T12:06:00Z\", \"core_project_num\": \"R34HL152047\", \"terms\": \"<Corticoids><Corticosteroids><Adrenal Cortex Hormones><Proventil><Salbutamol><Ventolin><Albuterol><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><Sickle Cell Anemia><Breathing><Respiratory Aspiration><Respiratory Inspiration><inspiration><Asthma><Bronchial Asthma><Blood Pressure><Blood Pressure Monitors><Continuous Sphygmomanometers><Bronchodilator Agents><Bronchial-Dilating Agents><Bronchodilators><lumen dilator><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Hospitalized Child><Chronic Disease><Chronic Illness><chronic disorder><Clinical Trials><intravenous administration><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Future><Goals><Hospitalization><Hospital Admission><Hypotension><Low Blood Pressure><Vascular Hypotensive Disorder><Magnesium><Mg element><Magnesium Sulfate><Magnesium SO4><Medicine><Needles><Patients><Drug Kinetics><Pharmacokinetics><Pilot Projects><pilot study><Placebos><Sham Treatment><sham therapy><Publishing><Recommendation><Research><Safety><Saline><Saline Solution><Schools><Serum Magnesium Level><Standardization><Steroids><Steroid Compound><Testing><Translating><Work><Measures><Cost Savings><Health Costs><Healthcare Costs><Health Care Costs><Guidelines><critically ill child><Critically ill children><Blood Sample><Blood specimen><improved><Procedures><Site><Acute><Clinical><Multi-center trial><Multicenter Trials><Evaluation><Blood Serum><Serum><pediatric><Childhood><Funding><Asthma in Children><Pediatric asthma><Childhood Asthma><Intravenous><Knowledge><Life><Complex><Protocols documentation><Protocol><Respiratory distress><Accident and Emergency department><Emergency Department><Emergency room><Infusion procedures><Infusion><infusions><experience><ionization><novel><Applied Research><Applied Science><Study Subject><Devices><Reporting><Positioning Attribute><Position><Pharmacodynamics><Modeling><Adverse event><Adverse Experience><Intervention><Intervention Strategies><interventional strategy><Meta-Analysis><patient safety><preventing><prevent><Address><Length><Dose><Consent><Data><Direct Costs><Randomized><randomisation><randomization><randomly assigned><Enrollment><enroll><Facilities and Administrative Costs><Indirect Costs><Patient-Focused Outcomes><Patient outcome><Patient-Centered Outcomes><patient oriented outcomes><Monitor><Intravenous Bolus><IV bolus><Development><developmental><Emergency Care><ED care><ER care><Emergency Department care><Emergency Room care><Emergency health care><Emergency healthcare><Emergency medical care><National Heart, Lung, and Blood Institute><NHLBI><pilot trial><randomized placebo control trial><randomized placebo controlled trial><double-blind placebo control trial><double-masked controlled trial><double-blind placebo controlled trial><pharmacokinetic model><pharmacodynamic model><designing><design><prospective><standard treatment><standard care><Randomization trial><randomized trial><arm><Inhaling><Inhalation><pediatric emergency><clinical database><randomized placebo-controlled clinical trial><patient enrollment><participant enrollment><homes><Home><pharmacologic><childcare allowance><childcare cost><trial planning>\", \"pref_terms\": \"Accident and Emergency department;Acute;Address;Adrenal Cortex Hormones;Adverse event;Albuterol;Applied Research;Asthma;Blood Pressure;Blood Pressure Monitors;Blood specimen;Breathing;Bronchodilator Agents;Child;Childhood;Childhood Asthma;Chronic Disease;Clinical;Clinical Trials;Complex;Consent;Cost Savings;Critically ill children;Data;Development;Devices;Direct Costs;Dose;Drug Kinetics;Emergency Care;Enrollment;Evaluation;Facilities and Administrative Costs;Funding;Future;Goals;Guidelines;Health Care Costs;Home;Hospitalization;Hospitalized Child;Hypotension;Infusion procedures;Inhalation;Intervention;Intravenous;Intravenous Bolus;Knowledge;Length;Life;Magnesium;Magnesium Sulfate;Measures;Medicine;Meta-Analysis;Modeling;Monitor;Multicenter Trials;National Heart, Lung, and Blood Institute;Needles;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Pharmacodynamics;Pilot Projects;Placebos;Positioning Attribute;Procedures;Protocols documentation;Publishing;Randomized;Recommendation;Reporting;Research;Respiratory distress;Safety;Saline;Schools;Serum;Serum Magnesium Level;Sickle Cell Anemia;Site;Standardization;Steroids;Study Subject;Testing;Translating;Work;arm;childcare allowance;clinical database;design;double-blind placebo controlled trial;experience;improved;intravenous administration;ionization;novel;participant enrollment;patient safety;pediatric emergency;pharmacodynamic model;pharmacokinetic model;pharmacologic;pilot trial;prevent;prospective;randomized placebo controlled trial;randomized placebo-controlled clinical trial;randomized trial;standard care;trial planning\", \"abstract_text\": \"PROJECT SUMMARY ABSTRACT\\\\nAsthma is the most common chronic illness of childhood and a leading cause of hospitalization and healthcare\\\\ncosts for children. Most children hospitalized for asthma first receive breathing treatments and steroid\\\\nmedicines in an emergency department (ED) according to national guidelines. An additional medicine,\\\\nintravenous magnesium sulfate (IVMg), may help severely sick children avoid hospitalization. National asthma\\\\nguidelines recommend IVMg for severely sick children, but note a lack of consistent evidence to support this\\\\nrecommendation. Only about one in four children hospitalized for asthma received IVMg in the ED. Estimates\\\\nof the potential effects of broader use of IVMg on hospitalization are limited by the small size of prior trials, but\\\\nincreased use could potentially avoid 18,000 hospitalizations each year, producing direct cost savings of $65\\\\nmillion yearly in addition to saving significant indirect costs of missed school and parental work.\\\\nA few major questions remain about IVMg. First, it has not been tested early in ED treatment, when the impact\\\\non hospitalization would be greatest. Second, the clinical impact of hypotension, a driver of low utilization, is\\\\nnot characterized in prior trials or clinical databases. Third, no trials have compared different IVMg doses or\\\\nmeasured serum magnesium levels to optimize dosing, so the most effective dose is unknown.\\\\nAll prior trials of IVMg in children with asthma have been small. A large randomized, placebo-controlled clinical\\\\ntrial of IVMg that could answer whether IVMg can reduce hospitalization might be challenging for a few\\\\nreasons. First, enrolling patients fast enough to give IVMg early in ED treatment is challenging. Second,\\\\nunderstanding blood pressure changes after IVMg is essential to plan safety monitoring for a larger trial. Third,\\\\nlittle pharmacologic information has been gathered to guide the doses of IVMg to be tested. We must conduct\\\\na small pilot clinical trial to test our procedures and gather necessary information to plan the large trial.\\\\nThe Pediatric Emergency Care Applied Research Network (PECARN) is a network of children\\\\u2019s EDs that has\\\\nconducted similar research involving acutely ill children. Our goals in this project are to:\\\\n1. Demonstrate the feasibility of enrolling children in the ED with severe acute asthma in a\\\\n multicenter, randomized, controlled trial of placebo, low-dose IVMg, or high-dose IVMg.\\\\n2. Demonstrate the feasibility of timely delivery of study medication to enrolled patients and\\\\n assessment of blood pressure and associated adverse events in a standardized protocol.\\\\n3. Externally validate a previously constructed PK model and develop a combined PK/PD model for\\\\n IVMg using magnesium (total and ionized) serum concentrations and their correlation with\\\\n measures of safety and respiratory distress in children with asthma.\\\\nAfter completing this pilot trial in three sites, we will plan a multi-center randomized trial of IVMg in children with\\\\nsevere acute asthma at more sites to enroll enough children to know if IVMg can reduce hospitalization.\", \"project_title\": \"Intravenous Magnesium: Prompt Use for Asthma in Children Treated in the Emergency Department (IMPACT-ED)\", \"phr_text\": \"PROJECT NARRATIVE\\\\nMany children currently being hospitalized with severe asthma could potentially avoid hospitalization and be\\\\nsent home if their treatment in the emergency department was more effective. We will conduct a pilot trial that\\\\nwill lead to a larger study to conclusively answer whether a simple and inexpensive medicine, intravenous\\\\nmagnesium sulfate, can be used in the emergency department to prevent hospitalization for these children.\", \"spending_categories_desc\": \"Asthma; Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Health Services; Lung; Patient Safety; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-04-01T12:04:00Z\", \"budget_end\": \"2024-09-30T12:09:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 267495, \"indirect_cost_amt\": 88186, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10599339\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 45}, page_content='{\"appl_id\": 10599013, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"3U01HG010217-04S1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"3\", \"activity_code\": \"U01\", \"award_amount\": 170779, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"3\", \"activity_code\": \"U01\", \"ic_code\": \"HG\", \"serial_num\": \"010217\", \"support_year\": \"04\", \"full_support_year\": \"04S1\", \"suffix_code\": \"S1\"}, \"principal_investigators\": [{\"profile_id\": 8959179, \"first_name\": \"Lorenzo\", \"middle_name\": \"Davide\", \"last_name\": \"Botto\", \"is_contact_pi\": true, \"full_name\": \"Lorenzo Davide Botto\", \"title\": \"\"}], \"contact_pi_name\": \"BOTTO, LORENZO DAVIDE\", \"agency_ic_admin\": {\"code\": \"HG\", \"abbreviation\": \"NHGRI\", \"name\": \"National Human Genome Research Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"OD\", \"name\": \"NIH Office of the Director\", \"abbreviation\": \"OD\", \"total_cost\": 170779, \"direct_cost_ic\": 111257, \"indirect_cost_ic\": 59522}], \"project_start_date\": \"2022-03-31T12:03:00Z\", \"project_end_date\": \"2023-04-30T12:04:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-272\", \"full_study_section\": {\"srg_code\": null, \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"50\", \"name\": null}, \"award_notice_date\": \"2022-06-29T12:06:00Z\", \"core_project_num\": \"U01HG010217\", \"terms\": \"<Adult><21+ years old><Adult Human><adulthood><Age><ages><California><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Research><Clinical Study><Communities><Comprehensive Health Care><Comprehensive Healthcare><comprehensive care><Data Analyses><Data Analysis><data interpretation><Diagnosis><Disease><Disorder><Family><Future><Patient Care><Patient Care Delivery><Genes><Geographic Locations><Geographic Area><Geographic Region><Geographical Location><geographic site><Geography><Goals><Healthcare Systems><Health Care Systems><Patients><Gestation><Pregnancy><Research Resources><Resources><Software><Computer software><Computer Software Tools><software toolkit><Software Tools><Specialty><medical specialties><Specimen Processing><Specimen Handling><Translating><United States><Universities><Utah><Caring><base><improved><Family Study><sample collection><specimen collection><Site><Area><Clinical><Phase><Variant><Variation><Biological><biologic><Evaluation><Funding><Genetic><tool><Diagnostic><programs><Protocol><Protocols documentation><experience><Participant><Genomics><scientific organization><Bio-Informatics><Bioinformatics><Low income><Disease Pathway><Catchment Area><research clinical testing><Clinical Evaluation><Clinical Testing><clinical test><Enrollment><enroll><Patient-Focused Outcomes><Patient outcome><Patient-Centered Outcomes><Process><follow-up><Active Follow-up><active followup><follow up><followed up><followup><clinical phenotype><Underserved Population><under served group><under served people><under served population><underserved group><underserved people><clinical research site><clinical site><Population><innovation><innovate><innovative><genome analysis><genomic tools><recruit><bioinformatics tool><bio-informatics tool><bioinformatics pipeline><bio-informatics pipeline><Rural Minority><sustainable resource><sustainable resources>\", \"pref_terms\": \"Adult;Age;Area;Bioinformatics;Biological;California;Caring;Catchment Area;Child;Clinical;Clinical Research;Communities;Comprehensive Health Care;Computer software;Data Analyses;Diagnosis;Diagnostic;Disease;Disease Pathway;Enrollment;Evaluation;Family;Family Study;Funding;Future;Genes;Genetic;Genomics;Geographic Locations;Geography;Goals;Healthcare Systems;Low income;Participant;Patient Care;Patient-Focused Outcomes;Patients;Phase;Population;Pregnancy;Process;Protocols documentation;Resources;Rural Minority;Site;Software Tools;Specimen Handling;Translating;Underserved Population;United States;Universities;Utah;Variant;base;bioinformatics pipeline;bioinformatics tool;clinical phenotype;clinical research site;experience;follow-up;genome analysis;genomic tools;improved;innovation;medical specialties;programs;recruit;research clinical testing;sample collection;scientific organization;sustainable resource;tool\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nYear 5 of the Intermountain West Clinical Site (University of Utah) for the Undiagnosed Disease Network will\\\\nbe focused on completing the evaluation of participants enrolled by June 30, 2022. Because of the pause in\\\\naccepting participants by other sites, the Intermountain West Clinical Site has been receiving in year 4 a\\\\nseveral-fold increase of applications from a wider geographic catchment area than was originally assigned to\\\\nthe site. This increased amount of effort in year 4 will translate in increased number of participants accepted in\\\\nyear 4 and having to be evaluated in year 5. The evaluation will follow the UDN protocols with the goal in year\\\\n5 of completing all evaluations accepted in year 4. The Intermountain West Clinical Site will bring the team,\\\\nexperience, resources, and institutional support to advance the shared goal of UDN \\\\u2013 improve the diagnosis\\\\nand management of difficult-to-diagnose and new diseases\\\\u2014efficiently, equitably, and sustainably.\", \"project_title\": \"Intermountain West Clinical Site for the Undiagnosed Disease Network (UDN) Phase 2 Supplement\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe Intermountain West Clinical Site of the Undiagnosed Disease Network (UDN) will help adults and children\\\\nwith undiagnosed diseases spread across over 10% of the Continental US get access to unprecedented\\\\ndiagnostic and care resources. Because of the pause in application review in some UDN clinical sites, the\\\\nIntermountain West Clinical Site is evaluating patients from a larger geographic area than previously assigned.\\\\nThe focus of this project period (year 5) is to complete the evaluation of participants accepted through the end\\\\nof year 4 (June 30,2022). The overall goal is to help families get better care through a precise diagnosis, and in\\\\ndoing so discover new genetic causes, disease pathways, and treatments that will help many more families in\\\\nfuture.\", \"spending_categories_desc\": \"Clinical Research; Health Disparities; Minority Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-07-01T12:07:00Z\", \"budget_end\": \"2023-04-30T12:04:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 111257, \"indirect_cost_amt\": 59522, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10599013\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 46}, page_content='{\"appl_id\": 10390861, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1R21HD107754-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R21\", \"award_amount\": 243917, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R21\", \"ic_code\": \"HD\", \"serial_num\": \"107754\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 9242106, \"first_name\": \"Mariana\", \"middle_name\": \"\", \"last_name\": \"Baserga\", \"is_contact_pi\": true, \"full_name\": \"Mariana  Baserga\", \"title\": \"MD\"}], \"contact_pi_name\": \"BASERGA, MARIANA \", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 243917, \"direct_cost_ic\": 160688, \"indirect_cost_ic\": 83229}], \"project_start_date\": \"2022-02-14T12:02:00Z\", \"project_end_date\": \"2024-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-20-299\", \"full_study_section\": {\"srg_code\": \"ZRG1\", \"srg_flex\": null, \"sra_designator_code\": \"EMNR\", \"sra_flex_code\": \"S\", \"group_code\": \"55\", \"name\": \"Special Emphasis Panel[ZRG1 EMNR-S (55)]\"}, \"award_notice_date\": \"2022-02-14T12:02:00Z\", \"core_project_num\": \"R21HD107754\", \"terms\": \"<Adrenergic Agonists><Adrenergic Receptor Agonist><Adrenomimetics><Adult><21+ years old><Adult Human><adulthood><Affect><Age><ages><Pain management><Pain Control><Pain Therapy><pain treatment><Animals><Arrhythmia><Cardiac Arrhythmia><Heart Arrhythmias><Asphyxia Neonatorum><birth asphyxia><neonatal asphyxia><perinatal asphyxia><post-natal asphyxia><postnatal asphyxia><Breathing><Respiratory Aspiration><Respiratory Inspiration><inspiration><Birth trauma><Birth Injuries><Blood><Blood Reticuloendothelial System><Brain><Brain Nervous System><Encephalon><Cerebral Palsy><Clinical Research><Clinical Study><Cessation of life><Death><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Gestational Age><Chronologic Fetal Maturity><Fetal Age><Hospitalization><Hospital Admission><Human><Modern Man><Hypertension><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><high blood pressure><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><Hypotension><Low Blood Pressure><Vascular Hypotensive Disorder><natural hypothermia><Hypothermia><Infant><Newborn Infant><0-4 weeks old><Newborns><newborn child><newborn children><Inflammation><Intensive Care Units><Ischemia><Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Laboratories><Learning><Mental Retardation><Morphine><Infumorph><Kadian><MS Contin><MSir><Morphia><Oramorph><Oramorph SR><Roxanol><Statex SR><Motor Skills><Movement><body movement><O element><O2 element><Oxygen><Painful><Pain><Parents><Patients><Pharmacokinetics><Drug Kinetics><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma><Public Health><Questionnaires><reperfusion><Reperfusion Therapy><Research><Risk><Safety><sedative><Seizures><Shivering><Testing><Time><Weaning><Measures><Encephalopathies><Liver Failure><Hepatic Failure><Agitation><Psychomotor Agitation><Psychomotor Excitement><Psychomotor Hyperactivity><Psychomotor Restlessness><Restlessness><Normal Range><Normal Values><Dexmedetomidine><Injury><injuries><Blood specimen><Blood Sample><improved><Clinical><Phase><Neurologic><Neurological><Survivors><motor disease><motor dysfunction><motor disorder><disability><Failure><pediatric><Childhood><Opiates><Opioid><Measurement><drug use><Drug usage><Early Intervention><Acquired brain injury><brain damage><brain-injured><Brain Injuries><Therapeutic><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Impaired cognition><sedation><Sedation procedure><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Absence of pain sensation><depressed><sadness><Depressed mood><Life><neonatal demise><neonatal death><vulnerable infant><high risk infant><Bradycardia><Hour><Severities><Continuous Infusion><Visit><Performance><neuroprotection><Animal Models and Related Studies><model of animal><model organism><Animal Model><Neural Development><neurodevelopment><Toxicities><Toxic effect><hypoxia ischemia><Brain Hypoxia-Ischemia><Modeling><Sampling><Property><Brain Trauma><traumatic brain damage><Traumatic Brain Injury><Adverse Experience><Adverse event><Therapeutic Uses><preventing><prevent><Dose><Data><Motor><randomisation><randomization><randomly assigned><Randomized><Development><developmental><neuron apoptosis><apoptosis of neuronal cells><neuronal apoptosis><neuronal cells programmed cell death><neurons programmed cell death><programmed cell death of neuronal cells by apoptosis><programmed cell death of neurons by apoptosis><pre-clinical><preclinical><design><designing><Neurodevelopmental Impairment><neonatal hypoxic-ischemic brain injury><hypoxic ischemic encephalopathy><neonatal HIE><neonatal hypoxia-ischemia><neonatal hypoxic-ischemic encephalopathy><Treatment Efficacy><intervention efficacy><therapeutic efficacy><therapy efficacy><Outcome><Neonatal><Population><arm><phase III trial><phase 3 trial><improved outcome><neonatal encephalopathy><study population><negative affect><negative affectivity><neonatal period><side effect><appropriate dose><optimal drug dosage><optimal drug dose><ventilation>\", \"pref_terms\": \"Absence of pain sensation;Acute Kidney Failure;Adrenergic Agonists;Adult;Adverse event;Affect;Age;Agitation;Animal Model;Animals;Arrhythmia;Asphyxia Neonatorum;Birth trauma;Blood;Blood specimen;Bradycardia;Brain;Brain Hypoxia-Ischemia;Brain Injuries;Breathing;Cerebral Palsy;Cessation of life;Childhood;Clinical;Clinical Research;Continuous Infusion;Data;Depressed mood;Development;Dexmedetomidine;Dose;Drug Kinetics;Drug usage;Early Intervention;Encephalopathies;Failure;Gestational Age;Hospitalization;Hour;Human;Hypertension;Hypotension;Impaired cognition;Infant;Inflammation;Injury;Intensive Care Units;Ischemia;Laboratories;Learning;Life;Liver Failure;Measurement;Measures;Mental Retardation;Modeling;Morphine;Motor;Motor Skills;Movement;Neonatal;Neurodevelopmental Impairment;Neurologic;Newborn Infant;Normal Range;Opioid;Outcome;Oxygen;Pain;Pain management;Parents;Patients;Performance;Pharmaceutical Preparations;Phase;Plasma;Population;Property;Public Health;Questionnaires;Randomized;Reperfusion Therapy;Research;Risk;Safety;Sampling;Sedation procedure;Seizures;Severities;Shivering;Survivors;Testing;Therapeutic;Therapeutic Uses;Time;Toxic effect;Traumatic Brain Injury;Treatment Efficacy;Visit;Weaning;appropriate dose;arm;design;disability;high risk infant;improved;improved outcome;motor disorder;natural hypothermia;negative affect;neonatal death;neonatal encephalopathy;neonatal hypoxic-ischemic brain injury;neonatal period;neurodevelopment;neuron apoptosis;neuroprotection;phase III trial;pre-clinical;prevent;sedative;side effect;study population;ventilation\", \"abstract_text\": \"PROJECT SUMMARY\\\\nDexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE trial)\\\\nHypoxia-ischemia encephalopathy (HIE, commonly called \\\\u201cbirth asphyxia\\\\u201d) is a condition where the brain\\\\ndoesn\\\\u2019t get enough oxygen. HIE affects 2 out of every 1,000 babies. Despite early intervention using brain\\\\ncooling, outcomes of death or major disability, such as cerebral palsy and mental retardation, still occurs in\\\\nnearly 30% of these babies. No other therapies have been proven to further reduce brain injury for these high\\\\nrisk infants. Furthermore, additional brain injury may be caused by concomitant use of drugs such as morphine\\\\nto treat pain and sedation in this population. Morphine use in animal models can increase neuronal apoptosis\\\\nand negatively affect neurodevelopment. Developing adjunctive therapies that improve outcomes in infants\\\\nwith HIE is an urgent, unmet public health need.\\\\nDexmedetomidine is a potent \\\\u03b12-adrenergic receptor agonist that may be a better alternative to morphine for\\\\nnewborns with neonatal HIE treated with cooling. Dexmedetomidine provides sedation, analgesia, and\\\\nprevents shivering but does not suppress breathing. Importantly, dexmedetomidine has been shown to protect\\\\nthe brain in animal models of brain injury. Recent clinical studies also suggest improved brain outcomes after\\\\ndexmedetomidine administration in adult patients with brain injury. Even though there are limited data on\\\\ndexmedetomidine safety and usefulness as well as pharmacokinetics (PK; drug levels in blood) in infants with\\\\nHIE it has been increasingly administered in many centers.\\\\nOur central hypothesis is that dexmedetomidine administered for sedation to full-term infants with HIE\\\\nundergoing cooling will be safe (AIM 1) and will be associated with improved short and long-term outcomes\\\\n(AIM 3). To test this hypothesis, we have designed a Phase II multicenter, randomized, safety and PK trial.\\\\nFifty infants (n=25 in each arm) with HIE and requiring sedation will be randomized to receive either\\\\ndexmedetomidine (1 \\\\u03bcg/kg for loading dose followed by 0.1 to 0.5 \\\\u03bcg/kg/h continuous infusion) or morphine\\\\n(0.02-0.03 mg/kg/dose intermittent dosing q 4 hours IV or as continuous infusion dose of 0.005- 0.01\\\\nmg/kg/hr). Two opportunistic PK samples (at time of routine laboratories) and a PRN PK sample any time there\\\\nis an adverse event will be obtained for measurement of Dexmedetomidine plasma concentrations (AIM 2).\\\\nPromising preliminary data show that dexmedetomidine may improve outcomes but optimal dosing, safety, and\\\\nefficacy still need to be established. We propose to confirm dexmedetomidine optimal dosing by collecting\\\\nopportunistic blood samples for PK data and determine safety of dexmedetomidine in this population in a\\\\nphase II safety trial. These data will inform a larger phase III trial to assess the efficacy of this therapy in\\\\nreducing the risk of long-term disabilities in infants with HIE who survive beyond the newborn period.\", \"project_title\": \"Dexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE trial)\", \"phr_text\": \"PROJECT NARRATIVE\\\\nIn spite of early intervention using brain cooling, outcomes of death or significant handicap still occur in nearly\\\\n30% of newborn babies with birth asphyxia. This study will help us learn if the drug dexmedetomidine, currently\\\\nused for sedation and pain in the intensive care units, is safe in these infants and will also tell us what the most\\\\nappropriate dose is. In recent studies Dexmedetomidine has been shown to protect the brain in animal and in\\\\nhuman studies of birth asphyxia or trauma.\", \"spending_categories_desc\": \"Brain Disorders; Cardiovascular; Cerebrovascular; Childhood Injury; Clinical Research; Clinical Trials and Supportive Activities; Infant Mortality; Intellectual and Developmental Disabilities (IDD); Neurosciences; Pain Research; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Preterm, Low Birth Weight and Health of the Newborn; Prevention; Stroke; Unintentional Childhood Injury\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-02-14T12:02:00Z\", \"budget_end\": \"2023-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 160688, \"indirect_cost_amt\": 83229, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10390861\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 47}, page_content='{\"appl_id\": 10571839, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R21HD107754-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R21\", \"award_amount\": 192448, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R21\", \"ic_code\": \"HD\", \"serial_num\": \"107754\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 9242106, \"first_name\": \"Mariana\", \"middle_name\": \"\", \"last_name\": \"Baserga\", \"is_contact_pi\": true, \"full_name\": \"Mariana  Baserga\", \"title\": \"MD\"}], \"contact_pi_name\": \"BASERGA, MARIANA \", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 192448, \"direct_cost_ic\": 134489, \"indirect_cost_ic\": 57959}], \"project_start_date\": \"2022-02-14T12:02:00Z\", \"project_end_date\": \"2025-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-20-299\", \"full_study_section\": {\"srg_code\": \"ZRG1\", \"srg_flex\": null, \"sra_designator_code\": \"EMNR\", \"sra_flex_code\": \"S\", \"group_code\": \"55\", \"name\": \"Special Emphasis Panel[ZRG1-EMNR-S(55)R]\"}, \"award_notice_date\": \"2023-01-27T12:01:00Z\", \"core_project_num\": \"R21HD107754\", \"terms\": \"<Adrenergic Receptor Agonist><Adrenomimetics><Adrenergic Agonists><21+ years old><Adult Human><adulthood><Adult><Affect><ages><Age><Pain Control><Pain Therapy><pain treatment><Pain management><Animals><Arrhythmia><Cardiac Arrhythmia><Heart Arrhythmias><Asphyxia Neonatorum><birth asphyxia><neonatal asphyxia><perinatal asphyxia><post-natal asphyxia><postnatal asphyxia><Breathing><Respiratory Aspiration><Respiratory Inspiration><inspiration><Birth trauma><Birth Injuries><Blood><Blood Reticuloendothelial System><Brain><Brain Nervous System><Encephalon><Brain Ischemia><Ischemic Encephalopathy><Cerebral Palsy><Clinical Research><Clinical Study><Cessation of life><Death><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Gestational Age><Chronologic Fetal Maturity><Fetal Age><Hospitalization><Hospital Admission><Human><Modern Man><Hypertension><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><high blood pressure><hyperpiesia><hyperpiesis><hypertensive disease><hypertensive disorder><Hypotension><Low Blood Pressure><Vascular Hypotensive Disorder><natural hypothermia><Hypothermia><Infant><Newborn Infant><0-4 weeks old><Newborns><newborn child><newborn children><Inflammation><Intensive Care Units><Ischemia><Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Laboratories><Learning><Mental Retardation><Morphine><Infumorph><Kadian><MS Contin><MSir><Morphia><Oramorph><Oramorph SR><Roxanol><Statex SR><Motor Skills><Movement><body movement><Oxygen><O element><O2 element><Pain><Painful><Parents><parent><Patients><Drug Kinetics><Pharmacokinetics><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Public Health><Questionnaires><Reperfusion Therapy><reperfusion><Research><Risk><Safety><sedative><Seizures><Shivering><Testing><Time><Weaning><Measures><Encephalopathies><Hepatic Failure><Liver Failure><Psychomotor Agitation><Psychomotor Excitement><Psychomotor Hyperactivity><Psychomotor Restlessness><Restlessness><Agitation><Normal Values><Normal Range><Dexmedetomidine><injuries><Injury><Blood Sample><Blood specimen><improved><Clinical><Phase><Neurological><Neurologic><Survivors><motor disease><motor dysfunction><motor disorder><disability><Failure><pediatric><Childhood><Opiates><Opioid><Measurement><drug use><Drug usage><Early Intervention><Acquired brain injury><brain damage><brain-injured><Brain Injuries><Therapeutic><Impaired cognition><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Sedation procedure><sedation><Absence of pain sensation><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Depressed mood><depressed><sadness><Life><neonatal death><neonatal demise><high risk infant><vulnerable infant><Bradycardia><Hour><Severities><Continuous Infusion><Visit><Performance><neuroprotection><neuroprotective><Animal Model><Animal Models and Related Studies><model of animal><neurodevelopment><Neural Development><Toxic effect><Toxicities><Modeling><Sampling><Property><Traumatic Brain Injury><Brain Trauma><traumatic brain damage><Adverse event><Adverse Experience><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><risk-reducing><Risk Reduction><Therapeutic Uses><preventing><prevent><Dose><Data><Motor><Randomized><randomisation><randomization><randomly assigned><Development><developmental><neuron apoptosis><apoptosis of neuronal cells><neuronal apoptosis><neuronal cells programmed cell death><neurons programmed cell death><programmed cell death of neuronal cells by apoptosis><programmed cell death of neurons by apoptosis><pre-clinical><preclinical><designing><design><Neurodevelopmental Impairment><hypoxic ischemic encephalopathy><neonatal HIE><neonatal hypoxia-ischemia><neonatal hypoxic-ischemic encephalopathy><neonatal hypoxic-ischemic brain injury><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy examination><evaluate efficacy><examine efficacy><efficacy evaluation><intervention efficacy><therapeutic efficacy><therapy efficacy><Treatment Efficacy><Outcome><Neonatal><Population><arm><phase 3 trial><phase III trial><improved outcome><neonatal encephalopathy><study population><negative affectivity><negative affect><neonatal period><side effect><optimal drug dosage><optimal drug dose><appropriate dose><ventilation>\", \"pref_terms\": \"Absence of pain sensation;Acute Kidney Failure;Adrenergic Agonists;Adult;Adverse event;Affect;Age;Agitation;Animal Model;Animals;Arrhythmia;Asphyxia Neonatorum;Birth trauma;Blood;Blood specimen;Bradycardia;Brain;Brain Injuries;Brain Ischemia;Breathing;Cerebral Palsy;Cessation of life;Childhood;Clinical;Clinical Research;Continuous Infusion;Data;Depressed mood;Development;Dexmedetomidine;Dose;Drug Kinetics;Drug usage;Early Intervention;Encephalopathies;Failure;Gestational Age;Hospitalization;Hour;Human;Hypertension;Hypotension;Impaired cognition;Infant;Inflammation;Injury;Intensive Care Units;Ischemia;Laboratories;Learning;Life;Liver Failure;Measurement;Measures;Mental Retardation;Modeling;Morphine;Motor;Motor Skills;Movement;Neonatal;Neurodevelopmental Impairment;Neurologic;Newborn Infant;Normal Range;Opioid;Outcome;Oxygen;Pain;Pain management;Parents;Patients;Performance;Pharmaceutical Preparations;Phase;Plasma;Population;Property;Public Health;Questionnaires;Randomized;Reperfusion Therapy;Research;Risk;Risk Reduction;Safety;Sampling;Sedation procedure;Seizures;Severities;Shivering;Survivors;Testing;Therapeutic;Therapeutic Uses;Time;Toxic effect;Traumatic Brain Injury;Treatment Efficacy;Visit;Weaning;appropriate dose;arm;design;disability;efficacy evaluation;high risk infant;improved;improved outcome;motor disorder;natural hypothermia;negative affect;neonatal death;neonatal encephalopathy;neonatal hypoxic-ischemic brain injury;neonatal period;neurodevelopment;neuron apoptosis;neuroprotection;phase III trial;pre-clinical;prevent;sedative;side effect;study population;ventilation\", \"abstract_text\": \"PROJECT SUMMARY\\\\nDexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE trial)\\\\nHypoxia-ischemia encephalopathy (HIE, commonly called \\\\u201cbirth asphyxia\\\\u201d) is a condition where the brain\\\\ndoesn\\\\u2019t get enough oxygen. HIE affects 2 out of every 1,000 babies. Despite early intervention using brain\\\\ncooling, outcomes of death or major disability, such as cerebral palsy and mental retardation, still occurs in\\\\nnearly 30% of these babies. No other therapies have been proven to further reduce brain injury for these high\\\\nrisk infants. Furthermore, additional brain injury may be caused by concomitant use of drugs such as morphine\\\\nto treat pain and sedation in this population. Morphine use in animal models can increase neuronal apoptosis\\\\nand negatively affect neurodevelopment. Developing adjunctive therapies that improve outcomes in infants\\\\nwith HIE is an urgent, unmet public health need.\\\\nDexmedetomidine is a potent \\\\u03b12-adrenergic receptor agonist that may be a better alternative to morphine for\\\\nnewborns with neonatal HIE treated with cooling. Dexmedetomidine provides sedation, analgesia, and\\\\nprevents shivering but does not suppress breathing. Importantly, dexmedetomidine has been shown to protect\\\\nthe brain in animal models of brain injury. Recent clinical studies also suggest improved brain outcomes after\\\\ndexmedetomidine administration in adult patients with brain injury. Even though there are limited data on\\\\ndexmedetomidine safety and usefulness as well as pharmacokinetics (PK; drug levels in blood) in infants with\\\\nHIE it has been increasingly administered in many centers.\\\\nOur central hypothesis is that dexmedetomidine administered for sedation to full-term infants with HIE\\\\nundergoing cooling will be safe (AIM 1) and will be associated with improved short and long-term outcomes\\\\n(AIM 3). To test this hypothesis, we have designed a Phase II multicenter, randomized, safety and PK trial.\\\\nFifty infants (n=25 in each arm) with HIE and requiring sedation will be randomized to receive either\\\\ndexmedetomidine (1 \\\\u03bcg/kg for loading dose followed by 0.1 to 0.5 \\\\u03bcg/kg/h continuous infusion) or morphine\\\\n(0.02-0.03 mg/kg/dose intermittent dosing q 4 hours IV or as continuous infusion dose of 0.005- 0.01\\\\nmg/kg/hr). Two opportunistic PK samples (at time of routine laboratories) and a PRN PK sample any time there\\\\nis an adverse event will be obtained for measurement of Dexmedetomidine plasma concentrations (AIM 2).\\\\nPromising preliminary data show that dexmedetomidine may improve outcomes but optimal dosing, safety, and\\\\nefficacy still need to be established. We propose to confirm dexmedetomidine optimal dosing by collecting\\\\nopportunistic blood samples for PK data and determine safety of dexmedetomidine in this population in a\\\\nphase II safety trial. These data will inform a larger phase III trial to assess the efficacy of this therapy in\\\\nreducing the risk of long-term disabilities in infants with HIE who survive beyond the newborn period.\", \"project_title\": \"Dexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE trial)\", \"phr_text\": \"PROJECT NARRATIVE\\\\nIn spite of early intervention using brain cooling, outcomes of death or significant handicap still occur in nearly\\\\n30% of newborn babies with birth asphyxia. This study will help us learn if the drug dexmedetomidine, currently\\\\nused for sedation and pain in the intensive care units, is safe in these infants and will also tell us what the most\\\\nappropriate dose is. In recent studies Dexmedetomidine has been shown to protect the brain in animal and in\\\\nhuman studies of birth asphyxia or trauma.\", \"spending_categories_desc\": \"Brain Disorders; Cardiovascular; Cerebrovascular; Childhood Injury; Clinical Research; Clinical Trials and Supportive Activities; Infant Mortality; Intellectual and Developmental Disabilities (IDD); Neurosciences; Pain Research; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Preterm, Low Birth Weight and Health of the Newborn; Prevention; Stroke; Unintentional Childhood Injury\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-02-01T12:02:00Z\", \"budget_end\": \"2025-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 134489, \"indirect_cost_amt\": 57959, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10571839\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 48}, page_content='{\"appl_id\": 10360802, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1T32GM139805-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"T32\", \"award_amount\": 219809, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"T32\", \"ic_code\": \"GM\", \"serial_num\": \"139805\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 11728904, \"first_name\": \"Kristen\", \"middle_name\": \"M\", \"last_name\": \"Kwan\", \"is_contact_pi\": false, \"full_name\": \"Kristen M Kwan\", \"title\": \"ASSISTANT PROFESSOR\"}, {\"profile_id\": 6684228, \"first_name\": \"H. Joseph\", \"middle_name\": \"\", \"last_name\": \"Yost\", \"is_contact_pi\": true, \"full_name\": \"H. Joseph  Yost\", \"title\": \"\"}], \"contact_pi_name\": \"YOST, H. JOSEPH \", \"agency_ic_admin\": {\"code\": \"GM\", \"abbreviation\": \"NIGMS\", \"name\": \"National Institute of General Medical Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"GM\", \"name\": \"National Institute of General Medical Sciences\", \"abbreviation\": \"NIGMS\", \"total_cost\": 219809, \"direct_cost_ic\": 209008, \"indirect_cost_ic\": 10801}], \"project_start_date\": \"2022-02-01T12:02:00Z\", \"project_end_date\": \"2027-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-21-025\", \"full_study_section\": {\"srg_code\": \"TWD\", \"srg_flex\": \"C\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Training and Workforce Development Study Section - C[TWD-C]\"}, \"award_notice_date\": \"2022-01-13T12:01:00Z\", \"core_project_num\": \"T32GM139805\", \"terms\": \"<Universities><Utah>\", \"pref_terms\": \"Universities;Utah\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\nThe mission of the IMSD@U2 program is to build a diverse biomedical workforce reflective of our general\\\\npopulation. In the past four years (2017-2020), the University of Utah\\\\u2019s commitment to diversity and inclusion\\\\nhas resulted in successful recruitment of Underrepresented (UR) students to the Biosciences PhD programs, so\\\\nthat UR students comprise 32% (49 UR/153 total) of the matriculated students. However, we recognize that\\\\nthese substantial gains in the diversity of our incoming PhD classes over the last four years might fail to produce\\\\nthe longer-term objectives of expanding diversity in the biomedical workforce, without effective, sustained and\\\\ncomprehensive inclusion efforts that fortify scientific career development for UR students. The aims of the\\\\nIMSD@U2 are to train and launch the careers of diverse, creative, and talented underrepresented (UR) students\\\\nby 1) continuing to build our successful recruitment program for UR students to our University of Utah Bioscience\\\\nPhD programs; 2) developing and utilizing innovative programs to retain UR students through our ExCEEDS\\\\n(Excellence in Career Enhancement, Education, Development and Diversity in Science) framework, thereby\\\\nlaunching our UR trainees into successful careers; 3) preparing IMSD@U2 trainees to become confident leaders\\\\nin biomedical research; and 4) mentoring faculty mentors, thus developing and fostering a research-intensive\\\\nand inclusive environment in which UR trainees and scientists can flourish.\\\\nIn order to accomplish these goals, key proposed activities that augment the current program include:\\\\npersonalized and cohort mentoring, peer outreach efforts and community building, a dynamic onboarding\\\\nexperience to support a successful start to graduate school, leadership development, faculty mentoring and\\\\ndevelopment to better meet the needs of the UR community. Ultimately, we intend for our trainees to complete\\\\ntheir qualifying exams, publish original research, apply for and obtain fellowships, complete their PhDs (70%\\\\nsuccess rate) with a mean time to degree of 6 years, and advance to high-quality postdoctoral and career\\\\npositions in science-intensive and science-related careers in academia, industry, and government.\", \"project_title\": \"IMSD at the University of Utah (IMSD@U2)\", \"phr_text\": \"PROJECT NARRATIVE\\\\nAn ongoing challenge in the biomedical sciences is to recruit, train, retain and launch the broadest and most\\\\ndiverse scientific talent pool possible. At the University of Utah, we are poised to take advantage of sustained\\\\nand unprecedented successes recruiting underrepresented students, in the state with the highest recent growth\\\\nin the life sciences industry. By developing and innovating programs and strategies for inclusion and retention,\\\\nwe aim to mentor and prepare our IMSD@U2 Trainees and Scholars, establishing their careers as outstanding\\\\nscientists and leaders in the biomedical sciences, while also developing and fostering our own research-intensive\\\\nenvironment where underrepresented scientists can flourish.\", \"spending_categories_desc\": \"Health Disparities; Minority Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-02-01T12:02:00Z\", \"budget_end\": \"2023-01-31T12:01:00Z\", \"funding_mechanism\": \"Training, Institutional\", \"direct_cost_amt\": 209008, \"indirect_cost_amt\": 10801, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10360802\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 49}, page_content='{\"appl_id\": 10399870, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"1R13HS028761-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R13\", \"award_amount\": 21526, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R13\", \"ic_code\": \"HS\", \"serial_num\": \"028761\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12559552, \"first_name\": \"Eric\", \"middle_name\": \"\", \"last_name\": \"Coon\", \"is_contact_pi\": true, \"full_name\": \"Eric  Coon\", \"title\": \"\"}], \"contact_pi_name\": \"COON, ERIC \", \"agency_ic_admin\": {\"code\": \"HS\", \"abbreviation\": \"AHRQ\", \"name\": \"Agency for Healthcare Research and Quality\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HS\", \"name\": \"Agency for Healthcare Research and Quality\", \"abbreviation\": \"AHRQ\", \"total_cost\": 21526, \"direct_cost_ic\": 21526, \"indirect_cost_ic\": 0}], \"project_start_date\": \"2022-01-01T12:01:00Z\", \"project_end_date\": \"2023-12-31T12:12:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-16-453\", \"full_study_section\": {\"srg_code\": \"ZHS1\", \"srg_flex\": null, \"sra_designator_code\": \"HSR\", \"sra_flex_code\": \"T\", \"group_code\": \"02\", \"name\": \"Special Emphasis Panel[ZHS1 HSR-T (02)]\"}, \"award_notice_date\": \"2021-12-22T12:12:00Z\", \"core_project_num\": \"R13HS028761\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"PROJECT SUMMARY\\\\nPediatric hospitalizations are common and costly in the US, yet there is a scant evidence base to guide\\\\ncare and ensure the best health outcomes for hospitalized children. In the US, there are over 6 million\\\\npediatric hospitalizations annually, leading to aggregate costs of nearly $50 billion. The majority of childhood\\\\nhospitalizations are for common conditions, but currently, there are major gaps in the evidence of how best to\\\\ncare for these conditions (e.g., \\\\u201cwhat is the most effective systemic corticosteroid regimen for children\\\\nhospitalized with asthma?\\\\u201d). Additionally, over 70% of US children are hospitalized in community hospitals, but\\\\nthe vast majority of federal funding for pediatric research goes to free-standing children\\\\u2019s hospitals. Evidence\\\\ngaps and the scarcity of research in community hospital settings contribute to suboptimal health outcomes for\\\\nhospitalized children, such as complications from unnecessary treatments, prolonged hospital stays, hospital\\\\nreadmissions, and poor chronic disease control. Randomized controlled trials (RCTs) can guide evidence-\\\\nbased care and improve child health outcomes. RCTs minimize potential biases in research findings by\\\\nrandomly allocating study participants to treatment groups. Thus, they represent the highest-quality studies for\\\\nguiding the care of hospitalized children.\\\\nOur overall objective is to develop a national RCT agenda in pediatric hospital medicine (PHM) and critical\\\\nresources for achieving that agenda. To achieve this objective, we propose to hold a research development\\\\nconference. We have recruited a diverse group of PHM stakeholders for this conference, including\\\\nmultidisciplinary PHM clinicians from children\\\\u2019s and community hospitals (e.g., physicians, nurses,\\\\npharmacists), clinical and health services researchers, patients and families, health equity experts, and\\\\npolicymakers. In Aim 1, we will engage conference attendees in using an established method, concept\\\\nmapping, to identify and prioritize RCT questions for the 20 most prevalent conditions in PHM. In Aim 2, we\\\\nwill identify barriers and facilitators to conducting PHM RCTs in community hospitals. In Aim 3, we will\\\\ndisseminate conference findings via three national partner organizations.\\\\nOur proposed conference will fill critical gaps by setting an actionable national PHM research agenda,\\\\nidentifying strategies for meaningfully engaging both children\\\\u2019s and community hospitals in achieving this\\\\nagenda, and assembling critical partners for carrying out this agenda. These findings will have an important\\\\npositive impact by guiding future research efforts to improve hospital care and health outcomes for children,\\\\nan AHRQ priority population. Thus, this work aligns with AHRQ\\\\u2019s mission to produce evidence to make health\\\\ncare safer and higher quality.\", \"project_title\": \"Developing a National Pediatric Hospital Medicine Randomized Controlled Trial Agenda\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThere is a scant evidence base to guide care and ensure the best health outcomes for hospitalized children, so\\\\nthe overall objective of the proposed research is to develop a randomized controlled trial agenda for pediatric\\\\nhospital medicine and critical resources for achieving that agenda. The proposed research is relevant to public\\\\nhealth because it can improve child health outcomes by setting an actionable national pediatric hospital\\\\nmedicine research agenda, identifying strategies for meaningfully engaging both children\\\\u2019s and community\\\\nhospitals in achieving this agenda, and assembling critical partners for carrying out this agenda. Thus, the\\\\nproposed research is relevant to AHRQ\\\\u2019s mission of producing evidence to make health care safer and higher\\\\nquality and focuses on a priority population, children.\", \"spending_categories_desc\": null, \"agency_code\": \"AHRQ\", \"budget_start\": \"2022-01-01T12:01:00Z\", \"budget_end\": \"2023-12-31T12:12:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 21526, \"indirect_cost_amt\": 0, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10399870\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 50}, page_content='{\"appl_id\": 10701864, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R01HD099250-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 515679, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HD\", \"serial_num\": \"099250\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10526558, \"first_name\": \"Shelley\", \"middle_name\": \"M\", \"last_name\": \"Lawrence\", \"is_contact_pi\": true, \"full_name\": \"Shelley M Lawrence\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"LAWRENCE, SHELLEY M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 515679, \"direct_cost_ic\": 485321, \"indirect_cost_ic\": 30358}], \"project_start_date\": \"2022-01-01T12:01:00Z\", \"project_end_date\": \"2025-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"ISD\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Instrumentation and Systems Development Study Section[ISD]\"}, \"award_notice_date\": \"2023-06-23T12:06:00Z\", \"core_project_num\": \"R01HD099250\", \"terms\": \"<Antibiotic Agents><Antibiotic Drugs><Miscellaneous Antibiotic><Antibiotics><Antibodies><Antiviral Agents><Antiviral Drugs><Antivirals><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><Base Sequence><Nucleotide Sequence><nucleic acid sequence><Biological Assay><Assay><Bioassay><Biologic Assays><Birth><Parturition><Blood><Blood Reticuloendothelial System><Blood Volume><California><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Clinical Research><Clinical Study><Cytomegalovirus><CMV><HCMV><Salivary Gland Viruses><cytomegalovirus group><Diagnosis><Disease><Disorder><DNA><Deoxyribonucleic Acid><Dyes><Coloring Agents><Epidemiology><epidemiologic><epidemiological><Fingerprint><Fluorescence><Genome><Genotype><Goals><Disabled Persons><Disabled Population><Handicapped><People with Disabilities><Persons with Disabilities><disabled><disabled individual><disabled people><individuals with disabilities><Health><Herpes Simplex Infections><Herpes Simplex><Herpes simplex disease><Herpesvirus hominis disease><herpes simplex virus 1 infection><herpes simplex virus infection><Immunoglobulin G><7S Gamma Globulin><IgG><Immunoglobulin M><19S Gamma Globulin><IgM><Infant><Newborn Infant><0-4 weeks old><Newborns><newborn child><newborn children><Infection><Laboratories><Modernization><Mothers><Neonatal Screening><Newborn Infant Screening><newborn screening><Nucleotides><Patients><Polymerase Chain Reaction><Pregnant Women><expectant mother><expecting mother><pregnant mothers><Research><Research Personnel><Investigators><Researchers><Risk><RNA><Non-Polyadenylated RNA><RNA Gene Products><Ribonucleic Acid><Saliva><Specificity><Technology><Testing><Time><Tissues><Body Tissues><Translating><United States><Universities><Urine><Measures><falls><timeline><Blinded><congenital CMV><congenital cytomegalovirus infection><congenital cytomegalovirus><Tube><Peripartum><Perinatal><Blood Sample><Blood specimen><Nucleic Acid Testing><Nucleic Acid Amplification Tests><Clinical><Variation><Variant><biologic><Biological><HSV><Herpes Simplex Virus><Herpes labialis Virus><Simplexvirus><Evaluation><Training><Failure><Individual><Data Bases><data base><Databases><Early Intervention><Funding><Congenital herpes simplex infection><HSV infection in neonates><Neonatal herpes simplex><congenital herpes simplex virus infection><neonatal HSV infection><neonatal herpes><Congenital herpes simplex><Collaborations><Therapeutic><Spottings><Diagnostic><Machine Learning><machine based learning><Life><Viral Load result><Viral Burden><Viral Load><Investigation><Hour><postnatal><Reaction><Techniques><Viral><rapid diagnosis><microbial><melting><intervention program><offspring><Modality><Reporting><Therapeutic Intervention><intervention therapy><Early identification><Sampling><single molecule><diagnosis standard><Pathogenicity><preventing><prevent><Causality><causation><disease causation><Etiology><Address><Culture Techniques><Antimicrobial Resistance><Antimicrobial resistant><Resistance to antimicrobial><anti-microbial resistance><anti-microbial resistant><resistance to anti-microbial><resistant to anti-microbial><resistant to antimicrobial><Symptoms><Advocate><Data><Detection><Dryness><Predictive Value><Resolution><resolutions><Enrollment><enroll><Genomic Segment><genome segment><genomic region><Update><technology validation><technology implementation><transmission process><Transmission><Molecular><point of care><neonate><cost><digital><latency/reactivation><reactivation from latency><Outcome><Neonatal><Antiviral resistant><anti-viral resistance><anti-viral resistant><Antiviral resistance><pathogen><Prevalence><prospective><Consumption><resistant><Resistance><anti-microbial><antimicrobial><Microbe><Pathogen detection><clinical relevance><clinically relevant><multidisciplinary><multidisciplinary approach><interdisciplinary approach><intercalation><biorepository><biobank><NGS Method><NGS system><next gen sequencing><nextgen sequencing><next generation sequencing><resistance locus><resistant gene><resistance gene><accurate diagnosis><diagnostic marker><diagnostic biomarker><screening program><machine learned algorithm><machine learning based algorithm><machine learning algorithm><viral pathogen><virus pathogen><pathogenic virus><clinical database><pathogen genomics><infected neonate><infected newborn><newborn infection><neonatal infection><detection limit><detection procedure><detection technique><detection method><clinical outcome measures><disease prognosis><disease prognostication><artificial intelligence algorithm><AI algorithm><diagnostic tool>\", \"pref_terms\": \"Address;Advocate;Antibiotics;Antibodies;Antimicrobial Resistance;Antiviral Agents;Antiviral resistance;Base Sequence;Biological;Biological Assay;Birth;Blinded;Blood;Blood Volume;Blood specimen;California;Child;Clinical;Clinical Research;Collaborations;Congenital herpes simplex;Consumption;Culture Techniques;Cytomegalovirus;DNA;Data;Databases;Detection;Diagnosis;Diagnostic;Disabled Persons;Disease;Dryness;Dyes;Early Intervention;Early identification;Enrollment;Epidemiology;Etiology;Evaluation;Failure;Fingerprint;Fluorescence;Funding;Genome;Genomic Segment;Genotype;Goals;Health;Herpes Simplex Infections;Hour;Immunoglobulin G;Immunoglobulin M;Individual;Infant;Infection;Investigation;Laboratories;Life;Machine Learning;Measures;Microbe;Modality;Modernization;Molecular;Mothers;Neonatal;Neonatal Screening;Newborn Infant;Nucleic Acid Amplification Tests;Nucleotides;Outcome;Pathogen detection;Pathogenicity;Patients;Perinatal;Polymerase Chain Reaction;Predictive Value;Pregnant Women;Prevalence;RNA;Reaction;Reporting;Research;Research Personnel;Resistance;Resolution;Risk;Saliva;Sampling;Simplexvirus;Specificity;Spottings;Symptoms;Techniques;Technology;Testing;Therapeutic;Therapeutic Intervention;Time;Tissues;Training;Translating;Tube;United States;Universities;Update;Urine;Variant;Viral;Viral Load result;accurate diagnosis;antimicrobial;artificial intelligence algorithm;biobank;clinical database;clinical outcome measures;clinically relevant;congenital cytomegalovirus;cost;detection limit;detection method;diagnosis standard;diagnostic biomarker;diagnostic tool;digital;disease prognosis;falls;intercalation;interdisciplinary approach;intervention program;machine learning algorithm;melting;microbial;multidisciplinary;neonatal infection;neonate;next generation sequencing;offspring;pathogen;pathogen genomics;pathogenic virus;point of care;postnatal;prevent;prospective;rapid diagnosis;reactivation from latency;resistance gene;screening program;single molecule;technology validation;timeline;transmission process\", \"abstract_text\": \"Project Summary\\\\n Congenital cytomegalovirus (cCMV) and neonatal herpes simplex virus (nHSV) impose major health threats on\\\\nneonates. Although CMV and HSV are lifelong infections with periods of latency and reactivation, most maternal\\\\ninfections remain undiagnosed due to nonspecific or absent clinical symptoms. In the United States, a child is\\\\npermanently disabled by cCMV infection every hour, even though 9 of 10 infants are asymptomatic after birth and\\\\nremain undiagnosed. Invasive nHSV, on the other hand, is a rare neonatal infection that presents with a broad\\\\nrange of clinical symptoms, including those that may be life-threatening. Viral culture and DNA detection by\\\\npolymerase chain reaction (PCR) have become the \\\\u201cGold Standard\\\\u201d for the diagnosis of cCMV and nHSV infection,\\\\ndespite poor sensitivity of PCR assays in neonates and time consuming culture techniques (up to 5-7 days).\\\\n Universal genotyping of pathogen genomic sequences using High Resolution Melt (U-HRM) provides a simple,\\\\nlow cost, rapid, and modern alternative to viral cultures and PCR techniques. By measuring the fluorescence of\\\\nan intercalating dye as PCR-amplified pathogen DNA or RNA fragments are heated and disassociate, sequence\\\\ndefined melt curves, or \\\\u201cfingerprints\\\\u201d, are generated with single-nucleotide resolution in a closed-tube reaction.\\\\nThese unique microbial \\\\u201cfingerprints\\\\u201d are then automatically identified and quantified using machine learning\\\\ntechnology, with an accuracy of 99-100% on minimal blood volume (1 mL), in a platform called NeoChip. Presently,\\\\nwe have established unique signature melt curves for 40 bacterial species and antimicrobial resistance genes that\\\\ncommonly infect neonates. Additionally, NeoChip has been expanded to distinguish individually amplified melt\\\\ncurve signatures for multiple pathogen identification and quantification, as required for polymicrobial infection.\\\\n In this proposal, we will build out NeoChip\\\\u2019s comprehensive database by incorporating clinical strains of CMV\\\\nand HSV with actionable antiviral resistance genes. Because NeoChip identifies variances in nucleic acid\\\\nsequences, individual differentiation and quantification of CMV and HSV strains are possible. We will also translate\\\\nthe NeoChip for specific and rapid diagnosis of cCMV and nHSV infection in a large prospective clinical study of\\\\npregnant women and their offspring(s), as well as directly compare the platform to standard quantitative nucleic\\\\nacid test (QNAT) assays, IgG/IgM antibody testing, and clinical outcome measures for statistical concordance\\\\n(predictive value). Finally, we will validate and translate NeoChip for cCMV detection and clinical correlation using\\\\ndried blood spot (DBS) samples for incorporation into standard universal newborn screening programs. NeoChip\\\\u2019s\\\\ngoal is to provide an accurate and valid test for the timely diagnosis of pathogen etiology (viral, bacterial, and\\\\nfungal) in a single test with efficacy on broad tissue matrices and capacity to inform microbial resistance, thereby\\\\nfacilitating early administration of targeted antimicrobials and therapeutics. This proposal directly addresses the\\\\nfunding call by applying a multidisciplinary approach to address the biomedical challenges of rapidly and accurately\\\\ndiagnosing cCMV and nHSV to facilitate disease prognostication and early therapeutic or intervention programs.\", \"project_title\": \"NeoChip for specific and rapid identification of congenital CMV and neonatal HSV infections on minimal sample volume\", \"phr_text\": \"Project Narrative\\\\nNeoChip combines real-time PCR, digital High Resolution Melting (dHRM) of DNA and RNA, and machine\\\\nlearning to create unique \\\\u201cfingerprints\\\\\" for microbes and antimicrobial resistance, allowing for faster and more\\\\nprecise detection of pathogen(s) causing neonatal infection. This project will build out NeoChip\\\\u2019s melt curve\\\\ndatabase to include clinically relevant strains of cytomegalovirus and herpes simplex virus infections, while\\\\nconcordantly assembling updated epidemiologic timelines and prevalence of perinatal CMV and HSV\\\\ntransmission. Our goals are to validate NeoChip for the rapid and specific diagnosis of congenital CMV and\\\\nneonatal HSV infection on multiple tissue matrices and translate the NeoChip platform for incorporation into\\\\nstandard universal newborn screening for the diagnosis of congenital cytomegalovirus on dried blood spot\\\\nsamples.\", \"spending_categories_desc\": \"Antimicrobial Resistance; Bioengineering; Biotechnology; Clinical Research; Conditions Affecting the Embryonic and Fetal Periods; Emerging Infectious Diseases; Genetics; Infectious Diseases; Machine Learning and Artificial Intelligence; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Prevention; Rare Diseases; Sexually Transmitted Infections\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-07-01T12:07:00Z\", \"budget_end\": \"2024-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 485321, \"indirect_cost_amt\": 30358, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10701864\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 51}, page_content='{\"appl_id\": 10874546, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5R01HD099250-05\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 485605, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HD\", \"serial_num\": \"099250\", \"support_year\": \"05\", \"full_support_year\": \"05\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10526558, \"first_name\": \"Shelley\", \"middle_name\": \"M\", \"last_name\": \"Lawrence\", \"is_contact_pi\": true, \"full_name\": \"Shelley M Lawrence\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"LAWRENCE, SHELLEY M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 485605, \"direct_cost_ic\": 457855, \"indirect_cost_ic\": 27750}], \"project_start_date\": \"2022-01-01T12:01:00Z\", \"project_end_date\": \"2025-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"ISD\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Instrumentation and Systems Development Study Section[ISD]\"}, \"award_notice_date\": \"2024-08-13T12:08:00Z\", \"core_project_num\": \"R01HD099250\", \"terms\": \"<0-11 years old><0-4 weeks old><19S Gamma Globulin><7S Gamma Globulin><AI algorithm><Address><Advocate><Anti-viral Agents><Anti-viral resistance><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Antibodies><Antimicrobial Resistance><Assay><Base Sequence><Bioassay><Biological><Biological Assay><Birth><Blinded><Blood><Blood Reticuloendothelial System><Blood Sample><Blood Volume><Blood specimen><Body Tissues><CMV><California><Causality><Child><Child Youth><Children (0-21)><Clinical><Clinical Research><Clinical Study><Collaborations><Coloring Agents><Congenital herpes simplex><Congenital herpes simplex infection><Consumption><Culture Techniques><Cytomegalovirus><DNA><Data><Data Bases><Databases><Deoxyribonucleic Acid><Detection><Diagnosis><Diagnostic><Disease><Disorder><Dryness><Dyes><Early Intervention><Early identification><Enrollment><Epidemiology><Etiology><Evaluation><Failure><Fingerprint><Fluorescence><Funding><Genome><Genomic Segment><Genotype><Goals><HCMV><HSV><HSV infection in neonates><Health><Herpes Simplex><Herpes Simplex Infections><Herpes Simplex Virus><Herpes labialis Virus><Herpes simplex disease><Herpesvirus hominis disease><Hour><IgG><IgM><Immunoglobulin G><Immunoglobulin M><Individual><Infant><Infection><Investigation><Investigators><Laboratories><Life><Machine Learning><Measures><Microbe><Miscellaneous Antibiotic><Modality><Modernization><Molecular><Mothers><NGS Method><NGS system><Neonatal><Neonatal Screening><Neonatal herpes simplex><Newborn Infant><Newborn Infant Screening><Newborns><Non-Polyadenylated RNA><Nucleic Acid Amplification Tests><Nucleic Acid Testing><Nucleotide Sequence><Nucleotides><Outcome><Parturition><Pathogen detection><Pathogenicity><Patients><Perinatal><Peripartum><Polymerase Chain Reaction><Predictive Value><Pregnant Women><Prevalence><RNA><RNA Gene Products><Reaction><Reporting><Research><Research Personnel><Researchers><Resistance><Resolution><Ribonucleic Acid><Risk><Saliva><Salivary Gland Viruses><Sampling><Simplexvirus><Specificity><Spottings><Symptoms><Techniques><Technology><Testing><Therapeutic><Therapeutic Intervention><Time><Tissues><Training><Translating><Transmission><Tube><United States><Universities><Update><Urine><Variant><Variation><Viral><Viral Burden><Viral Load><Viral Load result><accurate diagnosis><anti-microbial><anti-microbial resistant><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral resistant><anti-viral therapeutic><anti-virals><antimicrobial><artificial intelligence algorithm><biobank><biologic><biorepository><causation><clinical database><clinical outcome measures><clinical relevance><clinically relevant><congenital CMV><congenital cytomegalovirus><congenital cytomegalovirus infection><congenital herpes simplex virus infection><cost><cytomegalovirus group><data base><detection limit><detection method><detection procedure><detection technique><diagnosis standard><diagnostic biomarker><diagnostic marker><diagnostic tool><digital><disabled><disease causation><disease prognosis><disease prognostication><enroll><epidemiologic><epidemiological><expectant mother><expecting mother><genome segment><genomic region><herpes simplex virus 1 infection><herpes simplex virus infection><infected neonate><infected newborn><intercalation><interdisciplinary approach><intervention program><intervention therapy><kids><latency/reactivation><machine based learning><machine learned algorithm><machine learning algorithm><machine learning based algorithm><melting><microbial><multidisciplinary><multidisciplinary approach><neonatal HSV infection><neonatal herpes><neonatal infection><neonate><newborn child><newborn children><newborn infection><newborn screening><next gen sequencing><next generation sequencing><nextgen sequencing><nucleic acid sequence><offspring><pathogen><pathogen genomics><pathogenic virus><point of care><postnatal><pregnant mothers><prevent><preventing><prospective><rapid diagnosis><reactivation from latency><resistance gene><resistance locus><resistance to anti-microbial><resistant><resistant gene><resistant to antimicrobial><resolutions><screening program><single molecule><technology implementation><technology validation><timeline><transmission process><viral pathogen><virus pathogen><youngster>\", \"pref_terms\": \"Address;Advocate;Anti-viral Agents;Anti-viral resistance;Antibiotics;Antibodies;Antimicrobial Resistance;Base Sequence;Biological;Biological Assay;Birth;Blinded;Blood;Blood Volume;Blood specimen;California;Child;Clinical;Clinical Research;Collaborations;Congenital herpes simplex;Consumption;Culture Techniques;Cytomegalovirus;DNA;Data;Databases;Detection;Diagnosis;Diagnostic;Disease;Dryness;Dyes;Early Intervention;Early identification;Enrollment;Epidemiology;Etiology;Evaluation;Failure;Fingerprint;Fluorescence;Funding;Genome;Genomic Segment;Genotype;Goals;Health;Herpes Simplex Infections;Hour;Immunoglobulin G;Immunoglobulin M;Individual;Infant;Infection;Investigation;Laboratories;Life;Machine Learning;Measures;Microbe;Modality;Modernization;Molecular;Mothers;Neonatal;Neonatal Screening;Newborn Infant;Nucleic Acid Amplification Tests;Nucleotides;Outcome;Pathogen detection;Pathogenicity;Patients;Perinatal;Polymerase Chain Reaction;Predictive Value;Pregnant Women;Prevalence;RNA;Reaction;Reporting;Research;Research Personnel;Resistance;Resolution;Risk;Saliva;Sampling;Simplexvirus;Specificity;Spottings;Symptoms;Techniques;Technology;Testing;Therapeutic;Therapeutic Intervention;Time;Tissues;Training;Translating;Tube;United States;Universities;Update;Urine;Variant;Viral;Viral Load result;accurate diagnosis;antimicrobial;artificial intelligence algorithm;biobank;clinical database;clinical outcome measures;clinically relevant;congenital cytomegalovirus;cost;detection limit;detection method;diagnosis standard;diagnostic biomarker;diagnostic tool;digital;disabled;disease prognosis;intercalation;interdisciplinary approach;intervention program;machine learning algorithm;melting;microbial;multidisciplinary;neonatal infection;neonate;next generation sequencing;offspring;pathogen;pathogen genomics;pathogenic virus;point of care;postnatal;prevent;prospective;rapid diagnosis;reactivation from latency;resistance gene;screening program;single molecule;technology validation;timeline;transmission process\", \"abstract_text\": \"Project Summary\\\\n Congenital cytomegalovirus (cCMV) and neonatal herpes simplex virus (nHSV) impose major health threats on\\\\nneonates. Although CMV and HSV are lifelong infections with periods of latency and reactivation, most maternal\\\\ninfections remain undiagnosed due to nonspecific or absent clinical symptoms. In the United States, a child is\\\\npermanently disabled by cCMV infection every hour, even though 9 of 10 infants are asymptomatic after birth and\\\\nremain undiagnosed. Invasive nHSV, on the other hand, is a rare neonatal infection that presents with a broad\\\\nrange of clinical symptoms, including those that may be life-threatening. Viral culture and DNA detection by\\\\npolymerase chain reaction (PCR) have become the \\\\u201cGold Standard\\\\u201d for the diagnosis of cCMV and nHSV infection,\\\\ndespite poor sensitivity of PCR assays in neonates and time consuming culture techniques (up to 5-7 days).\\\\n Universal genotyping of pathogen genomic sequences using High Resolution Melt (U-HRM) provides a simple,\\\\nlow cost, rapid, and modern alternative to viral cultures and PCR techniques. By measuring the fluorescence of\\\\nan intercalating dye as PCR-amplified pathogen DNA or RNA fragments are heated and disassociate, sequence\\\\ndefined melt curves, or \\\\u201cfingerprints\\\\u201d, are generated with single-nucleotide resolution in a closed-tube reaction.\\\\nThese unique microbial \\\\u201cfingerprints\\\\u201d are then automatically identified and quantified using machine learning\\\\ntechnology, with an accuracy of 99-100% on minimal blood volume (1 mL), in a platform called NeoChip. Presently,\\\\nwe have established unique signature melt curves for 40 bacterial species and antimicrobial resistance genes that\\\\ncommonly infect neonates. Additionally, NeoChip has been expanded to distinguish individually amplified melt\\\\ncurve signatures for multiple pathogen identification and quantification, as required for polymicrobial infection.\\\\n In this proposal, we will build out NeoChip\\\\u2019s comprehensive database by incorporating clinical strains of CMV\\\\nand HSV with actionable antiviral resistance genes. Because NeoChip identifies variances in nucleic acid\\\\nsequences, individual differentiation and quantification of CMV and HSV strains are possible. We will also translate\\\\nthe NeoChip for specific and rapid diagnosis of cCMV and nHSV infection in a large prospective clinical study of\\\\npregnant women and their offspring(s), as well as directly compare the platform to standard quantitative nucleic\\\\nacid test (QNAT) assays, IgG/IgM antibody testing, and clinical outcome measures for statistical concordance\\\\n(predictive value). Finally, we will validate and translate NeoChip for cCMV detection and clinical correlation using\\\\ndried blood spot (DBS) samples for incorporation into standard universal newborn screening programs. NeoChip\\\\u2019s\\\\ngoal is to provide an accurate and valid test for the timely diagnosis of pathogen etiology (viral, bacterial, and\\\\nfungal) in a single test with efficacy on broad tissue matrices and capacity to inform microbial resistance, thereby\\\\nfacilitating early administration of targeted antimicrobials and therapeutics. This proposal directly addresses the\\\\nfunding call by applying a multidisciplinary approach to address the biomedical challenges of rapidly and accurately\\\\ndiagnosing cCMV and nHSV to facilitate disease prognostication and early therapeutic or intervention programs.\", \"project_title\": \"NeoChip for specific and rapid identification of congenital CMV and neonatal HSV infections on minimal sample volume\", \"phr_text\": \"Project Narrative\\\\nNeoChip combines real-time PCR, digital High Resolution Melting (dHRM) of DNA and RNA, and machine\\\\nlearning to create unique \\\\u201cfingerprints\\\\\" for microbes and antimicrobial resistance, allowing for faster and more\\\\nprecise detection of pathogen(s) causing neonatal infection. This project will build out NeoChip\\\\u2019s melt curve\\\\ndatabase to include clinically relevant strains of cytomegalovirus and herpes simplex virus infections, while\\\\nconcordantly assembling updated epidemiologic timelines and prevalence of perinatal CMV and HSV\\\\ntransmission. Our goals are to validate NeoChip for the rapid and specific diagnosis of congenital CMV and\\\\nneonatal HSV infection on multiple tissue matrices and translate the NeoChip platform for incorporation into\\\\nstandard universal newborn screening for the diagnosis of congenital cytomegalovirus on dried blood spot\\\\nsamples.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-07-01T12:07:00Z\", \"budget_end\": \"2025-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 457855, \"indirect_cost_amt\": 27750, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10874546\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 52}, page_content='{\"appl_id\": 10539056, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"7R01HD099250-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"7\", \"activity_code\": \"R01\", \"award_amount\": 567413, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"7\", \"activity_code\": \"R01\", \"ic_code\": \"HD\", \"serial_num\": \"099250\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10526558, \"first_name\": \"Shelley\", \"middle_name\": \"M\", \"last_name\": \"Lawrence\", \"is_contact_pi\": true, \"full_name\": \"Shelley M Lawrence\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"LAWRENCE, SHELLEY M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 567413, \"direct_cost_ic\": 501824, \"indirect_cost_ic\": 65589}], \"project_start_date\": \"2022-01-01T12:01:00Z\", \"project_end_date\": \"2025-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-21-268\", \"full_study_section\": {\"srg_code\": \"ISD\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Instrumentation and Systems Development Study Section[ISD]\"}, \"award_notice_date\": \"2022-09-09T12:09:00Z\", \"core_project_num\": \"R01HD099250\", \"terms\": \"<disabled people><individuals with disabilities><Health><Immunoglobulin G><7S Gamma Globulin><IgG><Immunoglobulin M><19S Gamma Globulin><IgM><Infant><Newborn Infant><0-4 weeks old><Newborns><newborn child><newborn children><Infection><Laboratories><Modernization><Mothers><Newborn Infant Screening><newborn screening><Neonatal Screening><Nucleotides><Patients><Polymerase Chain Reaction><expectant mother><expecting mother><pregnant mothers><Pregnant Women><Research><Investigators><Researchers><Research Personnel><Risk><Non-Polyadenylated RNA><RNA Gene Products><Ribonucleic Acid><RNA><Saliva><Sensitivity and Specificity><Technology><Testing><Time><Tissues><Body Tissues><Translating><United States><Universities><Urine><Urine Urinary System><Virus Diseases><Viral Diseases><viral infection><virus infection><virus-induced disease><Measures><TimeLine><Blinded><congenital cytomegalovirus><congenital CMV><congenital cytomegalovirus infection><Tube><base><Perinatal><Peripartum><Blood specimen><Blood Sample><Nucleic Acid Amplification Tests><Nucleic Acid Testing><Clinical><Variant><Variation><Biological><biologic><Simplexvirus><HSV><Herpes Simplex Virus><Herpes labialis Virus><Evaluation><Training><Failure><Individual><Data Bases><data base><Databases><Early Intervention><Funding><Congenital herpes simplex infection><Neonatal herpes simplex><congenital herpes simplex virus infection><neonatal herpes><Congenital herpes simplex><Therapeutic><Spottings><Diagnostic><machine learned><Machine Learning><Life><Viral Burden><Viral Load><Viral Load result><Investigation><Hour><postnatal><Reaction><Techniques><Viral><rapid diagnosis><microbial><melting><intervention program><offspring><Modality><Reporting><intervention therapy><Therapeutic Intervention><Early identification><Sampling><single molecule><diagnosis standard><Pathogenicity><preventing><prevent><Causality><causation><disease causation><Etiology><Address><Culture Techniques><Antimicrobial resistant><Resistance to antimicrobial><anti-microbial resistance><anti-microbial resistant><resistance to anti-microbial><resistant to anti-microbial><resistant to antimicrobial><Antimicrobial Resistance><Symptoms><Advocate><Data><Detection><Predictive Value><Resolution><Enrollment><enroll><Update><transmission process><Transmission><Molecular><point of care><neonate><cost><digital><viral detection><virus detection><Outcome><Neonatal><Antiviral resistance><Antiviral resistant><anti-viral resistance><anti-viral resistant><pathogen><Prevalence><prospective><Consumption><Resistance><resistant><antimicrobial><anti-microbial><Microbe><Pathogen detection><clinically relevant><clinical relevance><multidisciplinary><interdisciplinary approach><multidisciplinary approach><biobank><biorepository><next generation sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><resistance gene><resistance locus><resistant gene><accurate diagnosis><diagnostic biomarker><diagnostic marker><screening program><machine learning algorithm><machine learned algorithm><machine learning based algorithm><pathogenic virus><viral pathogen><virus pathogen><clinical database><pathogen genomics><neonatal infection><infected neonate><infected newborn><newborn infection><detection limit><detection method><detection procedure><detection technique><clinical outcome measures><disease prognosis><disease prognostication><artificial intelligence algorithm><AI algorithm><diagnostic tool><Antibiotics><Antibiotic Agents><Antibiotic Drugs><Miscellaneous Antibiotic><Antibodies><Antiviral Agents><Antiviral Drugs><Antivirals><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><Base Sequence><Nucleotide Sequence><nucleic acid sequence><Biological Assay><Assay><Bioassay><Biologic Assays><Birth><Parturition><Blood><Blood Reticuloendothelial System><Blood Volume><California><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Research><Clinical Study><Cytomegalovirus><CMV><HCMV><Salivary Gland Viruses><cytomegalovirus group><Diagnosis><Disease><Disorder><DNA><Deoxyribonucleic Acid><Dyes><Coloring Agents><Epidemiology><epidemiologic><epidemiological><Fingerprint><Fluorescence><Genome><Genotype><Goals><Gold><Disabled Persons><Disabled Population><Handicapped><People with Disabilities><Persons with Disabilities><disabled><disabled individual>\", \"pref_terms\": \"Address;Advocate;Antibiotics;Antibodies;Antimicrobial Resistance;Antiviral Agents;Antiviral resistance;Base Sequence;Biological;Biological Assay;Birth;Blinded;Blood;Blood Volume;Blood specimen;California;Child;Clinical;Clinical Research;Congenital herpes simplex;Consumption;Culture Techniques;Cytomegalovirus;DNA;Data;Databases;Detection;Diagnosis;Diagnostic;Disabled Persons;Disease;Dyes;Early Intervention;Early identification;Enrollment;Epidemiology;Etiology;Evaluation;Failure;Fingerprint;Fluorescence;Funding;Genome;Genotype;Goals;Gold;Health;Hour;Immunoglobulin G;Immunoglobulin M;Individual;Infant;Infection;Investigation;Laboratories;Life;Machine Learning;Measures;Microbe;Modality;Modernization;Molecular;Mothers;Neonatal;Neonatal Screening;Newborn Infant;Nucleic Acid Amplification Tests;Nucleotides;Outcome;Pathogen detection;Pathogenicity;Patients;Perinatal;Polymerase Chain Reaction;Predictive Value;Pregnant Women;Prevalence;RNA;Reaction;Reporting;Research;Research Personnel;Resistance;Resolution;Risk;Saliva;Sampling;Sensitivity and Specificity;Simplexvirus;Spottings;Symptoms;Techniques;Technology;Testing;Therapeutic;Therapeutic Intervention;Time;TimeLine;Tissues;Training;Translating;Tube;United States;Universities;Update;Urine;Variant;Viral;Viral Load result;Virus Diseases;accurate diagnosis;antimicrobial;artificial intelligence algorithm;base;biobank;clinical database;clinical outcome measures;clinically relevant;congenital cytomegalovirus;cost;detection limit;detection method;diagnosis standard;diagnostic biomarker;diagnostic tool;digital;disease prognosis;interdisciplinary approach;intervention program;machine learning algorithm;melting;microbial;multidisciplinary;neonatal infection;neonate;next generation sequencing;offspring;pathogen;pathogen genomics;pathogenic virus;point of care;postnatal;prevent;prospective;rapid diagnosis;resistance gene;screening program;single molecule;transmission process;viral detection\", \"abstract_text\": \"Project Summary\\\\n Congenital cytomegalovirus (cCMV) and neonatal herpes simplex virus (nHSV) impose major health threats on\\\\nneonates. Although CMV and HSV are lifelong infections with periods of latency and reactivation, most maternal\\\\ninfections remain undiagnosed due to nonspecific or absent clinical symptoms. In the United States, a child is\\\\npermanently disabled by cCMV infection every hour, even though 9 of 10 infants are asymptomatic after birth and\\\\nremain undiagnosed. Invasive nHSV, on the other hand, is a rare neonatal infection that presents with a broad\\\\nrange of clinical symptoms, including those that may be life-threatening. Viral culture and DNA detection by\\\\npolymerase chain reaction (PCR) have become the \\\\u201cGold Standard\\\\u201d for the diagnosis of cCMV and nHSV infection,\\\\ndespite poor sensitivity of PCR assays in neonates and time consuming culture techniques (up to 5-7 days).\\\\n Universal genotyping of pathogen genomic sequences using High Resolution Melt (U-HRM) provides a simple,\\\\nlow cost, rapid, and modern alternative to viral cultures and PCR techniques. By measuring the fluorescence of\\\\nan intercalating dye as PCR-amplified pathogen DNA or RNA fragments are heated and disassociate, sequence\\\\ndefined melt curves, or \\\\u201cfingerprints\\\\u201d, are generated with single-nucleotide resolution in a closed-tube reaction.\\\\nThese unique microbial \\\\u201cfingerprints\\\\u201d are then automatically identified and quantified using machine learning\\\\ntechnology, with an accuracy of 99-100% on minimal blood volume (1 mL), in a platform called NeoChip. Presently,\\\\nwe have established unique signature melt curves for 40 bacterial species and antimicrobial resistance genes that\\\\ncommonly infect neonates. Additionally, NeoChip has been expanded to distinguish individually amplified melt\\\\ncurve signatures for multiple pathogen identification and quantification, as required for polymicrobial infection.\\\\n In this proposal, we will build out NeoChip\\\\u2019s comprehensive database by incorporating clinical strains of CMV\\\\nand HSV with actionable antiviral resistance genes. Because NeoChip identifies variances in nucleic acid\\\\nsequences, individual differentiation and quantification of CMV and HSV strains are possible. We will also translate\\\\nthe NeoChip for specific and rapid diagnosis of cCMV and nHSV infection in a large prospective clinical study of\\\\npregnant women and their offspring(s), as well as directly compare the platform to standard quantitative nucleic\\\\nacid test (QNAT) assays, IgG/IgM antibody testing, and clinical outcome measures for statistical concordance\\\\n(predictive value). Finally, we will validate and translate NeoChip for cCMV detection and clinical correlation using\\\\ndried blood spot (DBS) samples for incorporation into standard universal newborn screening programs. NeoChip\\\\u2019s\\\\ngoal is to provide an accurate and valid test for the timely diagnosis of pathogen etiology (viral, bacterial, and\\\\nfungal) in a single test with efficacy on broad tissue matrices and capacity to inform microbial resistance, thereby\\\\nfacilitating early administration of targeted antimicrobials and therapeutics. This proposal directly addresses the\\\\nfunding call by applying a multidisciplinary approach to address the biomedical challenges of rapidly and accurately\\\\ndiagnosing cCMV and nHSV to facilitate disease prognostication and early therapeutic or intervention programs.\", \"project_title\": \"NeoChip for specific and rapid identification of congenital CMV and neonatal HSV infections on minimal sample volume\", \"phr_text\": \"Project Narrative\\\\nNeoChip combines real-time PCR, digital High Resolution Melting (dHRM) of DNA and RNA, and machine\\\\nlearning to create unique \\\\u201cfingerprints\\\\\" for microbes and antimicrobial resistance, allowing for faster and more\\\\nprecise detection of pathogen(s) causing neonatal infection. This project will build out NeoChip\\\\u2019s melt curve\\\\ndatabase to include clinically relevant strains of cytomegalovirus and herpes simplex virus infections, while\\\\nconcordantly assembling updated epidemiologic timelines and prevalence of perinatal CMV and HSV\\\\ntransmission. Our goals are to validate NeoChip for the rapid and specific diagnosis of congenital CMV and\\\\nneonatal HSV infection on multiple tissue matrices and translate the NeoChip platform for incorporation into\\\\nstandard universal newborn screening for the diagnosis of congenital cytomegalovirus on dried blood spot\\\\nsamples.\", \"spending_categories_desc\": \"Antimicrobial Resistance; Biotechnology; Clinical Research; Conditions Affecting the Embryonic and Fetal Periods; Emerging Infectious Diseases; Genetics; Infectious Diseases; Machine Learning and Artificial Intelligence; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Prevention; Rare Diseases; Sexually Transmitted Infections\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-07-01T12:07:00Z\", \"budget_end\": \"2023-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 501824, \"indirect_cost_amt\": 65589, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10539056\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 53}, page_content='{\"appl_id\": 10470273, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5R21HD104056-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R21\", \"award_amount\": 190625, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R21\", \"ic_code\": \"HD\", \"serial_num\": \"104056\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 7717532, \"first_name\": \"Kent\", \"middle_name\": \"\", \"last_name\": \"Lai\", \"is_contact_pi\": true, \"full_name\": \"Kent  Lai\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"LAI, KENT \", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 190625, \"direct_cost_ic\": 125000, \"indirect_cost_ic\": 65625}], \"project_start_date\": \"2021-08-17T12:08:00Z\", \"project_end_date\": \"2024-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-691\", \"full_study_section\": {\"srg_code\": \"TAG\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Therapeutic Approaches to Genetic Diseases Study Section[TAG]\"}, \"award_notice_date\": \"2022-08-26T12:08:00Z\", \"core_project_num\": \"R21HD104056\", \"terms\": \"<Affect><Age><ages><Animals><Ataxia><Ataxy><Coordination Impairment><Dyssynergia><Brain><Brain Nervous System><Encephalon><Cells><Cell Body><Clinical Trials><Cessation of life><Death><Diet><diets><Disease><Disorder><Disease susceptibility><Diathesis><liability to disease><Enzymes><Enzyme Gene><Escherichia coli><E coli><E. coli><Galactose><D-Galactose><Galactopyranose><Galactopyranoside><Galactosemias><gene therapy><DNA Therapy><Gene Transfer Clinical><Genetic Intervention><gene repair therapy><gene-based therapy><genetic therapy><genomic therapy><Glycoproteins><Goals><Growth><Generalized Growth><Tissue Growth><ontogeny><Hemorrhage><Bleeding><blood loss><Human><Modern Man><Industry><Newborn Infant><0-4 weeks old><Newborns><newborn child><newborn children><intravenous injection><Lead><Pb element><heavy metal Pb><heavy metal lead><Life Style><Lifestyle><Lipids><Liver><hepatic body system><hepatic organ system><Metabolic Diseases><Metabolic Disorder><Thesaurismosis><metabolism disorder><Metabolism><Intermediary Metabolism><Metabolic Processes><Inborn Errors of Metabolism><Hereditary Metabolic Disorder><inborn metabolism disorder><Mutant Strains Mice><mouse mutant><Mus><Mice><Mice Mammals><Murine><Spinal Muscular Atrophy><Aran-Duchenne disease><Cruveilhier disease><Mutation><Genetic Alteration><Genetic Change><Genetic defect><genome mutation><Newborn Infant Screening><newborn screening><Neonatal Screening><Neuropsychologies><neuropsychologic><Neuropsychology><oxidation><Patients><Phenotype><Inositide Phospholipids><Inositol Phosphoglycerides><Inositol Phospholipids><Phosphatidyl Inositol><Phosphoinositides><PtdIns><Phosphatidylinositols><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma><Production><Relaxation><Research><Rest><mRNA><Messenger RNA><Savings><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Signal Transduction><Testing><Tissues><Body Tissues><Translating><Tremor><United States><Work><galactose-1-phosphate><base><Organ><improved><Hepatic><Peripheral><Chronic><Clinical><premature><prematurity><Medical><insight><Hepatotoxic effect><Liver Toxicity><Toxic effect on liver cells><hepatic toxicity><hepatoxicity><Hepatotoxicity><Speech Delay><root><Plant Roots><enzyme activity><Classic Galactosemia><Galactose-1-Phosphate Uridyl-Transferase Deficiency Disease><UDPglucose Hexose-1-Phosphate Uridylyltransferase Deficiency><UTP Hexose-1-Phosphate Uridylyltransferase Deficiency><galactose 1 phosphate uridylyl transferase deficiency><Classical galactosemia><Therapeutic><Exposure to><tool><Life><diet restriction><restricted diet><dietary restriction><Hereditary><Inherited><postnatal><restoration><age group><early detection><Early Diagnosis><mutant><young animal><juvenile animal><Animal Models and Related Studies><model of animal><model organism><Animal Model><novel><Modality><Retinal Dystrophy><Intervention Strategies><interventional strategy><Intervention><Investigational Therapies><Experimental Therapies><Investigational Treatments><experimental therapeutic agents><experimental therapeutics><Online Mendelian Inheritance In Man><OMIM><Innovative Therapy><Pathogenicity><Galactose Metabolism><Galactose Metabolism Pathway><Effectiveness><Metabolic Pathway><preventing><prevent><tissue tropism><CD154><CD40L><CD40LG><TNFSF5><TRAP Gene><TNFSF5 gene><Address><Dose><Data><Predictive Value><Process><Development><developmental><disease phenotype><Sepsis><blood infection><bloodstream infection><efficacy evaluation><efficacy analysis><efficacy assessment><efficacy examination><evaluate efficacy><examine efficacy><Treatment Efficacy><intervention efficacy><therapeutic efficacy><therapy efficacy><Outcome><Neonatal><innovation><innovate><innovative><Early treatment><early therapy><mouse model><murine model><motor impairment><movement impairment><movement limitation><therapeutic development><therapeutic agent development><high risk><high reward><FDA approved><effective therapy><effective treatment><Biological Markers><bio-markers><biologic marker><biomarker><Regimen><targeted treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><primary ovarian insufficiency><Premature ovarian insufficiency><acute toxicity><screening program><subfertility><primary infertility><lipid nanoparticle><lipid based nanoparticle><side effect><treatment comparison><compare treatment><mRNA delivery><dietary>\", \"pref_terms\": \"Address;Affect;Age;Animal Model;Animals;Ataxia;Biological Markers;Brain;Cells;Cessation of life;Chronic;Classical galactosemia;Clinical;Clinical Trials;Data;Development;Diet;Disease;Disease susceptibility;Dose;Early Diagnosis;Early treatment;Effectiveness;Enzymes;Escherichia coli;Exposure to;FDA approved;Galactose;Galactose Metabolism Pathway;Galactosemias;Glycoproteins;Goals;Growth;Hemorrhage;Hepatic;Hepatotoxicity;Human;Inborn Errors of Metabolism;Industry;Inherited;Innovative Therapy;Intervention;Investigational Therapies;Lead;Life;Life Style;Lipids;Liver;Medical;Messenger RNA;Metabolic Diseases;Metabolic Pathway;Metabolism;Modality;Mus;Mutant Strains Mice;Mutation;Neonatal;Neonatal Screening;Neuropsychology;Newborn Infant;Online Mendelian Inheritance In Man;Organ;Outcome;Pathogenicity;Patients;Peripheral;Phenotype;Phosphatidylinositols;Plant Roots;Plasma;Predictive Value;Process;Production;Regimen;Relaxation;Research;Rest;Retinal Dystrophy;Savings;Sepsis;Signal Transduction;Speech Delay;Spinal Muscular Atrophy;TNFSF5 gene;Testing;Therapeutic;Tissues;Translating;Treatment Efficacy;Tremor;United States;Work;acute toxicity;age group;base;dietary;dietary restriction;disease phenotype;effective therapy;efficacy evaluation;enzyme activity;galactose-1-phosphate;gene therapy;high reward;high risk;improved;innovation;insight;intravenous injection;juvenile animal;lipid nanoparticle;mRNA delivery;motor impairment;mouse model;mutant;novel;oxidation;postnatal;premature;prevent;primary ovarian insufficiency;restoration;screening program;side effect;subfertility;targeted treatment;therapeutic development;tissue tropism;tool;treatment comparison\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\n Hereditary deficiency of galactose-1-phosphate uridylyltransferase (GALT, E.C. 2.7.7.12) activity in humans can\\\\nlead to a potentially lethal disease called Classic Galactosemia (OMIM 230400). Despite the life-saving consequences of\\\\nnewborn screening, early diagnosis, and a galactose-restricted diet, many patients with Classic Galactosemia suffer later in\\\\nlife from complications including growth, neuropsychological, and speech delays as well as primary ovarian insufficiency\\\\n(POI). There are currently no satisfactory treatments available to prevent/alleviate any of these complications. The precise\\\\npathogenic mechanisms of these complications remain unclear, although aberrant galactosylation of glycoproteins/lipids\\\\nand inositol phospholipid signaling caused by the chronic exposure to toxic intermediates of the blocked galactose metabolic\\\\npathway in susceptible tissues have been proposed. But regardless of the proposed mechanisms and any of the associated\\\\ncontroversies, no one will debate that the root cause for the disease is the deficiency of GALT enzyme activity in the affected\\\\ntissues. Therefore, we collaborated with colleagues at Moderna Inc. to explore if we could augment functional GALT\\\\nactivity in an animal model of Classic Galactosemia with an innovative GALT mRNA therapy. Specifically, we hypothesize\\\\nthat targeted augmentation of hepatic GALT activity by GALT mRNA therapy is sufficient to restore whole-body galactose\\\\nmetabolism and ameliorate the disease-relevant phenotypes in Classic Galactosemia. Preliminary results showed that\\\\nintravenous injection of human GALT mRNA in GalT-/- mice resulted in hepatic expression of active, long-lasting GALT\\\\nenzyme, which rapidly and effectively reduced gal-1P in liver and some other peripheral tissues and significantly lowered\\\\nplasma galactose. Yet, it is too early to tell if biomarker correction can lead to actual phenotypic improvements. Therefore,\\\\nwe aim to demonstrate in this application that sole augmentation of hepatic GALT activity in a mouse model of\\\\nGalactosemia is sufficient to ameliorate the disease-relevant phenotypes (Aim 1) and restore normal whole-body galactose\\\\nmetabolism (oxidation) (Aim 2). If we are successful, we will be able to advance this experimental mRNA therapy to\\\\nclinical trials (high reward), and this could bring an innovative therapy to address the unmet medical needs of the patients -\\\\na high-impact outcome. Moreover, the critical information about the optimal timing of treatment and predictive values of\\\\nthe biomarkers to be revealed in the proposed work will render significant insights to the disease process and guide the\\\\ndevelopment of other modalities, including gene therapy. Last but not least, if we can show that restoration of galactose\\\\nmetabolism in the liver can result in significant improvement of whole-body galactose oxidation, this could lead to diet\\\\nrelaxation (high impact) and such therapeutic strategy could be applied to other metabolic diseases at which targeted therapy\\\\nis preferred (wide impact).\", \"project_title\": \"Advancing a novel experimental mRNA-based therapy for Classic Galactosemia\", \"phr_text\": \"PROJECT NARRATIVE\\\\nClassic Galactosemia is a rare inborn error of metabolism that is included in all newborn screening programs in the United\\\\nStates. A galactose-restricted diet, which is currently the mainstay of treatment, can prevent neonatal lethality of the\\\\naffected patients, but has little effect on long-term complications such as primary ovarian insufficiency, tremors, and\\\\nataxia. The long-term goal of this project is to advance an innovative, experimental liver-specific GALT mRNA therapy\\\\ninto a new, safe, and more effective therapy to tackle the unmet medical needs of galactosemic patients.\", \"spending_categories_desc\": \"Biotechnology; Digestive Diseases; Genetics; Liver Disease; Nutrition; Orphan Drug; Pediatric; Prevention; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-08-01T12:08:00Z\", \"budget_end\": \"2024-07-31T12:07:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 125000, \"indirect_cost_amt\": 65625, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10470273\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 54}, page_content='{\"appl_id\": 10303541, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"1R21HD104056-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R21\", \"award_amount\": 228750, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R21\", \"ic_code\": \"HD\", \"serial_num\": \"104056\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 7717532, \"first_name\": \"Kent\", \"middle_name\": \"\", \"last_name\": \"Lai\", \"is_contact_pi\": true, \"full_name\": \"Kent  Lai\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"LAI, KENT \", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 228750, \"direct_cost_ic\": 150000, \"indirect_cost_ic\": 78750}], \"project_start_date\": \"2021-08-17T12:08:00Z\", \"project_end_date\": \"2023-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-691\", \"full_study_section\": {\"srg_code\": \"TAG\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Therapeutic Approaches to Genetic Diseases Study Section[TAG]\"}, \"award_notice_date\": \"2021-08-16T12:08:00Z\", \"core_project_num\": \"R21HD104056\", \"terms\": \"<Affect><Age><ages><Animals><Ataxia><Ataxy><Coordination Impairment><Dyssynergia><Brain><Brain Nervous System><Encephalon><Cells><Cell Body><Clinical Trials><Cessation of life><Death><Diet><diets><Disease><Disorder><Disease susceptibility><Diathesis><liability to disease><Enzymes><Enzyme Gene><Escherichia coli><E coli><E. coli><Galactose><D-Galactose><Galactopyranose><Galactopyranoside><Galactosemias><gene therapy><DNA Therapy><Gene Transfer Clinical><Genetic Intervention><gene-based therapy><genetic therapy><genomic therapy><Glycoproteins><Goals><Growth><Generalized Growth><Tissue Growth><ontogeny><Hemorrhage><Bleeding><blood loss><Human><Modern Man><Industry><Newborn Infant><0-4 weeks old><Newborns><newborn child><newborn children><intravenous injection><Lead><Pb element><heavy metal Pb><heavy metal lead><Life Style><Lifestyle><Lipids><Liver><hepatic body system><hepatic organ system><Metabolic Diseases><Metabolic Disorder><Thesaurismosis><metabolism disorder><Metabolism><Intermediary Metabolism><Metabolic Processes><Inborn Errors of Metabolism><Hereditary Metabolic Disorder><inborn metabolism disorder><Mutant Strains Mice><mouse mutant><Mus><Mice><Mice Mammals><Murine><Spinal Muscular Atrophy><Aran-Duchenne disease><Cruveilhier disease><Mutation><Genetic Alteration><Genetic Change><Genetic defect><genome mutation><Neonatal Screening><Newborn Infant Screening><newborn screening><Neuropsychology><Neuropsychologies><neuropsychologic><oxidation><Patients><Phenotype><Phosphatidylinositols><Inositide Phospholipids><Inositol Phosphoglycerides><Inositol Phospholipids><Phosphatidyl Inositol><Phosphoinositides><PtdIns><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Production><Relaxation><Research><Rest><Messenger RNA><mRNA><Savings><Signal Transduction><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Testing><Tissues><Body Tissues><Translating><Tremor><United States><Work><galactose-1-phosphate><base><Organ><improved><Hepatic><Peripheral><Chronic><Clinical><premature><prematurity><Medical><insight><Hepatotoxicity><Hepatotoxic effect><Liver Toxicity><Toxic effect on liver cells><hepatic toxicity><hepatoxicity><Speech Delay><Plant Roots><root><enzyme activity><Classical galactosemia><Classic Galactosemia><Galactose-1-Phosphate Uridyl-Transferase Deficiency Disease><UDPglucose Hexose-1-Phosphate Uridylyltransferase Deficiency><UTP Hexose-1-Phosphate Uridylyltransferase Deficiency><galactose 1 phosphate uridylyl transferase deficiency><Therapeutic><Exposure to><tool><Life><diet restriction><restricted diet><dietary restriction><Hereditary><Inherited><postnatal><restoration><age group><early detection><Early Diagnosis><mutant><young animal><juvenile animal><Animal Models and Related Studies><model of animal><model organism><Animal Model><novel><Modality><Retinal Dystrophy><Intervention Strategies><interventional strategy><Intervention><Experimental Therapies><Investigational Treatments><experimental therapeutic agents><experimental therapeutics><Investigational Therapies><OMIM><Online Mendelian Inheritance In Man><Innovative Therapy><Pathogenicity><Galactose Metabolism><Galactose Metabolism Pathway><Effectiveness><Metabolic Pathway><preventing><prevent><tissue tropism><CD154><CD40L><CD40LG><TNFSF5><TRAP Gene><TNFSF5 gene><Address><Dose><Data><Predictive Value><Process><Development><developmental><disease phenotype><Sepsis><blood infection><bloodstream infection><efficacy evaluation><efficacy analysis><efficacy assessment><efficacy examination><evaluate efficacy><examine efficacy><Treatment Efficacy><intervention efficacy><therapeutic efficacy><therapy efficacy><Outcome><Neonatal><innovation><innovate><innovative><Early treatment><early therapy><mouse model><murine model><motor impairment><movement impairment><movement limitation><therapeutic development><therapeutic agent development><high risk><high reward><FDA approved><effective therapy><effective treatment><Biological Markers><bio-markers><biologic marker><biomarker><Regimen><targeted treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><primary ovarian insufficiency><Premature ovarian insufficiency><acute toxicity><screening program><subfertility><primary infertility><lipid nanoparticle><side effect><treatment comparison><compare treatment><mRNA delivery><dietary>\", \"pref_terms\": \"Address;Affect;Age;Animal Model;Animals;Ataxia;Biological Markers;Brain;Cells;Cessation of life;Chronic;Classical galactosemia;Clinical;Clinical Trials;Data;Development;Diet;Disease;Disease susceptibility;Dose;Early Diagnosis;Early treatment;Effectiveness;Enzymes;Escherichia coli;Exposure to;FDA approved;Galactose;Galactose Metabolism Pathway;Galactosemias;Glycoproteins;Goals;Growth;Hemorrhage;Hepatic;Hepatotoxicity;Human;Inborn Errors of Metabolism;Industry;Inherited;Innovative Therapy;Intervention;Investigational Therapies;Lead;Life;Life Style;Lipids;Liver;Medical;Messenger RNA;Metabolic Diseases;Metabolic Pathway;Metabolism;Modality;Mus;Mutant Strains Mice;Mutation;Neonatal;Neonatal Screening;Neuropsychology;Newborn Infant;Online Mendelian Inheritance In Man;Organ;Outcome;Pathogenicity;Patients;Peripheral;Phenotype;Phosphatidylinositols;Plant Roots;Plasma;Predictive Value;Process;Production;Regimen;Relaxation;Research;Rest;Retinal Dystrophy;Savings;Sepsis;Signal Transduction;Speech Delay;Spinal Muscular Atrophy;TNFSF5 gene;Testing;Therapeutic;Tissues;Translating;Treatment Efficacy;Tremor;United States;Work;acute toxicity;age group;base;dietary;dietary restriction;disease phenotype;effective therapy;efficacy evaluation;enzyme activity;galactose-1-phosphate;gene therapy;high reward;high risk;improved;innovation;insight;intravenous injection;juvenile animal;lipid nanoparticle;mRNA delivery;motor impairment;mouse model;mutant;novel;oxidation;postnatal;premature;prevent;primary ovarian insufficiency;restoration;screening program;side effect;subfertility;targeted treatment;therapeutic development;tissue tropism;tool;treatment comparison\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\n Hereditary deficiency of galactose-1-phosphate uridylyltransferase (GALT, E.C. 2.7.7.12) activity in humans can\\\\nlead to a potentially lethal disease called Classic Galactosemia (OMIM 230400). Despite the life-saving consequences of\\\\nnewborn screening, early diagnosis, and a galactose-restricted diet, many patients with Classic Galactosemia suffer later in\\\\nlife from complications including growth, neuropsychological, and speech delays as well as primary ovarian insufficiency\\\\n(POI). There are currently no satisfactory treatments available to prevent/alleviate any of these complications. The precise\\\\npathogenic mechanisms of these complications remain unclear, although aberrant galactosylation of glycoproteins/lipids\\\\nand inositol phospholipid signaling caused by the chronic exposure to toxic intermediates of the blocked galactose metabolic\\\\npathway in susceptible tissues have been proposed. But regardless of the proposed mechanisms and any of the associated\\\\ncontroversies, no one will debate that the root cause for the disease is the deficiency of GALT enzyme activity in the affected\\\\ntissues. Therefore, we collaborated with colleagues at Moderna Inc. to explore if we could augment functional GALT\\\\nactivity in an animal model of Classic Galactosemia with an innovative GALT mRNA therapy. Specifically, we hypothesize\\\\nthat targeted augmentation of hepatic GALT activity by GALT mRNA therapy is sufficient to restore whole-body galactose\\\\nmetabolism and ameliorate the disease-relevant phenotypes in Classic Galactosemia. Preliminary results showed that\\\\nintravenous injection of human GALT mRNA in GalT-/- mice resulted in hepatic expression of active, long-lasting GALT\\\\nenzyme, which rapidly and effectively reduced gal-1P in liver and some other peripheral tissues and significantly lowered\\\\nplasma galactose. Yet, it is too early to tell if biomarker correction can lead to actual phenotypic improvements. Therefore,\\\\nwe aim to demonstrate in this application that sole augmentation of hepatic GALT activity in a mouse model of\\\\nGalactosemia is sufficient to ameliorate the disease-relevant phenotypes (Aim 1) and restore normal whole-body galactose\\\\nmetabolism (oxidation) (Aim 2). If we are successful, we will be able to advance this experimental mRNA therapy to\\\\nclinical trials (high reward), and this could bring an innovative therapy to address the unmet medical needs of the patients -\\\\na high-impact outcome. Moreover, the critical information about the optimal timing of treatment and predictive values of\\\\nthe biomarkers to be revealed in the proposed work will render significant insights to the disease process and guide the\\\\ndevelopment of other modalities, including gene therapy. Last but not least, if we can show that restoration of galactose\\\\nmetabolism in the liver can result in significant improvement of whole-body galactose oxidation, this could lead to diet\\\\nrelaxation (high impact) and such therapeutic strategy could be applied to other metabolic diseases at which targeted therapy\\\\nis preferred (wide impact).\", \"project_title\": \"Advancing a novel experimental mRNA-based therapy for Classic Galactosemia\", \"phr_text\": \"PROJECT NARRATIVE\\\\nClassic Galactosemia is a rare inborn error of metabolism that is included in all newborn screening programs in the United\\\\nStates. A galactose-restricted diet, which is currently the mainstay of treatment, can prevent neonatal lethality of the\\\\naffected patients, but has little effect on long-term complications such as primary ovarian insufficiency, tremors, and\\\\nataxia. The long-term goal of this project is to advance an innovative, experimental liver-specific GALT mRNA therapy\\\\ninto a new, safe, and more effective therapy to tackle the unmet medical needs of galactosemic patients.\", \"spending_categories_desc\": \"Biotechnology; Digestive Diseases; Genetics; Liver Disease; Nutrition; Orphan Drug; Pediatric; Prevention; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-08-17T12:08:00Z\", \"budget_end\": \"2022-07-31T12:07:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 150000, \"indirect_cost_amt\": 78750, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10303541\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 55}, page_content='{\"appl_id\": 10248812, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"1PL1HD105462-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"PL1\", \"award_amount\": 2413174, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"PL1\", \"ic_code\": \"HD\", \"serial_num\": \"105462\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": true, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}], \"contact_pi_name\": \"DEAN, JONATHAN MICHAEL\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 2413174, \"direct_cost_ic\": 1941165, \"indirect_cost_ic\": 472009}], \"project_start_date\": \"2021-08-13T12:08:00Z\", \"project_end_date\": \"2026-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HD-21-016\", \"full_study_section\": {\"srg_code\": \"ZHD1\", \"srg_flex\": null, \"sra_designator_code\": \"DSR\", \"sra_flex_code\": \"T\", \"group_code\": \"51\", \"name\": \"Special Emphasis Panel[ZHD1 DSR-T (51)]\"}, \"award_notice_date\": \"2021-08-12T12:08:00Z\", \"core_project_num\": \"PL1HD105462\", \"terms\": \"<Immunologic Adjuvants><Immunoactivators><Immunoadjuvants><Immunological Adjuvant><Immunopotentiators><Immunostimulants><immune adjuvant><Adult><21+ years old><Adult Human><adulthood><Biometry><Biometrics><Biostatistics><C-reactive protein><Proteins, specific or class, C-reactive><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Trials><Communication><Communities><Complement><Complement Proteins><Critical Care><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Family><Ferritin><Geography><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><immune suppression><Infant><Inflammation><Pediatric Intensive Care Units><Intervention Studies><intervention research><interventional research><interventional study><interventions research><Laboratories><Immunologic Monitoring><Immune Monitoring><Immunological Monitoring><Immunomonitoring><Morbidity - disease rate><Morbidity><mortality><Multiple Organ Failure><MOF syndrome><Multiple Organ Dysfunction Syndrome><multiorgan failure><multiple organ system failure><Patients><Phenotype><Placebos><Sham Treatment><sham therapy><Research><Research Personnel><Investigators><Researchers><Risk Factors><Science><Testing><Time><Treatment Protocols><Treatment Regimen><Treatment Schedule><Universities><Utah><Work><Granulocyte-Macrophage Colony-Stimulating Factor><GM-CSF><Histamine-Producing Cell-Stimulating Factor><Molgramostin><TC-GM-CSF><Tumor-Cell Human GM Colony-Stimulating Factor><granulocyte macrophage colony stimulating factor><Immunophenotyping><Immunologic Subtyping><immunophenotype><Measures><TimeLine><Critically ill children><critically ill child><Organ><improved><Procedures><Site><Clinical><Medical><Childhood><pediatric><Drug usage><drug use><Funding><anakinra><IL-1ra><IL1 febrile inhibitor><IL1RN><Interleukin-1 Receptor Antagonist><interleukin 1 receptor antagonist protein><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><Functional disorder><Dysfunction><Physiopathology><pathophysiology><Collaborations><Multicenter Studies><Multi-center studies><Randomized Controlled Trials><Immunological response><host response><immune system response><immunoresponse><Immune response><septic><Supportive Therapy><Supportive care><Scientist><Frequencies><Immunes><Immune><Severities><Protocol><Protocols documentation><meetings><Performance><Structure><Immunomodulation><immune modulation><immune regulation><immunologic reactivity control><immunomodulatory><immunoregulatory><immunoregulation><expectation><Position><Positioning Attribute><Admission><Admission activity><Cellular Immune Function><immune function><Address><Immune Targeting><NICHD><National Institute of Children\\'s Health and Human Development><National Institute of Child Health and Human Development><randomisation><randomization><randomly assigned><Randomized><Observational Study><Observation research><Observation study><Observational research><Development><developmental><Evidence based treatment><health related quality of life><Data Coordinating Center><Data Coordination Center><Sepsis><blood infection><bloodstream infection><clinical research site><clinical site><pathogen><innovation><innovate><innovative><racial and ethnic><ethnoracial><primary outcome><secondary outcome><adverse outcome><adverse consequence><targeted treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><improved outcome><ethnic diversity><ethnically diverse><socioeconomic diversity><socio-economic diversity><tocilizumab><Actemra>\", \"pref_terms\": \"Address;Admission activity;Adult;Biometry;C-reactive protein;Child;Childhood;Clinical;Clinical Trials;Collaborations;Communication;Communities;Complement;Critical Care;Critically ill children;Data Coordinating Center;Development;Drug usage;Evidence based treatment;Family;Ferritin;Frequencies;Functional disorder;Funding;Geography;Granulocyte-Macrophage Colony-Stimulating Factor;Immune;Immune Targeting;Immune response;Immunologic Adjuvants;Immunologic Monitoring;Immunophenotyping;Immunosuppression;Infant;Inflammation;Intervention Studies;Laboratories;Measures;Medical;Morbidity - disease rate;Multicenter Studies;Multiple Organ Failure;National Institute of Child Health and Human Development;Observational Study;Organ;Patients;Pediatric Intensive Care Units;Performance;Pharmaceutical Preparations;Phenotype;Placebos;Positioning Attribute;Procedures;Protocols documentation;Randomized;Randomized Controlled Trials;Research;Research Personnel;Risk Factors;Science;Scientist;Sepsis;Severities;Site;Structure;Supportive care;Testing;Time;TimeLine;Treatment Protocols;Universities;Utah;Work;adverse outcome;anakinra;clinical research site;ethnic diversity;expectation;health related quality of life;immune function;immunoregulation;improved;improved outcome;innovation;meetings;mortality;pathogen;primary outcome;racial and ethnic;secondary outcome;septic;socioeconomic diversity;targeted treatment;tocilizumab\", \"abstract_text\": \"Project Summary\\\\n In 2005, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\\\\nestablished the Collaborative Pediatric Critical Care Research Network (CPCCRN) to support multi-institutional\\\\nrandomized controlled trials (RCTs) and observational studies in critically ill children. This PL1 proposal from the\\\\nUniversity of Utah is submitted on behalf of a newly con\\\\ufb01gured CPCCRN network increased to 12 Clinical Sites\\\\nand 12 ancillary sites with > 61,000 annual ICU admissions. The expanded network has geographic, racial/ethnic\\\\nand socioeconomic diversity, and will be a platform to develop additional investigators, especially young clinician\\\\nscientists. The network will conduct a highly innovative large-scale multi-center study of personalized, targeted\\\\nimmune modulation in children with sepsis-induced multiple organ dysfunction syndrome (MODS). The study\\\\nincludes two concurrent, immunophenotype-driven placebo controlled RCTs that will address the central hypoth-\\\\nesis that individualized, pathophysiology-speci\\\\ufb01c immunomodulation will improve outcomes from sepsis-induced\\\\nMODS in children. This study builds on R01-funded CPCCRN studies that have demonstrated the existence of\\\\nspeci\\\\ufb01c immune phenotypes among children with sepsis-induced MODS (R01GM108618 PI: Carcillo) and suc-\\\\ncessful reversal of immunosuppression by administration of the immunostimulant granulocyte macrophage-colony\\\\nstimulating factor (GM-CSF) (R01GM094203 PI: Hall). It also complements the ongoing NICHD R01-funded study\\\\ninvestigating the risk factors for immunoparalysis in pediatric MODS (R01HD095976 MPI: Hall, Zuppa).\\\\n This application has three speci\\\\ufb01c aims: (1) Implement the CPCCRN organization; (2) Mount a comprehen-\\\\nsive strategy for development of young clinician scientists and submission of rigorous proposals to fund additional\\\\nresearch in critical care; (3) Conduct the Personalized Immunomodulation in Sepsis-induced MODS study. The\\\\n\\\\ufb01rst trial focuses on the use of the drug GM-CSF for the reversal of immunoparalysis. The second trial uses\\\\nadaptive randomization and focuses on the drugs anakinra and tocilizumab for the targeted treatment of hyper-\\\\nin\\\\ufb02ammation. The primary outcome of both trials will be duration and severity of organ dysfunction using the\\\\ncumulative PELOD-2 score, and secondary outcomes will assess health related quality of life and family function-\\\\ning at 3 and 12 months.\\\\n The Personalized Immunomodulation in Sepsis-Induced MODS study represents a paradigm shift in the man-\\\\nagement of pediatric sepsis, \\\\ufb01nally moving beyond simple supportive care. We are uniquely positioned to suc-\\\\ncessfully execute this approach to personalized, real-time, pathophysiology-directed sepsis treatment, leveraging\\\\nthe strengths of a diverse and highly accomplished group of investigators to deliver high-impact science to the\\\\nbene\\\\ufb01t of our patients and our \\\\ufb01eld.\", \"project_title\": \"Collaborative Pediatric Critical Care Research Network\", \"phr_text\": \"Project Narrative\\\\n The Collaborative Pediatric Critical Care Research Network (CPCCRN) includes 24 pediatric intensive care\\\\nunits and an established Data Coordinating Center with independent medical and biostatistical expertise. Build-\\\\ning on its strong track record of successful clinical trials and innovative work in immune phenotyping in pediatric\\\\nsepsis, the CPCCRN will carry out a large-scale multicenter randomized controlled trial using personalized test-\\\\ning and targeted management of immune function in infants and children with sepsis-induced multiple organ\\\\ndysfunction syndrome (MODS), one of the most frequent causes of mortality and morbidity in critical care.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2021-08-13T12:08:00Z\", \"budget_end\": \"2022-07-31T12:07:00Z\", \"funding_mechanism\": \"Research Centers\", \"direct_cost_amt\": 1941165, \"indirect_cost_amt\": 472009, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10248812\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 56}, page_content='{\"appl_id\": 10468842, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5PL1HD105462-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"PL1\", \"award_amount\": 2412756, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"PL1\", \"ic_code\": \"HD\", \"serial_num\": \"105462\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": true, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}], \"contact_pi_name\": \"DEAN, JONATHAN MICHAEL\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 2412756, \"direct_cost_ic\": 2039276, \"indirect_cost_ic\": 373480}], \"project_start_date\": \"2021-08-13T12:08:00Z\", \"project_end_date\": \"2026-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HD-21-016\", \"full_study_section\": {\"srg_code\": \"ZHD1\", \"srg_flex\": null, \"sra_designator_code\": \"DSR\", \"sra_flex_code\": \"T\", \"group_code\": \"51\", \"name\": \"ZHD1-DSR-T(51)\"}, \"award_notice_date\": \"2022-07-21T12:07:00Z\", \"core_project_num\": \"PL1HD105462\", \"terms\": \"<septic><Supportive Therapy><Supportive care><Scientist><Frequencies><Immunes><Immune><Severities><Protocol><Protocols documentation><meetings><Performance><Structure><Immunomodulation><immune modulation><immune regulation><immunologic reactivity control><immunomodulatory><immunoregulatory><immunoregulation><expectation><Position><Positioning Attribute><Admission><Admission activity><Cellular Immune Function><immune function><Address><Immune Targeting><NICHD><National Institute of Children\\'s Health and Human Development><National Institute of Child Health and Human Development><randomisation><randomization><randomly assigned><Randomized><Observational Study><Observation research><Observation study><Observational research><Development><developmental><Placebo Control><placebo controlled><Evidence based treatment><health related quality of life><Data Coordinating Center><Data Coordination Center><Sepsis><blood infection><bloodstream infection><clinical research site><clinical site><pathogen><innovation><innovate><innovative><racial and ethnic><ethnoracial><primary outcome><secondary outcome><adverse outcome><adverse consequence><targeted treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><improved outcome><ethnic diversity><ethnically diverse><socioeconomic diversity><socio-economic diversity><tocilizumab><Actemra><pediatric sepsis><sepsis in children><pediatric septic><Immunologic Adjuvants><Immunoactivators><Immunoadjuvants><Immunological Adjuvant><Immunopotentiators><Immunostimulants><immune adjuvant><Adult><21+ years old><Adult Human><adulthood><Biometry><Biometrics><Biostatistics><C-reactive protein><Proteins, specific or class, C-reactive><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Trials><Communication><Communities><Complement><Complement Proteins><Critical Care><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Family><Ferritin><Geography><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><immune suppression><immune suppressive activity><immune suppressive function><immunosuppressive activity><immunosuppressive function><Infant><Inflammation><Pediatric Intensive Care Units><Intervention Studies><intervention research><interventional research><interventional study><interventions research><Laboratories><Immunologic Monitoring><Immune Monitoring><Immunological Monitoring><Immunomonitoring><Morbidity - disease rate><Morbidity><mortality><Multiple Organ Failure><MOF syndrome><Multiple Organ Dysfunction Syndrome><multiorgan failure><multiple organ system failure><Patients><Phenotype><Research><Investigators><Researchers><Research Personnel><Risk Factors><Science><Testing><Time><Treatment Protocols><Treatment Regimen><Treatment Schedule><Universities><Utah><Work><Granulocyte-Macrophage Colony-Stimulating Factor><GM-CSF><Histamine-Producing Cell-Stimulating Factor><Molgramostin><TC-GM-CSF><Tumor-Cell Human GM Colony-Stimulating Factor><granulocyte macrophage colony stimulating factor><Immunophenotyping><Immunologic Subtyping><immunophenotype><Measures><TimeLine><Critically ill children><critically ill child><Organ><improved><Procedures><Site><Clinical><Medical><pediatric><Childhood><drug use><Drug usage><Funding><IL-1ra><IL1 febrile inhibitor><IL1RN><Interleukin-1 Receptor Antagonist><interleukin 1 receptor antagonist protein><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><anakinra><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Collaborations><Multi-center studies><Multicenter Studies><randomized control trial><Randomized Controlled Trials><Immunological response><host response><immune system response><immunoresponse><Immune response>\", \"pref_terms\": \"Address;Admission activity;Adult;Biometry;C-reactive protein;Child;Childhood;Clinical;Clinical Trials;Collaborations;Communication;Communities;Complement;Critical Care;Critically ill children;Data Coordinating Center;Development;Drug usage;Evidence based treatment;Family;Ferritin;Frequencies;Functional disorder;Funding;Geography;Granulocyte-Macrophage Colony-Stimulating Factor;Immune;Immune Targeting;Immune response;Immunologic Adjuvants;Immunologic Monitoring;Immunophenotyping;Immunosuppression;Infant;Inflammation;Intervention Studies;Laboratories;Measures;Medical;Morbidity - disease rate;Multicenter Studies;Multiple Organ Failure;National Institute of Child Health and Human Development;Observational Study;Organ;Patients;Pediatric Intensive Care Units;Performance;Pharmaceutical Preparations;Phenotype;Placebo Control;Positioning Attribute;Procedures;Protocols documentation;Randomized;Randomized Controlled Trials;Research;Research Personnel;Risk Factors;Science;Scientist;Sepsis;Severities;Site;Structure;Supportive care;Testing;Time;TimeLine;Treatment Protocols;Universities;Utah;Work;adverse outcome;anakinra;clinical research site;ethnic diversity;expectation;health related quality of life;immune function;immunoregulation;improved;improved outcome;innovation;meetings;mortality;pathogen;pediatric sepsis;primary outcome;racial and ethnic;secondary outcome;septic;socioeconomic diversity;targeted treatment;tocilizumab\", \"abstract_text\": \"Project Summary\\\\n In 2005, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\\\\nestablished the Collaborative Pediatric Critical Care Research Network (CPCCRN) to support multi-institutional\\\\nrandomized controlled trials (RCTs) and observational studies in critically ill children. This PL1 proposal from the\\\\nUniversity of Utah is submitted on behalf of a newly con\\\\ufb01gured CPCCRN network increased to 12 Clinical Sites\\\\nand 12 ancillary sites with > 61,000 annual ICU admissions. The expanded network has geographic, racial/ethnic\\\\nand socioeconomic diversity, and will be a platform to develop additional investigators, especially young clinician\\\\nscientists. The network will conduct a highly innovative large-scale multi-center study of personalized, targeted\\\\nimmune modulation in children with sepsis-induced multiple organ dysfunction syndrome (MODS). The study\\\\nincludes two concurrent, immunophenotype-driven placebo controlled RCTs that will address the central hypoth-\\\\nesis that individualized, pathophysiology-speci\\\\ufb01c immunomodulation will improve outcomes from sepsis-induced\\\\nMODS in children. This study builds on R01-funded CPCCRN studies that have demonstrated the existence of\\\\nspeci\\\\ufb01c immune phenotypes among children with sepsis-induced MODS (R01GM108618 PI: Carcillo) and suc-\\\\ncessful reversal of immunosuppression by administration of the immunostimulant granulocyte macrophage-colony\\\\nstimulating factor (GM-CSF) (R01GM094203 PI: Hall). It also complements the ongoing NICHD R01-funded study\\\\ninvestigating the risk factors for immunoparalysis in pediatric MODS (R01HD095976 MPI: Hall, Zuppa).\\\\n This application has three speci\\\\ufb01c aims: (1) Implement the CPCCRN organization; (2) Mount a comprehen-\\\\nsive strategy for development of young clinician scientists and submission of rigorous proposals to fund additional\\\\nresearch in critical care; (3) Conduct the Personalized Immunomodulation in Sepsis-induced MODS study. The\\\\n\\\\ufb01rst trial focuses on the use of the drug GM-CSF for the reversal of immunoparalysis. The second trial uses\\\\nadaptive randomization and focuses on the drugs anakinra and tocilizumab for the targeted treatment of hyper-\\\\nin\\\\ufb02ammation. The primary outcome of both trials will be duration and severity of organ dysfunction using the\\\\ncumulative PELOD-2 score, and secondary outcomes will assess health related quality of life and family function-\\\\ning at 3 and 12 months.\\\\n The Personalized Immunomodulation in Sepsis-Induced MODS study represents a paradigm shift in the man-\\\\nagement of pediatric sepsis, \\\\ufb01nally moving beyond simple supportive care. We are uniquely positioned to suc-\\\\ncessfully execute this approach to personalized, real-time, pathophysiology-directed sepsis treatment, leveraging\\\\nthe strengths of a diverse and highly accomplished group of investigators to deliver high-impact science to the\\\\nbene\\\\ufb01t of our patients and our \\\\ufb01eld.\", \"project_title\": \"Collaborative Pediatric Critical Care Research Network\", \"phr_text\": \"Project Narrative\\\\n The Collaborative Pediatric Critical Care Research Network (CPCCRN) includes 24 pediatric intensive care\\\\nunits and an established Data Coordinating Center with independent medical and biostatistical expertise. Build-\\\\ning on its strong track record of successful clinical trials and innovative work in immune phenotyping in pediatric\\\\nsepsis, the CPCCRN will carry out a large-scale multicenter randomized controlled trial using personalized test-\\\\ning and targeted management of immune function in infants and children with sepsis-induced multiple organ\\\\ndysfunction syndrome (MODS), one of the most frequent causes of mortality and morbidity in critical care.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2022-08-01T12:08:00Z\", \"budget_end\": \"2023-07-31T12:07:00Z\", \"funding_mechanism\": \"Research Centers\", \"direct_cost_amt\": 2039276, \"indirect_cost_amt\": 373480, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10468842\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 57}, page_content='{\"appl_id\": 10915491, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5PL1HD105462-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"PL1\", \"award_amount\": 2572115, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"PL1\", \"ic_code\": \"HD\", \"serial_num\": \"105462\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 2572115, \"direct_cost_ic\": 2191847, \"indirect_cost_ic\": 380268}], \"project_start_date\": \"2021-08-13T12:08:00Z\", \"project_end_date\": \"2026-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HD-21-016\", \"full_study_section\": {\"srg_code\": \"ZHD1\", \"srg_flex\": null, \"sra_designator_code\": \"DSR\", \"sra_flex_code\": \"T\", \"group_code\": \"51\", \"name\": \"ZHD1-DSR-T(51)\"}, \"award_notice_date\": \"2024-08-14T12:08:00Z\", \"core_project_num\": \"PL1HD105462\", \"terms\": \"<0-11 years old><21+ years old><Actemra><Admission><Admission activity><Adult><Adult Human><Biometrics><Biometry><Biostatistics><C-reactive protein><Cellular Immune Function><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Trials><Collaborations><Communication><Community Health Care><Community Healthcare><Critical Care><Critically ill children><Data Coordinating Center><Data Coordination Center><Development><Drug usage><Drugs><Dysfunction><Ethnic Origin><Ethnicity><Evidence based treatment><Family><Ferritin><Frequencies><Functional disorder><Funding><GM-CSF><Geography><Granulocyte-Macrophage Colony-Stimulating Factor><Histamine-Producing Cell-Stimulating Factor><IL-1ra><IL1 febrile inhibitor><IL1RN><Immune><Immune Monitoring><Immune Targeting><Immune response><Immunes><Immunoactivators><Immunoadjuvants><Immunologic Adjuvants><Immunologic Monitoring><Immunologic Subtyping><Immunological Monitoring><Immunological response><Immunomodulation><Immunomonitoring><Immunophenotyping><Immunopotentiators><Immunostimulants><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Infant><Inflammation><Institution><Interleukin-1 Receptor Antagonist><Intervention Studies><Investigators><Laboratories><MOF syndrome><Measures><Medical><Medication><Molgramostin><Morbidity><Morbidity - disease rate><Multi-center studies><Multicenter Studies><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><NICHD><National Institute of Child Health and Human Development><National Institute of Children\\'s Health and Human Development><Observation research><Observation study><Observational Study><Observational research><Organ><Patients><Pediatric Intensive Care Units><Performance><Pharmaceutical Preparations><Phenotype><Physiopathology><Placebo Control><Position><Positioning Attribute><Procedures><Proteins, specific or class, C-reactive><Protocol><Protocols documentation><Race><Races><Randomized><Randomized, Controlled Trials><Research><Research Personnel><Researchers><Risk Factors><Science><Scientist><Sepsis><Severities><Site><Structure><Supportive Therapy><Supportive care><TC-GM-CSF><Testing><Time><Treatment Protocols><Treatment Regimen><Treatment Schedule><Tumor-Cell Human GM Colony-Stimulating Factor><Universities><Utah><Work><adulthood><adverse consequence><adverse outcome><anakinra><blood infection><bloodstream infection><clinical research site><clinical site><community care><critically ill child><data management and coordinating center><data management center><developmental><drug use><drug/agent><expectation><granulocyte macrophage colony stimulating factor><health assessment><health related quality of life><host response><immune function><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immunologic reactivity control><immunomodulatory><immunophenotype><immunoregulation><immunoregulatory><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><improved outcome><innovate><innovation><innovative><interleukin 1 receptor antagonist protein><intervention research><interventional research><interventional study><interventions research><kids><meeting><meetings><mortality><multiorgan failure><multiple organ system failure><pathogen><pathophysiology><pediatric><pediatric sepsis><pediatric septic><placebo controlled><primary outcome><racial><racial background><racial origin><randomisation><randomization><randomized control trial><randomly assigned><secondary outcome><sepsis in children><septic><socio-economic diversity><socioeconomic diversity><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><timeline><tocilizumab><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><youngster>\", \"pref_terms\": \"Admission activity;Adult;Biometry;C-reactive protein;Child;Childhood;Clinical;Clinical Trials;Collaborations;Communication;Community Healthcare;Critical Care;Critically ill children;Data Coordinating Center;Development;Drug usage;Ethnic Origin;Evidence based treatment;Family;Ferritin;Frequencies;Functional disorder;Funding;Geography;Granulocyte-Macrophage Colony-Stimulating Factor;Immune;Immune Targeting;Immune response;Immunologic Adjuvants;Immunologic Monitoring;Immunophenotyping;Immunosuppression;Infant;Inflammation;Institution;Intervention Studies;Laboratories;Measures;Medical;Morbidity - disease rate;Multicenter Studies;Multiple Organ Failure;National Institute of Child Health and Human Development;Observational Study;Organ;Patients;Pediatric Intensive Care Units;Performance;Pharmaceutical Preparations;Phenotype;Placebo Control;Positioning Attribute;Procedures;Protocols documentation;Race;Randomized;Randomized, Controlled Trials;Research;Research Personnel;Risk Factors;Science;Scientist;Sepsis;Severities;Site;Structure;Supportive care;Testing;Time;Treatment Protocols;Universities;Utah;Work;adverse outcome;anakinra;clinical research site;expectation;health assessment;health related quality of life;immune function;immunoregulation;improved;improved outcome;innovation;meetings;mortality;pathogen;pediatric sepsis;primary outcome;secondary outcome;septic;socioeconomic diversity;targeted treatment;timeline;tocilizumab\", \"abstract_text\": \"Project Summary\\\\n In 2005, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\\\\nestablished the Collaborative Pediatric Critical Care Research Network (CPCCRN) to support multi-institutional\\\\nrandomized controlled trials (RCTs) and observational studies in critically ill children. This PL1 proposal from the\\\\nUniversity of Utah is submitted on behalf of a newly con\\\\ufb01gured CPCCRN network increased to 12 Clinical Sites\\\\nand 12 ancillary sites with > 61,000 annual ICU admissions. The expanded network has geographic, racial/ethnic\\\\nand socioeconomic diversity, and will be a platform to develop additional investigators, especially young clinician\\\\nscientists. The network will conduct a highly innovative large-scale multi-center study of personalized, targeted\\\\nimmune modulation in children with sepsis-induced multiple organ dysfunction syndrome (MODS). The study\\\\nincludes two concurrent, immunophenotype-driven placebo controlled RCTs that will address the central hypoth-\\\\nesis that individualized, pathophysiology-speci\\\\ufb01c immunomodulation will improve outcomes from sepsis-induced\\\\nMODS in children. This study builds on R01-funded CPCCRN studies that have demonstrated the existence of\\\\nspeci\\\\ufb01c immune phenotypes among children with sepsis-induced MODS (R01GM108618 PI: Carcillo) and suc-\\\\ncessful reversal of immunosuppression by administration of the immunostimulant granulocyte macrophage-colony\\\\nstimulating factor (GM-CSF) (R01GM094203 PI: Hall). It also complements the ongoing NICHD R01-funded study\\\\ninvestigating the risk factors for immunoparalysis in pediatric MODS (R01HD095976 MPI: Hall, Zuppa).\\\\n This application has three speci\\\\ufb01c aims: (1) Implement the CPCCRN organization; (2) Mount a comprehen-\\\\nsive strategy for development of young clinician scientists and submission of rigorous proposals to fund additional\\\\nresearch in critical care; (3) Conduct the Personalized Immunomodulation in Sepsis-induced MODS study. The\\\\n\\\\ufb01rst trial focuses on the use of the drug GM-CSF for the reversal of immunoparalysis. The second trial uses\\\\nadaptive randomization and focuses on the drugs anakinra and tocilizumab for the targeted treatment of hyper-\\\\nin\\\\ufb02ammation. The primary outcome of both trials will be duration and severity of organ dysfunction using the\\\\ncumulative PELOD-2 score, and secondary outcomes will assess health related quality of life and family function-\\\\ning at 3 and 12 months.\\\\n The Personalized Immunomodulation in Sepsis-Induced MODS study represents a paradigm shift in the man-\\\\nagement of pediatric sepsis, \\\\ufb01nally moving beyond simple supportive care. We are uniquely positioned to suc-\\\\ncessfully execute this approach to personalized, real-time, pathophysiology-directed sepsis treatment, leveraging\\\\nthe strengths of a diverse and highly accomplished group of investigators to deliver high-impact science to the\\\\nbene\\\\ufb01t of our patients and our \\\\ufb01eld.\", \"project_title\": \"Collaborative Pediatric Critical Care Research Network\", \"phr_text\": \"Project Narrative\\\\n The Collaborative Pediatric Critical Care Research Network (CPCCRN) includes 24 pediatric intensive care\\\\nunits and an established Data Coordinating Center with independent medical and biostatistical expertise. Build-\\\\ning on its strong track record of successful clinical trials and innovative work in immune phenotyping in pediatric\\\\nsepsis, the CPCCRN will carry out a large-scale multicenter randomized controlled trial using personalized test-\\\\ning and targeted management of immune function in infants and children with sepsis-induced multiple organ\\\\ndysfunction syndrome (MODS), one of the most frequent causes of mortality and morbidity in critical care.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-08-01T12:08:00Z\", \"budget_end\": \"2025-07-31T12:07:00Z\", \"funding_mechanism\": \"Research Centers\", \"direct_cost_amt\": 2191847, \"indirect_cost_amt\": 380268, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10915491\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 58}, page_content='{\"appl_id\": 10670222, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5PL1HD105462-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"PL1\", \"award_amount\": 2412756, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"PL1\", \"ic_code\": \"HD\", \"serial_num\": \"105462\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": false, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 2412756, \"direct_cost_ic\": 2039276, \"indirect_cost_ic\": 373480}], \"project_start_date\": \"2021-08-13T12:08:00Z\", \"project_end_date\": \"2026-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HD-21-016\", \"full_study_section\": {\"srg_code\": \"ZHD1\", \"srg_flex\": null, \"sra_designator_code\": \"DSR\", \"sra_flex_code\": \"T\", \"group_code\": \"51\", \"name\": \"ZHD1-DSR-T(51)\"}, \"award_notice_date\": \"2023-08-28T12:08:00Z\", \"core_project_num\": \"PL1HD105462\", \"terms\": \"<Immunoactivators><Immunoadjuvants><Immunological Adjuvant><Immunopotentiators><Immunostimulants><immune adjuvant><Immunologic Adjuvants><21+ years old><Adult Human><adulthood><Adult><Biometry><Biometrics><Biostatistics><C-reactive protein><Proteins, specific or class, C-reactive><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Clinical Trials><Communication><Complement><Complement Proteins><Critical Care><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Family><Ferritin><Geography><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><immune suppression><immune suppressive activity><immune suppressive function><immunosuppressive activity><immunosuppressive function><immunosuppressive response><Infant><Inflammation><Pediatric Intensive Care Units><Intervention Studies><intervention research><interventional research><interventional study><interventions research><Laboratories><Immunologic Monitoring><Immune Monitoring><Immunological Monitoring><Immunomonitoring><Morbidity - disease rate><Morbidity><mortality><Multiple Organ Failure><MOF syndrome><Multiple Organ Dysfunction Syndrome><multiorgan failure><multiple organ system failure><Patients><Phenotype><Race><Races><racial><racial background><racial origin><Research><Research Personnel><Investigators><Researchers><Risk Factors><Science><Testing><Time><Treatment Protocols><Treatment Regimen><Treatment Schedule><Universities><Utah><Work><Granulocyte-Macrophage Colony-Stimulating Factor><GM-CSF><Histamine-Producing Cell-Stimulating Factor><Molgramostin><TC-GM-CSF><Tumor-Cell Human GM Colony-Stimulating Factor><granulocyte macrophage colony stimulating factor><Immunophenotyping><Immunologic Subtyping><immunophenotype><Measures><Community Health Care><community care><Community Healthcare><timeline><critically ill child><Critically ill children><Organ><improved><Procedures><Site><Clinical><Medical><pediatric><Childhood><drug use><Drug usage><Funding><Ethnicity><Ethnic Origin><IL-1ra><IL1 febrile inhibitor><IL1RN><Interleukin-1 Receptor Antagonist><interleukin 1 receptor antagonist protein><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><anakinra><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Collaborations><Multi-center studies><Multicenter Studies><randomized control trial><Randomized, Controlled Trials><Immunological response><host response><immune system response><immunoresponse><Immune response><septic><Supportive care><Supportive Therapy><Scientist><Frequencies><Immune><Immunes><Severities><Protocols documentation><Protocol><meetings><meeting><Performance><Structure><immunoregulation><Immunomodulation><immune modulation><immune regulation><immunologic reactivity control><immunomodulatory><immunoregulatory><expectation><Positioning Attribute><Position><Admission activity><Admission><Cellular Immune Function><immune function><Institution><Immune Targeting><National Institute of Child Health and Human Development><NICHD><National Institute of Children\\'s Health and Human Development><Randomized><randomisation><randomization><randomly assigned><Observational Study><Observation research><Observation study><Observational research><Development><developmental><Placebo Control><placebo controlled><Evidence based treatment><health related quality of life><Data Coordination Center><data management and coordinating center><data management center><Data Coordinating Center><blood infection><bloodstream infection><Sepsis><clinical site><clinical research site><pathogen><innovate><innovative><innovation><primary outcome><secondary outcome><adverse consequence><adverse outcome><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><improved outcome><health assessment><socio-economic diversity><socioeconomic diversity><Actemra><tocilizumab><pediatric sepsis><pediatric septic><sepsis in children>\", \"pref_terms\": \"Admission activity;Adult;Biometry;C-reactive protein;Child;Childhood;Clinical;Clinical Trials;Collaborations;Communication;Community Healthcare;Complement;Critical Care;Critically ill children;Data Coordinating Center;Development;Drug usage;Ethnic Origin;Evidence based treatment;Family;Ferritin;Frequencies;Functional disorder;Funding;Geography;Granulocyte-Macrophage Colony-Stimulating Factor;Immune;Immune Targeting;Immune response;Immunologic Adjuvants;Immunologic Monitoring;Immunophenotyping;Immunosuppression;Infant;Inflammation;Institution;Intervention Studies;Laboratories;Measures;Medical;Morbidity - disease rate;Multicenter Studies;Multiple Organ Failure;National Institute of Child Health and Human Development;Observational Study;Organ;Patients;Pediatric Intensive Care Units;Performance;Pharmaceutical Preparations;Phenotype;Placebo Control;Positioning Attribute;Procedures;Protocols documentation;Race;Randomized;Randomized, Controlled Trials;Research;Research Personnel;Risk Factors;Science;Scientist;Sepsis;Severities;Site;Structure;Supportive care;Testing;Time;Treatment Protocols;Universities;Utah;Work;adverse outcome;anakinra;clinical research site;expectation;health assessment;health related quality of life;immune function;immunoregulation;improved;improved outcome;innovation;meetings;mortality;pathogen;pediatric sepsis;primary outcome;secondary outcome;septic;socioeconomic diversity;targeted treatment;timeline;tocilizumab\", \"abstract_text\": \"Project Summary\\\\n In 2005, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\\\\nestablished the Collaborative Pediatric Critical Care Research Network (CPCCRN) to support multi-institutional\\\\nrandomized controlled trials (RCTs) and observational studies in critically ill children. This PL1 proposal from the\\\\nUniversity of Utah is submitted on behalf of a newly con\\\\ufb01gured CPCCRN network increased to 12 Clinical Sites\\\\nand 12 ancillary sites with > 61,000 annual ICU admissions. The expanded network has geographic, racial/ethnic\\\\nand socioeconomic diversity, and will be a platform to develop additional investigators, especially young clinician\\\\nscientists. The network will conduct a highly innovative large-scale multi-center study of personalized, targeted\\\\nimmune modulation in children with sepsis-induced multiple organ dysfunction syndrome (MODS). The study\\\\nincludes two concurrent, immunophenotype-driven placebo controlled RCTs that will address the central hypoth-\\\\nesis that individualized, pathophysiology-speci\\\\ufb01c immunomodulation will improve outcomes from sepsis-induced\\\\nMODS in children. This study builds on R01-funded CPCCRN studies that have demonstrated the existence of\\\\nspeci\\\\ufb01c immune phenotypes among children with sepsis-induced MODS (R01GM108618 PI: Carcillo) and suc-\\\\ncessful reversal of immunosuppression by administration of the immunostimulant granulocyte macrophage-colony\\\\nstimulating factor (GM-CSF) (R01GM094203 PI: Hall). It also complements the ongoing NICHD R01-funded study\\\\ninvestigating the risk factors for immunoparalysis in pediatric MODS (R01HD095976 MPI: Hall, Zuppa).\\\\n This application has three speci\\\\ufb01c aims: (1) Implement the CPCCRN organization; (2) Mount a comprehen-\\\\nsive strategy for development of young clinician scientists and submission of rigorous proposals to fund additional\\\\nresearch in critical care; (3) Conduct the Personalized Immunomodulation in Sepsis-induced MODS study. The\\\\n\\\\ufb01rst trial focuses on the use of the drug GM-CSF for the reversal of immunoparalysis. The second trial uses\\\\nadaptive randomization and focuses on the drugs anakinra and tocilizumab for the targeted treatment of hyper-\\\\nin\\\\ufb02ammation. The primary outcome of both trials will be duration and severity of organ dysfunction using the\\\\ncumulative PELOD-2 score, and secondary outcomes will assess health related quality of life and family function-\\\\ning at 3 and 12 months.\\\\n The Personalized Immunomodulation in Sepsis-Induced MODS study represents a paradigm shift in the man-\\\\nagement of pediatric sepsis, \\\\ufb01nally moving beyond simple supportive care. We are uniquely positioned to suc-\\\\ncessfully execute this approach to personalized, real-time, pathophysiology-directed sepsis treatment, leveraging\\\\nthe strengths of a diverse and highly accomplished group of investigators to deliver high-impact science to the\\\\nbene\\\\ufb01t of our patients and our \\\\ufb01eld.\", \"project_title\": \"Collaborative Pediatric Critical Care Research Network\", \"phr_text\": \"Project Narrative\\\\n The Collaborative Pediatric Critical Care Research Network (CPCCRN) includes 24 pediatric intensive care\\\\nunits and an established Data Coordinating Center with independent medical and biostatistical expertise. Build-\\\\ning on its strong track record of successful clinical trials and innovative work in immune phenotyping in pediatric\\\\nsepsis, the CPCCRN will carry out a large-scale multicenter randomized controlled trial using personalized test-\\\\ning and targeted management of immune function in infants and children with sepsis-induced multiple organ\\\\ndysfunction syndrome (MODS), one of the most frequent causes of mortality and morbidity in critical care.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2023-08-01T12:08:00Z\", \"budget_end\": \"2024-07-31T12:07:00Z\", \"funding_mechanism\": \"Research Centers\", \"direct_cost_amt\": 2039276, \"indirect_cost_amt\": 373480, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10670222\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 59}, page_content='{\"appl_id\": 10884070, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"3PL1HD105462-03S1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"3\", \"activity_code\": \"PL1\", \"award_amount\": 173992, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"3\", \"activity_code\": \"PL1\", \"ic_code\": \"HD\", \"serial_num\": \"105462\", \"support_year\": \"03\", \"full_support_year\": \"03S1\", \"suffix_code\": \"S1\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": true, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}], \"contact_pi_name\": \"DEAN, JONATHAN MICHAEL\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 173992, \"direct_cost_ic\": 162073, \"indirect_cost_ic\": 11919}], \"project_start_date\": \"2021-08-13T12:08:00Z\", \"project_end_date\": \"2026-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-272\", \"full_study_section\": {\"srg_code\": \"ZHD1\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"51\", \"name\": \"ZHD1(51)\"}, \"award_notice_date\": \"2023-09-11T12:09:00Z\", \"core_project_num\": \"PL1HD105462\", \"terms\": \"<Acceleration><Adoption><21+ years old><Adult Human><adulthood><Adult><Biological Assay><Assay><Bioassay><Biologic Assays><Cells><Cell Body><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Child Care><Puericulture><Communities><Critical Care><Cessation of life><Death><Diagnosis><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Flow Cytometry><Flow Cytofluorometries><Flow Cytofluorometry><Flow Microfluorimetry><Flow Microfluorometry><flow cytophotometry><Future><HLA Antigens><HL-A Antigens><Human Leukocyte Antigens><Leukocyte Antigens><HLA-DR Antigens><HLA-BR><HLA-BR Antigens><HLA-D-Related Antigens><HLA-DR><HLA-MT><HLA-MT Antigens><Immune Tolerance><Immunologic Tolerance><immune system tolerance><immune unresponsiveness><immunological paralysis><Immunological Diagnosis><Immunodiagnoses><Immunodiagnosis><Immunologic Diagnosis><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><immune suppression><immune suppressive activity><immune suppressive function><immunosuppressive activity><immunosuppressive function><immunosuppressive response><Laboratories><Lipopolysaccharides><Methods><monocyte><Blood monocyte><Marrow monocyte><Morbidity - disease rate><Morbidity><mortality><Movement><body movement><Multiple Organ Failure><MOF syndrome><Multiple Organ Dysfunction Syndrome><multiorgan failure><multiple organ system failure><Patients><Phenotype><Placebos><Sham Treatment><sham therapy><Production><Research><Research Design><Study Type><study design><Testing><Time><cytokine><Granulocyte-Macrophage Colony-Stimulating Factor><GM-CSF><Histamine-Producing Cell-Stimulating Factor><Molgramostin><TC-GM-CSF><Tumor-Cell Human GM Colony-Stimulating Factor><granulocyte macrophage colony stimulating factor><Immunophenotyping><Immunologic Subtyping><immunophenotype><Measures><Data Set><Caring><critically ill child><Critically ill children><Organ><Blood Sample><Blood specimen><Site><Surface><Clinical><Antigen Presentation><Evaluation><Failure><pediatric><Childhood><Logistics><Measurement><Funding><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Therapeutic><septic><Diagnostic><Whole Blood><Adopted><Immune><Immunes><Event><Protocols documentation><Protocol><Route><Equation><cohort><immunological status><immunoregulation><Immunomodulation><immune modulation><immune regulation><immunologic reactivity control><immunomodulatory><immunoregulatory><Study Subject><TNF gene><(TNF)-\\\\u03b1><Cachectin><Macrophage-Derived TNF><Monocyte-Derived TNF><TNF><TNF A><TNF Alpha><TNF-\\\\u03b1><TNFA><TNF\\\\u03b1><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Sampling><response><Manufacturer><Dose><Administrative Supplement><Data><National Institute of Child Health and Human Development><NICHD><National Institute of Children\\'s Health and Human Development><Collection><cost><Data Coordination Center><data management and coordinating center><data management center><Data Coordinating Center><designing><design><blood infection><bloodstream infection><Sepsis><Outcome><FDA approved><primary outcome><response to therapy><response to treatment><therapeutic response><therapy response><treatment response><routine care><efficacy testing><innate immune function><adverse consequence><adverse outcome><temporal resolution><time measurement><temporal measurement><predictive outcomes><predictors of outcomes><outcome prediction><improved outcome><medical diagnostic><clinical diagnostics><intervention arm><treatment arm><pediatric sepsis><pediatric septic><sepsis in children><diagnostic tool><Immunologic Stimulation><Immunological Stimulation><Immunostimulation><immunostimulatory therapy><immunostimulatory treatment>\", \"pref_terms\": \"Acceleration;Administrative Supplement;Adopted;Adoption;Adult;Antigen Presentation;Biological Assay;Blood specimen;Caring;Cells;Cessation of life;Child;Child Care;Childhood;Clinical;Collection;Communities;Critical Care;Critically ill children;Data;Data Coordinating Center;Data Set;Diagnosis;Diagnostic;Dose;Equation;Evaluation;Event;FDA approved;Failure;Flow Cytometry;Functional disorder;Funding;Future;Granulocyte-Macrophage Colony-Stimulating Factor;HLA Antigens;HLA-DR Antigens;Immune;Immune Tolerance;Immunologic Stimulation;Immunological Diagnosis;Immunophenotyping;Immunosuppression;Laboratories;Lipopolysaccharides;Logistics;Manufacturer;Measurement;Measures;Methods;Morbidity - disease rate;Movement;Multiple Organ Failure;National Institute of Child Health and Human Development;Organ;Outcome;Patients;Pharmaceutical Preparations;Phenotype;Placebos;Production;Protocols documentation;Research;Research Design;Route;Sampling;Sepsis;Site;Study Subject;Surface;TNF gene;Testing;Therapeutic;Time;Whole Blood;adverse outcome;clinical diagnostics;cohort;cost;cytokine;design;diagnostic tool;efficacy testing;immunological status;immunoregulation;immunostimulatory therapy;improved outcome;innate immune function;monocyte;mortality;outcome prediction;pediatric sepsis;primary outcome;response;routine care;septic;temporal measurement;treatment arm;treatment response\", \"abstract_text\": \"Project Summary/Abstract\\\\nThe Personalized Immunomodulation in Pediatric Sepsis-induced MODS (PRECISE) study that is currently\\\\nbeing conducted by the NICHD\\\\u2019s Collaborative Pediatric Critical Care Research Network (CPCCRN) uses real-\\\\ntime immune phenotyping to assign subjects to treatment or observational cohorts based on their immune\\\\nstatus. The 24-site, 1000-subject PRECISE study currently uses the whole blood ex vivo LPS-induced TNF\\\\u03b1\\\\nproduction capacity (TNF\\\\u03b1 response) assay to diagnose severe innate immune suppression, termed\\\\n\\\\u201cimmunoparalysis\\\\u201d. An alternative approach to diagnosing immunoparalysis is the measurement of the\\\\nexpression of the antigen-presenting molecule HLA-DR on the surface of circulating monocytes (mHLA-DR)\\\\nusing flow cytometry. The current application proposes the addition of mHLA-DR expression measurement,\\\\nwhich is now much more feasible for multi-center use than at the time of the original study design, to the\\\\nPRECISE immunophenotyping panel. Though mHLA-DR expression will not be used to drive cohort\\\\nassignment, its addition will allow for the evaluation of mHLA-DR expression as a potential diagnostic tool that\\\\ncould drive treatment in the future. This is important because there are currently no FDA-approved laboratory\\\\ntests for the diagnosis of immunoparalysis, and if the PRECISE study is positive, there is currently no way to\\\\nrapidly generalize its results. The addition of mHLA-DR expression to the dataset provides a unique and time-\\\\nlimited opportunity to understand if thresholds of mHLA-DR expression exist that equate to the TNF\\\\u03b1 response\\\\ncutoff used in the PRECISE study; and to understand if mHLA-DR expression can serve as a predictor of a\\\\nfavorable response to GM-CSF. If positive, this could greatly accelerate the movement of immunoparalysis\\\\ndiagnostics to the clinical laboratory, to the benefit of critically ill children.\", \"project_title\": \"CPCCRN PRECISE Supplement\", \"phr_text\": \"Project Narrative\\\\nRelevance\\\\nSevere immune failure, termed immunoparalysis, is a common feature of sepsis-induced multiple organ\\\\ndysfunction syndrome (MODS) in children, yet there are no FDA-approved assays to diagnose\\\\nimmunoparalysis. The Personalized Immunomodulation in Pediatric Sepsis-induced MODS (PRECISE) study\\\\nuses real-time immune phenotyping to assign subjects to treatment arms based on their immune status, using\\\\nthe TNF\\\\u03b1 response to diagnose immune paralysis. We propose to add the measurement of monocyte HLA-\\\\nDR expression to the PRECISE immune phenotyping panel in hopes of provide an alternate route by which\\\\nimmunoparalysis testing can move more quickly to the clinical laboratory.\", \"spending_categories_desc\": \"Clinical Research; Clinical Trials and Supportive Activities; Hematology; Infectious Diseases; Pediatric; Sepsis\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-08-01T12:08:00Z\", \"budget_end\": \"2024-07-31T12:07:00Z\", \"funding_mechanism\": \"Research Centers\", \"direct_cost_amt\": 162073, \"indirect_cost_amt\": 11919, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10884070\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 60}, page_content='{\"appl_id\": 11160050, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"3PL1HD105462-04S1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"3\", \"activity_code\": \"PL1\", \"award_amount\": 150000, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"3\", \"activity_code\": \"PL1\", \"ic_code\": \"HD\", \"serial_num\": \"105462\", \"support_year\": \"04\", \"full_support_year\": \"04S1\", \"suffix_code\": \"S1\"}, \"principal_investigators\": [{\"profile_id\": 1963922, \"first_name\": \"Jonathan\", \"middle_name\": \"Michael\", \"last_name\": \"Dean\", \"is_contact_pi\": false, \"full_name\": \"Jonathan Michael Dean\", \"title\": \"PROFESSOR OF PEDIATRICS\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"OD\", \"name\": \"NIH Office of the Director\", \"abbreviation\": \"OD\", \"total_cost\": 150000, \"direct_cost_ic\": 97403, \"indirect_cost_ic\": 52597}], \"project_start_date\": \"2021-08-13T12:08:00Z\", \"project_end_date\": \"2026-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HD-21-016\", \"full_study_section\": {\"srg_code\": \"ZHD1\", \"srg_flex\": null, \"sra_designator_code\": \"DSR\", \"sra_flex_code\": \"T\", \"group_code\": \"51\", \"name\": \"ZHD1-DSR-T(51)\"}, \"award_notice_date\": \"2024-08-15T12:08:00Z\", \"core_project_num\": \"PL1HD105462\", \"terms\": \"<0-11 years old><21+ years old><Actemra><Admission><Admission activity><Adult><Adult Human><Biometrics><Biometry><Biostatistics><C-reactive protein><Cellular Immune Function><Child><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Trials><Collaborations><Communication><Community Health Care><Community Healthcare><Critical Care><Critically ill children><Data Coordinating Center><Data Coordination Center><Development><Drug usage><Drugs><Dysfunction><Ethnic Origin><Ethnicity><Evidence based treatment><Family><Ferritin><Frequencies><Functional disorder><Funding><GM-CSF><Geography><Granulocyte-Macrophage Colony-Stimulating Factor><Histamine-Producing Cell-Stimulating Factor><IL-1ra><IL1 febrile inhibitor><IL1RN><Immune><Immune Monitoring><Immune Targeting><Immune response><Immunes><Immunoactivators><Immunoadjuvants><Immunologic Adjuvants><Immunologic Monitoring><Immunologic Subtyping><Immunological Monitoring><Immunological response><Immunomodulation><Immunomonitoring><Immunophenotyping><Immunopotentiators><Immunostimulants><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Infant><Inflammation><Institution><Interleukin-1 Receptor Antagonist><Intervention Studies><Investigators><Laboratories><MOF syndrome><Measures><Medical><Medication><Molgramostin><Morbidity><Morbidity - disease rate><Multi-center studies><Multicenter Studies><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><NICHD><National Institute of Child Health and Human Development><National Institute of Children\\'s Health and Human Development><Observation research><Observation study><Observational Study><Observational research><Organ><Patients><Pediatric Intensive Care Units><Performance><Pharmaceutical Preparations><Phenotype><Physiopathology><Placebo Control><Position><Positioning Attribute><Procedures><Proteins, specific or class, C-reactive><Protocol><Protocols documentation><Race><Races><Randomized><Randomized, Controlled Trials><Research><Research Personnel><Researchers><Risk Factors><Science><Scientist><Sepsis><Severities><Site><Structure><Supportive Therapy><Supportive care><TC-GM-CSF><Testing><Time><Treatment Protocols><Treatment Regimen><Treatment Schedule><Tumor-Cell Human GM Colony-Stimulating Factor><Universities><Utah><Work><adulthood><adverse consequence><adverse outcome><anakinra><blood infection><bloodstream infection><clinical research site><clinical site><community care><critically ill child><data management and coordinating center><data management center><developmental><drug use><drug/agent><expectation><granulocyte macrophage colony stimulating factor><health assessment><health related quality of life><host response><immune function><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immunologic reactivity control><immunomodulatory><immunophenotype><immunoregulation><immunoregulatory><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><improved><improved outcome><innovate><innovation><innovative><interleukin 1 receptor antagonist protein><intervention research><interventional research><interventional study><interventions research><kids><meeting><meetings><mortality><multiorgan failure><multiple organ system failure><pathogen><pathophysiology><pediatric><pediatric sepsis><pediatric septic><placebo controlled><primary outcome><racial><racial background><racial origin><randomisation><randomization><randomized control trial><randomly assigned><secondary outcome><sepsis in children><septic><socio-economic diversity><socioeconomic diversity><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><timeline><tocilizumab><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><youngster>\", \"pref_terms\": \"Admission activity;Adult;Biometry;C-reactive protein;Child;Childhood;Clinical;Clinical Trials;Collaborations;Communication;Community Healthcare;Critical Care;Critically ill children;Data Coordinating Center;Development;Drug usage;Ethnic Origin;Evidence based treatment;Family;Ferritin;Frequencies;Functional disorder;Funding;Geography;Granulocyte-Macrophage Colony-Stimulating Factor;Immune;Immune Targeting;Immune response;Immunologic Adjuvants;Immunologic Monitoring;Immunophenotyping;Immunosuppression;Infant;Inflammation;Institution;Intervention Studies;Laboratories;Measures;Medical;Morbidity - disease rate;Multicenter Studies;Multiple Organ Failure;National Institute of Child Health and Human Development;Observational Study;Organ;Patients;Pediatric Intensive Care Units;Performance;Pharmaceutical Preparations;Phenotype;Placebo Control;Positioning Attribute;Procedures;Protocols documentation;Race;Randomized;Randomized, Controlled Trials;Research;Research Personnel;Risk Factors;Science;Scientist;Sepsis;Severities;Site;Structure;Supportive care;Testing;Time;Treatment Protocols;Universities;Utah;Work;adverse outcome;anakinra;clinical research site;expectation;health assessment;health related quality of life;immune function;immunoregulation;improved;improved outcome;innovation;meetings;mortality;pathogen;pediatric sepsis;primary outcome;secondary outcome;septic;socioeconomic diversity;targeted treatment;timeline;tocilizumab\", \"abstract_text\": \"Project Summary\\\\n In 2005, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\\\\nestablished the Collaborative Pediatric Critical Care Research Network (CPCCRN) to support multi-institutional\\\\nrandomized controlled trials (RCTs) and observational studies in critically ill children. This PL1 proposal from the\\\\nUniversity of Utah is submitted on behalf of a newly con\\\\ufb01gured CPCCRN network increased to 12 Clinical Sites\\\\nand 12 ancillary sites with > 61,000 annual ICU admissions. The expanded network has geographic, racial/ethnic\\\\nand socioeconomic diversity, and will be a platform to develop additional investigators, especially young clinician\\\\nscientists. The network will conduct a highly innovative large-scale multi-center study of personalized, targeted\\\\nimmune modulation in children with sepsis-induced multiple organ dysfunction syndrome (MODS). The study\\\\nincludes two concurrent, immunophenotype-driven placebo controlled RCTs that will address the central hypoth-\\\\nesis that individualized, pathophysiology-speci\\\\ufb01c immunomodulation will improve outcomes from sepsis-induced\\\\nMODS in children. This study builds on R01-funded CPCCRN studies that have demonstrated the existence of\\\\nspeci\\\\ufb01c immune phenotypes among children with sepsis-induced MODS (R01GM108618 PI: Carcillo) and suc-\\\\ncessful reversal of immunosuppression by administration of the immunostimulant granulocyte macrophage-colony\\\\nstimulating factor (GM-CSF) (R01GM094203 PI: Hall). It also complements the ongoing NICHD R01-funded study\\\\ninvestigating the risk factors for immunoparalysis in pediatric MODS (R01HD095976 MPI: Hall, Zuppa).\\\\n This application has three speci\\\\ufb01c aims: (1) Implement the CPCCRN organization; (2) Mount a comprehen-\\\\nsive strategy for development of young clinician scientists and submission of rigorous proposals to fund additional\\\\nresearch in critical care; (3) Conduct the Personalized Immunomodulation in Sepsis-induced MODS study. The\\\\n\\\\ufb01rst trial focuses on the use of the drug GM-CSF for the reversal of immunoparalysis. The second trial uses\\\\nadaptive randomization and focuses on the drugs anakinra and tocilizumab for the targeted treatment of hyper-\\\\nin\\\\ufb02ammation. The primary outcome of both trials will be duration and severity of organ dysfunction using the\\\\ncumulative PELOD-2 score, and secondary outcomes will assess health related quality of life and family function-\\\\ning at 3 and 12 months.\\\\n The Personalized Immunomodulation in Sepsis-Induced MODS study represents a paradigm shift in the man-\\\\nagement of pediatric sepsis, \\\\ufb01nally moving beyond simple supportive care. We are uniquely positioned to suc-\\\\ncessfully execute this approach to personalized, real-time, pathophysiology-directed sepsis treatment, leveraging\\\\nthe strengths of a diverse and highly accomplished group of investigators to deliver high-impact science to the\\\\nbene\\\\ufb01t of our patients and our \\\\ufb01eld.\", \"project_title\": \"Collaborative Pediatric Critical Care Research Network\", \"phr_text\": \"Project Narrative\\\\n The Collaborative Pediatric Critical Care Research Network (CPCCRN) includes 24 pediatric intensive care\\\\nunits and an established Data Coordinating Center with independent medical and biostatistical expertise. Build-\\\\ning on its strong track record of successful clinical trials and innovative work in immune phenotyping in pediatric\\\\nsepsis, the CPCCRN will carry out a large-scale multicenter randomized controlled trial using personalized test-\\\\ning and targeted management of immune function in infants and children with sepsis-induced multiple organ\\\\ndysfunction syndrome (MODS), one of the most frequent causes of mortality and morbidity in critical care.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-08-01T12:08:00Z\", \"budget_end\": \"2025-07-31T12:07:00Z\", \"funding_mechanism\": \"Research Centers\", \"direct_cost_amt\": 97403, \"indirect_cost_amt\": 52597, \"project_detail_url\": \"https://reporter.nih.gov/project-details/11160050\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 61}, page_content='{\"appl_id\": 10195141, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"1R21NS121491-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R21\", \"award_amount\": 419375, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R21\", \"ic_code\": \"NS\", \"serial_num\": \"121491\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 9880566, \"first_name\": \"Michelle\", \"middle_name\": \"Elena\", \"last_name\": \"Schober\", \"is_contact_pi\": true, \"full_name\": \"Michelle Elena Schober\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"SCHOBER, MICHELLE ELENA\", \"agency_ic_admin\": {\"code\": \"NS\", \"abbreviation\": \"NINDS\", \"name\": \"National Institute of Neurological Disorders and Stroke\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 419375, \"direct_cost_ic\": 275000, \"indirect_cost_ic\": 144375}], \"project_start_date\": \"2021-05-01T12:05:00Z\", \"project_end_date\": \"2023-10-31T12:10:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-18-358\", \"full_study_section\": {\"srg_code\": \"NOMD\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Neural Oxidative Metabolism and Death Study Section[NOMD]\"}, \"award_notice_date\": \"2021-04-20T12:04:00Z\", \"core_project_num\": \"R21NS121491\", \"terms\": \"<Adult><21+ years old><Adult Human><adulthood><Age><ages><Anatomy><Anatomic><Anatomic Sites><Anatomic structures><Anatomical Sciences><Antioxidants><anti-oxidant><Astrocytes><Astrocytus><Astroglia><astrocytic glia><Biological Assay><Assay><Bioassay><Biologic Assays><Brain><Brain Nervous System><Encephalon><Cell membrane><Cytoplasmic Membrane><Plasma Membrane><plasmalemma><Cells><Cell Body><Cerebrospinal Fluid><cerebral spinal fluid><spinal fluid><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Research><Clinical Study><Clinical Trials><DNA><Deoxyribonucleic Acid><Docosahexaenoic Acids><Docosahexaenoate><Docosahexenoic Acids><Encephalitis><Brain Inflammation><Essential Fatty Acids><Free Radicals><Future><Histology><Human><Modern Man><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><In Vitro><Infant><Inflammation><Light><Photoradiation><Lipids><Methodology><Mus><Mice><Mice Mammals><Murine><neurofilament><Neurons><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><neuronal><Nutritive Value><Biologic Nutritional Availability><Nutritional Availability><Nutritional Biological Availability><nutrient bioavailability><Proteins><Rattus><Common Rat Strains><Rat><Rats Mammals><Rodent><Rodentia><Rodents Mammals><Role><social role><Safety><Family suidae><Pigs><Suidae><Swine><porcine><suid><Testing><Urine><Urine Urinary System><cresyl violet><Fast Blue><cytokine><Measures><Acute Brain Injuries><Injury><injuries><base><Blood specimen><Blood Sample><improved><Acute><Clinical><Neurologic><Neurological><Microglia><Hortega cell><gitter cell><mesoglia><microglial cell><microgliocyte><perivascular glial cell><Serum><Blood Serum><disability><Childhood><pediatric><dietary supplements><diet supplement><nutritional supplement><Oxidative Stress><Neuroprotective Agents><Neuroprotectants><Neuroprotective Drugs><chemokine><Chemotactic Cytokines><Homologous Chemotactic Cytokines><Intercrines><SIS cytokines><chemoattractant cytokine><Exposure to><Inflammatory><Knowledge><Immunes><Immune><Severities><brain cell><double bond><pi bond><nerve cell death><nerve cell loss><neuron cell death><neuron cell loss><neuron death><neuronal cell death><neuronal cell loss><neuronal death><neuronal loss><neuron loss><Cellular injury><cell damage><cellular damage><damage to cells><injury to cells><cell injury><Animal Models and Related Studies><model of animal><model organism><Animal Model><Toxicities><Toxic effect><substantia alba><white matter><Nervous System Injuries><Nervous System damage><Neurological Damage><Neurological Injury><Neurological trauma><neurotrauma><Nervous System Trauma><Interventional trial><Intervention Trial><Modeling><Sampling><Property><Brain Trauma><traumatic brain damage><Traumatic Brain Injury><Isoprostanes><Inflammatory Response><Enteric><Enteral><Address><Dose><Data><Intake><Preclinical Models><Pre-Clinical Model><randomisation><randomization><randomly assigned><Randomized><Sum><Clinical Data><research clinical testing><Clinical Evaluation><Clinical Testing><clinical test><Nutritional><nutritious><Monitor><Development><developmental><pre-clinical><preclinical><white matter injury><white matter damage><sham surgery><fluid percussion injury><rapid growth><design><designing><functional outcomes><innovation><innovate><innovative><clinically relevant><clinical relevance><pup><effective therapy><effective treatment><Biological Markers><bio-markers><biologic marker><biomarker><oxidative damage><oxidative injury><phase 2 study><phase II study><pediatric traumatic brain injury><pediatric TBI><phase II trial><phase 2 trial><translational model><biomarker performance><biomarker utility>\", \"pref_terms\": \"Acute;Acute Brain Injuries;Address;Adult;Age;Anatomy;Animal Model;Antioxidants;Astrocytes;Biological Assay;Biological Markers;Blood specimen;Brain;Cell membrane;Cells;Cerebrospinal Fluid;Child;Childhood;Clinical;Clinical Data;Clinical Research;Clinical Trials;DNA;Data;Development;Docosahexaenoic Acids;Dose;Encephalitis;Enteral;Essential Fatty Acids;Exposure to;Family suidae;Fast Blue;Free Radicals;Future;Histology;Human;Immune;Immunohistochemistry;In Vitro;Infant;Inflammation;Inflammatory;Inflammatory Response;Injury;Intake;Intervention Trial;Isoprostanes;Knowledge;Light;Lipids;Measures;Methodology;Microglia;Modeling;Monitor;Mus;Nervous System Trauma;Neurologic;Neurons;Neuroprotective Agents;Nutritional;Nutritive Value;Oxidative Stress;Pre-Clinical Model;Property;Proteins;Randomized;Rattus;Rodent;Role;Safety;Sampling;Serum;Severities;Sum;Testing;Toxic effect;Traumatic Brain Injury;Urine;base;biomarker performance;brain cell;cell injury;chemokine;clinically relevant;cresyl violet;cytokine;design;dietary supplements;disability;effective therapy;fluid percussion injury;functional outcomes;improved;innovation;neurofilament;neuron loss;oxidative damage;pediatric traumatic brain injury;phase 2 study;phase II trial;pi bond;pre-clinical;pup;rapid growth;research clinical testing;sham surgery;translational model;white matter;white matter damage;white matter injury\", \"abstract_text\": \"PROJECT SUMMARY\\\\nTraumatic brain injury (TBI) is the leading cause of acquired neurologic disability in children. Agents that\\\\ndecrease oxidative stress and inflammation may decrease neurologic disability after TBI, particularly in\\\\nchildren. Docosahexaenoic Acid, or DHA, is a candidate therapy for childhood TBI. In our established rat pup\\\\nmodel of pediatric TBI, DHA improved functional outcome and decreased brain oxidative stress, white matter\\\\ninjury and inflammation. DHA is available as a nutritional supplement for infants and children. However, DHA\\\\ncannot be tested in clinical TBI trials until critical knowledge gaps are breached. Effects of DHA on oxidative\\\\nstress, white matter integrity and inflammation in the human brain after TBI are unknown, as are data on\\\\noptimal DHA dosing in humans after TBI. DHA safety and efficacy in the immature brain cannot be predicted\\\\nbased on adult studies. Relative to the adult brain, the immature brain has a more vigorous inflammatory\\\\nresponse and a lesser antioxidant capacity. DHA is a direct antioxidant, but at high doses its numerous double\\\\nbonds could instead magnify free radical damage after pediatric TBI. We propose to address these unknowns\\\\nusing fluid-percussion injury (FPI) in the piglet, a well-established model of pediatric TBI. Immature pig and\\\\nhuman brains share striking nutritional, anatomic and developmental similarities. Piglet FPI, unlike rodent TBI,\\\\nallows clinically relevant monitoring using serial cerebrospinal fluid (CSF), urine and blood sampling. We have\\\\ncharacterized piglet FPI of moderate severity and established a methodology of DHA administration and\\\\nbiofluid sampling. We hypothesize that acute DHA administration will decrease oxidative stress, white matter\\\\ndamage and inflammation, associated with biomarkers of efficacy and toxicity, in piglets after FPI. We will use\\\\n4-week old piglets exposed to FPI or SHAM surgery, treated with one of two DHA doses (40 or 200mg/kg/day)\\\\nor vehicle (VEH). We will measure biomarkers of oxidative stress, white matter damage and inflammation in\\\\nCSF, urine and blood samples taken at 1, 3 and 7 days after FPI. We will compare biomarker results between\\\\nDHA dosing groups, and to day 7 brain assays of neuronal death, white matter damage, inflammation and\\\\noxidative injury to proteins, lipids and DNA in the brain. This proposal is significant because it will lay the\\\\ngroundwork for efficacy and safety monitoring during future clinical trials of candidate neuroprotectants, such\\\\nas DHA, in children after TBI by providing data on DHA dosing and biomarkers of efficacy and toxicity in a\\\\ntranslational model. It is innovative because little is known about DHA after acute brain injury during\\\\ndevelopment or about the utility of biomarkers in pediatric TBI. It will impact the field by providing clinically\\\\nrelevant measures of efficacy and safety needed to design a Phase II trial and, ultimately, an interventional trial\\\\nof DHA with the potential to decrease the burden of acquired neurologic injury after pediatric TBI.\", \"project_title\": \"Effects of Docosahexaenoic Acid on Oxidative Stress White Matter Injury and Brain Inflammation in a Pre-Clinical Model of Pediatric TBI\", \"phr_text\": \"PROJECT NARRATIVE\\\\nTraumatic brain injury (TBI) is the leading cause of acquired disability in children, yet no effective therapies\\\\nexist. We will study effects of Docosahexaenoic Acid (DHA) on inflammation, white matter damage and\\\\noxidative stress in the piglet after TBI to guide future clinical testing of DHA as a therapy for childhood TBI.\", \"spending_categories_desc\": \"Brain Disorders; Childhood Injury; Complementary and Integrative Health; Dietary Supplements; Neurosciences; Pediatric; Physical Injury - Accidents and Adverse Effects; Rare Diseases; Traumatic Brain Injury (TBI); Traumatic Head and Spine Injury; Unintentional Childhood Injury\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-05-01T12:05:00Z\", \"budget_end\": \"2023-10-31T12:10:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 275000, \"indirect_cost_amt\": 144375, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10195141\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 62}, page_content='{\"appl_id\": 10106090, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"1R03HD104001-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R03\", \"award_amount\": 76250, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R03\", \"ic_code\": \"HD\", \"serial_num\": \"104001\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12365437, \"first_name\": \"Ron\", \"middle_name\": \"William\", \"last_name\": \"Reeder\", \"is_contact_pi\": true, \"full_name\": \"Ron William Reeder\", \"title\": \"BIOSTATISTICIAN III\"}], \"contact_pi_name\": \"REEDER, RON WILLIAM\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 76250, \"direct_cost_ic\": 50000, \"indirect_cost_ic\": 26250}], \"project_start_date\": \"2021-04-06T12:04:00Z\", \"project_end_date\": \"2023-03-31T12:03:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-17-299\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": \"A\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Pediatrics Study Section[CHHD-A]\"}, \"award_notice_date\": \"2021-04-06T12:04:00Z\", \"core_project_num\": \"R03HD104001\", \"terms\": \"<Affect><Age><ages><Biometry><Biometrics><Biostatistics><Cause of Death><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Child Care><Puericulture><Clinical Investigator><Clinical Protocols><Clinical Trials><Communities><Data Analyses><Data Analysis><data interpretation><Cessation of life><Death><Evaluation Studies><Faculty><Family><Fluid Balance><Fluid Homeostasis><Foundations><Goals><Hospitalization><Hospital Admission><Pediatric Hospitals><Children\\'s Hospital><Immune System Diseases><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immunodeficiency and Immunosuppression Disorders><Immunologic Diseases><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Pediatric Intensive Care Units><Leadership><Mentors><Mentorship><Mission><Morbidity - disease rate><Morbidity><mortality><United States National Institutes of Health><NIH><National Institutes of Health><Public Health><Publishing><Quality of life><QOL><Research><Research Personnel><Investigators><Researchers><Risk><Septic Shock><Testing><Generations><Caregivers><Care Givers><Hospital Mortality><In-house Mortalities><Inhospital Mortality><Family Caregiver><Family Care Giver><Mediating><Outcomes Research><physically handicapped><physical disability><physically disabled><Data Set><Dataset><Caring><Journals><Magazine><Organ><improved><Chronic><Clinical><Adolescent><Adolescent Youth><juvenile><juvenile human><Survivors><Evaluation><disability><Childhood><pediatric><Individual><Fostering><Databases><Data Bases><data base><Funding><Functional disorder><Dysfunction><Physiopathology><pathophysiology><Knowledge><Life><disease severity><Severity of illness><experience><functional status><Manuscripts><Environmental Factor><environmental risk><Environmental Risk Factor><Admission><Admission activity><psychological distress><QOC><Quality of Care><Intervention Strategies><interventional strategy><Intervention><Institution><preventing><prevent><Address><Data><NICHD><National Institute of Children\\'s Health and Human Development><National Institute of Child Health and Human Development><Cognitive><Enrollment><enroll><Characteristics><Development><developmental><Behavioral><health related quality of life><design><designing><Sepsis><blood infection><bloodstream infection><Outcome><pathogen><care giving burden><caregiving burden><caregiving stress><innovation><innovate><innovative><Impairment><evidence base><primary caregiver><primary care giver><improved outcome><Longitudinal cohort study><Long-term cohort study><Longterm cohort study><Prospective cohort study>\", \"pref_terms\": \"Address;Admission activity;Adolescent;Affect;Age;Behavioral;Biometry;Caregivers;Caring;Cause of Death;Cessation of life;Characteristics;Child;Child Care;Childhood;Chronic;Clinical;Clinical Investigator;Clinical Protocols;Clinical Trials;Cognitive;Communities;Data;Data Analyses;Data Set;Databases;Development;Enrollment;Environmental Risk Factor;Evaluation;Evaluation Studies;Faculty;Family;Family Caregiver;Fluid Balance;Fostering;Foundations;Functional disorder;Funding;Generations;Goals;Hospital Mortality;Hospitalization;Immune System Diseases;Impairment;Individual;Institution;Intervention;Journals;Knowledge;Leadership;Life;Longitudinal cohort study;Manuscripts;Mediating;Mentors;Mentorship;Mission;Morbidity - disease rate;National Institute of Child Health and Human Development;Organ;Outcome;Outcomes Research;Pediatric Hospitals;Pediatric Intensive Care Units;Prospective cohort study;Public Health;Publishing;Quality of Care;Quality of life;Research;Research Personnel;Risk;Sepsis;Septic Shock;Severity of illness;Survivors;Testing;United States National Institutes of Health;care giving burden;design;disability;evidence base;experience;functional status;health related quality of life;improved;improved outcome;innovation;mortality;pathogen;physically handicapped;prevent;primary caregiver;psychological distress\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nCommunity-acquired septic shock is a major cause of death among children and often leads to poor long-term\\\\nhealth-related quality-of-life (HRQL) among survivors. Long-term HRQL following pediatric septic shock may be\\\\naffected by many baseline and clinical factors that have not yet been adequately investigated. The long-term\\\\ngoal of this research is to improve outcomes from pediatric community-acquired septic shock. The overall\\\\nobjective is to identify modifiable factors related to the clinical course of children with septic shock as well as pre-\\\\nexisting child or environmental factors that may impact long-term morbidity and mortality. The central hypothesis\\\\nis that identifiable, modifiable factors during pediatric community-acquired septic shock may affect the risk of\\\\nlong-term morbidity and mortality among children encountering septic shock, as well as the risk of family\\\\ndysfunction and psychological distress among their caregivers. The expected outcomes of the research are new\\\\nknowledge about factors contributing to adverse child and family outcomes following pediatric septic shock. This\\\\nnew knowledge will have a positive impact because it will provide an evidence-base for the development and\\\\ntesting of new interventions targeted at modifiable factors. The specific aims of this project are Aim 1) Identify\\\\nbaseline characteristics that are associated with impaired long-term functional status and health-related quality\\\\nof life among children following community-acquired septic shock. Aim 2) Identify aspects of the clinical course\\\\nthat are associated with impaired long-term functional status and health-related quality of life among children\\\\nfollowing community-acquired septic shock. Aim 3) Identify factors associated with long-term family functioning\\\\nand psychological distress of the primary caregiver following their child\\\\u2019s hospitalization for community-acquired\\\\nseptic shock. The approach to address these aims is to collaborate with junior investigators and their local\\\\nmentors from several academic institutions to answer important questions about pediatric sepsis using a publicly\\\\navailable dataset from the NIH-funded Life After Pediatric Sepsis Evaluation (LAPSE) study. Junior investigators\\\\nwill be provided with complete biostatistical support and additional mentorship from experts in pediatric sepsis\\\\nand the LAPSE study. This contribution is significant because it will provide an evidence basis for designing\\\\ndefinitive clinical trials and developing clinical protocols that address modifiable factors to optimizing care and\\\\nimproving long-term child and family outcomes following septic shock. The research proposed is innovative\\\\nbecause it will result in a substantial departure from the status quo by introducing junior investigators to the\\\\nbenefits of using established public use databases and providing them with an educational experience in their\\\\nuse.\", \"project_title\": \"Utilizing publicly available data to improve long-term quality of life following pediatric sepsis while fostering a new generation of sepsis investigators\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe proposed research is relevant to public health because it will provide an evidence-base for the development\\\\nand testing of new interventions targeted at modifiable factors associated with long-term quality of life following\\\\npediatric sepsis. The project is relevant to NICHD\\\\u2019s mission because it will lay the foundation for interventions\\\\naimed at enhancing the lives of children and adolescents after hospitalization for septic shock.\", \"spending_categories_desc\": \"Behavioral and Social Science; Caregiving Research; Clinical Research; Health Services; Hematology; Infectious Diseases; Minority Health; Pediatric; Sepsis\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-04-06T12:04:00Z\", \"budget_end\": \"2022-03-31T12:03:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 50000, \"indirect_cost_amt\": 26250, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10106090\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 63}, page_content='{\"appl_id\": 10385710, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5R03HD104001-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R03\", \"award_amount\": 76250, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R03\", \"ic_code\": \"HD\", \"serial_num\": \"104001\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12365437, \"first_name\": \"Ron\", \"middle_name\": \"William\", \"last_name\": \"Reeder\", \"is_contact_pi\": true, \"full_name\": \"Ron William Reeder\", \"title\": \"BIOSTATISTICIAN III\"}], \"contact_pi_name\": \"REEDER, RON WILLIAM\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 76250, \"direct_cost_ic\": 50000, \"indirect_cost_ic\": 26250}], \"project_start_date\": \"2021-04-06T12:04:00Z\", \"project_end_date\": \"2023-03-31T12:03:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-17-299\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Pediatrics Study Section[CHHD-A]\"}, \"award_notice_date\": \"2022-05-12T12:05:00Z\", \"core_project_num\": \"R03HD104001\", \"terms\": \"<Affect><Age><ages><Biometry><Biometrics><Biostatistics><Cause of Death><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Child Care><Puericulture><Clinical Investigator><Clinical Protocols><Clinical Trials><Communities><Data Analyses><Data Analysis><data interpretation><Cessation of life><Death><Evaluation Studies><Faculty><Family><Fluid Balance><Fluid Homeostasis><Foundations><Goals><Hospitalization><Hospital Admission><Pediatric Hospitals><Children\\'s Hospital><Immune System Diseases><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immunodeficiency and Immunosuppression Disorders><Immunologic Diseases><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Pediatric Intensive Care Units><Leadership><Mentors><Mentorship><Mission><Morbidity - disease rate><Morbidity><mortality><NIH><National Institutes of Health><United States National Institutes of Health><Public Health><Publishing><QOL><Quality of life><Research><Investigators><Researchers><Research Personnel><Risk><Septic Shock><Testing><Generations><Caregivers><Care Givers><Hospital Mortality><In-house Mortalities><Inhospital Mortality><Family Caregiver><Family Care Giver><Mediating><Outcomes Research><physically handicapped><physical disability><physically disabled><Data Set><Dataset><Caring><Journals><Magazine><Organ><improved><Chronic><Clinical><Adolescent><Adolescent Youth><juvenile><juvenile human><Survivors><Evaluation><disability><pediatric><Childhood><Individual><Fostering><Data Bases><data base><Databases><Funding><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Knowledge><Life><disease severity><Severity of illness><experience><functional status><Manuscripts><Environmental Factor><environmental risk><Environmental Risk Factor><Admission><Admission activity><psychological distress><QOC><Quality of Care><Intervention Strategies><interventional strategy><Intervention><Institution><preventing><prevent><Address><Data><NICHD><National Institute of Children\\'s Health and Human Development><National Institute of Child Health and Human Development><Cognitive><Enrollment><enroll><Characteristics><Development><developmental><Behavioral><health related quality of life><design><designing><Sepsis><blood infection><bloodstream infection><Outcome><pathogen><care giving burden><caregiving burden><caregiving stress><innovation><innovate><innovative><Impairment><evidence base><primary caregiver><primary care giver><improved outcome><Longitudinal cohort study><Long-term cohort study><Longterm cohort study><Prospective cohort study><pediatric sepsis><sepsis in children><pediatric septic>\", \"pref_terms\": \"Address;Admission activity;Adolescent;Affect;Age;Behavioral;Biometry;Caregivers;Caring;Cause of Death;Cessation of life;Characteristics;Child;Child Care;Childhood;Chronic;Clinical;Clinical Investigator;Clinical Protocols;Clinical Trials;Cognitive;Communities;Data;Data Analyses;Data Set;Databases;Development;Enrollment;Environmental Risk Factor;Evaluation;Evaluation Studies;Faculty;Family;Family Caregiver;Fluid Balance;Fostering;Foundations;Functional disorder;Funding;Generations;Goals;Hospital Mortality;Hospitalization;Immune System Diseases;Impairment;Individual;Institution;Intervention;Journals;Knowledge;Leadership;Life;Longitudinal cohort study;Manuscripts;Mediating;Mentors;Mentorship;Mission;Morbidity - disease rate;National Institute of Child Health and Human Development;Organ;Outcome;Outcomes Research;Pediatric Hospitals;Pediatric Intensive Care Units;Prospective cohort study;Public Health;Publishing;Quality of Care;Quality of life;Research;Research Personnel;Risk;Sepsis;Septic Shock;Severity of illness;Survivors;Testing;United States National Institutes of Health;care giving burden;design;disability;evidence base;experience;functional status;health related quality of life;improved;improved outcome;innovation;mortality;pathogen;pediatric sepsis;physically handicapped;prevent;primary caregiver;psychological distress\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nCommunity-acquired septic shock is a major cause of death among children and often leads to poor long-term\\\\nhealth-related quality-of-life (HRQL) among survivors. Long-term HRQL following pediatric septic shock may be\\\\naffected by many baseline and clinical factors that have not yet been adequately investigated. The long-term\\\\ngoal of this research is to improve outcomes from pediatric community-acquired septic shock. The overall\\\\nobjective is to identify modifiable factors related to the clinical course of children with septic shock as well as pre-\\\\nexisting child or environmental factors that may impact long-term morbidity and mortality. The central hypothesis\\\\nis that identifiable, modifiable factors during pediatric community-acquired septic shock may affect the risk of\\\\nlong-term morbidity and mortality among children encountering septic shock, as well as the risk of family\\\\ndysfunction and psychological distress among their caregivers. The expected outcomes of the research are new\\\\nknowledge about factors contributing to adverse child and family outcomes following pediatric septic shock. This\\\\nnew knowledge will have a positive impact because it will provide an evidence-base for the development and\\\\ntesting of new interventions targeted at modifiable factors. The specific aims of this project are Aim 1) Identify\\\\nbaseline characteristics that are associated with impaired long-term functional status and health-related quality\\\\nof life among children following community-acquired septic shock. Aim 2) Identify aspects of the clinical course\\\\nthat are associated with impaired long-term functional status and health-related quality of life among children\\\\nfollowing community-acquired septic shock. Aim 3) Identify factors associated with long-term family functioning\\\\nand psychological distress of the primary caregiver following their child\\\\u2019s hospitalization for community-acquired\\\\nseptic shock. The approach to address these aims is to collaborate with junior investigators and their local\\\\nmentors from several academic institutions to answer important questions about pediatric sepsis using a publicly\\\\navailable dataset from the NIH-funded Life After Pediatric Sepsis Evaluation (LAPSE) study. Junior investigators\\\\nwill be provided with complete biostatistical support and additional mentorship from experts in pediatric sepsis\\\\nand the LAPSE study. This contribution is significant because it will provide an evidence basis for designing\\\\ndefinitive clinical trials and developing clinical protocols that address modifiable factors to optimizing care and\\\\nimproving long-term child and family outcomes following septic shock. The research proposed is innovative\\\\nbecause it will result in a substantial departure from the status quo by introducing junior investigators to the\\\\nbenefits of using established public use databases and providing them with an educational experience in their\\\\nuse.\", \"project_title\": \"Utilizing publicly available data to improve long-term quality of life following pediatric sepsis while fostering a new generation of sepsis investigators\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe proposed research is relevant to public health because it will provide an evidence-base for the development\\\\nand testing of new interventions targeted at modifiable factors associated with long-term quality of life following\\\\npediatric sepsis. The project is relevant to NICHD\\\\u2019s mission because it will lay the foundation for interventions\\\\naimed at enhancing the lives of children and adolescents after hospitalization for septic shock.\", \"spending_categories_desc\": \"Behavioral and Social Science; Caregiving Research; Clinical Research; Health Services; Hematology; Infectious Diseases; Minority Health; Pediatric; Sepsis\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-04-01T12:04:00Z\", \"budget_end\": \"2023-03-31T12:03:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 50000, \"indirect_cost_amt\": 26250, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10385710\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 64}, page_content='{\"appl_id\": 10308109, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5R03CA256263-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R03\", \"award_amount\": 76250, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R03\", \"ic_code\": \"CA\", \"serial_num\": \"256263\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 11233567, \"first_name\": \"Anne\", \"middle_name\": \"C\", \"last_name\": \"Kirchhoff\", \"is_contact_pi\": true, \"full_name\": \"Anne C Kirchhoff\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"KIRCHHOFF, ANNE C\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 76250, \"direct_cost_ic\": 50000, \"indirect_cost_ic\": 26250}], \"project_start_date\": \"2020-12-01T12:12:00Z\", \"project_end_date\": \"2022-11-30T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-20-052\", \"full_study_section\": {\"srg_code\": \"ZCA1\", \"srg_flex\": null, \"sra_designator_code\": \"SRB\", \"sra_flex_code\": \"2\", \"group_code\": \"O1\", \"name\": \"ZCA1-SRB-2(O1)\"}, \"award_notice_date\": \"2021-11-30T12:11:00Z\", \"core_project_num\": \"R03CA256263\", \"terms\": \"<Affect><Age><ages><Air Pollution><Anthracycline><Breathing><Respiratory Aspiration><Respiratory Inspiration><inspiration><Bleomycin><Bleo><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cardiovascular system><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Communities><Diagnosis><Disease><Disorder><Environmental Pollutants><Goals><Health><Heart><Hospitalization><Hospital Admission><Hospitals><Institutes><Lung><Lung Respiratory System><pulmonary><melanoma><Malignant Melanoma><Morbidity - disease rate><Morbidity><mortality><Myocardial Infarction><Cardiac infarction><Myocardial Infarct><cardiac infarct><coronary attack><coronary infarct><coronary infarction><heart attack><heart infarct><heart infarction><Persons><Out-patients><Outpatients><Public Health><QOL><Quality of life><Racial Group><Racial Stocks><Race><Radiotherapeutics><Radiotherapy><radiation treatment><treatment with radiation><Radiation therapy><Records><Registries><Research><Risk><social role><Role><Smoking><Stress><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><Stroke><survivorship><Thyroid><Thyroid Head and Neck><Thyroid Gland><Time><Tissues><Body Tissues><Treatment Protocols><Treatment Regimen><Treatment Schedule><United States><Utah><Measures><Socioeconomic Status><Socio-economic status><socio-economic position><socioeconomic position><Cross-Over Studies><Crossover Studies><improved><Physiological><Physiologic><Survivors><Link><Susceptibility><Predisposition><insight><Individual><Health Care Utilization><health care service use><healthcare service use><healthcare service utilization><healthcare utilization><health care service utilization><SEER-Surveillance, Epidemiology, and End Results><Surveillance, Epidemiology and End Results><Surveillance, Epidemiology, and End Results Program><SEER Program><Cross-Over Designs><Crossover Design><Ethnicity><Ethnic Origin><Personal Medical History><Personal Medical History Epidemiology><Medical History><Lung damage><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><lung injury><Exposure to><Breast Lymphoma><Knowledge><Pollution><Hour><Event><respiratory><interest><Emergency Department><Emergency room><Accident and Emergency department><experience><physiologic stresses><physiological stresses><physiologic stressor><cohort><Toxicities><Toxic effect><General Public><General Population><Reporting><cancer registry><neoplasm registry><Thorace><Thoracic><Thorax><Chest><cardiovascular risk><cardiovascular risk factor><Radiation><Sampling><cessation of treatment><treatment cessation><Withholding Treatment><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><myocardium disease><myocardium disorder><Cardiomyopathies><cancer therapy><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer-directed therapy><preventing><prevent><Address><Health system><Data><Population Database><Subgroup><Cancer Survivor><survive cancer><Smoking Status><sex><Modification><follow-up><Active Follow-up><active followup><follow up><followed up><followup><Development><developmental><Particulate Matter><anticancer research><anti-cancer research><cancer research><Outcome><Population><Wildfire><wild fire><wildland fire><chemotherapy><high risk><Adolescent and Young Adult><Emergency department visit><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><adolescent health outcomes><young cancer survivor><respiratory health><Airway health><cardiovascular health><Cardiac health><Heart health><fine particles><PM2.5><fine particulate matter><Time trend><Temporal trend><Trends over time><data resource><Chemotherapy and/or radiation><Chemotherapy and Radiation><lung health><pulmonary health><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder>\", \"pref_terms\": \"Accident and Emergency department;Address;Adolescent and Young Adult;Affect;Age;Air Pollution;Anthracycline;Bleomycin;Breast Lymphoma;Breathing;Cancer Survivor;Cardiac health;Cardiomyopathies;Cardiovascular system;Chemotherapy and/or radiation;Chest;Communities;Cross-Over Studies;Crossover Design;Data;Development;Diagnosis;Disease;Emergency department visit;Environmental Pollutants;Ethnic Origin;Event;Exposure to;General Population;Goals;Health;Health system;Heart;Hospitalization;Hospitals;Hour;Individual;Institutes;Knowledge;Link;Lung;Malignant Neoplasms;Measures;Medical History;Modification;Morbidity - disease rate;Myocardial Infarction;Outcome;Outpatients;Particulate Matter;Persons;Physiological;Pollution;Population;Population Database;Predisposition;Public Health;Quality of life;Race;Radiation;Radiation therapy;Records;Registries;Reporting;Research;Respiratory Disease;Risk;Role;SEER Program;Sampling;Smoking;Smoking Status;Socioeconomic Status;Stress;Stroke;Subgroup;Survivors;Thyroid Gland;Time;Time trend;Tissues;Toxic effect;Treatment Protocols;United States;Utah;Wildfire;Withholding Treatment;adolescent health outcomes;anticancer research;cancer therapy;cardiovascular health;cardiovascular risk factor;chemotherapy;cohort;data resource;experience;fine particles;follow-up;health care service utilization;high risk;improved;insight;interest;lung health;lung injury;melanoma;mortality;neoplasm registry;physiologic stressor;prevent;respiratory;respiratory health;sex;survivorship;young cancer survivor\", \"abstract_text\": \"PROJECT SUMMARY ABSTRACT\\\\nCardiovascular (CV) and respiratory toxicity from cancer treatments are a major causes of morbidity among\\\\nadolescent and young adult (AYA) cancer survivors. This toxicity may reduce a survivor\\\\u2019s ability to neutralize\\\\nthe added physiologic stress from short-term air pollution exposure, leading to a higher risk for cardiovascular\\\\nand respiratory problems. However, the health effects of exposure to air pollution on AYA cancer survivors are\\\\nlargely unknown. To fill this knowledge gap, we will examine how fine particulate matter (PM2.5) is associated\\\\nwith CV and respiratory health events among survivors diagnosed with the five most common AYA cancers in\\\\nthe state of Utah (thyroid, melanoma, breast, lymphoma, testicular) between 1997 and 2016 (N=9,382). We will\\\\nemploy a case-crossover design nested in this preexisting cohort to examine the effects of short-term PM2.5 on\\\\nthe risk for cardiovascular and respiratory health events defined from statewide hospital discharge and\\\\nemergency department data, and outpatient records from Utah\\\\u2019s two largest health systems serving >85% of\\\\nUtah. Using data from the Utah Population Database, we can measure residential PM2.5 exposure at the\\\\naddress level for our sample. We will: 1) Investigate the association between short-term PM2.5 and CV and\\\\nrespiratory health events among AYA cancer survivors, and compare survivors\\\\u2019 risk of PM2.5-associated health\\\\nevents to a cancer-free sample, and 2) Determine whether treatments with known toxicities modify the\\\\nassociation between short-term PM2.5 and CV and respiratory health events among AYA cancer survivors. We\\\\nwill identify temporal trends in these associations among survivors from diagnosis to the end of follow-up.\\\\nSubgroups of survivors will be investigated to determine differences by smoking, race/ethnicity, and other\\\\nrelevant factors. Utah has severe PM2.5 pollution due to winter inversions and summer wildfires. Because of the\\\\npervasiveness of air pollution in United States and the lack of data on how environmental pollutants affect\\\\ncancer survivors, this project represents a unique opportunity to determine whether air pollution is a risk factor\\\\nfor cardiovascular and respiratory health problems among AYA cancer survivors. Our study will provide a deep\\\\nexamination of cancer treatment, health care utilization, and PM2.5 exposure, and expand upon the established\\\\nperspective of survivorship research by adding information the role air pollution on the risk for health events\\\\namong cancer survivors.\", \"project_title\": \"Identifying the role of short-term fine particulate matter air pollution in the heart and lung health outcomes of adolescent and young adult cancer survivors\", \"phr_text\": \"PROJECT NARRATIVE\\\\nCancer therapies can damage the lung and heart tissue of adolescent and young adult (AYA) cancer survivors,\\\\nresulting in major health problems after therapy ends. Breathing air pollution also damages lung and heart\\\\ntissue and may cause additional health problems for survivors. This study will examine how short-term air\\\\npollution exposure increases the risk for lung and heart problems in AYA cancer survivors and how risk may be\\\\nmodified for survivors who were treated with chemotherapy, and will provide new information on how to\\\\nprevent health problems in cancer survivor populations.\", \"spending_categories_desc\": \"Cancer; Cardiovascular; Climate-Related Exposures and Conditions; Clinical Research; Health Services; Lung; Lung Cancer; Pediatric; Pediatric Cancer; Prevention; Rare Diseases; Social Determinants of Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-12-01T12:12:00Z\", \"budget_end\": \"2022-11-30T12:11:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 50000, \"indirect_cost_amt\": 26250, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10308109\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 65}, page_content='{\"appl_id\": 10114084, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"1R03CA256263-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R03\", \"award_amount\": 76250, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R03\", \"ic_code\": \"CA\", \"serial_num\": \"256263\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 11233567, \"first_name\": \"Anne\", \"middle_name\": \"C\", \"last_name\": \"Kirchhoff\", \"is_contact_pi\": true, \"full_name\": \"Anne C Kirchhoff\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"KIRCHHOFF, ANNE C\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 76250, \"direct_cost_ic\": 50000, \"indirect_cost_ic\": 26250}], \"project_start_date\": \"2020-12-01T12:12:00Z\", \"project_end_date\": \"2022-11-30T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-20-052\", \"full_study_section\": {\"srg_code\": \"ZCA1\", \"srg_flex\": null, \"sra_designator_code\": \"SRB\", \"sra_flex_code\": \"2\", \"group_code\": \"O1\", \"name\": \"Special Emphasis Panel[ZCA1 SRB-2 (O1)]\"}, \"award_notice_date\": \"2020-11-25T12:11:00Z\", \"core_project_num\": \"R03CA256263\", \"terms\": \"<Affect><Age><ages><Air Pollution><Anthracycline><Breathing><Respiratory Aspiration><Respiratory Inspiration><inspiration><Bleomycin><Bleo><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cardiovascular system><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Communities><Diagnosis><Disease><Disorder><Environmental Pollutants><Goals><Health><Heart><Hospitalization><Hospital Admission><Hospitals><Institutes><Lung><Lung Respiratory System><pulmonary><Lung diseases><Pulmonary Diseases><Pulmonary Disorder><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><disease of the lung><disorder of the lung><lung disorder><melanoma><Malignant Melanoma><Morbidity - disease rate><Morbidity><mortality><Myocardial Infarction><Cardiac infarction><Myocardial Infarct><cardiac infarct><coronary attack><coronary infarct><coronary infarction><heart attack><heart infarct><heart infarction><Persons><Outpatients><Out-patients><Public Health><Quality of life><QOL><Race><Racial Group><Racial Stocks><Radiation therapy><Radiotherapeutics><Radiotherapy><radiation treatment><radio-therapy><treatment with radiation><Records><Registries><Research><Risk><Role><social role><Smoking><Stress><Stroke><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><survivorship><Thyroid Gland><Thyroid><Thyroid Head and Neck><Time><Tissues><Body Tissues><Treatment Protocols><Treatment Regimen><Treatment Schedule><United States><Utah><Measures><Socioeconomic Status><Socio-economic status><socio-economic position><socioeconomic position><Cross-Over Studies><Crossover Studies><improved><Physiological><Physiologic><Survivors><Link><Predisposition><Susceptibility><insight><Individual><health care service utilization><Health Care Utilization><health care service use><healthcare service use><healthcare service utilization><healthcare utilization><SEER Program><SEER-Surveillance, Epidemiology, and End Results><Surveillance, Epidemiology and End Results><Surveillance, Epidemiology, and End Results Program><Crossover Design><Cross-Over Designs><Ethnic Origin><Ethnicity><Medical History><Personal Medical History><Personal Medical History Epidemiology><lung injury><Lung damage><Exposure to><Breast Lymphoma><Knowledge><Pollution><Hour><Event><respiratory><interest><Emergency Department><Emergency room><Accident and Emergency department><experience><physiologic stresses><physiological stresses><physiologic stressor><cohort><Toxicities><Toxic effect><General Public><General Population><Reporting><cancer registry><neoplasm registry><Thorace><Thoracic><Thorax><Chest><cardiovascular risk><cardiovascular risk factor><Radiation><Sampling><cessation of treatment><treatment cessation><Withholding Treatment><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><myocardium disease><myocardium disorder><Cardiomyopathies><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer-directed therapy><cancer therapy><preventing><prevent><Address><Health system><Data><Population Database><Subgroup><Cancer Survivor><survive cancer><Smoking Status><sex><Modification><follow-up><Active Follow-up><active followup><follow up><followed up><followup><Development><developmental><Particulate Matter><anticancer research><anti-cancer research><cancer research><Outcome><Population><Wildfire><chemotherapy><high risk><Adolescent and Young Adult><Emergency department visit><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><adolescent health outcomes><young cancer survivor><respiratory health><cardiovascular health><fine particles><PM2.5><fine particulate matter><Time trend><Temporal trend><Trends over time><data resource><Chemotherapy and/or radiation><Chemotherapy and Radiation>\", \"pref_terms\": \"Accident and Emergency department;Address;Adolescent and Young Adult;Affect;Age;Air Pollution;Anthracycline;Bleomycin;Breast Lymphoma;Breathing;Cancer Survivor;Cardiomyopathies;Cardiovascular system;Chemotherapy and/or radiation;Chest;Communities;Cross-Over Studies;Crossover Design;Data;Development;Diagnosis;Disease;Emergency department visit;Environmental Pollutants;Ethnic Origin;Event;Exposure to;General Population;Goals;Health;Health system;Heart;Hospitalization;Hospitals;Hour;Individual;Institutes;Knowledge;Link;Lung;Lung diseases;Malignant Neoplasms;Measures;Medical History;Modification;Morbidity - disease rate;Myocardial Infarction;Outcome;Outpatients;Particulate Matter;Persons;Physiological;Pollution;Population;Population Database;Predisposition;Public Health;Quality of life;Race;Radiation;Radiation therapy;Records;Registries;Reporting;Research;Risk;Role;SEER Program;Sampling;Smoking;Smoking Status;Socioeconomic Status;Stress;Stroke;Subgroup;Survivors;Thyroid Gland;Time;Time trend;Tissues;Toxic effect;Treatment Protocols;United States;Utah;Wildfire;Withholding Treatment;adolescent health outcomes;anticancer research;cancer therapy;cardiovascular health;cardiovascular risk factor;chemotherapy;cohort;data resource;experience;fine particles;follow-up;health care service utilization;high risk;improved;insight;interest;lung injury;melanoma;mortality;neoplasm registry;physiologic stressor;prevent;respiratory;respiratory health;sex;survivorship;young cancer survivor\", \"abstract_text\": \"PROJECT SUMMARY ABSTRACT\\\\nCardiovascular (CV) and respiratory toxicity from cancer treatments are a major causes of morbidity among\\\\nadolescent and young adult (AYA) cancer survivors. This toxicity may reduce a survivor\\\\u2019s ability to neutralize\\\\nthe added physiologic stress from short-term air pollution exposure, leading to a higher risk for cardiovascular\\\\nand respiratory problems. However, the health effects of exposure to air pollution on AYA cancer survivors are\\\\nlargely unknown. To fill this knowledge gap, we will examine how fine particulate matter (PM2.5) is associated\\\\nwith CV and respiratory health events among survivors diagnosed with the five most common AYA cancers in\\\\nthe state of Utah (thyroid, melanoma, breast, lymphoma, testicular) between 1997 and 2016 (N=9,382). We will\\\\nemploy a case-crossover design nested in this preexisting cohort to examine the effects of short-term PM2.5 on\\\\nthe risk for cardiovascular and respiratory health events defined from statewide hospital discharge and\\\\nemergency department data, and outpatient records from Utah\\\\u2019s two largest health systems serving >85% of\\\\nUtah. Using data from the Utah Population Database, we can measure residential PM2.5 exposure at the\\\\naddress level for our sample. We will: 1) Investigate the association between short-term PM2.5 and CV and\\\\nrespiratory health events among AYA cancer survivors, and compare survivors\\\\u2019 risk of PM2.5-associated health\\\\nevents to a cancer-free sample, and 2) Determine whether treatments with known toxicities modify the\\\\nassociation between short-term PM2.5 and CV and respiratory health events among AYA cancer survivors. We\\\\nwill identify temporal trends in these associations among survivors from diagnosis to the end of follow-up.\\\\nSubgroups of survivors will be investigated to determine differences by smoking, race/ethnicity, and other\\\\nrelevant factors. Utah has severe PM2.5 pollution due to winter inversions and summer wildfires. Because of the\\\\npervasiveness of air pollution in United States and the lack of data on how environmental pollutants affect\\\\ncancer survivors, this project represents a unique opportunity to determine whether air pollution is a risk factor\\\\nfor cardiovascular and respiratory health problems among AYA cancer survivors. Our study will provide a deep\\\\nexamination of cancer treatment, health care utilization, and PM2.5 exposure, and expand upon the established\\\\nperspective of survivorship research by adding information the role air pollution on the risk for health events\\\\namong cancer survivors.\", \"project_title\": \"Identifying the role of short-term fine particulate matter air pollution in the heart and lung health outcomes of adolescent and young adult cancer survivors\", \"phr_text\": \"PROJECT NARRATIVE\\\\nCancer therapies can damage the lung and heart tissue of adolescent and young adult (AYA) cancer survivors,\\\\nresulting in major health problems after therapy ends. Breathing air pollution also damages lung and heart\\\\ntissue and may cause additional health problems for survivors. This study will examine how short-term air\\\\npollution exposure increases the risk for lung and heart problems in AYA cancer survivors and how risk may be\\\\nmodified for survivors who were treated with chemotherapy, and will provide new information on how to\\\\nprevent health problems in cancer survivor populations.\", \"spending_categories_desc\": \"Cancer; Climate-Related Exposures and Conditions; Clinical Research; Health Services; Lung; Lung Cancer; Pediatric; Pediatric Cancer; Prevention; Rare Diseases; Social Determinants of Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-12-01T12:12:00Z\", \"budget_end\": \"2021-11-30T12:11:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 50000, \"indirect_cost_amt\": 26250, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10114084\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 66}, page_content='{\"appl_id\": 10265464, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"5U24HL148563-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 565144, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"148563\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 565144, \"direct_cost_ic\": 547322, \"indirect_cost_ic\": 287344}], \"project_start_date\": \"2020-09-20T12:09:00Z\", \"project_end_date\": \"2026-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"F1\", \"name\": \"ZHL1-CSR-H(F1)\"}, \"award_notice_date\": \"2021-09-13T12:09:00Z\", \"core_project_num\": \"U24HL148563\", \"terms\": \"<Affect><Amino Acids><aminoacid><Hemolytic Anemia><Sickle Cell Anemia><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><arginase><Hepatic Proliferation Inhibitor><L arginine amidinohydrolase><Liver Immunoregulatory Protein><Liver-Derived Inhibitory Protein><arginine amidinase><canavanase><Arginine><L-Arginine><Biological Availability><Bioavailability><Biologic Availability><Physiologic Availability><Biometry><Biometrics><Biostatistics><Blood><Blood Reticuloendothelial System><Blood Cells><Peripheral Blood Cell><Blood Vessels><vascular><Cell Adhesion Molecules><Adhesion Molecule><Cell Adhesion Molecule Gene><cell adhesion protein><Cells><Cell Body><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Child Care><Puericulture><Communication><Controlled Clinical Trials><Data Collection><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Down-Regulation><Downregulation><Electrons><Negative Beta Particle><Negatrons><Erythrocytes><Blood erythrocyte><Erythrocytic><Marrow erythrocyte><Red Blood Cells><Red Cell><blood corpuscles><Patient Care><Patient Care Delivery><Goals><Hemolysis><erythrolysis><Hospitalization><Hospital Admission><Hospitals><Inpatients><Lead><Pb element><heavy metal Pb><heavy metal lead><Leadership><Length of Stay><Number of Days in Hospital><hospital days><hospital length of stay><hospital stay><Maintenance><Manuals><Transgenic Mice><Mitochondria><mitochondrial><mortality><Narcotics><Nitric Oxide><Endogenous Nitrate Vasodilator><Endothelium-Derived Nitric Oxide><Mononitrogen Monoxide><Nitrogen Monoxide><Nitrogen Protoxide><endothelial cell derived relaxing factor><oxidation><Pain><Painful><Patients><Perfusion><Drug Kinetics><Pharmacokinetics><Physiology><Placebos><Sham Treatment><sham therapy><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Production><Reperfusion Injury><Ischemia-Reperfusion Injury><Reperfusion Damage><Research><Research Personnel><Investigators><Researchers><Safety><Schools><Syndrome><Testing><Time><Universities><Utah><Vasodilator Agents><Vasodilating Agent><Vasodilator Drugs><Vasodilators><Technical Expertise><technical skills><African American><Afro American><Afroamerican><Black Populations><black American><Data Set><Dataset><Cell Density><base><improved><Acute Pain><Area><Acute><Clinical><Phase><Biological><Death Rate><Training><Sickle Cell><sickle RBC><sickle erythrocyte><sickle red blood cell><Childhood><pediatric><Individual><Logistics><lung injury><Lung damage><Inflammatory><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Absence of pain sensation><Research Specimen><Specimen><Hour><Hereditary><Inherited><Complex><Event><Protocol><Protocols documentation><Emergency Department><Emergency room><Accident and Emergency department><data management><experience><pleiotropic effect><pleiotropy><pleiotropism><Manpower><personnel><Human Resources><Reporting><Intervention Strategies><interventional strategy><Intervention><Platelet Aggregation Inhibition><ward><Hydration><Hydration status><Dose><Data><randomisation><randomization><randomly assigned><Randomized><Resolution><Supplementation><Monitor><trend><Preparation><Pathway interactions><pathway><double-blind placebo controlled trial><double-masked controlled trial><neglect><Data Coordinating Center><Data Coordination Center><design><designing><aged><clinically relevant><clinical relevance><arginine treatment><novel therapeutics><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel therapy><mitochondrial dysfunction><mouse model><murine model><new therapeutic target><new drug target><new druggable target><new pharmacotherapy target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><standard of care><product development><clinical practice><safety testing><efficacy testing><vaso-occlusive pain><vasoocclusive pain><operation><Emergency department visit><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><Therapy trial><phase III trial><phase 3 trial><metabolome><metabonome><opioid use><opiate consumption><opiate drug use><opiate intake><opiate use><opioid consumption><opioid drug use><opioid intake><emergency settings><pediatric emergency><pain score><primary endpoint><primary end point><acute care><randomized placebo-controlled clinical trial><clinical trial analysis><efficacious intervention>\", \"pref_terms\": \"Absence of pain sensation;Accident and Emergency department;Acute;Acute Pain;Affect;African American;Amino Acids;Area;Arginine;Biological;Biological Availability;Biometry;Blood;Blood Cells;Blood Vessels;Cell Adhesion Molecules;Cell Density;Cells;Child;Child Care;Childhood;Clinical;Communication;Complex;Controlled Clinical Trials;Data;Data Collection;Data Coordinating Center;Data Set;Death Rate;Disease;Dose;Double-Blind Method;Down-Regulation;Drug Kinetics;Electrons;Emergency department visit;Erythrocytes;Event;Goals;Hemolysis;Hemolytic Anemia;Hospitalization;Hospitals;Hour;Human Resources;Hydration status;Individual;Inflammatory;Inherited;Inpatients;Intervention;Lead;Leadership;Length of Stay;Logistics;Maintenance;Manuals;Mitochondria;Monitor;Narcotics;Nitric Oxide;Pain;Pathway interactions;Patient Care;Patients;Perfusion;Phase;Physiology;Placebos;Plasma;Platelet Aggregation Inhibition;Preparation;Production;Protocols documentation;Randomized;Reperfusion Injury;Reporting;Research;Research Personnel;Resolution;Safety;Schools;Sickle Cell;Sickle Cell Anemia;Specimen;Supplementation;Syndrome;Technical Expertise;Testing;Therapy trial;Time;Training;Transgenic Mice;Universities;Utah;Vasodilator Agents;acute care;aged;arginase;arginine treatment;base;clinical practice;clinical trial analysis;clinically relevant;data management;design;double-blind placebo controlled trial;efficacious intervention;efficacy testing;emergency settings;experience;improved;lung injury;metabolome;mitochondrial dysfunction;mortality;mouse model;neglect;new therapeutic target;novel therapeutics;operation;opioid use;oxidation;pain score;pediatric emergency;phase III trial;pleiotropism;primary endpoint;product development;randomized placebo-controlled clinical trial;safety testing;standard of care;trend;vaso-occlusive pain;ward\", \"abstract_text\": \"Project Summary/Abstract\\\\nVaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) are the leading cause of hospitalizations,\\\\nemergency room (ED) visits, and missed school, and are associated with an increased mortality rate. There are\\\\nno current therapies to relieve vaso-occlusion, with interventions limited to hydration and analgesia. Nitric oxide\\\\n(NO), produced by the 5-electron oxidation of L-arginine, is a potent vasodilator and exerts pleiotropic effects on\\\\nvascular and circulating blood cells, including the inhibition of platelet aggregation, down-regulation of adhesion\\\\nmolecules, and modulation of ischemia-reperfusion injury, all pathways adversely affected during VOE. We have\\\\nfound that pediatric SCD patients admitted with VOE have depleted plasma L-arginine levels. Additionally, we\\\\nhave now completed a single-center randomized, double-blinded, placebo-controlled trial of arginine therapy in\\\\n54 children with VOE requiring hospitalization. We observed a reduction in total opioid use (mg/kg) by 54% and\\\\nsigni\\\\ufb01cantly lower pain scores at discharge in children who received 5 days IV L-arginine therapy every 8 hours\\\\ncompared to placebo, as well as a clinically relevant trend in reduced length of hospital stay of approximately\\\\n17 hours. In pharmacokinetic studies, we found that IV arginine induced a dose-dependent improvement in\\\\nmitochondrial function in children with SCD hospitalized for pain. We now propose to extend these results to a\\\\npivotal phase 3 trial of L-arginine for VOE. We hypothesize that arginine is a safe intervention with narcotic-sparing\\\\neffects in pediatric SCD patients with VOE that will decrease the time children experience severe pain. Aim 1 of\\\\nthis study will determine the ef\\\\ufb01cacy of IV arginine therapy on the primary endpoint, time-to-crisis resolution, as\\\\nwell as total parenteral opioid use (mg/kg) and pain scores in children with SCD and VOE compared to placebo\\\\n(Ef\\\\ufb01cacy). Aim 2 will monitor for safety of IV L-arginine (Safety). Aim 3 will characterize alterations in the\\\\narginine metabolome and mitochondrial function in children with SCD and VOE, and evaluate how it is impacted\\\\nby IV arginine therapy (Exploratory). This proposal will provide essential data for product development and FDA\\\\nregulatory approval for use of arginine in SCD. Acute care of patients with SCD and pain in the ED is a neglected\\\\narea of research. The results of this study may ultimately lead to change in clinical practice for children with SCD\\\\nin both the ED and inpatient hospital wards. ED-based studies and novel therapies that target mechanisms of\\\\nvaso-occlusion and pain are needed in SCD.\", \"project_title\": \"2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial\", \"phr_text\": \"Project Narrative\\\\nPain is the hallmark of sickle cell disease (SCD), and is the leading cause of hospitalizations, emergency room\\\\nvisits, missed school, and is associated with an increased death rate. We found that patients with SCD and pain\\\\nhad low levels of the amino acid arginine in their blood, and we also demonstrated that arginine supplementation\\\\nduring acute pain events signi\\\\ufb01cantly reduced the amount of narcotics needed to treat sickle cell pain in children\\\\nand dramatically improved pain scores at discharge compared to placebo. We propose to investigate the bene\\\\ufb01ts\\\\nand safety of arginine for the treatment of patients with SCD and pain in a phase 3 randomized, placebo-controlled\\\\nclinical trial where neither the patient nor the clinical team know which therapy the patient is receiving, since\\\\nArginine is a promising new therapy that could change the way we treat acute pain in SCD.\", \"spending_categories_desc\": \"Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Hematology; Orphan Drug; Pain Research; Pediatric; Rare Diseases; Sickle Cell Disease\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-09-01T12:09:00Z\", \"budget_end\": \"2022-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 547322, \"indirect_cost_amt\": 287344, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10265464\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 67}, page_content='{\"appl_id\": 10925255, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5U24HL148563-05\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 541241, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"148563\", \"support_year\": \"05\", \"full_support_year\": \"05\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 541241, \"direct_cost_ic\": 354912, \"indirect_cost_ic\": 186329}], \"project_start_date\": \"2020-09-20T12:09:00Z\", \"project_end_date\": \"2026-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"F1\", \"name\": \"ZHL1-CSR-H(F1)\"}, \"award_notice_date\": \"2024-08-27T12:08:00Z\", \"core_project_num\": \"U24HL148563\", \"terms\": \"<0-11 years old><Absence of pain sensation><Absence of sensibility to pain><Accident and Emergency department><Acute><Acute Pain><Adhesion Molecule><Affect><African American group><African American individual><African American people><African American population><African Americans><Amino Acids><Area><Arginine><Bioavailability><Biological><Biological Availability><Biometrics><Biometry><Biostatistics><Blood><Blood Cells><Blood Plasma><Blood Reticuloendothelial System><Blood Vessels><Blood erythrocyte><Cell Adhesion Molecule Gene><Cell Adhesion Molecules><Cell Density><Child><Child Care><Child Youth><Childhood><Children (0-21)><Clinical><Clinical Trials><Communication><Complex><Data><Data Collection><Data Coordinating Center><Data Coordination Center><Data Set><Death Rate><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Down-Regulation><Drug Kinetics><ED visit><ER visit><Electrons><Emergency Department><Emergency care visit><Emergency department visit><Emergency hospital visit><Emergency room><Emergency room visit><Endogenous Nitrate Vasodilator><Endothelium-Derived Nitric Oxide><Erythrocytes><Erythrocytic><Event><Feels no pain><Goals><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemolysis><Hemolytic Anemia><Hepatic Proliferation Inhibitor><Hereditary><Hospital Admission><Hospitalization><Hospitals><Hour><Human Resources><Hydration><Hydration status><Individual><Inflammatory><Inherited><Inpatients><Intervention><Intervention Strategies><Investigators><Ischemia-Reperfusion Injury><L arginine amidinohydrolase><L-Arginine><Leadership><Length of Stay><Liver Immunoregulatory Protein><Liver-Derived Inhibitory Protein><Lung damage><Maintenance><Manpower><Manuals><Marrow erythrocyte><Mitochondria><Monitor><Mononitrogen Monoxide><Narcotics><Negative Beta Particle><Negatrons><Nitric Oxide><Nitrogen Monoxide><Nitrogen Protoxide><No sensitivity to pain><Number of Days in Hospital><Pain><Painful><Pathway interactions><Patient Admission><Patient Care><Patient Care Delivery><Patients><Perfusion><Peripheral Blood Cell><Pharmacokinetics><Phase><Physiologic Availability><Physiology><Placebo Control><Placebos><Plasma><Plasma Serum><Platelet Aggregation Inhibition><Preparation><Production><Protocol><Protocols documentation><Puericulture><Qualifying><Randomized><Red Blood Cells><Red Cell><Reperfusion Damage><Reperfusion Injury><Reporting><Research><Research Personnel><Research Specimen><Researchers><Resolution><Reticuloendothelial System, Serum, Plasma><Safety><Schools><Sham Treatment><Sickle Cell><Sickle Cell Anemia><Specimen><Supplementation><Syndrome><Technical Expertise><Testing><Therapy trial><Time><Training><Transgenic Mice><Universities><Utah><Vasodilating Agent><Vasodilator Agents><Vasodilator Drugs><Vasodilators><acute care><aged><aminoacid><analgesia><arginase><arginine amidinase><arginine treatment><biologic><blood corpuscles><canavanase><care for patients><care of patients><caring for patients><cell adhesion protein><clinical practice><clinical relevance><clinical trial analysis><clinically relevant><data management><data management and coordinating center><data management center><design><designing><determine efficacy><double-blind placebo control trial><double-blind placebo controlled trial><double-masked controlled trial><efficacious intervention><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><emergency settings><endothelial cell derived relaxing factor><erythrolysis><evaluate efficacy><examine efficacy><experience><hospital days><hospital length of stay><hospital stay><improved><interventional strategy><kids><lung injury><metabolome><metabonome><mitochondrial><mitochondrial dysfunction><mortality><mortality rate><mortality ratio><mouse model><murine model><neglect><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><operation><operations><opiate consumption><opiate drug use><opiate intake><opiate use><opioid consumption><opioid drug use><opioid intake><opioid use><oxidation><pain score><pathway><pediatric><pediatric emergency><personnel><phase 3 trial><phase III trial><placebo controlled><pleiotropic effect><pleiotropism><pleiotropy><preparations><primary end point><primary endpoint><product development><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><randomisation><randomization><randomized placebo-controlled clinical trial><randomly assigned><resolutions><safety testing><sham therapy><sickle RBC><sickle cell disease><sickle cell disorder><sickle disease><sickle erythrocyte><sickle red blood cell><sicklemia><standard of care><technical skills><trend><vascular><vaso-occlusive pain><vasoocclusive pain><ward><youngster>\", \"pref_terms\": \"Absence of pain sensation;Accident and Emergency department;Acute;Acute Pain;Affect;African American population;Amino Acids;Area;Arginine;Biological;Biological Availability;Biometry;Blood;Blood Cells;Blood Vessels;Cell Adhesion Molecules;Cell Density;Child;Child Care;Childhood;Clinical;Clinical Trials;Communication;Complex;Data;Data Collection;Data Coordinating Center;Data Set;Death Rate;Dose;Double-Blind Method;Down-Regulation;Drug Kinetics;Electrons;Emergency department visit;Erythrocytes;Event;Goals;Hemolysis;Hemolytic Anemia;Hospitalization;Hospitals;Hour;Human Resources;Hydration status;Individual;Inflammatory;Inherited;Inpatients;Intervention;Leadership;Length of Stay;Maintenance;Manuals;Mitochondria;Monitor;Narcotics;Nitric Oxide;Pain;Pathway interactions;Patient Admission;Patient Care;Patients;Perfusion;Phase;Physiology;Placebo Control;Placebos;Plasma;Platelet Aggregation Inhibition;Preparation;Production;Protocols documentation;Qualifying;Randomized;Reperfusion Injury;Reporting;Research;Research Personnel;Resolution;Safety;Schools;Sickle Cell;Sickle Cell Anemia;Specimen;Supplementation;Syndrome;Technical Expertise;Testing;Therapy trial;Time;Training;Transgenic Mice;Universities;Utah;Vasodilator Agents;acute care;aged;arginase;arginine treatment;clinical practice;clinical trial analysis;clinically relevant;data management;design;double-blind placebo controlled trial;efficacious intervention;efficacy evaluation;efficacy testing;emergency settings;experience;improved;lung injury;metabolome;mitochondrial dysfunction;mortality;mouse model;neglect;new therapeutic target;novel therapeutics;operation;opioid use;oxidation;pain score;pediatric emergency;phase III trial;pleiotropism;primary endpoint;product development;randomized placebo-controlled clinical trial;safety testing;standard of care;trend;vaso-occlusive pain;ward\", \"abstract_text\": \"Project Summary/Abstract\\\\nVaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) are the leading cause of hospitalizations,\\\\nemergency room (ED) visits, and missed school, and are associated with an increased mortality rate. There are\\\\nno current therapies to relieve vaso-occlusion, with interventions limited to hydration and analgesia. Nitric oxide\\\\n(NO), produced by the 5-electron oxidation of L-arginine, is a potent vasodilator and exerts pleiotropic effects on\\\\nvascular and circulating blood cells, including the inhibition of platelet aggregation, down-regulation of adhesion\\\\nmolecules, and modulation of ischemia-reperfusion injury, all pathways adversely affected during VOE. We have\\\\nfound that pediatric SCD patients admitted with VOE have depleted plasma L-arginine levels. Additionally, we\\\\nhave now completed a single-center randomized, double-blinded, placebo-controlled trial of arginine therapy in\\\\n54 children with VOE requiring hospitalization. We observed a reduction in total opioid use (mg/kg) by 54% and\\\\nsigni\\\\ufb01cantly lower pain scores at discharge in children who received 5 days IV L-arginine therapy every 8 hours\\\\ncompared to placebo, as well as a clinically relevant trend in reduced length of hospital stay of approximately\\\\n17 hours. In pharmacokinetic studies, we found that IV arginine induced a dose-dependent improvement in\\\\nmitochondrial function in children with SCD hospitalized for pain. We now propose to extend these results to a\\\\npivotal phase 3 trial of L-arginine for VOE. We hypothesize that arginine is a safe intervention with narcotic-sparing\\\\neffects in pediatric SCD patients with VOE that will decrease the time children experience severe pain. Aim 1 of\\\\nthis study will determine the ef\\\\ufb01cacy of IV arginine therapy on the primary endpoint, time-to-crisis resolution, as\\\\nwell as total parenteral opioid use (mg/kg) and pain scores in children with SCD and VOE compared to placebo\\\\n(Ef\\\\ufb01cacy). Aim 2 will monitor for safety of IV L-arginine (Safety). Aim 3 will characterize alterations in the\\\\narginine metabolome and mitochondrial function in children with SCD and VOE, and evaluate how it is impacted\\\\nby IV arginine therapy (Exploratory). This proposal will provide essential data for product development and FDA\\\\nregulatory approval for use of arginine in SCD. Acute care of patients with SCD and pain in the ED is a neglected\\\\narea of research. The results of this study may ultimately lead to change in clinical practice for children with SCD\\\\nin both the ED and inpatient hospital wards. ED-based studies and novel therapies that target mechanisms of\\\\nvaso-occlusion and pain are needed in SCD.\", \"project_title\": \"2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial\", \"phr_text\": \"Project Narrative\\\\nPain is the hallmark of sickle cell disease (SCD), and is the leading cause of hospitalizations, emergency room\\\\nvisits, missed school, and is associated with an increased death rate. We found that patients with SCD and pain\\\\nhad low levels of the amino acid arginine in their blood, and we also demonstrated that arginine supplementation\\\\nduring acute pain events signi\\\\ufb01cantly reduced the amount of narcotics needed to treat sickle cell pain in children\\\\nand dramatically improved pain scores at discharge compared to placebo. We propose to investigate the bene\\\\ufb01ts\\\\nand safety of arginine for the treatment of patients with SCD and pain in a phase 3 randomized, placebo-controlled\\\\nclinical trial where neither the patient nor the clinical team know which therapy the patient is receiving, since\\\\nArginine is a promising new therapy that could change the way we treat acute pain in SCD.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 354912, \"indirect_cost_amt\": 186329, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10925255\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 68}, page_content='{\"appl_id\": 9972221, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"1U24HL148563-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"U24\", \"award_amount\": 659657, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"148563\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 659657, \"direct_cost_ic\": 432562, \"indirect_cost_ic\": 227095}], \"project_start_date\": \"2020-09-20T12:09:00Z\", \"project_end_date\": \"2026-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"F1\", \"name\": \"Special Emphasis Panel[ZHL1 CSR-H (F1)]\"}, \"award_notice_date\": \"2020-09-17T12:09:00Z\", \"core_project_num\": \"U24HL148563\", \"terms\": \"<Affect><Amino Acids><aminoacid><Hemolytic Anemia><Sickle Cell Anemia><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle disease><sicklemia><arginase><Hepatic Proliferation Inhibitor><L arginine amidinohydrolase><Liver Immunoregulatory Protein><Liver-Derived Inhibitory Protein><arginine amidinase><canavanase><Arginine><L-Arginine><Biological Availability><Bioavailability><Biologic Availability><Physiologic Availability><Biometry><Biometrics><Biostatistics><Blood><Blood Reticuloendothelial System><Blood Cells><Peripheral Blood Cell><Blood Vessels><vascular><Cell Adhesion Molecules><Adhesion Molecule><Cell Adhesion Molecule Gene><cell adhesion protein><Cells><Cell Body><Child><0-11 years old><Child Youth><Children (0-21)><children><childrens\\'><youngster><Child Care><Puericulture><Communication><Controlled Clinical Trials><Data Collection><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Down-Regulation><Downregulation><Electrons><Negative Beta Particle><Negatrons><Erythrocytes><Blood erythrocyte><Erythrocytic><Marrow erythrocyte><Red Blood Cells><Red Cell><blood corpuscles><Patient Care><Patient Care Delivery><Goals><Hemolysis><erythrolysis><Hospitalization><Hospital Admission><Hospitals><Inpatients><Lead><Pb element><heavy metal Pb><heavy metal lead><Leadership><Length of Stay><Number of Days in Hospital><hospital days><hospital length of stay><hospital stay><Maintenance><Manuals><Transgenic Mice><Mitochondria><mitochondrial><mortality><Narcotics><Nitric Oxide><Endogenous Nitrate Vasodilator><Endothelium-Derived Nitric Oxide><Mononitrogen Monoxide><Nitrogen Monoxide><Nitrogen Protoxide><endothelial cell derived relaxing factor><oxidation><Pain><Painful><Patients><Perfusion><Drug Kinetics><Pharmacokinetics><Physiology><Placebos><Sham Treatment><sham therapy><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Production><Reperfusion Injury><Ischemia-Reperfusion Injury><Reperfusion Damage><Research><Research Personnel><Investigators><Researchers><Safety><Schools><Syndrome><Testing><Time><Universities><Utah><Vasodilator Agents><Vasodilating Agent><Vasodilator Drugs><Vasodilators><Technical Expertise><technical skills><Afro American><Afroamerican><Black Populations><black American><African American><Dataset><Data Set><Cell Density><base><improved><Acute Pain><Area><Acute><Clinical><Phase><Biological><Death Rate><Training><sickle RBC><sickle erythrocyte><sickle red blood cell><Sickle Cell><pediatric><Childhood><Individual><Logistics><Lung damage><lung injury><Inflammatory><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Absence of pain sensation><Research Specimen><Specimen><Hour><Hereditary><Inherited><Complex><Event><Protocol><Protocols documentation><Emergency Department><Emergency room><Accident and Emergency department><data management><experience><pleiotropic effect><pleiotropy><pleiotropism><Manpower><personnel><Human Resources><Reporting><Intervention Strategies><interventional strategy><Intervention><Platelet Aggregation Inhibition><ward><Hydration><Hydration status><Dose><Data><randomisation><randomization><randomly assigned><Randomized><Resolution><Supplementation><Monitor><trend><Preparation><pathway><Pathway interactions><implementation trial><double-masked controlled trial><double-blind placebo controlled trial><neglect><Data Coordination Center><Data Coordinating Center><designing><design><aged><clinical relevance><clinically relevant><arginine treatment><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel therapy><novel therapeutics><mitochondrial dysfunction><murine model><mouse model><new drug target><new druggable target><new pharmacotherapy target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><new therapeutic target><standard of care><product development><clinical practice><safety testing><efficacy testing><vasoocclusive pain><vaso-occlusive pain><operation><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><Emergency department visit><Therapy trial><phase 3 trial><phase III trial><metabonome><metabolome><opiate consumption><opiate drug use><opiate intake><opiate use><opioid consumption><opioid drug use><opioid intake><opioid use><emergency settings><pediatric emergency><pain score><primary end point><primary endpoint><acute care><randomized placebo-controlled clinical trial><clinical trial analysis>\", \"pref_terms\": \"Absence of pain sensation;Accident and Emergency department;Acute;Acute Pain;Affect;African American;Amino Acids;Area;Arginine;Biological;Biological Availability;Biometry;Blood;Blood Cells;Blood Vessels;Cell Adhesion Molecules;Cell Density;Cells;Child;Child Care;Childhood;Clinical;Communication;Complex;Controlled Clinical Trials;Data;Data Collection;Data Coordinating Center;Data Set;Death Rate;Disease;Dose;Double-Blind Method;Down-Regulation;Drug Kinetics;Electrons;Emergency department visit;Erythrocytes;Event;Goals;Hemolysis;Hemolytic Anemia;Hospitalization;Hospitals;Hour;Human Resources;Hydration status;Individual;Inflammatory;Inherited;Inpatients;Intervention;Lead;Leadership;Length of Stay;Logistics;Maintenance;Manuals;Mitochondria;Monitor;Narcotics;Nitric Oxide;Pain;Pathway interactions;Patient Care;Patients;Perfusion;Phase;Physiology;Placebos;Plasma;Platelet Aggregation Inhibition;Preparation;Production;Protocols documentation;Randomized;Reperfusion Injury;Reporting;Research;Research Personnel;Resolution;Safety;Schools;Sickle Cell;Sickle Cell Anemia;Specimen;Supplementation;Syndrome;Technical Expertise;Testing;Therapy trial;Time;Training;Transgenic Mice;Universities;Utah;Vasodilator Agents;acute care;aged;arginase;arginine treatment;base;clinical practice;clinical trial analysis;clinically relevant;data management;design;double-blind placebo controlled trial;efficacy testing;emergency settings;experience;implementation trial;improved;lung injury;metabolome;mitochondrial dysfunction;mortality;mouse model;neglect;new therapeutic target;novel therapeutics;operation;opioid use;oxidation;pain score;pediatric emergency;phase III trial;pleiotropism;primary endpoint;product development;randomized placebo-controlled clinical trial;safety testing;standard of care;trend;vaso-occlusive pain;ward\", \"abstract_text\": \"Project Summary/Abstract\\\\nVaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) are the leading cause of hospitalizations,\\\\nemergency room (ED) visits, and missed school, and are associated with an increased mortality rate. There are\\\\nno current therapies to relieve vaso-occlusion, with interventions limited to hydration and analgesia. Nitric oxide\\\\n(NO), produced by the 5-electron oxidation of L-arginine, is a potent vasodilator and exerts pleiotropic effects on\\\\nvascular and circulating blood cells, including the inhibition of platelet aggregation, down-regulation of adhesion\\\\nmolecules, and modulation of ischemia-reperfusion injury, all pathways adversely affected during VOE. We have\\\\nfound that pediatric SCD patients admitted with VOE have depleted plasma L-arginine levels. Additionally, we\\\\nhave now completed a single-center randomized, double-blinded, placebo-controlled trial of arginine therapy in\\\\n54 children with VOE requiring hospitalization. We observed a reduction in total opioid use (mg/kg) by 54% and\\\\nsigni\\\\ufb01cantly lower pain scores at discharge in children who received 5 days IV L-arginine therapy every 8 hours\\\\ncompared to placebo, as well as a clinically relevant trend in reduced length of hospital stay of approximately\\\\n17 hours. In pharmacokinetic studies, we found that IV arginine induced a dose-dependent improvement in\\\\nmitochondrial function in children with SCD hospitalized for pain. We now propose to extend these results to a\\\\npivotal phase 3 trial of L-arginine for VOE. We hypothesize that arginine is a safe intervention with narcotic-sparing\\\\neffects in pediatric SCD patients with VOE that will decrease the time children experience severe pain. Aim 1 of\\\\nthis study will determine the ef\\\\ufb01cacy of IV arginine therapy on the primary endpoint, time-to-crisis resolution, as\\\\nwell as total parenteral opioid use (mg/kg) and pain scores in children with SCD and VOE compared to placebo\\\\n(Ef\\\\ufb01cacy). Aim 2 will monitor for safety of IV L-arginine (Safety). Aim 3 will characterize alterations in the\\\\narginine metabolome and mitochondrial function in children with SCD and VOE, and evaluate how it is impacted\\\\nby IV arginine therapy (Exploratory). This proposal will provide essential data for product development and FDA\\\\nregulatory approval for use of arginine in SCD. Acute care of patients with SCD and pain in the ED is a neglected\\\\narea of research. The results of this study may ultimately lead to change in clinical practice for children with SCD\\\\nin both the ED and inpatient hospital wards. ED-based studies and novel therapies that target mechanisms of\\\\nvaso-occlusion and pain are needed in SCD.\", \"project_title\": \"2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial\", \"phr_text\": \"Project Narrative\\\\nPain is the hallmark of sickle cell disease (SCD), and is the leading cause of hospitalizations, emergency room\\\\nvisits, missed school, and is associated with an increased death rate. We found that patients with SCD and pain\\\\nhad low levels of the amino acid arginine in their blood, and we also demonstrated that arginine supplementation\\\\nduring acute pain events signi\\\\ufb01cantly reduced the amount of narcotics needed to treat sickle cell pain in children\\\\nand dramatically improved pain scores at discharge compared to placebo. We propose to investigate the bene\\\\ufb01ts\\\\nand safety of arginine for the treatment of patients with SCD and pain in a phase 3 randomized, placebo-controlled\\\\nclinical trial where neither the patient nor the clinical team know which therapy the patient is receiving, since\\\\nArginine is a promising new therapy that could change the way we treat acute pain in SCD.\", \"spending_categories_desc\": \"Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Hematology; Orphan Drug; Pain Research; Pediatric; Rare Diseases; Sickle Cell Disease\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-09-20T12:09:00Z\", \"budget_end\": \"2021-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 432562, \"indirect_cost_amt\": 227095, \"project_detail_url\": \"https://reporter.nih.gov/project-details/9972221\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 69}, page_content='{\"appl_id\": 10681380, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5U24HL148563-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 535940, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"148563\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 535940, \"direct_cost_ic\": 364519, \"indirect_cost_ic\": 191373}], \"project_start_date\": \"2020-09-20T12:09:00Z\", \"project_end_date\": \"2026-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"F1\", \"name\": \"ZHL1-CSR-H(F1)\"}, \"award_notice_date\": \"2023-09-08T12:09:00Z\", \"core_project_num\": \"U24HL148563\", \"terms\": \"<Affect><aminoacid><Amino Acids><Hemolytic Anemia><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><Sickle Cell Anemia><arginase><Hepatic Proliferation Inhibitor><L arginine amidinohydrolase><Liver Immunoregulatory Protein><Liver-Derived Inhibitory Protein><arginine amidinase><canavanase><Arginine><L-Arginine><Biological Availability><Bioavailability><Physiologic Availability><Biometry><Biometrics><Biostatistics><Blood><Blood Reticuloendothelial System><Blood Cells><Peripheral Blood Cell><Blood Vessels><vascular><Cell Adhesion Molecules><Adhesion Molecule><Cell Adhesion Molecule Gene><cell adhesion protein><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Child Care><Puericulture><Clinical Trials><Communication><Data Collection><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Down-Regulation><Electrons><Negative Beta Particle><Negatrons><Erythrocytes><Blood erythrocyte><Erythrocytic><Marrow erythrocyte><Red Blood Cells><Red Cell><blood corpuscles><Patient Care><Patient Care Delivery><Goals><Hemolysis><erythrolysis><Hospitalization><Hospital Admission><Hospitals><Inpatients><Leadership><Length of Stay><Number of Days in Hospital><hospital days><hospital length of stay><hospital stay><Maintenance><Manuals><Transgenic Mice><Mitochondria><mitochondrial><mortality><Narcotics><Nitric Oxide><Endogenous Nitrate Vasodilator><Endothelium-Derived Nitric Oxide><Mononitrogen Monoxide><Nitrogen Monoxide><Nitrogen Protoxide><endothelial cell derived relaxing factor><oxidation><Pain><Painful><Patient Admission><Patients><Perfusion><Drug Kinetics><Pharmacokinetics><Physiology><Placebos><Sham Treatment><sham therapy><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Production><Reperfusion Injury><Ischemia-Reperfusion Injury><Reperfusion Damage><Research><Research Personnel><Investigators><Researchers><Safety><Schools><Syndrome><Testing><Time><Universities><Utah><Vasodilator Agents><Vasodilating Agent><Vasodilator Drugs><Vasodilators><Technical Expertise><technical skills><Data Set><Cell Density><improved><Acute Pain><Area><Acute><Clinical><Phase><biologic><Biological><Death Rate><Training><sickle RBC><sickle erythrocyte><sickle red blood cell><Sickle Cell><pediatric><Childhood><Individual><Lung damage><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><lung injury><Inflammatory><Absence of pain sensation><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Specimen><Research Specimen><Hour><Inherited><Hereditary><Complex><Event><Protocols documentation><Protocol><Accident and Emergency department><Emergency Department><Emergency room><data management><experience><pleiotropism><pleiotropic effect><pleiotropy><Human Resources><Manpower><personnel><Reporting><Intervention><Intervention Strategies><interventional strategy><Platelet Aggregation Inhibition><ward><Hydration><Hydration status><Dose><Data><Qualifying><Randomized><randomisation><randomization><randomly assigned><Resolution><resolutions><Supplementation><Monitor><trend><Preparation><preparations><Pathway interactions><pathway><Placebo Control><placebo controlled><double-blind placebo control trial><double-masked controlled trial><double-blind placebo controlled trial><neglect><Data Coordination Center><data management and coordinating center><data management center><Data Coordinating Center><designing><design><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy examination><evaluate efficacy><examine efficacy><efficacy evaluation><aged><clinical relevance><clinically relevant><arginine treatment><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapy><novel therapeutics><mitochondrial dysfunction><murine model><mouse model><new drug target><new druggable target><new pharmacotherapy target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><new therapeutic target><standard of care><product development><clinical practice><safety testing><efficacy testing><vasoocclusive pain><vaso-occlusive pain><operations><operation><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><Emergency department visit><Therapy trial><phase 3 trial><phase III trial><metabonome><metabolome><opiate consumption><opiate drug use><opiate intake><opiate use><opioid consumption><opioid drug use><opioid intake><opioid use><emergency settings><pediatric emergency><pain score><primary end point><primary endpoint><acute care><randomized placebo-controlled clinical trial><clinical trial analysis><efficacious intervention><African American population><African American group><African American individual><African American people><African Americans>\", \"pref_terms\": \"Absence of pain sensation;Accident and Emergency department;Acute;Acute Pain;Affect;African American population;Amino Acids;Area;Arginine;Biological;Biological Availability;Biometry;Blood;Blood Cells;Blood Vessels;Cell Adhesion Molecules;Cell Density;Child;Child Care;Childhood;Clinical;Clinical Trials;Communication;Complex;Data;Data Collection;Data Coordinating Center;Data Set;Death Rate;Dose;Double-Blind Method;Down-Regulation;Drug Kinetics;Electrons;Emergency department visit;Erythrocytes;Event;Goals;Hemolysis;Hemolytic Anemia;Hospitalization;Hospitals;Hour;Human Resources;Hydration status;Individual;Inflammatory;Inherited;Inpatients;Intervention;Leadership;Length of Stay;Maintenance;Manuals;Mitochondria;Monitor;Narcotics;Nitric Oxide;Pain;Pathway interactions;Patient Admission;Patient Care;Patients;Perfusion;Phase;Physiology;Placebo Control;Placebos;Plasma;Platelet Aggregation Inhibition;Preparation;Production;Protocols documentation;Qualifying;Randomized;Reperfusion Injury;Reporting;Research;Research Personnel;Resolution;Safety;Schools;Sickle Cell;Sickle Cell Anemia;Specimen;Supplementation;Syndrome;Technical Expertise;Testing;Therapy trial;Time;Training;Transgenic Mice;Universities;Utah;Vasodilator Agents;acute care;aged;arginase;arginine treatment;clinical practice;clinical trial analysis;clinically relevant;data management;design;double-blind placebo controlled trial;efficacious intervention;efficacy evaluation;efficacy testing;emergency settings;experience;improved;lung injury;metabolome;mitochondrial dysfunction;mortality;mouse model;neglect;new therapeutic target;novel therapeutics;operation;opioid use;oxidation;pain score;pediatric emergency;phase III trial;pleiotropism;primary endpoint;product development;randomized placebo-controlled clinical trial;safety testing;standard of care;trend;vaso-occlusive pain;ward\", \"abstract_text\": \"Project Summary/Abstract\\\\nVaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) are the leading cause of hospitalizations,\\\\nemergency room (ED) visits, and missed school, and are associated with an increased mortality rate. There are\\\\nno current therapies to relieve vaso-occlusion, with interventions limited to hydration and analgesia. Nitric oxide\\\\n(NO), produced by the 5-electron oxidation of L-arginine, is a potent vasodilator and exerts pleiotropic effects on\\\\nvascular and circulating blood cells, including the inhibition of platelet aggregation, down-regulation of adhesion\\\\nmolecules, and modulation of ischemia-reperfusion injury, all pathways adversely affected during VOE. We have\\\\nfound that pediatric SCD patients admitted with VOE have depleted plasma L-arginine levels. Additionally, we\\\\nhave now completed a single-center randomized, double-blinded, placebo-controlled trial of arginine therapy in\\\\n54 children with VOE requiring hospitalization. We observed a reduction in total opioid use (mg/kg) by 54% and\\\\nsigni\\\\ufb01cantly lower pain scores at discharge in children who received 5 days IV L-arginine therapy every 8 hours\\\\ncompared to placebo, as well as a clinically relevant trend in reduced length of hospital stay of approximately\\\\n17 hours. In pharmacokinetic studies, we found that IV arginine induced a dose-dependent improvement in\\\\nmitochondrial function in children with SCD hospitalized for pain. We now propose to extend these results to a\\\\npivotal phase 3 trial of L-arginine for VOE. We hypothesize that arginine is a safe intervention with narcotic-sparing\\\\neffects in pediatric SCD patients with VOE that will decrease the time children experience severe pain. Aim 1 of\\\\nthis study will determine the ef\\\\ufb01cacy of IV arginine therapy on the primary endpoint, time-to-crisis resolution, as\\\\nwell as total parenteral opioid use (mg/kg) and pain scores in children with SCD and VOE compared to placebo\\\\n(Ef\\\\ufb01cacy). Aim 2 will monitor for safety of IV L-arginine (Safety). Aim 3 will characterize alterations in the\\\\narginine metabolome and mitochondrial function in children with SCD and VOE, and evaluate how it is impacted\\\\nby IV arginine therapy (Exploratory). This proposal will provide essential data for product development and FDA\\\\nregulatory approval for use of arginine in SCD. Acute care of patients with SCD and pain in the ED is a neglected\\\\narea of research. The results of this study may ultimately lead to change in clinical practice for children with SCD\\\\nin both the ED and inpatient hospital wards. ED-based studies and novel therapies that target mechanisms of\\\\nvaso-occlusion and pain are needed in SCD.\", \"project_title\": \"2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial\", \"phr_text\": \"Project Narrative\\\\nPain is the hallmark of sickle cell disease (SCD), and is the leading cause of hospitalizations, emergency room\\\\nvisits, missed school, and is associated with an increased death rate. We found that patients with SCD and pain\\\\nhad low levels of the amino acid arginine in their blood, and we also demonstrated that arginine supplementation\\\\nduring acute pain events signi\\\\ufb01cantly reduced the amount of narcotics needed to treat sickle cell pain in children\\\\nand dramatically improved pain scores at discharge compared to placebo. We propose to investigate the bene\\\\ufb01ts\\\\nand safety of arginine for the treatment of patients with SCD and pain in a phase 3 randomized, placebo-controlled\\\\nclinical trial where neither the patient nor the clinical team know which therapy the patient is receiving, since\\\\nArginine is a promising new therapy that could change the way we treat acute pain in SCD.\", \"spending_categories_desc\": \"Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Hematology; Orphan Drug; Pain Research; Pediatric; Rare Diseases; Sickle Cell Disease\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-09-01T12:09:00Z\", \"budget_end\": \"2024-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 364519, \"indirect_cost_amt\": 191373, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10681380\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 70}, page_content='{\"appl_id\": 10488190, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5U24HL148563-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 553409, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"148563\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 553409, \"direct_cost_ic\": 426969, \"indirect_cost_ic\": 224159}], \"project_start_date\": \"2020-09-20T12:09:00Z\", \"project_end_date\": \"2026-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"F1\", \"name\": \"ZHL1-CSR-H(F1)\"}, \"award_notice_date\": \"2022-08-10T12:08:00Z\", \"core_project_num\": \"U24HL148563\", \"terms\": \"<Affect><Amino Acids><aminoacid><Hemolytic Anemia><Sickle Cell Anemia><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><arginase><Hepatic Proliferation Inhibitor><L arginine amidinohydrolase><Liver Immunoregulatory Protein><Liver-Derived Inhibitory Protein><arginine amidinase><canavanase><Arginine><L-Arginine><Biological Availability><Bioavailability><Biologic Availability><Physiologic Availability><Biometry><Biometrics><Biostatistics><Blood><Blood Reticuloendothelial System><Blood Cells><Peripheral Blood Cell><Blood Vessels><vascular><Cell Adhesion Molecules><Adhesion Molecule><Cell Adhesion Molecule Gene><cell adhesion protein><Cells><Cell Body><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Child Care><Puericulture><Communication><Controlled Clinical Trials><Data Collection><Disease><Disorder><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Down-Regulation><Downregulation><Electrons><Negative Beta Particle><Negatrons><Erythrocytes><Blood erythrocyte><Erythrocytic><Marrow erythrocyte><Red Blood Cells><Red Cell><blood corpuscles><Patient Care><Patient Care Delivery><Goals><Hemolysis><erythrolysis><Hospitalization><Hospital Admission><Hospitals><Inpatients><Lead><Pb element><heavy metal Pb><heavy metal lead><Leadership><Length of Stay><Number of Days in Hospital><hospital days><hospital length of stay><hospital stay><Maintenance><Manuals><Transgenic Mice><Mitochondria><mitochondrial><mortality><Narcotics><Endogenous Nitrate Vasodilator><Endothelium-Derived Nitric Oxide><Mononitrogen Monoxide><Nitrogen Monoxide><Nitrogen Protoxide><endothelial cell derived relaxing factor><Nitric Oxide><oxidation><Painful><Pain><Patients><Perfusion><Pharmacokinetics><Drug Kinetics><Physiology><Sham Treatment><sham therapy><Placebos><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma><Production><Ischemia-Reperfusion Injury><Reperfusion Damage><Reperfusion Injury><Research><Investigators><Researchers><Research Personnel><Safety><Schools><Syndrome><Testing><Time><Universities><Utah><Vasodilator Agents><Vasodilating Agent><Vasodilator Drugs><Vasodilators><Technical Expertise><technical skills><Data Set><Dataset><Cell Density><base><improved><Acute Pain><Area><Acute><Clinical><Phase><Biological><biologic><Death Rate><Training><sickle RBC><sickle erythrocyte><sickle red blood cell><Sickle Cell><pediatric><Childhood><Individual><Logistics><Lung damage><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><lung injury><Inflammatory><Absence of sensibility to pain><Feels no pain><No sensitivity to pain><analgesia><Absence of pain sensation><Research Specimen><Specimen><Hour><Hereditary><Inherited><Complex><Event><Protocol><Protocols documentation><Emergency Department><Emergency room><Accident and Emergency department><data management><experience><pleiotropic effect><pleiotropy><pleiotropism><Manpower><personnel><Human Resources><Reporting><Intervention Strategies><interventional strategy><Intervention><Platelet Aggregation Inhibition><ward><Hydration><Hydration status><Dose><Data><randomisation><randomization><randomly assigned><Randomized><Resolution><Supplementation><Monitor><trend><Preparation><Pathway interactions><pathway><Placebo Control><placebo controlled><double-blind placebo controlled trial><double-blind placebo control trial><double-masked controlled trial><neglect><Data Coordinating Center><Data Coordination Center><design><designing><aged><clinically relevant><clinical relevance><arginine treatment><novel therapeutics><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel therapy><mitochondrial dysfunction><mouse model><murine model><new therapeutic target><new drug target><new druggable target><new pharmacotherapy target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><standard of care><product development><clinical practice><safety testing><efficacy testing><vaso-occlusive pain><vasoocclusive pain><operation><Emergency department visit><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><Therapy trial><phase III trial><phase 3 trial><metabolome><metabonome><opioid use><opiate consumption><opiate drug use><opiate intake><opiate use><opioid consumption><opioid drug use><opioid intake><emergency settings><pediatric emergency><pain score><primary endpoint><primary end point><acute care><randomized placebo-controlled clinical trial><clinical trial analysis><efficacious intervention><African American population><African American group><African American individual><African American people><African Americans>\", \"pref_terms\": \"Absence of pain sensation;Accident and Emergency department;Acute;Acute Pain;Affect;African American population;Amino Acids;Area;Arginine;Biological;Biological Availability;Biometry;Blood;Blood Cells;Blood Vessels;Cell Adhesion Molecules;Cell Density;Cells;Child;Child Care;Childhood;Clinical;Communication;Complex;Controlled Clinical Trials;Data;Data Collection;Data Coordinating Center;Data Set;Death Rate;Disease;Dose;Double-Blind Method;Down-Regulation;Drug Kinetics;Electrons;Emergency department visit;Erythrocytes;Event;Goals;Hemolysis;Hemolytic Anemia;Hospitalization;Hospitals;Hour;Human Resources;Hydration status;Individual;Inflammatory;Inherited;Inpatients;Intervention;Lead;Leadership;Length of Stay;Logistics;Maintenance;Manuals;Mitochondria;Monitor;Narcotics;Nitric Oxide;Pain;Pathway interactions;Patient Care;Patients;Perfusion;Phase;Physiology;Placebo Control;Placebos;Plasma;Platelet Aggregation Inhibition;Preparation;Production;Protocols documentation;Randomized;Reperfusion Injury;Reporting;Research;Research Personnel;Resolution;Safety;Schools;Sickle Cell;Sickle Cell Anemia;Specimen;Supplementation;Syndrome;Technical Expertise;Testing;Therapy trial;Time;Training;Transgenic Mice;Universities;Utah;Vasodilator Agents;acute care;aged;arginase;arginine treatment;base;clinical practice;clinical trial analysis;clinically relevant;data management;design;double-blind placebo controlled trial;efficacious intervention;efficacy testing;emergency settings;experience;improved;lung injury;metabolome;mitochondrial dysfunction;mortality;mouse model;neglect;new therapeutic target;novel therapeutics;operation;opioid use;oxidation;pain score;pediatric emergency;phase III trial;pleiotropism;primary endpoint;product development;randomized placebo-controlled clinical trial;safety testing;standard of care;trend;vaso-occlusive pain;ward\", \"abstract_text\": \"Project Summary/Abstract\\\\nVaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) are the leading cause of hospitalizations,\\\\nemergency room (ED) visits, and missed school, and are associated with an increased mortality rate. There are\\\\nno current therapies to relieve vaso-occlusion, with interventions limited to hydration and analgesia. Nitric oxide\\\\n(NO), produced by the 5-electron oxidation of L-arginine, is a potent vasodilator and exerts pleiotropic effects on\\\\nvascular and circulating blood cells, including the inhibition of platelet aggregation, down-regulation of adhesion\\\\nmolecules, and modulation of ischemia-reperfusion injury, all pathways adversely affected during VOE. We have\\\\nfound that pediatric SCD patients admitted with VOE have depleted plasma L-arginine levels. Additionally, we\\\\nhave now completed a single-center randomized, double-blinded, placebo-controlled trial of arginine therapy in\\\\n54 children with VOE requiring hospitalization. We observed a reduction in total opioid use (mg/kg) by 54% and\\\\nsigni\\\\ufb01cantly lower pain scores at discharge in children who received 5 days IV L-arginine therapy every 8 hours\\\\ncompared to placebo, as well as a clinically relevant trend in reduced length of hospital stay of approximately\\\\n17 hours. In pharmacokinetic studies, we found that IV arginine induced a dose-dependent improvement in\\\\nmitochondrial function in children with SCD hospitalized for pain. We now propose to extend these results to a\\\\npivotal phase 3 trial of L-arginine for VOE. We hypothesize that arginine is a safe intervention with narcotic-sparing\\\\neffects in pediatric SCD patients with VOE that will decrease the time children experience severe pain. Aim 1 of\\\\nthis study will determine the ef\\\\ufb01cacy of IV arginine therapy on the primary endpoint, time-to-crisis resolution, as\\\\nwell as total parenteral opioid use (mg/kg) and pain scores in children with SCD and VOE compared to placebo\\\\n(Ef\\\\ufb01cacy). Aim 2 will monitor for safety of IV L-arginine (Safety). Aim 3 will characterize alterations in the\\\\narginine metabolome and mitochondrial function in children with SCD and VOE, and evaluate how it is impacted\\\\nby IV arginine therapy (Exploratory). This proposal will provide essential data for product development and FDA\\\\nregulatory approval for use of arginine in SCD. Acute care of patients with SCD and pain in the ED is a neglected\\\\narea of research. The results of this study may ultimately lead to change in clinical practice for children with SCD\\\\nin both the ED and inpatient hospital wards. ED-based studies and novel therapies that target mechanisms of\\\\nvaso-occlusion and pain are needed in SCD.\", \"project_title\": \"2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial\", \"phr_text\": \"Project Narrative\\\\nPain is the hallmark of sickle cell disease (SCD), and is the leading cause of hospitalizations, emergency room\\\\nvisits, missed school, and is associated with an increased death rate. We found that patients with SCD and pain\\\\nhad low levels of the amino acid arginine in their blood, and we also demonstrated that arginine supplementation\\\\nduring acute pain events signi\\\\ufb01cantly reduced the amount of narcotics needed to treat sickle cell pain in children\\\\nand dramatically improved pain scores at discharge compared to placebo. We propose to investigate the bene\\\\ufb01ts\\\\nand safety of arginine for the treatment of patients with SCD and pain in a phase 3 randomized, placebo-controlled\\\\nclinical trial where neither the patient nor the clinical team know which therapy the patient is receiving, since\\\\nArginine is a promising new therapy that could change the way we treat acute pain in SCD.\", \"spending_categories_desc\": \"Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Hematology; Orphan Drug; Pain Research; Pediatric; Rare Diseases; Sickle Cell Disease\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-09-01T12:09:00Z\", \"budget_end\": \"2023-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 426969, \"indirect_cost_amt\": 224159, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10488190\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 71}, page_content='{\"appl_id\": 9891812, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"1U24HL147018-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"U24\", \"award_amount\": 906728, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"147018\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 906728, \"direct_cost_ic\": 594576, \"indirect_cost_ic\": 312152}], \"project_start_date\": \"2020-09-15T12:09:00Z\", \"project_end_date\": \"2025-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"O1\", \"name\": \"Special Emphasis Panel[ZHL1 CSR-H (O1)]\"}, \"award_notice_date\": \"2020-09-14T12:09:00Z\", \"core_project_num\": \"U24HL147018\", \"terms\": \"<Age><ages><airway obstruction><airflow limitation><airflow obstruction><airway limitation><obstructed airflow><obstructed airway><Ambulatory Care Facilities><Outpatient Clinics><Antibiotics><Antibiotic Agents><Antibiotic Drugs><Miscellaneous Antibiotic><Asthma><Bronchial Asthma><Bacteria><Bacterial Infections><bacteria infection><bacterial disease><Biometry><Biometrics><Biostatistics><Cephalosporins><Child><0-11 years old><Child Youth><Children (0-21)><children><childrens\\'><youngster><Preschool Child><1-5 years old><preschool child (1-5)><Clinical Trials><Communication><Data Collection><Diagnosis><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Future><Goals><Hospitalization><Hospital Admission><Leadership><Maintenance><Manuals><Microbiology><Nasopharynx><Rhinopharynx><nasopharnygeal><Penicillins><Pharyngeal structure><Pharynx><Throat><Placebos><Sham Treatment><sham therapy><Play><Production><Recommendation><Research><Research Personnel><Investigators><Researchers><Risk><Risk Factors><Role><social role><Nursery Schools><pre-k><pre-kindergarten><preschool><Testing><United States><Universities><Utah><Virus><Wheezing><wheeze><Azithromycin><Azadose><Azitrocin><Azythromycin><Ultreon><Zithromax><Zitromax><Technical Expertise><technical skills><Health Care Costs><Health Costs><Healthcare Costs><Dataset><Data Set><Bacteria resistance><Bacteria resistant><Bacterial resistant><resistance to Bacteria><resistance to Bacterial><resistant to Bacteria><resistant to Bacterial><bacterial resistance><Guidelines><Acute><Clinical><Biological><psychological><psychologic><Training><disability><Health Care Utilization><health care service use><healthcare service use><healthcare service utilization><healthcare utilization><health care service utilization><Logistics><Antibacterial Agents><anti-bacterial><antibacterial><Anti-Bacterial Agents><Macrolides><Genetic><Research Specimen><Specimen><Life><Severities><Event><Protocol><Protocols documentation><Source><lower respiratory tract><Lower respiratory tract structure><respiratory><Emergency Department><Emergency room><Accident and Emergency department><age group><data management><experience><microbial><Applied Science><Applied Research><Toddler><Manpower><personnel><Human Resources><Reporting><social><Admission><Admission activity><Sampling><Property><response><Symptoms><Multi-center clinical trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><Multi-Institutional Clinical Trial><randomisation><randomization><randomly assigned><Randomized><anti-inflammatory effect><Antiinflammatory Effect><Clinical Trials Design><Monitor><Preparation><ED care><ER care><Emergency Department care><Emergency Room care><Emergency health care><Emergency healthcare><Emergency medical care><Emergency Care><implementation trial><Data Coordination Center><Data Coordinating Center><designing><design><clinical site><clinical research site><Outcome><bacterial pathogen><pathogenic bacteria><Population><Prevalence><aged><6 years of age><age 6 years><six year old><six years of age><6 year old><resistant><Resistance><community microbes><microbial community><Microbe><high risk><improve symptom><symptom improvement><symptomatic improvement><efficacy testing><arm><operation><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><Emergency department visit><emergency settings><pediatric emergency><hospitalization rates><treatment guidelines><clinical trial analysis>\", \"pref_terms\": \"6 year old;Accident and Emergency department;Acute;Admission activity;Age;Ambulatory Care Facilities;Anti-Bacterial Agents;Antibiotics;Antiinflammatory Effect;Applied Research;Asthma;Azithromycin;Bacteria;Bacterial Infections;Biological;Biometry;Cephalosporins;Child;Clinical;Clinical Trials;Clinical Trials Design;Communication;Data Collection;Data Coordinating Center;Data Set;Diagnosis;Double-Blind Method;Emergency Care;Emergency department visit;Event;Future;Genetic;Goals;Guidelines;Health Care Costs;Hospitalization;Human Resources;Leadership;Life;Logistics;Lower respiratory tract structure;Macrolides;Maintenance;Manuals;Microbe;Microbiology;Monitor;Multi-Institutional Clinical Trial;Nasopharynx;Nursery Schools;Outcome;Penicillins;Pharyngeal structure;Placebos;Play;Population;Preparation;Preschool Child;Prevalence;Production;Property;Protocols documentation;Randomized;Recommendation;Reporting;Research;Research Personnel;Resistance;Risk;Risk Factors;Role;Sampling;Severities;Source;Specimen;Symptoms;Technical Expertise;Testing;Toddler;Training;United States;Universities;Utah;Virus;Wheezing;age group;aged;airway obstruction;arm;bacterial resistance;clinical research site;clinical trial analysis;data management;design;disability;efficacy testing;emergency settings;experience;health care service utilization;high risk;hospitalization rates;implementation trial;microbial;microbial community;operation;pathogenic bacteria;pediatric emergency;psychologic;respiratory;response;social;symptomatic improvement;treatment guidelines\", \"abstract_text\": \"Project Summary/Abstract\\\\nOver 2.2 million children aged 2\\\\u20135 years have wheezing episodes that are severe enough to require Emergency\\\\nDepartment (ED) visits each year in the United States, and 15% of these children require hospitalization. There\\\\nis new evidence suggesting that harmful bacteria growing in the throat may play an important role in determining\\\\nwhich preschoolers will wheeze and then go on to develop asthma. Bacteria and viruses are equally associated\\\\nwith the risk of acute episodes of wheezing in preschoolers, and antibiotics may be a potential treatment. Two\\\\nlarge, well-designed clinical trials performed in outpatient clinics recently showed a signi\\\\ufb01cant reduction in severe\\\\nsymptoms when children were treated with the antibiotic Azithromycin (AZ) either before or after they started\\\\nwheezing. Though these results are encouraging, we are not sure how this bene\\\\ufb01t occurs since AZ has both\\\\nanti-bacterial and anti-in\\\\ufb02ammatory effects. In addition, we do not know if AZ could be effective in more severe\\\\ncases, like those requiring ED visits. The relatively underprivileged preschoolers who present to the ED for care\\\\nof their severe wheezing episodes are usually sicker and with greater risk factors for bacterial infections. They\\\\nare, therefore, the population that may get the greatest bene\\\\ufb01t, if AZ is shown to be effective in this setting. We\\\\npropose a trial in preschool age children coming to the ED with severe wheezing who will be treated with either\\\\nAZ or placebo. We will also determine which bacteria are growing in the children\\'s pharynx. This will answer the\\\\nquestion \\\\u201cDoes Azithromycin make children with severe wheezing better sooner and, if so, is that bene\\\\ufb01t seen\\\\nin all the children treated or only in those with potentially harmful bacteria in their throats?\\\\u201d There is concern\\\\nthat excessive use of antibiotics may cause bacterial resistance to their effects. We will thus determine if genetic\\\\nfactors or the populations of microbes present in the pharynx can identify children that are more likely to respond\\\\nto AZ. This will allow us to target the use of AZ to these children in the future. By testing treatment of high risk\\\\nchildren with severe wheezing in the ED with AZ and determining which bacteria are growing in their throats, our\\\\nstudy may identify a new way to treat these severe, frightening, and dif\\\\ufb01cult to treat illnesses.\", \"project_title\": \"2/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)\", \"phr_text\": \"Project Narrative\\\\nThe proposed project is a multicenter clinical trial that seeks to determine the ef\\\\ufb01cacy of Azithromycin for the\\\\ntreatment of severe wheezing in preschoolers who present to the Emergency Department. The trial will also\\\\ndetermine the prevalence of bacteria and viruses associated with these events and any correlation with respon-\\\\nsiveness to Azithromycin. The trial will be conducted at six clinical sites from the Pediatric Emergency Care\\\\nApplied Research Network (PECARN).\", \"spending_categories_desc\": \"Asthma; Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Health Services; Infectious Diseases; Lung; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-09-15T12:09:00Z\", \"budget_end\": \"2021-11-15T12:11:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 594576, \"indirect_cost_amt\": 312152, \"project_detail_url\": \"https://reporter.nih.gov/project-details/9891812\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 72}, page_content='{\"appl_id\": 10263304, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5U24HL147018-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 510392, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"147018\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 510392, \"direct_cost_ic\": 460239, \"indirect_cost_ic\": 241625}], \"project_start_date\": \"2020-09-15T12:09:00Z\", \"project_end_date\": \"2025-11-15T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"O1\", \"name\": \"ZHL1-CSR-H(O1)\"}, \"award_notice_date\": \"2021-11-12T12:11:00Z\", \"core_project_num\": \"U24HL147018\", \"terms\": \"<Clinical><Biological><biologic><psychologic><psychological><Training><disability><Health Care Utilization><health care service use><healthcare service use><healthcare service utilization><healthcare utilization><health care service utilization><Logistics><Antibacterial Agents><anti-bacterial><antibacterial><Anti-Bacterial Agents><Macrolides><Genetic><Research Specimen><Specimen><Life><Severities><Event><Protocol><Protocols documentation><Source><lower respiratory tract><Lower respiratory tract structure><respiratory><Emergency Department><Emergency room><Accident and Emergency department><age group><data management><experience><microbial><Applied Science><Applied Research><Toddler><Manpower><personnel><Human Resources><Reporting><social><Admission><Admission activity><Sampling><Property><response><Symptoms><Multi-center clinical trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><Multi-Institutional Clinical Trial><randomisation><randomization><randomly assigned><Randomized><Antiinflammatory Effect><anti-inflammatory effect><Clinical Trials Design><Monitor><Preparation><Emergency Care><ED care><ER care><Emergency Department care><Emergency Room care><Emergency healthcare><Emergency medical care><Emergency health care><Placebo Control><placebo controlled><Data Coordinating Center><Data Coordination Center><design><designing><clinical research site><clinical site><Outcome><pathogenic bacteria><bacteria pathogen><bacterial pathogen><Population><Prevalence><aged><6 year old><6 years of age><age 6 years><six year old><six years of age><Resistance><resistant><microbial community><community microbes><Microbe><high risk><symptomatic improvement><improve symptom><symptom improvement><efficacy testing><arm><operation><Emergency department visit><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><emergency settings><pediatric emergency><hospitalization rates><treatment guidelines><clinical trial analysis><Age><ages><airway obstruction><airflow limitation><airflow obstruction><airway limitation><obstructed airflow><obstructed airway><respiratory airway obstruction><Ambulatory Care Facilities><Outpatient Clinics><Antibiotics><Antibiotic Agents><Antibiotic Drugs><Miscellaneous Antibiotic><Asthma><Bronchial Asthma><Bacteria><Bacterial Infections><bacteria infection><bacterial disease><Biometry><Biometrics><Biostatistics><Cephalosporins><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Preschool Child><1-5 years old><preschool child (1-5)><Clinical Trials><Communication><Data Collection><Diagnosis><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Future><Goals><Hospitalization><Hospital Admission><Leadership><Maintenance><Manuals><Microbiology><Rhinopharynx><nasopharnygeal><Nasopharynx><Penicillins><Pharynx><Throat><Pharyngeal structure><Sham Treatment><sham therapy><Placebos><Play><Production><Recommendation><Research><Investigators><Researchers><Research Personnel><Risk><Risk Factors><social role><Role><pre-k><pre-kindergarten><preschool><Nursery Schools><Testing><United States><Universities><Utah><Virus><Wheezing><wheeze><Azithromycin><Azadose><Azitrocin><Azythromycin><Ultreon><Zithromax><Zitromax><Technical Expertise><technical skills><Health Care Costs><Health Costs><Healthcare Costs><Data Set><Dataset><bacterial resistance><Bacteria resistance><Bacteria resistant><Bacterial resistant><resistance to Bacteria><resistance to Bacterial><resistant to Bacteria><resistant to Bacterial><Guidelines><Acute>\", \"pref_terms\": \"6 year old;Accident and Emergency department;Acute;Admission activity;Age;Ambulatory Care Facilities;Anti-Bacterial Agents;Antibiotics;Antiinflammatory Effect;Applied Research;Asthma;Azithromycin;Bacteria;Bacterial Infections;Biological;Biometry;Cephalosporins;Child;Clinical;Clinical Trials;Clinical Trials Design;Communication;Data Collection;Data Coordinating Center;Data Set;Diagnosis;Double-Blind Method;Emergency Care;Emergency department visit;Event;Future;Genetic;Goals;Guidelines;Health Care Costs;Hospitalization;Human Resources;Leadership;Life;Logistics;Lower respiratory tract structure;Macrolides;Maintenance;Manuals;Microbe;Microbiology;Monitor;Multi-Institutional Clinical Trial;Nasopharynx;Nursery Schools;Outcome;Penicillins;Pharyngeal structure;Placebo Control;Placebos;Play;Population;Preparation;Preschool Child;Prevalence;Production;Property;Protocols documentation;Randomized;Recommendation;Reporting;Research;Research Personnel;Resistance;Risk;Risk Factors;Role;Sampling;Severities;Source;Specimen;Symptoms;Technical Expertise;Testing;Toddler;Training;United States;Universities;Utah;Virus;Wheezing;age group;aged;airway obstruction;arm;bacterial resistance;clinical research site;clinical trial analysis;data management;design;disability;efficacy testing;emergency settings;experience;health care service utilization;high risk;hospitalization rates;microbial;microbial community;operation;pathogenic bacteria;pediatric emergency;psychologic;respiratory;response;social;symptomatic improvement;treatment guidelines\", \"abstract_text\": \"Project Summary/Abstract\\\\nOver 2.2 million children aged 2\\\\u20135 years have wheezing episodes that are severe enough to require Emergency\\\\nDepartment (ED) visits each year in the United States, and 15% of these children require hospitalization. There\\\\nis new evidence suggesting that harmful bacteria growing in the throat may play an important role in determining\\\\nwhich preschoolers will wheeze and then go on to develop asthma. Bacteria and viruses are equally associated\\\\nwith the risk of acute episodes of wheezing in preschoolers, and antibiotics may be a potential treatment. Two\\\\nlarge, well-designed clinical trials performed in outpatient clinics recently showed a signi\\\\ufb01cant reduction in severe\\\\nsymptoms when children were treated with the antibiotic Azithromycin (AZ) either before or after they started\\\\nwheezing. Though these results are encouraging, we are not sure how this bene\\\\ufb01t occurs since AZ has both\\\\nanti-bacterial and anti-in\\\\ufb02ammatory effects. In addition, we do not know if AZ could be effective in more severe\\\\ncases, like those requiring ED visits. The relatively underprivileged preschoolers who present to the ED for care\\\\nof their severe wheezing episodes are usually sicker and with greater risk factors for bacterial infections. They\\\\nare, therefore, the population that may get the greatest bene\\\\ufb01t, if AZ is shown to be effective in this setting. We\\\\npropose a trial in preschool age children coming to the ED with severe wheezing who will be treated with either\\\\nAZ or placebo. We will also determine which bacteria are growing in the children\\'s pharynx. This will answer the\\\\nquestion \\\\u201cDoes Azithromycin make children with severe wheezing better sooner and, if so, is that bene\\\\ufb01t seen\\\\nin all the children treated or only in those with potentially harmful bacteria in their throats?\\\\u201d There is concern\\\\nthat excessive use of antibiotics may cause bacterial resistance to their effects. We will thus determine if genetic\\\\nfactors or the populations of microbes present in the pharynx can identify children that are more likely to respond\\\\nto AZ. This will allow us to target the use of AZ to these children in the future. By testing treatment of high risk\\\\nchildren with severe wheezing in the ED with AZ and determining which bacteria are growing in their throats, our\\\\nstudy may identify a new way to treat these severe, frightening, and dif\\\\ufb01cult to treat illnesses.\", \"project_title\": \"2/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)\", \"phr_text\": \"Project Narrative\\\\nThe proposed project is a multicenter clinical trial that seeks to determine the ef\\\\ufb01cacy of Azithromycin for the\\\\ntreatment of severe wheezing in preschoolers who present to the Emergency Department. The trial will also\\\\ndetermine the prevalence of bacteria and viruses associated with these events and any correlation with respon-\\\\nsiveness to Azithromycin. The trial will be conducted at six clinical sites from the Pediatric Emergency Care\\\\nApplied Research Network (PECARN).\", \"spending_categories_desc\": \"Asthma; Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Health Services; Infectious Diseases; Lung; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-11-16T12:11:00Z\", \"budget_end\": \"2022-11-15T12:11:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 460239, \"indirect_cost_amt\": 241625, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10263304\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 73}, page_content='{\"appl_id\": 10525255, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5U24HL147018-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 467393, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"147018\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 467393, \"direct_cost_ic\": 412610, \"indirect_cost_ic\": 216621}], \"project_start_date\": \"2020-09-15T12:09:00Z\", \"project_end_date\": \"2025-11-15T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"O1\", \"name\": \"ZHL1-CSR-H(O1)\"}, \"award_notice_date\": \"2022-12-02T12:12:00Z\", \"core_project_num\": \"U24HL147018\", \"terms\": \"<airflow limitation><airflow obstruction><airway limitation><obstructed airflow><obstructed airway><respiratory airway obstruction><airway obstruction><Outpatient Clinics><Ambulatory Care Facilities><Antibiotic Agents><Antibiotic Drugs><Miscellaneous Antibiotic><Antibiotics><Asthma><Bronchial Asthma><Bacteria><Bacterial Infections><bacteria infection><bacterial disease><Biometry><Biometrics><Biostatistics><Cephalosporins><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Preschool Child><1-5 years old><preschool child (1-5)><Clinical Trials><Communication><Data Collection><Diagnosis><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Future><Goals><Hospitalization><Hospital Admission><Leadership><Maintenance><Manuals><Nasopharynx><Rhinopharynx><nasopharnygeal><Penicillins><Pharyngeal structure><Pharynx><Throat><Placebos><Sham Treatment><sham therapy><Play><Production><Recommendation><Research><Research Personnel><Investigators><Researchers><Risk><Risk Factors><Role><social role><Nursery Schools><pre-k><pre-kindergarten><preschool><Testing><United States><Universities><Utah><Virus><Wheezing><wheeze><Azithromycin><Azadose><Azitrocin><Azythromycin><Ultreon><Zithromax><Zitromax><Technical Expertise><technical skills><Health Costs><Healthcare Costs><Health Care Costs><Data Set><Bacteria resistance><Bacteria resistant><Bacterial resistant><resistance to Bacteria><resistance to Bacterial><resistant to Bacteria><resistant to Bacterial><bacterial resistance><Guidelines><improved><Acute><Clinical><biologic><Biological><psychological><psychologic><Training><disability><Health Care Utilization><health care service use><healthcare service use><healthcare service utilization><healthcare utilization><health care service utilization><school age><School-Age Population><Antibacterial Agents><anti-bacterial><antibacterial><Anti-Bacterial Agents><Macrolides><Genetic><Specimen><Research Specimen><Life><Severities><Event><Protocols documentation><Protocol><Source><Lower respiratory tract structure><lower respiratory tract><respiratory><Accident and Emergency department><Emergency Department><Emergency room><age group><data management><experience><microbial><Applied Research><Applied Science><Toddler><Human Resources><Manpower><personnel><Reporting><social><Admission activity><Admission><Sampling><Property><response><Symptoms><Multi-Institutional Clinical Trial><Multi-center clinical trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><Qualifying><Randomized><randomisation><randomization><randomly assigned><Antiinflammatory Effect><anti-inflammatory effect><Clinical Trials Design><Monitor><Preparation><preparations><Emergency Care><ED care><ER care><Emergency Department care><Emergency Room care><Emergency health care><Emergency healthcare><Emergency medical care><Placebo Control><placebo controlled><Data Coordination Center><data management and coordinating center><data management center><Data Coordinating Center><designing><design><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy examination><evaluate efficacy><examine efficacy><efficacy evaluation><clinical site><clinical research site><Outcome><bacteria pathogen><bacterial pathogen><pathogenic bacteria><Population><Prevalence><aged><6 years of age><age 6 years><six year old><six years of age><6 year old><resistant><Resistance><community microbes><microbial community><Microbe><high risk><improve symptom><symptom improvement><symptomatic improvement><efficacy testing><arm><operations><operation><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><Emergency department visit><emergency settings><pediatric emergency><hospitalization rates><treatment guidelines><clinical trial analysis>\", \"pref_terms\": \"6 year old;Accident and Emergency department;Acute;Admission activity;Ambulatory Care Facilities;Anti-Bacterial Agents;Antibiotics;Antiinflammatory Effect;Applied Research;Asthma;Azithromycin;Bacteria;Bacterial Infections;Biological;Biometry;Cephalosporins;Child;Clinical;Clinical Trials;Clinical Trials Design;Communication;Data Collection;Data Coordinating Center;Data Set;Diagnosis;Double-Blind Method;Emergency Care;Emergency department visit;Event;Future;Genetic;Goals;Guidelines;Health Care Costs;Hospitalization;Human Resources;Leadership;Life;Lower respiratory tract structure;Macrolides;Maintenance;Manuals;Microbe;Monitor;Multi-Institutional Clinical Trial;Nasopharynx;Nursery Schools;Outcome;Penicillins;Pharyngeal structure;Placebo Control;Placebos;Play;Population;Preparation;Preschool Child;Prevalence;Production;Property;Protocols documentation;Qualifying;Randomized;Recommendation;Reporting;Research;Research Personnel;Resistance;Risk;Risk Factors;Role;Sampling;School-Age Population;Severities;Source;Specimen;Symptoms;Technical Expertise;Testing;Toddler;Training;United States;Universities;Utah;Virus;Wheezing;age group;aged;airway obstruction;arm;bacterial resistance;clinical research site;clinical trial analysis;data management;design;disability;efficacy evaluation;efficacy testing;emergency settings;experience;health care service utilization;high risk;hospitalization rates;improved;microbial;microbial community;operation;pathogenic bacteria;pediatric emergency;psychologic;respiratory;response;social;symptomatic improvement;treatment guidelines\", \"abstract_text\": \"Project Summary/Abstract\\\\nOver 2.2 million children aged 2\\\\u20135 years have wheezing episodes that are severe enough to require Emergency\\\\nDepartment (ED) visits each year in the United States, and 15% of these children require hospitalization. There\\\\nis new evidence suggesting that harmful bacteria growing in the throat may play an important role in determining\\\\nwhich preschoolers will wheeze and then go on to develop asthma. Bacteria and viruses are equally associated\\\\nwith the risk of acute episodes of wheezing in preschoolers, and antibiotics may be a potential treatment. Two\\\\nlarge, well-designed clinical trials performed in outpatient clinics recently showed a signi\\\\ufb01cant reduction in severe\\\\nsymptoms when children were treated with the antibiotic Azithromycin (AZ) either before or after they started\\\\nwheezing. Though these results are encouraging, we are not sure how this bene\\\\ufb01t occurs since AZ has both\\\\nanti-bacterial and anti-in\\\\ufb02ammatory effects. In addition, we do not know if AZ could be effective in more severe\\\\ncases, like those requiring ED visits. The relatively underprivileged preschoolers who present to the ED for care\\\\nof their severe wheezing episodes are usually sicker and with greater risk factors for bacterial infections. They\\\\nare, therefore, the population that may get the greatest bene\\\\ufb01t, if AZ is shown to be effective in this setting. We\\\\npropose a trial in preschool age children coming to the ED with severe wheezing who will be treated with either\\\\nAZ or placebo. We will also determine which bacteria are growing in the children\\'s pharynx. This will answer the\\\\nquestion \\\\u201cDoes Azithromycin make children with severe wheezing better sooner and, if so, is that bene\\\\ufb01t seen\\\\nin all the children treated or only in those with potentially harmful bacteria in their throats?\\\\u201d There is concern\\\\nthat excessive use of antibiotics may cause bacterial resistance to their effects. We will thus determine if genetic\\\\nfactors or the populations of microbes present in the pharynx can identify children that are more likely to respond\\\\nto AZ. This will allow us to target the use of AZ to these children in the future. By testing treatment of high risk\\\\nchildren with severe wheezing in the ED with AZ and determining which bacteria are growing in their throats, our\\\\nstudy may identify a new way to treat these severe, frightening, and dif\\\\ufb01cult to treat illnesses.\", \"project_title\": \"2/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)\", \"phr_text\": \"Project Narrative\\\\nThe proposed project is a multicenter clinical trial that seeks to determine the ef\\\\ufb01cacy of Azithromycin for the\\\\ntreatment of severe wheezing in preschoolers who present to the Emergency Department. The trial will also\\\\ndetermine the prevalence of bacteria and viruses associated with these events and any correlation with respon-\\\\nsiveness to Azithromycin. The trial will be conducted at six clinical sites from the Pediatric Emergency Care\\\\nApplied Research Network (PECARN).\", \"spending_categories_desc\": \"Asthma; Clinical Research; Clinical Trials and Supportive Activities; Emergency Care; Health Services; Infectious Diseases; Lung; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-11-16T12:11:00Z\", \"budget_end\": \"2023-11-15T12:11:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 412610, \"indirect_cost_amt\": 216621, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10525255\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 74}, page_content='{\"appl_id\": 10747908, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5U24HL147018-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 458043, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"147018\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 458043, \"direct_cost_ic\": 300356, \"indirect_cost_ic\": 157687}], \"project_start_date\": \"2020-09-15T12:09:00Z\", \"project_end_date\": \"2025-11-15T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"O1\", \"name\": \"ZHL1-CSR-H(O1)\"}, \"award_notice_date\": \"2023-12-20T12:12:00Z\", \"core_project_num\": \"U24HL147018\", \"terms\": \"<arm><operation><operations><Emergency department visit><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><emergency settings><pediatric emergency><hospitalization rates><treatment guidelines><clinical trial analysis><airflow limitation><airflow obstruction><airway limitation><obstructed airflow><obstructed airway><respiratory airway obstruction><airway obstruction><Outpatient Clinics><Ambulatory Care Facilities><Antibiotic Agents><Antibiotic Drugs><Miscellaneous Antibiotic><Antibiotics><Bronchial Asthma><Asthma><Bacteria><bacteria infection><bacterial disease><Bacterial Infections><Biometrics><Biostatistics><Biometry><Cephalosporins><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Child><1-5 years old><preschool child (1-5)><Preschool Child><Clinical Trials><Communication><Data Collection><Diagnosis><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Double-Blind Method><Future><Goals><Hospital Admission><Hospitalization><Leadership><Maintenance><Manuals><Nasopharynx><Rhinopharynx><nasopharnygeal><Penicillins><Pharyngeal structure><Pharynx><Throat><Placebos><Sham Treatment><sham therapy><Play><Production><Recommendation><Research><Research Personnel><Investigators><Researchers><Risk><Risk Factors><Role><social role><Nursery Schools><pre-k><pre-kindergarten><preschool><Testing><United States><Universities><Utah><Virus><Wheezing><wheeze><Azithromycin><Azadose><Azitrocin><Azythromycin><Ultreon><Zithromax><Zitromax><technical skills><Technical Expertise><Health Costs><Healthcare Costs><Health Care Costs><Data Set><Bacteria resistance><Bacteria resistant><Bacterial resistant><resistance to Bacteria><resistance to Bacterial><resistant to Bacteria><resistant to Bacterial><bacterial resistance><Guidelines><improved><Acute><Clinical><biologic><Biological><psychological><psychologic><Training><disability><Health Care Utilization><health care service use><healthcare service use><healthcare service utilization><healthcare utilization><health care service utilization><school age><School-Age Population><anti-bacterial><Anti-Bacterial Agents><Macrolides><Genetic><Research Specimen><Specimen><Life><Severities><Event><Protocol><Protocols documentation><Source><lower respiratory tract><Lower respiratory tract structure><respiratory><Accident and Emergency department><Emergency Department><Emergency room><age group><data management><experience><microbial><Applied Research><Applied Science><Toddler><Human Resources><Manpower><personnel><Reporting><social><Admission activity><Admission><Sampling><Property><response><Symptoms><Multi-Institutional Clinical Trial><Multi-center clinical trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><Qualifying><Randomized><randomisation><randomization><randomly assigned><Antiinflammatory Effect><anti-inflammatory effect><Clinical Trials Design><Monitor><Preparation><preparations><Emergency Care><ED care><ER care><Emergency Department care><Emergency Room care><Emergency health care><Emergency healthcare><Emergency medical care><Placebo Control><placebo controlled><Data Coordinating Center><Data Coordination Center><data management and coordinating center><data management center><design><designing><efficacy evaluation><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy examination><evaluate efficacy><examine efficacy><clinical research site><clinical site><Outcome><pathogenic bacteria><bacteria pathogen><bacterial pathogen><Population><Prevalence><aged><6 year old><6 years of age><age 6 years><six year old><six years of age><Resistance><resistant><microbial community><community microbes><Microbe><high risk><symptomatic improvement><improve symptom><symptom improvement><efficacy testing>\", \"pref_terms\": \"6 year old;Accident and Emergency department;Acute;Admission activity;Ambulatory Care Facilities;Anti-Bacterial Agents;Antibiotics;Antiinflammatory Effect;Applied Research;Asthma;Azithromycin;Bacteria;Bacterial Infections;Biological;Biometry;Cephalosporins;Child;Clinical;Clinical Trials;Clinical Trials Design;Communication;Data Collection;Data Coordinating Center;Data Set;Diagnosis;Double-Blind Method;Emergency Care;Emergency department visit;Event;Future;Genetic;Goals;Guidelines;Health Care Costs;Hospitalization;Human Resources;Leadership;Life;Lower respiratory tract structure;Macrolides;Maintenance;Manuals;Microbe;Monitor;Multi-Institutional Clinical Trial;Nasopharynx;Nursery Schools;Outcome;Penicillins;Pharyngeal structure;Placebo Control;Placebos;Play;Population;Preparation;Preschool Child;Prevalence;Production;Property;Protocols documentation;Qualifying;Randomized;Recommendation;Reporting;Research;Research Personnel;Resistance;Risk;Risk Factors;Role;Sampling;School-Age Population;Severities;Source;Specimen;Symptoms;Technical Expertise;Testing;Toddler;Training;United States;Universities;Utah;Virus;Wheezing;age group;aged;airway obstruction;arm;bacterial resistance;clinical research site;clinical trial analysis;data management;design;disability;efficacy evaluation;efficacy testing;emergency settings;experience;health care service utilization;high risk;hospitalization rates;improved;microbial;microbial community;operation;pathogenic bacteria;pediatric emergency;psychologic;respiratory;response;social;symptomatic improvement;treatment guidelines\", \"abstract_text\": \"Project Summary/Abstract\\\\nOver 2.2 million children aged 2\\\\u20135 years have wheezing episodes that are severe enough to require Emergency\\\\nDepartment (ED) visits each year in the United States, and 15% of these children require hospitalization. There\\\\nis new evidence suggesting that harmful bacteria growing in the throat may play an important role in determining\\\\nwhich preschoolers will wheeze and then go on to develop asthma. Bacteria and viruses are equally associated\\\\nwith the risk of acute episodes of wheezing in preschoolers, and antibiotics may be a potential treatment. Two\\\\nlarge, well-designed clinical trials performed in outpatient clinics recently showed a signi\\\\ufb01cant reduction in severe\\\\nsymptoms when children were treated with the antibiotic Azithromycin (AZ) either before or after they started\\\\nwheezing. Though these results are encouraging, we are not sure how this bene\\\\ufb01t occurs since AZ has both\\\\nanti-bacterial and anti-in\\\\ufb02ammatory effects. In addition, we do not know if AZ could be effective in more severe\\\\ncases, like those requiring ED visits. The relatively underprivileged preschoolers who present to the ED for care\\\\nof their severe wheezing episodes are usually sicker and with greater risk factors for bacterial infections. They\\\\nare, therefore, the population that may get the greatest bene\\\\ufb01t, if AZ is shown to be effective in this setting. We\\\\npropose a trial in preschool age children coming to the ED with severe wheezing who will be treated with either\\\\nAZ or placebo. We will also determine which bacteria are growing in the children\\'s pharynx. This will answer the\\\\nquestion \\\\u201cDoes Azithromycin make children with severe wheezing better sooner and, if so, is that bene\\\\ufb01t seen\\\\nin all the children treated or only in those with potentially harmful bacteria in their throats?\\\\u201d There is concern\\\\nthat excessive use of antibiotics may cause bacterial resistance to their effects. We will thus determine if genetic\\\\nfactors or the populations of microbes present in the pharynx can identify children that are more likely to respond\\\\nto AZ. This will allow us to target the use of AZ to these children in the future. By testing treatment of high risk\\\\nchildren with severe wheezing in the ED with AZ and determining which bacteria are growing in their throats, our\\\\nstudy may identify a new way to treat these severe, frightening, and dif\\\\ufb01cult to treat illnesses.\", \"project_title\": \"2/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)\", \"phr_text\": \"Project Narrative\\\\nThe proposed project is a multicenter clinical trial that seeks to determine the ef\\\\ufb01cacy of Azithromycin for the\\\\ntreatment of severe wheezing in preschoolers who present to the Emergency Department. The trial will also\\\\ndetermine the prevalence of bacteria and viruses associated with these events and any correlation with respon-\\\\nsiveness to Azithromycin. The trial will be conducted at six clinical sites from the Pediatric Emergency Care\\\\nApplied Research Network (PECARN).\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2023-11-16T12:11:00Z\", \"budget_end\": \"2024-11-15T12:11:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 300356, \"indirect_cost_amt\": 157687, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10747908\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 75}, page_content='{\"appl_id\": 11002732, \"subproject_id\": null, \"fiscal_year\": 2025, \"project_num\": \"5U24HL147018-05\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U24\", \"award_amount\": 505281, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U24\", \"ic_code\": \"HL\", \"serial_num\": \"147018\", \"support_year\": \"05\", \"full_support_year\": \"05\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8880225, \"first_name\": \"Theron\", \"middle_name\": \"C\", \"last_name\": \"Casper\", \"is_contact_pi\": true, \"full_name\": \"Theron C Casper\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"CASPER, THERON C\", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2025, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 505281, \"direct_cost_ic\": 331332, \"indirect_cost_ic\": 173949}], \"project_start_date\": \"2020-09-15T12:09:00Z\", \"project_end_date\": \"2025-11-15T12:11:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-410\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"H\", \"group_code\": \"O1\", \"name\": \"ZHL1-CSR-H(O1)\"}, \"award_notice_date\": \"2024-11-26T12:11:00Z\", \"core_project_num\": \"U24HL147018\", \"terms\": \"<0-11 years old><1-5 years old><6 year old><6 years of age><Accident and Emergency department><Acute><Admission><Admission activity><age 6 years><age group><aged><airflow limitation><airflow obstruction><airway limitation><airway obstruction><Ambulatory Care Facilities><anti-bacterial><Anti-Bacterial Agents><anti-inflammatory effect><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Antiinflammatory Effect><Applied Research><Applied Science><arm><Asthma><Azadose><Azithromycin><Azitrocin><Azythromycin><Bacteria><bacteria infection><bacteria pathogen><Bacteria resistance><Bacteria resistant><bacterial disease><Bacterial Infections><bacterial pathogen><bacterial resistance><Bacterial resistant><biologic><Biological><Biometrics><Biometry><Biostatistics><Bronchial Asthma><Cephalosporins><Child><Child Youth><Children (0-21)><Clinical><clinical research site><clinical site><clinical trial analysis><Clinical Trials><Clinical Trials Design><Communication><community microbes><Data Collection><Data Coordinating Center><Data Coordination Center><data management><data management and coordinating center><data management center><Data Set><design><designing><determine efficacy><Diagnosis><disability><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><ED care><ED visit><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy testing><Emergency Care><Emergency care visit><Emergency Department><Emergency Department care><Emergency department visit><Emergency health care><Emergency hospital visit><Emergency medical care><Emergency room><Emergency Room care><Emergency room visit><emergency settings><ER care><ER visit><evaluate efficacy><Event><examine efficacy><experience><Future><Genetic><Goals><Guidelines><Health Care Costs><health care service use><health care service utilization><Health Care Utilization><Health Costs><high risk><Hospital Admission><Hospitalization><hospitalization rates><Human Resources><improve symptom><improved><Investigators><kids><Leadership><Life><lower respiratory tract><Lower respiratory tract structure><Macrolides><Maintenance><Manpower><Manuals><Microbe><microbe community><microbial><microbial community><microorganism community><Miscellaneous Antibiotic><Monitor><Multi-center clinical trial><Multi-Institutional Clinical Trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><nasopharnygeal><Nasopharynx><Nursery Schools><obstructed airflow><obstructed airway><operation><operations><Outcome><Outpatient Clinics><pathogenic bacteria><pediatric emergency><Penicillins><personnel><Pharyngeal structure><Pharynx><Placebo Control><placebo controlled><Placebos><Play><polymicrobial community><Population><pre-k><pre-kindergarten><Preparation><preparations><preschool><Preschool Child><preschool child (1-5)><Prevalence><Production><Property><Protocol><Protocols documentation><psychologic><psychological><Qualifying><randomisation><randomization><Randomized><randomly assigned><Recommendation><Reporting><Research><Research Personnel><Research Specimen><Researchers><Resistance><resistance to Bacteria><resistance to Bacterial><resistant><resistant to Bacteria><resistant to Bacterial><respiratory><respiratory airway obstruction><response><Rhinopharynx><Risk><Risk Factors><Role><Sampling><school age><School-Age Population><Severities><sham therapy><Sham Treatment><six year old><six years of age><social><social role><Source><Specimen><symptom improvement><symptomatic improvement><Symptoms><Technical Expertise><technical skills><Testing><Throat><Toddler><Training><treatment guidelines><Ultreon><United States><Universities><Utah><Virus><wheeze><Wheezing><youngster><Zithromax><Zitromax>\", \"pref_terms\": \"6 year old;Accident and Emergency department;Acute;Admission activity;Ambulatory Care Facilities;Anti-Bacterial Agents;Antibiotics;Antiinflammatory Effect;Applied Research;Asthma;Azithromycin;Bacteria;Bacterial Infections;Biological;Biometry;Cephalosporins;Child;Clinical;Clinical Trials;Clinical Trials Design;Communication;Data Collection;Data Coordinating Center;Data Set;Diagnosis;Double-Blind Method;Emergency Care;Emergency department visit;Event;Future;Genetic;Goals;Guidelines;Health Care Costs;Hospitalization;Human Resources;Leadership;Life;Lower respiratory tract structure;Macrolides;Maintenance;Manuals;Microbe;Monitor;Multi-Institutional Clinical Trial;Nasopharynx;Nursery Schools;Outcome;Penicillins;Pharyngeal structure;Placebo Control;Placebos;Play;Population;Preparation;Preschool Child;Prevalence;Production;Property;Protocols documentation;Qualifying;Randomized;Recommendation;Reporting;Research;Research Personnel;Resistance;Risk;Risk Factors;Role;Sampling;School-Age Population;Severities;Source;Specimen;Symptoms;Technical Expertise;Testing;Toddler;Training;United States;Universities;Utah;Virus;Wheezing;age group;aged;airway obstruction;arm;bacterial resistance;clinical research site;clinical trial analysis;data management;design;disability;efficacy evaluation;efficacy testing;emergency settings;experience;health care service utilization;high risk;hospitalization rates;improved;microbial;microbial community;operation;pathogenic bacteria;pediatric emergency;psychologic;respiratory;response;social;symptomatic improvement;treatment guidelines\", \"abstract_text\": \"Project Summary/Abstract\\\\nOver 2.2 million children aged 2\\\\u20135 years have wheezing episodes that are severe enough to require Emergency\\\\nDepartment (ED) visits each year in the United States, and 15% of these children require hospitalization. There\\\\nis new evidence suggesting that harmful bacteria growing in the throat may play an important role in determining\\\\nwhich preschoolers will wheeze and then go on to develop asthma. Bacteria and viruses are equally associated\\\\nwith the risk of acute episodes of wheezing in preschoolers, and antibiotics may be a potential treatment. Two\\\\nlarge, well-designed clinical trials performed in outpatient clinics recently showed a signi\\\\ufb01cant reduction in severe\\\\nsymptoms when children were treated with the antibiotic Azithromycin (AZ) either before or after they started\\\\nwheezing. Though these results are encouraging, we are not sure how this bene\\\\ufb01t occurs since AZ has both\\\\nanti-bacterial and anti-in\\\\ufb02ammatory effects. In addition, we do not know if AZ could be effective in more severe\\\\ncases, like those requiring ED visits. The relatively underprivileged preschoolers who present to the ED for care\\\\nof their severe wheezing episodes are usually sicker and with greater risk factors for bacterial infections. They\\\\nare, therefore, the population that may get the greatest bene\\\\ufb01t, if AZ is shown to be effective in this setting. We\\\\npropose a trial in preschool age children coming to the ED with severe wheezing who will be treated with either\\\\nAZ or placebo. We will also determine which bacteria are growing in the children\\'s pharynx. This will answer the\\\\nquestion \\\\u201cDoes Azithromycin make children with severe wheezing better sooner and, if so, is that bene\\\\ufb01t seen\\\\nin all the children treated or only in those with potentially harmful bacteria in their throats?\\\\u201d There is concern\\\\nthat excessive use of antibiotics may cause bacterial resistance to their effects. We will thus determine if genetic\\\\nfactors or the populations of microbes present in the pharynx can identify children that are more likely to respond\\\\nto AZ. This will allow us to target the use of AZ to these children in the future. By testing treatment of high risk\\\\nchildren with severe wheezing in the ED with AZ and determining which bacteria are growing in their throats, our\\\\nstudy may identify a new way to treat these severe, frightening, and dif\\\\ufb01cult to treat illnesses.\", \"project_title\": \"2/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)\", \"phr_text\": \"Project Narrative\\\\nThe proposed project is a multicenter clinical trial that seeks to determine the ef\\\\ufb01cacy of Azithromycin for the\\\\ntreatment of severe wheezing in preschoolers who present to the Emergency Department. The trial will also\\\\ndetermine the prevalence of bacteria and viruses associated with these events and any correlation with respon-\\\\nsiveness to Azithromycin. The trial will be conducted at six clinical sites from the Pediatric Emergency Care\\\\nApplied Research Network (PECARN).\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-11-16T12:11:00Z\", \"budget_end\": \"2025-11-15T12:11:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 331332, \"indirect_cost_amt\": 173949, \"project_detail_url\": \"https://reporter.nih.gov/project-details/11002732\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 76}, page_content='{\"appl_id\": 9881961, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"1R03CA238957-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R03\", \"award_amount\": 152500, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R03\", \"ic_code\": \"CA\", \"serial_num\": \"238957\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 11233567, \"first_name\": \"Anne\", \"middle_name\": \"C\", \"last_name\": \"Kirchhoff\", \"is_contact_pi\": true, \"full_name\": \"Anne C Kirchhoff\", \"title\": \"ASSISTANT PROFESSOR\"}], \"contact_pi_name\": \"KIRCHHOFF, ANNE C\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 152500, \"direct_cost_ic\": 100000, \"indirect_cost_ic\": 52500}], \"project_start_date\": \"2020-09-08T12:09:00Z\", \"project_end_date\": \"2022-08-30T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-021\", \"full_study_section\": {\"srg_code\": \"ZCA1\", \"srg_flex\": null, \"sra_designator_code\": \"RPRB\", \"sra_flex_code\": \"6\", \"group_code\": \"O2\", \"name\": \"Special Emphasis Panel[ZCA1 RPRB-6 (O2)]\"}, \"award_notice_date\": \"2020-09-08T12:09:00Z\", \"core_project_num\": \"R03CA238957\", \"terms\": \"<Affect><Aftercare><After Care><After-Treatment><post treatment><Air><Air Pollutants><Air Pollution><Ambulatory Surgical Procedures><Ambulatory Surgery><Outpatient Surgery><Breathing><Respiratory Aspiration><Respiratory Inspiration><inspiration><Asthma><Bronchial Asthma><malignant breast neoplasm><Breast Cancer><malignant breast tumor><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cardiovascular Diseases><cardiovascular disorder><Cardiovascular system><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Malignant neoplasm of cervix uteri><Cervical Cancer><Cervix Cancer><Malignant Cervical Neoplasm><Malignant Cervical Tumor><Malignant Neoplasm of the Cervix><Malignant Tumor of the Cervix><Malignant Tumor of the Cervix Uteri><Malignant Uterine Cervix Neoplasm><Malignant Uterine Cervix Tumor><Uterine Cervix Cancer><Cisplatin><CDDP><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatina><Cisplatinum><Cysplatyna><Dichlorodiammineplatinum><Peyrone\\'s Chloride><Peyrone\\'s Salt><Platinum Diamminodichloride><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><Communities><Coronary Arteriosclerosis><Coronary Artery Disease><Coronary Artery Disorder><Coronary Atherosclerosis><atherosclerotic coronary disease><coronary arterial disease><Cessation of life><Death><Diagnosis><Disease><Disorder><Environmental Pollutants><Exhibits><Goals><Health><Health behavior><Heart><Hospitalization><Hospital Admission><Hospitals><Lung><Lung Respiratory System><pulmonary><Lung diseases><Pulmonary Diseases><Pulmonary Disorder><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><disease of the lung><disorder of the lung><lung disorder><Medical Records><men><men\\'s><Myocardial Infarction><Cardiac infarction><Myocardial Infarct><cardiac infarct><coronary attack><coronary infarct><coronary infarction><heart attack><heart infarct><heart infarction><Outpatients><Out-patients><Ozone><Play><Pneumonia><Public Health><Race><Racial Group><Racial Stocks><Records><Registries><Respiratory Tract Infections><Respiratory Infections><Risk><Risk Factors><Role><social role><Smoking><Stroke><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><Thromboembolism><Time><Tissues><Body Tissues><United States><Utah><County><Health Hazards><Measures><health care><Healthcare><Crossover Studies><Cross-Over Studies><Malignant Testicular Neoplasm><Malignant Testicular Tumor><Malignant Tumor of the Testis><Testicular Cancer><Testis Cancer><Malignant neoplasm of testis><Guidelines><base><Organ><improved><Acute><Chronic><Solid><Survivors><Link><residential building><residential site><residence><Individual><O3 exposure><ozone exposure><Licensing><Malignant Tumor of the Lung><Pulmonary Cancer><Pulmonary malignant Neoplasm><lung cancer><Malignant neoplasm of lung><SEER-Surveillance, Epidemiology, and End Results><Surveillance, Epidemiology and End Results><Surveillance, Epidemiology, and End Results Program><SEER Program><Cross-Over Designs><Crossover Design><Ethnicity><Ethnic Origin><Lung damage><lung injury><Exposure to><Knowledge><Pollution><Event><respiratory><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Operative Surgical Procedures><experience><Toxicities><Toxic effect><General Public><General Population><cancer registry><neoplasm registry><land use><Lung Parenchyma><Lung Tissue><Structure of parenchyma of lung><Modeling><Sampling><cessation of treatment><treatment cessation><Withholding Treatment><Intervention Strategies><interventional strategy><Intervention><Cancer Treatment><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><anti-cancer therapy><anticancer therapy><cancer therapy><cancer diagnosis><cancer epidemiology><vulnerable group><Vulnerable Populations><Malignant Ovarian Neoplasm><Malignant Ovarian Tumor><Malignant Tumor of the Ovary><Ovary Cancer><ovarian cancer><Malignant neoplasm of ovary><Vital Status><preventing><prevent><Address><Health system><Data><Population Database><Subgroup><Testicular Parenchyma><Testicular Tissue><survive cancer><Cancer Survivor><Cancer Survivorship><Smoking History><Modification><Particulate Matter><comparator group><comparison group><Outcome><Population><tailored messaging><chemotherapy><high risk><population based><adolescent man><adolescent men><young man><urgent care><Adolescent and Young Adult><ED visit><ER visit><Emergency care visit><Emergency hospital visit><Emergency room visit><Emergency department visit><respiratory health><cardiovascular health><Heart health><Cardiac health><PM2.5><fine particulate matter><fine particles>\", \"pref_terms\": \"Acute;Address;Adolescent and Young Adult;Affect;Aftercare;Air;Air Pollutants;Air Pollution;Ambulatory Surgical Procedures;Asthma;Breathing;Cancer Survivor;Cancer Survivorship;Cardiac health;Cardiovascular Diseases;Cardiovascular system;Cessation of life;Chronic;Cisplatin;Communities;Coronary Arteriosclerosis;County;Cross-Over Studies;Crossover Design;Data;Diagnosis;Disease;Emergency department visit;Environmental Pollutants;Ethnic Origin;Event;Exhibits;Exposure to;General Population;Goals;Guidelines;Health;Health Hazards;Health behavior;Health system;Healthcare;Heart;Hospitalization;Hospitals;Individual;Intervention;Knowledge;Licensing;Link;Lung;Lung diseases;Malignant Neoplasms;Malignant neoplasm of cervix uteri;Malignant neoplasm of lung;Malignant neoplasm of ovary;Malignant neoplasm of testis;Measures;Medical Records;Modeling;Modification;Myocardial Infarction;Operative Surgical Procedures;Organ;Outcome;Outpatients;Ozone;Particulate Matter;Play;Pneumonia;Pollution;Population;Population Database;Public Health;Race;Records;Registries;Respiratory Tract Infections;Risk;Risk Factors;Role;SEER Program;Sampling;Smoking;Smoking History;Solid;Stroke;Structure of parenchyma of lung;Subgroup;Survivors;Testicular Tissue;Thromboembolism;Time;Tissues;Toxic effect;United States;Utah;Vital Status;Vulnerable Populations;Withholding Treatment;base;cancer diagnosis;cancer epidemiology;cancer therapy;cardiovascular health;chemotherapy;comparison group;experience;fine particles;high risk;improved;land use;lung injury;malignant breast neoplasm;men;neoplasm registry;ozone exposure;population based;prevent;residence;respiratory;respiratory health;tailored messaging;urgent care;young man\", \"abstract_text\": \"PROJECT SUMMARY ABSTRACT\\\\nFine particulate matter (PM2.5) and ozone (O3) pollution are major risk factors for respiratory and cardiovascular\\\\ndisease and death. For survivors of testicular cancer, one of the most common and curable cancers occurring\\\\nin young men, respiratory and cardiovascular conditions often arise shortly after their treatment ceases. These\\\\nhealth conditions are attributed to the chemotherapies used to cure testicular cancer that also exhibit toxic\\\\neffects on heart and lung tissue. Post-treatment exposure to air pollution among testicular cancer survivors\\\\nmay exacerbate previous damage from chemotherapy, leading to a higher risk for respiratory and\\\\ncardiovascular problems. The effects of air pollution exposure on testicular cancer survivors, however, are\\\\nunknown. To fill this knowledge gap, we will examine how air pollution is associated with respiratory and\\\\ncardiovascular health care encounters among 1,293 testicular cancer survivors diagnosed between 1999 and\\\\n2017 who live in Utah, a state with severe air pollution problems. Using the nation\\\\u2019s only statewide population\\\\nregistry, the Utah Population Database (UPDB), we can link individual identifying information from statewide\\\\nadministrative data, statewide hospital and ambulatory surgery records, and outpatient medical records from\\\\nUtah\\\\u2019s largest health systems to residential data on short-term air pollution exposure for both PM2.5 and O3. We\\\\nwill: 1) Investigate the association of short-term air pollution exposure with respiratory and cardiovascular\\\\nhealth events among testicular cancer survivors, measured through statewide healthcare encounter data, and\\\\ncompare the risk between survivors and a cancer-free sample, and 2) Investigate treatments and health\\\\nbehaviors that may modify the relationship between air pollution exposure and respiratory and cardiovascular\\\\nevents among testicular cancer survivors. We will also assess how the relationship varies over time. Both aims\\\\nwill use a case-crossover design to examine the effects of short-term pollution exposure on the risk for\\\\nrespiratory and cardiovascular-associated outpatient, urgent care, and emergency department visits and\\\\nhospitalizations. We will also examine how risk differs among subgroups of survivors based on treatment (e.g.,\\\\nsurgery alone vs. surgery and chemotherapy), smoking, time since diagnosis, race/ethnicity, and other factors.\\\\nBecause of the pervasiveness of air pollution in United States and the lack of data on how environmental\\\\npollutants affect vulnerable populations such as cancer survivors, this project represents a unique opportunity\\\\nto determine whether air pollution is a risk factor for respiratory and cardiovascular health problems among\\\\ntesticular cancer survivors. Moreover, our findings will have implications for other populations of cancer\\\\nsurvivors and can help inform cancer survivorship guidelines on reducing air pollution exposure.\", \"project_title\": \"Identifying the role of air pollution in the lung and heart health outcomes of testicular cancer survivors\", \"phr_text\": \"PROJECT NARRATIVE\\\\nCancer therapies can damage the lung and heart tissue of testicular cancer survivors, resulting in major health\\\\nproblems after therapy ends. Breathing air pollution also damages lung and heart tissue and may cause\\\\nadditional health problems among testicular cancer survivors. This study will examine how short-term air\\\\npollution exposure increases the risk for lung and heart problems in testicular cancer survivors and how risk\\\\nmay be modified for survivors who were treated with chemotherapy, and will provide new information on how to\\\\nprevent health problems in cancer survivor populations.\", \"spending_categories_desc\": \"Cancer; Climate-Related Exposures and Conditions; Clinical Research; Health Services; Lung; Lung Cancer; Prevention; Rare Diseases; Rehabilitation; Social Determinants of Health; Urologic Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-09-08T12:09:00Z\", \"budget_end\": \"2022-08-30T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 100000, \"indirect_cost_amt\": 52500, \"project_detail_url\": \"https://reporter.nih.gov/project-details/9881961\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 77}, page_content='{\"appl_id\": 10692852, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5U01HL153007-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U01\", \"award_amount\": 1459982, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U01\", \"ic_code\": \"HL\", \"serial_num\": \"153007\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 7387185, \"first_name\": \"Gabor\", \"middle_name\": \"T\", \"last_name\": \"Marth\", \"is_contact_pi\": false, \"full_name\": \"Gabor T Marth\", \"title\": \"PROFESSOR OF HUMAN GENETICS\"}, {\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": false, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 6684228, \"first_name\": \"H. Joseph\", \"middle_name\": \"\", \"last_name\": \"Yost\", \"is_contact_pi\": true, \"full_name\": \"H. Joseph  Yost\", \"title\": \"\"}], \"contact_pi_name\": \"YOST, H. JOSEPH \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 1459982, \"direct_cost_ic\": 998877, \"indirect_cost_ic\": 461105}], \"project_start_date\": \"2020-08-20T12:08:00Z\", \"project_end_date\": \"2025-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HL-20-017\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"B\", \"group_code\": \"M1\", \"name\": \"ZHL1-CSR-B(M1)\"}, \"award_notice_date\": \"2023-08-09T12:08:00Z\", \"core_project_num\": \"U01HL153007\", \"terms\": \"<Acceleration><Affect><Alligators><Cardiovascular system><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Heart Vascular><circulatory system><Chickens><Gallus domesticus><Gallus gallus><Gallus gallus domesticus><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Chromatin><Client><Communities><Consultations><consultation><Disease><Disorder><DNA><Deoxyribonucleic Acid><Education><Educational aspects><Ethics><ethical><Future><Science of genetics><Genome><Human Genome><human whole genome><Goals><Heart><Human><Modern Man><Human Genetics><Internships><intern><Investments><Leadership><Mus><Mice><Mice Mammals><Murine><Organism><living system><Parents><parent><Patients><Pilot Projects><pilot study><Rana><Frog><Research><Research Personnel><Investigators><Researchers><Resources><Research Resources><Science><Sheep><Ovine><Ovis><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><Turtles><tortoise><United States><Universities><Utah><Zebrafish><Brachydanio rerio><Danio rerio><Zebra Danio><Zebra Fish><Outcomes Research><Data Set><congenital cardiac abnormality><congenital cardiac disease><congenital cardiac disorder><congenital cardiac malformation><congenital heart abnormality><congenital heart anomaly><congenital heart disease><congenital heart malformation><congenital heart disorder><Clinical><Link><Training><pediatric><Childhood><intuitive><Intuition><Visual><Discipline><Individual><Data Bases><data base><Databases><Collaborations><Native Americans><Genetic><tool><Computational Biology><computer biology><programs><Scientist><Complex><Country><meetings><meeting><experience><human data><mutant><Basic Science><Basic Research><outreach><outreach program><Genomics><Bio-Informatics><Bioinformatics><Cardiac development><heart development><heart formation><cardiogenesis><Institution><Causality><causation><disease causation><Etiology><genome sequencing><Chromatin Remodeling Factor><Chromatin Remodeling Complex><chromatin modifier><Address><Data><Epigenetic Process><Epigenetic><Epigenetic Change><Epigenetic Mechanism><epigenetically><Preparation><preparations><Molecular><follow-up><Active Follow-up><active followup><follow up><followed up><followup><Development><developmental><National Heart, Lung, and Blood Institute><NHLBI><clinical phenotype><Gene variant><allele variant><allelic variant><genomic variant><genetic variant><virtual><designing><design><next generation><visualization tool><Visualization software><Outcome><Computational Science><innovate><innovative><innovation><analytical tool><online tutorial><tool development><discover genes><gene discovery><social implication><legal implication><NGS Method><NGS system><next gen sequencing><nextgen sequencing><next generation sequencing><exome-seq><exome sequencing><methylome><epigenome><cloud based><Underrepresented Students><summer research><multiomics><multiple omics><global gene expression><global transcription profile><transcriptome><human genomics><Pediatric Cardiac Genomics Consortium><Underrepresented Groups><under representation of groups><under represented groups><under represented people><under represented populations><underrepresentation of groups><underrepresented people><Underrepresented Populations><entire genome><full genome><whole genome><genomic data-set><genomic dataset><genomic data><experiment><experimental research><experiments><experimental study><data resource><recruit><genetic condition><genetic disorder><Genetic Diseases><genomic science><genome sciences><data warehouse><multiple omic data><Multiomic Data><Visualization><multiple data sets><multiple datasets><Minority Health Research><Minority research><research in minorities><research on minorities><research related to minorities><research with minorities><mosaic><model organism>\", \"pref_terms\": \"Acceleration;Address;Affect;Alligators;Basic Science;Bioinformatics;Cardiovascular system;Chickens;Child;Childhood;Chromatin;Chromatin Remodeling Factor;Client;Clinical;Collaborations;Communities;Complex;Computational Biology;Computational Science;Consultations;Country;DNA;Data;Data Set;Databases;Development;Discipline;Disease;Education;Epigenetic Process;Ethics;Etiology;Future;Genetic;Genetic Diseases;Genome;Genomics;Goals;Heart;Human;Human Genetics;Human Genome;Individual;Institution;Internships;Intuition;Investments;Leadership;Link;Minority Health Research;Molecular;Multiomic Data;Mus;National Heart, Lung, and Blood Institute;Native Americans;Organism;Outcome;Outcomes Research;Parents;Patients;Pediatric Cardiac Genomics Consortium;Pilot Projects;Preparation;Rana;Research;Research Personnel;Resources;Science;Science of genetics;Scientist;Sheep;Training;Turtles;Underrepresented Populations;Underrepresented Students;United States;Universities;Utah;Visual;Visualization;Visualization software;Zebrafish;analytical tool;cardiogenesis;clinical phenotype;cloud based;congenital heart disorder;data resource;data warehouse;design;epigenome;exome sequencing;experience;experimental study;follow-up;gene discovery;genetic variant;genome sciences;genome sequencing;genomic data;human data;human genomics;innovation;legal implication;meetings;methylome;model organism;mosaic;multiple datasets;multiple omics;mutant;next generation;next generation sequencing;online tutorial;outreach;outreach program;programs;recruit;social implication;summer research;tool;tool development;transcription factor;transcriptome;virtual;whole genome\", \"abstract_text\": \"PROJECT SUMMARY\\\\nCongenital heart disease (CHD) affects approximately 1% of all children born per year in the United States.\\\\nThe NHLBI has made significant investments to discover the causes and outcomes of CHD, including research\\\\nin the Bench-to-Bassinet (B2B) Consortia that spans fundamental discovery science in the Cardiovascular\\\\nDevelopment Consortium (CvDC), sequencing the genomes of clinically phenotyped children with CHD and\\\\ntheir parents in the Pediatric Cardiac Genomics Consortium (PCGC), and long-term clinical follow-up and\\\\noutcomes research in the Pediatric Heart Network (PHN). The advent of Next Generation Sequencing (NGS)\\\\nhas rapidly accelerated discoveries in cardiovascular development and the genetics and epigenetics of CHD.\\\\nBoth the CvDC and the PCGC have extensive NGS datasets. The CvDC DataHub at the University of Utah\\\\ncurrently serves as the programmatic data warehouse and distribution server that organizes NGS datasets and\\\\nmakes them available online. CvDC datasets are complex, containing NGS experiments from seven \\\\u2018model\\\\norganism\\\\u2019 species (mice, zebrafish, humans, alligator, turtle, chicken, sheep and frogs) and humans.\\\\nImportantly, the experiments in the CvDC explore the molecular etiology of cardiovascular development\\\\nthrough several coordinated -omics approaches, studying changes in the whole-genome transcriptome and in\\\\nthe epigenome (chromatin modifiers, transcription factors, the DNA methylome and higher-order organization\\\\nof chromatin) during cardiac development and in several mutant genetic backgrounds.\\\\nThe Cardiovascular Development Data Resource Center (CDDRC) will be built on the innovative Mosaic\\\\nplatform to provide a cloud-based collaborative space for organizing, visualizing and understanding genomic\\\\ndata, and for pointing analytic tools to datasets housed anywhere on the cloud. The CDDRC is designed by\\\\nexperts in computational sciences and bioinformatics, in consultation with leaders in the CvDC, PCGC and\\\\nPHN to be used by non-experts, basic scientists, human geneticists and clinicians. The University of Utah is\\\\none of a few institutions in the country that has leadership in all three B2B consortia, reflecting the depth and\\\\ndiversity of our expertise and our commitment to cross-disciplinary collaborations. The CDDRC will provide a\\\\nsuite of cloud-compatible tools and a coordinated and a harmonized set of datasets transported from the\\\\nprevious CvDC DataHub, imported from current CvDC projects, and recruited from the cardiovascular\\\\ndevelopment and pediatric CHD research communities. The CDDRC will facilitate dynamic and investigator-\\\\ninteractive interfaces with multiple -omics datasets from humans and multiple model organisms, resulting in\\\\ncollaborative discoveries of the genetic and epigenetic causes of CHD. In addition, our program will have\\\\neducational components in Ethical, Legal and Social Implications (ELSI) of CHD genetics and genomics, and\\\\nan outreach program in CHD computational biology for students from underrepresented groups.\", \"project_title\": \"Cardiovascular Development Data Resource Center (CDDRC)\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe Cardiovascular Development Data Resource Center (CDDRC) will provide an innovative cloud-based\\\\nplatform to facilitate the analysis, visualization and sharing of genomic data from research in heart\\\\ndevelopment in several species. The CDDRC will bring together researchers with a diverse range of expertise,\\\\nwith the goal of understanding the causes of congenital heart disease in children.\", \"spending_categories_desc\": \"Biotechnology; Cardiovascular; Congenital Heart Disease; Congenital Structural Anomalies; Genetics; Heart Disease; Human Genome; Networking and Information Technology R&D (NITRD); Pediatric; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-08-01T12:08:00Z\", \"budget_end\": \"2024-07-31T12:07:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 998877, \"indirect_cost_amt\": 461105, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10692852\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 78}, page_content='{\"appl_id\": 10903877, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5U01HL153007-05\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U01\", \"award_amount\": 1430782, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U01\", \"ic_code\": \"HL\", \"serial_num\": \"153007\", \"support_year\": \"05\", \"full_support_year\": \"05\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 7387185, \"first_name\": \"Gabor\", \"middle_name\": \"T\", \"last_name\": \"Marth\", \"is_contact_pi\": false, \"full_name\": \"Gabor T Marth\", \"title\": \"PROFESSOR OF HUMAN GENETICS\"}, {\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": false, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 6684228, \"first_name\": \"H. Joseph\", \"middle_name\": \"\", \"last_name\": \"Yost\", \"is_contact_pi\": true, \"full_name\": \"H. Joseph  Yost\", \"title\": \"\"}], \"contact_pi_name\": \"YOST, H. JOSEPH \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 1430782, \"direct_cost_ic\": 978899, \"indirect_cost_ic\": 451883}], \"project_start_date\": \"2020-08-20T12:08:00Z\", \"project_end_date\": \"2025-07-31T12:07:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-HL-20-017\", \"full_study_section\": {\"srg_code\": \"ZHL1\", \"srg_flex\": null, \"sra_designator_code\": \"CSR\", \"sra_flex_code\": \"B\", \"group_code\": \"M1\", \"name\": \"ZHL1-CSR-B(M1)\"}, \"award_notice_date\": \"2024-07-31T12:07:00Z\", \"core_project_num\": \"U01HL153007\", \"terms\": \"<0-11 years old><Acceleration><Active Follow-up><Address><Affect><Alligators><Basal Transcription Factor><Basal transcription factor genes><Basic Research><Basic Science><Bio-Informatics><Bioinformatics><Brachydanio rerio><Cardiac Malformation><Cardiac development><Cardiovascular><Cardiovascular Body System><Cardiovascular Organ System><Cardiovascular system><Causality><Chickens><Child><Child Youth><Childhood><Children (0-21)><Chromatin><Chromatin Remodeling Complex><Chromatin Remodeling Factor><Client><Clinical><Collaborations><Communities><Complex><Computational Biology><Computational Science><Consultations><Country><DNA><Danio rerio><Data><Data Bases><Data Set><Databases><Deoxyribonucleic Acid><Development><Discipline><Disease><Disorder><ELSI><Education><Educational aspects><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Etiology><Frog><Future><Gallus domesticus><Gallus gallus><Gallus gallus domesticus><Gene variant><General Transcription Factor Gene><General Transcription Factors><Genetic><Genetic Diseases><Genome><Genomics><Goals><Heart><Heart Malformation><Heart Vascular><Human><Human Genetics><Human Genome><Individual><Institution><Internships><Intuition><Investigators><Investments><Leadership><Link><Mice><Mice Mammals><Minority Health Research><Minority research><Modern Man><Molecular><Multiomic Data><Murine><Mus><NGS Method><NGS system><NHLBI><National Heart, Lung, and Blood Institute><Native Americans><Organism><Outcome><Outcomes Research><Ovine><Ovis><Parents><Patients><Pediatric Cardiac Genomics Consortium><Pilot Projects><Preparation><Rana><Research><Research Personnel><Research Resources><Researchers><Resources><Science><Science of genetics><Scientist><Sheep><Training><Transcription Factor Proto-Oncogene><Transcription factor genes><Turtles><Underrepresented Groups><Underrepresented Populations><Underrepresented Students><United States><Universities><Utah><Visual><Visualization><Visualization software><Zebra Danio><Zebra Fish><Zebrafish><abnormal heart development><active followup><allele variant><allelic variant><analytical tool><cardiogenesis><causation><chromatin modifier><circulatory system><clinical phenotype><cloud based><computer biology><congenital cardiac abnormality><congenital cardiac anomalies><congenital cardiac disease><congenital cardiac disorder><congenital cardiac malformation><congenital heart abnormality><congenital heart anomaly><congenital heart disease><congenital heart disorder><congenital heart malformation><consultation><data base><data resource><data warehouse><design><designing><developmental><discover genes><disease causation><entire genome><epigenetically><epigenome><ethical legal and social><ethical, legal, and social implication><exome sequencing><exome-seq><experience><experiment><experimental research><experimental study><experiments><follow up><follow-up><followed up><followup><full genome><gene discovery><genetic condition><genetic disorder><genetic variant><genome sciences><genome sequencing><genomic data><genomic data-set><genomic dataset><genomic science><genomic variant><global gene expression><global transcription profile><heart development><heart formation><human data><human genomics><human whole genome><innovate><innovation><innovative><intern><intuitive><kids><living system><meeting><meetings><methylome><model organism><mosaic><multiomics><multiple data sets><multiple datasets><multiple omic data><multiple omics><mutant><next gen sequencing><next generation><next generation sequencing><nextgen sequencing><online tutorial><outreach><outreach program><panomics><parent><pediatric><pilot study><preparations><programs><recruit><research in minorities><research on minorities><research related to minorities><research with minorities><summer research><tool><tool development><tortoise><transcription factor><transcriptome><under representation of groups><under represented groups><under represented people><under represented populations><underrepresentation of groups><underrepresented people><virtual><visualization tool><whole genome><youngster>\", \"pref_terms\": \"Acceleration;Address;Affect;Alligators;Basic Science;Bioinformatics;Cardiovascular system;Chickens;Child;Childhood;Chromatin;Chromatin Remodeling Factor;Client;Clinical;Collaborations;Communities;Complex;Computational Biology;Computational Science;Consultations;Country;DNA;Data;Data Set;Databases;Development;Discipline;Disease;Education;Epigenetic Process;Etiology;Future;Genetic;Genetic Diseases;Genome;Genomics;Goals;Heart;Human;Human Genetics;Human Genome;Individual;Institution;Internships;Intuition;Investments;Leadership;Link;Minority Health Research;Molecular;Multiomic Data;Mus;National Heart, Lung, and Blood Institute;Native Americans;Organism;Outcome;Outcomes Research;Parents;Patients;Pediatric Cardiac Genomics Consortium;Pilot Projects;Preparation;Rana;Research;Research Personnel;Resources;Science;Science of genetics;Scientist;Sheep;Training;Turtles;Underrepresented Populations;Underrepresented Students;United States;Universities;Utah;Visual;Visualization;Visualization software;Zebrafish;analytical tool;cardiogenesis;clinical phenotype;cloud based;congenital heart abnormality;data resource;data warehouse;design;epigenome;ethical, legal, and social implication;exome sequencing;experience;experimental study;follow-up;gene discovery;genetic variant;genome sciences;genome sequencing;genomic data;human data;human genomics;innovation;meetings;methylome;model organism;mosaic;multiple datasets;multiple omics;mutant;next generation;next generation sequencing;online tutorial;outreach;outreach program;programs;recruit;summer research;tool;tool development;transcription factor;transcriptome;virtual;whole genome\", \"abstract_text\": \"PROJECT SUMMARY\\\\nCongenital heart disease (CHD) affects approximately 1% of all children born per year in the United States.\\\\nThe NHLBI has made significant investments to discover the causes and outcomes of CHD, including research\\\\nin the Bench-to-Bassinet (B2B) Consortia that spans fundamental discovery science in the Cardiovascular\\\\nDevelopment Consortium (CvDC), sequencing the genomes of clinically phenotyped children with CHD and\\\\ntheir parents in the Pediatric Cardiac Genomics Consortium (PCGC), and long-term clinical follow-up and\\\\noutcomes research in the Pediatric Heart Network (PHN). The advent of Next Generation Sequencing (NGS)\\\\nhas rapidly accelerated discoveries in cardiovascular development and the genetics and epigenetics of CHD.\\\\nBoth the CvDC and the PCGC have extensive NGS datasets. The CvDC DataHub at the University of Utah\\\\ncurrently serves as the programmatic data warehouse and distribution server that organizes NGS datasets and\\\\nmakes them available online. CvDC datasets are complex, containing NGS experiments from seven \\\\u2018model\\\\norganism\\\\u2019 species (mice, zebrafish, humans, alligator, turtle, chicken, sheep and frogs) and humans.\\\\nImportantly, the experiments in the CvDC explore the molecular etiology of cardiovascular development\\\\nthrough several coordinated -omics approaches, studying changes in the whole-genome transcriptome and in\\\\nthe epigenome (chromatin modifiers, transcription factors, the DNA methylome and higher-order organization\\\\nof chromatin) during cardiac development and in several mutant genetic backgrounds.\\\\nThe Cardiovascular Development Data Resource Center (CDDRC) will be built on the innovative Mosaic\\\\nplatform to provide a cloud-based collaborative space for organizing, visualizing and understanding genomic\\\\ndata, and for pointing analytic tools to datasets housed anywhere on the cloud. The CDDRC is designed by\\\\nexperts in computational sciences and bioinformatics, in consultation with leaders in the CvDC, PCGC and\\\\nPHN to be used by non-experts, basic scientists, human geneticists and clinicians. The University of Utah is\\\\none of a few institutions in the country that has leadership in all three B2B consortia, reflecting the depth and\\\\ndiversity of our expertise and our commitment to cross-disciplinary collaborations. The CDDRC will provide a\\\\nsuite of cloud-compatible tools and a coordinated and a harmonized set of datasets transported from the\\\\nprevious CvDC DataHub, imported from current CvDC projects, and recruited from the cardiovascular\\\\ndevelopment and pediatric CHD research communities. The CDDRC will facilitate dynamic and investigator-\\\\ninteractive interfaces with multiple -omics datasets from humans and multiple model organisms, resulting in\\\\ncollaborative discoveries of the genetic and epigenetic causes of CHD. In addition, our program will have\\\\neducational components in Ethical, Legal and Social Implications (ELSI) of CHD genetics and genomics, and\\\\nan outreach program in CHD computational biology for students from underrepresented groups.\", \"project_title\": \"Cardiovascular Development Data Resource Center (CDDRC)\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe Cardiovascular Development Data Resource Center (CDDRC) will provide an innovative cloud-based\\\\nplatform to facilitate the analysis, visualization and sharing of genomic data from research in heart\\\\ndevelopment in several species. The CDDRC will bring together researchers with a diverse range of expertise,\\\\nwith the goal of understanding the causes of congenital heart disease in children.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-08-01T12:08:00Z\", \"budget_end\": \"2025-07-31T12:07:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 978899, \"indirect_cost_amt\": 451883, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10903877\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 79}, page_content='{\"appl_id\": 10653775, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R01HL153025-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 722659, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HL\", \"serial_num\": \"153025\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": true, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"TRISTANI-FIROUZI, MARTIN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 722659, \"direct_cost_ic\": 473875, \"indirect_cost_ic\": 248784}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2025-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"ESTA\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Electrical Signaling, Ion Transport, and Arrhythmias Study Section[ESTA]\"}, \"award_notice_date\": \"2023-07-12T12:07:00Z\", \"core_project_num\": \"R01HL153025\", \"terms\": \"<Abbreviations><Action Potentials><Algorithms><Anti-Arrhythmia Drugs><Anti-Arrhythmics><Antiarrhythmia Agents><Antiarrhythmia Drugs><Antiarrhythmic Drugs><antiarrhythmic agent><arrhythmic agent><Anti-Arrhythmia Agents><Arrhythmia><Cardiac Arrhythmia><Heart Arrhythmias><Atrial Fibrillation><Auricular Fibrillation><Binding Sites><Combining Site><Reactive Site><Biological Assay><Assay><Bioassay><Biologic Assays><Cardiovascular Diseases><cardiovascular disorder><Cell Culture Techniques><cell culture><cell cultures><Cell Line><CellLine><Strains Cell Lines><cultured cell line><Cells><Cell Body><Sudden Death><Electrophysiology (science)><Electrophysiology><Neurophysiology / Electrophysiology><electrophysiological><Enzyme-Linked Immunosorbent Assay><ELISA><enzyme linked immunoassay><Evolution><Family><Fishes><Foundations><Future><Gene Expression><Genes><Genome><Goals><Heart><Heart Atrium><Atrial><Cardiac Atrium><atrium><Human><Modern Man><Human Genetics><Ion Channel><Ionic Channels><Membrane Channels><Isoproterenol><Isoprenaline><Isopropyl Noradrenaline><Isopropylarterenol><Isopropylnoradrenaline><Isopropylnorepinephrine><Isuprel><Luciferases><Luciferase Immunologic><Methodology><Mutation><Genetic Alteration><Genetic Change><Genetic defect><genome mutation><Optics><optical><Sinus><Accessory Sinuses><Nasal Sinuses><Nasal cavity/Paranasal><Nasal cavity/Paranasal sinuses><Paranasal Sinuses><Patients><genetic pedigree><Pedigree><pedigree structure><Phenotype><Repression><Risk><Role><social role><Siblings><Signal Pathway><Mass Spectrum Analysis><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Testing><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><Genetic Transcription><Gene Transcription><RNA Expression><Transcription><Utah><Zebrafish><Brachydanio rerio><Danio rerio><Zebra Danio><Zebra Fish><Measures><segregation><Tachyarrhythmias><tachyrhythmia><Health Costs><Healthcare Costs><Health Care Costs><Mediating><customs><Custom><Transcription Activation><Transcriptional Activation><Catheter Ablation><Cardiac ablation><improved><Site><Refractory><Variation><Variant><Biochemical><Adolescent Youth><juvenile><juvenile human><Adolescent><Susceptibility><Predisposition><insight><Individual><Recovery><Measurement><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Reporter><Nature><Techniques><Location><Penetrance><experience><Muscle Cells><Myocytes><mutant><Animal Model><Animal Models and Related Studies><model of animal><Transgenic Organisms><transgenic><novel><General Population><General Public><Modality><Pathogenesis><Modeling><Property><response><Cardiac Electrophysiologic Techniques><Cardiac Electrophysiological Diagnostics><cardiac electrophysiology><Pathogenicity><Bio-Informatics><Bioinformatics><DNA Binding Interaction><DNA bound><DNA Binding><Cardiac development><heart development><heart formation><cardiogenesis><Molecular Interaction><Binding><Heart Hypertrophy><cardiac hypertrophy><Affinity><Data><Economic Burden><Nuclear Translocation><Pathologic><Molecular><Cardiac><Pathway interactions><pathway><disease phenotype><GWA study><GWAS><genome wide association><genome wide association scan><genome wide association studies><genomewide association scan><genomewide association studies><genomewide association study><whole genome association analysis><whole genome association studies><whole genome association study><genome wide association study><designing><design><innovate><innovative><innovation><Predisposition gene><predisposing gene><susceptibility allele><susceptibility locus><susceptibility variant><Susceptibility Gene><mutation carrier><high risk><overexpress><overexpression><standard treatment><standard care><clinical practice><ChIP Sequencing><ChIPseq><chromatin immunoprecipitation-sequencing><ChIP-seq><RNA Seq><RNA sequencing><RNAseq><transcriptomic sequencing><transcriptome sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><next generation sequencing><exome-seq><exome sequencing><rare allele><rare variant><differentially expressed><transcriptional differences><differential expression><genomic editing><genome editing><stratify risk><risk stratification><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><risk for stroke><risk of stroke><stroke risk><bio-informatics tool><bioinformatics tool><Familial atrial fibrillation><in silico><gene network><induced pluripotent stem cell derived cardiomyocytes><iPS cell derived cardiomyocytes><iPSC derived cardiomyocytes>\", \"pref_terms\": \"Abbreviations;Action Potentials;Adolescent;Affinity;Algorithms;Animal Model;Anti-Arrhythmia Agents;Arrhythmia;Atrial Fibrillation;Binding;Binding Sites;Biochemical;Bioinformatics;Biological Assay;Cardiac;Cardiac Electrophysiologic Techniques;Cardiac ablation;Cardiovascular Diseases;Cell Culture Techniques;Cell Line;Cells;ChIP-seq;Custom;DNA Binding;Data;Economic Burden;Electrophysiology (science);Enzyme-Linked Immunosorbent Assay;Evolution;Familial atrial fibrillation;Family;Fishes;Foundations;Functional disorder;Future;Gene Expression;General Population;Genes;Genetic Transcription;Genome;Goals;Health Care Costs;Heart;Heart Atrium;Heart Hypertrophy;Human;Human Genetics;Individual;Ion Channel;Isoproterenol;Location;Luciferases;Mass Spectrum Analysis;Measurement;Measures;Mediating;Methodology;Modality;Modeling;Molecular;Muscle Cells;Mutation;Nature;Nuclear Translocation;Optics;Pathogenesis;Pathogenicity;Pathologic;Pathway interactions;Patients;Penetrance;Phenotype;Predisposition;Property;Recovery;Refractory;Reporter;Repression;Risk;Role;Siblings;Signal Pathway;Sinus;Site;Sudden Death;Susceptibility Gene;Tachyarrhythmias;Techniques;Testing;Transcriptional Activation;Transgenic Organisms;Utah;Variant;Zebrafish;bioinformatics tool;cardiogenesis;clinical practice;design;differential expression;disease phenotype;exome sequencing;experience;gene network;genetic pedigree;genome editing;genome wide association study;high risk;improved;in silico;induced pluripotent stem cell derived cardiomyocytes;innovation;insight;mutant;mutation carrier;next generation sequencing;novel;overexpression;rare variant;response;risk stratification;segregation;single-cell RNA sequencing;standard care;stroke risk;transcription factor;transcriptome sequencing\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation (AF) susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. AF, the most common sustained arrhythmia encountered in clinical practice, has an economic burden\\\\nexceeding $7 billion in annual health care costs. Emerging evidence implicates cardiac transcription factors in\\\\nthe pathogenesis in both familial forms of AF and AF in the general population. We identified a mutation in the\\\\ncardiac transcription factor NFATC1 in a high-risk Utah pedigree defined by young onset AF. NFATC1 is a Ca2+-\\\\ndependent transcription factor postulated to play a role in cardiac development, but up until now has never been\\\\nassociated with cardiac excitability. Our exciting preliminary data identify a novel role for NFATC1 in modulating\\\\natrial excitability, in that nfatc1 null zebrafish develop spontaneous atrial tachyarrhythmia and juvenile sudden\\\\ndeath. Aim 1 seeks to define the biochemical, molecular and electrophysiological basis of the mutant NFATC1\\\\ndysfunction, using the HL-1 atrial cell line, a human cell culture model (patient-specific and genome-edited\\\\ninduced pluripotent stem cell derived cardiomyocytes, iPSC-CMs), and a whole animal model (transgenic\\\\nzebrafish). Aim 2 characterizes the role of NFATC1 in modulating atrial excitability by exploring the molecular\\\\nand electrophysiological basis for the atrial tachyarrhythmia in nfatc1 null zebrafish. Aim 3 will define NFATC1-\\\\ncontrolled transcriptional networks and gene pathways that regulate cardiac excitability, using single-cell RNA-\\\\nSeq, ChIP-Seq and ChIP-Mass Spectroscopy in human atrium and NFATC1 null and WT iPSC-CMs.\\\\nOur proposal leverages human genetics, genome-editing techniques, state-of-the-art Next-Gen sequencing\\\\nmodalities and bioinformatics, and electrophysiology to comprehensively characterize the novel role of NFATC1\\\\nin cardiac excitability and AF pathogenesis. An understanding of a key transcriptional network that regulates ion\\\\nchannel gene expression and atrial excitability will provide a broader, and more comprehensive understanding\\\\nof arrhythmia susceptibility and lay the foundation for novel AF therapies.\", \"project_title\": \"A Novel Role for NFATC1 in Modulating Cardiac Excitability\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. This proposal encompasses innovative concepts and methodologies that will advance the study\\\\nof cardiac electrophysiology and arrhythmia susceptibility.\", \"spending_categories_desc\": \"Biotechnology; Cardiovascular; Genetics; Heart Disease; Human Genome; Pediatric; Stem Cell Research; Stem Cell Research - Induced Pluripotent Stem Cell; Stem Cell Research - Induced Pluripotent Stem Cell - Human\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-07-01T12:07:00Z\", \"budget_end\": \"2025-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 473875, \"indirect_cost_amt\": 248784, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10653775\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 80}, page_content='{\"appl_id\": 10618397, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5R01NS114635-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 347624, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"NS\", \"serial_num\": \"114635\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 9880566, \"first_name\": \"Michelle\", \"middle_name\": \"Elena\", \"last_name\": \"Schober\", \"is_contact_pi\": true, \"full_name\": \"Michelle Elena Schober\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"SCHOBER, MICHELLE ELENA\", \"agency_ic_admin\": {\"code\": \"NS\", \"abbreviation\": \"NINDS\", \"name\": \"National Institute of Neurological Disorders and Stroke\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 347624, \"direct_cost_ic\": 227950, \"indirect_cost_ic\": 119674}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2025-04-30T12:04:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"BINP\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Brain Injury and Neurovascular Pathologies Study Section[BINP]\"}, \"award_notice_date\": \"2024-04-30T12:04:00Z\", \"core_project_num\": \"R01NS114635\", \"terms\": \"<Affect><ages><Age><Anatomic Sites><Anatomic structures><Anatomy><Anti-Inflammatories><Anti-inflammatory><Anti-Inflammatory Agents><Antioxidants><Assay><Bioassay><Biological Assay><Brain Nervous System><Encephalon><Brain><necrocytosis><Cell Death><Cytoplasmic Membrane><Plasma Membrane><plasmalemma><Cell membrane><Cell Isolation><Cell Segregation><Cell Separation Technology><cell sorting><Cell Separation><Cell Body><Cells><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Child><Clinical Trials><Caspase Gene><Cell-Death Protease><Cysteine Endopeptidases><Cysteine Protease><Cysteine Proteinases><ICE-like protease><cystein protease><cystein proteinase><cysteine endopeptidase><Caspase><diets><Diet><Docosahexaenoate><Docosahexenoic Acids><Docosahexaenoic Acids><Dropsy><Hydrops><Edema><Brain Inflammation><Encephalitis><Family><Essential Fatty Acids><Female><Flow Cytofluorometries><Flow Cytofluorometry><Flow Microfluorimetry><Flow Microfluorometry><flow cytophotometry><Flow Cytometry><Future><Genes><Generalized Growth><Tissue Growth><ontogeny><Growth><Histology><In Vitro><Inflammation><IFN><Interferons><Beta Proprotein Interleukin 1><IL-1 beta><IL-1 \\\\u03b2><IL-1-b><IL-1\\\\u03b2><IL1-Beta><IL1-\\\\u03b2><IL1B Protein><IL1F2><IL1\\\\u03b2><Interleukin 1beta><Interleukin-1\\\\u03b2><Preinterleukin 1 Beta><Interleukin-1 beta><Learning><Longterm Effects><Long-Term Effects><Macrophage><M\\\\u03c6><Magnetic Resonance Imaging><MR Imaging><MR Tomography><MRI><MRIs><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><NMR Imaging><NMR Tomography><Nuclear Magnetic Resonance Imaging><Zeugmatography><male><Phagocytosis><Phenotype><Production><Rattus><Common Rat Strains><Rat><Rats Mammals><Messenger RNA><mRNA><Signal Transduction><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Testing><Time><Tissues><Body Tissues><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><NADPH Oxidase><Measures><Mediating><measurable outcome><outcome measurement><Outcome Measure><Active Oxygen><Oxygen Radicals><Pro-Oxidants><Reactive Oxygen Species><Secondary to><injuries><Injury><improved><Acute><Chronic><Neurological><Neurologic><Hortega cell><gitter cell><mesoglia><microglial cell><microgliocyte><perivascular glial cell><Microglia><Lesion><disability><pediatric><Childhood><Memory Deficit><memory dysfunction><Memory impairment><Recovery><Oxidative Stress><Stat-1 protein><Stat-91 protein><Stat91 protein><signal transducer and activator of transcription 1><transcription factor Stat91><STAT1 protein><Therapeutic><Infiltration><Inflammatory><tool><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Impaired cognition><Functional MRI><fMRI><Functional Magnetic Resonance Imaging><Knowledge><mechanic><mechanical><Mechanics><Immunes><Immune><intraperitoneal><Pattern><brain cell><neuroprotection><neuroprotective><object recognition><novel><Nervous System Trauma><Nervous System Injuries><Nervous System damage><Neurological Damage><Neurological Injury><Neurological trauma><neurotrauma><TNF gene><(TNF)-\\\\u03b1><Cachectin><Macrophage-Derived TNF><Monocyte-Derived TNF><TNF><TNF A><TNF Alpha><TNF-\\\\u03b1><TNFA><TNF\\\\u03b1><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Modeling><response><Traumatic Brain Injury><Brain Trauma><traumatic brain damage><Membrane Microdomains><Cell Membrane Lipid Rafts><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><lipid raft><Inflammatory Response><Binding><Molecular Interaction><IFNGR1 gene><AVP, Type II><Antiviral Protein, Type II><CD119><CD119 Antigen><CDw119 antigen><IFN-gamma receptor 1><IFN-gammaR><IFN-\\\\u03b3R><IFNGR><IFNGR1><Interferon Gamma Receptor-1><Interferon-Gamma Receptor 1><interferon gamma receptor><STAT1 gene><STAT1><STAT91><TLR4 gene><Homolog of Drosophila TOLL><TLR4><Toll Homologue><toll-like receptor 4><STAT protein><Signal Transducer and Activator of Transcription><Dose><cytotoxic><Receptor Signaling><in vivo><research clinical testing><Clinical Evaluation><Clinical Testing><clinical test><Molecular><sex><Development><developmental><pre-clinical><preclinical><white matter injury><sham surgery><controlled cortical impact><morris water maze><morris watermaze><Outcome><Neurological outcome><Neurologic outcome><innovation><innovate><innovative><clinically relevant><clinical relevance><pup><inflammatory marker><inflammation marker><effective therapy><effective treatment><pediatric traumatic brain injury><pediatric TBI><TBI treatment><TBI therapy><traumatic brain injury therapy><traumatic brain injury treatment><glial activation><glial cell activation><protein biomarkers><protein markers><experimental study><experiment><experimental research><experiments><Neurological disability>\", \"pref_terms\": \"Acute;Affect;Age;Anatomy;Anti-Inflammatory Agents;Antioxidants;Binding;Biological Assay;Brain;Caspase;Cell Death;Cell Separation;Cell membrane;Cells;Child;Childhood;Chronic;Clinical Trials;Development;Diet;Docosahexaenoic Acids;Dose;Edema;Encephalitis;Essential Fatty Acids;Family;Female;Flow Cytometry;Functional Magnetic Resonance Imaging;Future;Genes;Growth;Histology;IFNGR1 gene;Immune;Impaired cognition;In Vitro;Infiltration;Inflammation;Inflammatory;Inflammatory Response;Injury;Interferons;Interleukin-1 beta;Knowledge;Learning;Lesion;Long-Term Effects;Macrophage;Magnetic Resonance Imaging;Measures;Mechanics;Mediating;Membrane Microdomains;Memory impairment;Messenger RNA;Microglia;Modeling;Molecular;NADPH Oxidase;Nervous System Trauma;Neurologic;Neurological disability;Neurological outcome;Outcome;Outcome Measure;Oxidative Stress;Pattern;Phagocytosis;Phenotype;Production;Rattus;Reactive Oxygen Species;Receptor Signaling;Recovery;STAT protein;STAT1 gene;STAT1 protein;Secondary to;Signal Transduction;TBI treatment;TLR4 gene;TNF gene;Testing;Therapeutic;Time;Tissues;Traumatic Brain Injury;brain cell;clinically relevant;controlled cortical impact;cytotoxic;disability;effective therapy;experimental study;glial activation;improved;in vivo;inflammatory marker;innovation;intraperitoneal;male;morris water maze;neuroprotection;novel;object recognition;pediatric traumatic brain injury;pre-clinical;protein biomarkers;pup;research clinical testing;response;sex;sham surgery;tool;transcription factor;white matter injury\", \"abstract_text\": \"PROJECT SUMMARY Traumatic brain injury (TBI) is the leading cause of acquired neurologic disability in\\\\nchildren; yet, no effective therapies exist. Secondary injury from inflammation increases neurologic disability\\\\nfrom damage after impact. Microglia (the brain\\'s resident immune cells) mediate inflammatory release of\\\\nreactive oxygen species (ROS) and cytotoxic factors early after TBI. Microglia that become reparatory remove\\\\ndebris by phagocytosis and resolve inflammation. The immature brain is highly vulnerable to secondary injury\\\\ndue to its low antioxidant reserve and vigorous inflammatory response. Agents that move microglia away from\\\\ninflammatory towards reparatory activity may decrease neurologic disability after TBI, particularly in children.\\\\nDocosahexaenoic Acid, or DHA, is a candidate therapy for childhood TBI. DHA is a fatty acid essential for\\\\nnormal brain growth and function that has antioxidant and anti-inflammatory activity. In rats, DHA restores\\\\nbrain DHA losses after TBI. In cultured microglia, DHA promotes reparatory activity. Using our pediatric TBI\\\\nmodel, controlled cortical impact (CCI) in male 17-day old (P17) rats, DHA diet before CCI reduced learning\\\\ndeficits (Morris Water Maze, MWM) brain lesion volume and white matter injury (histology and MRI, Magnetic\\\\nResonance Imaging). We also showed that DHA given after CCI improved rat pup outcomes. Intraperitoneal\\\\n(IP) DHA at 30 minutes after CCI, followed by up to 60 days of DHA diet, decreased ROS, microglial\\\\ninflammatory genes at post injury day 7(PID7) and memory dysfunction (Novel Object Recognition, NOR).\\\\nWhether DHA affects brain inflammatory markers in female pups, or if DHA affects microglial activity (ROS\\\\nproduction and phagocytosis) after TBI in either sex, is unknown. Similarly, whether delayed (later than 30 min\\\\nafter CCI) or short (7-day course) DHA will retain acute and chronic neuroprotection, is not known. Finally, little\\\\nis known about how DHA may modulate microglial activation after TBI. We hypothesize that either DHA at 30\\\\nmin or 3h after CCI will decrease PID7 microglial inflammation in males and that only long term DHA will\\\\nimprove PID45-60 outcomes in both sexes. We hypothesize that DHA will decrease PID7 inflammation\\\\nassociated with decreased TLR4 and activated STAT1 proteins on cell membranes and caspase activity. We\\\\nwill use male and female P17 rat pups and CCI or sham surgery. We will compare onset of DHA (30 min or 3h)\\\\nand duration (7 days to 60 days) to control. During week 1 after CCI, we will use cell membrane assays, tissue\\\\nand microglial protein markers, and microglial activity to assess inflammation. From PID 45 to 60 we will use\\\\nNOR/ MWM testing, histology and MRI for functional, anatomic and inflammatory outcomes. This proposal is\\\\nsignificant because it focuses on the immature brain after severe TBI, a devastating condition for which no\\\\neffective therapies exist. It will yield new knowledge on the effects of sex and DHA on microglial function after\\\\nTBI and on optimal DHA initiation and duration timing. Results will enable future clinical trials of DHA with the\\\\npotential to decrease the burden of pediatric acquired neurologic injury after TBI.\", \"project_title\": \"Microglial Function and Neurologic Outcome in Rat Pups after Experimental Traumatic Brain Injury: Effects of Timing and Duration of Docosahexaenoic Acid Therapy\", \"phr_text\": \"PROJECT NARRATIVE\\\\nWe will use male and female rat pups to study inflammation in the young brain after traumatic brain injury\\\\n(TBI). TBI is the leading cause of acquired disability in children, yet no effective therapies exist. Our results will\\\\ninform future testing of Docosahexaenoic Acid (DHA), a promising therapy, in children after TBI.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-05-01T12:05:00Z\", \"budget_end\": \"2025-04-30T12:04:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 227950, \"indirect_cost_amt\": 119674, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10618397\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 81}, page_content='{\"appl_id\": 10402878, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5R01NS114635-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 358375, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"NS\", \"serial_num\": \"114635\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 9880566, \"first_name\": \"Michelle\", \"middle_name\": \"Elena\", \"last_name\": \"Schober\", \"is_contact_pi\": true, \"full_name\": \"Michelle Elena Schober\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"SCHOBER, MICHELLE ELENA\", \"agency_ic_admin\": {\"code\": \"NS\", \"abbreviation\": \"NINDS\", \"name\": \"National Institute of Neurological Disorders and Stroke\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 358375, \"direct_cost_ic\": 235000, \"indirect_cost_ic\": 123375}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2025-04-30T12:04:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"BINP\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Brain Injury and Neurovascular Pathologies Study Section[BINP]\"}, \"award_notice_date\": \"2022-05-05T12:05:00Z\", \"core_project_num\": \"R01NS114635\", \"terms\": \"<Affect><Age><ages><Anatomy><Anatomic><Anatomic Sites><Anatomic structures><Anatomical Sciences><Anti-Inflammatory Agents><Anti-Inflammatories><Anti-inflammatory><Antiinflammatories><Antiinflammatory Agents><antiinflammatory><Antioxidants><anti-oxidant><Biological Assay><Assay><Bioassay><Biologic Assays><Brain><Brain Nervous System><Encephalon><Cell Death><necrocytosis><Cell membrane><Cytoplasmic Membrane><Plasma Membrane><plasmalemma><Cells><Cell Body><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Trials><Caspase><Caspase Gene><Cell-Death Protease><Cysteine Endopeptidases><Cysteine Protease><Cysteine Proteinases><ICE-like protease><cystein protease><cystein proteinase><cysteine endopeptidase><Diet><diets><Docosahexaenoic Acids><Docosahexaenoate><Docosahexenoic Acids><Edema><Dropsy><Hydrops><Encephalitis><Brain Inflammation><Family><Essential Fatty Acids><Female><Flow Cytometry><Flow Cytofluorometries><Flow Cytofluorometry><Flow Microfluorimetry><Flow Microfluorometry><flow cytophotometry><Future><Genes><Growth><Generalized Growth><Tissue Growth><ontogeny><Histology><In Vitro><Inflammation><Interferons><IFN><Interleukin-1 beta><Beta Proprotein Interleukin 1><IL-1 beta><IL-1 \\\\u03b2><IL-1-b><IL-1\\\\u03b2><IL1-Beta><IL1-\\\\u03b2><IL1B Protein><IL1F2><IL1\\\\u03b2><Interleukin 1beta><Interleukin-1\\\\u03b2><Preinterleukin 1 Beta><Learning><Long-Term Effects><Longterm Effects><macrophage><M\\\\u03c6><Magnetic Resonance Imaging><MR Imaging><MR Tomography><MRI><MRIs><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><NMR Imaging><NMR Tomography><Nuclear Magnetic Resonance Imaging><Zeugmatography><male><Phagocytosis><Phenotype><Production><Proteins><Common Rat Strains><Rat><Rats Mammals><Rattus><mRNA><Messenger RNA><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Signal Transduction><Testing><Time><Tissues><Body Tissues><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><NADPH Oxidase><Measures><Mediating><Outcome Measure><Reactive Oxygen Species><Active Oxygen><Oxygen Radicals><Pro-Oxidants><Secondary to><Injury><injuries><base><improved><Acute><Chronic><Neurologic><Neurological><Microglia><Hortega cell><gitter cell><mesoglia><microglial cell><microgliocyte><perivascular glial cell><Lesion><disability><pediatric><Childhood><Memory Deficit><memory dysfunction><Memory impairment><Recovery><Oxidative Stress><Therapeutic><Inflammatory><tool><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Impaired cognition><Functional MRI><fMRI><Functional Magnetic Resonance Imaging><Knowledge><mechanical><Mechanics><Immunes><Immune><intraperitoneal><Pattern><brain cell><Receptor Protein><receptor><neuroprotection><object recognition><novel><Nervous System Injuries><Nervous System damage><Neurological Damage><Neurological Injury><Neurological trauma><neurotrauma><Nervous System Trauma><(TNF)-\\\\u03b1><Cachectin><Macrophage-Derived TNF><Monocyte-Derived TNF><TNF><TNF A><TNF Alpha><TNF-\\\\u03b1><TNFA><TNF\\\\u03b1><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><TNF gene><Modeling><response><Brain Trauma><traumatic brain damage><Traumatic Brain Injury><Cell Membrane Lipid Rafts><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><lipid raft><Membrane Microdomains><Inflammatory Response><Molecular Interaction><Binding><Homolog of Drosophila TOLL><TLR4><Toll Homologue><toll-like receptor 4><TLR4 gene><Signal Transducer and Activator of Transcription><STAT protein><Dose><cytotoxic><Receptor Signaling><Sum><in vivo><research clinical testing><Clinical Evaluation><Clinical Testing><clinical test><Molecular><sex><Development><developmental><pre-clinical><preclinical><white matter injury><sham surgery><controlled cortical impact><morris water maze><morris watermaze><Outcome><Neurological outcome><Neurologic outcome><innovation><innovate><innovative><clinically relevant><clinical relevance><pup><inflammatory marker><inflammation marker><effective therapy><effective treatment><pediatric traumatic brain injury><pediatric TBI><TBI treatment><TBI therapy><traumatic brain injury therapy><traumatic brain injury treatment><protein biomarkers><protein markers><experimental study><experiment><experimental research>\", \"pref_terms\": \"Acute;Affect;Age;Anatomy;Anti-Inflammatory Agents;Antioxidants;Binding;Biological Assay;Brain;Caspase;Cell Death;Cell membrane;Cells;Child;Childhood;Chronic;Clinical Trials;Development;Diet;Docosahexaenoic Acids;Dose;Edema;Encephalitis;Essential Fatty Acids;Family;Female;Flow Cytometry;Functional Magnetic Resonance Imaging;Future;Genes;Growth;Histology;Immune;Impaired cognition;In Vitro;Inflammation;Inflammatory;Inflammatory Response;Injury;Interferons;Interleukin-1 beta;Knowledge;Learning;Lesion;Long-Term Effects;Magnetic Resonance Imaging;Measures;Mechanics;Mediating;Membrane Microdomains;Memory impairment;Messenger RNA;Microglia;Modeling;Molecular;NADPH Oxidase;Nervous System Trauma;Neurologic;Neurological outcome;Outcome;Outcome Measure;Oxidative Stress;Pattern;Phagocytosis;Phenotype;Production;Proteins;Rattus;Reactive Oxygen Species;Receptor Signaling;Recovery;STAT protein;Secondary to;Signal Transduction;Sum;TBI treatment;TLR4 gene;TNF gene;Testing;Therapeutic;Time;Tissues;Traumatic Brain Injury;base;brain cell;clinically relevant;controlled cortical impact;cytotoxic;disability;effective therapy;experimental study;improved;in vivo;inflammatory marker;innovation;intraperitoneal;macrophage;male;morris water maze;neuroprotection;novel;object recognition;pediatric traumatic brain injury;pre-clinical;protein biomarkers;pup;receptor;research clinical testing;response;sex;sham surgery;tool;transcription factor;white matter injury\", \"abstract_text\": \"PROJECT SUMMARY Traumatic brain injury (TBI) is the leading cause of acquired neurologic disability in\\\\nchildren; yet, no effective therapies exist. Secondary injury from inflammation increases neurologic disability\\\\nfrom damage after impact. Microglia (the brain\\'s resident immune cells) mediate inflammatory release of\\\\nreactive oxygen species (ROS) and cytotoxic factors early after TBI. Microglia that become reparatory remove\\\\ndebris by phagocytosis and resolve inflammation. The immature brain is highly vulnerable to secondary injury\\\\ndue to its low antioxidant reserve and vigorous inflammatory response. Agents that move microglia away from\\\\ninflammatory towards reparatory activity may decrease neurologic disability after TBI, particularly in children.\\\\nDocosahexaenoic Acid, or DHA, is a candidate therapy for childhood TBI. DHA is a fatty acid essential for\\\\nnormal brain growth and function that has antioxidant and anti-inflammatory activity. In rats, DHA restores\\\\nbrain DHA losses after TBI. In cultured microglia, DHA promotes reparatory activity. Using our pediatric TBI\\\\nmodel, controlled cortical impact (CCI) in male 17-day old (P17) rats, DHA diet before CCI reduced learning\\\\ndeficits (Morris Water Maze, MWM) brain lesion volume and white matter injury (histology and MRI, Magnetic\\\\nResonance Imaging). We also showed that DHA given after CCI improved rat pup outcomes. Intraperitoneal\\\\n(IP) DHA at 30 minutes after CCI, followed by up to 60 days of DHA diet, decreased ROS, microglial\\\\ninflammatory genes at post injury day 7(PID7) and memory dysfunction (Novel Object Recognition, NOR).\\\\nWhether DHA affects brain inflammatory markers in female pups, or if DHA affects microglial activity (ROS\\\\nproduction and phagocytosis) after TBI in either sex, is unknown. Similarly, whether delayed (later than 30 min\\\\nafter CCI) or short (7-day course) DHA will retain acute and chronic neuroprotection, is not known. Finally, little\\\\nis known about how DHA may modulate microglial activation after TBI. We hypothesize that either DHA at 30\\\\nmin or 3h after CCI will decrease PID7 microglial inflammation in males and that only long term DHA will\\\\nimprove PID45-60 outcomes in both sexes. We hypothesize that DHA will decrease PID7 inflammation\\\\nassociated with decreased TLR4 and activated STAT1 proteins on cell membranes and caspase activity. We\\\\nwill use male and female P17 rat pups and CCI or sham surgery. We will compare onset of DHA (30 min or 3h)\\\\nand duration (7 days to 60 days) to control. During week 1 after CCI, we will use cell membrane assays, tissue\\\\nand microglial protein markers, and microglial activity to assess inflammation. From PID 45 to 60 we will use\\\\nNOR/ MWM testing, histology and MRI for functional, anatomic and inflammatory outcomes. This proposal is\\\\nsignificant because it focuses on the immature brain after severe TBI, a devastating condition for which no\\\\neffective therapies exist. It will yield new knowledge on the effects of sex and DHA on microglial function after\\\\nTBI and on optimal DHA initiation and duration timing. Results will enable future clinical trials of DHA with the\\\\npotential to decrease the burden of pediatric acquired neurologic injury after TBI.\", \"project_title\": \"Microglial Function and Neurologic Outcome in Rat Pups after Experimental Traumatic Brain Injury: Effects of Timing and Duration of Docosahexaenoic Acid Therapy\", \"phr_text\": \"PROJECT NARRATIVE\\\\nWe will use male and female rat pups to study inflammation in the young brain after traumatic brain injury\\\\n(TBI). TBI is the leading cause of acquired disability in children, yet no effective therapies exist. Our results will\\\\ninform future testing of Docosahexaenoic Acid (DHA), a promising therapy, in children after TBI.\", \"spending_categories_desc\": \"Brain Disorders; Childhood Injury; Neurosciences; Pediatric; Physical Injury - Accidents and Adverse Effects; Traumatic Brain Injury (TBI); Traumatic Head and Spine Injury; Unintentional Childhood Injury; Women\\'s Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-05-01T12:05:00Z\", \"budget_end\": \"2024-04-30T12:04:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 235000, \"indirect_cost_amt\": 123375, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10402878\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 82}, page_content='{\"appl_id\": 10449135, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5R01HL153025-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 722659, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HL\", \"serial_num\": \"153025\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": true, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"TRISTANI-FIROUZI, MARTIN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 722659, \"direct_cost_ic\": 473875, \"indirect_cost_ic\": 248784}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2024-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"ESTA\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Electrical Signaling, Ion Transport, and Arrhythmias Study Section[ESTA]\"}, \"award_notice_date\": \"2022-06-26T12:06:00Z\", \"core_project_num\": \"R01HL153025\", \"terms\": \"<Action Potentials><Algorithms><Anti-Arrhythmia Agents><Anti-Arrhythmia Drugs><Anti-Arrhythmics><Antiarrhythmia Agents><Antiarrhythmia Drugs><Antiarrhythmic Drugs><antiarrhythmic agent><arrhythmic agent><Arrhythmia><Cardiac Arrhythmia><Heart Arrhythmias><Atrial Fibrillation><Auricular Fibrillation><Binding Sites><Combining Site><Reactive Site><Biological Assay><Assay><Bioassay><Biologic Assays><Cardiovascular Diseases><cardiovascular disorder><Cell Culture Techniques><cell culture><cell cultures><Cell Line><CellLine><Strains Cell Lines><cultured cell line><Cells><Cell Body><Sudden Death><Electrophysiology (science)><Electrophysiology><Neurophysiology / Electrophysiology><electrophysiological><Enzyme-Linked Immunosorbent Assay><ELISA><enzyme linked immunoassay><Evolution><Family><Fishes><Foundations><Future><Gene Expression><Genes><Genome><Goals><Heart><Heart Atrium><Atrial><Cardiac Atrium><atrium><Human><Modern Man><Human Genetics><Ion Channel><Ionic Channels><Membrane Channels><Isoproterenol><Isoprenaline><Isopropyl Noradrenaline><Isopropylarterenol><Isopropylnoradrenaline><Isopropylnorepinephrine><Isuprel><Luciferases><Luciferase Immunologic><Methodology><Mutation><Genetic Alteration><Genetic Change><Genetic defect><genome mutation><optical><Optics><Accessory Sinuses><Nasal Sinuses><Nasal cavity/Paranasal><Nasal cavity/Paranasal sinuses><Paranasal Sinuses><Sinus><Patients><Pedigree><pedigree structure><genetic pedigree><Phenotype><Play><Risk><social role><Role><Siblings><Signal Pathway><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Testing><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><Genetic Transcription><Gene Transcription><RNA Expression><Transcription><Utah><Zebrafish><Brachydanio rerio><Danio rerio><Zebra Danio><Zebra Fish><Measures><Tachyarrhythmias><tachyrhythmia><Health Care Costs><Health Costs><Healthcare Costs><Mediating><Custom><Transcriptional Activation><Transcription Activation><Cardiac ablation><Catheter Ablation><base><improved><Site><Refractory><Variant><Variation><Biochemical><Adolescent><Adolescent Youth><juvenile><juvenile human><Susceptibility><Predisposition><insight><Individual><Recovery><Measurement><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Reporter><Nature><Techniques><Location><Penetrance><experience><Myocytes><Muscle Cells><mutant><Animal Models and Related Studies><model of animal><model organism><Animal Model><transgenic><Transgenic Organisms><novel><General Public><General Population><Modality><Pathogenesis><Modeling><Property><response><Cardiac Electrophysiological Diagnostics><cardiac electrophysiology><Cardiac Electrophysiologic Techniques><Pathogenicity><Bio-Informatics><Bioinformatics><DNA Binding Interaction><DNA bound><DNA Binding><Molecular Interaction><Binding><cardiac hypertrophy><Heart Hypertrophy><Affinity><Data><Economic Burden><Nuclear Translocation><Pathologic><Molecular><Cardiac><Pathway interactions><pathway><disease phenotype><genome wide association study><GWA study><GWAS><genome wide association><genome wide association scan><genome wide association studies><genomewide association scan><genomewide association studies><genomewide association study><whole genome association analysis><whole genome association studies><whole genome association study><design><designing><innovation><innovate><innovative><Susceptibility Gene><Predisposition gene><predisposing gene><susceptibility allele><susceptibility locus><susceptibility variant><induced pluripotent stem cell><iPS><iPSC><iPSCs><inducible pluripotent stem cell><mutation carrier><high risk><overexpression><overexpress><standard care><standard treatment><clinical practice><ChIP-seq><ChIP Sequencing><chromatin immunoprecipitation-sequencing><transcriptome sequencing><RNA Seq><RNA sequencing><RNAseq><next generation sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><exome sequencing><exome-seq><rare variant><rare allele><Cardiac development><differential expression><differentially expressed><transcriptional differences><genome editing><genomic editing><risk stratification><stratify risk><single-cell RNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><stroke risk><risk for stroke><risk of stroke><bioinformatics tool><bio-informatics tool><Familial atrial fibrillation><in silico><gene network><induced pluripotent stem cell derived cardiomyocytes><iPS cell derived cardiomyocytes><iPSC derived cardiomyocytes>\", \"pref_terms\": \"Action Potentials;Adolescent;Affinity;Algorithms;Animal Model;Anti-Arrhythmia Agents;Arrhythmia;Atrial Fibrillation;Binding;Binding Sites;Biochemical;Bioinformatics;Biological Assay;Cardiac;Cardiac Electrophysiologic Techniques;Cardiac ablation;Cardiac development;Cardiovascular Diseases;Cell Culture Techniques;Cell Line;Cells;ChIP-seq;Custom;DNA Binding;Data;Economic Burden;Electrophysiology (science);Enzyme-Linked Immunosorbent Assay;Evolution;Familial atrial fibrillation;Family;Fishes;Foundations;Functional disorder;Future;Gene Expression;General Population;Genes;Genetic Transcription;Genome;Goals;Health Care Costs;Heart;Heart Atrium;Heart Hypertrophy;Human;Human Genetics;Individual;Ion Channel;Isoproterenol;Location;Luciferases;Mass Spectrum Analysis;Measurement;Measures;Mediating;Methodology;Modality;Modeling;Molecular;Muscle Cells;Mutation;Nature;Nuclear Translocation;Optics;Pathogenesis;Pathogenicity;Pathologic;Pathway interactions;Patients;Penetrance;Phenotype;Play;Predisposition;Property;Recovery;Refractory;Reporter;Risk;Role;Siblings;Signal Pathway;Sinus;Site;Sudden Death;Susceptibility Gene;Tachyarrhythmias;Techniques;Testing;Transcriptional Activation;Transgenic Organisms;Utah;Variant;Zebrafish;base;bioinformatics tool;clinical practice;design;differential expression;disease phenotype;exome sequencing;experience;gene network;genetic pedigree;genome editing;genome wide association study;high risk;improved;in silico;induced pluripotent stem cell;induced pluripotent stem cell derived cardiomyocytes;innovation;insight;mutant;mutation carrier;next generation sequencing;novel;overexpression;rare variant;response;risk stratification;single-cell RNA sequencing;standard care;stroke risk;transcription factor;transcriptome sequencing\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation (AF) susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. AF, the most common sustained arrhythmia encountered in clinical practice, has an economic burden\\\\nexceeding $7 billion in annual health care costs. Emerging evidence implicates cardiac transcription factors in\\\\nthe pathogenesis in both familial forms of AF and AF in the general population. We identified a mutation in the\\\\ncardiac transcription factor NFATC1 in a high-risk Utah pedigree defined by young onset AF. NFATC1 is a Ca2+-\\\\ndependent transcription factor postulated to play a role in cardiac development, but up until now has never been\\\\nassociated with cardiac excitability. Our exciting preliminary data identify a novel role for NFATC1 in modulating\\\\natrial excitability, in that nfatc1 null zebrafish develop spontaneous atrial tachyarrhythmia and juvenile sudden\\\\ndeath. Aim 1 seeks to define the biochemical, molecular and electrophysiological basis of the mutant NFATC1\\\\ndysfunction, using the HL-1 atrial cell line, a human cell culture model (patient-specific and genome-edited\\\\ninduced pluripotent stem cell derived cardiomyocytes, iPSC-CMs), and a whole animal model (transgenic\\\\nzebrafish). Aim 2 characterizes the role of NFATC1 in modulating atrial excitability by exploring the molecular\\\\nand electrophysiological basis for the atrial tachyarrhythmia in nfatc1 null zebrafish. Aim 3 will define NFATC1-\\\\ncontrolled transcriptional networks and gene pathways that regulate cardiac excitability, using single-cell RNA-\\\\nSeq, ChIP-Seq and ChIP-Mass Spectroscopy in human atrium and NFATC1 null and WT iPSC-CMs.\\\\nOur proposal leverages human genetics, genome-editing techniques, state-of-the-art Next-Gen sequencing\\\\nmodalities and bioinformatics, and electrophysiology to comprehensively characterize the novel role of NFATC1\\\\nin cardiac excitability and AF pathogenesis. An understanding of a key transcriptional network that regulates ion\\\\nchannel gene expression and atrial excitability will provide a broader, and more comprehensive understanding\\\\nof arrhythmia susceptibility and lay the foundation for novel AF therapies.\", \"project_title\": \"A Novel Role for NFATC1 in Modulating Cardiac Excitability\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. This proposal encompasses innovative concepts and methodologies that will advance the study\\\\nof cardiac electrophysiology and arrhythmia susceptibility.\", \"spending_categories_desc\": \"Biotechnology; Cardiovascular; Genetics; Heart Disease; Human Genome; Stem Cell Research; Stem Cell Research - Induced Pluripotent Stem Cell; Stem Cell Research - Induced Pluripotent Stem Cell - Human\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-07-01T12:07:00Z\", \"budget_end\": \"2023-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 473875, \"indirect_cost_amt\": 248784, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10449135\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 83}, page_content='{\"appl_id\": 10052648, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"1R01NS114635-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R01\", \"award_amount\": 358375, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R01\", \"ic_code\": \"NS\", \"serial_num\": \"114635\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 9880566, \"first_name\": \"Michelle\", \"middle_name\": \"Elena\", \"last_name\": \"Schober\", \"is_contact_pi\": true, \"full_name\": \"Michelle Elena Schober\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"SCHOBER, MICHELLE ELENA\", \"agency_ic_admin\": {\"code\": \"NS\", \"abbreviation\": \"NINDS\", \"name\": \"National Institute of Neurological Disorders and Stroke\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 358375, \"direct_cost_ic\": 235000, \"indirect_cost_ic\": 123375}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2024-04-30T12:04:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"BINP\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Brain Injury and Neurovascular Pathologies Study Section[BINP]\"}, \"award_notice_date\": \"2020-06-26T12:06:00Z\", \"core_project_num\": \"R01NS114635\", \"terms\": \"<Affect><Age><ages><Anatomy><Anatomic><Anatomic Sites><Anatomic structures><Anatomical Sciences><Anti-Inflammatory Agents><Anti-Inflammatories><Anti-inflammatory><Antiinflammatories><Antiinflammatory Agents><antiinflammatory><Antioxidants><anti-oxidant><Biological Assay><Assay><Bioassay><Biologic Assays><Brain><Brain Nervous System><Encephalon><Cell Death><necrocytosis><Cell membrane><Cytoplasmic Membrane><Plasma Membrane><plasmalemma><Cells><Cell Body><Child><0-11 years old><Child Youth><Children (0-21)><children><childrens\\'><youngster><Clinical Trials><Caspase><Caspase Gene><Cell-Death Protease><Cysteine Endopeptidases><Cysteine Protease><Cysteine Proteinases><ICE-like protease><cystein protease><cystein proteinase><cysteine endopeptidase><Diet><dietary><Docosahexaenoic Acids><Docosahexaenoate><Docosahexenoic Acids><Edema><Dropsy><Hydrops><Encephalitis><Brain Inflammation><Family><Essential Fatty Acids><Female><Flow Cytometry><Flow Cytofluorometries><Flow Cytofluorometry><Flow Microfluorimetry><Flow Microfluorometry><flow cytophotometry><Future><Genes><Growth><Generalized Growth><Tissue Growth><ontogeny><Histology><In Vitro><Inflammation><Interferons><IFN><Interleukin-1 beta><Beta Proprotein Interleukin 1><IL-1 beta><IL-1 \\\\u03b2><IL-1-b><IL-1\\\\u03b2><IL1-Beta><IL1-\\\\u03b2><IL1B Protein><IL1F2><IL1\\\\u03b2><Interleukin 1beta><Interleukin-1\\\\u03b2><Preinterleukin 1 Beta><Learning><Long-Term Effects><Longterm Effects><macrophage><Magnetic Resonance Imaging><MR Imaging><MR Tomography><MRI><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><NMR Imaging><NMR Tomography><Nuclear Magnetic Resonance Imaging><Zeugmatography><male><Phagocytosis><Phenotype><Production><Proteins><Rattus><Common Rat Strains><Rat><Rats Mammals><Messenger RNA><mRNA><Signal Transduction><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Testing><Time><Tissues><Body Tissues><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><NADPH Oxidase><Measures><Mediating><Outcome Measure><Active Oxygen><Oxygen Radicals><Pro-Oxidants><Reactive Oxygen Species><Secondary to><injuries><Injury><base><improved><Acute><Chronic><Neurological><Neurologic><Hortega cell><gitter cell><mesoglia><microglial cell><microgliocyte><perivascular glial cell><Microglia><Lesion><disability><pediatric><Childhood><Memory Deficit><memory dysfunction><Memory impairment><Recovery><Oxidative Stress><Therapeutic><Inflammatory><tool><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Impaired cognition><Functional MRI><fMRI><Functional Magnetic Resonance Imaging><Knowledge><mechanical><Mechanics><Immunes><Immune><intraperitoneal><Pattern><brain cell><Receptor Protein><receptor><neuroprotection><object recognition><novel><Nervous System Injuries><Nervous System damage><Neurological Damage><Neurological Injury><Neurological trauma><neurotrauma><Nervous System Trauma><(TNF)-\\\\u03b1><Cachectin><Macrophage-Derived TNF><Monocyte-Derived TNF><TNF><TNF A><TNF Alpha><TNF-\\\\u03b1><TNFA><TNF\\\\u03b1><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><TNF gene><Modeling><response><Brain Trauma><traumatic brain damage><Traumatic Brain Injury><Cell Membrane Lipid Rafts><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><lipid raft><Membrane Microdomains><Inflammatory Response><Molecular Interaction><Binding><Homolog of Drosophila TOLL><TLR4><Toll Homologue><toll-like receptor 4><TLR4 gene><Signal Transducer and Activator of Transcription><STAT protein><Dose><cytotoxic><Receptor Signaling><Sum><in vivo><Clinical Evaluation><Clinical Testing><clinical test><research clinical testing><Molecular><sex><developmental><Development><preclinical><pre-clinical><white matter injury><sham surgery><controlled cortical impact><morris watermaze><morris water maze><Outcome><Neurologic outcome><Neurological outcome><innovate><innovative><innovation><clinical relevance><clinically relevant><pup><inflammation marker><inflammatory marker><effective treatment><effective therapy><pediatric TBI><pediatric traumatic brain injury><TBI therapy><traumatic brain injury therapy><traumatic brain injury treatment><TBI treatment><protein markers><protein biomarkers><experiment><experimental research><experimental study>\", \"pref_terms\": \"Acute;Affect;Age;Anatomy;Anti-Inflammatory Agents;Antioxidants;Binding;Biological Assay;Brain;Caspase;Cell Death;Cell membrane;Cells;Child;Childhood;Chronic;Clinical Trials;Development;Diet;Docosahexaenoic Acids;Dose;Edema;Encephalitis;Essential Fatty Acids;Family;Female;Flow Cytometry;Functional Magnetic Resonance Imaging;Future;Genes;Growth;Histology;Immune;Impaired cognition;In Vitro;Inflammation;Inflammatory;Inflammatory Response;Injury;Interferons;Interleukin-1 beta;Knowledge;Learning;Lesion;Long-Term Effects;Magnetic Resonance Imaging;Measures;Mechanics;Mediating;Membrane Microdomains;Memory impairment;Messenger RNA;Microglia;Modeling;Molecular;NADPH Oxidase;Nervous System Trauma;Neurologic;Neurological outcome;Outcome;Outcome Measure;Oxidative Stress;Pattern;Phagocytosis;Phenotype;Production;Proteins;Rattus;Reactive Oxygen Species;Receptor Signaling;Recovery;STAT protein;Secondary to;Signal Transduction;Sum;TBI treatment;TLR4 gene;TNF gene;Testing;Therapeutic;Time;Tissues;Traumatic Brain Injury;base;brain cell;clinically relevant;controlled cortical impact;cytotoxic;disability;effective therapy;experimental study;improved;in vivo;inflammatory marker;innovation;intraperitoneal;macrophage;male;morris water maze;neuroprotection;novel;object recognition;pediatric traumatic brain injury;pre-clinical;protein biomarkers;pup;receptor;research clinical testing;response;sex;sham surgery;tool;transcription factor;white matter injury\", \"abstract_text\": \"PROJECT SUMMARY Traumatic brain injury (TBI) is the leading cause of acquired neurologic disability in\\\\nchildren; yet, no effective therapies exist. Secondary injury from inflammation increases neurologic disability\\\\nfrom damage after impact. Microglia (the brain\\'s resident immune cells) mediate inflammatory release of\\\\nreactive oxygen species (ROS) and cytotoxic factors early after TBI. Microglia that become reparatory remove\\\\ndebris by phagocytosis and resolve inflammation. The immature brain is highly vulnerable to secondary injury\\\\ndue to its low antioxidant reserve and vigorous inflammatory response. Agents that move microglia away from\\\\ninflammatory towards reparatory activity may decrease neurologic disability after TBI, particularly in children.\\\\nDocosahexaenoic Acid, or DHA, is a candidate therapy for childhood TBI. DHA is a fatty acid essential for\\\\nnormal brain growth and function that has antioxidant and anti-inflammatory activity. In rats, DHA restores\\\\nbrain DHA losses after TBI. In cultured microglia, DHA promotes reparatory activity. Using our pediatric TBI\\\\nmodel, controlled cortical impact (CCI) in male 17-day old (P17) rats, DHA diet before CCI reduced learning\\\\ndeficits (Morris Water Maze, MWM) brain lesion volume and white matter injury (histology and MRI, Magnetic\\\\nResonance Imaging). We also showed that DHA given after CCI improved rat pup outcomes. Intraperitoneal\\\\n(IP) DHA at 30 minutes after CCI, followed by up to 60 days of DHA diet, decreased ROS, microglial\\\\ninflammatory genes at post injury day 7(PID7) and memory dysfunction (Novel Object Recognition, NOR).\\\\nWhether DHA affects brain inflammatory markers in female pups, or if DHA affects microglial activity (ROS\\\\nproduction and phagocytosis) after TBI in either sex, is unknown. Similarly, whether delayed (later than 30 min\\\\nafter CCI) or short (7-day course) DHA will retain acute and chronic neuroprotection, is not known. Finally, little\\\\nis known about how DHA may modulate microglial activation after TBI. We hypothesize that either DHA at 30\\\\nmin or 3h after CCI will decrease PID7 microglial inflammation in males and that only long term DHA will\\\\nimprove PID45-60 outcomes in both sexes. We hypothesize that DHA will decrease PID7 inflammation\\\\nassociated with decreased TLR4 and activated STAT1 proteins on cell membranes and caspase activity. We\\\\nwill use male and female P17 rat pups and CCI or sham surgery. We will compare onset of DHA (30 min or 3h)\\\\nand duration (7 days to 60 days) to control. During week 1 after CCI, we will use cell membrane assays, tissue\\\\nand microglial protein markers, and microglial activity to assess inflammation. From PID 45 to 60 we will use\\\\nNOR/ MWM testing, histology and MRI for functional, anatomic and inflammatory outcomes. This proposal is\\\\nsignificant because it focuses on the immature brain after severe TBI, a devastating condition for which no\\\\neffective therapies exist. It will yield new knowledge on the effects of sex and DHA on microglial function after\\\\nTBI and on optimal DHA initiation and duration timing. Results will enable future clinical trials of DHA with the\\\\npotential to decrease the burden of pediatric acquired neurologic injury after TBI.\", \"project_title\": \"Microglial Function and Neurologic Outcome in Rat Pups after Experimental Traumatic Brain Injury: Effects of Timing and Duration of Docosahexaenoic Acid Therapy\", \"phr_text\": \"PROJECT NARRATIVE\\\\nWe will use male and female rat pups to study inflammation in the young brain after traumatic brain injury\\\\n(TBI). TBI is the leading cause of acquired disability in children, yet no effective therapies exist. Our results will\\\\ninform future testing of Docosahexaenoic Acid (DHA), a promising therapy, in children after TBI.\", \"spending_categories_desc\": \"Brain Disorders; Injury - Childhood Injuries; Injury - Trauma - (Head and Spine); Injury - Traumatic brain injury; Injury - Unintentional Childhood Injury; Neurosciences; Pediatric; Physical Injury - Accidents and Adverse Effects; Women\\'s Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-07-01T12:07:00Z\", \"budget_end\": \"2021-04-30T12:04:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 235000, \"indirect_cost_amt\": 123375, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10052648\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 84}, page_content='{\"appl_id\": 10204141, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"5R01NS114635-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 358375, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"NS\", \"serial_num\": \"114635\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 9880566, \"first_name\": \"Michelle\", \"middle_name\": \"Elena\", \"last_name\": \"Schober\", \"is_contact_pi\": true, \"full_name\": \"Michelle Elena Schober\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"SCHOBER, MICHELLE ELENA\", \"agency_ic_admin\": {\"code\": \"NS\", \"abbreviation\": \"NINDS\", \"name\": \"National Institute of Neurological Disorders and Stroke\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 358375, \"direct_cost_ic\": 235000, \"indirect_cost_ic\": 123375}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2024-04-30T12:04:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"BINP\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Brain Injury and Neurovascular Pathologies Study Section[BINP]\"}, \"award_notice_date\": \"2021-05-07T12:05:00Z\", \"core_project_num\": \"R01NS114635\", \"terms\": \"<Affect><Age><ages><Anatomy><Anatomic><Anatomic Sites><Anatomic structures><Anatomical Sciences><Anti-Inflammatory Agents><Anti-Inflammatories><Anti-inflammatory><Antiinflammatories><Antiinflammatory Agents><antiinflammatory><Antioxidants><anti-oxidant><Biological Assay><Assay><Bioassay><Biologic Assays><Brain><Brain Nervous System><Encephalon><Cell Death><necrocytosis><Cell membrane><Cytoplasmic Membrane><Plasma Membrane><plasmalemma><Cells><Cell Body><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Trials><Caspase><Caspase Gene><Cell-Death Protease><Cysteine Endopeptidases><Cysteine Protease><Cysteine Proteinases><ICE-like protease><cystein protease><cystein proteinase><cysteine endopeptidase><Diet><diets><Docosahexaenoic Acids><Docosahexaenoate><Docosahexenoic Acids><Edema><Dropsy><Hydrops><Encephalitis><Brain Inflammation><Family><Essential Fatty Acids><Female><Flow Cytometry><Flow Cytofluorometries><Flow Cytofluorometry><Flow Microfluorimetry><Flow Microfluorometry><flow cytophotometry><Future><Genes><Growth><Generalized Growth><Tissue Growth><ontogeny><Histology><In Vitro><Inflammation><Interferons><IFN><Interleukin-1 beta><Beta Proprotein Interleukin 1><IL-1 beta><IL-1 \\\\u03b2><IL-1-b><IL-1\\\\u03b2><IL1-Beta><IL1-\\\\u03b2><IL1B Protein><IL1F2><IL1\\\\u03b2><Interleukin 1beta><Interleukin-1\\\\u03b2><Preinterleukin 1 Beta><Learning><Long-Term Effects><Longterm Effects><macrophage><M\\\\u03c6><Magnetic Resonance Imaging><MR Imaging><MR Tomography><MRI><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><NMR Imaging><NMR Tomography><Nuclear Magnetic Resonance Imaging><Zeugmatography><male><Phagocytosis><Phenotype><Production><Proteins><Rattus><Common Rat Strains><Rat><Rats Mammals><Messenger RNA><mRNA><Signal Transduction><Cell Communication and Signaling><Cell Signaling><Intracellular Communication and Signaling><Signal Transduction Systems><Signaling><biological signal transduction><Testing><Time><Tissues><Body Tissues><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><NADPH Oxidase><Measures><Mediating><Outcome Measure><Reactive Oxygen Species><Active Oxygen><Oxygen Radicals><Pro-Oxidants><Secondary to><Injury><injuries><base><improved><Acute><Chronic><Neurologic><Neurological><Microglia><Hortega cell><gitter cell><mesoglia><microglial cell><microgliocyte><perivascular glial cell><Lesion><disability><Childhood><pediatric><Memory impairment><Memory Deficit><memory dysfunction><Recovery><Oxidative Stress><Therapeutic><Inflammatory><tool><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Disturbance in cognition><cognitive dysfunction><cognitive loss><Impaired cognition><Functional MRI><fMRI><Functional Magnetic Resonance Imaging><Knowledge><mechanical><Mechanics><Immunes><Immune><intraperitoneal><Pattern><brain cell><Receptor Protein><receptor><neuroprotection><object recognition><novel><Nervous System Injuries><Nervous System damage><Neurological Damage><Neurological Injury><Neurological trauma><neurotrauma><Nervous System Trauma><(TNF)-\\\\u03b1><Cachectin><Macrophage-Derived TNF><Monocyte-Derived TNF><TNF><TNF A><TNF Alpha><TNF-\\\\u03b1><TNFA><TNF\\\\u03b1><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><TNF gene><Modeling><response><Brain Trauma><traumatic brain damage><Traumatic Brain Injury><Cell Membrane Lipid Rafts><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><lipid raft><Membrane Microdomains><Inflammatory Response><Molecular Interaction><Binding><Homolog of Drosophila TOLL><TLR4><Toll Homologue><toll-like receptor 4><TLR4 gene><Signal Transducer and Activator of Transcription><STAT protein><Dose><cytotoxic><Receptor Signaling><Sum><in vivo><research clinical testing><Clinical Evaluation><Clinical Testing><clinical test><Molecular><sex><Development><developmental><pre-clinical><preclinical><white matter injury><sham surgery><controlled cortical impact><morris water maze><morris watermaze><Outcome><Neurological outcome><Neurologic outcome><innovation><innovate><innovative><clinically relevant><clinical relevance><pup><inflammatory marker><inflammation marker><effective therapy><effective treatment><pediatric traumatic brain injury><pediatric TBI><TBI treatment><TBI therapy><traumatic brain injury therapy><traumatic brain injury treatment><protein biomarkers><protein markers><experimental study><experiment><experimental research>\", \"pref_terms\": \"Acute;Affect;Age;Anatomy;Anti-Inflammatory Agents;Antioxidants;Binding;Biological Assay;Brain;Caspase;Cell Death;Cell membrane;Cells;Child;Childhood;Chronic;Clinical Trials;Development;Diet;Docosahexaenoic Acids;Dose;Edema;Encephalitis;Essential Fatty Acids;Family;Female;Flow Cytometry;Functional Magnetic Resonance Imaging;Future;Genes;Growth;Histology;Immune;Impaired cognition;In Vitro;Inflammation;Inflammatory;Inflammatory Response;Injury;Interferons;Interleukin-1 beta;Knowledge;Learning;Lesion;Long-Term Effects;Magnetic Resonance Imaging;Measures;Mechanics;Mediating;Membrane Microdomains;Memory impairment;Messenger RNA;Microglia;Modeling;Molecular;NADPH Oxidase;Nervous System Trauma;Neurologic;Neurological outcome;Outcome;Outcome Measure;Oxidative Stress;Pattern;Phagocytosis;Phenotype;Production;Proteins;Rattus;Reactive Oxygen Species;Receptor Signaling;Recovery;STAT protein;Secondary to;Signal Transduction;Sum;TBI treatment;TLR4 gene;TNF gene;Testing;Therapeutic;Time;Tissues;Traumatic Brain Injury;base;brain cell;clinically relevant;controlled cortical impact;cytotoxic;disability;effective therapy;experimental study;improved;in vivo;inflammatory marker;innovation;intraperitoneal;macrophage;male;morris water maze;neuroprotection;novel;object recognition;pediatric traumatic brain injury;pre-clinical;protein biomarkers;pup;receptor;research clinical testing;response;sex;sham surgery;tool;transcription factor;white matter injury\", \"abstract_text\": \"PROJECT SUMMARY Traumatic brain injury (TBI) is the leading cause of acquired neurologic disability in\\\\nchildren; yet, no effective therapies exist. Secondary injury from inflammation increases neurologic disability\\\\nfrom damage after impact. Microglia (the brain\\'s resident immune cells) mediate inflammatory release of\\\\nreactive oxygen species (ROS) and cytotoxic factors early after TBI. Microglia that become reparatory remove\\\\ndebris by phagocytosis and resolve inflammation. The immature brain is highly vulnerable to secondary injury\\\\ndue to its low antioxidant reserve and vigorous inflammatory response. Agents that move microglia away from\\\\ninflammatory towards reparatory activity may decrease neurologic disability after TBI, particularly in children.\\\\nDocosahexaenoic Acid, or DHA, is a candidate therapy for childhood TBI. DHA is a fatty acid essential for\\\\nnormal brain growth and function that has antioxidant and anti-inflammatory activity. In rats, DHA restores\\\\nbrain DHA losses after TBI. In cultured microglia, DHA promotes reparatory activity. Using our pediatric TBI\\\\nmodel, controlled cortical impact (CCI) in male 17-day old (P17) rats, DHA diet before CCI reduced learning\\\\ndeficits (Morris Water Maze, MWM) brain lesion volume and white matter injury (histology and MRI, Magnetic\\\\nResonance Imaging). We also showed that DHA given after CCI improved rat pup outcomes. Intraperitoneal\\\\n(IP) DHA at 30 minutes after CCI, followed by up to 60 days of DHA diet, decreased ROS, microglial\\\\ninflammatory genes at post injury day 7(PID7) and memory dysfunction (Novel Object Recognition, NOR).\\\\nWhether DHA affects brain inflammatory markers in female pups, or if DHA affects microglial activity (ROS\\\\nproduction and phagocytosis) after TBI in either sex, is unknown. Similarly, whether delayed (later than 30 min\\\\nafter CCI) or short (7-day course) DHA will retain acute and chronic neuroprotection, is not known. Finally, little\\\\nis known about how DHA may modulate microglial activation after TBI. We hypothesize that either DHA at 30\\\\nmin or 3h after CCI will decrease PID7 microglial inflammation in males and that only long term DHA will\\\\nimprove PID45-60 outcomes in both sexes. We hypothesize that DHA will decrease PID7 inflammation\\\\nassociated with decreased TLR4 and activated STAT1 proteins on cell membranes and caspase activity. We\\\\nwill use male and female P17 rat pups and CCI or sham surgery. We will compare onset of DHA (30 min or 3h)\\\\nand duration (7 days to 60 days) to control. During week 1 after CCI, we will use cell membrane assays, tissue\\\\nand microglial protein markers, and microglial activity to assess inflammation. From PID 45 to 60 we will use\\\\nNOR/ MWM testing, histology and MRI for functional, anatomic and inflammatory outcomes. This proposal is\\\\nsignificant because it focuses on the immature brain after severe TBI, a devastating condition for which no\\\\neffective therapies exist. It will yield new knowledge on the effects of sex and DHA on microglial function after\\\\nTBI and on optimal DHA initiation and duration timing. Results will enable future clinical trials of DHA with the\\\\npotential to decrease the burden of pediatric acquired neurologic injury after TBI.\", \"project_title\": \"Microglial Function and Neurologic Outcome in Rat Pups after Experimental Traumatic Brain Injury: Effects of Timing and Duration of Docosahexaenoic Acid Therapy\", \"phr_text\": \"PROJECT NARRATIVE\\\\nWe will use male and female rat pups to study inflammation in the young brain after traumatic brain injury\\\\n(TBI). TBI is the leading cause of acquired disability in children, yet no effective therapies exist. Our results will\\\\ninform future testing of Docosahexaenoic Acid (DHA), a promising therapy, in children after TBI.\", \"spending_categories_desc\": \"Brain Disorders; Childhood Injury; Neurosciences; Pediatric; Physical Injury - Accidents and Adverse Effects; Traumatic Brain Injury (TBI); Traumatic Head and Spine Injury; Unintentional Childhood Injury; Women\\'s Health\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-05-01T12:05:00Z\", \"budget_end\": \"2022-04-30T12:04:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 235000, \"indirect_cost_amt\": 123375, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10204141\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 85}, page_content='{\"appl_id\": 10173882, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"5R01HL153025-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 747656, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HL\", \"serial_num\": \"153025\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": true, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"TRISTANI-FIROUZI, MARTIN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 747656, \"direct_cost_ic\": 490266, \"indirect_cost_ic\": 257390}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2024-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"ESTA\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Electrical Signaling, Ion Transport, and Arrhythmias Study Section[ESTA]\"}, \"award_notice_date\": \"2021-07-10T12:07:00Z\", \"core_project_num\": \"R01HL153025\", \"terms\": \"<Action Potentials><Algorithms><Anti-Arrhythmia Agents><Anti-Arrhythmia Drugs><Anti-Arrhythmics><Antiarrhythmia Agents><Antiarrhythmia Drugs><Antiarrhythmic Drugs><antiarrhythmic agent><arrhythmic agent><Arrhythmia><Cardiac Arrhythmia><Heart Arrhythmias><Atrial Fibrillation><Auricular Fibrillation><Binding Sites><Combining Site><Reactive Site><Biological Assay><Assay><Bioassay><Biologic Assays><Cardiovascular Diseases><cardiovascular disorder><Cell Culture Techniques><cell culture><Cell Line><CellLine><Strains Cell Lines><cultured cell line><Cells><Cell Body><Sudden Death><Electrophysiology (science)><Electrophysiology><Neurophysiology / Electrophysiology><electrophysiological><Enzyme-Linked Immunosorbent Assay><ELISA><Evolution><Family><Fishes><Foundations><Future><Gene Expression><Genes><Genome><Goals><Heart><Heart Atrium><Atrial><Cardiac Atrium><atrium><Human><Modern Man><Human Genetics><Ion Channel><Ionic Channels><Membrane Channels><Isoproterenol><Isoprenaline><Isopropyl Noradrenaline><Isopropylarterenol><Isopropylnoradrenaline><Isopropylnorepinephrine><Isuprel><Luciferases><Luciferase Immunologic><Methodology><Mutation><Genetic Alteration><Genetic Change><Genetic defect><genome mutation><Optics><optical><Sinus><Accessory Sinuses><Nasal Sinuses><Nasal cavity/Paranasal><Nasal cavity/Paranasal sinuses><Paranasal Sinuses><Patients><genetic pedigree><Pedigree><pedigree structure><Phenotype><Play><Risk><Role><social role><Siblings><Signal Pathway><Mass Spectrum Analysis><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Testing><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><Genetic Transcription><Gene Transcription><RNA Expression><Transcription><Utah><Zebrafish><Brachydanio rerio><Danio rerio><Zebra Danio><Zebra Fish><Measures><Tachyarrhythmias><tachyrhythmia><Health Care Costs><Health Costs><Healthcare Costs><Mediating><Custom><Transcriptional Activation><Transcription Activation><Cardiac ablation><Catheter Ablation><base><improved><Site><Refractory><Variant><Variation><Biochemical><Adolescent><Adolescent Youth><juvenile><juvenile human><Predisposition><Susceptibility><Cardiac Myocytes><Cardiac Muscle Cells><Cardiocyte><Heart Muscle Cells><Heart myocyte><cardiomyocyte><insight><Individual><Recovery><Measurement><Functional disorder><Dysfunction><Physiopathology><pathophysiology><Reporter><Nature><Techniques><Location><Penetrance><experience><Myocytes><Muscle Cells><mutant><Animal Models and Related Studies><model of animal><model organism><Animal Model><transgenic><Transgenic Organisms><novel><General Public><General Population><Modality><Pathogenesis><Modeling><Property><response><Cardiac Electrophysiological Diagnostics><cardiac electrophysiology><Cardiac Electrophysiologic Techniques><Pathogenicity><Bio-Informatics><Bioinformatics><DNA Binding Interaction><DNA bound><DNA Binding><Molecular Interaction><Binding><cardiac hypertrophy><Heart Hypertrophy><Affinity><Data><Economic Burden><Nuclear Translocation><Pathologic><Molecular><Cardiac><Pathway interactions><pathway><disease phenotype><genome wide association study><GWA study><GWAS><genome wide association><genome wide association scan><genome wide association studies><genomewide association scan><genomewide association studies><genomewide association study><whole genome association analysis><whole genome association studies><whole genome association study><design><designing><innovation><innovate><innovative><Susceptibility Gene><Predisposition gene><predisposing gene><susceptibility allele><susceptibility locus><susceptibility variant><induced pluripotent stem cell><iPS><iPSC><iPSCs><mutation carrier><high risk><overexpression><overexpress><standard care><standard treatment><clinical practice><ChIP-seq><ChIP Sequencing><chromatin immunoprecipitation-sequencing><transcriptome sequencing><RNA Seq><RNA sequencing><RNAseq><next generation sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><exome sequencing><exome-seq><rare variant><rare allele><Cardiac development><differential expression><differentially expressed><transcriptional differences><genome editing><genomic editing><risk stratification><stratify risk><single-cell RNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><stroke risk><risk for stroke><risk of stroke><bioinformatics tool><bio-informatics tool><Familial atrial fibrillation><in silico>\", \"pref_terms\": \"Action Potentials;Adolescent;Affinity;Algorithms;Animal Model;Anti-Arrhythmia Agents;Arrhythmia;Atrial Fibrillation;Binding;Binding Sites;Biochemical;Bioinformatics;Biological Assay;Cardiac;Cardiac Electrophysiologic Techniques;Cardiac Myocytes;Cardiac ablation;Cardiac development;Cardiovascular Diseases;Cell Culture Techniques;Cell Line;Cells;ChIP-seq;Custom;DNA Binding;Data;Economic Burden;Electrophysiology (science);Enzyme-Linked Immunosorbent Assay;Evolution;Familial atrial fibrillation;Family;Fishes;Foundations;Functional disorder;Future;Gene Expression;General Population;Genes;Genetic Transcription;Genome;Goals;Health Care Costs;Heart;Heart Atrium;Heart Hypertrophy;Human;Human Genetics;Individual;Ion Channel;Isoproterenol;Location;Luciferases;Mass Spectrum Analysis;Measurement;Measures;Mediating;Methodology;Modality;Modeling;Molecular;Muscle Cells;Mutation;Nature;Nuclear Translocation;Optics;Pathogenesis;Pathogenicity;Pathologic;Pathway interactions;Patients;Penetrance;Phenotype;Play;Predisposition;Property;Recovery;Refractory;Reporter;Risk;Role;Siblings;Signal Pathway;Sinus;Site;Sudden Death;Susceptibility Gene;Tachyarrhythmias;Techniques;Testing;Transcriptional Activation;Transgenic Organisms;Utah;Variant;Zebrafish;base;bioinformatics tool;clinical practice;design;differential expression;disease phenotype;exome sequencing;experience;genetic pedigree;genome editing;genome wide association study;high risk;improved;in silico;induced pluripotent stem cell;innovation;insight;mutant;mutation carrier;next generation sequencing;novel;overexpression;rare variant;response;risk stratification;single-cell RNA sequencing;standard care;stroke risk;transcription factor;transcriptome sequencing\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation (AF) susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. AF, the most common sustained arrhythmia encountered in clinical practice, has an economic burden\\\\nexceeding $7 billion in annual health care costs. Emerging evidence implicates cardiac transcription factors in\\\\nthe pathogenesis in both familial forms of AF and AF in the general population. We identified a mutation in the\\\\ncardiac transcription factor NFATC1 in a high-risk Utah pedigree defined by young onset AF. NFATC1 is a Ca2+-\\\\ndependent transcription factor postulated to play a role in cardiac development, but up until now has never been\\\\nassociated with cardiac excitability. Our exciting preliminary data identify a novel role for NFATC1 in modulating\\\\natrial excitability, in that nfatc1 null zebrafish develop spontaneous atrial tachyarrhythmia and juvenile sudden\\\\ndeath. Aim 1 seeks to define the biochemical, molecular and electrophysiological basis of the mutant NFATC1\\\\ndysfunction, using the HL-1 atrial cell line, a human cell culture model (patient-specific and genome-edited\\\\ninduced pluripotent stem cell derived cardiomyocytes, iPSC-CMs), and a whole animal model (transgenic\\\\nzebrafish). Aim 2 characterizes the role of NFATC1 in modulating atrial excitability by exploring the molecular\\\\nand electrophysiological basis for the atrial tachyarrhythmia in nfatc1 null zebrafish. Aim 3 will define NFATC1-\\\\ncontrolled transcriptional networks and gene pathways that regulate cardiac excitability, using single-cell RNA-\\\\nSeq, ChIP-Seq and ChIP-Mass Spectroscopy in human atrium and NFATC1 null and WT iPSC-CMs.\\\\nOur proposal leverages human genetics, genome-editing techniques, state-of-the-art Next-Gen sequencing\\\\nmodalities and bioinformatics, and electrophysiology to comprehensively characterize the novel role of NFATC1\\\\nin cardiac excitability and AF pathogenesis. An understanding of a key transcriptional network that regulates ion\\\\nchannel gene expression and atrial excitability will provide a broader, and more comprehensive understanding\\\\nof arrhythmia susceptibility and lay the foundation for novel AF therapies.\", \"project_title\": \"A Novel Role for NFATC1 in Modulating Cardiac Excitability\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. This proposal encompasses innovative concepts and methodologies that will advance the study\\\\nof cardiac electrophysiology and arrhythmia susceptibility.\", \"spending_categories_desc\": \"Biotechnology; Cardiovascular; Genetics; Heart Disease; Human Genome; Stem Cell Research; Stem Cell Research - Induced Pluripotent Stem Cell; Stem Cell Research - Induced Pluripotent Stem Cell - Human\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-07-01T12:07:00Z\", \"budget_end\": \"2022-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 490266, \"indirect_cost_amt\": 257390, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10173882\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 86}, page_content='{\"appl_id\": 10026527, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"1R01HL153025-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R01\", \"award_amount\": 753756, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R01\", \"ic_code\": \"HL\", \"serial_num\": \"153025\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 2106171, \"first_name\": \"MARTIN\", \"middle_name\": \"\", \"last_name\": \"TRISTANI-FIROUZI\", \"is_contact_pi\": true, \"full_name\": \"MARTIN  TRISTANI-FIROUZI\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"TRISTANI-FIROUZI, MARTIN \", \"agency_ic_admin\": {\"code\": \"HL\", \"abbreviation\": \"NHLBI\", \"name\": \"National Heart Lung and Blood Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"HL\", \"name\": \"National Heart Lung and Blood Institute\", \"abbreviation\": \"NHLBI\", \"total_cost\": 753756, \"direct_cost_ic\": 494266, \"indirect_cost_ic\": 259490}], \"project_start_date\": \"2020-07-01T12:07:00Z\", \"project_end_date\": \"2024-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"ESTA\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Electrical Signaling, Ion Transport, and Arrhythmias Study Section[ESTA]\"}, \"award_notice_date\": \"2020-05-28T12:05:00Z\", \"core_project_num\": \"R01HL153025\", \"terms\": \"<Action Potentials><Algorithms><Anti-Arrhythmia Agents><Anti-Arrhythmia Drugs><Anti-Arrhythmics><Antiarrhythmia Agents><Antiarrhythmia Drugs><Antiarrhythmic Drugs><antiarrhythmic agent><arrhythmic agent><Arrhythmia><Cardiac Arrhythmia><Heart Arrhythmias><Atrial Fibrillation><Auricular Fibrillation><Binding Sites><Combining Site><Reactive Site><Biological Assay><Assay><Bioassay><Biologic Assays><Cardiovascular Diseases><cardiovascular disorder><Cell Culture Techniques><cell culture><Cell Line><CellLine><Strains Cell Lines><cultured cell line><Cells><Cell Body><Sudden Death><Electrophysiology (science)><Electrophysiology><Neurophysiology / Electrophysiology><electrophysiological><Enzyme-Linked Immunosorbent Assay><ELISA><Evolution><Family><Fishes><Foundations><Future><Gene Expression><Genes><Genome><Goals><Heart><Heart Atrium><Atrial><Cardiac Atrium><atrium><Human><Modern Man><Human Genetics><Ion Channel><Ionic Channels><Membrane Channels><Isoproterenol><Isoprenaline><Isopropyl Noradrenaline><Isopropylarterenol><Isopropylnoradrenaline><Isopropylnorepinephrine><Isuprel><Luciferases><Luciferase Immunologic><Methodology><Mutation><Genetic Alteration><Genetic Change><Genetic defect><genome mutation><Optics><optical><Sinus><Accessory Sinuses><Nasal Sinuses><Nasal cavity/Paranasal><Nasal cavity/Paranasal sinuses><Paranasal Sinuses><Patients><genetic pedigree><Pedigree><pedigree structure><Phenotype><Play><Risk><Role><social role><Siblings><Signal Pathway><Mass Spectrum Analysis><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Testing><transcription factor><Basal Transcription Factor><Basal transcription factor genes><General Transcription Factor Gene><General Transcription Factors><Transcription Factor Proto-Oncogene><Transcription factor genes><Genetic Transcription><Gene Transcription><RNA Expression><Transcription><Utah><Zebrafish><Brachydanio rerio><Danio rerio><Zebra Danio><Zebra Fish><Measures><Tachyarrhythmias><tachyrhythmia><Health Care Costs><Health Costs><Healthcare Costs><Mediating><Custom><Transcription Activation><Transcriptional Activation><Catheter Ablation><Cardiac ablation><base><improved><Site><Refractory><Variation><Variant><Biochemical><Adolescent Youth><juvenile><juvenile human><Adolescent><Susceptibility><Predisposition><Cardiac Muscle Cells><Cardiocyte><Heart Muscle Cells><Heart myocyte><cardiomyocyte><Cardiac Myocytes><insight><Individual><Recovery><Measurement><Dysfunction><Physiopathology><pathophysiology><Functional disorder><Reporter><Nature><Techniques><Location><Penetrance><experience><Myocytes><Muscle Cells><mutant><Animal Models and Related Studies><model of animal><model organism><Animal Model><transgenic><Transgenic Organisms><novel><General Public><General Population><Modality><Pathogenesis><Modeling><Property><response><Cardiac Electrophysiological Diagnostics><cardiac electrophysiology><Cardiac Electrophysiologic Techniques><Pathogenicity><Bio-Informatics><Bioinformatics><DNA Binding Interaction><DNA bound><DNA Binding><Molecular Interaction><Binding><cardiac hypertrophy><Heart Hypertrophy><Affinity><Data><Economic Burden><Nuclear Translocation><Pathologic><Molecular><Cardiac><pathway><Pathway interactions><disease phenotype><GWA study><GWAS><genome wide association><genome wide association scan><genome wide association studies><genomewide association scan><genomewide association studies><genomewide association study><whole genome association analysis><whole genome association studies><whole genome association study><genome wide association study><designing><design><innovate><innovative><innovation><Predisposition gene><predisposing gene><susceptibility allele><susceptibility locus><susceptibility variant><Susceptibility Gene><iPS><iPSC><iPSCs><induced pluripotent stem cell><mutation carrier><high risk><overexpress><overexpression><standard treatment><standard care><clinical practice><ChIP Sequencing><chromatin immunoprecipitation-sequencing><ChIP-seq><RNA Seq><RNA sequencing><RNAseq><transcriptome sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><next generation sequencing><exome-seq><exome sequencing><rare allele><rare variant><Cardiac development><differentially expressed><transcriptional differences><differential expression><genomic editing><genome editing><Risk stratification><scRNA-seq><single cell RNA-seq><single cell RNAseq><single-cell RNA sequencing><risk for stroke><risk of stroke><stroke risk><bio-informatics tool><bioinformatics tool><Familial atrial fibrillation ><in silico>\", \"pref_terms\": \"Action Potentials;Adolescent;Affinity;Algorithms;Animal Model;Anti-Arrhythmia Agents;Arrhythmia;Atrial Fibrillation;Binding;Binding Sites;Biochemical;Bioinformatics;Biological Assay;Cardiac;Cardiac Electrophysiologic Techniques;Cardiac Myocytes;Cardiac ablation;Cardiac development;Cardiovascular Diseases;Cell Culture Techniques;Cell Line;Cells;ChIP-seq;Custom;DNA Binding;Data;Economic Burden;Electrophysiology (science);Enzyme-Linked Immunosorbent Assay;Evolution;Familial atrial fibrillation ;Family;Fishes;Foundations;Functional disorder;Future;Gene Expression;General Population;Genes;Genetic Transcription;Genome;Goals;Health Care Costs;Heart;Heart Atrium;Heart Hypertrophy;Human;Human Genetics;Individual;Ion Channel;Isoproterenol;Location;Luciferases;Mass Spectrum Analysis;Measurement;Measures;Mediating;Methodology;Modality;Modeling;Molecular;Muscle Cells;Mutation;Nature;Nuclear Translocation;Optics;Pathogenesis;Pathogenicity;Pathologic;Pathway interactions;Patients;Penetrance;Phenotype;Play;Predisposition;Property;Recovery;Refractory;Reporter;Risk;Risk stratification;Role;Siblings;Signal Pathway;Sinus;Site;Sudden Death;Susceptibility Gene;Tachyarrhythmias;Techniques;Testing;Transcriptional Activation;Transgenic Organisms;Utah;Variant;Zebrafish;base;bioinformatics tool;clinical practice;design;differential expression;disease phenotype;exome sequencing;experience;genetic pedigree;genome editing;genome wide association study;high risk;improved;in silico;induced pluripotent stem cell;innovation;insight;mutant;mutation carrier;next generation sequencing;novel;overexpression;rare variant;response;single-cell RNA sequencing;standard care;stroke risk;transcription factor;transcriptome sequencing\", \"abstract_text\": \"PROJECT SUMMARY / ABSTRACT\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation (AF) susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. AF, the most common sustained arrhythmia encountered in clinical practice, has an economic burden\\\\nexceeding $7 billion in annual health care costs. Emerging evidence implicates cardiac transcription factors in\\\\nthe pathogenesis in both familial forms of AF and AF in the general population. We identified a mutation in the\\\\ncardiac transcription factor NFATC1 in a high-risk Utah pedigree defined by young onset AF. NFATC1 is a Ca2+-\\\\ndependent transcription factor postulated to play a role in cardiac development, but up until now has never been\\\\nassociated with cardiac excitability. Our exciting preliminary data identify a novel role for NFATC1 in modulating\\\\natrial excitability, in that nfatc1 null zebrafish develop spontaneous atrial tachyarrhythmia and juvenile sudden\\\\ndeath. Aim 1 seeks to define the biochemical, molecular and electrophysiological basis of the mutant NFATC1\\\\ndysfunction, using the HL-1 atrial cell line, a human cell culture model (patient-specific and genome-edited\\\\ninduced pluripotent stem cell derived cardiomyocytes, iPSC-CMs), and a whole animal model (transgenic\\\\nzebrafish). Aim 2 characterizes the role of NFATC1 in modulating atrial excitability by exploring the molecular\\\\nand electrophysiological basis for the atrial tachyarrhythmia in nfatc1 null zebrafish. Aim 3 will define NFATC1-\\\\ncontrolled transcriptional networks and gene pathways that regulate cardiac excitability, using single-cell RNA-\\\\nSeq, ChIP-Seq and ChIP-Mass Spectroscopy in human atrium and NFATC1 null and WT iPSC-CMs.\\\\nOur proposal leverages human genetics, genome-editing techniques, state-of-the-art Next-Gen sequencing\\\\nmodalities and bioinformatics, and electrophysiology to comprehensively characterize the novel role of NFATC1\\\\nin cardiac excitability and AF pathogenesis. An understanding of a key transcriptional network that regulates ion\\\\nchannel gene expression and atrial excitability will provide a broader, and more comprehensive understanding\\\\nof arrhythmia susceptibility and lay the foundation for novel AF therapies.\", \"project_title\": \"A Novel Role for NFATC1 in Modulating Cardiac Excitability\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe overall goal of this proposal is to explore the molecular and electrophysiological role of NFATC1 as a novel\\\\natrial fibrillation susceptibility gene and to define the previously unknown contribution of NFATC1 to atrial\\\\nexcitability. This proposal encompasses innovative concepts and methodologies that will advance the study\\\\nof cardiac electrophysiology and arrhythmia susceptibility.\", \"spending_categories_desc\": \"Biotechnology; Cardiovascular; Genetics; Heart Disease; Human Genome; Stem Cell Research; Stem Cell Research - Induced Pluripotent Stem Cell; Stem Cell Research - Induced Pluripotent Stem Cell - Human\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-07-01T12:07:00Z\", \"budget_end\": \"2021-06-30T12:06:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 494266, \"indirect_cost_amt\": 259490, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10026527\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 87}, page_content='{\"appl_id\": 10569086, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R37CA246183-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R37\", \"award_amount\": 341867, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R37\", \"ic_code\": \"CA\", \"serial_num\": \"246183\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10761209, \"first_name\": \"Hunter\", \"middle_name\": \"Reeve\", \"last_name\": \"Underhill\", \"is_contact_pi\": true, \"full_name\": \"Hunter Reeve Underhill\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"UNDERHILL, HUNTER REEVE\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 341867, \"direct_cost_ic\": 224175, \"indirect_cost_ic\": 117692}], \"project_start_date\": \"2020-02-01T12:02:00Z\", \"project_end_date\": \"2025-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"CBSS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cancer Biomarkers Study Section[CBSS]\"}, \"award_notice_date\": \"2023-01-31T12:01:00Z\", \"core_project_num\": \"R37CA246183\", \"terms\": \"<Genetic Diversity><Work><promotor><promoter><customs><Custom><Apoptosis Pathway><Programmed Cell Death><Apoptosis><Point Mutation><improved><Procedures><Clinical><Malignant><Malignant - descriptor><Variation><Variant><Histologically><Histologic><Lesion><Genetic Heterogeneity><Relapsed Disease><Recurrent disease><Solid Tumor><Solid Neoplasm><Attenuated><attenuate><attenuates><Diagnostic><Knowledge><Catalogs><catalog><Diagnostic Procedure><Diagnostic Method><Diagnostic Technique><Frequencies><Source><Tumor Tissue><Xenograft procedure><Heterograft><Heterologous Transplantation><Xenograft><Xenotransplantation><xeno-transplant><xeno-transplantation><Neurologic Deficit><Operative Surgical Procedures><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><success><diagnostic accuracy><Accuracy of Diagnosis><Animal Model><Animal Models and Related Studies><model of animal><Stable Disease><Appearance><Excision><Abscission><Extirpation><Removal><Surgical Removal><resection><Positioning Attribute><Position><Primary Brain Neoplasms><Primary Brain Tumors><Cell Fraction><Modeling><Sampling><Central Nervous System><CNS Nervous System><Neuraxis><Tissue Sample><Length><Data><Detection><Molecular Profiling><Molecular Fingerprinting><molecular profile><molecular signature><Clinical Management><Newly Diagnosed><Tumor-Derived><Monitor><Image><imaging><Gene variant><allele variant><allelic variant><genomic variant><genetic variant><designing><design><treatment effect><tumor><response to therapy><response to treatment><therapeutic response><therapy response><treatment response><bio-markers><biologic marker><biomarker><Biological Markers><NGS Method><NGS system><next gen sequencing><nextgen sequencing><next generation sequencing><Radiation necrosis><tumor cell DNA><tumor-specific DNA><tumor DNA><cell free circulating DNA><cell free DNA><patient profile><profiles in patients><stem-like cell><variant detection><Circulation><21+ years old><Adult Human><adulthood><Adult><Affect><Brain><Brain Nervous System><Encephalon><Brain Neoplasms><Brain Neoplasia><Brain Tumors><tumors in the brain><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cells><Cell Body><Diagnosis><Disease><Disorder><DNA><Deoxyribonucleic Acid><Gene Frequency><Allele Frequency><allelic frequency><Patient Care><Patient Care Delivery><Genes><Genotype><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><glioblastoma multiforme><spongioblastoma multiforme><Glioma><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Neuroglial Neoplasm><Neuroglial Tumor><glial-derived tumor><neuroglia neoplasm><neuroglia tumor><Goals><Human><Modern Man><Methods><Neoplasm Metastasis><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Secondary Neoplasm><Secondary Tumor><cancer metastasis><tumor cell metastasis><Noise><Patients><Perfusion><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma Cells><Blood Plasma Cell><Plasmacytes><plasmocyte><Rattus><Common Rat Strains><Rat><Rats Mammals><Recurrence><Recurrent><Risk><Specificity><Stroke><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><stroked><strokes><Testing><Time><Translating><Translations><translation><Genetic Variation>\", \"pref_terms\": \"Adult;Affect;Animal Model;Apoptosis;Appearance;Attenuated;Biological Markers;Brain;Brain Neoplasms;Catalogs;Cell Fraction;Cells;Central Nervous System;Circulation;Clinical;Clinical Management;Custom;DNA;Data;Detection;Diagnosis;Diagnostic;Diagnostic Procedure;Disease;Excision;Frequencies;Gene Frequency;Genes;Genetic Heterogeneity;Genetic Variation;Genotype;Glioblastoma;Glioma;Goals;Histologic;Human;Image;Knowledge;Length;Lesion;Malignant - descriptor;Malignant Neoplasms;Methods;Modeling;Molecular Profiling;Monitor;Neoplasm Metastasis;Neurologic Deficit;Newly Diagnosed;Noise;Operative Surgical Procedures;Patient Care;Patients;Perfusion;Plasma;Plasma Cells;Point Mutation;Positioning Attribute;Primary Brain Neoplasms;Procedures;Radiation necrosis;Rattus;Recurrence;Recurrent disease;Risk;Sampling;Solid Neoplasm;Source;Specificity;Stable Disease;Stroke;Testing;Time;Tissue Sample;Translating;Translations;Tumor Tissue;Tumor-Derived;Variant;Work;Xenograft procedure;cell free DNA;design;diagnostic accuracy;genetic variant;improved;next generation sequencing;profiles in patients;promoter;stem-like cell;success;treatment effect;treatment response;tumor;tumor DNA;variant detection\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nGlioblastoma (GBM) is the most common and most aggressive adult primary brain tumor. Regardless of\\\\ntherapy, the median survival time is less than 15 months as GBM nearly always recurs. Diagnosing GBM\\\\ncurrently depends on acquiring tumor tissue for histologic examination to differentiate GBM from other types of\\\\nbrain lesions with a similar imaging appearance. Detecting GBM recurrence is also challenging as treatment\\\\neffects such as pseudoprogression and radiation necrosis mimic recurrent disease. Thus, risk-associated\\\\ndiagnostic invasive procedures remain a critical aspect of GBM patient care even though surgically acquired\\\\nneurologic deficits may reduce an already short survival time. Therefore, a non-invasive approach to diagnose\\\\nGBM and identify true recurrence has the potential to directly impact patient care throughout the entire disease\\\\ncourse. DNA released from cells during programmed cell death, termed cell-free DNA, is an emerging\\\\nbiomarker for diagnosing human cancers and monitoring response to therapy. Detection of tumor-derived cell-\\\\nfree DNA in plasma, also known as circulating tumor DNA (ctDNA), has previously been largely unsuccessful\\\\nin humans with GBM due to an inability to find the ctDNA amongst the abundant background of normally\\\\noccurring cell-free DNA. The large intra- and inter-tumor genetic heterogeneity of GBM has hindered searches\\\\nfor specific tumor variants in cell-free DNA, while the rarity of GBM to metastasize beyond the central nervous\\\\nsystem has considerably restricted the quantity of ctDNA present. However, our uncovering of ctDNA in a\\\\nxenograft brain tumor model using human GBM stem-like cells strongly supports the feasibility of detecting\\\\nGBM-derived ctDNA in humans. Moreover, our previous success in the animal model provides direction for the\\\\nhuman translation \\\\u2013 reducing or eliminating noise associated with next-generation sequencing (NGS) that\\\\ninterferes with the detection of very low frequency variants is necessary to allow searches for ctDNA that are\\\\nnot dependent on a priori knowledge of solid tumor variants. In this proposal, we attenuate NGS-related noise\\\\nand demonstrate the unbiased detection of GBM-derived ctDNA at time of initial diagnosis and at recurrence.\\\\nWe also show that identification of GBM solid tumor DNA variants in ctDNA is enhanced by reducing errors\\\\nassociated with NGS to improve sampling of the solid tumor genetic heterogeneity typical of GBM. Therefore,\\\\nthis proposal seeks to translate plasma cell-free DNA as a biomarker to detect GBM in humans by suppressing\\\\nerrors associated with NGS to improve variant detection at very low allele frequencies. The successful\\\\napplication of ctDNA biomarkers to non-invasively assess GBM will directly affect patient care by enabling the\\\\noptimization of clinical management prior to or instead of risk-associated invasive diagnostic procedures.\", \"project_title\": \"Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe most common and most aggressive adult primary brain tumor is glioblastoma (GBM). In this study, we\\\\nseek to develop tumor-derived cell-free DNA present in the circulation as a non-invasive biomarker to diagnose\\\\nGBM and detect recurrent disease. The non-invasive assessment of GBM has the potential to directly affect\\\\npatient care by enabling the optimization of clinical management prior to or instead of risk-associated invasive\\\\ndiagnostic procedures.\", \"spending_categories_desc\": \"Brain Cancer; Brain Disorders; Cancer; Cancer Genomics; Clinical Research; Genetics; Human Genome; Neurosciences; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-02-01T12:02:00Z\", \"budget_end\": \"2024-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 224175, \"indirect_cost_amt\": 117692, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10569086\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 88}, page_content='{\"appl_id\": 9864833, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"1R37CA246183-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"R37\", \"award_amount\": 348844, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"R37\", \"ic_code\": \"CA\", \"serial_num\": \"246183\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10761209, \"first_name\": \"Hunter\", \"middle_name\": \"Reeve\", \"last_name\": \"Underhill\", \"is_contact_pi\": true, \"full_name\": \"Hunter Reeve Underhill\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"UNDERHILL, HUNTER REEVE\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 348844, \"direct_cost_ic\": 228750, \"indirect_cost_ic\": 120094}], \"project_start_date\": \"2020-02-01T12:02:00Z\", \"project_end_date\": \"2025-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"CBSS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cancer Biomarkers Study Section[CBSS]\"}, \"award_notice_date\": \"2020-01-01T12:01:00Z\", \"core_project_num\": \"R37CA246183\", \"terms\": \"<Translations><Genetic Variation><Genetic Diversity><Work><promotor><promoter><Custom><Apoptosis Pathway><Programmed Cell Death><Apoptosis><Point Mutation><base><improved><Procedures><Clinical><Malignant><Malignant - descriptor><Variation><Variant><Histologically><Histologic><Lesion><Genetic Heterogeneity><Relapsed Disease><Recurrent disease><Solid Tumor><Solid Neoplasm><Attenuated><Diagnostic><Knowledge><Catalogs><Diagnostic Method><Diagnostic Technique><Diagnostic Procedure><Frequencies><Source><Tumor Tissue><Heterograft><Heterologous Transplantation><Xenograft><Xenotransplantation><xeno-transplant><xeno-transplantation><Xenograft procedure><Neurologic Deficit><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Operative Surgical Procedures><success><Accuracy of Diagnosis><diagnostic accuracy><Animal Models and Related Studies><model of animal><model organism><Animal Model><Stable Disease><Appearance><Abscission><Extirpation><Removal><Surgical Removal><resection><Excision><Position><Positioning Attribute><Primary Brain Tumors><Primary Brain Neoplasms><Cell Fraction><Modeling><Sampling><response><CNS Nervous System><Central Nervous System><Neuraxis><Tissue Sample><Length><Data><Detection><Molecular Fingerprinting><molecular profile><molecular signature><Molecular Profiling><Clinical Management><Newly Diagnosed><Tumor-Derived><Monitor><imaging><Image><Gene variant><allele variant><allelic variant><genomic variant><genetic variant><designing><design><treatment effect><tumor><bio-markers><biologic marker><biomarker><Biological Markers><NGS Method><NGS system><next gen sequencing><nextgen sequencing><next generation sequencing><Radiation necrosis><tumor cell DNA><tumor-specific DNA><tumor DNA><cell free circulating DNA><cell free DNA><patient profile><profiles in patients><stem-like cell><variant detection><Adult><21+ years old><Adult Human><adulthood><Affect><Blood Circulation><Bloodstream><Circulation><Brain><Brain Nervous System><Encephalon><Brain Neoplasms><Brain Neoplasia><Brain Tumors><tumors in the brain><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cells><Cell Body><Diagnosis><Disease><Disorder><DNA><Deoxyribonucleic Acid><Gene Frequency><Allele Frequency><allelic frequency><Patient Care><Patient Care Delivery><Genotype><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><glioblastoma multiforme><spongioblastoma multiforme><Glioma><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Neuroglial Neoplasm><Neuroglial Tumor><glial-derived tumor><neuroglia neoplasm><neuroglia tumor><Goals><Human><Modern Man><Methods><Neoplasm Metastasis><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Secondary Neoplasm><Secondary Tumor><cancer metastasis><tumor cell metastasis><Noise><Patients><Perfusion><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma Cells><Blood Plasma Cell><Plasmacytes><plasmocyte><Rattus><Common Rat Strains><Rat><Rats Mammals><Recurrence><Recurrent><Risk><Specificity><Stroke><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><Testing><Time><Translating>\", \"pref_terms\": \"Adult;Affect;Animal Model;Apoptosis;Appearance;Attenuated;Biological Markers;Blood Circulation;Brain;Brain Neoplasms;Catalogs;Cell Fraction;Cells;Clinical;Clinical Management;Custom;DNA;Data;Detection;Diagnosis;Diagnostic;Diagnostic Procedure;Disease;Excision;Frequencies;Gene Frequency;Genetic Heterogeneity;Genetic Variation;Genotype;Glioblastoma;Glioma;Goals;Histologic;Human;Image;Knowledge;Length;Lesion;Malignant - descriptor;Malignant Neoplasms;Methods;Modeling;Molecular Profiling;Monitor;Neoplasm Metastasis;Neuraxis;Neurologic Deficit;Newly Diagnosed;Noise;Operative Surgical Procedures;Patient Care;Patients;Perfusion;Plasma;Plasma Cells;Point Mutation;Positioning Attribute;Primary Brain Neoplasms;Procedures;Radiation necrosis;Rattus;Recurrence;Recurrent disease;Risk;Sampling;Solid Neoplasm;Source;Specificity;Stable Disease;Stroke;Testing;Time;Tissue Sample;Translating;Translations;Tumor Tissue;Tumor-Derived;Variant;Work;Xenograft procedure;base;cell free DNA;design;diagnostic accuracy;genetic variant;improved;next generation sequencing;profiles in patients;promoter;response;stem-like cell;success;treatment effect;tumor;tumor DNA;variant detection\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nGlioblastoma (GBM) is the most common and most aggressive adult primary brain tumor. Regardless of\\\\ntherapy, the median survival time is less than 15 months as GBM nearly always recurs. Diagnosing GBM\\\\ncurrently depends on acquiring tumor tissue for histologic examination to differentiate GBM from other types of\\\\nbrain lesions with a similar imaging appearance. Detecting GBM recurrence is also challenging as treatment\\\\neffects such as pseudoprogression and radiation necrosis mimic recurrent disease. Thus, risk-associated\\\\ndiagnostic invasive procedures remain a critical aspect of GBM patient care even though surgically acquired\\\\nneurologic deficits may reduce an already short survival time. Therefore, a non-invasive approach to diagnose\\\\nGBM and identify true recurrence has the potential to directly impact patient care throughout the entire disease\\\\ncourse. DNA released from cells during programmed cell death, termed cell-free DNA, is an emerging\\\\nbiomarker for diagnosing human cancers and monitoring response to therapy. Detection of tumor-derived cell-\\\\nfree DNA in plasma, also known as circulating tumor DNA (ctDNA), has previously been largely unsuccessful\\\\nin humans with GBM due to an inability to find the ctDNA amongst the abundant background of normally\\\\noccurring cell-free DNA. The large intra- and inter-tumor genetic heterogeneity of GBM has hindered searches\\\\nfor specific tumor variants in cell-free DNA, while the rarity of GBM to metastasize beyond the central nervous\\\\nsystem has considerably restricted the quantity of ctDNA present. However, our uncovering of ctDNA in a\\\\nxenograft brain tumor model using human GBM stem-like cells strongly supports the feasibility of detecting\\\\nGBM-derived ctDNA in humans. Moreover, our previous success in the animal model provides direction for the\\\\nhuman translation \\\\u2013 reducing or eliminating noise associated with next-generation sequencing (NGS) that\\\\ninterferes with the detection of very low frequency variants is necessary to allow searches for ctDNA that are\\\\nnot dependent on a priori knowledge of solid tumor variants. In this proposal, we attenuate NGS-related noise\\\\nand demonstrate the unbiased detection of GBM-derived ctDNA at time of initial diagnosis and at recurrence.\\\\nWe also show that identification of GBM solid tumor DNA variants in ctDNA is enhanced by reducing errors\\\\nassociated with NGS to improve sampling of the solid tumor genetic heterogeneity typical of GBM. Therefore,\\\\nthis proposal seeks to translate plasma cell-free DNA as a biomarker to detect GBM in humans by suppressing\\\\nerrors associated with NGS to improve variant detection at very low allele frequencies. The successful\\\\napplication of ctDNA biomarkers to non-invasively assess GBM will directly affect patient care by enabling the\\\\noptimization of clinical management prior to or instead of risk-associated invasive diagnostic procedures.\", \"project_title\": \"Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe most common and most aggressive adult primary brain tumor is glioblastoma (GBM). In this study, we\\\\nseek to develop tumor-derived cell-free DNA present in the circulation as a non-invasive biomarker to diagnose\\\\nGBM and detect recurrent disease. The non-invasive assessment of GBM has the potential to directly affect\\\\npatient care by enabling the optimization of clinical management prior to or instead of risk-associated invasive\\\\ndiagnostic procedures.\", \"spending_categories_desc\": \"Brain Cancer; Brain Disorders; Cancer; Cancer Genomics; Clinical Research; Genetics; Health Disparities; Human Genome; Minority Health; Neurosciences; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-02-01T12:02:00Z\", \"budget_end\": \"2021-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 228750, \"indirect_cost_amt\": 120094, \"project_detail_url\": \"https://reporter.nih.gov/project-details/9864833\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 89}, page_content='{\"appl_id\": 10078947, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"5R37CA246183-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R37\", \"award_amount\": 348844, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R37\", \"ic_code\": \"CA\", \"serial_num\": \"246183\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10761209, \"first_name\": \"Hunter\", \"middle_name\": \"Reeve\", \"last_name\": \"Underhill\", \"is_contact_pi\": true, \"full_name\": \"Hunter Reeve Underhill\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"UNDERHILL, HUNTER REEVE\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 348844, \"direct_cost_ic\": 228750, \"indirect_cost_ic\": 120094}], \"project_start_date\": \"2020-02-01T12:02:00Z\", \"project_end_date\": \"2025-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"CBSS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cancer Biomarkers Study Section[CBSS]\"}, \"award_notice_date\": \"2021-01-14T12:01:00Z\", \"core_project_num\": \"R37CA246183\", \"terms\": \"<Adult><21+ years old><Adult Human><adulthood><Affect><Blood Circulation><Bloodstream><Circulation><Brain><Brain Nervous System><Encephalon><Brain Neoplasms><Brain Neoplasia><Brain Tumors><tumors in the brain><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cells><Cell Body><Diagnosis><Disease><Disorder><DNA><Deoxyribonucleic Acid><Gene Frequency><Allele Frequency><allelic frequency><Patient Care><Patient Care Delivery><Genotype><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><glioblastoma multiforme><spongioblastoma multiforme><Glioma><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Neuroglial Neoplasm><Neuroglial Tumor><glial-derived tumor><neuroglia neoplasm><neuroglia tumor><Goals><Human><Modern Man><Methods><Neoplasm Metastasis><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Secondary Neoplasm><Secondary Tumor><cancer metastasis><tumor cell metastasis><Noise><Patients><Perfusion><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma Cells><Blood Plasma Cell><Plasmacytes><plasmocyte><Rattus><Common Rat Strains><Rat><Rats Mammals><Recurrence><Recurrent><Risk><Specificity><Stroke><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><Testing><Time><Translating><Translations><Genetic Variation><Genetic Diversity><Work><promoter><promotor><Custom><Apoptosis><Apoptosis Pathway><Programmed Cell Death><Point Mutation><base><improved><Procedures><Clinical><Malignant - descriptor><Malignant><Variant><Variation><Histologic><Histologically><Lesion><Genetic Heterogeneity><Recurrent disease><Relapsed Disease><Solid Neoplasm><Solid Tumor><Attenuated><Diagnostic><Knowledge><catalog><Catalogs><Diagnostic Method><Diagnostic Technique><Diagnostic Procedure><Frequencies><Source><Tumor Tissue><Heterograft><Heterologous Transplantation><Xenograft><Xenotransplantation><xeno-transplant><xeno-transplantation><Xenograft procedure><Neurologic Deficit><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Operative Surgical Procedures><success><Accuracy of Diagnosis><diagnostic accuracy><Animal Models and Related Studies><model of animal><model organism><Animal Model><Stable Disease><Appearance><Abscission><Extirpation><Removal><Surgical Removal><resection><Excision><Position><Positioning Attribute><Primary Brain Tumors><Primary Brain Neoplasms><Cell Fraction><Modeling><Sampling><response><CNS Nervous System><Central Nervous System><Neuraxis><Tissue Sample><Length><Data><Detection><Molecular Fingerprinting><molecular profile><molecular signature><Molecular Profiling><Clinical Management><Newly Diagnosed><Tumor-Derived><Monitor><Image><imaging><genetic variant><Gene variant><allele variant><allelic variant><genomic variant><design><designing><treatment effect><tumor><Biological Markers><bio-markers><biologic marker><biomarker><next generation sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><Radiation necrosis><tumor DNA><tumor cell DNA><tumor-specific DNA><cell free DNA><cell free circulating DNA><profiles in patients><patient profile><stem-like cell><variant detection>\", \"pref_terms\": \"Adult;Affect;Animal Model;Apoptosis;Appearance;Attenuated;Biological Markers;Blood Circulation;Brain;Brain Neoplasms;Catalogs;Cell Fraction;Cells;Clinical;Clinical Management;Custom;DNA;Data;Detection;Diagnosis;Diagnostic;Diagnostic Procedure;Disease;Excision;Frequencies;Gene Frequency;Genetic Heterogeneity;Genetic Variation;Genotype;Glioblastoma;Glioma;Goals;Histologic;Human;Image;Knowledge;Length;Lesion;Malignant - descriptor;Malignant Neoplasms;Methods;Modeling;Molecular Profiling;Monitor;Neoplasm Metastasis;Neuraxis;Neurologic Deficit;Newly Diagnosed;Noise;Operative Surgical Procedures;Patient Care;Patients;Perfusion;Plasma;Plasma Cells;Point Mutation;Positioning Attribute;Primary Brain Neoplasms;Procedures;Radiation necrosis;Rattus;Recurrence;Recurrent disease;Risk;Sampling;Solid Neoplasm;Source;Specificity;Stable Disease;Stroke;Testing;Time;Tissue Sample;Translating;Translations;Tumor Tissue;Tumor-Derived;Variant;Work;Xenograft procedure;base;cell free DNA;design;diagnostic accuracy;genetic variant;improved;next generation sequencing;profiles in patients;promoter;response;stem-like cell;success;treatment effect;tumor;tumor DNA;variant detection\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nGlioblastoma (GBM) is the most common and most aggressive adult primary brain tumor. Regardless of\\\\ntherapy, the median survival time is less than 15 months as GBM nearly always recurs. Diagnosing GBM\\\\ncurrently depends on acquiring tumor tissue for histologic examination to differentiate GBM from other types of\\\\nbrain lesions with a similar imaging appearance. Detecting GBM recurrence is also challenging as treatment\\\\neffects such as pseudoprogression and radiation necrosis mimic recurrent disease. Thus, risk-associated\\\\ndiagnostic invasive procedures remain a critical aspect of GBM patient care even though surgically acquired\\\\nneurologic deficits may reduce an already short survival time. Therefore, a non-invasive approach to diagnose\\\\nGBM and identify true recurrence has the potential to directly impact patient care throughout the entire disease\\\\ncourse. DNA released from cells during programmed cell death, termed cell-free DNA, is an emerging\\\\nbiomarker for diagnosing human cancers and monitoring response to therapy. Detection of tumor-derived cell-\\\\nfree DNA in plasma, also known as circulating tumor DNA (ctDNA), has previously been largely unsuccessful\\\\nin humans with GBM due to an inability to find the ctDNA amongst the abundant background of normally\\\\noccurring cell-free DNA. The large intra- and inter-tumor genetic heterogeneity of GBM has hindered searches\\\\nfor specific tumor variants in cell-free DNA, while the rarity of GBM to metastasize beyond the central nervous\\\\nsystem has considerably restricted the quantity of ctDNA present. However, our uncovering of ctDNA in a\\\\nxenograft brain tumor model using human GBM stem-like cells strongly supports the feasibility of detecting\\\\nGBM-derived ctDNA in humans. Moreover, our previous success in the animal model provides direction for the\\\\nhuman translation \\\\u2013 reducing or eliminating noise associated with next-generation sequencing (NGS) that\\\\ninterferes with the detection of very low frequency variants is necessary to allow searches for ctDNA that are\\\\nnot dependent on a priori knowledge of solid tumor variants. In this proposal, we attenuate NGS-related noise\\\\nand demonstrate the unbiased detection of GBM-derived ctDNA at time of initial diagnosis and at recurrence.\\\\nWe also show that identification of GBM solid tumor DNA variants in ctDNA is enhanced by reducing errors\\\\nassociated with NGS to improve sampling of the solid tumor genetic heterogeneity typical of GBM. Therefore,\\\\nthis proposal seeks to translate plasma cell-free DNA as a biomarker to detect GBM in humans by suppressing\\\\nerrors associated with NGS to improve variant detection at very low allele frequencies. The successful\\\\napplication of ctDNA biomarkers to non-invasively assess GBM will directly affect patient care by enabling the\\\\noptimization of clinical management prior to or instead of risk-associated invasive diagnostic procedures.\", \"project_title\": \"Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe most common and most aggressive adult primary brain tumor is glioblastoma (GBM). In this study, we\\\\nseek to develop tumor-derived cell-free DNA present in the circulation as a non-invasive biomarker to diagnose\\\\nGBM and detect recurrent disease. The non-invasive assessment of GBM has the potential to directly affect\\\\npatient care by enabling the optimization of clinical management prior to or instead of risk-associated invasive\\\\ndiagnostic procedures.\", \"spending_categories_desc\": \"Brain Cancer; Brain Disorders; Cancer; Cancer Genomics; Clinical Research; Genetics; Health Disparities; Human Genome; Minority Health; Neurosciences; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-02-01T12:02:00Z\", \"budget_end\": \"2022-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 228750, \"indirect_cost_amt\": 120094, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10078947\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 90}, page_content='{\"appl_id\": 10773172, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"5R37CA246183-05\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R37\", \"award_amount\": 331402, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R37\", \"ic_code\": \"CA\", \"serial_num\": \"246183\", \"support_year\": \"05\", \"full_support_year\": \"05\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10761209, \"first_name\": \"Hunter\", \"middle_name\": \"Reeve\", \"last_name\": \"Underhill\", \"is_contact_pi\": true, \"full_name\": \"Hunter Reeve Underhill\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"UNDERHILL, HUNTER REEVE\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 331402, \"direct_cost_ic\": 217313, \"indirect_cost_ic\": 114089}], \"project_start_date\": \"2020-02-01T12:02:00Z\", \"project_end_date\": \"2025-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"CBSS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cancer Biomarkers Study Section[CBSS]\"}, \"award_notice_date\": \"2024-01-04T12:01:00Z\", \"core_project_num\": \"R37CA246183\", \"terms\": \"<21+ years old><Adult Human><adulthood><Adult><Affect><Brain Nervous System><Encephalon><Brain><Brain Neoplasia><Brain Tumors><tumors in the brain><Brain Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Malignant Neoplasms><Cell Body><Cells><Diagnosis><Disorder><Disease><Deoxyribonucleic Acid><DNA><DNA biomarkers><DNA Markers><Allele Frequency><allelic frequency><Gene Frequency><Patient Care Delivery><care for patients><care of patients><caring for patients><Patient Care><Genes><Genotype><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><glioblastoma multiforme><spongioblastoma multiforme><Glioblastoma><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Neuroglial Neoplasm><Neuroglial Tumor><glial-derived tumor><neuroglia neoplasm><neuroglia tumor><Glioma><Goals><Modern Man><Human><Methods><Neoplasm Metastasis><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Secondary Neoplasm><Secondary Tumor><cancer metastasis><tumor cell metastasis><Noise><Patients><Perfusion><Plasma><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma Cells><Blood Plasma Cell><Plasmacytes><plasmocyte><Rattus><Common Rat Strains><Rat><Rats Mammals><Recurrence><Recurrent><Risk><Specificity><Stroke><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><stroked><strokes><Testing><Time><Translating><Translations><translation><Genetic Variation><Genetic Diversity><Work><promotor><promoter><customs><Custom><Apoptosis Pathway><Programmed Cell Death><Apoptosis><Point Mutation><improved><Procedures><Clinical><Malignant><Malignant - descriptor><Variation><Variant><Histologically><Histologic><Lesion><Genetic Heterogeneity><Relapsed Disease><Recurrent disease><Solid Tumor><Solid Neoplasm><attenuate><attenuates><Attenuated><Diagnostic><Knowledge><catalog><Catalogs><Diagnostic Method><Diagnostic Technique><Diagnostic Procedure><Frequencies><Source><Tumor Tissue><Heterograft><Heterologous Transplantation><Xenograft><Xenotransplantation><xeno-transplant><xeno-transplantation><Xenograft procedure><Neurologic Deficit><Operative Surgical Procedures><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Somatic Mutation><somatic variant><success><diagnostic accuracy><Accuracy of Diagnosis><Animal Model><Animal Models and Related Studies><model of animal><Stable Disease><Appearance><Excision><Abscission><Extirpation><Removal><Surgical Removal><resection><Positioning Attribute><Position><Primary Brain Neoplasms><Primary Brain Tumors><Cell Fraction><Modeling><Sampling><Central Nervous System><CNS Nervous System><Neuraxis><Tissue Sample><Length><Data><Detection><Molecular Profiling><Molecular Fingerprinting><molecular profile><molecular signature><Clinical Management><Newly Diagnosed><Tumor-Derived><Monitor><Image><imaging><genetic variant><Gene variant><allele variant><allelic variant><genomic variant><design><designing><treatment effect><tumor><treatment response><response to therapy><response to treatment><therapeutic response><therapy response><treatment responsiveness><Biological Markers><bio-markers><biologic marker><biomarker><next generation sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><Radiation necrosis><tumor DNA><tumor cell DNA><tumor-specific DNA><cell free DNA><cell free circulating DNA><profiles in patients><patient profile><stem-like cell><progenitor-like cell><variant detection><Circulation><personalized biomarkers><individualized biomarkers>\", \"pref_terms\": \"Adult;Affect;Animal Model;Apoptosis;Appearance;Attenuated;Biological Markers;Brain;Brain Neoplasms;Catalogs;Cell Fraction;Cells;Central Nervous System;Circulation;Clinical;Clinical Management;Custom;DNA;DNA Markers;Data;Detection;Diagnosis;Diagnostic;Diagnostic Procedure;Disease;Excision;Frequencies;Gene Frequency;Genes;Genetic Heterogeneity;Genetic Variation;Genotype;Glioblastoma;Glioma;Goals;Histologic;Human;Image;Knowledge;Length;Lesion;Malignant - descriptor;Malignant Neoplasms;Methods;Modeling;Molecular Profiling;Monitor;Neoplasm Metastasis;Neurologic Deficit;Newly Diagnosed;Noise;Operative Surgical Procedures;Patient Care;Patients;Perfusion;Plasma;Plasma Cells;Point Mutation;Positioning Attribute;Primary Brain Neoplasms;Procedures;Radiation necrosis;Rattus;Recurrence;Recurrent disease;Risk;Sampling;Solid Neoplasm;Somatic Mutation;Source;Specificity;Stable Disease;Stroke;Testing;Time;Tissue Sample;Translating;Translations;Tumor Tissue;Tumor-Derived;Variant;Work;Xenograft procedure;cell free DNA;design;diagnostic accuracy;genetic variant;improved;next generation sequencing;personalized biomarkers;profiles in patients;promoter;stem-like cell;success;treatment effect;treatment response;tumor;tumor DNA;variant detection\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nGlioblastoma (GBM) is the most common and most aggressive adult primary brain tumor. Regardless of\\\\ntherapy, the median survival time is less than 15 months as GBM nearly always recurs. Diagnosing GBM\\\\ncurrently depends on acquiring tumor tissue for histologic examination to differentiate GBM from other types of\\\\nbrain lesions with a similar imaging appearance. Detecting GBM recurrence is also challenging as treatment\\\\neffects such as pseudoprogression and radiation necrosis mimic recurrent disease. Thus, risk-associated\\\\ndiagnostic invasive procedures remain a critical aspect of GBM patient care even though surgically acquired\\\\nneurologic deficits may reduce an already short survival time. Therefore, a non-invasive approach to diagnose\\\\nGBM and identify true recurrence has the potential to directly impact patient care throughout the entire disease\\\\ncourse. DNA released from cells during programmed cell death, termed cell-free DNA, is an emerging\\\\nbiomarker for diagnosing human cancers and monitoring response to therapy. Detection of tumor-derived cell-\\\\nfree DNA in plasma, also known as circulating tumor DNA (ctDNA), has previously been largely unsuccessful\\\\nin humans with GBM due to an inability to find the ctDNA amongst the abundant background of normally\\\\noccurring cell-free DNA. The large intra- and inter-tumor genetic heterogeneity of GBM has hindered searches\\\\nfor specific tumor variants in cell-free DNA, while the rarity of GBM to metastasize beyond the central nervous\\\\nsystem has considerably restricted the quantity of ctDNA present. However, our uncovering of ctDNA in a\\\\nxenograft brain tumor model using human GBM stem-like cells strongly supports the feasibility of detecting\\\\nGBM-derived ctDNA in humans. Moreover, our previous success in the animal model provides direction for the\\\\nhuman translation \\\\u2013 reducing or eliminating noise associated with next-generation sequencing (NGS) that\\\\ninterferes with the detection of very low frequency variants is necessary to allow searches for ctDNA that are\\\\nnot dependent on a priori knowledge of solid tumor variants. In this proposal, we attenuate NGS-related noise\\\\nand demonstrate the unbiased detection of GBM-derived ctDNA at time of initial diagnosis and at recurrence.\\\\nWe also show that identification of GBM solid tumor DNA variants in ctDNA is enhanced by reducing errors\\\\nassociated with NGS to improve sampling of the solid tumor genetic heterogeneity typical of GBM. Therefore,\\\\nthis proposal seeks to translate plasma cell-free DNA as a biomarker to detect GBM in humans by suppressing\\\\nerrors associated with NGS to improve variant detection at very low allele frequencies. The successful\\\\napplication of ctDNA biomarkers to non-invasively assess GBM will directly affect patient care by enabling the\\\\noptimization of clinical management prior to or instead of risk-associated invasive diagnostic procedures.\", \"project_title\": \"Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe most common and most aggressive adult primary brain tumor is glioblastoma (GBM). In this study, we\\\\nseek to develop tumor-derived cell-free DNA present in the circulation as a non-invasive biomarker to diagnose\\\\nGBM and detect recurrent disease. The non-invasive assessment of GBM has the potential to directly affect\\\\npatient care by enabling the optimization of clinical management prior to or instead of risk-associated invasive\\\\ndiagnostic procedures.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-02-01T12:02:00Z\", \"budget_end\": \"2025-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 217313, \"indirect_cost_amt\": 114089, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10773172\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 91}, page_content='{\"appl_id\": 10328895, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5R37CA246183-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R37\", \"award_amount\": 348844, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R37\", \"ic_code\": \"CA\", \"serial_num\": \"246183\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10761209, \"first_name\": \"Hunter\", \"middle_name\": \"Reeve\", \"last_name\": \"Underhill\", \"is_contact_pi\": true, \"full_name\": \"Hunter Reeve Underhill\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"UNDERHILL, HUNTER REEVE\", \"agency_ic_admin\": {\"code\": \"CA\", \"abbreviation\": \"NCI\", \"name\": \"National Cancer Institute\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"CA\", \"name\": \"National Cancer Institute\", \"abbreviation\": \"NCI\", \"total_cost\": 348844, \"direct_cost_ic\": 228750, \"indirect_cost_ic\": 120094}], \"project_start_date\": \"2020-02-01T12:02:00Z\", \"project_end_date\": \"2025-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-19-056\", \"full_study_section\": {\"srg_code\": \"CBSS\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Cancer Biomarkers Study Section[CBSS]\"}, \"award_notice_date\": \"2022-02-07T12:02:00Z\", \"core_project_num\": \"R37CA246183\", \"terms\": \"<Adult><21+ years old><Adult Human><adulthood><Affect><Blood Circulation><Bloodstream><Circulation><Brain><Brain Nervous System><Encephalon><Brain Neoplasms><Brain Neoplasia><Brain Tumors><tumors in the brain><Malignant Neoplasms><Cancers><Malignant Tumor><malignancy><neoplasm/cancer><Cells><Cell Body><Diagnosis><Disease><Disorder><DNA><Deoxyribonucleic Acid><Gene Frequency><Allele Frequency><allelic frequency><Patient Care><Patient Care Delivery><Genotype><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><glioblastoma multiforme><spongioblastoma multiforme><Glioma><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Neuroglial Neoplasm><Neuroglial Tumor><glial-derived tumor><neuroglia neoplasm><neuroglia tumor><Goals><Human><Modern Man><Methods><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Secondary Neoplasm><Secondary Tumor><cancer metastasis><tumor cell metastasis><Neoplasm Metastasis><Noise><Patients><Perfusion><Blood Plasma><Plasma Serum><Reticuloendothelial System, Serum, Plasma><Plasma><Blood Plasma Cell><Plasmacytes><plasmocyte><Plasma Cells><Common Rat Strains><Rat><Rats Mammals><Rattus><Recurrent><Recurrence><Risk><Specificity><Apoplexy><Brain Vascular Accident><Cerebral Stroke><Cerebrovascular Apoplexy><Cerebrovascular Stroke><brain attack><cerebral vascular accident><cerebrovascular accident><Stroke><Testing><Time><Translating><Translations><Genetic Variation><Genetic Diversity><Work><promoter><promotor><Custom><Apoptosis><Apoptosis Pathway><Programmed Cell Death><Point Mutation><base><improved><Procedures><Clinical><Malignant - descriptor><Malignant><Variant><Variation><Histologic><Histologically><Lesion><Genetic Heterogeneity><Relapsed Disease><Recurrent disease><Solid Tumor><Solid Neoplasm><Attenuated><Diagnostic><Knowledge><catalog><Catalogs><Diagnostic Method><Diagnostic Technique><Diagnostic Procedure><Frequencies><Source><Tumor Tissue><Heterograft><Heterologous Transplantation><Xenograft><Xenotransplantation><xeno-transplant><xeno-transplantation><Xenograft procedure><Neurologic Deficit><Operative Procedures><Surgical><Surgical Interventions><Surgical Procedure><surgery><Operative Surgical Procedures><success><Accuracy of Diagnosis><diagnostic accuracy><Animal Models and Related Studies><model of animal><model organism><Animal Model><Stable Disease><Appearance><Abscission><Extirpation><Removal><Surgical Removal><resection><Excision><Position><Positioning Attribute><Primary Brain Tumors><Primary Brain Neoplasms><Cell Fraction><Modeling><Sampling><Neuraxis><CNS Nervous System><Central Nervous System><Tissue Sample><Length><Data><Detection><Molecular Fingerprinting><molecular profile><molecular signature><Molecular Profiling><Clinical Management><Newly Diagnosed><Tumor-Derived><Monitor><Image><imaging><genetic variant><Gene variant><allele variant><allelic variant><genomic variant><design><designing><treatment effect><tumor><treatment response><response to therapy><response to treatment><therapeutic response><therapy response><Biological Markers><bio-markers><biologic marker><biomarker><next generation sequencing><NGS Method><NGS system><next gen sequencing><nextgen sequencing><Radiation necrosis><tumor DNA><tumor cell DNA><tumor-specific DNA><cell free DNA><cell free circulating DNA><profiles in patients><patient profile><stem-like cell><variant detection>\", \"pref_terms\": \"Adult;Affect;Animal Model;Apoptosis;Appearance;Attenuated;Biological Markers;Blood Circulation;Brain;Brain Neoplasms;Catalogs;Cell Fraction;Cells;Clinical;Clinical Management;Custom;DNA;Data;Detection;Diagnosis;Diagnostic;Diagnostic Procedure;Disease;Excision;Frequencies;Gene Frequency;Genetic Heterogeneity;Genetic Variation;Genotype;Glioblastoma;Glioma;Goals;Histologic;Human;Image;Knowledge;Length;Lesion;Malignant - descriptor;Malignant Neoplasms;Methods;Modeling;Molecular Profiling;Monitor;Neoplasm Metastasis;Neuraxis;Neurologic Deficit;Newly Diagnosed;Noise;Operative Surgical Procedures;Patient Care;Patients;Perfusion;Plasma;Plasma Cells;Point Mutation;Positioning Attribute;Primary Brain Neoplasms;Procedures;Radiation necrosis;Rattus;Recurrence;Recurrent disease;Risk;Sampling;Solid Neoplasm;Source;Specificity;Stable Disease;Stroke;Testing;Time;Tissue Sample;Translating;Translations;Tumor Tissue;Tumor-Derived;Variant;Work;Xenograft procedure;base;cell free DNA;design;diagnostic accuracy;genetic variant;improved;next generation sequencing;profiles in patients;promoter;stem-like cell;success;treatment effect;treatment response;tumor;tumor DNA;variant detection\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nGlioblastoma (GBM) is the most common and most aggressive adult primary brain tumor. Regardless of\\\\ntherapy, the median survival time is less than 15 months as GBM nearly always recurs. Diagnosing GBM\\\\ncurrently depends on acquiring tumor tissue for histologic examination to differentiate GBM from other types of\\\\nbrain lesions with a similar imaging appearance. Detecting GBM recurrence is also challenging as treatment\\\\neffects such as pseudoprogression and radiation necrosis mimic recurrent disease. Thus, risk-associated\\\\ndiagnostic invasive procedures remain a critical aspect of GBM patient care even though surgically acquired\\\\nneurologic deficits may reduce an already short survival time. Therefore, a non-invasive approach to diagnose\\\\nGBM and identify true recurrence has the potential to directly impact patient care throughout the entire disease\\\\ncourse. DNA released from cells during programmed cell death, termed cell-free DNA, is an emerging\\\\nbiomarker for diagnosing human cancers and monitoring response to therapy. Detection of tumor-derived cell-\\\\nfree DNA in plasma, also known as circulating tumor DNA (ctDNA), has previously been largely unsuccessful\\\\nin humans with GBM due to an inability to find the ctDNA amongst the abundant background of normally\\\\noccurring cell-free DNA. The large intra- and inter-tumor genetic heterogeneity of GBM has hindered searches\\\\nfor specific tumor variants in cell-free DNA, while the rarity of GBM to metastasize beyond the central nervous\\\\nsystem has considerably restricted the quantity of ctDNA present. However, our uncovering of ctDNA in a\\\\nxenograft brain tumor model using human GBM stem-like cells strongly supports the feasibility of detecting\\\\nGBM-derived ctDNA in humans. Moreover, our previous success in the animal model provides direction for the\\\\nhuman translation \\\\u2013 reducing or eliminating noise associated with next-generation sequencing (NGS) that\\\\ninterferes with the detection of very low frequency variants is necessary to allow searches for ctDNA that are\\\\nnot dependent on a priori knowledge of solid tumor variants. In this proposal, we attenuate NGS-related noise\\\\nand demonstrate the unbiased detection of GBM-derived ctDNA at time of initial diagnosis and at recurrence.\\\\nWe also show that identification of GBM solid tumor DNA variants in ctDNA is enhanced by reducing errors\\\\nassociated with NGS to improve sampling of the solid tumor genetic heterogeneity typical of GBM. Therefore,\\\\nthis proposal seeks to translate plasma cell-free DNA as a biomarker to detect GBM in humans by suppressing\\\\nerrors associated with NGS to improve variant detection at very low allele frequencies. The successful\\\\napplication of ctDNA biomarkers to non-invasively assess GBM will directly affect patient care by enabling the\\\\noptimization of clinical management prior to or instead of risk-associated invasive diagnostic procedures.\", \"project_title\": \"Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe most common and most aggressive adult primary brain tumor is glioblastoma (GBM). In this study, we\\\\nseek to develop tumor-derived cell-free DNA present in the circulation as a non-invasive biomarker to diagnose\\\\nGBM and detect recurrent disease. The non-invasive assessment of GBM has the potential to directly affect\\\\npatient care by enabling the optimization of clinical management prior to or instead of risk-associated invasive\\\\ndiagnostic procedures.\", \"spending_categories_desc\": \"Brain Cancer; Brain Disorders; Cancer; Cancer Genomics; Clinical Research; Genetics; Health Disparities; Human Genome; Minority Health; Neurosciences; Rare Diseases\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-02-01T12:02:00Z\", \"budget_end\": \"2023-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 228750, \"indirect_cost_amt\": 120094, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10328895\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 92}, page_content='{\"appl_id\": 10576321, \"subproject_id\": null, \"fiscal_year\": 2023, \"project_num\": \"5R01HD097775-06\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 297278, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HD\", \"serial_num\": \"097775\", \"support_year\": \"06\", \"full_support_year\": \"06\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2023, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 297278, \"direct_cost_ic\": 201022, \"indirect_cost_ic\": 96256}], \"project_start_date\": \"2019-10-21T12:10:00Z\", \"project_end_date\": \"2025-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-215\", \"full_study_section\": {\"srg_code\": \"ZRG1\", \"srg_flex\": null, \"sra_designator_code\": \"EMNR\", \"sra_flex_code\": \"S\", \"group_code\": \"56\", \"name\": \"Special Emphasis Panel[ZRG1-EMNR-S(56)R]\"}, \"award_notice_date\": \"2023-02-18T12:02:00Z\", \"core_project_num\": \"R01HD097775\", \"terms\": \"<Adsorption><Affect><ages><Age><Birth><Parturition><Child><0-11 years old><Child Youth><Children (0-21)><kids><youngster><Clinical Research><Clinical Study><Clinical Trials><Critical Illness><Critically Ill><Cessation of life><Death><Dialysis procedure><Dialysis><dialysis therapy><Disease><Disorder><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Environment><Equipment><Extracorporeal Membrane Oxygenation><Goals><Recording of previous events><History><histories><Laboratories><Mathematics><Math><Medical Device><Patients><Drug Kinetics><Pharmacokinetics><Drug Prescriptions><Drug Prescribing><medication prescription><prescribed medication><Public Health><Recommendation><Research><Research Institute><Research Personnel><Investigators><Researchers><Safety><Science><Technology><Translating><Work><Child Support><Investigational New Drug Application><Tube><critically ill child><Critically ill children><Label><improved><Clinical><Physiologic><Physiological><Kidney Replacement Therapy><Renal Replacement Therapy><Training><Failure><pediatric><Childhood><Ligand Binding Protein><Ligand Binding Protein Gene><Protein Binding><bound protein><Binding Proteins><drug use><Drug usage><Therapeutic><tool><Knowledge><Life><Side><Protocols documentation><Protocol><System><Cardiopulmonary><data management><experience><human old age (65+)><65+ years old><Aged 65 and Over><age 65 and greater><age 65 and older><aged 65 and greater><aged \\\\u226565><old age><Special Population><lipophilicity><skills><drug action><Modeling><Sampling><response><mathematical model><Math Models><mathematic model><mathematical modeling><Pharmaceutical Agent><Pharmaceuticals><Pharmacological Substance><pharmaceutical><Pharmacologic Substance><Effectiveness><Address><Dose><Data><Doctor of Philosophy><Ph.D.><PhD><National Institute of Child Health and Human Development><NICHD><National Institute of Children\\'s Health and Human Development><Qualifying><in vivo><Monitoring Clinical Trials><Collection><Enrollment><enroll><Translational Research><Translational Science><translation research><translational investigation><Validation><validations><Principal Investigator><pharmacokinetic model><Population><prospective><customized therapy><customized treatment><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><patient specific therapies><patient specific treatment><tailored medical treatment><tailored therapy><tailored treatment><unique treatment><individualized medicine><experiment><experimental research><experiments><experimental study><Infrastructure><dose information><drug disposition><optimal drug dosage><optimal drug dose><appropriate dose><pediatric drug development>\", \"pref_terms\": \"Address;Adsorption;Affect;Age;Binding Proteins;Birth;Cardiopulmonary;Cessation of life;Child;Child Support;Childhood;Clinical;Clinical Research;Clinical Trials;Collection;Critical Illness;Critically ill children;Data;Dialysis procedure;Disease;Doctor of Philosophy;Dose;Drug Kinetics;Drug Prescriptions;Drug usage;Effectiveness;Enrollment;Environment;Equipment;Extracorporeal Membrane Oxygenation;Failure;Goals;Infrastructure;Investigational New Drug Application;Knowledge;Label;Laboratories;Life;Mathematics;Medical Device;Modeling;Monitoring Clinical Trials;National Institute of Child Health and Human Development;Patients;Pharmaceutical Preparations;Pharmacologic Substance;Physiological;Population;Principal Investigator;Protocols documentation;Public Health;Qualifying;Recommendation;Recording of previous events;Renal Replacement Therapy;Research;Research Institute;Research Personnel;Safety;Sampling;Science;Side;Special Population;System;Technology;Therapeutic;Training;Translating;Translational Research;Tube;Validation;Work;appropriate dose;data management;dose information;drug action;drug disposition;experience;experimental study;human old age (65+);improved;in vivo;individualized medicine;lipophilicity;mathematical model;pediatric drug development;pharmacokinetic model;prospective;response;skills;tool\", \"abstract_text\": \"Extracorporeal life support (ECLS) is a life-saving technology in critically ill children. Children supported with\\\\nECLS receive numerous drugs to treat critical illness and the underlying disease. Unfortunately, the majority of\\\\ndrugs prescribed to children on ECLS lack dosing information. Our preliminary data demonstrate that dosing is\\\\ndifferent in this population because the ECLS circuit components, like filters and tubing, as well as physiologic\\\\nalterations triggered by critical illness affect drug disposition substantially. The lack of appropriate dosing\\\\ninformation is an urgent, unmet public health need that can result in therapeutic failure and death. Dose\\\\nselection to achieve safe and effective use of drugs in children on ECLS is not feasible with traditional\\\\npharmacokinetic (PK) trials for two reasons: 1) the effect of ECLS on drug disposition is drug- and age-specific,\\\\nnecessitating trials for all possible drug-, age-, and ECLS circuit combinations; thus requiring large numbers of\\\\nchildren; and 2) these trials would need to be repeated whenever new ECLS circuit equipment is developed to\\\\nquantify the effect of the new equipment on dosing. Our team has proof of concept of an alternative approach\\\\nthat addresses these limitations by using sophisticated physiologically-based pharmacokinetic (PBPK)\\\\nmathematical models to translate benchside ECLS experiments into bedside dosing recommendations.\\\\nHowever, this approach lacks generalizability thus far because its application is currently limited to two drugs\\\\nand only one mode of cardio-pulmonary ECLS (i.e., ECMO). In this proposal, we will build upon our prior work\\\\nto expand the approach to other forms of ECLS (i.e., dialysis) for multiple commonly used drugs in children.\\\\nThe objective of this proposal is to evaluate ECLS circuit extraction of drugs by continuous renal replacement\\\\ntherapy (CRRT) and extracorporeal membrane oxygenation (ECMO) circuits in an ex vivo system for 10\\\\ncommonly used drugs (AIM 1). These data will be used to develop ECLS-PBPK models and predict dosing in\\\\nchildren supported with CRRT and ECMO (AIM 2). The models and dosing recommendations will be validated\\\\nwith data collected in a prospective PK study (AIM 3). Evaluating multiple drugs in different types of ECLS will\\\\nshow the broad generalizability of this approach. The common use of these drugs provides additional public\\\\nhealth impact and lends feasibility to the proposed research.\", \"project_title\": \"Physiologically-Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support\", \"phr_text\": \"Enrolling children in clinical trials to establish the safest and most efficacious dose of commonly used drugs is\\\\nchallenging. This proposal will evaluate a mathematical tool, population physiologically-based pharmacokinetic\\\\nmodels, to reduce the number of children enrolled in clinical trials without compromising the quality of dosing\\\\ninformation.\", \"spending_categories_desc\": \"Clinical Research; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2023-02-01T12:02:00Z\", \"budget_end\": \"2025-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 201022, \"indirect_cost_amt\": 96256, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10576321\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 93}, page_content='{\"appl_id\": 10116989, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"5R01HD097775-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 593476, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HD\", \"serial_num\": \"097775\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 593476, \"direct_cost_ic\": 395129, \"indirect_cost_ic\": 198347}], \"project_start_date\": \"2019-10-21T12:10:00Z\", \"project_end_date\": \"2024-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-215\", \"full_study_section\": {\"srg_code\": \"ZRG1\", \"srg_flex\": null, \"sra_designator_code\": \"EMNR\", \"sra_flex_code\": \"S\", \"group_code\": \"56\", \"name\": \"Special Emphasis Panel[ZRG1-EMNR-S(56)R]\"}, \"award_notice_date\": \"2021-01-30T12:01:00Z\", \"core_project_num\": \"R01HD097775\", \"terms\": \"<Affect><Age><ages><Birth><Parturition><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Research><Clinical Study><Clinical Trials><Critical Illness><Critically Ill><Cessation of life><Death><Dialysis procedure><Dialysis><dialysis therapy><Disease><Disorder><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Environment><Equipment><Extracorporeal Membrane Oxygenation><Goals><Recording of previous events><History><Laboratories><Mathematics><Math><Medical Device><Patients><Drug Kinetics><Pharmacokinetics><Drug Prescriptions><Drug Prescribing><medication prescription><prescribed medication><Public Health><Recommendation><Research><Research Institute><Research Personnel><Investigators><Researchers><Safety><Savings><Science><Technology><Translating><Work><Child Support><Investigational New Drug Application><Critically ill children><critically ill child><base><Label><improved><Clinical><Physiological><Physiologic><Renal Replacement Therapy><Kidney Replacement Therapy><Training><Failure><Childhood><pediatric><Binding Proteins><Ligand Binding Protein><Ligand Binding Protein Gene><Protein Binding><bound protein><Drug usage><drug use><Therapeutic><tool><Knowledge><Life><Protocol><Protocols documentation><System><Cardiopulmonary><data management><experience><65+ years old><Aged 65 and Over><age 65 and greater><age 65 and older><aged 65 and greater><aged \\\\u226565><old age><human old age (65+)><Special Population><lipophilicity><skills><drug action><Modeling><Sampling><response><Math Models><mathematic model><mathematical modeling><mathematical model><Pharmaceutical Agent><Pharmaceuticals><Pharmacological Substance><Pharmacologic Substance><Effectiveness><Address><Dose><Data><Ph.D.><PhD><Doctor of Philosophy><NICHD><National Institute of Children\\'s Health and Human Development><National Institute of Child Health and Human Development><in vivo><Monitoring Clinical Trials><Collection><Enrollment><enroll><Translational Research><Translational Science><translation research><Validation><Principal Investigator><pharmacokinetic model><Population><prospective><individualized medicine><customized therapy><customized treatment><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><patient specific therapies><patient specific treatment><tailored medical treatment><tailored therapy><tailored treatment><unique treatment><experimental study><experiment><experimental research><Infrastructure><dose information><drug disposition><appropriate dose><optimal drug dosage><optimal drug dose><pediatric drug development>\", \"pref_terms\": \"Address;Affect;Age;Binding Proteins;Birth;Cardiopulmonary;Cessation of life;Child;Child Support;Childhood;Clinical;Clinical Research;Clinical Trials;Collection;Critical Illness;Critically ill children;Data;Dialysis procedure;Disease;Doctor of Philosophy;Dose;Drug Kinetics;Drug Prescriptions;Drug usage;Effectiveness;Enrollment;Environment;Equipment;Extracorporeal Membrane Oxygenation;Failure;Goals;Infrastructure;Investigational New Drug Application;Knowledge;Label;Laboratories;Life;Mathematics;Medical Device;Modeling;Monitoring Clinical Trials;National Institute of Child Health and Human Development;Patients;Pharmaceutical Preparations;Pharmacologic Substance;Physiological;Population;Principal Investigator;Protocols documentation;Public Health;Recommendation;Recording of previous events;Renal Replacement Therapy;Research;Research Institute;Research Personnel;Safety;Sampling;Savings;Science;Special Population;System;Technology;Therapeutic;Training;Translating;Translational Research;Validation;Work;appropriate dose;base;data management;dose information;drug action;drug disposition;experience;experimental study;human old age (65+);improved;in vivo;individualized medicine;lipophilicity;mathematical model;pediatric drug development;pharmacokinetic model;prospective;response;skills;tool\", \"abstract_text\": \"Extracorporeal life support (ECLS) is a life-saving technology in critically ill children. Children supported with\\\\nECLS receive numerous drugs to treat critical illness and the underlying disease. Unfortunately, the majority of\\\\ndrugs prescribed to children on ECLS lack dosing information. Our preliminary data demonstrate that dosing is\\\\ndifferent in this population because the ECLS circuit components, like filters and tubing, as well as physiologic\\\\nalterations triggered by critical illness affect drug disposition substantially. The lack of appropriate dosing\\\\ninformation is an urgent, unmet public health need that can result in therapeutic failure and death. Dose\\\\nselection to achieve safe and effective use of drugs in children on ECLS is not feasible with traditional\\\\npharmacokinetic (PK) trials for two reasons: 1) the effect of ECLS on drug disposition is drug- and age-specific,\\\\nnecessitating trials for all possible drug-, age-, and ECLS circuit combinations; thus requiring large numbers of\\\\nchildren; and 2) these trials would need to be repeated whenever new ECLS circuit equipment is developed to\\\\nquantify the effect of the new equipment on dosing. Our team has proof of concept of an alternative approach\\\\nthat addresses these limitations by using sophisticated physiologically-based pharmacokinetic (PBPK)\\\\nmathematical models to translate benchside ECLS experiments into bedside dosing recommendations.\\\\nHowever, this approach lacks generalizability thus far because its application is currently limited to two drugs\\\\nand only one mode of cardio-pulmonary ECLS (i.e., ECMO). In this proposal, we will build upon our prior work\\\\nto expand the approach to other forms of ECLS (i.e., dialysis) for multiple commonly used drugs in children.\\\\nThe objective of this proposal is to evaluate ECLS circuit extraction of drugs by continuous renal replacement\\\\ntherapy (CRRT) and extracorporeal membrane oxygenation (ECMO) circuits in an ex vivo system for 10\\\\ncommonly used drugs (AIM 1). These data will be used to develop ECLS-PBPK models and predict dosing in\\\\nchildren supported with CRRT and ECMO (AIM 2). The models and dosing recommendations will be validated\\\\nwith data collected in a prospective PK study (AIM 3). Evaluating multiple drugs in different types of ECLS will\\\\nshow the broad generalizability of this approach. The common use of these drugs provides additional public\\\\nhealth impact and lends feasibility to the proposed research.\", \"project_title\": \"Physiologically-Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support\", \"phr_text\": \"Enrolling children in clinical trials to establish the safest and most efficacious dose of commonly used drugs is\\\\nchallenging. This proposal will evaluate a mathematical tool, population physiologically-based pharmacokinetic\\\\nmodels, to reduce the number of children enrolled in clinical trials without compromising the quality of dosing\\\\ninformation.\", \"spending_categories_desc\": \"Clinical Research; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2021-02-01T12:02:00Z\", \"budget_end\": \"2022-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 395129, \"indirect_cost_amt\": 198347, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10116989\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 94}, page_content='{\"appl_id\": 9869018, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"5R01HD097775-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 614847, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HD\", \"serial_num\": \"097775\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 614847, \"direct_cost_ic\": 403193, \"indirect_cost_ic\": 211654}], \"project_start_date\": \"2019-10-21T12:10:00Z\", \"project_end_date\": \"2024-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-215\", \"full_study_section\": {\"srg_code\": \"ZRG1\", \"srg_flex\": null, \"sra_designator_code\": \"EMNR\", \"sra_flex_code\": \"S\", \"group_code\": \"56\", \"name\": \"Special Emphasis Panel[ZRG1-EMNR-S(56)R]\"}, \"award_notice_date\": \"2020-02-28T12:02:00Z\", \"core_project_num\": \"R01HD097775\", \"terms\": \"<Affect><Age><ages><Birth><Parturition><Child><0-11 years old><Child Youth><Children (0-21)><children><childrens\\'><youngster><Clinical Research><Clinical Study><Clinical Trials><Critical Illness><Critically Ill><Cessation of life><Death><Dialysis procedure><Dialysis><dialysis therapy><Disease><Disorder><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Environment><Equipment><Extracorporeal Membrane Oxygenation><Goals><Recording of previous events><History><Laboratories><Mathematics><Math><Medical Device><Patients><Drug Kinetics><Pharmacokinetics><Drug Prescriptions><Drug Prescribing><Public Health><Recommendation><Research><Research Institute><Research Personnel><Investigators><Researchers><Safety><Savings><Science><Technology><Translating><Work><Child Support><Investigational New Drug Application><critically ill child><Critically ill children><base><Label><improved><Clinical><Physiologic><Physiological><Kidney Replacement Therapy><Renal Replacement Therapy><Training><Failure><pediatric><Childhood><Ligand Binding Protein><Ligand Binding Protein Gene><Protein Binding><bound protein><Binding Proteins><drug use><Drug usage><Therapeutic><tool><Knowledge><Life><Protocol><Protocols documentation><System><Cardiopulmonary><data management><experience><Special Population><named group><lipophilicity><skills><drug action><Modeling><Sampling><response><Math Models><mathematic model><mathematical modeling><mathematical model><Pharmaceutical Agent><Pharmaceuticals><Pharmacological Substance><Pharmacologic Substance><Effectiveness><Address><Dose><Data><Ph.D.><PhD><Doctor of Philosophy><NICHD><National Institute of Children\\'s Health and Human Development><National Institute of Child Health and Human Development><in vivo><Monitoring Clinical Trials><Collection><enroll><Enrollment><Translational Science><translation research><Translational Research><Validation><Principal Investigator><pharmacokinetic model><Population><prospective><customized therapy><customized treatment><individualized patient treatment><individualized therapy><individualized treatment><patient specific therapies><patient specific treatment><tailored medical treatment><tailored therapy><tailored treatment><unique treatment><individualized medicine><experiment><experimental research><experimental study><Infrastructure><dose information><drug disposition><optimal drug dosage><optimal drug dose><appropriate dose><pediatric drug development>\", \"pref_terms\": \"Address;Affect;Age;Binding Proteins;Birth;Cardiopulmonary;Cessation of life;Child;Child Support;Childhood;Clinical;Clinical Research;Clinical Trials;Collection;Critical Illness;Critically ill children;Data;Dialysis procedure;Disease;Doctor of Philosophy;Dose;Drug Kinetics;Drug Prescriptions;Drug usage;Effectiveness;Enrollment;Environment;Equipment;Extracorporeal Membrane Oxygenation;Failure;Goals;Infrastructure;Investigational New Drug Application;Knowledge;Label;Laboratories;Life;Mathematics;Medical Device;Modeling;Monitoring Clinical Trials;National Institute of Child Health and Human Development;Patients;Pharmaceutical Preparations;Pharmacologic Substance;Physiological;Population;Principal Investigator;Protocols documentation;Public Health;Recommendation;Recording of previous events;Renal Replacement Therapy;Research;Research Institute;Research Personnel;Safety;Sampling;Savings;Science;System;Technology;Therapeutic;Training;Translating;Translational Research;Validation;Work;appropriate dose;base;data management;dose information;drug action;drug disposition;experience;experimental study;improved;in vivo;individualized medicine;lipophilicity;mathematical model;named group;pediatric drug development;pharmacokinetic model;prospective;response;skills;tool\", \"abstract_text\": \"Extracorporeal life support (ECLS) is a life-saving technology in critically ill children. Children supported with\\\\nECLS receive numerous drugs to treat critical illness and the underlying disease. Unfortunately, the majority of\\\\ndrugs prescribed to children on ECLS lack dosing information. Our preliminary data demonstrate that dosing is\\\\ndifferent in this population because the ECLS circuit components, like filters and tubing, as well as physiologic\\\\nalterations triggered by critical illness affect drug disposition substantially. The lack of appropriate dosing\\\\ninformation is an urgent, unmet public health need that can result in therapeutic failure and death. Dose\\\\nselection to achieve safe and effective use of drugs in children on ECLS is not feasible with traditional\\\\npharmacokinetic (PK) trials for two reasons: 1) the effect of ECLS on drug disposition is drug- and age-specific,\\\\nnecessitating trials for all possible drug-, age-, and ECLS circuit combinations; thus requiring large numbers of\\\\nchildren; and 2) these trials would need to be repeated whenever new ECLS circuit equipment is developed to\\\\nquantify the effect of the new equipment on dosing. Our team has proof of concept of an alternative approach\\\\nthat addresses these limitations by using sophisticated physiologically-based pharmacokinetic (PBPK)\\\\nmathematical models to translate benchside ECLS experiments into bedside dosing recommendations.\\\\nHowever, this approach lacks generalizability thus far because its application is currently limited to two drugs\\\\nand only one mode of cardio-pulmonary ECLS (i.e., ECMO). In this proposal, we will build upon our prior work\\\\nto expand the approach to other forms of ECLS (i.e., dialysis) for multiple commonly used drugs in children.\\\\nThe objective of this proposal is to evaluate ECLS circuit extraction of drugs by continuous renal replacement\\\\ntherapy (CRRT) and extracorporeal membrane oxygenation (ECMO) circuits in an ex vivo system for 10\\\\ncommonly used drugs (AIM 1). These data will be used to develop ECLS-PBPK models and predict dosing in\\\\nchildren supported with CRRT and ECMO (AIM 2). The models and dosing recommendations will be validated\\\\nwith data collected in a prospective PK study (AIM 3). Evaluating multiple drugs in different types of ECLS will\\\\nshow the broad generalizability of this approach. The common use of these drugs provides additional public\\\\nhealth impact and lends feasibility to the proposed research.\", \"project_title\": \"Physiologically-Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support\", \"phr_text\": \"Enrolling children in clinical trials to establish the safest and most efficacious dose of commonly used drugs is\\\\nchallenging. This proposal will evaluate a mathematical tool, population physiologically-based pharmacokinetic\\\\nmodels, to reduce the number of children enrolled in clinical trials without compromising the quality of dosing\\\\ninformation.\", \"spending_categories_desc\": \"Clinical Research; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2020-02-01T12:02:00Z\", \"budget_end\": \"2021-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 403193, \"indirect_cost_amt\": 211654, \"project_detail_url\": \"https://reporter.nih.gov/project-details/9869018\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 95}, page_content='{\"appl_id\": 10337072, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5R01HD097775-05\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"R01\", \"award_amount\": 536386, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"R01\", \"ic_code\": \"HD\", \"serial_num\": \"097775\", \"support_year\": \"05\", \"full_support_year\": \"05\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 536386, \"direct_cost_ic\": 357821, \"indirect_cost_ic\": 178565}], \"project_start_date\": \"2019-10-21T12:10:00Z\", \"project_end_date\": \"2024-01-31T12:01:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PAR-18-215\", \"full_study_section\": {\"srg_code\": \"ZRG1\", \"srg_flex\": null, \"sra_designator_code\": \"EMNR\", \"sra_flex_code\": \"S\", \"group_code\": \"56\", \"name\": \"Special Emphasis Panel[ZRG1-EMNR-S(56)R]\"}, \"award_notice_date\": \"2022-02-17T12:02:00Z\", \"core_project_num\": \"R01HD097775\", \"terms\": \"<Affect><Age><ages><Birth><Parturition><Child><0-11 years old><Child Youth><Children (0-21)><youngster><Clinical Research><Clinical Study><Clinical Trials><Critical Illness><Critically Ill><Cessation of life><Death><Dialysis procedure><Dialysis><dialysis therapy><Disease><Disorder><Pharmaceutical Preparations><Drugs><Medication><Pharmaceutic Preparations><drug/agent><Environment><Equipment><Extracorporeal Membrane Oxygenation><Goals><Recording of previous events><History><Laboratories><Mathematics><Math><Medical Device><Patients><Pharmacokinetics><Drug Kinetics><Drug Prescribing><medication prescription><prescribed medication><Drug Prescriptions><Public Health><Recommendation><Research><Research Institute><Investigators><Researchers><Research Personnel><Safety><Savings><Science><Technology><Translating><Work><Child Support><Investigational New Drug Application><Critically ill children><critically ill child><base><Label><improved><Clinical><Physiological><Physiologic><Renal Replacement Therapy><Kidney Replacement Therapy><Training><Failure><pediatric><Childhood><Ligand Binding Protein><Ligand Binding Protein Gene><Protein Binding><bound protein><Binding Proteins><drug use><Drug usage><Therapeutic><tool><Knowledge><Life><Protocol><Protocols documentation><System><Cardiopulmonary><data management><experience><65+ years old><Aged 65 and Over><age 65 and greater><age 65 and older><aged 65 and greater><aged \\\\u226565><old age><human old age (65+)><Special Population><lipophilicity><skills><drug action><Modeling><Sampling><response><Math Models><mathematic model><mathematical modeling><mathematical model><Pharmaceutical Agent><Pharmaceuticals><Pharmacological Substance><Pharmacologic Substance><Effectiveness><Address><Dose><Data><Ph.D.><PhD><Doctor of Philosophy><NICHD><National Institute of Children\\'s Health and Human Development><National Institute of Child Health and Human Development><in vivo><Monitoring Clinical Trials><Collection><Enrollment><enroll><Translational Research><Translational Science><translation research><Validation><Principal Investigator><pharmacokinetic model><Population><prospective><individualized medicine><customized therapy><customized treatment><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><patient specific therapies><patient specific treatment><tailored medical treatment><tailored therapy><tailored treatment><unique treatment><experimental study><experiment><experimental research><Infrastructure><dose information><drug disposition><appropriate dose><optimal drug dosage><optimal drug dose><pediatric drug development>\", \"pref_terms\": \"Address;Affect;Age;Binding Proteins;Birth;Cardiopulmonary;Cessation of life;Child;Child Support;Childhood;Clinical;Clinical Research;Clinical Trials;Collection;Critical Illness;Critically ill children;Data;Dialysis procedure;Disease;Doctor of Philosophy;Dose;Drug Kinetics;Drug Prescriptions;Drug usage;Effectiveness;Enrollment;Environment;Equipment;Extracorporeal Membrane Oxygenation;Failure;Goals;Infrastructure;Investigational New Drug Application;Knowledge;Label;Laboratories;Life;Mathematics;Medical Device;Modeling;Monitoring Clinical Trials;National Institute of Child Health and Human Development;Patients;Pharmaceutical Preparations;Pharmacologic Substance;Physiological;Population;Principal Investigator;Protocols documentation;Public Health;Recommendation;Recording of previous events;Renal Replacement Therapy;Research;Research Institute;Research Personnel;Safety;Sampling;Savings;Science;Special Population;System;Technology;Therapeutic;Training;Translating;Translational Research;Validation;Work;appropriate dose;base;data management;dose information;drug action;drug disposition;experience;experimental study;human old age (65+);improved;in vivo;individualized medicine;lipophilicity;mathematical model;pediatric drug development;pharmacokinetic model;prospective;response;skills;tool\", \"abstract_text\": \"Extracorporeal life support (ECLS) is a life-saving technology in critically ill children. Children supported with\\\\nECLS receive numerous drugs to treat critical illness and the underlying disease. Unfortunately, the majority of\\\\ndrugs prescribed to children on ECLS lack dosing information. Our preliminary data demonstrate that dosing is\\\\ndifferent in this population because the ECLS circuit components, like filters and tubing, as well as physiologic\\\\nalterations triggered by critical illness affect drug disposition substantially. The lack of appropriate dosing\\\\ninformation is an urgent, unmet public health need that can result in therapeutic failure and death. Dose\\\\nselection to achieve safe and effective use of drugs in children on ECLS is not feasible with traditional\\\\npharmacokinetic (PK) trials for two reasons: 1) the effect of ECLS on drug disposition is drug- and age-specific,\\\\nnecessitating trials for all possible drug-, age-, and ECLS circuit combinations; thus requiring large numbers of\\\\nchildren; and 2) these trials would need to be repeated whenever new ECLS circuit equipment is developed to\\\\nquantify the effect of the new equipment on dosing. Our team has proof of concept of an alternative approach\\\\nthat addresses these limitations by using sophisticated physiologically-based pharmacokinetic (PBPK)\\\\nmathematical models to translate benchside ECLS experiments into bedside dosing recommendations.\\\\nHowever, this approach lacks generalizability thus far because its application is currently limited to two drugs\\\\nand only one mode of cardio-pulmonary ECLS (i.e., ECMO). In this proposal, we will build upon our prior work\\\\nto expand the approach to other forms of ECLS (i.e., dialysis) for multiple commonly used drugs in children.\\\\nThe objective of this proposal is to evaluate ECLS circuit extraction of drugs by continuous renal replacement\\\\ntherapy (CRRT) and extracorporeal membrane oxygenation (ECMO) circuits in an ex vivo system for 10\\\\ncommonly used drugs (AIM 1). These data will be used to develop ECLS-PBPK models and predict dosing in\\\\nchildren supported with CRRT and ECMO (AIM 2). The models and dosing recommendations will be validated\\\\nwith data collected in a prospective PK study (AIM 3). Evaluating multiple drugs in different types of ECLS will\\\\nshow the broad generalizability of this approach. The common use of these drugs provides additional public\\\\nhealth impact and lends feasibility to the proposed research.\", \"project_title\": \"Physiologically-Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support\", \"phr_text\": \"Enrolling children in clinical trials to establish the safest and most efficacious dose of commonly used drugs is\\\\nchallenging. This proposal will evaluate a mathematical tool, population physiologically-based pharmacokinetic\\\\nmodels, to reduce the number of children enrolled in clinical trials without compromising the quality of dosing\\\\ninformation.\", \"spending_categories_desc\": \"Clinical Research; Pediatric\", \"agency_code\": \"NIH\", \"budget_start\": \"2022-02-01T12:02:00Z\", \"budget_end\": \"2023-01-31T12:01:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": 357821, \"indirect_cost_amt\": 178565, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10337072\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 96}, page_content='{\"appl_id\": 10220733, \"subproject_id\": null, \"fiscal_year\": 2021, \"project_num\": \"5U01DD001246-03\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U01\", \"award_amount\": 80000, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U01\", \"ic_code\": \"DD\", \"serial_num\": \"001246\", \"support_year\": \"03\", \"full_support_year\": \"03\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8962485, \"first_name\": \"Marcia\", \"middle_name\": \"Lynn\", \"last_name\": \"Feldkamp\", \"is_contact_pi\": true, \"full_name\": \"Marcia Lynn Feldkamp\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"FELDKAMP, MARCIA LYNN\", \"agency_ic_admin\": {\"code\": \"DD\", \"abbreviation\": \"NCBDDD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\"}, \"agency_ic_fundings\": [{\"fy\": 2021, \"code\": \"DD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\", \"abbreviation\": \"NCBDDD\", \"total_cost\": 80000, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2019-09-01T12:09:00Z\", \"project_end_date\": \"2024-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DD-19-002\", \"full_study_section\": {\"srg_code\": \"ZDD1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"05\", \"name\": \"ZDD1-KVA(05)\"}, \"award_notice_date\": \"2021-06-25T12:06:00Z\", \"core_project_num\": \"U01DD001246\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThe muscular dystrophies (MD) are disorders of muscle leading to progressive muscle weakness, and reduced\\\\nquality of life and mortality due to respiratory and cardiac complications. In addition to significant motor,\\\\nrespiratory, and cardiac complications, affected individuals and families have social, psychological, and\\\\ncognitive issues which are not well understood. For the MD STARnet project, nine muscular dystrophies are\\\\nincluded: Duchenne and Becker muscular dystrophy (DBMD), distal, Emery-Dreifuss, limb-girdle,\\\\noculopharyngeal, congenital, myotonic dystrophy, and facioscapulohumeral dystrophy. Recent development\\\\nand implementation of standardized care guidelines for DBMD, and other neuromuscular conditions are\\\\nexpected to result in improved clinical outcomes; however, published evidence remains limited. Emerging\\\\ntherapeutic options for these disorders are a source of great hope and opportunity for realizing improved\\\\noutcomes; however, a better understanding of the range of disease severity and current care burden in these\\\\ndisorders is critical to the success of such initiatives. The University of Utah MD STARnet team has been\\\\nactive during the current funding cycle (DD001108: 9/1/2014-8/31/2019) and is uniquely situated to continue to\\\\nconduct research as part of Component C. As part of Component A, our engagement with local and national\\\\nneuromuscular foundations has been important to determine questions that our research can answer in order\\\\nto address gaps in knowledge. For Component C, we will focus on the objectives and approach outlined in the\\\\nfunding opportunity announcement with an overall goal to continue our existing projects with proposed new\\\\nresearch projects using MD STARnet data. Furthermore, we plan to conduct surveys to evaluate the\\\\npsychological and neurobehavioral function, and health-related quality of life in patients with MDs. We will\\\\ndisseminate our findings through local, national, and international presentations at professional society\\\\nmeetings and submit manuscripts to peer-reviewed journals. Our existing program\\\\u2019s strengths and resources\\\\nwill increase knowledge of the medical issues and barriers to care facing these individuals, and enhance our\\\\nability to provide more consistent quality care to our patients. Furthermore, we propose that this project will\\\\nallow us to assess the impact of implementation of standardized care guidelines on clinical outcomes and cost\\\\nof care for such patients. We will analyze high-priority questions addressed in the MD STARnet Research\\\\nAgenda (Aim 1), identify additional gaps in understanding with a focus on psychological and neurobehavioral\\\\ncomorbidities and health-related quality of life (Aim 2), and provide secondary analyst support for other MD\\\\nSTARnet sites on a minimum of three research projects (Aim 3).\", \"project_title\": \"Component C - The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) in Utah\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe muscular dystrophies are disorders of muscle leading to progressive muscle weakness, and reduced\\\\nquality of life and mortality due to respiratory and cardiac complications. In addition to significant motor,\\\\nrespiratory, and cardiac complications, affected individuals and families have social, and psychological, and\\\\ncognitive issues which are not well understood. Our proposal seeks to assess their prevalence, and study\\\\nrelevant gaps in understanding including issues psychological and neurobehavioral function and health-related\\\\nquality of life.\", \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2021-09-01T12:09:00Z\", \"budget_end\": \"2022-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10220733\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 97}, page_content='{\"appl_id\": 10441107, \"subproject_id\": null, \"fiscal_year\": 2022, \"project_num\": \"5U01DD001249-04\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U01\", \"award_amount\": 415000, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U01\", \"ic_code\": \"DD\", \"serial_num\": \"001249\", \"support_year\": \"04\", \"full_support_year\": \"04\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8962485, \"first_name\": \"Marcia\", \"middle_name\": \"Lynn\", \"last_name\": \"Feldkamp\", \"is_contact_pi\": true, \"full_name\": \"Marcia Lynn Feldkamp\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"FELDKAMP, MARCIA LYNN\", \"agency_ic_admin\": {\"code\": \"DD\", \"abbreviation\": \"NCBDDD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\"}, \"agency_ic_fundings\": [{\"fy\": 2022, \"code\": \"DD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\", \"abbreviation\": \"NCBDDD\", \"total_cost\": 415000, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2019-09-01T12:09:00Z\", \"project_end_date\": \"2024-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DD-19-002\", \"full_study_section\": {\"srg_code\": \"ZDD1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"05\", \"name\": \"ZDD1-KVA(05)\"}, \"award_notice_date\": \"2022-06-27T12:06:00Z\", \"core_project_num\": \"U01DD001249\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThe muscular dystrophies are disorders of muscle leading to progressive muscle weakness and reduced\\\\nquality of life and mortality due to respiratory and cardiac complications. In addition to motor, respiratory, and\\\\ncardiac complications, affected individuals and families have significant social, psychological, and cognitive\\\\nissues that are major gaps in understanding. As part of the MD STARnet project, we have identified cases of\\\\nall muscular dystrophy types in Utah, using a combination of unique resources available in our state. These\\\\nresources include our neuromuscular subspecialty clinics at the University of Utah and Primary Children\\\\u2019s\\\\nHospital where we are the only muscular dystrophy specialty clinics in the intermountain west. Relevant\\\\nelectronic health systems from the University of Utah and Intermountain Healthcare capture health care\\\\nencounters for the majority 95% of the Utah population. A unique electronic resource, the Utah Population\\\\nDatabase, links all individuals in Utah to multiple data sources, including extensive pedigrees, hospital records,\\\\ndeath certificates, birth certificates, ambulatory care and emergency room visits, and the Utah cancer registry.\\\\nThe proposed project focuses on continuing our surveillance efforts using these resources and enhancing our\\\\nlongitudinal surveillance for eligible muscular dystrophy cases in order to contribute to the understanding of\\\\nprevalence, comorbidities impacting health and well-being, and to address gaps in understanding including\\\\nissues psychological and neurobehavioral function and health-related quality of life. This information is critical\\\\nfor future disease modifying therapeutic trials, and for the detection and care of those individuals who may not\\\\ncurrently have access to the standard of care.\", \"project_title\": \"Component A - The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) in Utah\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe muscular dystrophies are disorders of muscle leading to progressive muscle weakness, and reduced\\\\nquality of life and mortality due to respiratory and cardiac complications. Our proposal seeks to continue to\\\\nabstract the medical records of eligible muscular dystrophy cases to assess their prevalence in Utah, and as\\\\npart of the consortium, study relevant gaps in understanding including issues psychological and\\\\nneurobehavioral function and health-related quality of life.\", \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2022-09-01T12:09:00Z\", \"budget_end\": \"2023-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10441107\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 98}, page_content='{\"appl_id\": 10051391, \"subproject_id\": null, \"fiscal_year\": 2020, \"project_num\": \"5U01DD001282-02\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"5\", \"activity_code\": \"U01\", \"award_amount\": 20478, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"5\", \"activity_code\": \"U01\", \"ic_code\": \"DD\", \"serial_num\": \"001282\", \"support_year\": \"02\", \"full_support_year\": \"02\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12168296, \"first_name\": \"Chad\", \"middle_name\": \"\", \"last_name\": \"Wallis\", \"is_contact_pi\": true, \"full_name\": \"Chad  Wallis\", \"title\": \"PROFESSOR OF SURGERY\"}], \"contact_pi_name\": \"WALLIS, CHAD \", \"agency_ic_admin\": {\"code\": \"DD\", \"abbreviation\": \"NCBDDD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\"}, \"agency_ic_fundings\": [{\"fy\": 2020, \"code\": \"DD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\", \"abbreviation\": \"NCBDDD\", \"total_cost\": 20478, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2019-09-01T12:09:00Z\", \"project_end_date\": \"2021-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DD-19-001\", \"full_study_section\": {\"srg_code\": \"ZDD1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"07\", \"name\": \"ZDD1-KVA(07)\"}, \"award_notice_date\": \"2020-06-24T12:06:00Z\", \"core_project_num\": \"U01DD001282\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"\", \"project_title\": \"Research Approaches to Improve the Care and Outcomes of People Living with Spina Bifida - 2019\", \"phr_text\": null, \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2020-09-01T12:09:00Z\", \"budget_end\": \"2021-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10051391\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 99}, page_content='{\"appl_id\": 9871967, \"subproject_id\": null, \"fiscal_year\": 2019, \"project_num\": \"1U01DD001246-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"U01\", \"award_amount\": 80000, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"U01\", \"ic_code\": \"DD\", \"serial_num\": \"001246\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 8962485, \"first_name\": \"Marcia\", \"middle_name\": \"Lynn\", \"last_name\": \"Feldkamp\", \"is_contact_pi\": true, \"full_name\": \"Marcia Lynn Feldkamp\", \"title\": \"PROFESSOR\"}], \"contact_pi_name\": \"FELDKAMP, MARCIA LYNN\", \"agency_ic_admin\": {\"code\": \"DD\", \"abbreviation\": \"NCBDDD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\"}, \"agency_ic_fundings\": [{\"fy\": 2019, \"code\": \"DD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\", \"abbreviation\": \"NCBDDD\", \"total_cost\": 80000, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2019-09-01T12:09:00Z\", \"project_end_date\": \"2024-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DD-19-002\", \"full_study_section\": {\"srg_code\": \"ZDD1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"05\", \"name\": \"Special Emphasis Panel[ZDD1 KVA (05)]\"}, \"award_notice_date\": \"2019-08-01T12:08:00Z\", \"core_project_num\": \"U01DD001246\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\\\nThe muscular dystrophies (MD) are disorders of muscle leading to progressive muscle weakness, and reduced\\\\nquality of life and mortality due to respiratory and cardiac complications. In addition to significant motor,\\\\nrespiratory, and cardiac complications, affected individuals and families have social, psychological, and\\\\ncognitive issues which are not well understood. For the MD STARnet project, nine muscular dystrophies are\\\\nincluded: Duchenne and Becker muscular dystrophy (DBMD), distal, Emery-Dreifuss, limb-girdle,\\\\noculopharyngeal, congenital, myotonic dystrophy, and facioscapulohumeral dystrophy. Recent development\\\\nand implementation of standardized care guidelines for DBMD, and other neuromuscular conditions are\\\\nexpected to result in improved clinical outcomes; however, published evidence remains limited. Emerging\\\\ntherapeutic options for these disorders are a source of great hope and opportunity for realizing improved\\\\noutcomes; however, a better understanding of the range of disease severity and current care burden in these\\\\ndisorders is critical to the success of such initiatives. The University of Utah MD STARnet team has been\\\\nactive during the current funding cycle (DD001108: 9/1/2014-8/31/2019) and is uniquely situated to continue to\\\\nconduct research as part of Component C. As part of Component A, our engagement with local and national\\\\nneuromuscular foundations has been important to determine questions that our research can answer in order\\\\nto address gaps in knowledge. For Component C, we will focus on the objectives and approach outlined in the\\\\nfunding opportunity announcement with an overall goal to continue our existing projects with proposed new\\\\nresearch projects using MD STARnet data. Furthermore, we plan to conduct surveys to evaluate the\\\\npsychological and neurobehavioral function, and health-related quality of life in patients with MDs. We will\\\\ndisseminate our findings through local, national, and international presentations at professional society\\\\nmeetings and submit manuscripts to peer-reviewed journals. Our existing program\\\\u2019s strengths and resources\\\\nwill increase knowledge of the medical issues and barriers to care facing these individuals, and enhance our\\\\nability to provide more consistent quality care to our patients. Furthermore, we propose that this project will\\\\nallow us to assess the impact of implementation of standardized care guidelines on clinical outcomes and cost\\\\nof care for such patients. We will analyze high-priority questions addressed in the MD STARnet Research\\\\nAgenda (Aim 1), identify additional gaps in understanding with a focus on psychological and neurobehavioral\\\\ncomorbidities and health-related quality of life (Aim 2), and provide secondary analyst support for other MD\\\\nSTARnet sites on a minimum of three research projects (Aim 3).\", \"project_title\": \"Component C - The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) in Utah\", \"phr_text\": \"PROJECT NARRATIVE\\\\nThe muscular dystrophies are disorders of muscle leading to progressive muscle weakness, and reduced\\\\nquality of life and mortality due to respiratory and cardiac complications. In addition to significant motor,\\\\nrespiratory, and cardiac complications, affected individuals and families have social, and psychological, and\\\\ncognitive issues which are not well understood. Our proposal seeks to assess their prevalence, and study\\\\nrelevant gaps in understanding including issues psychological and neurobehavioral function and health-related\\\\nquality of life.\", \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2019-09-01T12:09:00Z\", \"budget_end\": \"2020-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/9871967\"}'),\n",
      " Document(metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/projects_data.json', 'seq_num': 100}, page_content='{\"appl_id\": 9895947, \"subproject_id\": null, \"fiscal_year\": 2019, \"project_num\": \"1U01DD001282-01\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"U01\", \"award_amount\": 20478, \"is_active\": false, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"U01\", \"ic_code\": \"DD\", \"serial_num\": \"001282\", \"support_year\": \"01\", \"full_support_year\": \"01\", \"suffix_code\": \"\"}, \"principal_investigators\": [{\"profile_id\": 12168296, \"first_name\": \"Chad\", \"middle_name\": \"\", \"last_name\": \"Wallis\", \"is_contact_pi\": true, \"full_name\": \"Chad  Wallis\", \"title\": \"PROFESSOR OF SURGERY\"}], \"contact_pi_name\": \"WALLIS, CHAD \", \"agency_ic_admin\": {\"code\": \"DD\", \"abbreviation\": \"NCBDDD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\"}, \"agency_ic_fundings\": [{\"fy\": 2019, \"code\": \"DD\", \"name\": \"National Center on Birth Defects and Developmental Disabilities\", \"abbreviation\": \"NCBDDD\", \"total_cost\": 20478, \"direct_cost_ic\": null, \"indirect_cost_ic\": null}], \"project_start_date\": \"2019-09-01T12:09:00Z\", \"project_end_date\": \"2024-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"RFA-DD-19-001\", \"full_study_section\": {\"srg_code\": \"ZDD1\", \"srg_flex\": null, \"sra_designator_code\": \"KVA\", \"sra_flex_code\": null, \"group_code\": \"07\", \"name\": \"Special Emphasis Panel[ZDD1 KVA (07)]\"}, \"award_notice_date\": \"2019-07-29T12:07:00Z\", \"core_project_num\": \"U01DD001282\", \"terms\": null, \"pref_terms\": null, \"abstract_text\": null, \"project_title\": \"Research Approaches to Improve the Care and Outcomes of People Living with Spina Bifida - 2019\", \"phr_text\": null, \"spending_categories_desc\": null, \"agency_code\": \"ALLCDC\", \"budget_start\": \"2019-09-01T12:09:00Z\", \"budget_end\": \"2020-08-31T12:08:00Z\", \"funding_mechanism\": \"Non-SBIR/STTR\", \"direct_cost_amt\": null, \"indirect_cost_amt\": null, \"project_detail_url\": \"https://reporter.nih.gov/project-details/9895947\"}')]\n"
     ]
    }
   ],
   "source": [
    "loader = JSONLoader(\n",
    "    file_path='data/projects_data.json',\n",
    "    jq_schema='.results[]',\n",
    "    text_content=False)\n",
    "\n",
    "projects = loader.load()\n",
    "\n",
    "pprint.pprint(projects)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### JSON Splitter (not sure if this is needed)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'data' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[22], line 4\u001b[0m\n\u001b[1;32m      1\u001b[0m splitter \u001b[38;5;241m=\u001b[39m RecursiveJsonSplitter(max_chunk_size\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m300\u001b[39m)\n\u001b[1;32m      3\u001b[0m \u001b[38;5;66;03m# Recursively split json data - If you need to access/manipulate the smaller json chunks\u001b[39;00m\n\u001b[0;32m----> 4\u001b[0m json_chunks \u001b[38;5;241m=\u001b[39m splitter\u001b[38;5;241m.\u001b[39msplit_json(json_data\u001b[38;5;241m=\u001b[39m\u001b[43mdata\u001b[49m)\n\u001b[1;32m      6\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m chunk \u001b[38;5;129;01min\u001b[39;00m json_chunks[:\u001b[38;5;241m3\u001b[39m]:\n\u001b[1;32m      7\u001b[0m     \u001b[38;5;28mprint\u001b[39m(chunk)\n",
      "\u001b[0;31mNameError\u001b[0m: name 'data' is not defined"
     ]
    }
   ],
   "source": [
    "splitter = RecursiveJsonSplitter(max_chunk_size=300)\n",
    "\n",
    "# Recursively split json data - If you need to access/manipulate the smaller json chunks\n",
    "json_chunks = splitter.split_json(json_data=data)\n",
    "\n",
    "for chunk in json_chunks[:3]:\n",
    "    print(chunk)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Projects into Vector Store"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "ename": "ResponseHandlingException",
     "evalue": "timed out",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mConnectTimeout\u001b[0m                            Traceback (most recent call last)",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_transports/default.py:101\u001b[0m, in \u001b[0;36mmap_httpcore_exceptions\u001b[0;34m()\u001b[0m\n\u001b[1;32m    100\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 101\u001b[0m     \u001b[38;5;28;01myield\u001b[39;00m\n\u001b[1;32m    102\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m exc:\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_transports/default.py:250\u001b[0m, in \u001b[0;36mHTTPTransport.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    249\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_httpcore_exceptions():\n\u001b[0;32m--> 250\u001b[0m     resp \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_pool\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mreq\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    252\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(resp\u001b[38;5;241m.\u001b[39mstream, typing\u001b[38;5;241m.\u001b[39mIterable)\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpcore/_sync/connection_pool.py:256\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    255\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_close_connections(closing)\n\u001b[0;32m--> 256\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m    258\u001b[0m \u001b[38;5;66;03m# Return the response. Note that in this case we still have to manage\u001b[39;00m\n\u001b[1;32m    259\u001b[0m \u001b[38;5;66;03m# the point at which the response is closed.\u001b[39;00m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpcore/_sync/connection_pool.py:236\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    234\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    235\u001b[0m     \u001b[38;5;66;03m# Send the request on the assigned connection.\u001b[39;00m\n\u001b[0;32m--> 236\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mconnection\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    237\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpool_request\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\n\u001b[1;32m    238\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    239\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m ConnectionNotAvailable:\n\u001b[1;32m    240\u001b[0m     \u001b[38;5;66;03m# In some cases a connection may initially be available to\u001b[39;00m\n\u001b[1;32m    241\u001b[0m     \u001b[38;5;66;03m# handle a request, but then become unavailable.\u001b[39;00m\n\u001b[1;32m    242\u001b[0m     \u001b[38;5;66;03m#\u001b[39;00m\n\u001b[1;32m    243\u001b[0m     \u001b[38;5;66;03m# In this case we clear the connection and try again.\u001b[39;00m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpcore/_sync/connection.py:101\u001b[0m, in \u001b[0;36mHTTPConnection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    100\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_connect_failed \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[0;32m--> 101\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc\n\u001b[1;32m    103\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_connection\u001b[38;5;241m.\u001b[39mhandle_request(request)\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpcore/_sync/connection.py:78\u001b[0m, in \u001b[0;36mHTTPConnection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m     77\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_connection \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m---> 78\u001b[0m     stream \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_connect\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m     80\u001b[0m     ssl_object \u001b[38;5;241m=\u001b[39m stream\u001b[38;5;241m.\u001b[39mget_extra_info(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mssl_object\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpcore/_sync/connection.py:124\u001b[0m, in \u001b[0;36mHTTPConnection._connect\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    123\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m Trace(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mconnect_tcp\u001b[39m\u001b[38;5;124m\"\u001b[39m, logger, request, kwargs) \u001b[38;5;28;01mas\u001b[39;00m trace:\n\u001b[0;32m--> 124\u001b[0m     stream \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_network_backend\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mconnect_tcp\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    125\u001b[0m     trace\u001b[38;5;241m.\u001b[39mreturn_value \u001b[38;5;241m=\u001b[39m stream\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpcore/_backends/sync.py:207\u001b[0m, in \u001b[0;36mSyncBackend.connect_tcp\u001b[0;34m(self, host, port, timeout, local_address, socket_options)\u001b[0m\n\u001b[1;32m    202\u001b[0m exc_map: ExceptionMapping \u001b[38;5;241m=\u001b[39m {\n\u001b[1;32m    203\u001b[0m     socket\u001b[38;5;241m.\u001b[39mtimeout: ConnectTimeout,\n\u001b[1;32m    204\u001b[0m     \u001b[38;5;167;01mOSError\u001b[39;00m: ConnectError,\n\u001b[1;32m    205\u001b[0m }\n\u001b[0;32m--> 207\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_exceptions(exc_map):\n\u001b[1;32m    208\u001b[0m     sock \u001b[38;5;241m=\u001b[39m socket\u001b[38;5;241m.\u001b[39mcreate_connection(\n\u001b[1;32m    209\u001b[0m         address,\n\u001b[1;32m    210\u001b[0m         timeout,\n\u001b[1;32m    211\u001b[0m         source_address\u001b[38;5;241m=\u001b[39msource_address,\n\u001b[1;32m    212\u001b[0m     )\n",
      "File \u001b[0;32m/Library/Frameworks/Python.framework/Versions/3.13/lib/python3.13/contextlib.py:162\u001b[0m, in \u001b[0;36m_GeneratorContextManager.__exit__\u001b[0;34m(self, typ, value, traceback)\u001b[0m\n\u001b[1;32m    161\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 162\u001b[0m     \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgen\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mthrow\u001b[49m\u001b[43m(\u001b[49m\u001b[43mvalue\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    163\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mStopIteration\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[1;32m    164\u001b[0m     \u001b[38;5;66;03m# Suppress StopIteration *unless* it's the same exception that\u001b[39;00m\n\u001b[1;32m    165\u001b[0m     \u001b[38;5;66;03m# was passed to throw().  This prevents a StopIteration\u001b[39;00m\n\u001b[1;32m    166\u001b[0m     \u001b[38;5;66;03m# raised inside the \"with\" statement from being suppressed.\u001b[39;00m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpcore/_exceptions.py:14\u001b[0m, in \u001b[0;36mmap_exceptions\u001b[0;34m(map)\u001b[0m\n\u001b[1;32m     13\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(exc, from_exc):\n\u001b[0;32m---> 14\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m to_exc(exc) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21;01mexc\u001b[39;00m\n\u001b[1;32m     15\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m\n",
      "\u001b[0;31mConnectTimeout\u001b[0m: timed out",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001b[0;31mConnectTimeout\u001b[0m                            Traceback (most recent call last)",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/http/api_client.py:116\u001b[0m, in \u001b[0;36mApiClient.send_inner\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    115\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 116\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    117\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_client.py:914\u001b[0m, in \u001b[0;36mClient.send\u001b[0;34m(self, request, stream, auth, follow_redirects)\u001b[0m\n\u001b[1;32m    912\u001b[0m auth \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_build_request_auth(request, auth)\n\u001b[0;32m--> 914\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_auth\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    915\u001b[0m \u001b[43m    \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    916\u001b[0m \u001b[43m    \u001b[49m\u001b[43mauth\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mauth\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    917\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    918\u001b[0m \u001b[43m    \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    919\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    920\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_client.py:942\u001b[0m, in \u001b[0;36mClient._send_handling_auth\u001b[0;34m(self, request, auth, follow_redirects, history)\u001b[0m\n\u001b[1;32m    941\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 942\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_redirects\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    943\u001b[0m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    944\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    945\u001b[0m \u001b[43m        \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mhistory\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    946\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    947\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_client.py:979\u001b[0m, in \u001b[0;36mClient._send_handling_redirects\u001b[0;34m(self, request, follow_redirects, history)\u001b[0m\n\u001b[1;32m    977\u001b[0m     hook(request)\n\u001b[0;32m--> 979\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_single_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    980\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_client.py:1014\u001b[0m, in \u001b[0;36mClient._send_single_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m   1013\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m request_context(request\u001b[38;5;241m=\u001b[39mrequest):\n\u001b[0;32m-> 1014\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mtransport\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1016\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response\u001b[38;5;241m.\u001b[39mstream, SyncByteStream)\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_transports/default.py:249\u001b[0m, in \u001b[0;36mHTTPTransport.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    237\u001b[0m req \u001b[38;5;241m=\u001b[39m httpcore\u001b[38;5;241m.\u001b[39mRequest(\n\u001b[1;32m    238\u001b[0m     method\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mmethod,\n\u001b[1;32m    239\u001b[0m     url\u001b[38;5;241m=\u001b[39mhttpcore\u001b[38;5;241m.\u001b[39mURL(\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    247\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mextensions,\n\u001b[1;32m    248\u001b[0m )\n\u001b[0;32m--> 249\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_httpcore_exceptions():\n\u001b[1;32m    250\u001b[0m     resp \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_pool\u001b[38;5;241m.\u001b[39mhandle_request(req)\n",
      "File \u001b[0;32m/Library/Frameworks/Python.framework/Versions/3.13/lib/python3.13/contextlib.py:162\u001b[0m, in \u001b[0;36m_GeneratorContextManager.__exit__\u001b[0;34m(self, typ, value, traceback)\u001b[0m\n\u001b[1;32m    161\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 162\u001b[0m     \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mgen\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mthrow\u001b[49m\u001b[43m(\u001b[49m\u001b[43mvalue\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    163\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mStopIteration\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[1;32m    164\u001b[0m     \u001b[38;5;66;03m# Suppress StopIteration *unless* it's the same exception that\u001b[39;00m\n\u001b[1;32m    165\u001b[0m     \u001b[38;5;66;03m# was passed to throw().  This prevents a StopIteration\u001b[39;00m\n\u001b[1;32m    166\u001b[0m     \u001b[38;5;66;03m# raised inside the \"with\" statement from being suppressed.\u001b[39;00m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/httpx/_transports/default.py:118\u001b[0m, in \u001b[0;36mmap_httpcore_exceptions\u001b[0;34m()\u001b[0m\n\u001b[1;32m    117\u001b[0m message \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mstr\u001b[39m(exc)\n\u001b[0;32m--> 118\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m mapped_exc(message) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21;01mexc\u001b[39;00m\n",
      "\u001b[0;31mConnectTimeout\u001b[0m: timed out",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[0;31mResponseHandlingException\u001b[0m                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[12], line 3\u001b[0m\n\u001b[1;32m      1\u001b[0m embeddings \u001b[38;5;241m=\u001b[39m OpenAIEmbeddings(model\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtext-embedding-3-small\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m----> 3\u001b[0m projects_qdrant \u001b[38;5;241m=\u001b[39m \u001b[43mQdrantVectorStore\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfrom_documents\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m      4\u001b[0m \u001b[43m    \u001b[49m\u001b[43mprojects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m      5\u001b[0m \u001b[43m    \u001b[49m\u001b[43membeddings\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m      6\u001b[0m \u001b[43m    \u001b[49m\u001b[43murl\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43murl\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m      7\u001b[0m \u001b[43m    \u001b[49m\u001b[43mprefer_grpc\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m      8\u001b[0m \u001b[43m    \u001b[49m\u001b[43mapi_key\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mos\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43menviron\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mQDRANT_API_KEY\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m      9\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcollection_name\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprojects\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     10\u001b[0m \u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/langchain_core/vectorstores/base.py:852\u001b[0m, in \u001b[0;36mVectorStore.from_documents\u001b[0;34m(cls, documents, embedding, **kwargs)\u001b[0m\n\u001b[1;32m    849\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28many\u001b[39m(ids):\n\u001b[1;32m    850\u001b[0m         kwargs[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mids\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m ids\n\u001b[0;32m--> 852\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mcls\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfrom_texts\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtexts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43membedding\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadatas\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmetadatas\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/langchain_qdrant/qdrant.py:343\u001b[0m, in \u001b[0;36mQdrantVectorStore.from_texts\u001b[0;34m(cls, texts, embedding, metadatas, ids, collection_name, location, url, port, grpc_port, prefer_grpc, https, api_key, prefix, timeout, host, path, distance, content_payload_key, metadata_payload_key, vector_name, retrieval_mode, sparse_embedding, sparse_vector_name, collection_create_options, vector_params, sparse_vector_params, batch_size, force_recreate, validate_embeddings, validate_collection_config, **kwargs)\u001b[0m\n\u001b[1;32m    311\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"Construct an instance of `QdrantVectorStore` from a list of texts.\u001b[39;00m\n\u001b[1;32m    312\u001b[0m \n\u001b[1;32m    313\u001b[0m \u001b[38;5;124;03mThis is a user-friendly interface that:\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    326\u001b[0m \u001b[38;5;124;03m    qdrant = Qdrant.from_texts(texts, embeddings, url=\"http://localhost:6333\")\u001b[39;00m\n\u001b[1;32m    327\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m    328\u001b[0m client_options \u001b[38;5;241m=\u001b[39m {\n\u001b[1;32m    329\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mlocation\u001b[39m\u001b[38;5;124m\"\u001b[39m: location,\n\u001b[1;32m    330\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124murl\u001b[39m\u001b[38;5;124m\"\u001b[39m: url,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    340\u001b[0m     \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs,\n\u001b[1;32m    341\u001b[0m }\n\u001b[0;32m--> 343\u001b[0m qdrant \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mcls\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mconstruct_instance\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    344\u001b[0m \u001b[43m    \u001b[49m\u001b[43membedding\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    345\u001b[0m \u001b[43m    \u001b[49m\u001b[43mretrieval_mode\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    346\u001b[0m \u001b[43m    \u001b[49m\u001b[43msparse_embedding\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    347\u001b[0m \u001b[43m    \u001b[49m\u001b[43mclient_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    348\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcollection_name\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    349\u001b[0m \u001b[43m    \u001b[49m\u001b[43mdistance\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    350\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcontent_payload_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    351\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmetadata_payload_key\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    352\u001b[0m \u001b[43m    \u001b[49m\u001b[43mvector_name\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    353\u001b[0m \u001b[43m    \u001b[49m\u001b[43msparse_vector_name\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    354\u001b[0m \u001b[43m    \u001b[49m\u001b[43mforce_recreate\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    355\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcollection_create_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    356\u001b[0m \u001b[43m    \u001b[49m\u001b[43mvector_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    357\u001b[0m \u001b[43m    \u001b[49m\u001b[43msparse_vector_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    358\u001b[0m \u001b[43m    \u001b[49m\u001b[43mvalidate_embeddings\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    359\u001b[0m \u001b[43m    \u001b[49m\u001b[43mvalidate_collection_config\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    360\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    361\u001b[0m qdrant\u001b[38;5;241m.\u001b[39madd_texts(texts, metadatas, ids, batch_size)\n\u001b[1;32m    362\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m qdrant\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/langchain_qdrant/qdrant.py:810\u001b[0m, in \u001b[0;36mQdrantVectorStore.construct_instance\u001b[0;34m(cls, embedding, retrieval_mode, sparse_embedding, client_options, collection_name, distance, content_payload_key, metadata_payload_key, vector_name, sparse_vector_name, force_recreate, collection_create_options, vector_params, sparse_vector_params, validate_embeddings, validate_collection_config)\u001b[0m\n\u001b[1;32m    807\u001b[0m collection_name \u001b[38;5;241m=\u001b[39m collection_name \u001b[38;5;129;01mor\u001b[39;00m uuid\u001b[38;5;241m.\u001b[39muuid4()\u001b[38;5;241m.\u001b[39mhex\n\u001b[1;32m    808\u001b[0m client \u001b[38;5;241m=\u001b[39m QdrantClient(\u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mclient_options)\n\u001b[0;32m--> 810\u001b[0m collection_exists \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcollection_exists\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcollection_name\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    812\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m collection_exists \u001b[38;5;129;01mand\u001b[39;00m force_recreate:\n\u001b[1;32m    813\u001b[0m     client\u001b[38;5;241m.\u001b[39mdelete_collection(collection_name)\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/qdrant_client.py:2166\u001b[0m, in \u001b[0;36mQdrantClient.collection_exists\u001b[0;34m(self, collection_name, **kwargs)\u001b[0m\n\u001b[1;32m   2156\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"Check whether collection already exists\u001b[39;00m\n\u001b[1;32m   2157\u001b[0m \n\u001b[1;32m   2158\u001b[0m \u001b[38;5;124;03mArgs:\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   2162\u001b[0m \u001b[38;5;124;03m    True if collection exists, False if not\u001b[39;00m\n\u001b[1;32m   2163\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m   2164\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(kwargs) \u001b[38;5;241m==\u001b[39m \u001b[38;5;241m0\u001b[39m, \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mUnknown arguments: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mlist\u001b[39m(kwargs\u001b[38;5;241m.\u001b[39mkeys())\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m-> 2166\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcollection_exists\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcollection_name\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcollection_name\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/qdrant_remote.py:2594\u001b[0m, in \u001b[0;36mQdrantRemote.collection_exists\u001b[0;34m(self, collection_name, **kwargs)\u001b[0m\n\u001b[1;32m   2588\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_prefer_grpc:\n\u001b[1;32m   2589\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mgrpc_collections\u001b[38;5;241m.\u001b[39mCollectionExists(\n\u001b[1;32m   2590\u001b[0m         grpc\u001b[38;5;241m.\u001b[39mCollectionExistsRequest(collection_name\u001b[38;5;241m=\u001b[39mcollection_name),\n\u001b[1;32m   2591\u001b[0m         timeout\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_timeout,\n\u001b[1;32m   2592\u001b[0m     )\u001b[38;5;241m.\u001b[39mresult\u001b[38;5;241m.\u001b[39mexists\n\u001b[0;32m-> 2594\u001b[0m result: Optional[models\u001b[38;5;241m.\u001b[39mCollectionExistence] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhttp\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcollections_api\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcollection_exists\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m   2595\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcollection_name\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcollection_name\u001b[49m\n\u001b[1;32m   2596\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241m.\u001b[39mresult\n\u001b[1;32m   2597\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m result \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mCollection exists returned None\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   2598\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m result\u001b[38;5;241m.\u001b[39mexists\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/http/api/collections_api.py:281\u001b[0m, in \u001b[0;36mSyncCollectionsApi.collection_exists\u001b[0;34m(self, collection_name)\u001b[0m\n\u001b[1;32m    274\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mcollection_exists\u001b[39m(\n\u001b[1;32m    275\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m    276\u001b[0m     collection_name: \u001b[38;5;28mstr\u001b[39m,\n\u001b[1;32m    277\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m m\u001b[38;5;241m.\u001b[39mInlineResponse2007:\n\u001b[1;32m    278\u001b[0m \u001b[38;5;250m    \u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m    279\u001b[0m \u001b[38;5;124;03m    Returns \\\"true\\\" if the given collection name exists, and \\\"false\\\" otherwise\u001b[39;00m\n\u001b[1;32m    280\u001b[0m \u001b[38;5;124;03m    \"\"\"\u001b[39;00m\n\u001b[0;32m--> 281\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_build_for_collection_exists\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    282\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcollection_name\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcollection_name\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    283\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/http/api/collections_api.py:67\u001b[0m, in \u001b[0;36m_CollectionsApi._build_for_collection_exists\u001b[0;34m(self, collection_name)\u001b[0m\n\u001b[1;32m     62\u001b[0m path_params \u001b[38;5;241m=\u001b[39m {\n\u001b[1;32m     63\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcollection_name\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;28mstr\u001b[39m(collection_name),\n\u001b[1;32m     64\u001b[0m }\n\u001b[1;32m     66\u001b[0m headers \u001b[38;5;241m=\u001b[39m {}\n\u001b[0;32m---> 67\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mapi_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m     68\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtype_\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mm\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mInlineResponse2007\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     69\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmethod\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mGET\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     70\u001b[0m \u001b[43m    \u001b[49m\u001b[43murl\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/collections/\u001b[39;49m\u001b[38;5;132;43;01m{collection_name}\u001b[39;49;00m\u001b[38;5;124;43m/exists\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     71\u001b[0m \u001b[43m    \u001b[49m\u001b[43mheaders\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mheaders\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mheaders\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m     72\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpath_params\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mpath_params\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     73\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/http/api_client.py:89\u001b[0m, in \u001b[0;36mApiClient.request\u001b[0;34m(self, type_, method, url, path_params, **kwargs)\u001b[0m\n\u001b[1;32m     87\u001b[0m     kwargs[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtimeout\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mint\u001b[39m(kwargs[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mparams\u001b[39m\u001b[38;5;124m\"\u001b[39m][\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtimeout\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[1;32m     88\u001b[0m request \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_client\u001b[38;5;241m.\u001b[39mbuild_request(method, url, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[0;32m---> 89\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtype_\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/http/api_client.py:106\u001b[0m, in \u001b[0;36mApiClient.send\u001b[0;34m(self, request, type_)\u001b[0m\n\u001b[1;32m    105\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21msend\u001b[39m(\u001b[38;5;28mself\u001b[39m, request: Request, type_: Type[T]) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m T:\n\u001b[0;32m--> 106\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmiddleware\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend_inner\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    107\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m response\u001b[38;5;241m.\u001b[39mstatus_code \u001b[38;5;129;01min\u001b[39;00m [\u001b[38;5;241m200\u001b[39m, \u001b[38;5;241m201\u001b[39m, \u001b[38;5;241m202\u001b[39m]:\n\u001b[1;32m    108\u001b[0m         \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/http/api_client.py:215\u001b[0m, in \u001b[0;36mBaseMiddleware.__call__\u001b[0;34m(self, request, call_next)\u001b[0m\n\u001b[1;32m    214\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21m__call__\u001b[39m(\u001b[38;5;28mself\u001b[39m, request: Request, call_next: Send) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Response:\n\u001b[0;32m--> 215\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mcall_next\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/qdrant_client/http/api_client.py:118\u001b[0m, in \u001b[0;36mApiClient.send_inner\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    116\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_client\u001b[38;5;241m.\u001b[39msend(request)\n\u001b[1;32m    117\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[0;32m--> 118\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m ResponseHandlingException(e)\n\u001b[1;32m    119\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "\u001b[0;31mResponseHandlingException\u001b[0m: timed out"
     ]
    }
   ],
   "source": [
    "embeddings = OpenAIEmbeddings(model=\"text-embedding-3-small\")\n",
    "\n",
    "projects_qdrant = QdrantVectorStore.from_documents(\n",
    "    projects,\n",
    "    embeddings,\n",
    "    url=url,\n",
    "    prefer_grpc=False,\n",
    "    api_key=os.environ[\"QDRANT_API_KEY\"],\n",
    "    collection_name=\"projects\",\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Test Similarity Search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'projects_qdrant' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[11], line 2\u001b[0m\n\u001b[1;32m      1\u001b[0m query \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mWhat is PA-20-206\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m----> 2\u001b[0m found_docs \u001b[38;5;241m=\u001b[39m \u001b[43mprojects_qdrant\u001b[49m\u001b[38;5;241m.\u001b[39msimilarity_search(query, k\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m)\n\u001b[1;32m      3\u001b[0m pprint\u001b[38;5;241m.\u001b[39mpprint(found_docs)\n",
      "\u001b[0;31mNameError\u001b[0m: name 'projects_qdrant' is not defined"
     ]
    }
   ],
   "source": [
    "query = \"What is PA-20-206\"\n",
    "found_docs = projects_qdrant.similarity_search(query, k=1)\n",
    "pprint.pprint(found_docs)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Projects Retriever (change k value as needed)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "projects_retriever = projects_qdrant.as_retriever(search_kwargs={\"k\": 2})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Projects Prompt Template"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "projects_rag_prompt_template = \"\"\"\\\n",
    "Use the provide context to answer the provided user question. Only use the provided context to answer the question. If you do not know the answer, or it's not contained in the provided context response with \"I don't know\"\n",
    "\n",
    "Context:\n",
    "{context}\n",
    "\n",
    "Question:\n",
    "{question}\n",
    "\"\"\"\n",
    "\n",
    "projects_rag_prompt = ChatPromptTemplate.from_template(projects_rag_prompt_template)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Instantiate Chat Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai.chat_models import ChatOpenAI\n",
    "\n",
    "projects_llm = ChatOpenAI(model=\"gpt-4o-mini\", tags=[\"projects_llm\"])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Projects RAG Chain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "projects_rag_chain = (\n",
    "    # INVOKE CHAIN WITH: {\"question\" : \"<<SOME USER QUESTION>>\"}\n",
    "    # \"question\" : populated by getting the value of the \"question\" key\n",
    "    # \"context\"  : populated by getting the value of the \"question\" key and chaining it into the base_retriever\n",
    "    {\"context\": itemgetter(\"question\") | projects_retriever, \"question\": itemgetter(\"question\")}\n",
    "    # \"context\"  : is assigned to a RunnablePassthrough object (will not be called or considered in the next step)\n",
    "    #              by getting the value of the \"context\" key from the previous step\n",
    "    | RunnablePassthrough.assign(context=itemgetter(\"context\"))\n",
    "    # \"response\" : the \"context\" and \"question\" values are used to format our prompt object and then piped\n",
    "    #              into the LLM and stored in a key called \"response\"\n",
    "    # \"context\"  : populated by getting the value of the \"context\" key from the previous step\n",
    "    | {\"response\": projects_rag_prompt | projects_llm, \"context\": itemgetter(\"context\")}\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install -qU grandalf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "          +---------------------------------+      \n",
      "          | Parallel<context,question>Input |      \n",
      "          +---------------------------------+      \n",
      "                    **            **               \n",
      "                  **                **             \n",
      "                **                    **           \n",
      "         +--------+                     **         \n",
      "         | Lambda |                      *         \n",
      "         +--------+                      *         \n",
      "              *                          *         \n",
      "              *                          *         \n",
      "              *                          *         \n",
      "  +----------------------+          +--------+     \n",
      "  | VectorStoreRetriever |          | Lambda |     \n",
      "  +----------------------+          +--------+     \n",
      "                    **            **               \n",
      "                      **        **                 \n",
      "                        **    **                   \n",
      "          +----------------------------------+     \n",
      "          | Parallel<context,question>Output |     \n",
      "          +----------------------------------+     \n",
      "                            *                      \n",
      "                            *                      \n",
      "                            *                      \n",
      "              +------------------------+           \n",
      "              | Parallel<context>Input |           \n",
      "              +------------------------+           \n",
      "                     ***        ***                \n",
      "                    *              *               \n",
      "                  **                **             \n",
      "           +--------+          +-------------+     \n",
      "           | Lambda |          | Passthrough |     \n",
      "           +--------+          +-------------+     \n",
      "                     ***        ***                \n",
      "                        *      *                   \n",
      "                         **  **                    \n",
      "              +-------------------------+          \n",
      "              | Parallel<context>Output |          \n",
      "              +-------------------------+          \n",
      "                            *                      \n",
      "                            *                      \n",
      "                            *                      \n",
      "          +---------------------------------+      \n",
      "          | Parallel<response,context>Input |      \n",
      "          +---------------------------------+      \n",
      "                   **              ***             \n",
      "                ***                   **           \n",
      "              **                        ***        \n",
      "+--------------------+                     **      \n",
      "| ChatPromptTemplate |                      *      \n",
      "+--------------------+                      *      \n",
      "           *                                *      \n",
      "           *                                *      \n",
      "           *                                *      \n",
      "    +------------+                     +--------+  \n",
      "    | ChatOpenAI |                     | Lambda |  \n",
      "    +------------+*                  **+--------+  \n",
      "                   **              **              \n",
      "                     ***        ***                \n",
      "                        **    **                   \n",
      "          +----------------------------------+     \n",
      "          | Parallel<response,context>Output |     \n",
      "          +----------------------------------+     \n"
     ]
    }
   ],
   "source": [
    "print(projects_rag_chain.get_graph().draw_ascii())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = projects_rag_chain.invoke({\"question\" : \"assess the study design complexity for the PA-20-206 opportunity\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('The study design complexity for the PA-20-206 opportunity involves several '\n",
      " 'key aspects:\\n'\n",
      " '\\n'\n",
      " '1. **Focus on Differences of Sex Development (DSD)**: The study aims to '\n",
      " 'explore the decisional needs of adolescents and young adults with DSD, which '\n",
      " 'inherently involves understanding a complex and sensitive topic that '\n",
      " 'includes biological, psychological, and social dimensions.\\n'\n",
      " '\\n'\n",
      " '2. **Shared Decision Making Framework**: The project incorporates shared '\n",
      " 'decision making (SDM) principles, which adds complexity as it requires the '\n",
      " 'development and implementation of tools that facilitate this process between '\n",
      " 'patients, caregivers, and healthcare providers.\\n'\n",
      " '\\n'\n",
      " '3. **Development of Decision Aids (DAs)**: The creation of evidence-based '\n",
      " 'decision aids for surgical decisions necessitates rigorous research and '\n",
      " 'design processes to ensure that the tools are effective and cater to the '\n",
      " 'specific needs of the target population.\\n'\n",
      " '\\n'\n",
      " '4. **Pilot Testing and Multi-site Trial**: The study includes plans for '\n",
      " 'piloting the DAs, followed by testing in a multi-site trial, which '\n",
      " 'introduces additional logistical and methodological challenges, including '\n",
      " 'coordination between different sites and ensuring consistency in the '\n",
      " 'implementation of the intervention.\\n'\n",
      " '\\n'\n",
      " '5. **Involvement of a Multidisciplinary Team**: A dedicated team of mentors '\n",
      " 'and advisors with diverse areas of expertise has been assembled to guide the '\n",
      " 'project, indicating a need for collaborative approaches and possibly '\n",
      " 'complicating communication and decision-making processes.\\n'\n",
      " '\\n'\n",
      " '6. **Assessment of Psychosocial Outcomes**: The project aims to evaluate the '\n",
      " 'psychosocial and health outcomes of pediatric patients with DSD, which '\n",
      " 'involves measuring complex variables that may require advanced statistical '\n",
      " 'techniques and a thorough understanding of how these outcomes are influenced '\n",
      " 'by various factors.\\n'\n",
      " '\\n'\n",
      " 'Overall, the complexity arises from the intersection of rigorous research '\n",
      " 'design, the sensitive nature of the population, the integration of multiple '\n",
      " 'disciplines, and the need for effective communication and strategy across '\n",
      " 'various stakeholders.')\n"
     ]
    }
   ],
   "source": [
    "pprint.pprint(response[\"response\"].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Context:\n",
      "page_content='{\"appl_id\": 10985653, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"1K23HD113825-01A1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"1\", \"activity_code\": \"K23\", \"award_amount\": 167455, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"1\", \"activity_code\": \"K23\", \"ic_code\": \"HD\", \"serial_num\": \"113825\", \"support_year\": \"01\", \"full_support_year\": \"01A1\", \"suffix_code\": \"A1\"}, \"principal_investigators\": [{\"profile_id\": 12163589, \"first_name\": \"Kristina\", \"middle_name\": \"Irene\", \"last_name\": \"Suorsa-Johnson\", \"is_contact_pi\": true, \"full_name\": \"Kristina Irene Suorsa-Johnson\", \"title\": \"\"}], \"contact_pi_name\": \"SUORSA-JOHNSON, KRISTINA IRENE\", \"agency_ic_admin\": {\"code\": \"HD\", \"abbreviation\": \"NICHD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"HD\", \"name\": \"Eunice Kennedy Shriver National Institute of Child Health and Human Development\", \"abbreviation\": \"NICHD\", \"total_cost\": 167455}], \"project_start_date\": \"2024-09-18T12:09:00Z\", \"project_end_date\": \"2029-06-30T12:06:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-206\", \"full_study_section\": {\"srg_code\": \"CHHD\", \"srg_flex\": \"M\", \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": null, \"name\": \"Health, Behavior, and Context Study Section[CHHD-M]\"}, \"award_notice_date\": \"2024-09-18T12:09:00Z\", \"core_project_num\": \"K23HD113825\", \"terms\": \"<0-11 years old><Address><Adolescent and Young Adult><Anatomic Sites><Anatomic structures><Anatomy><Award><Care Givers><Caregivers><Caring><Child><Child Youth><Childhood><Children (0-21)><Clinic><Clinic Visits><Clinical><Clinical Management><Clinical Trials><Code><Coding System><Collaborations><Conflict><Conflict (Psychology)><Data><Decision Aid><Decision Making><Dedications><Development><Differences of sex development><Doctor of Philosophy><Education><Education and Training><Educational Materials><Educational aspects><Elements><Ensure><Exercise><Feedback><Funding><Future><Gender and Sexual Minorities><Genital Organs><Genitalia><Genitourinary><Genitourinary Surgery><Genitourinary system><Goals><Health><Health Care Providers><Health Instruction><Health Personnel><Health Tutoring><Health education><Healthcare Providers><Healthcare worker><Infant><International><Intervention><Intervention Strategies><Interview><Investigators><Jordan><K23 Award><K23 Mechanism><K23 Program><Knowledge><Leadership><Licensing><Life><Lived experience><Lived experiences><Medical><Mentored Patient-Oriented Research Career Development Award><Mentored Patient-Oriented Research Career Development Award (K23)><Mentors><Methods><Modeling><NICHD><NIH><National Institute of Child Health and Human Development><National Institute of Children's Health and Human Development><National Institutes of Health><Nature><Operative Procedures><Operative Surgical Procedures><Outcome><Outcome Measure><Participant><Patients><Perception><Persons><Ph.D.><PhD><Population><Process><Provider><Psychologist><Randomized><Randomized, Controlled Trials><Recommendation><Registries><Research><Research Personnel><Research Resources><Research Training><Researchers><Resources><Risk><Sexual Development><Sexual Health><Sexual and Gender Minorities><Site><Standardization><Surgical><Surgical Interventions><Surgical Procedure><Survey Instrument><Surveys><Techniques><Testing><Training Programs><Training and Education><Translational Research><Translational Science><United States National Institutes of Health><Urogenital><Urogenital Surgery><Urogenital Surgical Procedures><Urogenital System><Work><acceptability and feasibility><care as usual><career><career development><child patients><community advisory board><community advisory committee><community advisory panel><design><designing><developmental><disorder of sexual development><dissemination science><evidence base><health care personnel><health care worker><health provider><health workforce><healthcare personnel><implementation science><improved><innovate><innovation><innovative><interventional strategy><kids><measurable outcome><medical personnel><multi-site trial><multisite trial><outcome measurement><participant engagement><patient engagement><pediatric><pediatric health outcomes><pediatric patients><physical conditioning><physical health><pilot test><pilot trial><preference><psychosocial><psychosocial outcome><psychosocial sequelae><randomisation><randomization><randomized control trial><randomly assigned><recruit><reproductive><sex development><sex development disorder><shared decision making><skills><standardized care><success><support tools><surgery><tool><translation research><translational investigation><treatment as usual><treatment provider><trial design><user centered design><usual care><youngster>\", \"pref_terms\": \"Address;Adolescent and Young Adult;Anatomy;Award;Caregivers;Caring;Child;Childhood;Clinic;Clinic Visits;Clinical;Clinical Management;Clinical Trials;Code;Collaborations;Conflict (Psychology);Data;Decision Aid;Decision Making;Dedications;Development;Doctor of Philosophy;Education;Educational Materials;Elements;Ensure;Exercise;Feedback;Funding;Future;Genitalia;Genitourinary system;Goals;Health;Health Personnel;Health education;Infant;International;Intervention;Interview;Jordan;Knowledge;Leadership;Licensing;Life;Lived experience;Medical;Mentored Patient-Oriented Research Career Development Award;Mentors;Methods;Modeling;National Institute of Child Health and Human Development;Nature;Operative Surgical Procedures;Outcome;Outcome Measure;Participant;Patients;Perception;Persons;Population;Process;Provider;Psychologist;Randomized;Randomized, Controlled Trials;Recommendation;Registries;Research;Research Personnel;Research Training;Resources;Risk;Sexual Development;Sexual Health;Sexual and Gender Minorities;Site;Standardization;Surveys;Techniques;Testing;Training Programs;Training and Education;Translational Research;United States National Institutes of Health;Urogenital Surgical Procedures;Work;acceptability and feasibility;career;career development;community advisory board;design;dissemination science;evidence base;implementation science;improved;innovation;multi-site trial;patient engagement;pediatric health outcomes;pediatric patients;physical conditioning;pilot test;pilot trial;preference;psychosocial;psychosocial outcome;recruit;reproductive;sex development disorder;shared decision making;skills;standardized care;success;support tools;tool;treatment as usual;trial design;user centered design\", \"abstract_text\": \"PROJECT SUMMARY/ABSTRACT\\nThe proposed 5-year K23 award describes a research training program for Kristina Suorsa-Johnson, PhD, a\\nlicensed pediatric psychologist who specializes in differences of sex development (DSD). Her overarching\\ncareer goal is to become an independently funded investigator focused on improving the psychosocial and\\nhealth outcomes of pediatric patients with DSD by creating tools to facilitate patient engagement in medical\\ndecision making through shared decision making (SDM). This award provides support for Dr. Suorsa-Johnson\\nto achieve the following Career Development Aims: Aim 1: Obtain expertise in SDM, including the\\ndevelopment of decision aids (DAs) for adolescents and young adults (AYAs); Aim 2: Gain sexual health\\neducation training, particularly as it relates to the creation of educational materials to enhance surgical SDM;\\nAim 3: Develop expertise in evaluating and implementing DAs; and Aim 4: Expand and strengthen research\\nleadership and management skills. To achieve these goals, Dr. Suorsa-Johnson has assembled a dedicated\\nteam of mentors and advisors with expertise in SDM (Angela Fagerlin, PhD), SDM in AYAs (Ellen Lipstein,\\nMD), sexual health education (Jordan Rullo, PhD), dissemination and implementation science (Jennie Hill,\\nPhD), qualitative design and clinical trials (Melissa Watt, PhD and Angela Fagerlin, PhD), multi-site trial design\\n(Gregory Stoddard, MBA, MPH), urogenital/gonadal surgeries in AYAs (Kathleen van Leeuwen, PhD), and\\nDSD education (David Sandberg, PhD and Erica Weidler, MEd, MS). A person with lived experience, Noi\\nLiang, MBA, MCPA, is consulting to ensure all aspects of the project align with the needs of those with DSD.\\nDSD are congenital conditions where chromosomal, gonadal, or anatomical sex development is atypical. AYAs\\nwith DSD make critical and potentially irreversible, life-altering urogenital/gonadal surgical decisions. However,\\nwe know little about how AYAs approach surgical decision making and no standardized SDM resources exist.\\nAs such, Dr. Suorsa-Johnson proposes to create and pilot a set of surgical DAs for AYAs with DSD. This will\\nbe achieved through three Specific Aims: Aim 1: Identify informational needs and values influencing surgical\\ndecision making for AYAs with DSD; Aim 2: Develop a set of evidence-based DAs for surgical decisions to\\nfacilitate SDM for AYAs and their caregivers; and Aim 3: Pilot test and refine DA content, delivery, and\\nfeasibility. This project will result in a set of surgical decision aids ready to be tested in a multi-site trial.\\nThis project is significant because it will change how we provide care and improve engagement in surgical\\ndecision making for this underserved, NIH-designated sexual and gender minority subpopulation. This\\ninnovative project is the first to explore the needs of AYAs with DSD making surgical decisions from a SDM\\nframework and create associated decision support tools.\", \"project_title\": \"Adolescents and Young Adults: Dilemmas, Education, and Choices Impacting Decisions (AYAs DECIDe) Study\", \"phr_text\": \"PROJECT NARRATIVE\\nAdolescents and young adults with differences of sex development make critical and potentially irreversible,\\nlife-altering surgical decisions about their bodies without standardized resources to support their engagement\\nin shared decision making. To fill this gap, the proposed research will examine the decisional needs of\\nadolescents and young adults with differences of sex development, as well as develop and pilot a set of\\nsurgical decision aids addressing identified needs. Standardized decision aid use will promote adolescent and\\nyoung adult engagement in shared decision making, leading to improved care, patient health, and\\npsychosocial outcomes.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-18T12:09:00Z\", \"budget_end\": \"2025-06-30T12:06:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 155051, \"indirect_cost_amt\": 12404, \"project_detail_url\": \"https://reporter.nih.gov/project-details/10985653\"}' metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/response_data.json', 'seq_num': 1, '_id': 'd6bf1c9fe22749388838ebaefa045cb0', '_collection_name': 'projects'}\n",
      "----\n",
      "Context:\n",
      "page_content='{\"appl_id\": 11088654, \"subproject_id\": null, \"fiscal_year\": 2024, \"project_num\": \"3U24TR004315-03S1\", \"organization\": {\"org_name\": \"UNIVERSITY OF UTAH\", \"city\": null, \"country\": null, \"org_city\": \"SALT LAKE CITY\", \"org_country\": \"UNITED STATES\", \"org_state\": \"UT\", \"org_state_name\": null, \"dept_type\": \"PEDIATRICS\", \"fips_country_code\": null, \"org_duns\": [\"009095365\"], \"org_ueis\": [\"LL8GLEVH6MG3\"], \"primary_duns\": \"009095365\", \"primary_uei\": \"LL8GLEVH6MG3\", \"org_fips\": \"US\", \"org_ipf_code\": \"514002\", \"org_zipcode\": \"841129049\", \"external_org_id\": 514002}, \"award_type\": \"3\", \"activity_code\": \"U24\", \"award_amount\": 797002, \"is_active\": true, \"project_num_split\": {\"appl_type_code\": \"3\", \"activity_code\": \"U24\", \"ic_code\": \"TR\", \"serial_num\": \"004315\", \"support_year\": \"03\", \"full_support_year\": \"03S1\", \"suffix_code\": \"S1\"}, \"principal_investigators\": [{\"profile_id\": 10458455, \"first_name\": \"Jamie\", \"middle_name\": \"P.\", \"last_name\": \"Dwyer\", \"is_contact_pi\": false, \"full_name\": \"Jamie P. Dwyer\", \"title\": \"PROFESSOR OF MEDICINE\"}, {\"profile_id\": 9256467, \"first_name\": \"KATHERINE\", \"middle_name\": \"ANN\", \"last_name\": \"SWARD\", \"is_contact_pi\": false, \"full_name\": \"KATHERINE ANN SWARD\", \"title\": \"PROFESSOR\"}, {\"profile_id\": 10531258, \"first_name\": \"Kevin\", \"middle_name\": \"M\", \"last_name\": \"Watt\", \"is_contact_pi\": true, \"full_name\": \"Kevin M Watt\", \"title\": \"ASSOCIATE PROFESSOR\"}], \"contact_pi_name\": \"WATT, KEVIN M\", \"agency_ic_admin\": {\"code\": \"TR\", \"abbreviation\": \"NCATS\", \"name\": \"National Center for Advancing Translational Sciences\"}, \"agency_ic_fundings\": [{\"fy\": 2024, \"code\": \"NS\", \"name\": \"National Institute of Neurological Disorders and Stroke\", \"abbreviation\": \"NINDS\", \"total_cost\": 797002}], \"project_start_date\": \"2024-09-01T12:09:00Z\", \"project_end_date\": \"2027-08-31T12:08:00Z\", \"organization_type\": {\"name\": \"SCHOOLS OF MEDICINE\", \"code\": \"10\", \"is_other\": false}, \"opportunity_number\": \"PA-20-272\", \"full_study_section\": {\"srg_code\": \"ZTR1\", \"srg_flex\": null, \"sra_designator_code\": null, \"sra_flex_code\": null, \"group_code\": \"01\", \"name\": \"ZTR1(01)\"}, \"award_notice_date\": \"2024-09-04T12:09:00Z\", \"core_project_num\": \"U24TR004315\", \"terms\": \"<Acute pain management><Administrative Supplement><Clinical Trials><Clinical Trials Data Monitoring Committees><Clinical Trials Network><Collaborations><Collection><Common Data Element><Data><Data Analyses><Data Analysis><Data Bases><Data Collection><Data Monitoring Committees><Data Set><Data and Safety Monitoring Boards><Databases><Deposit><Deposition><Development><Dose><HEAL Initiative><Helping End Addiction Long-term><Helping End Addiction Longterm><Helping to End Addiction Long-term><Helping to End Addiction Longterm><IRB><IRBs><Institutional Review Boards><Investigators><Leadership><Monitor><NIH><National Institutes of Health><Opiate Addiction><Opiate Dependence><Opiates><Opioid><Pain><Pain Control><Pain Therapy><Pain management><Painful><Preparation><Protocol><Protocols documentation><Public Health><Publications><Quality Control><Randomized><Regimen><Reporting><Research Personnel><Research Resources><Researchers><Resources><Risk Assessment><Risk Reduction><Safety Monitoring Boards><Scientific Publication><Speed><System><Training><Translational Research><Translational Science><United States National Institutes of Health><Universities><Utah><Work><Writing><addiction><addictive disorder><chronic pain><comparative effectiveness trial><cost><data base><data ecosystem><data interpretation><data management><data sharing><data sharing ecosystem><depository><design><designing><developmental><effectiveness research><opioid addiction><opioid dependence><opioid dependent><pain treatment><preparations><prevention effectiveness trial><programs><randomisation><randomization><randomly assigned><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><repository><risk-reducing><success><translation research><translational investigation>\", \"pref_terms\": \"Acute pain management;Administrative Supplement;Clinical Trials;Clinical Trials Data Monitoring Committees;Clinical Trials Network;Collaborations;Collection;Common Data Element;Data;Data Analyses;Data Collection;Data Set;Databases;Deposition;Development;Dose;Helping to End Addiction Long-term;Institutional Review Boards;Leadership;Monitor;Opiate Addiction;Opioid;Pain;Pain management;Preparation;Protocols documentation;Public Health;Publications;Quality Control;Randomized;Regimen;Reporting;Research Personnel;Resources;Risk Assessment;Risk Reduction;Speed;System;Training;Translational Research;United States National Institutes of Health;Universities;Utah;Work;Writing;addiction;chronic pain;comparative effectiveness trial;cost;data ecosystem;data management;data sharing;design;effectiveness research;prevention effectiveness trial;programs;repository;success\", \"abstract_text\": \"Abstract\\nThe NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scientic solutions to the\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\nreducing risk of addiction. Five ERN trials have been implemented with data coordination support from the\\nUniversity of Utah Data Coordinating Resource Center. This proposal is written to provide continued support for\\nthree of these trials that are expected to require no-cost extensions. As the Data Coordination Resource Center,\\nwe will continue to work collaboratively with each ERN study team and the other HEAL ERN Resource Centers\\nto 1) develop, implement and monitor the ERN trials; 2) help respond to issues/protocol changes that emerge\\nduring trial implementation and initiate timely necessary changes to assure trial success; 3) provide collection\\nand analysis of data; and 4) assist with timely publication of study results. Our supplement application has two\\nSpecic Aims: Specifc Aim 1: Work with ERN investigators and other HEAL ERN Resource Centers to provide\\ncollaborative clinical trial expertise and assistance in study and protocol design, single IRB, study implementation\\nand management, accrual of subjects, interim study reporting, nal study analyses, and assistance with timely\\npublication and dissemination of study results. Specific Aim 2: Provide comprehensive data management for\\ncurrent and new ERN trials, including database and data collection systems, data management plans, data\\nrisk assessment and quality control, implementation of randomization, assistance with Data Safety Monitoring\\nBoard (DSMB) reports, and training for using the data collection systems. Additionally, we will facilitate sharing\\nof data from HEAL/ERN trials by incorporating HEAL Common Data Elements(CDEs) into protocols, continuing\\nto support NIH program staff in development of HEAL CDEs, continued participation in the HEAL Collective\\nBoard, and preparation of nal data sets suitable for deposit in NIH-designated repositories for incorporation into\\nthe HEAL Data Ecosystem. Our continued collaboration with ERN investigators and integration with the other\\nResource Centers will maximize the likelihood of successful and timely completion of the HEAL ERN clinical\\ntrials, leading to translation of research ndings to the effective management of acute and chronic pain, while\\nminimizing addictive opioid dosing regimens.\", \"project_title\": \"HEAL ERN: Data Coordinating Resource Center\", \"phr_text\": \"Narrative\\nThe NIH created the Helping to End Addiction Long-term (HEAL) initiative to speed scientic solutions to the\\nnational opioid public health crisis. As part of the HEAL initiative, the HEAL Effectiveness Research Network\\n(ERN) was established to conduct comparative effectiveness trials for prevention and management of pain, while\\nreducing risk of addiction. The University of Utah will provide data coordination support for these trials, leading to\\nmore effective management of acute and chronic pain while reducing the risk of opioid addiction.\", \"spending_categories_desc\": null, \"agency_code\": \"NIH\", \"budget_start\": \"2024-09-01T12:09:00Z\", \"budget_end\": \"2025-08-31T12:08:00Z\", \"funding_mechanism\": \"Other Research-Related\", \"direct_cost_amt\": 517534, \"indirect_cost_amt\": 279468, \"project_detail_url\": \"https://reporter.nih.gov/project-details/11088654\"}' metadata={'source': '/Users/christinemahler/Desktop/AIE5/Midterm/data/response_data.json', 'seq_num': 2, '_id': '6deb3696d97348c3b89f5cb1012d3ca4', '_collection_name': 'projects'}\n",
      "----\n"
     ]
    }
   ],
   "source": [
    "for context in response[\"context\"]:\n",
    "  print(\"Context:\")\n",
    "  print(context)\n",
    "  print(\"----\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Opportunities Vector Store"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/christinemahler/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "Some weights of BertModel were not initialized from the model checkpoint at christinemahler/aie5-midterm and are newly initialized: ['pooler.dense.bias', 'pooler.dense.weight']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"
     ]
    }
   ],
   "source": [
    "from langchain_huggingface import HuggingFaceEmbeddings\n",
    "\n",
    "finetune_embeddings = HuggingFaceEmbeddings(model_name=\"christinemahler/aie5-midterm\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "url = \"https://e788c0ea-f5df-4d96-85ac-350da677aadf.us-west-2-0.aws.cloud.qdrant.io\"\n",
    "\n",
    "opportunities_qdrant = QdrantVectorStore.from_documents(\n",
    "    opportunities,\n",
    "    finetune_embeddings,\n",
    "    url=url,\n",
    "    prefer_grpc=False,\n",
    "    api_key=os.environ[\"QDRANT_API_KEY\"],\n",
    "    collection_name=\"opportunities\",\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Test Similarity Search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'Header 1': 'PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Part 2. Full Text of Announcement', '_id': '8e80b9e1-b60c-466c-bbbb-0319a80f8709', '_collection_name': 'opportunities'}, page_content='PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Part 2. Full Text of Announcement'),\n",
      " Document(metadata={'Header 1': 'PAR-25-352: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional) Part 2. Full Text of Announcement', '_id': '8584a02b-5afc-430b-8247-507a142be92a', '_collection_name': 'opportunities'}, page_content='PAR-25-352: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional) Part 2. Full Text of Announcement'),\n",
      " Document(metadata={'Header 2': 'PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Section I. Notice of Funding Opportunity Description', '_id': 'd285afdc-7304-48a5-a5f7-c7cfeb8ec807', '_collection_name': 'opportunities'}, page_content='PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Section I. Notice of Funding Opportunity Description\\n    \\n \\n \\n \\n \\n     Purpose\\n     \\n \\n \\n    The intent of this NOFO is to encourage applications from academic, biotechnology, biomedical device industry, or pharmaceutical industry investigators interested in participating with the National Institute of Mental Health (NIMH) \\xa0in a National Cooperative Drug/Device Discovery/Development Group (NCDDG) program. The objectives of this program are: to advance the discovery, preclinical development, early-stage human studies, and/or proof of concept (PoC)\\xa0testing of new, rationally based candidate agents or devices to treat mental disorders; and to develop novel ligands and novel brain circuit-modulator technologies as tools to advance biological research on the function of genes, cells, biochemical pathways, distributed neural circuits, and neural oscillatory patterns implicated in the etiology and pathophysiology of mental disorders, and as potential new therapeutics. Partnerships between academia and industry are strongly encouraged.\\n    \\n \\n    Each NCDDG program should consist of a multidisciplinary team of scientists with appropriate expertise to further the development and evaluation of novel candidate agents or proposed biomedical devices. Scientists from both academia and the pharmaceutical industry are encouraged to participate within an NCDDG; scientists from foreign institutions and NIH Intramural laboratories may participate in some aspects. It is anticipated that the interaction of academic and non-profit research institutions with industry and NIH via the NCDDG model will: 1) accelerate the discovery and development of new therapeutics for mental disorders; 2) increase the availability of pharmacologic and device-based research tools (including imaging agents) for basic and clinical research; 3) facilitate the development and validation of neurophysiological and pharmacokinetic (PK) and pharmacodynamic (PD) measures to evaluate novel therapeutics for mental disorders; 4) increase the availability of new compounds, agents, and devices suitable for testing in humans; 5) facilitate the development and validation of new clinical measures or biomarkers suitable for use in human PoC trials of novel therapeutics for mental disorders; and/or 6) develop and validate novel neurostimulation technologies and protocols for mental disorders.\\n    \\n \\n    The goal of the NCDDG program is not to duplicate or compete with the private sector but to complement and accelerate the development of research tools for new molecular and circuit targets implicated in mental disorders, and effective compounds, agents, and devices for the prevention and treatment of psychiatric and addictive disorders, as well as core features of these illnesses, especially in areas of unmet medical need.\\n    \\n \\n \\n     Background and Research Objectives\\n     \\n \\n \\n    Significant advances in neuroscience, genomics, genetics, and related omics, behavioral neuroscience, together with technological developments (structural biology,\\n     \\n     in silico\\n     \\n    and high throughput screening (HTS),\\n     \\n     in vivo\\n     \\n    imaging methods), have provided a rich knowledge base for understanding pathophysiology, identifying new molecular targets for drug discovery, new circuit/oscillatory targets for device development, and developing rational pharmacotherapies and neuromodulation interventions for the treatment of psychiatric disorders. With the wealth of potential new drug/device targets, the opportunity exists to accelerate the process of target validation and medication discovery to make great strides toward novel and effective treatments for mental disorders.\\n    \\n \\n    An application submitted to this NOFO can include two to three scientific projects along with Scientific and/or Administrative Cores. Applications proposing only a single research project and no cores should respond to the companion NOFO utilizing the U01 mechanism (see\\n     \\n     PAR-25-352\\n     \\n    ).\\n    \\n \\n    Points to consider relevant to this announcement:\\n    \\n \\n \\n     The development of analogs of established or well-studied agents for the treatment of mental disorders is not appropriate for this NOFO.\\n     \\n \\n \\n \\n     NIMH\\'s Objectives and Interests for the NCDDG Program\\n     \\n \\n \\n    NIMHs objective for the NCDDG program is to support innovative, high-impact research focused on the discovery of pharmacological agents selective for novel molecular targets and new neuromodulation devices targeting novel neural circuit and neural oscillatory targets with the potential to prevent or reverse pathophysiological processes underlying mood and anxiety disorders, schizophrenia, eating disorders, obsessive-compulsive disorder, fragile x, autism, and other mental illnesses. Public-private partnerships are particularly encouraged.\\n    \\n \\n    NIMH-relevant NCDDG research projects should focus on novel interventions, using either pharmacological agents or neuromodulation devices that interrogate a molecular, circuit, or clinical target that is linked to a biological mechanism or pathophysiology of the proposed mental disorder.\\n    \\n \\n    The NIMH strongly encourages an experimental medicine approach to therapeutic development. This NOFO will support up through First-in-Human (FIH) for devices or Phase Ia or Ib trials for pharmacological agents. For these trials, studies are expected to assess the agent/device for 1) safety and tolerability, 2) target engagement, and 3) pharmacodynamic effects on relevant circuits or systems. Data resulting from Phase I trials in healthy controls and in the target patient population are expected to determine optimal clinical dosing and to establish feasibility for further testing in PoC and efficacy trials. Agents/devices should be sufficiently potent and selective for critical evaluation of target engagement and brain exposure. The agent/indication (if successful) should have a major, not merely incremental, impact on unmet medical needs in psychiatric disorders. In support of this effort, NIMH recognizes the need for the timely development of new positron emission tomography\\xa0(PET) radiotracers for targets that are of interest for assessing target engagement/dose selection for clinical trials of novel therapeutics and for studies of the pathophysiology of psychiatric disorders.\\n    \\n \\n    Consistent with NIMHs Research Domain Criteria (RDoC) initiative, research projects directed towards ameliorating pathophysiology that is potentially more proximal to specific functional deficits (domains) than DSM diagnostic entities are encouraged. Additional information about the RDoC approach can be found on the\\n     \\n     RDoC website\\n     \\n    . The testing of functional domains not included specifically in RDoC may also be considered, if well justified.\\n    \\n \\n    NIMH encourages applications ranging from ligand discovery and testing in preclinical assays through human Phase I studies of novel agents. Examples include, but are not limited to:\\n    \\n \\n \\n     A multidisciplinary approach that integrates machine learning (ML) tools, including human-in-the-loop ML (an ML model that requires researcher interaction), \\xa0into drug discovery processes at any of its stages, from hit/lead identification to lead optimization.\\n      \\n \\n       Use of generative ML models in de-novo design of drug chemical structures with desired properties\\n       \\n \\n       Ligand-based virtual screening and computational hit expansion following high-throughput screening (HTS) campaigns.\\n       \\n \\n       Use of ML in the design of new molecules employing phenotypic and high content screening data and assessing their potency, selectivity, and binding affinity\\n       \\n \\n       Use of ML models for predicting bioactivity and ADMET parameters of compounds\\n       \\n \\n \\n \\n     Ligand discovery for therapeutics development or as clinical research tools (e.g., imaging probes) for novel molecular targets implicated in mental illnesses.\\n     \\n \\n     Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).\\n     \\n \\n     Development and application of novel assays for evaluating brain pharmacodynamic (PD)/pharmacokinetic (PK) relationships in preclinical and early phase human studies.\\n     \\n \\n     Initial Good Laboratory Practice (GLP) toxicology, safety pharmacology, and pharmacokinetics to support an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) to begin human clinical testing.\\n     \\n \\n     Phase I studies (FIH pharmacology experiments) that include pharmacokinetic/ pharmacokinetic (PD/PK) biomarkers to assess target engagement, functional pharmacological activity or physiological effect, safety, and tolerability of new drugs.\\n     \\n \\n     Novel tool and biomarker development to enable studies to assess target engagement, brain PD and PK for innovative drug targets; for example, PET tracers for evaluating receptor occupancy and interrogating dose-response relationships.\\n     \\n \\n     Phase Ib studies in the proposed disease population to confirm target engagement, establish optimal dosing, PK/PD, CNS exposure, functional pharmacological or neurophysiological activity, and tolerability of the novel compound, agent, or device.\\n     \\n \\n     The inclusion of PD measures to assess functional pharmacological activity of the agent is encouraged in dose-finding studies.\\n     \\n \\n     The Phase IIa PoC study should provide sufficient objective data on CNS pharmacological activity and associations with functional measures for projects to be \"de-risked\" to attract public or private funding for further clinical and commercial development.\\n     \\n \\n \\n    NIMH also encourages applications ranging from early-stage, pre-clinical, device development to FIH clinical trials. Examples include, but are not limited to:\\n    \\n \\n \\n     Regulatory activities, including pre-submission meetings with FDA, Investigational Device Exemption (IDE) submission, risk determinations, or other FDA regulatory submissions.\\n     \\n \\n     Device, software, and firmware design verification and validation activities.\\n     \\n \\n     Non-GLP animal studies to develop techniques relevant to the device, optimize relevant therapeutic parameters, and refine device design as necessary for subsequent GLP testing or additional clinical studies for regulatory approval.\\n     \\n \\n     Bench-top and/or animal testing to demonstrate compliance with FDA Recognized Standards.\\n     \\n \\n     GLP compliant large animal model safety and/or testing of an implanted device.\\n     \\n \\n     Activities to become current Good Manufacturing Practice (GMP) compliant.\\n     \\n \\n     Activities to bring the development process under Design and Quality Systems Control.\\n     \\n \\n     Development of packaging, connectors, and other accessories necessary for the translation of this technology.\\n     \\n \\n     FIH, PoC studies that may assess initial measures of safety and efficacy and lead to further refinement of the device.\\n     \\n \\n     Linkage of behavior with brain recordings via high-density recordings of both.\\n     \\n \\n     Modeling technologies capable of precisely characterizing delivered dose of neuromodulation technologies (e.g., electric field modeling) and accurately measuring the impact of the delivered dosage on neural functioning (e.g., simultaneous TMS-EEG, TMS-fMRI or other technologies to demonstrate engagement of the targeted distributed network or neural oscillatory target).\\n     \\n \\n \\n    For PoC studies, priority will be given to novel agents that are IND-ready or IDE-ready with pre-clinical profiles suggesting the possibility of therapeutic effect in mental disorders. Testing of novel indications for already approved agents/devices will be considered, based on feasibility, strong theoretical rationale, and unmet clinical or medical need.\\n    \\n \\n \\n     Summary\\n     \\n \\n \\n    In summary, the NCDDG Program will support broad, innovative, multidisciplinary approaches to the discovery of new, rationally based treatments and research tools for mental disorders. Since the creative talents in the required scientific disciplines are rarely available in a single institution, a multi-institutional, group approach involving academic, nonprofit, commercial, and/or industrial institutions is envisioned. Academic, pharmaceutical, and biomedical technology scientists are strongly encouraged to form partnerships that take full advantage of their combined intellectual and material resources for drug discovery, lead optimization, model development, and clinical testing. Further, the interaction of academic and non-profit research institutions with\\xa0the\\xa0pharmaceutical and biomedical device industry and NIH is expected to facilitate subsequent development and marketing of new pharmacologic and device treatments, although these latter activities are not within the scope of this\\xa0NOFO. Molecular targets for drug/device discovery, and the sources and types of chemical/circuit entities to be investigated will be selected by the applying group. Both novel\\xa0mechanisms of action and disease-oriented approaches are of interest.\\n    \\n \\n \\n     Research Scope\\n     \\n \\n \\n    The objective of this NOFO is to establish NCDDG Groups to conduct innovative, high impact research focused on the discovery and testing of chemical entities for novel molecular targets, as well as novel devices for novel circuit/neural dynamic targets implicated in the pathophysiology of mental disorders. The NCDDG serves as a vehicle for pharmaceutical, biomedical device and academic scientists to pool intellectual and material resources for the translation of basic science findings into the conceptualization, discovery, and evaluation of new chemical entities and devices. Groups are encouraged to select molecular targets for drug discovery and circuit targets for device discovery based on recent findings in basic and clinical neuroscience, genetics, and proteomics relevant to the understanding of mental disorders.\\n    \\n \\n    The identification of lead compounds/candidate agents/devices and refining them for target validation and medication development are important goals of this initiative.\\n    \\n \\n    Applicants seeking additional sources of support for preclinical development activities such as toxicology and safety pharmacology assessment, bulk synthesis, GMP synthesis, and formulation development should consider the\\n     \\n     NIH Blueprint Neurotherapeutics Network program\\n     \\n    and/or the\\n     \\n     NIH Bridging Interventional Development Gaps (BrIDGs) Program.\\n     \\n \\n \\n    Prior to submission of an application, applicants are strongly encouraged to contact the relevant Scientific/Research Contact listed in Section VII of this NOFO to determine if the proposed Research Project would be considered a priority for NIMH.\\n    \\n \\n    Applications with data collection plans that involve multiple respondent groups (e.g., clients/patients, therapists/providers, supervisors, administrators) should consider provisions for human subject protections and consenting procedures for all participant groups, accordingly.\\n    \\n \\n    The NIMH has published updated policies and guidance for investigators regarding human research protection and clinical research data and safety monitoring (\\n     \\n     NOT-MH-19-027\\n     \\n    ). The applications PHS Human Subjects and Clinical Trials Information, including the Data and Safety Monitoring Plan, should reflect the policies and guidance in this notice. Plans for the protection of research participants and data and safety monitoring will be reviewed by the NIMH for consistency with NIMH and NIH policies and federal regulations.\\n    \\n \\n \\n     Applications Not Responsive to this NOFO.\\n     \\n \\n \\n    The following types of studies are not responsive to this NOFO. Applications proposing such studies will be considered non-responsive and will not be reviewed or considered for funding.\\n    \\n \\n \\n     Applications proposing Clinical Trials that lack a Clinical and Data Monitoring Plan\\n     \\n \\n     Applications that lack a Milestone Plan\\n     \\n \\n     Applications proposing Clinical Trials that lack the \\'Common Data Elements Applicability\\' attachment\\n     \\n \\n \\n    The NIMH has published updated policies and guidance for investigators regarding human research protection and clinical research data and safety monitoring (\\n     \\n     NOT-MH-19-027\\n     \\n    ). The applications PHS Human Subjects and Clinical Trials Information, including the Data and Safety Monitoring Plan, should reflect the policies and guidance in this notice. Plans for the protection of research participants and data and safety monitoring will be reviewed by the NIMH for consistency with NIMH and NIH policies and federal regulations.\\n    \\n \\n \\n \\n    Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.\\n    \\n \\n \\n \\n    See\\n     \\n     Section VIII. Other Information\\n     \\n    for award authorities and regulations.'),\n",
      " Document(metadata={'Header 2': 'PAR-25-352: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional) Section I. Notice of Funding Opportunity Description', '_id': 'ddf085ac-7994-4cd6-aea4-033a5540dd87', '_collection_name': 'opportunities'}, page_content=\"PAR-25-352: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional) Section I. Notice of Funding Opportunity Description\\n    \\n \\n \\n \\n \\n     Purpose\\n     \\n \\n \\n    The intent of this NOFO is to encourage applications from academic, biotechnology, biomedical device industry, or pharmaceutical industry investigators interested in participating with the National Institute of Mental Health (NIMH) in a National Cooperative Drug/Device Discovery/Development Group (NCDDG) program. The objectives of this program are: to advance the discovery, preclinical development, early-stage human studies, and/or proof of concept testing of new, rationally based candidate agents or devices to treat mental disorders, and to develop novel ligands and novel brain circuit-modulatory technologies as tools to advance biological research on the function of genes, cells, biochemical pathways, distributed neural circuits, and neural oscillatory patterns implicated in the etiology and pathophysiology of mental disorders, and as potential new therapeutics. Partnerships between academia and industry are strongly encouraged. This program strongly encourages in-kind resource contributions of the partners within the NCDDG (e.g., biotechnology, pharmaceutical, or disease foundations).\\n    \\n \\n    Each NCDDG program should consist of a multidisciplinary team of scientists with appropriate expertise to further the development and evaluation of novel candidate agents or proposed biomedical devices. Scientists from both academia and pharmaceutical industry are encouraged to participate within an NCDDG; scientists from foreign institutions and NIH Intramural laboratories may participate in some aspects. It is anticipated that the interaction of academic and non-profit research institutions with industry and NIH via the NCDDG model will: 1) accelerate the discovery and development of new therapeutics for mental disorders; 2) increase the availability of pharmacologic and device-based research tools (including Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) imaging agents) for basic and clinical research; 3) facilitate the development and validation of neurophysiological, pharmacokinetic (PK), and pharmacodynamic (PD) measures to evaluate novel therapeutics for mental disorders; 4) increase the availability of new compounds, agents, and devices suitable for testing in humans; 5) facilitate the development and validation of new clinical measures or biomarkers suitable for use in human Proof of Concept (PoC) trials of novel therapeutics for mental disorders; and/or 6) develop and validate novel neurostimulation technologies and protocols for mental disorders.\\n    \\n \\n    The goal of the NCDDG program is not to duplicate or compete with the private sector but to complement and accelerate the development of research tools for new molecular and circuit targets implicated in mental disorders, and effective compounds, agents, and devices for the prevention and treatment of psychiatric and addictive disorders, as well as core features of these illnesses, especially in areas of unmet medical need.\\n    \\n \\n \\n     Background and Research Objectives\\n     \\n \\n \\n    Significant advances in neuroscience, genetics, genomics, and related omics, behavioral neuroscience, together with technological developments (structural biology,\\n     \\n     in silico\\n     \\n    and high throughput screening,\\n     \\n     in vivo\\n     \\n    imaging methods), have provided a rich knowledge base for understanding pathophysiology, identifying new molecular targets for drug discovery, new circuit/oscillatory targets for device development, and developing rational pharmacotherapies and neuromodulation interventions for the treatment of psychiatric disorders. With the wealth of potential new drug/device targets, the opportunity exists to accelerate the process of target validation and medication discovery to make great strides toward novel and effective treatments for mental disorders.\\n    \\n \\n    A U01 application can include no more than a single Research Project. Applications proposing two or more Research Projects along with Scientific and/or Administrative Core components should respond to the companion NOFO utilizing the U19 mechanism (\\n     \\n     PAR-25-353\\n     \\n    )\\n    \\n \\n \\n     NIMH's Objectives and Interests for the NCDDG Program\\n     \\n \\n \\n    NIMHs objective for the NCDDG program is to support innovative, high impact research focused on the discovery of pharmacological agents selective for novel molecular targets and new neuromodulation devices targeting novel neural circuit and neural oscillatory targets with potential to prevent or reverse pathophysiological processes underlying mood and anxiety disorders, schizophrenia, eating disorders, obsessive-compulsive disorder, fragile x, autism, and other mental illnesses. Public-Private partnerships are particularly encouraged.\\n    \\n \\n    NIMH-relevant NCDDG research projects should focus on novel interventions, using either pharmacological agents or neuromodulation devices that interrogate a molecular, circuit or clinical target that is linked to a biological mechanism or pathophysiology of the proposed mental disorder.\\n    \\n \\n    The NIMH strongly encourages an experimental medicine approach to therapeutic development. This NOFO will support up through First-in-Human (FIH) for devices or Phase Ia or Ib trials for pharmacological agents. For these trials, studies are expected to assess the agent/device for 1) safety and tolerability, 2) target engagement, and 3) pharmacodynamic effects on relevant circuits or systems. Data resulting from Phase I trials in healthy controls and in the target patient population are expected to determine optimal clinical dosing and to establish feasibility for further testing in PoC and efficacy trials. Agents/devices should be sufficiently potent and selective for critical evaluation of target engagement and brain exposure. The agent/indication (if successful) should have a major, not merely incremental, impact on unmet medical need in psychiatric disorders. In support of this effort, NIMH recognizes the need for the timely development of new PET tracers for targets that are of interest for assessing target engagement/dose selection for clinical trials of novel therapeutics and for studies of the pathophysiology of psychiatric disorders.\\n    \\n \\n    Consistent with NIMHs Research Domain Criteria (RDoC) initiative, research projects directed towards ameliorating pathophysiology that is potentially more proximal to specific functional deficits (domains) than Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic entities are encouraged. Additional information about the RDoC approach can be found on the\\n     \\n     RDoC website\\n     \\n    . The testing of functional domains not included specifically in RDoC may also be considered, if well justified.\\n    \\n \\n    NIMH encourages applications ranging from ligand discovery and testing in preclinical assays through human Phase I studies of novel agents. Examples include, but are not limited to:\\n    \\n \\n \\n     An application that integrates machine learning (ML) tools, including human-in-the-loop ML (an ML model that requires researcher interaction), into the drug discovery process at any of its stages, from hit/lead identification to lead optimization.\\n      \\n \\n       Use of generative ML models in de-novo design of drug chemical structures with desired properties\\n       \\n \\n       Ligand-based virtual screening and computational hit expansion following high-throughput screening (HTS) campaigns\\n       \\n \\n       Use of ML in the design of new molecules employing phenotypic and high-content screening data and assessing their potency, selectivity, and binding affinity\\n       \\n \\n       Use of ML models for predicting bioactivity and ADMET parameters of compounds\\n       \\n \\n \\n \\n     Ligand discovery for therapeutics development or as clinical research tools (e.g., imaging probes) for novel molecular targets implicated in mental illnesses.\\n     \\n \\n     Biotechnology products and biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).\\n     \\n \\n     The inclusion of measures to assess the functional pharmacological activity of the agent is encouraged in dose-finding studies.\\n     \\n \\n     Phase Ib studies in the proposed disease population to confirm target engagement, establish optimal dosing, pharmacokinetic/pharmacodynamic (PK/PD), CNS exposure, functional pharmacological or neurophysiological activity, and tolerability of the novel agent, compound, or device.\\n     \\n \\n     Novel tool and biomarker development to enable studies to assess target engagement, brain PD, and PK for innovative drug targets; for example, PET or SPECT tracers for evaluating receptor occupancy and interrogating dose-response relationships.\\n     \\n \\n     Phase I studies (FIH pharmacology experiments) that include (PD/PK biomarkers to assess target engagement, functional pharmacological activity or neurophysiological effect, safety, and tolerability of new drugs.\\n     \\n \\n     Initial Good Laboratory Practice (GLP) toxicology, safety pharmacology, and pharmacokinetics to support an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) to begin human clinical testing.\\n     \\n \\n     Development and application of novel assays for evaluating brain PD/PK relationships in preclinical and early-phase human studies.\\n     \\n \\n \\n    NIMH also encourages applications ranging from early-stage, pre-clinical, device development to FIH clinical trials. Examples include, but are not limited to:\\n    \\n \\n \\n     Regulatory activities, including pre-submission meetings with FDA, Investigational Device Exemption (IDE) submission, risk determinations, or other FDA regulatory submissions.\\n     \\n \\n     Modeling technologies capable of precisely characterizing delivered dose of neuromodulation technologies (e.g., electric field modeling) and to accurately measure the impact of the delivered dosage on neural functioning (e.g., simultaneous TMS-EEG, TMS-fMRI or other technologies to demonstrate engagement of the targeted distributed network or neural oscillatory target).\\n     \\n \\n     Linkage of behavior with brain recordings via high-density recordings of both.\\n     \\n \\n     FIH, proof of concept studies that may assess initial measures of safety and efficacy and lead to further refinement of the device.\\n     \\n \\n     Development of packaging, connectors, and other accessories necessary for the translation of this technology.\\n     \\n \\n     Activities to bring the development process under Design and Quality Systems Control.\\n     \\n \\n     Activities to become current Good Manufacturing Practice (GMP) compliant.\\n     \\n \\n     GLP compliant large animal model safety and/or testing of an implanted device.\\n     \\n \\n     Bench-top and/or animal testing to demonstrate compliance with FDA Recognized Standards.\\n     \\n \\n     Non-GLP animal studies to develop techniques relevant to the device, optimize relevant therapeutic parameters, and refine device design as necessary for subsequent GLP testing or additional clinical studies for regulatory approval.\\n     \\n \\n     Device, software, and firmware design verification and validation activities.\\n     \\n \\n \\n \\n     Summary\\n     \\n \\n \\n    In summary, the NCDDG Program will support broad, innovative, multidisciplinary approaches to the discovery of new, rationally based treatments and research tools for mental disorders. Since the creative talents in the required scientific disciplines are rarely available in a single institution, a multi-institutional, group approach involving academic, nonprofit, commercial, and/or industrial institutions is envisioned. Academic, pharmaceutical, and biomedical technology scientists are strongly encouraged to form partnerships that take full advantage of their combined intellectual and material resources for drug discovery, lead optimization, model development, and clinical testing. Further, the interaction of academic and non-profit research institutions with the pharmaceutical and biomedical device industry and NIH is expected to facilitate subsequent development and marketing of new pharmacologic and device treatments, although these latter activities are not within the scope of this NOFO. Molecular targets for drug/device discovery, and the sources and types of chemical/circuit entities to be investigated will be selected by the applying group. Both novel mechanisms of action and disease-oriented approaches are of interest.\\n    \\n \\n \\n     Research Scope\\n     \\n \\n \\n    The objective of this NOFO is to establish NCDDG Groups to conduct innovative, high-impact research focused on the discovery and testing of small molecules or biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies) \\xa0for novel molecular targets, as well as novel devices for novel circuit/neural dynamic targets implicated in the pathophysiology of mental disorders. The NCDDG serves as a vehicle for pharmaceutical, biomedical devices, and academic scientists to pool intellectual and material resources for the translation of basic science findings into the conceptualization, discovery, and evaluation of new chemical entities and devices. Groups are encouraged to select molecular targets for drug discovery and circuit targets for device discovery based on recent findings in basic and clinical neuroscience, genetics, and proteomics relevant to the understanding of mental disorders.\\n    \\n \\n    The identification of lead compounds/candidate agents/devices and refining them for target validation and medication development are important goals of this initiative.\\n    \\n \\n    It is anticipated that the interaction of academic and non-profit research institutions with NIH and pharmaceutical industry will facilitate timely evaluation and development of preclinical and clinical research tools, models, and novel therapeutics.\\n    \\n \\n    Applicants seeking additional sources of support for preclinical development activities such as toxicology and safety pharmacology assessment, bulk synthesis, GMP synthesis, and formulation development should consider the NIH Blueprint Neurotherapeutics Network program (\\n     \\n     http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm\\n     \\n    or\\n     \\n \\n      https://neuroscienceblueprint.nih.gov/neurotherapeutics/bpn-biologics\\n      \\n \\n    ) and/or the\\n     \\n     NIH Bridging Interventional Development Gaps (BrIDGs) Program\\n     \\n    .\\n    \\n \\n    Prior to submission of an application, applicants are strongly encouraged to contact the relevant Scientific/Research Contact listed in Section VII of this NOFO to determine if the proposed Research Project would be considered a priority for NIMH.\\n    \\n \\n    Applications with data collection plans that involve multiple respondent groups (e.g., clients/patients, therapists/providers, supervisors, administrators) should consider provisions for human subject protections and consenting procedures for all participant groups, accordingly.\\n    \\n \\n    The NIMH has published updated policies and guidance for investigators regarding human research protection and clinical research data and safety monitoring (\\n     \\n     NOT-MH-19-027\\n     \\n    ). The applications PHS Human Subjects and Clinical Trials Information, including the Data and Safety Monitoring Plan, should reflect the policies and guidance in this notice. Plans for the protection of research participants and data and safety monitoring will be reviewed by the NIMH for consistency with NIMH and NIH policies and federal regulations.\\n    \\n \\n \\n \\n    Investigators proposing NIH-defined clinical trials may refer to the\\n     \\n     Research Methods Resources\\n     \\n    website for information about developing statistical methods and study designs.\\n    \\n \\n \\n \\n    See\\n     \\n     Section VIII. Other Information\\n     \\n    for award authorities and regulations.\"),\n",
      " Document(metadata={'Header 1': 'PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Part 1. Overview Information', '_id': 'cf52b143-e3cb-48b6-9877-86fd0eb54c3f', '_collection_name': 'opportunities'}, page_content='PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Part 1. Overview Information\\n    \\n \\n \\n   Participating Organization(s)\\n    \\n    National Institutes of Health (\\n     \\n     NIH\\n     \\n    )\\n    \\n \\n \\n   Components of Participating Organizations\\n    \\n    National Institute of Mental Health (\\n     \\n     NIMH\\n     \\n    )\\n    \\n \\n \\n   Funding Opportunity Title\\n    \\n    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)\\n    \\n \\n \\n   Activity Code\\n    \\n \\n     U19\\n     \\n    Research Program  Cooperative Agreements\\n    \\n \\n \\n   Announcement Type\\n   Reissue of\\n    \\n    PAR-22-144\\n    \\n \\n \\n \\n   Related Notices\\n    \\n \\n \\n      April 4, 2024\\n      \\n     - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice\\n      \\n      NOT-OD-24-084\\n      \\n     .\\n     \\n \\n \\n      August 31, 2022\\n      \\n     - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice\\n      \\n      NOT-OD-22-198\\n      \\n     .\\n     \\n \\n \\n      August 5, 2022\\n      \\n     - Implementation Details for the NIH Data Management and Sharing Policy. See Notice\\n      \\n      NOT-OD-22-189\\n      \\n     .\\n     \\n \\n \\n \\n   Funding Opportunity Number (FON)\\n    \\n    PAR-25-353\\n    \\n \\n \\n   Companion Notice of Funding Opportunity\\n    \\n    PAR-25-352\\n    \\n \\n    ,\\n    \\n \\n    U01\\n    \\n   Research Project (Cooperative Agreements)\\n    \\n \\n \\n   Number of Applications\\n    \\n    See\\n     \\n     Section III. 3. Additional Information on Eligibility\\n     \\n    .\\n    \\n \\n \\n   Assistance Listing Number(s)\\n   93.242\\n    \\n \\n   Notice of Funding Opportunity Purpose\\n    \\n    The purpose of this notice of funding opportunity (NOFO) is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders. This NOFO encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.\\n    \\n \\n    This NOFO supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary, and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion NOFO (\\n     \\n     PAR-25-352\\n     \\n    ).\\n    \\n \\n    This NOFO will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).\\n    \\n \\n \\n   Funding Opportunity Goal(s)\\n    \\n    The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure.\\n    \\n This variable defines that we need to start a new row.')]\n"
     ]
    }
   ],
   "source": [
    "query = \"What is NCDDG\"\n",
    "found_docs = opportunities_qdrant.similarity_search(query, k=5)\n",
    "pprint.pprint(found_docs)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Opportunities Retriever"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "opportunities_retriever = opportunities_qdrant.as_retriever(search_kwargs={\"k\": 2})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Opportunities Retriever Node"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve(state):\n",
    "  retrieved_docs = opportunities_retriever.invoke(state[\"question\"])\n",
    "  return {\"context\" : retrieved_docs}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Opportunities RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'ChatPromptTemplate' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[1], line 23\u001b[0m\n\u001b[1;32m      1\u001b[0m opportunities_rag_prompt_template \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\"\"\u001b[39m\u001b[38;5;130;01m\\\u001b[39;00m\n\u001b[1;32m      2\u001b[0m \u001b[38;5;124mUse the provided context to answer the user\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124ms question. Only use the provided context to answer the question.\u001b[39m\n\u001b[1;32m      3\u001b[0m \n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m     20\u001b[0m \u001b[38;5;132;01m{question}\u001b[39;00m\n\u001b[1;32m     21\u001b[0m \u001b[38;5;124m\"\"\"\u001b[39m\n\u001b[0;32m---> 23\u001b[0m opportunities_rag_prompt \u001b[38;5;241m=\u001b[39m \u001b[43mChatPromptTemplate\u001b[49m\u001b[38;5;241m.\u001b[39mfrom_template(opportunities_rag_prompt_template)\n",
      "\u001b[0;31mNameError\u001b[0m: name 'ChatPromptTemplate' is not defined"
     ]
    }
   ],
   "source": [
    "opportunities_rag_prompt_template = \"\"\"\\\n",
    "Use the provided context to answer the user's question. Only use the provided context to answer the question.\n",
    "\n",
    "If the user asks you to provide a list of opportunities, provide a list with the unique id, title, funding type, application due date, and a link to the funding page.\n",
    "\n",
    "If the user asks you to evaluate the study complexity, provide a complexity score of high, medium, or low and a reason for all of the following categories:\n",
    "1) Regulatory and Compliance (rank higher if study requires compliance with multiple regulations and provide examples)\n",
    "2) Data Collection and Management (identify data elements needed, data complexity, data sensitivity, and data collection frequency)\n",
    "3) Statistical Analysis and Manuscript Development (provide examples)\n",
    "4) Information Technology (identify data collection services and equipment needed along with software licenses and subscriptions)\n",
    "5) Operational (includes project administration and site onboarding, coordination and training)\n",
    "6) Financial (includes budget management and effort allocation over entire duration of project; rank higher if more resources are required)\n",
    "\n",
    "If you do not know the answer, or it's not contained in the provided context response with \"I don't know\"\n",
    "\n",
    "Context:\n",
    "{context}\n",
    "\n",
    "Question:\n",
    "{question}\n",
    "\"\"\"\n",
    "\n",
    "opportunities_rag_prompt = ChatPromptTemplate.from_template(opportunities_rag_prompt_template)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Initialize Opportunities Chat Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai.chat_models import ChatOpenAI\n",
    "\n",
    "opportunities_llm = ChatOpenAI(model=\"gpt-4o-mini\", tags=[\"opportunities_llm\"])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Opportunities Generate Node"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate(state):\n",
    "  docs_content = \"\\n\\n\".join(doc.page_content for doc in state[\"context\"])\n",
    "  messages = opportunities_rag_prompt.format_messages(question=state[\"question\"], context=docs_content)\n",
    "  response = opportunities_llm.invoke(messages)\n",
    "  return {\"response\" : response.content}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Initialize LangGraph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langgraph.graph import START, StateGraph\n",
    "from typing_extensions import List, TypedDict\n",
    "from langchain_core.documents import Document\n",
    "\n",
    "class State(TypedDict):\n",
    "  question: str\n",
    "  context: List[Document]\n",
    "  response: str"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Add Retrieve and Generate Nodes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "graph_builder = StateGraph(State).add_sequence([retrieve, generate])\n",
    "graph_builder.add_edge(START, \"retrieve\")\n",
    "graph = graph_builder.compile()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from IPython.display import Image, display\n",
    "\n",
    "try:\n",
    "    display(Image(graph.get_graph(xray=True).draw_mermaid_png()))\n",
    "except:\n",
    "    pass"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Test LangGraph RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = graph.invoke({\"question\" : \"evaluate the study complexity of the PAR-25-353 funding opportunity\"})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Print Response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "pprint.pprint(response[\"response\"])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Agent Time"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from operator import itemgetter\n",
    "from langchain.schema.output_parser import StrOutputParser\n",
    "\n",
    "opportunities_rag_chain = (\n",
    "    {\"context\": itemgetter(\"question\") | opportunities_retriever, \"question\": itemgetter(\"question\")}\n",
    "    | opportunities_rag_prompt | opportunities_llm | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "opportunities_rag_chain.invoke({\"question\" : \"evaluate the study complexity of the PAR-25-353 funding opportunity\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import Annotated, List, Tuple, Union\n",
    "from langchain_core.tools import tool\n",
    "\n",
    "@tool\n",
    "def retrieve_opportunities_information(\n",
    "    query: Annotated[str, \"query to ask the retrieve information tool\"]\n",
    "    ):\n",
    "  \"\"\"Use Retrieval Augmented Generation to retrieve information about the NIH funding opportunties\"\"\"\n",
    "  return opportunities_rag_chain.invoke({\"question\" : query})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import Any, Callable, List, Optional, TypedDict, Union\n",
    "\n",
    "from langchain.agents import AgentExecutor, create_openai_functions_agent\n",
    "from langchain.output_parsers.openai_functions import JsonOutputFunctionsParser\n",
    "from langchain_core.prompts import ChatPromptTemplate, MessagesPlaceholder\n",
    "from langchain_core.messages import AIMessage, BaseMessage, HumanMessage\n",
    "from langchain_core.runnables import Runnable\n",
    "from langchain_core.tools import BaseTool\n",
    "from langchain_openai import ChatOpenAI\n",
    "\n",
    "from langgraph.graph import END, StateGraph"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Agent Node Creator Helper Function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def agent_node(state, agent, name):\n",
    "    result = agent.invoke(state)\n",
    "    return {\"messages\": [HumanMessage(content=result[\"output\"], name=name)]}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_agent(\n",
    "    llm: ChatOpenAI,\n",
    "    tools: list,\n",
    "    system_prompt: str,\n",
    ") -> str:\n",
    "    \"\"\"Create a function-calling agent and add it to the graph.\"\"\"\n",
    "    system_prompt += (\"\\nWork autonomously according to your specialty, using the tools available to you.\"\n",
    "    \" Do not ask for clarification.\"\n",
    "    \" Your other team members (and other teams) will collaborate with you with their own specialties.\"\n",
    "    \" You are chosen for a reason! You are one of the following team members: {team_members}.\")\n",
    "    prompt = ChatPromptTemplate.from_messages(\n",
    "        [\n",
    "            (\n",
    "                \"system\",\n",
    "                system_prompt,\n",
    "            ),\n",
    "            MessagesPlaceholder(variable_name=\"messages\"),\n",
    "            MessagesPlaceholder(variable_name=\"agent_scratchpad\"),\n",
    "        ]\n",
    "    )\n",
    "    agent = create_openai_functions_agent(llm, tools, prompt)\n",
    "    executor = AgentExecutor(agent=agent, tools=tools)\n",
    "    return executor"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_team_supervisor(llm: ChatOpenAI, system_prompt, members) -> str:\n",
    "    \"\"\"An LLM-based router.\"\"\"\n",
    "    options = [\"FINISH\"] + members\n",
    "    function_def = {\n",
    "        \"name\": \"route\",\n",
    "        \"description\": \"Select the next role.\",\n",
    "        \"parameters\": {\n",
    "            \"title\": \"routeSchema\",\n",
    "            \"type\": \"object\",\n",
    "            \"properties\": {\n",
    "                \"next\": {\n",
    "                    \"title\": \"Next\",\n",
    "                    \"anyOf\": [\n",
    "                        {\"enum\": options},\n",
    "                    ],\n",
    "                },\n",
    "            },\n",
    "            \"required\": [\"next\"],\n",
    "        },\n",
    "    }\n",
    "    prompt = ChatPromptTemplate.from_messages(\n",
    "        [\n",
    "            (\"system\", system_prompt),\n",
    "            MessagesPlaceholder(variable_name=\"messages\"),\n",
    "            (\n",
    "                \"system\",\n",
    "                \"Given the conversation above, who should act next?\"\n",
    "                \" Or should we FINISH? Select one of: {options}\",\n",
    "            ),\n",
    "        ]\n",
    "    ).partial(options=str(options), team_members=\", \".join(members))\n",
    "    return (\n",
    "        prompt\n",
    "        | llm.bind_functions(functions=[function_def], function_call=\"route\")\n",
    "        | JsonOutputFunctionsParser()\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import functools\n",
    "import operator\n",
    "\n",
    "from langchain_core.messages import AIMessage, BaseMessage, HumanMessage\n",
    "from langchain_openai.chat_models import ChatOpenAI\n",
    "import functools\n",
    "\n",
    "class ResearchTeamState(TypedDict):\n",
    "    messages: Annotated[List[BaseMessage], operator.add]\n",
    "    team_members: List[str]\n",
    "    next: str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm = ChatOpenAI(model=\"gpt-4-turbo\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "opportunities_agent = create_agent(\n",
    "    llm,\n",
    "    [retrieve_opportunities_information],\n",
    "    \"You are a research assistant who can provide specific information on funding opportunties. You must only respond with information about the opportunities related to the request.\",\n",
    ")\n",
    "research_node = functools.partial(agent_node, agent=opportunities_agent, name=\"OpportunitiesInformationRetriever\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "supervisor_agent = create_team_supervisor(\n",
    "    llm,\n",
    "    (\"You are a supervisor tasked with managing a conversation between the\"\n",
    "    \" following workers:  OpportunitiesInformationRetriever. Given the following user request,\"\n",
    "    \" determine the subject to be researched and respond with the worker to act next. Each worker will perform a\"\n",
    "    \" task and respond with their results and status. \"\n",
    "    \" You should never ask your team to do anything beyond research. They are not required to write content or posts.\"\n",
    "    \" You should only pass tasks to workers that are specifically research focused.\"\n",
    "    \" When finished, respond with FINISH.\"),\n",
    "    [\"OpportunitiesInformationRetriever\"],\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "research_graph = StateGraph(ResearchTeamState)\n",
    "\n",
    "research_graph.add_node(\"OpportunitiesInformationRetriever\", research_node)\n",
    "research_graph.add_node(\"supervisor\", supervisor_agent)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "research_graph.add_edge(\"OpportunitiesInformationRetriever\", \"supervisor\")\n",
    "research_graph.add_conditional_edges(\n",
    "    \"supervisor\",\n",
    "    lambda x: x[\"next\"],\n",
    "    {\"OpportunitiesInformationRetriever\": \"OpportunitiesInformationRetriever\", \"FINISH\": END},\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "research_graph.set_entry_point(\"supervisor\")\n",
    "chain = research_graph.compile()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from IPython.display import Image, display\n",
    "\n",
    "try:\n",
    "    display(Image(chain.get_graph(xray=True).draw_mermaid_png()))\n",
    "except:\n",
    "    pass"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def enter_chain(message: str):\n",
    "    results = {\n",
    "        \"messages\": [HumanMessage(content=message)],\n",
    "    }\n",
    "    return results\n",
    "\n",
    "research_chain = enter_chain | chain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for s in research_chain.stream(\n",
    "    \"What are the main takeaways from the paper `Extending Llama-3's Context Ten-Fold Overnight'? Please use Search and PaperInformationRetriever!\", {\"recursion_limit\": 100}\n",
    "):\n",
    "    if \"__end__\" not in s:\n",
    "        print(s)\n",
    "        print(\"---\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from pathlib import Path\n",
    "from tempfile import TemporaryDirectory\n",
    "from typing import Dict, Optional\n",
    "from typing_extensions import TypedDict\n",
    "import uuid\n",
    "import os\n",
    "\n",
    "os.makedirs('/content/data', exist_ok=True)\n",
    "\n",
    "def create_random_subdirectory():\n",
    "    random_id = str(uuid.uuid4())[:8]  # Use first 8 characters of a UUID\n",
    "    subdirectory_path = os.path.join('/content/data', random_id)\n",
    "    os.makedirs(subdirectory_path, exist_ok=True)\n",
    "    return subdirectory_path\n",
    "\n",
    "WORKING_DIRECTORY = Path(create_random_subdirectory())\n",
    "\n",
    "@tool\n",
    "def create_outline(\n",
    "    points: Annotated[List[str], \"List of main points or sections.\"],\n",
    "    file_name: Annotated[str, \"File path to save the outline.\"],\n",
    ") -> Annotated[str, \"Path of the saved outline file.\"]:\n",
    "    \"\"\"Create and save an outline.\"\"\"\n",
    "    with (WORKING_DIRECTORY / file_name).open(\"w\") as file:\n",
    "        for i, point in enumerate(points):\n",
    "            file.write(f\"{i + 1}. {point}\\n\")\n",
    "    return f\"Outline saved to {file_name}\"\n",
    "\n",
    "\n",
    "@tool\n",
    "def read_document(\n",
    "    file_name: Annotated[str, \"File path to save the document.\"],\n",
    "    start: Annotated[Optional[int], \"The start line. Default is 0\"] = None,\n",
    "    end: Annotated[Optional[int], \"The end line. Default is None\"] = None,\n",
    ") -> str:\n",
    "    \"\"\"Read the specified document.\"\"\"\n",
    "    with (WORKING_DIRECTORY / file_name).open(\"r\") as file:\n",
    "        lines = file.readlines()\n",
    "    if start is not None:\n",
    "        start = 0\n",
    "    return \"\\n\".join(lines[start:end])\n",
    "\n",
    "\n",
    "@tool\n",
    "def write_document(\n",
    "    content: Annotated[str, \"Text content to be written into the document.\"],\n",
    "    file_name: Annotated[str, \"File path to save the document.\"],\n",
    ") -> Annotated[str, \"Path of the saved document file.\"]:\n",
    "    \"\"\"Create and save a text document.\"\"\"\n",
    "    with (WORKING_DIRECTORY / file_name).open(\"w\") as file:\n",
    "        file.write(content)\n",
    "    return f\"Document saved to {file_name}\"\n",
    "\n",
    "\n",
    "@tool\n",
    "def edit_document(\n",
    "    file_name: Annotated[str, \"Path of the document to be edited.\"],\n",
    "    inserts: Annotated[\n",
    "        Dict[int, str],\n",
    "        \"Dictionary where key is the line number (1-indexed) and value is the text to be inserted at that line.\",\n",
    "    ] = {},\n",
    ") -> Annotated[str, \"Path of the edited document file.\"]:\n",
    "    \"\"\"Edit a document by inserting text at specific line numbers.\"\"\"\n",
    "\n",
    "    with (WORKING_DIRECTORY / file_name).open(\"r\") as file:\n",
    "        lines = file.readlines()\n",
    "\n",
    "    sorted_inserts = sorted(inserts.items())\n",
    "\n",
    "    for line_number, text in sorted_inserts:\n",
    "        if 1 <= line_number <= len(lines) + 1:\n",
    "            lines.insert(line_number - 1, text + \"\\n\")\n",
    "        else:\n",
    "            return f\"Error: Line number {line_number} is out of range.\"\n",
    "\n",
    "    with (WORKING_DIRECTORY / file_name).open(\"w\") as file:\n",
    "        file.writelines(lines)\n",
    "\n",
    "    return f\"Document edited and saved to {file_name}\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def prelude(state):\n",
    "    written_files = []\n",
    "    if not WORKING_DIRECTORY.exists():\n",
    "        WORKING_DIRECTORY.mkdir()\n",
    "    try:\n",
    "        written_files = [\n",
    "            f.relative_to(WORKING_DIRECTORY) for f in WORKING_DIRECTORY.rglob(\"*\")\n",
    "        ]\n",
    "    except:\n",
    "        pass\n",
    "    if not written_files:\n",
    "        return {**state, \"current_files\": \"No files written.\"}\n",
    "    return {\n",
    "        **state,\n",
    "        \"current_files\": \"\\nBelow are files your team has written to the directory:\\n\"\n",
    "        + \"\\n\".join([f\" - {f}\" for f in written_files]),\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "budget_writer_agent = create_agent(\n",
    "    llm,\n",
    "    [write_document, edit_document, read_document],\n",
    "    (\"You are an expert writing budget documents based on the following template.\\n\"\n",
    "    \"Below are files currently in your directory:\\n{current_files}\"),\n",
    ")\n",
    "context_aware_doc_writer_agent = prelude | doc_writer_agent\n",
    "doc_writing_node = functools.partial(\n",
    "    agent_node, agent=context_aware_doc_writer_agent, name=\"DocWriter\"\n",
    ")\n",
    "\n",
    "note_taking_agent = create_agent(\n",
    "    llm,\n",
    "    [create_outline, read_document],\n",
    "    (\"You are an expert senior researcher tasked with writing a LinkedIn post outline and\"\n",
    "    \" taking notes to craft a LinkedIn post.\\n{current_files}\"),\n",
    ")\n",
    "context_aware_note_taking_agent = prelude | note_taking_agent\n",
    "note_taking_node = functools.partial(\n",
    "    agent_node, agent=context_aware_note_taking_agent, name=\"NoteTaker\"\n",
    ")\n",
    "\n",
    "copy_editor_agent = create_agent(\n",
    "    llm,\n",
    "    [write_document, edit_document, read_document],\n",
    "    (\"You are an expert copy editor who focuses on fixing grammar, spelling, and tone issues\\n\"\n",
    "    \"Below are files currently in your directory:\\n{current_files}\"),\n",
    ")\n",
    "context_aware_copy_editor_agent = prelude | copy_editor_agent\n",
    "copy_editing_node = functools.partial(\n",
    "    agent_node, agent=context_aware_copy_editor_agent, name=\"CopyEditor\"\n",
    ")\n",
    "\n",
    "dopeness_editor_agent = create_agent(\n",
    "    llm,\n",
    "    [write_document, edit_document, read_document],\n",
    "    (\"You are an expert in dopeness, litness, coolness, etc - you edit the document to make sure it's dope. Make sure to use a number of emojis.\"\n",
    "    \"Below are files currently in your directory:\\n{current_files}\"),\n",
    ")\n",
    "context_aware_dopeness_editor_agent = prelude | dopeness_editor_agent\n",
    "dopeness_node = functools.partial(\n",
    "    agent_node, agent=context_aware_dopeness_editor_agent, name=\"DopenessEditor\"\n",
    ")\n",
    "\n",
    "doc_writing_supervisor = create_team_supervisor(\n",
    "    llm,\n",
    "    (\"You are a supervisor tasked with managing a conversation between the\"\n",
    "    \" following workers: {team_members}. You should always verify the technical\"\n",
    "    \" contents after any edits are made. \"\n",
    "    \"Given the following user request,\"\n",
    "    \" respond with the worker to act next. Each worker will perform a\"\n",
    "    \" task and respond with their results and status. When each team is finished,\"\n",
    "    \" you must respond with FINISH.\"),\n",
    "    [\"DocWriter\", \"NoteTaker\", \"DopenessEditor\", \"CopyEditor\"],\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Ragas Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "from ragas.llms import LangchainLLMWrapper\n",
    "from ragas.embeddings import LangchainEmbeddingsWrapper\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "\n",
    "generator_llm = LangchainLLMWrapper(ChatOpenAI(model=\"gpt-4o\"))\n",
    "generator_embeddings = LangchainEmbeddingsWrapper(OpenAIEmbeddings())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Applying HeadlinesExtractor:  48%|     | 40/84 [02:26<03:44,  5.11s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Request too large for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Requested 43020. The input or output tokens must be reduced in order to run successfully. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying HeadlinesExtractor:  86%| | 72/84 [05:58<02:01, 10.13s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29600, Requested 8077. Please try again in 15.354s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying HeadlineSplitter:   0%|          | 0/132 [00:00<?, ?it/s]          unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "Applying HeadlineSplitter:  68%|   | 90/132 [00:00<00:00, 895.63it/s]unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "unable to apply transformation: 'headlines' property not found in this node\n",
      "Applying SummaryExtractor:  22%|       | 23/106 [01:33<08:58,  6.49s/it] unable to apply transformation: Error code: 429 - {'error': {'message': 'Request too large for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Requested 42893. The input or output tokens must be reduced in order to run successfully. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying SummaryExtractor:  59%|    | 63/106 [05:37<03:05,  4.31s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28045, Requested 7009. Please try again in 10.108s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying SummaryExtractor:  65%|   | 69/106 [06:03<02:36,  4.24s/it]Property 'summary' already exists in node '014aa5'. Skipping!\n",
      "Applying SummaryExtractor:  66%|   | 70/106 [06:09<02:51,  4.76s/it]Property 'summary' already exists in node '983c00'. Skipping!\n",
      "Applying SummaryExtractor:  67%|   | 71/106 [06:13<02:38,  4.53s/it]Property 'summary' already exists in node 'aaac18'. Skipping!\n",
      "Applying SummaryExtractor:  68%|   | 72/106 [06:16<02:18,  4.06s/it]Property 'summary' already exists in node '04b0b9'. Skipping!\n",
      "Applying SummaryExtractor:  70%|   | 74/106 [06:21<01:45,  3.30s/it]Property 'summary' already exists in node 'c33aa3'. Skipping!\n",
      "Applying SummaryExtractor:  71%|   | 75/106 [06:23<01:30,  2.92s/it]Property 'summary' already exists in node '4c7ced'. Skipping!\n",
      "Applying SummaryExtractor:  72%|  | 76/106 [06:26<01:29,  3.00s/it]Property 'summary' already exists in node '3da5d6'. Skipping!\n",
      "Applying SummaryExtractor:  73%|  | 77/106 [06:27<01:03,  2.17s/it]Property 'summary' already exists in node '5eeb13'. Skipping!\n",
      "Applying SummaryExtractor:  74%|  | 78/106 [06:33<01:34,  3.36s/it]Property 'summary' already exists in node '75fcf5'. Skipping!\n",
      "Applying SummaryExtractor:  75%|  | 79/106 [06:35<01:24,  3.14s/it]Property 'summary' already exists in node 'ad7b8c'. Skipping!\n",
      "Applying SummaryExtractor:  75%|  | 80/106 [06:39<01:24,  3.25s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29355, Requested 8386. Please try again in 15.482s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying SummaryExtractor:  76%|  | 81/106 [06:40<01:04,  2.59s/it]Property 'summary' already exists in node 'ad8eb5'. Skipping!\n",
      "Applying SummaryExtractor:  77%|  | 82/106 [06:40<00:45,  1.90s/it]Property 'summary' already exists in node 'e0931d'. Skipping!\n",
      "Applying SummaryExtractor:  78%|  | 83/106 [06:45<01:07,  2.92s/it]Property 'summary' already exists in node '873acd'. Skipping!\n",
      "Applying SummaryExtractor:  79%|  | 84/106 [06:49<01:06,  3.02s/it]Property 'summary' already exists in node 'c188ec'. Skipping!\n",
      "Applying SummaryExtractor:  80%|  | 85/106 [06:52<01:04,  3.08s/it]Property 'summary' already exists in node '5e66e6'. Skipping!\n",
      "Applying SummaryExtractor:  81%|  | 86/106 [06:58<01:20,  4.04s/it]Property 'summary' already exists in node '8453d9'. Skipping!\n",
      "Applying SummaryExtractor:  82%| | 87/106 [06:59<00:59,  3.14s/it]Property 'summary' already exists in node '8da53c'. Skipping!\n",
      "Applying SummaryExtractor:  83%| | 88/106 [07:05<01:08,  3.80s/it]Property 'summary' already exists in node '8fc0db'. Skipping!\n",
      "Applying SummaryExtractor:  84%| | 89/106 [07:07<00:56,  3.33s/it]Property 'summary' already exists in node 'fca610'. Skipping!\n",
      "Applying SummaryExtractor:  85%| | 90/106 [07:10<00:54,  3.39s/it]Property 'summary' already exists in node 'b49012'. Skipping!\n",
      "Applying SummaryExtractor:  86%| | 91/106 [07:14<00:52,  3.49s/it]Property 'summary' already exists in node '417c63'. Skipping!\n",
      "Applying SummaryExtractor:  87%| | 92/106 [07:18<00:50,  3.60s/it]Property 'summary' already exists in node 'aa79f8'. Skipping!\n",
      "Applying SummaryExtractor:  88%| | 93/106 [07:22<00:48,  3.71s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 25718, Requested 7949. Please try again in 7.334s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying SummaryExtractor:  91%| | 96/106 [07:56<01:30,  9.07s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29151, Requested 7918. Please try again in 14.138s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying SummaryExtractor:  92%|| 98/106 [08:08<00:57,  7.20s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28808, Requested 10121. Please try again in 17.858s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying SummaryExtractor:  94%|| 100/106 [08:23<00:40,  6.69s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29306, Requested 10913. Please try again in 20.438s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:   0%|          | 0/229 [00:00<?, ?it/s]          Node 46a8f9e5-ef38-40f4-b6f8-2439c760ad2d does not have a summary. Skipping filtering.\n",
      "Node 02ccfe0f-3121-4476-b821-0a5a73f89a78 does not have a summary. Skipping filtering.\n",
      "Node 67925e16-94cb-4e30-acd4-dedd0a8753f0 does not have a summary. Skipping filtering.\n",
      "Node fbf9a4f4-5d85-4d34-b979-f0abbc2007fe does not have a summary. Skipping filtering.\n",
      "Node a217046a-74ab-4bcc-88a8-45dde9607379 does not have a summary. Skipping filtering.\n",
      "Node fd5dda3f-9faa-49fa-ae0c-5e6e13286d14 does not have a summary. Skipping filtering.\n",
      "Node 2571ea9a-bfb2-470d-8b59-2b2f31df434e does not have a summary. Skipping filtering.\n",
      "Node eb87ab20-36a9-47b1-a349-29112b9ba0fb does not have a summary. Skipping filtering.\n",
      "Node e1dec9d7-94bf-47e7-beb4-6187a20668d5 does not have a summary. Skipping filtering.\n",
      "Node 934f6d95-305b-4c1b-b960-74ee2a6e6870 does not have a summary. Skipping filtering.\n",
      "Node 1c0fc7b0-f639-48b6-a2a5-2fbd2f2f08ca does not have a summary. Skipping filtering.\n",
      "Node 5279aa7e-d5d6-4ce6-a4e6-f8913ad31d5e does not have a summary. Skipping filtering.\n",
      "Node 3981c7df-7c78-4c78-a981-c5ca3e84d7b2 does not have a summary. Skipping filtering.\n",
      "Applying CustomNodeFilter:  21%|        | 48/229 [01:09<07:23,  2.45s/it]Node 6e0dbbc8-2027-4883-9f0e-d97d3b641659 does not have a summary. Skipping filtering.\n",
      "Node bfc37966-6b96-47e0-bc0a-c427e3cb2bfe does not have a summary. Skipping filtering.\n",
      "Applying CustomNodeFilter:  21%|       | 49/229 [01:10<06:29,  2.16s/it]Node 2f5e71cb-0a88-4a88-a08c-4c460aff0909 does not have a summary. Skipping filtering.\n",
      "Node fe4e1d9b-705e-4e99-b12a-efd51995f680 does not have a summary. Skipping filtering.\n",
      "Node 6850d4f9-7763-4833-9eb9-20cf23695ac8 does not have a summary. Skipping filtering.\n",
      "Node c70ed751-6160-4668-b21c-c678c65aa9b2 does not have a summary. Skipping filtering.\n",
      "Applying CustomNodeFilter:  32%|      | 73/229 [01:59<07:48,  3.01s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29935, Requested 2346. Please try again in 4.562s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  36%|      | 83/229 [02:27<06:59,  2.87s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28795, Requested 2356. Please try again in 2.302s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  39%|      | 89/229 [02:36<05:02,  2.16s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29897, Requested 2367. Please try again in 4.528s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  40%|      | 91/229 [02:37<02:58,  1.29s/it]Node 995d2ded-ad4f-4518-b902-829d1ec055e1 does not have a summary. Skipping filtering.\n",
      "Node a61cebb0-d43f-4a36-baac-5ebbdcf586cf does not have a summary. Skipping filtering.\n",
      "Applying CustomNodeFilter:  40%|      | 92/229 [02:39<03:01,  1.32s/it]Node 878867bb-db87-4396-8dd9-50001f194723 does not have a summary. Skipping filtering.\n",
      "Node 90200947-7d6f-495d-88b0-ef82c0eb2324 does not have a summary. Skipping filtering.\n",
      "Node 20d99148-e7f3-4e69-8430-1920df11e6fb does not have a summary. Skipping filtering.\n",
      "Node 66b5935f-6dbb-4bed-a01d-0a1c67572e0d does not have a summary. Skipping filtering.\n",
      "Applying CustomNodeFilter:  44%|     | 101/229 [02:46<02:24,  1.13s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28837, Requested 2362. Please try again in 2.398s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  48%|     | 109/229 [03:06<05:22,  2.69s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29903, Requested 2404. Please try again in 4.614s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  52%|    | 119/229 [03:30<05:41,  3.11s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28853, Requested 2313. Please try again in 2.332s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  53%|    | 122/229 [03:33<03:14,  1.81s/it]Node b9924a1c-83d1-4dcf-b5bf-528b27e38901 does not have a summary. Skipping filtering.\n",
      "Node 31d6094a-8d6d-4d93-b76a-9084f39a25a1 does not have a summary. Skipping filtering.\n",
      "Applying CustomNodeFilter:  54%|    | 123/229 [03:34<02:47,  1.58s/it]Node 6c12019f-a621-4890-9666-3ade467b2f8f does not have a summary. Skipping filtering.\n",
      "Node c8e40aa5-6347-481b-9362-ecf1f9bdb5e1 does not have a summary. Skipping filtering.\n",
      "Node 1c9e01a7-2e99-4ab7-b937-81745a5774dc does not have a summary. Skipping filtering.\n",
      "Applying CustomNodeFilter:  56%|    | 129/229 [03:38<01:32,  1.08it/s]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29122, Requested 2561. Please try again in 3.366s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  61%|    | 139/229 [03:59<03:17,  2.20s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29813, Requested 2480. Please try again in 4.586s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  64%|   | 146/229 [04:17<03:56,  2.85s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28665, Requested 2427. Please try again in 2.184s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  66%|   | 150/229 [04:23<02:44,  2.09s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28966, Requested 2393. Please try again in 2.718s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  72%|  | 164/229 [04:56<02:36,  2.40s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29276, Requested 2385. Please try again in 3.322s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  73%|  | 168/229 [05:03<02:17,  2.26s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28717, Requested 2395. Please try again in 2.224s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  74%|  | 170/229 [05:05<01:38,  1.66s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28823, Requested 2342. Please try again in 2.33s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  76%|  | 173/229 [05:09<01:30,  1.62s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28843, Requested 2373. Please try again in 2.432s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  79%|  | 181/229 [05:25<01:47,  2.23s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29840, Requested 2387. Please try again in 4.454s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  80%|  | 184/229 [05:31<01:37,  2.17s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29060, Requested 2375. Please try again in 2.87s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  88%| | 202/229 [06:13<01:09,  2.56s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29003, Requested 2448. Please try again in 2.902s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  91%|| 209/229 [06:26<00:44,  2.23s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28351, Requested 2532. Please try again in 1.766s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying CustomNodeFilter:  93%|| 214/229 [06:34<00:30,  2.04s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29100, Requested 2433. Please try again in 3.066s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:   0%|          | 0/554 [00:00<?, ?it/s]Property 'summary_embedding' already exists in node '014aa5'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '983c00'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'aaac18'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '04b0b9'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'c33aa3'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '4c7ced'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '3da5d6'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '5eeb13'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'ad8eb5'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '75fcf5'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'ad7b8c'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '5e66e6'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'e0931d'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '8453d9'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '873acd'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'c188ec'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'aa79f8'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '8da53c'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '417c63'. Skipping!\n",
      "Property 'summary_embedding' already exists in node '8fc0db'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'fca610'. Skipping!\n",
      "Property 'summary_embedding' already exists in node 'b49012'. Skipping!\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:   0%|          | 1/554 [00:41<6:22:34, 41.51s/it]unable to apply transformation: node.property('summary') must be a string, found '<class 'NoneType'>'\n",
      "unable to apply transformation: node.property('summary') must be a string, found '<class 'NoneType'>'\n",
      "unable to apply transformation: node.property('summary') must be a string, found '<class 'NoneType'>'\n",
      "unable to apply transformation: node.property('summary') must be a string, found '<class 'NoneType'>'\n",
      "unable to apply transformation: node.property('summary') must be a string, found '<class 'NoneType'>'\n",
      "unable to apply transformation: node.property('summary') must be a string, found '<class 'NoneType'>'\n",
      "unable to apply transformation: node.property('summary') must be a string, found '<class 'NoneType'>'\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  37%|      | 203/554 [03:17<13:06,  2.24s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29289, Requested 2078. Please try again in 2.734s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  38%|      | 208/554 [03:27<11:46,  2.04s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28604, Requested 2036. Please try again in 1.28s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  38%|      | 209/554 [03:27<08:42,  1.52s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29311, Requested 2143. Please try again in 2.908s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  38%|      | 213/554 [03:33<08:20,  1.47s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29668, Requested 2001. Please try again in 3.338s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  39%|      | 216/554 [03:38<09:05,  1.61s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29324, Requested 2001. Please try again in 2.65s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  39%|      | 218/554 [03:41<08:24,  1.50s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28689, Requested 1771. Please try again in 920ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  40%|      | 222/554 [03:45<07:46,  1.41s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29323, Requested 1934. Please try again in 2.514s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  40%|      | 224/554 [03:48<08:04,  1.47s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29920, Requested 1988. Please try again in 3.816s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  43%|     | 237/554 [04:13<09:18,  1.76s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29677, Requested 2072. Please try again in 3.498s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  45%|     | 251/554 [04:43<12:23,  2.45s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29855, Requested 2074. Please try again in 3.857s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  46%|     | 256/554 [04:51<09:12,  1.85s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29722, Requested 2139. Please try again in 3.722s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  47%|     | 259/554 [04:54<07:32,  1.53s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29238, Requested 2133. Please try again in 2.742s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  49%|     | 271/554 [05:22<12:31,  2.65s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28716, Requested 2003. Please try again in 1.438s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  52%|    | 290/554 [06:02<08:48,  2.00s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29863, Requested 2139. Please try again in 4.004s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  53%|    | 296/554 [06:15<08:35,  2.00s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28565, Requested 2103. Please try again in 1.336s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  55%|    | 306/554 [06:31<07:30,  1.82s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29495, Requested 2010. Please try again in 3.01s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  55%|    | 307/554 [06:32<06:39,  1.62s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29426, Requested 2140. Please try again in 3.132s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  56%|    | 308/554 [06:32<04:50,  1.18s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29380, Requested 2109. Please try again in 2.978s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  57%|    | 316/554 [06:42<05:49,  1.47s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29605, Requested 2108. Please try again in 3.426s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  57%|    | 317/554 [06:42<04:50,  1.23s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29556, Requested 2139. Please try again in 3.39s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  60%|    | 333/554 [07:18<10:00,  2.72s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29283, Requested 2124. Please try again in 2.814s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  61%|   | 340/554 [07:31<07:35,  2.13s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28808, Requested 2107. Please try again in 1.83s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  62%|   | 342/554 [07:32<05:33,  1.57s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29522, Requested 2073. Please try again in 3.19s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  63%|   | 351/554 [07:48<06:22,  1.88s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29741, Requested 2126. Please try again in 3.734s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  66%|   | 364/554 [08:14<08:26,  2.67s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29796, Requested 2152. Please try again in 3.895s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  66%|   | 365/554 [08:16<08:15,  2.62s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29457, Requested 2135. Please try again in 3.184s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  67%|   | 372/554 [08:28<06:44,  2.22s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29408, Requested 2085. Please try again in 2.986s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  68%|   | 379/554 [08:38<04:45,  1.63s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29900, Requested 2167. Please try again in 4.134s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  69%|   | 380/554 [08:39<03:51,  1.33s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29348, Requested 1827. Please try again in 2.35s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  71%|  | 396/554 [09:11<04:51,  1.85s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29060, Requested 2013. Please try again in 2.146s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  72%|  | 399/554 [09:15<03:36,  1.40s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29937, Requested 1922. Please try again in 3.718s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  73%|  | 407/554 [09:38<07:20,  3.00s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29660, Requested 2037. Please try again in 3.394s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  76%|  | 421/554 [10:03<04:36,  2.08s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29676, Requested 2048. Please try again in 3.448s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  77%|  | 425/554 [10:11<04:30,  2.09s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29596, Requested 2018. Please try again in 3.228s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  77%|  | 429/554 [10:18<04:04,  1.96s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29660, Requested 2094. Please try again in 3.508s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  79%|  | 440/554 [10:44<04:36,  2.42s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29078, Requested 2091. Please try again in 2.338s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  80%|  | 445/554 [10:51<02:48,  1.55s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28583, Requested 2053. Please try again in 1.272s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  81%|  | 449/554 [10:58<03:11,  1.82s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29229, Requested 2155. Please try again in 2.768s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  82%| | 452/554 [11:00<01:36,  1.06it/s]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28206, Requested 2089. Please try again in 590ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  83%| | 458/554 [11:14<03:21,  2.10s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28363, Requested 2075. Please try again in 876ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  83%| | 459/554 [11:15<02:40,  1.69s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28308, Requested 2100. Please try again in 816ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  85%| | 472/554 [11:39<03:21,  2.45s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29474, Requested 2023. Please try again in 2.994s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  88%| | 485/554 [12:07<02:28,  2.16s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29264, Requested 2048. Please try again in 2.624s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  88%| | 488/554 [12:11<01:54,  1.73s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29631, Requested 2007. Please try again in 3.276s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  88%| | 490/554 [12:14<01:50,  1.73s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28924, Requested 2149. Please try again in 2.146s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  92%|| 512/554 [13:07<01:58,  2.82s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 28354, Requested 2081. Please try again in 870ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  95%|| 524/554 [13:28<00:56,  1.88s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29719, Requested 2155. Please try again in 3.748s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  95%|| 525/554 [13:28<00:42,  1.48s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29714, Requested 2156. Please try again in 3.74s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  96%|| 530/554 [13:33<00:30,  1.27s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29129, Requested 2125. Please try again in 2.508s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  96%|| 531/554 [13:36<00:38,  1.66s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29278, Requested 2157. Please try again in 2.87s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  97%|| 535/554 [13:40<00:19,  1.01s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29915, Requested 2124. Please try again in 4.077s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  98%|| 541/554 [13:49<00:23,  1.77s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29247, Requested 2126. Please try again in 2.746s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [EmbeddingExtractor, ThemesExtractor, NERExtractor]:  98%|| 544/554 [13:55<00:20,  2.01s/it]unable to apply transformation: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Used 29363, Requested 2120. Please try again in 2.966s. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}\n",
      "Applying [CosineSimilarityBuilder, OverlapScoreBuilder]:   0%|          | 0/2 [00:00<?, ?it/s]                 unable to apply transformation: Node 61c69e2f-5724-40bf-b2f1-2d5d612f3a9a has no summary_embedding\n",
      "unable to apply transformation: Node 46a8f9e5-ef38-40f4-b6f8-2439c760ad2d or 02ccfe0f-3121-4476-b821-0a5a73f89a78 has no entities\n",
      "Generating personas: 100%|| 3/3 [00:01<00:00,  2.41it/s]                            \n",
      "Generating Scenarios: 100%|| 1/1 [00:28<00:00, 28.32s/it]\n",
      "Generating Samples: 100%|| 10/10 [00:03<00:00,  2.94it/s]\n"
     ]
    }
   ],
   "source": [
    "from ragas.testset import TestsetGenerator\n",
    "\n",
    "generator = TestsetGenerator(llm=generator_llm, embedding_model=generator_embeddings)\n",
    "dataset = generator.generate_with_langchain_docs(opportunities, testset_size=10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>user_input</th>\n",
       "      <th>reference_contexts</th>\n",
       "      <th>reference</th>\n",
       "      <th>synthesizer_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>What is the AADCRC program and how does it con...</td>\n",
       "      <td>[Objectives and Scope The objective of this NO...</td>\n",
       "      <td>The AADCRC program aims to improve the underst...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>What role does a Scientific Core play in the A...</td>\n",
       "      <td>[AADCRC components Administrative Core (requir...</td>\n",
       "      <td>A Scientific Core in the AADCRC structure is o...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Wht r the eligiblity critera for Alaskaa Nativ...</td>\n",
       "      <td>[RFA-AI-24-079: Asthma and Allergic Diseases C...</td>\n",
       "      <td>Alaska Native and Native Hawaiian Serving Inst...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Wht are the eligibilty critera for NIH IPF num...</td>\n",
       "      <td>[Eligible Individuals (Program Director/Princi...</td>\n",
       "      <td>Only one application per institution, identifi...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>What is the role of the Clinical Core in suppo...</td>\n",
       "      <td>[Administrative Core: required, 1 Data Steward...</td>\n",
       "      <td>The Clinical Core is optional and can have a m...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>What is the role of the Data and Safety Monito...</td>\n",
       "      <td>[When involving human subjects research, clini...</td>\n",
       "      <td>For all clinical trials, NIAID will provide a ...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Wht is the role of ASSIST in the clinical core...</td>\n",
       "      <td>[of the Overall component. Note : Specific det...</td>\n",
       "      <td>ASSIST screens will show an asterisk for the P...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>What go in appendix?</td>\n",
       "      <td>[alternative approaches to be implemented, if ...</td>\n",
       "      <td>Only limited items are allowed in the Appendix...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Wht is NIAID's role in clinical trials?</td>\n",
       "      <td>[Apply- Application Guide must be followed. De...</td>\n",
       "      <td>For all clinical trials, NIAID will provide a ...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>What is System for Award Management and why it...</td>\n",
       "      <td>[protocol development, the plan for study impl...</td>\n",
       "      <td>The System for Award Management (SAM) is a req...</td>\n",
       "      <td>single_hop_specifc_query_synthesizer</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                          user_input  \\\n",
       "0  What is the AADCRC program and how does it con...   \n",
       "1  What role does a Scientific Core play in the A...   \n",
       "2  Wht r the eligiblity critera for Alaskaa Nativ...   \n",
       "3  Wht are the eligibilty critera for NIH IPF num...   \n",
       "4  What is the role of the Clinical Core in suppo...   \n",
       "5  What is the role of the Data and Safety Monito...   \n",
       "6  Wht is the role of ASSIST in the clinical core...   \n",
       "7                               What go in appendix?   \n",
       "8            Wht is NIAID's role in clinical trials?   \n",
       "9  What is System for Award Management and why it...   \n",
       "\n",
       "                                  reference_contexts  \\\n",
       "0  [Objectives and Scope The objective of this NO...   \n",
       "1  [AADCRC components Administrative Core (requir...   \n",
       "2  [RFA-AI-24-079: Asthma and Allergic Diseases C...   \n",
       "3  [Eligible Individuals (Program Director/Princi...   \n",
       "4  [Administrative Core: required, 1 Data Steward...   \n",
       "5  [When involving human subjects research, clini...   \n",
       "6  [of the Overall component. Note : Specific det...   \n",
       "7  [alternative approaches to be implemented, if ...   \n",
       "8  [Apply- Application Guide must be followed. De...   \n",
       "9  [protocol development, the plan for study impl...   \n",
       "\n",
       "                                           reference  \\\n",
       "0  The AADCRC program aims to improve the underst...   \n",
       "1  A Scientific Core in the AADCRC structure is o...   \n",
       "2  Alaska Native and Native Hawaiian Serving Inst...   \n",
       "3  Only one application per institution, identifi...   \n",
       "4  The Clinical Core is optional and can have a m...   \n",
       "5  For all clinical trials, NIAID will provide a ...   \n",
       "6  ASSIST screens will show an asterisk for the P...   \n",
       "7  Only limited items are allowed in the Appendix...   \n",
       "8  For all clinical trials, NIAID will provide a ...   \n",
       "9  The System for Award Management (SAM) is a req...   \n",
       "\n",
       "                       synthesizer_name  \n",
       "0  single_hop_specifc_query_synthesizer  \n",
       "1  single_hop_specifc_query_synthesizer  \n",
       "2  single_hop_specifc_query_synthesizer  \n",
       "3  single_hop_specifc_query_synthesizer  \n",
       "4  single_hop_specifc_query_synthesizer  \n",
       "5  single_hop_specifc_query_synthesizer  \n",
       "6  single_hop_specifc_query_synthesizer  \n",
       "7  single_hop_specifc_query_synthesizer  \n",
       "8  single_hop_specifc_query_synthesizer  \n",
       "9  single_hop_specifc_query_synthesizer  "
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataset.to_pandas()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Testset uploaded! View at https://app.ragas.io/dashboard/alignment/testset/0842bbec-e388-4a45-8e5f-faf4950361f9\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'https://app.ragas.io/dashboard/alignment/testset/0842bbec-e388-4a45-8e5f-faf4950361f9'"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataset.upload()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "for test_row in dataset:\n",
    "  response = graph.invoke({\"question\" : test_row.eval_sample.user_input})\n",
    "  test_row.eval_sample.response = response[\"response\"]\n",
    "  test_row.eval_sample.retrieved_contexts = [context.page_content for context in response[\"context\"]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "from ragas import EvaluationDataset\n",
    "\n",
    "evaluation_dataset = EvaluationDataset.from_pandas(dataset.to_pandas())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "from ragas import evaluate\n",
    "from ragas.llms import LangchainLLMWrapper\n",
    "\n",
    "evaluator_llm = LangchainLLMWrapper(ChatOpenAI(model=\"gpt-4o\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Evaluating:  12%|        | 7/60 [00:14<02:06,  2.39s/it]Exception raised in Job[20]: TypeError(ufunc 'invert' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe'')\n",
      "Evaluating:  15%|        | 9/60 [00:36<05:41,  6.70s/it]Exception raised in Job[14]: TypeError(ufunc 'invert' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe'')\n",
      "Evaluating:  22%|       | 13/60 [00:41<01:56,  2.47s/it]Exception raised in Job[26]: TypeError(ufunc 'invert' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe'')\n",
      "Evaluating:  38%|      | 23/60 [02:02<03:53,  6.32s/it]Exception raised in Job[38]: TypeError(ufunc 'invert' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe'')\n",
      "Evaluating:  58%|    | 35/60 [04:32<07:53, 18.94s/it]Exception raised in Job[50]: TypeError(ufunc 'invert' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe'')\n",
      "Evaluating:  63%|   | 38/60 [04:59<05:04, 13.83s/it]Exception raised in Job[43]: RateLimitError(Error code: 429 - {'error': {'message': 'Request too large for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Requested 44562. The input or output tokens must be reduced in order to run successfully. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}})\n",
      "Evaluating:  65%|   | 39/60 [05:09<04:27, 12.76s/it]Exception raised in Job[42]: RateLimitError(Error code: 429 - {'error': {'message': 'Request too large for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Requested 44550. The input or output tokens must be reduced in order to run successfully. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}})\n",
      "Evaluating:  68%|   | 41/60 [05:30<03:45, 11.88s/it]Exception raised in Job[56]: TypeError(ufunc 'invert' not supported for the input types, and the inputs could not be safely coerced to any supported types according to the casting rule ''safe'')\n",
      "Evaluating:  73%|  | 44/60 [05:53<02:28,  9.30s/it]Exception raised in Job[7]: TimeoutError()\n",
      "Evaluating:  75%|  | 45/60 [06:00<02:06,  8.45s/it]Exception raised in Job[10]: TimeoutError()\n",
      "Exception raised in Job[11]: TimeoutError()\n",
      "Exception raised in Job[47]: RateLimitError(Error code: 429 - {'error': {'message': 'Request too large for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Requested 43568. The input or output tokens must be reduced in order to run successfully. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}})\n",
      "Evaluating:  80%|  | 48/60 [06:21<01:32,  7.71s/it]Exception raised in Job[24]: TimeoutError()\n",
      "Evaluating:  82%| | 49/60 [06:36<01:40,  9.16s/it]Exception raised in Job[46]: RateLimitError(Error code: 429 - {'error': {'message': 'Request too large for gpt-4o in organization org-fG4XzykR5yuSt2Wp6ZlK7gAJ on tokens per min (TPM): Limit 30000, Requested 44216. The input or output tokens must be reduced in order to run successfully. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}})\n",
      "Evaluating:  83%| | 50/60 [06:40<01:20,  8.05s/it]Exception raised in Job[28]: TimeoutError()\n",
      "Evaluating:  85%| | 51/60 [06:41<00:56,  6.25s/it]Exception raised in Job[29]: TimeoutError()\n",
      "Evaluating:  87%| | 52/60 [06:49<00:54,  6.78s/it]/Users/christinemahler/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/numpy/_core/fromnumeric.py:3860: RuntimeWarning: Mean of empty slice.\n",
      "  return _methods._mean(a, axis=axis, dtype=dtype,\n",
      "/Users/christinemahler/Desktop/AIE5/Midterm/.venv/lib/python3.13/site-packages/numpy/_core/_methods.py:145: RuntimeWarning: invalid value encountered in scalar divide\n",
      "  ret = ret.dtype.type(ret / rcount)\n",
      "Evaluating:  88%| | 53/60 [06:52<00:40,  5.83s/it]Exception raised in Job[30]: TimeoutError()\n",
      "Evaluating:  90%| | 54/60 [07:07<00:50,  8.44s/it]Exception raised in Job[31]: TimeoutError()\n",
      "Evaluating:  93%|| 56/60 [07:31<00:43, 10.81s/it]Exception raised in Job[34]: TimeoutError()\n",
      "Evaluating:  95%|| 57/60 [07:41<00:30, 10.33s/it]Exception raised in Job[35]: TimeoutError()\n",
      "Evaluating: 100%|| 60/60 [08:27<00:00,  8.45s/it]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'context_recall': 0.5000, 'faithfulness': 0.3056, 'factual_correctness': 0.6250, 'answer_relevancy': 0.3755, 'context_entity_recall': 0.3567, 'noise_sensitivity_relevant': 0.0667}"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from ragas.metrics import LLMContextRecall, Faithfulness, FactualCorrectness, ResponseRelevancy, ContextEntityRecall, NoiseSensitivity\n",
    "from ragas import evaluate, RunConfig\n",
    "\n",
    "custom_run_config = RunConfig(timeout=360)\n",
    "\n",
    "result = evaluate(\n",
    "    dataset=evaluation_dataset,\n",
    "    metrics=[LLMContextRecall(), Faithfulness(), FactualCorrectness(), ResponseRelevancy(), ContextEntityRecall(), NoiseSensitivity()],\n",
    "    llm=evaluator_llm,\n",
    "    run_config=custom_run_config\n",
    ")\n",
    "result"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
